<SEC-DOCUMENT>0001558370-23-003259.txt : 20230309
<SEC-HEADER>0001558370-23-003259.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309074439
ACCESSION NUMBER:		0001558370-23-003259
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39801
		FILM NUMBER:		23718219

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>xoma-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/8/2023 8:16:32 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: d1595162-3043-49a2-9ef4-7f47d8b494b3 -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xoma="http://www.xoma.com/20221231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityCentralIndexKey" id="Tc_Ko6kHFVqW0K7Y9zR34NSIA_2_1">0000791908</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentFiscalYearFocus" id="Tc_Vp2cTCW2UEOI1rglQ3PKLA_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentFiscalPeriodFocus" id="Tc_ppEdwEOXIkuf8uhxQIQGDQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:AmendmentFlag" id="Tc_WOONeeSf8UujfskMw0Mqdg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" xs:nil="true" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_QTvgDvLQpk2h-LwDeIqFAg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" xs:nil="true" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_MXTd9XYspk-r4SDqONPKow"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityWellKnownSeasonedIssuer" id="Hidden_wmlnCmGi9UaTuKy0fPEZIA">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityVoluntaryFilers" id="Hidden_etWwIGkuCUidf1uC_QoY1A">No</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityCurrentReportingStatus" id="Hidden_m7mbWAfU6ka4R4vo0FBMHw">Yes</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityInteractiveDataCurrent" id="Hidden_MWtPRgmjjkCHN97YCziAHw">Yes</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_V62nRCE_MUKPRncFNFDb4Q" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_osQASCJOc0aG36cPBan18A">0.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" xs:nil="true" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_SoJMkvQEd0GCqEyppA4jKg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" xs:nil="true" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_-opkpTvh2U-sJds8V7C3Yw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA" decimals="INF" name="xoma:DepositarySharesRatioToPreferredStock" id="Hidden_bylnvwbfT0qC2wS2bhBX0Q">0.001</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Ud1xPuhf60KUwxKzTrATfQ" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_cbQH9ljBJEebaeTjfrtxMg">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_SNdPlNffB0uww3AF1AK5Yg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_Ns1YY3UqQkOJK6UyTHN1bg">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_6oBXO6b-I0mpgNiU83WWgA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_KkEuaC7pjUygw9Z4wgEdgA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yz_sn-UE30-ULY9heqfBuw" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_Z4eBHZawv0inBmuQccPnkA">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_s2s7EUHKIU-1G1XKSBWUDA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_AffMX3HfskqqtMAs2dYFqA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_HMDAQklqkUG0fZ521YdL4A" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_rVEGkExq70yCFYYZq4K5yQ">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_RCbYz-Iv-Ee2b0eoyibbgw" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_LQOgbcYcy0O5Ut6RtuujLg">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ZexR-kNri0e-hmnNihJ6mg" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_Kelm5qnj-EOoeAXowZDZbA">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iqfNwPqtQUKQ72qNgqgT2g" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_xxzwN1Kink2tMJX3CRXlnA">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e-eX2y3du0SjIMU4Khgc_w" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_NoKAl2q6DEWcRsp0Y0mt6g">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_qrhyGaKdHU2y0jcE4pD9zA" decimals="INF" name="xoma:StockIssuedDuringPeriodSharesWarrantsExercised" id="Hidden_FXGxJuaD7Eqmui9GgIgKuw">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_292B7Rrmb0OIBzdjG3jt5w">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="xoma-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_83JqH9MaqUu4NibTiAAyew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_T4pTOnp0j0KTjb2iHvM7fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_qrhyGaKdHU2y0jcE4pD9zA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AQY72CQvV02u0NTeC1tQxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f4LrCv2BoEiulseA8lIUQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Qzz2di3EtU2QVCStAbp7Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kjZwwrEtk-QxVmWmdRujQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VTkPPsj7uUqml3L2CsbZfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qLzFyf8POkuPzS_GjeXV5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_kB9yfId7VkK_kt3X391buA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_9IG6mnsXWkKJ-8l8yrS4Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_m0XXi-6V7kqy8Lqgpe0vfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_j83jgfg09UidGXoNWAtd8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_I3wo0vb-CUixzfe_qIAyTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GF-6_dQKikmqEGqiVXM_qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_daw_HrxdKUKz56KM-1KXIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-11-01</xbrli:startDate><xbrli:endDate>2006-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_e4kVRRL9ukOGf7-2PTwdVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_SHL2DGznK0y-hmUTeZ2Q-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_43509g1PLEqQVPLib8nQng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_kQY9oDQ6-02HjwmVuO7AAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_p4dgpct0ik2knGpohVsu9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lP-1sgwP7kC3A25KNKaI5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_rJ-F8BD5CUu-Uk0PG_Pfyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_aPOJphzjLkGSA83nJdzBJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ugLN8Eo-O0CB7wwIKyDDpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_1HuefpXb_UKf4eNJQw4how"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_sp6WSCeDk02ydf80LtVc8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_HhSShoGRe0G87HW8PMEEcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_3Ps32ZWrf0q2EllGoG3fog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_EbXYjQ5mzUCNFK-esz7zlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_s6Xmk-SskE67Bmh6cHSc5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5i_Uy5BsyEObHFG9u5GxwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-26</xbrli:startDate><xbrli:endDate>2019-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_j4ElNZhA0E-_JPRkD0IGeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_jKmiP9r9_kuqlBxvTOdkgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_A4To0NeQ0UybzQYa3NDSxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Tuhk6nZzwk6xT736Ru4Zyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qIclTWez7UKcmOfuHD_oAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ibRXt1hd3k63S2armpWFhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WnhYpE1OH0qWIIqY-1VSWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qkTeCxJPbk-sQaXhYuVwgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CXsrLLVq5kSPUm74NYuFBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_yudqPJgz7UaaG7AG1-aQYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_jfpTunIQFUqf7I8Jy9MJPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_p24xpBTiUk-dfPSrxHMCZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_c9juPFjI2UyPCCkvD4DUNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_V_cdDAl530WO8X_Yw2S8dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qccAUP40R0mSuKlRmGHvKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_10_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mfqGdjZYME-gcLNsUw5Lng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2020-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_JQNeN2TEeU24mxPrSn9wUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_13_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gX6CfAtkvUmCg-Bai3Zw_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_v4dNNnJyNk2mkUC5mofV7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VbBrsLclIUqIJDiHDqkKUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lVrv91FNZU23z9vv3AQpjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_8Lp1iopY80moFAsWA0Oicw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wVSdoYr4jUereb7ZG5cXaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_MAbD5nWZf0aUq7Ov_NLXRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NqA3jpIWgUS-c7ELvkpPVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_f0_HvkLSs0CosO5uys_l2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_8nHUuSkvaUSLpkODfJC36A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_rAroNAm8f0G6gOtRf-Uv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_DWIu-n3lPUiIYGcRZmhJLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_9ni1jDQqGE2MNc84XrIr5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7DasBvaAtkS6lYyw7kjKSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_gb8Mq7RYNUyPvOuADsltaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lLvvXbzgEakGtNGbJg_Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-02-01</xbrli:startDate><xbrli:endDate>2009-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FwHL2hBqk0yF5G8wK5a2qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_r1ERX-00-kOo1Xhy1OfigQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_k_sLWKXSlEu9WIjrFJoc0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraKurosAffitechObsevaAndMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4kBNFywoskiicslz4mbomw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_FAnAp8a72E6w0d6JVWeLow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1cbEl4Re006vJtiqqHtFKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xgElIxuKbE-siKQSQ-ga1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_q-sxs5W_mkKsWzMqNMcjqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_cOp6nGVAs0WrsYuMFKEFVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qeDzPAJvEkG3H6Q0IdTsfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4AJG2U9b-06BTayaXGugZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-30</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yTZvacgI1ke_u3yIpm8d6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_bYn_MgYoV0WUzvqn6X6Z0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_4s6qFO24NU6iO5tq9Aj0Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ty0cbCyI1UahHddWl2YJhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sO-ZiH9JX0a2e36VG0bf-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_W-KLX26PfE2wxKbylONFcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_s24vGEKFqEy3_8cKQImkMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_UYkiYmAOIk2ogIy_KnYMTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_V62nRCE_MUKPRncFNFDb4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RKKUO79jyUSa60B9WdlKKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHPRrMM4WkiFXB-GwNaVCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7mSqMJYiC0-QLMIxAQYuXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9iAqnNnr4UCD-KQ4aTDILg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zMpMm6r57kGoeIrwyong2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bnirjFhGZEq0-FJZJXu1DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i9sxLuyDfkyzZdNDX8SCMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ciJIa6qAFU2yV5PeZYq7oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_mcDXIe1eeUuUz9qtOy-1xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_c3q8pXA60E2IFa_nifIVng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_le_sU7N1A06C93O-_SOo1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_innzPLhQmEaLAZC2EVjFOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2Eq4oPH3-kmCmCEtd6jqOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gTYL1gbNEamV73yFBPD9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_4_yOcoEhi0evQ1_wlkZgQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeTerminatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_S_3GoTwkMUmL0YDsH6p4lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2rqqrvz1g0ady6TBHhDp8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NmtXsMtquUe4CqwtZxHDmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_Dtmc_sm9HUOpkVYHoPRuoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_BRZefaTLEE2Yy6v52PFdig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember_kIunflkcykiOnsDFbUFC3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember_OSUGOQpK0k66rX6ilVlChg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_uq3xBIh_ZEu0t2lz65AnGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_BsX5M1Uu6EOTSHfP8EnvNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_aM7qfAJs_Ue2FngKRak2-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_aQqKR6_fy0yZBwIQWrikJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_7wxTmOyFPkGXQt3cSa57RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_8SsPA-cdo0K4zx7dDhkPMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_H1WDisLgxkqIvK7clGpKEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_kNUrGAqyEkalFB8W0WRezg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wmOMUEuzuk6yS0QoDP0Ysw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xdeG_av2K0qt9xOQHo2aRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_cenBgMUh9Uyccspm0H9hgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_867K-w4nlkWwUkggr9tW3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_P4EQyfpsBUSEXZiG7S71Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pQS3U8aNZU-yXj_-Ru7Piw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_PL6qNM8JgkeHSr5yXfQ1uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_EuXVMgiSQkKFYqjEXEEp2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UWK0SRUsv06_NuNedSDLfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_x7uVaLNyW025G4gxpaAXkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1sPaZ1NGOUiQwEfq8TQ6mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IXa196Wdf0SCxbIeQySyiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WMb-KT8So0uQN8syGEGdzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eC4aFolUA0GTxlIWZ6Cc1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U2mBKo7TtEGcPUHwD7IglQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_r11OGkPAXkWTZaN_G9-weg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_G8esAtNmakKoYvkKmZ81HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_uxkL92PMnEKbjnT9gFRfjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_PyU4HZ2-MUyl0mkJzT2hGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_P9oH2exeW068heueh9jTxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_A1kceVHEZkC9lyFdU9dnZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_HlTz8mGzA0mZC7-lIrM7Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ItyWObStzkWwMfLcO4SwBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ECC3Oq74RkeaDZlwSNK7uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_VF5VDW6QuUuc3CbbuaDBkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_3Xidd4rXq0CdoCYMGseM6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HvH-K2iJckyzvUJ368yfOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_l3gJWyDRYUKye9TcMvxKkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_DUPN51MSmkqx8eTsUOxe0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_qfx1aT0hdUKuLGbIUvod5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_10e0GTXDRUWaRkscI-rq2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mxRsfmorrkSEqfBuonPH7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EHfSyV3gW0yDNOYLjydoRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CkHConVlPkaisM4vx4ktDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BeZq4eB_bk2TnmlVTH1lsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-20</xbrli:startDate><xbrli:endDate>2022-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nnI_V8OIx0mQwuOLxFWnCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-20</xbrli:startDate><xbrli:endDate>2022-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_9mhY0z8wFkeA-5k_gob2uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_uXlwrNWockK5GTzJTR4xtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-18</xbrli:startDate><xbrli:endDate>2022-05-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lbU7cay48kKD_gmRJwUG_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T3jnk2RjiUevKoKd9EnTqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-17</xbrli:startDate><xbrli:endDate>2022-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oU8u6lClxEOfghqL98sZqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-20</xbrli:startDate><xbrli:endDate>2021-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_WrEKyI_BW0KQR6sl9XSdjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-20</xbrli:startDate><xbrli:endDate>2021-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iqfNwPqtQUKQ72qNgqgT2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e-eX2y3du0SjIMU4Khgc_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_RCbYz-Iv-Ee2b0eoyibbgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-17</xbrli:startDate><xbrli:endDate>2022-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ZexR-kNri0e-hmnNihJ6mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-17</xbrli:startDate><xbrli:endDate>2022-10-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_s2s7EUHKIU-1G1XKSBWUDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_HMDAQklqkUG0fZ521YdL4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_6oBXO6b-I0mpgNiU83WWgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-15</xbrli:startDate><xbrli:endDate>2022-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yz_sn-UE30-ULY9heqfBuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-15</xbrli:startDate><xbrli:endDate>2022-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Ud1xPuhf60KUwxKzTrATfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-18</xbrli:startDate><xbrli:endDate>2022-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_SNdPlNffB0uww3AF1AK5Yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-18</xbrli:startDate><xbrli:endDate>2022-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-09</xbrli:startDate><xbrli:endDate>2021-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_I3IaD-K-xEGI556fraBoOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTSoj4BvgUOQEPopJD5s6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wf94VZSnXU-Wpl7zah_jxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cxJRCFdTx0yjmZeqnao7Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ObP3X6UuqEmc0v7i_E4cnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_gA6KAG_rhUGJzhjdDOAkdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_tIDqLvdLRU-RDFaGl32d5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_mDszNS3HWE2vdHDJSeC0mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0k8XC5hhM0GGrBlYX_tVYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_FLXGWQjtYkORU4sQnEG_vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_bdWwrZZvA0WUmM4wVRe4tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_dqF-u1exn0eMTofXVXH82g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_uQJXomIUj0Gu7qpcedCwyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Bp0iF72XDUmK5_A2DxhSyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_-p2i8myCR0Cc2q5-v8T5eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_k3R6O4_a8E2Uzc-CrSZ8Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_9UQegpZ6pk6Io8imyOcdnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_0HQ2F4usPUGiRtw00ne_tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_mS1sKPw6CE2n0SBLlBsMLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_hxzif6f6wkKNy-S4FYzklQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hJHO8BzhGkm3pdbOfFsQrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qy9rE8Y_SEaSHkgLxZXqAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y18GrbyNrEilibNOBjl-og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pFFI1aKmY0-JrE7vjxLafg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W069niAtjE6EsmPfY337qA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_2vBGTX6yJEWsXPa205KCrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rUQ9aQoP0UevSR54GD1sWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wKH3zH90P0eBo19y-1AFvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_u8nxMvP_akullwQz4lc9rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_q87bEsiOOE6OxrrZkp0I_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_5aGHU9JvxUq_BpGHRTnqYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_gxn9ucloMEePqYe0bPpnKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_SwAbSDClgkW7N51ti2Pz6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvwASmfkaEWRGoQyRqS1Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_Qy0R61UYDEOWWQR8GJxwCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_LRJ7NhbvUk6MDLLl-Q0iCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_6_2023_36F4JsyQ5kOhUztw-GFovQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ"><xbrli:measure>xoma:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw"><xbrli:measure>xoma:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg"><xbrli:measure>xoma:facility</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ"><xbrli:measure>xoma:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ"><xbrli:measure>xoma:M</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ"><xbrli:measure>xoma:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A"><xbrli:measure>xoma:segment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA"><xbrli:measure>xoma:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ"><xbrli:measure>xoma:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_fwE8yWfrn0K-IqzRprsY2A"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw"><xbrli:measure>xoma:period</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b134ff75_f5ea_4c70_8d2b_8ab00557c831"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentType" id="Narr_QPYx4oMeRUGjZhjWrANIgQ"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentAnnualReport" id="Narr_HqveaDo_5kK6djqEmTNOng"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 or 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentPeriodEndDate" id="Narr_zxUuUxK-20m7HKiQR0vNDA"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:CurrentFiscalYearEndDate" id="Narr_3yYKpsNsfEmRTEPfwg85YA"><b style="font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-weight:bold;">, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:DocumentTransitionReport" id="Narr_0D_QAApif0-GgB_dVkT32A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;<b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES&#160;EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><b style="font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Commission File Number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityFileNumber" id="Narr_5uAKtK-DiUWVQglCDgI-Rg"><b style="font-weight:bold;">001-39801</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityRegistrantName" id="Narr_GtQ-dfwTskSgwb7Xrit8og"><b style="font-weight:bold;">XOMA CORPORATION</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5fd3dc42_cb01_45f8_86b7_5452446139c4"></a><a id="Tc_IncfamHUpkeSjJCmgl8Iog_1_0"></a><a id="Tc_2629Ww5awkCkfS6XRblBqA_1_1"></a><a id="Tc_CRqV-xb-YECZxT1GJYJ7zg_3_0"></a><a id="Tc_FqSndI7i7kiP5lNgzgNuwA_4_0"></a><a id="Tc_-3vVBi5HgUaKIT0_NCMZsA_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityIncorporationStateCountryCode" id="Tc_wfWDuUcNMkSq1MRPp8SwwA_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityTaxIdentificationNumber" id="Tc_etHbzS3IrEGEuOEQZ3hGQQ_0_1"><b style="font-size:9pt;font-weight:bold;">52-2154066</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b> <b style="font-weight:bold;">of incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityAddressAddressLine1" id="Narr_RZC-13jJnk-g351jPc3Bdg"><b style="font-size:9pt;font-weight:bold;">2200 Powell Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityAddressAddressLine2" id="Narr_dnkMCWYtD0eK1qXtNW_hrQ"><b style="font-size:9pt;font-weight:bold;">Suite 310</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">,</b><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityAddressCityOrTown" id="Narr__cw9yhJHeUuKTG5_nwuIPA"><b style="font-size:9pt;font-weight:bold;">Emeryville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityAddressStateOrProvince" id="Narr_HZuTYw4xGEmA5X2OQaasZw"><b style="font-size:9pt;font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityAddressPostalZipCode" id="Tc_0WShIeDZNEet7nFdbG4eKw_3_1"><b style="font-size:9pt;font-weight:bold;">94608</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:CityAreaCode" id="Narr_aLUSO-MZoUmvxlgMVqNrYQ"><b style="font-size:9pt;font-weight:bold;">510</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:LocalPhoneNumber" id="Narr_O_Dy1W3hK0CooRFdb2RSOA"><b style="font-size:9pt;font-weight:bold;">204-7200</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act: </p><a id="_c788aa25_9f64_47a4_8bef_62a9f20bc0f8"></a><a id="Tc_Rxqi3cGIRU61tft6lufUYA_1_0"></a><a id="Tc_lwmiPPY52kGh7S4BpwPg1g_1_2"></a><a id="Tc_cCUYkwmTlkC-9wNzbgmciA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;each&#160;class</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:15%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading&#160;Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:32%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g" name="dei:Security12bTitle" id="Tc_x5IxcGwnq0C1YZivujVcRQ_2_0"><span style="font-size:9pt;">Common Stock, $0.0075 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g" name="dei:TradingSymbol" id="Tc_GGxD6m40kU-eKVnsksQ6Aw_2_2"><span style="font-size:9pt;">XOMA</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g" name="dei:SecurityExchangeName" id="Tc_mdM9_b-fXEqFsAIo91a0VA_2_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w" name="dei:Security12bTitle" id="Tc_Owrf5TdptUem8n0qc5hEJQ_3_0"><span style="font-size:9pt;">8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w" name="dei:TradingSymbol" id="Tc_NO1kxgxzFEq8dWFFD39KzA_3_2"><span style="font-size:9pt;">XOMAP</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w" name="dei:SecurityExchangeName" id="Tc_OiSRnyxPMUqaKld5nq2I2w_3_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg" name="dei:Security12bTitle" id="Tc_dIV6Gb-KIUSWiKgv6Dqp4g_4_0"><span style="font-size:9pt;">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg" name="dei:TradingSymbol" id="Tc_DEnkXhoj-EyDpsK4vTCHTQ_4_2"><span style="font-size:9pt;">XOMAO</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg" name="dei:SecurityExchangeName" id="Tc_UYGvToHsc0OIDZK8_e0fng_4_4"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_wmlnCmGi9UaTuKy0fPEZIA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;YES&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;</span><span style="-sec-ix-hidden:Hidden_etWwIGkuCUidf1uC_QoY1A;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">NO</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><span style="-sec-ix-hidden:Hidden_m7mbWAfU6ka4R4vo0FBMHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;</span><span style="-sec-ix-hidden:Hidden_MWtPRgmjjkCHN97YCziAHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">YES</span></span><span style="font-size:9pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_abed4513_41e2_4106_8eca_7f7505653c9d"></a><a id="Tc_h9iFmJg42kGIBJhhVQkkOg_0_0"></a><a id="Tc_UtO4Lx1a4UW8y3Cki8ht2w_0_1"></a><a id="Tc_EpcwzsP_o0-XH1oahEOlzg_0_3"></a><a id="Tc_Augs07Fack2ctbL0-NXDSg_0_4"></a><a id="Tc_0k1OTQLAQE-HsieRLsQvWg_1_1"></a><a id="Tc_y-O49jLiaU-KttqGhdCkuA_1_3"></a><a id="Tc_ynYsgTps8UamxQklwIJOYw_2_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityFilerCategory" id="Tc_8Pc65GegxE6gUfgMEP7WNw_1_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntitySmallBusiness" id="Tc_MyUb99FepUWLKHBHjkATDg_1_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:22.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityEmergingGrowthCompany" id="Tc_r4ywu6o4PU-NW4wMxen_rQ_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:9pt;"> </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:IcfrAuditorAttestationFlag" id="Narr_ddAE1Atkc0KQsH6_Ruh2OA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;YES&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:EntityShellCompany" id="Narr_saXNnWhOaEG8p4ABtW2CKA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;NO&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on the Nasdaq Global Market on June&#160;30, 2022, was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_6_30_2022_LRJ7NhbvUk6MDLLl-Q0iCQ" decimals="0" name="dei:EntityPublicFloat" id="Narr_KhRimUO1_E2r4ymfoKtKBA">154,564,269</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">Number of shares of Registrant&#8217;s Common Stock outstanding as of March&#160;6, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_6_2023_36F4JsyQ5kOhUztw-GFovQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_0vj9ikabxUaUMu5JzHJgRg">11,460,968</ix:nonFraction>.<span style="background:#00ff00;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 3pt 0pt;">Portions of the Registrant&#8217;s Definitive Proxy Statement relating to the Company&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:18pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_384c3ce6_e6fe_407e_933e_d3c946ab8057"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">2022 FORM&#160;10-K ANNUAL REPORT</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Glossary"><span style="font-style:normal;font-weight:normal;">Glossary of Terms and Abbreviations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_220029"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1Business_495058"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1Business_495058"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item 1A</span></a>.</p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1BUnresolvedStaffComments_868310"><span style="font-style:normal;font-weight:normal;">Item 1B.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item1BUnresolvedStaffComments_868310"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item2Properties_752211"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item2Properties_752211"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item3LegalProceedings_945310"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item3LegalProceedings_945310"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_972169"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_972169"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_531471"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item6SelectedConsolidatedFinancialData_8"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item6SelectedConsolidatedFinancialData_8"><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9AControlsandProcedures_282993"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item9AControlsandProcedures_282993"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_968719"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_968719"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9C"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_322550"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersCorporat"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersCorporat"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item11ExecutiveCompensation_327220"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item11ExecutiveCompensation_327220"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_208578"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:top;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10KSummary_564652"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:75.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><a href="#Item16Form10KSummary_564652"><span style="font-style:normal;font-weight:normal;">Form 10</span><span style="font-style:normal;font-weight:normal;">&#8209;</span><span style="font-style:normal;font-weight:normal;">K Summary</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">68</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_975745"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">69</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ffb5bb77_0267_4ae8_8854_24d0634046fe"></a><a id="Glossary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">GLOSSARY OF TERMS AND ABBREVIATIONS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:70.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Abbreviations</b></p></td><td style="vertical-align:bottom;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2010 Plan</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s 2010 Long Term Incentive and Stock Award Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2018 Common Stock ATM Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with HCW dated December 18, 2018</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">&#8216;40 Act</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Investment Company Act of 1940</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ACA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affimed</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affimed N.V.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech Research AS</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech CPPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Commercial Payment Purchase Agreement with Affitech dated October 6, 2021</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s Royalty Purchase Agreement with Agenus dated September 20, 2018</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anti-TGF&#946; Antibody License Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s License Agreement with Novartis dated September 30, 2015</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 2022 Letter Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Letter Agreement to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns dated April 1, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aronora</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aronora, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Aronora RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Aronora dated April 7, 2019</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">AstraZeneca</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">AstraZeneca plc</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Accounting Standards Codification</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 310</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 310, Receivables</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 450</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 450, Contingencies</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 606</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 606, Revenue from Contracts with Customers</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 730</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 730, Research and Development</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 805</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 805, Business Combinations</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 815</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 815, Derivatives and Hedging</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASU</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Accounting Standards Update</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bayer</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bayer Pharma AG</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis Technologies, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Bioasis dated February 25, 2019</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BLA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biologic License Application</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Black-Scholes Model</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Black-Scholes Option Pricing Model</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">B. Riley</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">B. Riley Securities, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BVF</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biotechnology Value Fund, L.P.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CCPA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">California Consumer Privacy Act of 2018, collectively the Act and its regulations</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CARES</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Coronavirus Aid, Relief, and Economic Security</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cGMP</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">current Good Manufacturing Processes</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi Farmaceutici S.p.A.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron Corporation</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron Collaboration Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Chiron dated February 27, 2004, as amended in May 2005, July 2008 and September 2015</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Company</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, including subsidiaries</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">CPPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Commercial Payment Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">CPRA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">California Privacy Rights Act</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EC</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Commission</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EMA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Medicines Agency</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ESPP</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2015 Employee Stock Purchase Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EU</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Union</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">FCPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">U.S. Foreign Corrupt Practices Act of 1977, as amended</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Food and Drug Administration</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generally accepted accounting principles</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">G&amp;A</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GDPR</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Data Protection Regulation</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gevokizumab License Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s License Agreement with Novartis dated August 24, 2017</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HCRP</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Healthcare Royalty Partners II, L.P.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HCW</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">H.C. Wainwright &amp; Co., LLC</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HIPAA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Federal Health Insurance Portability and Accountability Act of 1996</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ICE&#174;<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Innate cell engager</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IP</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Intellectual Property</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Janssen</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Janssen Biotech, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros RPA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Kuros dated July 14, 2021</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck Sharp &amp; Dohme Corp</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck KGaA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ares Trading SA </p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck KGaA License Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva Agreement)</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NDA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">New Drug Application</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NIH</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">National Institutes of Health </p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NOL</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">net operating loss</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Novartis</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">November 2022 Letter Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">November 1, 2022 amendment to the April 2022 Letter Agreement</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva SA</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva IP Acquisition Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s IP Acquisition Agreement with ObsEva dated November 21, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ology Bioservices </p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon International GmbH </p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon License Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement)</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palo</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palobiofarma, S.L.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palo RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Palo dated September 26, 2019</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pfizer</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pfizer, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Regeneron</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Regeneron Pharmaceuticals, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Amended Retention Plan</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">October 25, 2022 amendment to the Retention Plan </p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Retention Plan</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Retention and Severance Plan dated March 31, 2022</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute, Inc., formerly Antria Bio, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute License Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">RPA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Royalty Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Roche</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">F. Hoffmann-La Roche AG</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SEC</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Securities and Exchange Commission</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Second Bioasis RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Bioasis dated November 2, 2020</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series A and Series B Preferred Stock</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A Preferred Stock and Series B Preferred Stock, collectively </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series B Depositary Shares</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet BioTherapeutics, Inc., formerly Oncobiologics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet Collaboration Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SOX</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sarbanes-Oxley Act of 2002</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SVB</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Silicon Valley Bank</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SVB Loan Agreement</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="white-space:pre-wrap;">the loan and security agreement with SVB dated May 7, 2018, as amended  (terminated upon repayment in June 2021)</span></p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SVB Loan</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="white-space:pre-wrap;">the loan with SVB pursuant to the SVB Loan Agreement (extinguished upon repayment in June 2021)  </span></p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda Pharmaceutical Company Limited</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda Collaboration Agreement</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">TGF&#946;</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">transforming growth factor beta </p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">VABYSMO</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">faricimab-svoa</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:29.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta RPA</p></td><td style="vertical-align:top;width:70.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Viracta dated March 22, 2021</p></td></tr><tr><td style="vertical-align:top;width:29.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA</p></td><td style="vertical-align:top;width:70.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, a Delaware corporation, including subsidiaries</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_220029"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, which are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, the assumptions underlying our business model; the extent to which issued and pending patents may protect the products and processes in which we have an ownership or royalty interest and prevent the use of the covered subject matter by third parties, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the amount and timing of receipt of those payments, and the impact of the evolving COVID-19 pandemic. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s); we may be unable to retain our key employees; litigation, arbitration or other disputes with third parties may have a material adverse effect on us; our product candidates subject to our out-license agreements are still being developed, and our licensees&#8217; may require substantial funds to continue development which may not be available;</i> <i style="font-style:italic;">we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties. These and other risks, including those related to current economic and financial market conditions, are contained principally in Item&#160;1, Business; Item&#160;1A, Risk Factors; Item&#160;7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations; and other sections of this Annual Report on Form&#160;10-K. Factors that could cause or contribute to these differences include those discussed in Item&#160;1A, Risk Factors, as well as those discussed elsewhere in this Annual Report on Form&#160;10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. We do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Annual Report on Form&#160;10-K to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references to &#8220;portfolio&#8221; in this Annual Report on Form 10-K are to milestone and/or royalty rights associated with a basket of drug products in development.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">We use our trademarks, trade names and services marks in this report as well as trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.</i></p><a id="_Hlk88478613"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risk Factors Summary </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K as part of your evaluation of the risks associated with an investment in our securities. </p><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s) or licensee(s), and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, errors, may be undetectable and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies to resolve any disputes resulting from any such audit.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The ongoing COVID-19 pandemic, macroeconomic conditions, such as rising inflation rates, uncertain credit and global financial markets and supply chain disruptions, and geopolitical events, have adversely impacted and could materially and adversely impact the future our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we were to become an &#8220;investment company&#8221; and be subject to the restrictions of the 1940 Act, those restrictions would likely require significant changes in the way we do business and add significant administrative burdens to our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require us to raise additional funds to acquire</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our anticipated rates of returns. Reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect on our financial condition and results of operations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely heavily on license and collaboration relationships, and any litigation, arbitration or other disputes with our licensees, collaborators and their partners or termination or breach of any of the related agreements could reduce the financial resources available to us. In the event of any disagreement that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product or involved in costly and time-consuming arbitration or litigation, which could materially adversely affect our financial condition, results of operation and future prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential milestone and royalty providers may </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could adversely affect our potential milestone and royalty providers&#8217; product candidate development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates. If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership, milestone or royalty interest.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a continuing obligation to pay quarterly dividends to holders of our Series A and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds.&#160;</span></td></tr></table><div style="margin-top:12pt;"><a id="Item1Business_495058"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;&#160;Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview and Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">portfolio was built through acquisitions of rights to future milestones and royalties that we have made since our royalty aggregator business model was implemented in 2017 combined with outlicensing our proprietary products and platforms from our legacy discovery and development business. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to expand our portfolio by acquiring additional potential milestone and royalty revenue streams on drug product candidates from third parties. Expanding our portfolio through these acquisitions can allow for further diversification across therapeutic areas and development stages. Our ideal target acquisitions are in pre-commercial stages of development, have an expected long duration of market exclusivity, have high revenue potential, and are partnered with a large pharmaceutical or biopharmaceutical enterprise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Portfolio Highlights </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table highlights key assets included in our portfolio of potential future milestone and royalty streams. This table does not include all assets because certain assets are subject to confidentiality agreements.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.32%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:middle;width:22.86%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:26.09%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:21.35%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td colspan="2" style="vertical-align:middle;width:28.8%;margin:0pt;padding:2.04pt 0.75pt 2.04pt 0.75pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:22.86%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMPANY</b></p></td><td colspan="2" style="vertical-align:middle;width:26.09%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ASSET NAME</b></p></td><td colspan="2" style="vertical-align:middle;width:21.35%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TARGET</b></p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:2.25pt solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1.0pt solid #ffffff;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ROYALTY RATE</b></p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Affimed</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AFM13</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD30/CD16A</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Affimed</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AFM24</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EGRF/CD16A</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Confidential</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB002 (proCase/E-WE thrombin)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Protein kinase C</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB023 (xisomab, 3G3)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XI</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Aronora</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AB054</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XII</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AstraZeneca</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AZD2936</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIGIT/PD-1</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">AVEO Oncology</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AV-299 (ficlatuzumab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HGF</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Bayer (Aronora RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BAY1213790 (osocimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factor XIa</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Regeneron</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMP-001 (vidutolimod)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TLR9</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit to double-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Chiesi (Bioasis RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lysosomal Storage Disorders Enzymes</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Enzyme replacement therapy</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Compugen</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COM902</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIGIT</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Day One</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DAY101 (tovorafenib)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pan-RAF</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denovo Biopharma</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">vosaroxin</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Topoisomerase II</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte (Agenus RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN1876</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GITR</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte (Agenus RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN1949</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">OX-40</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte (Agenus RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN02390</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TIM-3</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low to mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Incyte (Agenus RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INCAGN2385</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LAG-3</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low to mid-single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Janssen Biotech</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">JNJ-63723283 (cetrelimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PD-1</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.75%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Merck (Agenus RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MK-4830</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ILT-4</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Molecular Templates</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MT-0169</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD-38</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Novartis </b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CFZ533 (iscalimab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD-40</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit to low-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Novartis</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">VPM087 (gevokizumab)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IL-1&#223;</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit to mid-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Novartis</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NIS793</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TGF&#223;</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mid-single-digit to low teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Novartis (Palobiofarma RPA)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NIR178</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A2a receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:99.32%;"><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Ology Bioservices</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">G03-52-01</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Botulinum neurotoxins</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Organon (ObsEva IP Acquisition Agreement)</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ebopiprant</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prostaglandin F2&#945; (PGF2&#945;) receptor </p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low- to mid-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palo</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-680</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A1 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palo</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-677</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A3 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palo</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-999</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A2a receptor/ Phosphodiesterase 10 (PDE-10)</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palo</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-1129</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A2b receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Palo</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBF-1650</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adenosine A3 receptor</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rezolute</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RZ358</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSR</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">High single-digit to mid-teens</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Rezolute</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">RZ402</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plasma kallikrein</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Low single-digit</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Roche</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">faricimab (faricimab-svoa)</p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Angiopoietin-2 and VEGF-A</p></td><td colspan="3" style="vertical-align:middle;width:28.96%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">0.5%</p></td></tr><tr style="height:6.85pt;"><td colspan="2" style="vertical-align:middle;width:23.09%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Takeda</b></p></td><td colspan="2" style="vertical-align:middle;width:26.31%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TAK-079 (mezagitamab) </p></td><td colspan="2" style="vertical-align:middle;width:21.48%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CD-38</p></td><td colspan="2" style="vertical-align:middle;width:28.8%;border-bottom:1px solid #d9d9d9;border-left:1.0pt solid #ffffff;border-right:1.0pt solid #ffffff;border-top:1px solid #d9d9d9;margin:0pt;padding:2.04pt 0.25pt 2.04pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquisitions</p><a id="_Hlk92442267"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva Intellectual Property Acquisition Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we entered into the ObsEva IP Acquisition Agreement pursuant to which we acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. We also assumed ObsEva&#8217;s ongoing obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. &#160;If ebopiprant is successfully commercialized, we will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA. &#160;We paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what we will receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we entered into the Affitech CPPA, pursuant to which we purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $6.0 million. We are eligible to receive commercial payments from Roche consisting of 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Pursuant to the Affitech CPPA, we paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, in connection with Roche receiving approval from the European Commission to commercialize VABYSMO for the treatment of neovascular or &#8216;wet&#8217; age-related macular degeneration and visual impairment due to diabetic macular edema, we made a $3.0 million milestone payment to Affitech pursuant to the terms of the Affitech CPPA. As a result of the EC Approval, we are eligible to receive a 0.5% commercial payment stream for ten years from the first commercial sale of VABYSMO in Europe. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, we received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022, and in February 2023 we received $2.4 million for sales of VABYSMO during the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement</p><a id="_Hlk95249032"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, we entered into the Kuros RPA, pursuant to which we acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. We may pay additional sales-based milestones to Kuros of up to $142.5 million representing a portion of the future royalties on commercial sales.</p><a id="_Hlk107915979"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. &#160;Pursuant to the Kuros RPA, we were entitled to 50% of the milestone payment, which we received in July 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, we entered into the Viracta RPA, pursuant to which we acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. We acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2018, we entered into the Agenus RPA, pursuant to which we acquired the right to receive 33% of the future royalties due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and sales milestones on sales of six Incyte immuno-oncology assets. In addition, we acquired the right to receive 33% of the future royalties due to Agenus from Merck and 10% of all future developmental, regulatory and sales milestones on sales of MK-4830, an immuno-oncology product currently in clinical development. Pursuant to the Agenus Royalty Purchase Agreement, our share in future potential development, regulatory and commercial milestones is up to $59.5 million, and the royalties have no limit. Under the terms of the Agenus Royalty Purchase Agreement, we paid Agenus $15.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced to Phase 2 development stage. As a result of the advancement, Agenus earned a $10.0 million clinical development milestone pursuant to its license agreement with Merck, of which we received $1.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2019, we entered into the Bioasis RPA, pursuant to which we acquired future milestone, royalty and option fee payment rights from Bioasis for product candidates that are being developed pursuant to a License Agreement between Bioasis and Prothena Biosciences Limited. Under the terms of the Bioasis RPA, we paid Bioasis an upfront cash payment of $0.3 million and will be required to make contingent future cash payments of up to $0.2 million to Bioasis if and when the licensed product candidates reach certain development milestones. As of December 31, 2021, none of the development milestones had been achieved. In addition, we were granted an option to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, we entered into the Second Bioasis RPA, pursuant to which we acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. We paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2019, we entered into the Aronora RPA, pursuant to which we acquired the rights to potential royalties and a portion of upfront, milestone, and option payments associated with five anti-thrombotic hematology drug products in development: three candidates subject to Aronora&#8217;s collaboration Bayer (the &#8220;Bayer Products&#8221;) and two additional early-stage candidates (the &#8220;non-Bayer Products&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, we made a $6.0 million upfront payment to Aronora&#160;when the transaction closed on June 26, 2019, and in September 2019 we made an additional $3.0 million payment for the three Bayer Products that were active as of September 1, 2019. Pursuant to the Aronora RPA, if we receive $250.0 million in cumulative royalties on net sales per product, we will be required to pay associated tiered milestones payments to Aronora in an aggregate amount of up to $85.0 million per product. The tiered milestones will be paid based on various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product. We will retain royalties per product in excess of $250.0 million. We will receive, on average, low single-digit royalties on future sales of the Bayer Products and 10% of all future developmental, regulatory and sales milestones related to the Bayer Products. In addition, we purchased from Aronora the right to receive low single-digit percentage of net sales of the non-Bayer Products and 10% of all future payments, including upfront payments, option payments and developmental, regulatory and sales milestone payments on potential future sales of the non-Bayer Products. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, we entered into the Palo RPA, pursuant to which we acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis, nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. Under the terms of the Palo RPA, we paid Palo $10.0 million for the rights to potential royalty payments on future sales of the Palo Licensed Products. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Selected Programs Underlying Our Portfolio</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, we have licensed product candidates or provided research and development collaboration services to world-class organizations, such as Novartis and Takeda, in pursuit of new antibody products under which we are eligible to receive potential future milestone payments and royalties. The following is a summary of material license and collaboration agreements that represent a significant component of our portfolio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2015, we and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which we granted Novartis an exclusive, worldwide, royalty-bearing license to our anti-TGF&#946; antibody program (&#8220;NIS793&#8221;). Novartis is solely responsible for the development and commercialization of the antibodies and products containing the antibodies arising from this program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the Anti-TGF&#946; Antibody License Agreement, we received a $37.0 million upfront fee, and were eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones. We also are eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and have percentage rates ranging from mid-single-digits to low double-digits. Novartis&#8217; obligation to pay royalties with respect to a particular product and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country. This program is currently in clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, we earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms the Anti-TGF&#946; Antibody License Agreement, we received $17.7 million in cash and the remaining balance of $7.3 million was recognized as a reduction to our debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, Novartis announced the FDA had granted Orphan Drug Designation to NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. We are eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGF&#946; Antibody License Agreement. Upon receipt of regulatory approval to commercialize NIS793, we will receive tiered royalties on net product sales that range from the mid-single-digit to the low double-digits percentage rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2017, we and Novartis entered into the Gevokizumab License Agreement, under which we granted Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;) (a clinical-stage anti-IL-1<span style="font-family:'Symbol';">b</span> product candidate) and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing such antibody.</p><a id="_Hlk94274043"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, we received total consideration of $30.0 million in 2017 for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#8364;12.0 million) was paid by Novartis, on our behalf, to settle our loan with Les Laboratories Servier. In addition, Novartis extended the maturity date on our debt to Novartis to September&#160;30, 2022. In June 2021, we repaid its entire outstanding debt balance to Novartis. We also received $5.0 million related to the sale of 539,131 shares of our common stock, at a price per share of $9.2742. Based on the achievement of pre-specified criteria, we are eligible to receive up to $438.0 million in development, regulatory and commercial milestones. We also are eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and have percentage rates ranging from mid-single digit to mid-teens. This program is in Phase 1 clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Gevokizumab License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety with six&#160;months&#8217; prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2023, Novartis notified us that based upon a strategic review of the development program, Novartis will not initiate further studies of gevokizumab in gastrointestinal cancers. &#160;Novartis&#8217; study to evaluate treatment with gevokizumab with standard of care anti-cancer therapies in patients with metastatic colorectal, gastroesophageal, and renal cancers will continue to primary analysis, which is anticipated later this year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-CD40 Antibody </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2004, we entered into an exclusive, worldwide, multi-product collaboration agreement with Chiron to research, develop and commercialize multiple antibody products for the treatment of cancer, and such agreement was replaced with the Chiron Collaboration Agreement entered in May of 2005. The Chiron Collaboration Agreement was a risk-sharing arrangement whereby Chiron and XOMA shared expenses and revenues on a 70-30 basis, with XOMA&#8217;s share being 30%. Financial terms included a loan facility from Chiron to XOMA, secured by XOMA&#8217;s 30% ownership interest in the collaboration, of up to $50.0&#160;million to fund up to 75% of our share of expenses beginning in 2005. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2005, Chiron announced it had entered into a definitive merger agreement with Novartis under which Novartis acquired all of the shares of Chiron that it did not already own. This transaction closed in 2006 at which time Novartis acquired Chiron&#8217;s interest in the Chiron Collaboration Agreement. In July of 2008, Novartis and XOMA restructured the Chiron Collaboration Agreement, which involved six development programs including iscalimab, a fully human anti-CD40 antagonist antibody intended as a treatment for B-cell mediated diseases, including malignancies and autoimmune diseases. As part of the restructuring, Novartis, the successor to Chiron, was granted, among other things, control over the ongoing product development collaborations remaining thereunder, including iscalimab. In September 2015, the parties agreed to reduce the royalty-style payments that XOMA is eligible to receive on sales of Novartis&#8217; clinical-stage anti-CD40 antibodies (such as iscalimab). These royalty-style payments are tiered based on sales levels and now have percentage rates ranging from mid-single-digit to low teens. </p><a id="_Hlk125124069"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant. Novartis is continuing iscalimab studies in other indications such as Sj&#246;gren&#8217;s Syndrome, Lupus Nephritis and Hidradenitis Suppurativa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our right to royalty-style payments expires on the later of&#160;the expiration of any licensed patent covering each product or&#160;10&#160;years from the first commercial sale of each product in each country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November&#160;2006, we entered into the Takeda Collaboration Agreement with Takeda under which we agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Takeda Collaboration Agreement, we may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products subject to this license, including TAK-169, which entered a phase 1 study in February 2020. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, we expanded our existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. We may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. Our right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. Our right to royalties expires on the later of 10&#160;years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and we earned a $2.0 million milestone payment from Takeda. We are eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, we earned a development milestone of $0.8 million pursuant to the Takeda Collaboration Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2017, we entered into a license agreement with Rezolute pursuant to which we granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) products for all indications. We and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to us, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to us of up to $232.0&#160;million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, we are also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or&#160;twelve years&#160;from the date of the first commercial sale of the product in that country. Rezolute&#8217;s future royalty obligations in the United States will be reduced by&#160;20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, we are eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of&#160;twelve years&#160;from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on&#160;ninety days&#8217; notice at any time. To the extent permitted by applicable laws, we have the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No&#160;consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to us upon the occurrence of Rezolute&#8217;s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, we received a total of $6.0&#160;million upon Rezolute&#8217;s achievement of financing activities and $8.5&#160;million in installment payments through October 2020. We also received&#160;161,861 shares of common stock of Rezolute (on an as-adjusted post reverse-split basis). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to XOMA pursuant to our Rezolute License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and Janssen were parties to a license agreement which was terminated in 2017. In August 2019, we and Janssen entered into a new agreement pursuant to which we granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under our patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to us. Additionally, for each drug candidate, we are entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates, which are the subject of multiple clinical trials. Upon commercialization, we are eligible to receive a 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, we announced we earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In December 2021, we earned a $0.2 million milestone pursuant to our agreement with Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, we entered into a new agreement with Affimed, under which we are eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and pre-loaded natural killer cells containing the ICE<span style="font-size:12pt;"> </span>molecules. Additionally, we are eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Compugen </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, we earned a $0.5 million milestone payment under our license agreement with Compugen triggered by the dosing of the first patient in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902 and is being developed by AstraZeneca.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we earned a $0.8 million milestone payment under our license agreement with Compugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sonnet Biotherapeutics </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2012, we entered into the Sonnet Collaboration Agreement which was amended in May 2019 to develop various products using Sonnet&#8217;s ABD platform. &#8239;Under the terms of the Sonnet Collaboration Agreement, we may receive milestone payments aggregating up to $3.75 million and low single-digit royalties from Sonnet on future commercial sales of such products.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, Sonnet initiated a Phase 1 clinical trial of SON-1010 in adult patients with advanced solid tumors, and we earned a $0.5 million development milestone from Sonnet.&#8239; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are subject to continuous and substantial technological change. Some of the drugs our licensees or milestone and royalty partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our licensees&#8217; or royalty partners&#8217; competitors. There can be no assurance that developments by others, including, without limitation, the development of generics or biosimilars, will not render our licensees&#8217; or royalty partners&#8217; products or technologies obsolete or uncompetitive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, our royalty aggregator model faces competition on at least two fronts. First, there are other companies, funds and other investment vehicles seeking to aggregate royalties or provide alternative financing to development-stage biotechnology and pharmaceutical companies. These competitive companies, funds and other investment vehicles may have a lower target rate of return, a lower cost of capital or access to greater amounts of capital and thereby may be able to acquire assets that we are also targeting for acquisitions. Second, existing or potential competitors to our partners and licensees&#8217; products, particularly large pharmaceutical companies, may have greater financial, technical and human resources than our licensees. Accordingly, these competitors may be better equipped to develop, manufacture and market products. Many of these companies also have extensive experience in preclinical testing and human clinical trials, obtaining FDA and other regulatory approvals and manufacturing and marketing pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks associated with competition, see below under &#8220;Item&#160;1A. Risk Factors.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation and Environmental Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries. We and our partners and licensees, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. The Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products and there are often comparable regulations that apply at the state level. Further, various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security law, may also apply. There are similar regulations in other countries as well. For both currently marketed and products in development, failure to comply with applicable regulatory requirements can, among other things, result in delays, the suspension of regulatory approvals, as well as possible civil and criminal sanctions. Development stage products in our portfolio require approval by the FDA before we will recognize any royalties from sales. In addition, changes in existing regulations could have a material adverse effect on us or our partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the EU and other significant or potentially significant markets for our portfolio and product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services. In the United States, the volume of drug pricing-related legislation has dramatically increased in recent years. For example, Congress has enacted laws requiring manufacturers to refund the Centers for Medicare &amp; Medicaid Services, or CMS, for certain discarded amounts of drugs from single-use vials beginning in 2023 and eliminating the existing cap on Medicaid rebate amounts beginning in 2024. Also, in August 2022 Congress enacted the Inflation Reduction Act of 2022, which, among other things, requires the Department of Health and Human Services to negotiate Medicare prices for certain drugs, imposes an inflation-based rebate on Medicare Part B and D utilization, restructures the Medicare Part D benefit and increases manufacturer contributions in some or all of the Medicare Part D benefit phases. In addition, many state legislatures are considering, or have already passed into law, legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as requiring manufacturers to publicly report proprietary pricing information, creating review boards for prices to state agencies, and encouraging the use of generic drugs. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Further, many countries outside the United States, including the EU member states, have established complex and lengthy procedures to obtain price approvals and coverage reimbursement and periodically review their pricing and reimbursement decisions. If any pricing-related regulation impacts products in our portfolio, it would result in lower royalties received by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe there are no compliance issues with laws and regulations that have been enacted or adopted regulating the discharge of materials into the environment, or otherwise relating to the protection of the environment, that have adversely affected, or are reasonably expected to adversely affect, our business, financial condition and results of operations, and we currently do not anticipate material capital expenditures arising from environmental regulation. We believe climate change could present risks to our business. Some of the potential impacts of climate change to our business include increased operating costs due to additional regulatory requirements and the risk of disruptions to our business. We do not believe these risks are material to our business at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For a discussion of the risks associated with government regulations, see below under &#8220;Item&#160;1A. Risk Factors.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Intellectual property is important to our business and our future income streams will depend in part on our partners and licensees&#8217;, ability to obtain issued patents and to operate without infringing on the proprietary rights of others. We hold and have filed applications for a number of patents in the United States and internationally to protect our products and technology. We also have obtained or have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the patent position of biotechnology companies generally is highly uncertain and consistent policy regarding the breadth of allowed claims has not emerged from the actions of the U.S. Patent and Trademark Office with respect to biotechnology patents. Accordingly, no assurance can be given that our, or our partners </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">or licensees&#8217; patents will afford protection against competitors with similar products or that others will not obtain patents claiming aspects similar to those covered by our, or our partners&#8217; or licensees&#8217; patent applications. Some of our agreements, or those of our partners or licensees, contain &#8220;step-down&#8221; provisions where the royalty rate is reduced following patent expiration or revocation. Below is a list of representative patents and patent applications related to our licensed programs:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:32.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:15.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licensee</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Program</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Representative<br />Patents/Applications</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject matter</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected&#160;last expiration in family </p></th></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Novartis</p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Anti-IL-1<span style="font-family:'Symbol';">b</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 3.6pt;">US 7,531,166<br />US 7,582,742<br />EP 1 899 378</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Gevokizumab (VPM087) and other antibodies and antibody fragments with similar binding properties for IL-1&#946;</p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">2027</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 7,695,718<br />US 8,101,166<br />US 8,586,036<br />US 9,163,082</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating Type 2 diabetes or Type 2 diabetes-induced diseases or conditions with high affinity antibodies and antibody fragments that bind to IL-1&#946;</p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,637,029</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating gout with certain doses of IL-1&#946; binding antibodies or binding fragments</p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">JP 5763625</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,611,832</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pharmaceutical compositions comprising anti-IL-1&#946; binding antibodies or fragments for reducing acute coronary syndrome in a subject with a history of myocardial infarction.</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Novartis</p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anti-TGF<span style="font-family:'Symbol';">b</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,569,462<br />US 9,145,458<br />US 9,714,285</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,358,486</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 2714735</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 21186327</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">JP 6363948</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TGF&#946; antibodies and methods of use thereof</p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,167,334</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 277 716</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">JP 6901400</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Combination therapy using an inhibitor of TGF<span style="font-family:'Symbol';">b</span> and an inhibitor of PD-1 for treating or preventing recurrence of cancer</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2036</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rezolute</p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-INSR</p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 9,944,698<br />EP 2 480 254<br />JP 5849050</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insulin receptor-modulating antibodies having the functional properties of RZ358</p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,711,067</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 265 491A1</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Methods of treating or preventing post-prandial hypoglycemia after gastric bypass surgery using a negative modulator antibody to the insulin receptor</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2036</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ology Bioservices</p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-BoNT</p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,821,879<br />EP 2 473 191</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Coformulations of anti- botulinum neurotoxin antibodies</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2030</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:2pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Various</p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Phage display libraries</p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,546,307<br />EP 2 344 686</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA phage display library components</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2032</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:32.78%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:15.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Licensee</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Program</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Representative<br />Patents/Applications</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject matter</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected&#160;last expiration in family </p></th></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Seeking out license</p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Anti-IL2</p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 3.6pt;">US 10,858,428*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 518 969A2*</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">Interleukin-2 Antibodies and Uses Thereof</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:4pt 0pt 0pt 0pt;">2037</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Seeking out license</p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Anti-PTH1R</p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 10,519,250</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 490 600A1</p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Parathyroid Hormone Receptor 1 Antibodies and Uses Thereof</p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2037</p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Organon</p></td><td style="vertical-align:top;width:13.08%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">Ebopiprant</p></td><td style="vertical-align:top;width:19.33%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">US 8,451,480*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP1 487 442*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">9,447,055*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">9,834,528*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">10,259,795*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 400 217*** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">10,555,934**** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">11,524,003 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">**** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">EP 3 397 622**** </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">  <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;">11,534,428****</p></td><td style="vertical-align:top;width:32.78%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generically covers ebopiprant &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ebopiprant; prodrug valine ester; method of synthesizing ebopiprant, method of treating or preventing preterm labor by administering ebopiprant&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treating pre-term labor or delaying onset of labor with&#160;Ebopiprant or prodrug valine ester plus an additional agent such as nifedipine or atosiban&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaying onset of delivery by administering ebopiprant and about 20mg of nifedipine&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2036&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2037&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2039&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:19.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:4pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3.6pt;"><span style="font-size:4pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;Jointly owned with Medical University of South Carolina Foundation for Research Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">** Jointly owned with Novartis Vaccines and Diagnostics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">***Owned by Merck Serono S.A.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">****Owned by XOMA (US) LLC&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our partners and licensees may require certain licenses from others to develop and commercialize certain potential products incorporating our technology. There can be no assurance that such licenses, if required, will be available on acceptable terms. If such licenses are obtained, our partners and licensees may be able to deduct some or all of the costs from the royalties they owe to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We protect our proprietary information, in part, by confidentiality agreements with our employees, consultants and partners. These parties may breach these agreements, and we may not have adequate remedies for any breach. To the extent that we or our consultants or partners use intellectual property owned by others, we may have disputes with our consultants or partners or other third parties, as to the rights in related or resulting know-how and inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business model is dependent on third parties achieving specified development milestones and product sales. Our portfolio currently includes over 70 fully funded programs from which we could potentially receive royalties or other payments if the programs achieve marketability. Novartis is developing several of the programs in our portfolio. While we do not expect the discontinuation of any one program would have a material impact on our business, the discontinuation of all programs by Novartis could have a material effect on our business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in 1981 and became a Bermuda-exempted company in December&#160;1998. Effective December&#160;31, 2011, we changed our jurisdiction of incorporation from Bermuda to Delaware and changed our name from XOMA&#160;Ltd. to XOMA Corporation. When referring to a time or period before December&#160;31, 1998, or after December&#160;31, 2011, the terms &#8220;Company&#8221; and &#8220;XOMA&#8221; refer to XOMA Corporation, a Delaware corporation; when referring to a time or period between December&#160;31, 1998, and December&#160;31, 2011, such terms refer to XOMA&#160;Ltd., a Bermuda company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 2200 Powell Street, Suite&#160;310, Emeryville, California 94608. Our telephone number at our principal executive offices is (510) 204-7200. Our website address is <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.xoma.com</span>. The information found on our website is not part of this or any other report filed with or furnished to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impact of COVID-19 Pandemic</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic continues to pose risks to our business as clinical trials industry-wide have slowed. Our business is dependent on the continued development and commercialization efforts of our licensees and our royalty agreement counterparties and their licensees. We have been monitoring and continue to monitor our portfolio programs for potential delays in underlying research programs and elections of our partners to continue or cease development. Delays in clinical trials and underlying research programs may lead to delayed revenue from milestones from our licensees and royalty agreement counterparties or, if certain research programs are discontinued, we may recognize impairment charges for our royalty receivables. COVID-19 and the related variants may impact our underlying programs in a variety of ways which are unknown in length and scope at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on a small number of skilled, experienced, and innovative employees to conduct the operations of our company. As of March&#160;6, 2023, we employed 12 full-time employees and one part-time employee primarily engaged in executive, business development, legal, finance and administrative positions. We also utilize independent contractors and consultants to supplement our workforce. </p><a id="_4bbb5515_8705_4b29_ae89_bdfb02c6a975"></a><a id="_Hlk88064321"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Item&#160;<b style="font-weight:bold;white-space:pre-wrap;">1A.    Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following risk factors and other information included in this Annual Report should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us also may impair our business operations. If any of the following risks occur, our business, financial condition, operating results and cash flows could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Royalty Aggregator Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;under the applicable license agreement(s)&#160;covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are engaged in a continual review of opportunities to acquire future royalties, milestones and other payments related to drug development and sales as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. Generally, at any time, we seek to have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, probability, timing and amount of potential future royalty and milestone payments as well as the viability of the underlying technology and intellectual property. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of these acquisitions may expose us to credit risk in the event of a default by or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;that are parties to the applicable license agreement(s)&#160;covering the potential milestone and royalty streams being acquired. In addition, recent volatility in the capital markets may limit our licensees or royalty-agreement counterparties&#8217; ability to access additional funding. While we generally try to structure our receipt of potential milestone and royalty payments to minimize the risk associated with such a default or bankruptcy, there can be no assurance that any such default or bankruptcy will not adversely affect our ability to receive future potential royalty and/or milestone payments. To mitigate this risk, on occasion, we may obtain a security interest as collateral in such royalty, milestone and other payments. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the agreements covering the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our royalty aggregator strategy, we may continue to purchase future potential milestone and royalty streams associated with drug products which are in clinical development and have not yet received marketing approval by any regulatory authority or been commercialized. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. To the extent that any such drug products are not successfully developed and subsequently commercialized, the value of our acquired potential milestone and royalty streams will be negatively affected. The ultimate success of our royalty aggregator strategy will depend on our ability to properly identify and acquire high quality products and the ability of the applicable counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so would negatively affect our ability to receive royalty and/or milestone payments. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as protection of a patent estate, adequate reporting and other protections, and their failure to do so would presumably negatively impact our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalty, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer, less invasive or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could have a material adverse effect on our business, financial condition and results of operations. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to continue, and may increase, this strategy of acquiring development-stage product candidates. While we believe that we can readily evaluate and gain conviction about the likelihood of a development-stage product candidate&#8217;s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The ongoing COVID-19 pandemic may continue to, and other actual or threatened epidemics, pandemics, outbreaks, or public health crises may in the future, adversely affect our and our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global spread of COVID-19 and other actual or threatened epidemics, pandemics, outbreaks, or public health crises has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties or their licensees, which has and could further cause delays, suspensions or cancellations of their drug development efforts including, without limitation, their clinical trials, which would correspondingly delay, suspend or negate the timing of our potential receipts of milestones and royalties under our out-licensing or royalty acquisition agreements. The disruptions to our licensees or RPA counterparties or their licensees could include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in recruiting and enrolling new patients in their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as their clinical trial sites and hospital staff supporting the conduct of their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of their clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption in global shipping that may affect the transport of clinical trial supplies and materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential refusal by the FDA to accept data, including from clinical trials in affected geographies or failure to comply with updated FDA guidance and expectations related to the conduct of clinical trials during the COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from the FDA, the EMA and other U.S. and foreign federal, state and local regulatory authorities to initiate their planned clinical trials or to market their products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The extent to which the COVID-19 pandemic continues to impact our business and prospects and the overall economies of the United States and other countries will depend on numerous evolving factors, which are highly uncertain and cannot be predicted with confidence, such as the duration and scope of the pandemic and mutations in the COVID-19 virus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The evolving effects of the COVID-19 pandemic and restrictive government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as significant reductions in business related activities have occurred, supply chains have been disrupted, and manufacturing and clinical development activities have been curtailed or suspended. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, quarantines, stay-at-home, executive and similar government orders, shutdowns or other restrictions on the conduct of business operations continue to impact personnel at third-party clinical testing sites, manufacturing </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">facilities, and the availability or cost of materials, which could disrupt our licensees&#8217; and RPA counterparties and their licensees&#8217; supply chains.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spread of COVID-19, which has already resulted in a significant disruption of global financial markets, may materially affect us economically. While the evolving economic impacts brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has already significantly disrupted global financial markets, and may limit our ability to access capital, which could in the future negatively affect our liquidity. A recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While several of our partners have experienced delays due to the COVID-19 pandemic, we do not yet know the full extent of potential delays or impacts on our business, clinical trials, healthcare systems or the global economy as a whole. However, the effects could continue to have an impact on our operations and could have a material adverse effect on our business, financial condition, results of operations and prospects in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to sales risks. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, loss of patent protection, government regulations, the impact of &#160;COVID-19 or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our future potential milestones and/or royalties may be reduced or cease. In addition, these potential payments may be delayed, causing our near-term financial performance to be weaker than expected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to substantial competition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a potential milestone or royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a potential milestone or royalty, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our potential milestones and royalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Competitive factors affecting the market position and success of each product include:</span>&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety and side effect profile; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price, including third-party insurance reimbursement policies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing and introduction of the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of marketing strategy and execution; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governmental regulation; </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of lower-cost generics and/or biosimilars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment innovations that eliminate or minimize the need for a product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical products that have the potential to generate future milestones and royalties for us may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. These developments could have a material adverse effect on the sales of the biopharmaceutical products that have potential to generate our milestones and royalties, and consequently could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from any such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalty, milestone and other payments we may receive are dependent on our licensees and royalty agreement counterparties and their licensees&#8217; achievement of regulatory and developmental milestones and product sales. Each licensee&#8217;s calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee and/or a licensee may fail to report the achievement of royalties or milestones in whole or in part. Our license and royalty agreements typically provide us the primary or back-up right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many&#160;months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on our part. Further, our licensees and royalty-agreement counterparties may be uncooperative or have insufficient records, which may complicate and delay the audit process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we intend to regularly exercise our royalty audit rights as necessary and to the extent available, we rely in the first instance on our licensees and royalty-agreement counterparties to accurately report the achievement of milestones and royalty sales and calculate and pay applicable milestones and royalties and, upon exercise of such royalty and other audit rights, we rely on licensees&#8217; and royalty-agreement counterparties&#8217; cooperation in performing such audits. In the absence of such cooperation, we may be forced to incur expenses to exercise legal remedies, if available, to enforce our agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally acquire milestone and royalty rights that have limited secondary resale markets and may be subject to transfer restrictions. The illiquidity of most of our milestone and royalty receivable assets may make it difficult for us to dispose of them at a favorable price if at all and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a forced liquidation or otherwise. In addition, if we liquidate all or a portion of our potential future milestone and/or purchased royalty stream interests quickly or relating to a forced liquidation, we may realize significantly less than the value at which we had previously recorded these interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The rules&#160;and interpretations of the SEC and the courts, relating to the definition of &quot;investment company&quot; are very complex. While we currently intend to conduct our operations so that we will not be an investment company under </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">applicable SEC interpretations, we can provide no assurance that the SEC would not take the position that the Company would be required to register under the &#8216;40 Act and comply with the &#8216;40 Act&#8217;s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. We monitor our assets and income for compliance under the &#8216;40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of &#8220;investment company&#8221; or that we qualify under one of the exemptions or exclusions provided by the &#8216;40 Act and corresponding SEC regulations. If we were to become an &#8220;investment company&#8221; and be subject to the restrictions of the &#8216;40 Act, those restrictions likely would require significant changes in the way we do business and add significant administrative costs and burdens to our operations. To ensure we do not fall within the &#8216;40 Act, we may need to take various actions which we might otherwise not pursue. These actions may include restructuring the Company and/or modifying our mixture of assets and income or a liquidation of certain of our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our licensees or royalty-agreement counterparties or their licensees could be subject to natural disasters, public health crises, political crises and other catastrophic events that could hinder or disrupt development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties and their licensees to successfully develop and commercialize product candidates for which we may receive milestone, royalty and other payments in the future. Our licensees and royalty-agreement counterparties and their licensees operate research and development efforts in various locations in the United States and internationally. If any of their facilities is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability, labor disputes or strikes, other conflict, or other events outside of their control, their research and development efforts could be disrupted, which could result in the delay or discontinuation of development of one or more of the product candidates in which we have rights to future milestone and/or royalty payments which could have a material adverse effect on our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Financial Results and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have sustained losses in the past, and we expect to sustain losses in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception. Although we generated net income of $15.8 million and positive cash flows from operations of $22.7 million for the year ended December 31, 2021, we generated net loss of $17.1 million and negative cash flows from operations of $12.9 million for the year ended December 31, 2022 and we had an accumulated deficit of $1.2 billion as of December 31, 2022. We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of equity securities and debt and royalty interests, and payments received under our collaboration and licensing arrangements. The size of our future net losses will depend, in part, on the rate of our future expenditures and our and our partners&#8217; ability to generate revenues. If our partners&#8217; product candidates are not successfully developed or commercialized, or if revenues are insufficient following regulatory approval, we will not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our and our partners&#8217; ability to license product candidates, and the success of our partners&#8217; development programs, both of which are uncertain. Our success is also dependent on our partners obtaining regulatory approval to market product candidates which may not materialize or prove to be successful. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and global economic conditions may have adverse consequences on our business, financial condition and stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The global credit and financial markets have experienced volatility, including as a result of the COVID-19 pandemic, changes in interest rates, and economic inflation, which has included diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and changes in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could heighten market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our royalty aggregator strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. Failure to secure any necessary financing in a timely manner could have a material adverse effect on our growth strategy, financial performance and stock price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require us to raise additional funds to acquire<span style="font-style:normal;font-weight:normal;"> </span>milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may need to commit substantial funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult and more costly. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders, including pursuant to our 2018 Common Stock ATM Agreement, as amended and to our 2021 Series B Preferred Stock ATM Agreement. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If adequate funds are not available on a timely basis, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce or eliminate royalty aggregation efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further reduce our capital or operating expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">curtail our spending on protecting our intellectual property; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take other actions which may adversely affect our financial condition or results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the potential royalty acquisition market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire potential milestones and royalties, fewer potential milestones and royalties (or potential milestones or royalties of significant scale) being available, or increased competition for potential royalties. Even if we continue to acquire potential royalties and they become actual royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to acquire potential milestones and royalties as we have in the past, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a continuing obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds.</span><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Dividends on the Series A Preferred Stock will </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">accumulate and be cumulative from, and including, the date of original issue by us of the Series A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of shares of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared), before any distribution or payment may be made to holders of shares of common stock or any other class or series of our equity stock ranking, as to liquidation rights, junior to the Series A Preferred Stock. The shares of Series A Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26.00 per share to $25.00 per share, plus any accrued and unpaid dividends, depending on the date of redemption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). Dividends on the Series B Preferred Stock will accumulate and be cumulative from, and including, the date of original issue by us of the Series B Preferred Stock. Dividends are payable in arrears on or about the 15th day of January, April, July and October. The shares of Series B Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26,000.00 per share ($26.00 per depositary share) to $25,000.00 per share ($25.00 per depositary share), plus any accrued and unpaid dividends, depending on the date of redemption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment of cash dividends and share repurchases is subject to limitations under applicable laws and the discretion of our Board of Directors and is determined after considering current conditions, including earnings, other operating results and capital requirements. Decreases in asset values or increases in liabilities can reduce net earnings and stockholders&#8217; equity. A deficit in stockholders&#8217; equity could limit our ability to pay dividends and make share repurchases under Delaware law. On the other hand, our continued obligation to pay dividends to the holders of our Series A Preferred Stock and depositary shares representing interests in Series B Preferred Stock could restrict us from additional borrowings or make them more costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The holders of preferred stock have rights that are senior to those of our common stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had issued and outstanding 984,000 shares of Series A Preferred Stock with a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Additionally, as of December 31, 2022, we had issued and outstanding 1,600,000 depositary shares, each representing a 1/1000th fractional interest in a share of our Series B Preferred Stock with a liquidation preference of $25,000 per share of Series B Preferred Stock ($25.00 per depositary share), plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Our preferred stock is senior to our shares of common stock in right of payment of dividends and other distributions. In the event of our bankruptcy, dissolution or liquidation, the holders of our preferred stock must be satisfied before any distributions can be made to our common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may have limited information concerning the products generating the future potential milestones and royalties we are evaluating for acquisition. Often following our acquisition, the information we have regarding products underlying a potential milestone or royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by sponsors of the products of others or the nature or number of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual potential cash flow from a potential royalty may be significantly lower than our estimates. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business model is based on multiple-year internal and external forecasts regarding potential product sales and numerous product-specific assumptions in connection with each potential milestone and royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding potential product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us potential royalties may also prove to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate our projected returns or in the time periods we expect. This could negatively impact our results of operation for a given period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reductions or declines in income from potential milestones and royalties, or significant reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount and duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as payments to third party licensors, whether the product is sold singly or in combination, patent expiration dates, regulatory exclusivity, years from first commercial sale of the applicable drug product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, claims of patent misuse, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing of the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. If an unexpected reduction in a royalty amount or shortening of a potential royalty term were to occur, it could result in a reduction in potential income from milestones and royalties, a significant reduction in potential milestones and royalty payments compared to expectations, or a permanent impairment of such potential milestones and royalty payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our asset portfolio may not be fully diversified by product, therapeutic area, geographic region or other criteria. Any significant deterioration in the amount or likelihood of receipt of potential cash flows from the top products in our asset portfolio could have a material adverse effect on our business, financial condition and results of operation. For example, in September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant. In addition, should the payor of any future potential milestones or royalties decline to pay such potential milestones and royalties for any reason, such failure may result in a material adverse effect on our financial condition and results of operation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Milestone and Royalty Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire and/or in-license potential milestone and royalty streams or companies. Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, indemnification and risk allocation, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers&#8217; product candidates cannot be manufactured and marketed in the United States or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our partners&#8217; product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical development and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">record keeping;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion and marketing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">importing and exporting.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials. This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a NDA for a drug, and in the form of a BLA for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several&#160;years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our potential royalty providers ultimately may not be able to obtain approval in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or cause them to repeat or perform additional preclinical, clinical or manufacturing-related studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees&#8217; submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our potential royalty providers&#8217; interpretation or understanding of the FDA&#8217;s or other regulatory agencies&#8217; requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development has inherent risk, and our potential milestone and royalty providers are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible our potential royalty providers may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our potential milestone and royalty providers&#8217; product candidates require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of&#160;years. As clinical results frequently are susceptible to varying </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; future filings will be delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; preclinical studies will be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be successful in generating viable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be able to provide necessary data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of future clinical trials by our potential milestone and royalty providers will justify further development; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers ultimately will achieve regulatory approval for product candidates in which we have an interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing of the commencement, continuation and completion of clinical trials by our potential milestone and royalty providers may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, inability to engage contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we and our royalty agreement counterparties license our product candidates to others to fund and conduct clinical trials, we, and they, have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our potential milestone and royalty providers may conduct clinical trials in foreign countries, which may subject them to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose our potential milestone and royalty providers to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">New products and technologies of other companies may render some or all of our potential milestone and royalty providers&#8217; product candidates noncompetitive or obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">New developments by others may render our potential milestone and royalty providers&#8217; product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing continuously and substantially. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. Many of these competitors may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be able to develop products and processes competitive with or superior to our potential milestone and royalty providers for many reasons, including that they may have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly greater financial resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">larger research and development staffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extensive experience in preclinical testing and human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors may enable others to develop products and processes competitive with or superior to our own or those of our potential milestone and royalty providers. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our potential milestone and royalty providers may not be able to track development of competitive products, particularly at the early stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our licensed product will fail, our potential milestone and royalty providers may halt development of product candidates in which we have an interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of our products, which would prevent our potential royalty providers&#8217; products from becoming profitable and negatively affect the royalties we may receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our potential royalty providers succeed in bringing our product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow our potential royalty providers to sell the products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Significant uncertainty exists as to the coverage and reimbursement status of any products for which our potential royalty providers may obtain regulatory approval. Even if coverage is available, the associated reimbursement rate may not be adequate for our potential royalty providers to cover related marketing costs. Additionally, coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. Therefore, the process of obtaining coverage and reimbursement is often time-consuming and costly. Thus, even if our partners&#8217; product candidates are approved by the FDA, our royalty partners may not be able to price the products effectively or obtain coverage and adequate reimbursement for their products, which could adversely affect the royalties we receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our or our potential milestone and royalty providers&#8217; businesses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, our potential royalty providers may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over a product in which we have an ownership or royalty interest). Consequently, we do not know if physicians or patients will adopt or use products in which we have an ownership or royalty interest for their approved indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market which may lead to litigation, increased costs and delays or removal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are exposed to an increased risk of product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability. In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage. A significant product liability claim for which we were not adequately covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse effect on our business, financial condition and the value of our common stock. To the extent we have sufficient insurance coverage, such a claim would presumably result in higher subsequent insurance rates. In addition, product liability claims can have various other ramifications, regardless of merit or eventual outcome, including loss of future sales opportunities, discontinuation of clinical trials, increased costs associated with replacing products, a negative impact on our goodwill and reputation, costs to defend litigation, and divert our management&#8217;s attention from our business, each of which could also adversely affect our business and operating results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our potential royalty providers rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates. However, these means may afford only limited protection and may not:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from duplicating our products and those of our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from gaining access to our proprietary information and technology and that of our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit us or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to gain or maintain a competitive advantage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Because of the length of time and the expense associated with bringing new products to the marketplace, we and our potential royalty providers hold and are in the process of applying for a number of patents in the United States and abroad to protect product candidates and important processes and also have obtained or have the right to obtain exclusive </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Federal Courts, the U.S. Patent&#160;&amp; Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us <span style="letter-spacing:-0.1pt;">or our licensees </span>may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our, and our potential royalty providers intellectual property rights are not protected adequately, our potential royalty providers may not be able to commercialize technologies or products in which we have an ownership or royalty interest, and their competitors could commercialize such technologies or products, which could result in a decrease in our potential royalty providers&#8217; sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate or available in the future. Accordingly, there is uncertainty as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether any pending or future patent applications held by us or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether competitors will be able to design around our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217; patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our or our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8217;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, reduce the royalty rate due to us, and prevent our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential royalty providers</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from using our technology or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our potential royalty providers may require licenses from others to develop and commercialize certain potential products in which we have an ownership or royalty interest. These licenses, if required, may not be available on acceptable terms, or may trigger contractual royalty offset clauses in our license agreements, or those of our royalty-agreement counterparties. We may become involved in litigation to determine the proprietary rights of others, and any such litigation will presumably be costly, time consuming, may not be adequately covered by insurance and may have other adverse effects on our business, such as inhibiting our potential royalty providers&#8217; ability to compete in the marketplace and absorbing significant management time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our licensees&#8217; ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that our, or our partners or licensees&#8217; patents will be extended upon expiration, which may have an effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We hold and have filed applications for a number of patents in the United States and internationally to protect our products and technology and have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the life of a patent, and thus the protection it affords, is limited. Significant patents in our portfolio will expire in the coming years and while various extensions may be available, on a&#160;jurisdiction-by-jurisdiction&#160;basis, continuous patent protection is not guaranteed. While we expect to seek, and expect our partners to seek, extensions of patent terms for issued patents where available and when necessary, failure to secure patent extensions may have an effect on our financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we are required to engage in litigation, arbitration or other proceedings to protect our intellectual property and/or enforce our contractual rights against former or current licensees or third parties, including third-party collaborators of such licensees. The cost to us of complex proceedings of this type, even if resolved in our favor, can be substantial, and the parties opposing us in such proceedings may be able to sustain the cost of such proceedings more effectively than we can if they have substantially greater resources than we have. Any such proceedings and any negotiations leading up to them also may be time-consuming and can divert management&#8217;s attention and resources. If a proceeding of this type is resolved against us, we may lose the value associated with contract rights contained in our arrangements with licensees and third parties, the patents that are the subject of such proceeding may be declared invalid, we could be exposed to counterclaims against us, and we could be held liable for significant damages, fees and/or costs. While it is our current plan to continue to review and pursue, on a selective basis, potential material contractual breaches against licensees and third parties (including third-party collaborators of licensees) and/or infringement of our intellectual property rights or technology, there can be no assurance that any such enforcement actions will be successful, or if successful, the timing of such success or that we will have sufficient capital to prosecute any such actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, we initiated an arbitration proceeding against one of our licensees (the &#8220;Licensee&#8221;) with the American Arbitration Association/International Centre for Dispute Resolution. &#160;We believe that the Licensee violated the terms of our License Agreement (the &#8220;License Agreement&#8221;) and that we are entitled to milestone and royalty payments under the License Agreement, and that the Licensee impermissibly attempted to sublicense our licensed patent rights. &#160;We also seek damages and fees and costs of the arbitration (which fees and costs are currently estimated to be in the mid-single-digit millions of U.S. dollars range). &#160;In response, the Licensee seeks declarations that the License Agreement, under our interpretation, is unlawful, void and unenforceable, and that the License Agreement has expired. &#160;To date, the Licensee has not filed any counterclaims against us. However, to the extent the Licensee is deemed to be the prevailing party, the arbitrators, in their discretion, may require us to pay the Licensee&#8217;s fees and costs of the arbitration (currently estimated to be in the mid-single-digit millions of U.S. dollars range). A hearing before a panel of arbitrators was held on this matter in November 2022, and the parties have submitted post-hearing briefs. A decision is expected in the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be subject to claims that we, or our licensees, are infringing other parties&#8217; patents. If such claims are resolved against us, we or our licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party. Such a license may not be available on reasonable terms or at all, thus preventing us, or our licensees, from using these products, processes or services and adversely affecting our potential future revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Uncertainties resulting from our participation in litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our or our partners&#8217; ability to compete in the marketplace. There could also be public announcements of the results of hearings, motions or interim proceedings or developments. If securities analysts or investors perceive these results to be negative, the perceived value of the drug product candidates as to which we hold potential milestone or royalty interests, or intellectual property or contractual rights could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation and continuation of litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our business, financial condition and results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our partners rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License or collaboration agreements relating to the products generating our future potential milestones and royalties and other payment rights may be terminated, which may adversely affect sales of such products and therefore the potential payments we may receive. For example, under certain license or collaboration agreements, marketers may retain the right to unilaterally terminate the agreements. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate the applicable license or collaboration agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor (which may be us in the case of our out-licensed products) or collaborator may no longer receive all of the payments it expected to receive from the applicable licensee or collaborator and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license or collaboration agreement that has been terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, license or collaboration agreements may fail to provide significant protection for the applicable licensor (which may be us in the case of our out-licensed products) or collaborator in case of the applicable licensee&#8217;s or collaborator&#8217;s failure to perform or in the event of disputes. License and collaboration agreements which relate to the products underlying our potential future milestones, royalties and other payment rights, are complex and certain provisions in such agreements may be susceptible to multiple interpretations. Disputes may arise regarding intellectual property, royalty terms, payment rights or other contractual terms subject to a license or collaboration agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope or duration of rights granted under the license or collaboration agreement and other interpretative issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts or timing of royalties, milestones or other payments due under the license or collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent or other rights under our license or collaboration relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diligence obligations under the license or collaboration </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement and what activities satisfy such diligence obligations:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us or our partners; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The resolution of any contract interpretation disagreement that may arise could narrow what the licensor (which may be us in the case of our out-licensed products) or collaborator believes to be the scope of its rights to the relevant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">intellectual property or technology, or decrease the licensee&#8217;s or collaborator&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our potential royalties, milestones and other payments and have a material adverse effect on our business, financial condition, results of operations and prospects. If a marketer were to default on its obligations under a license or collaboration agreement, the licensor&#8217;s or collaborator&#8217;s remedy may be limited either to terminating certain licenses or collaborations related to certain countries or to generally terminate the license or collaboration agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor or collaborator (if not us) and we may be required to rely on the resources and willingness of the licensor or collaborator (if not us) to enforce its rights against the applicable licensee or collaborator. In any of these situations, if the expected upfront, milestone, royalty or other payments under the license or collaboration agreements do not materialize, this could result in a significant loss to us and materially adversely affect our business, financial condition and results of operation. At any given time, the Company may be engaged in discussions with its licensees or collaborators regarding the interpretation of the payment and other provisions relating to products as to which we have milestones and potential royalty or other payment rights. Should any such discussions result in a disagreement regarding a particular product that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product should it successfully progress through clinical development and be approved for commercialization. Should our milestone and future potential royalty or other payment interests be reduced or eliminated as a result of any such disagreement, it could have an adverse effect on our business, financial condition, results of operation and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future arrangements to develop and commercialize our unpartnered assets. Generally, our current collaborative partners have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all or failing to engage in commercially reasonable efforts to develop products if required), our product development under these agreements will be delayed or terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers&#8217; product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties provide services in connection with preclinical and clinical development programs, including <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo</i> studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which our potential milestone and royalty providers have contracted, or cease to continue operations, and our potential milestone and royalty partners are not able to find a replacement provider quickly or lose information or items associated with their drug product candidates, our potential milestone and royalty providers&#8217; development programs and receipt of any potential resulting income may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agreements with other third parties, many of which are material to our business, expose us to numerous risks and have caused us to incur additional liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not know whether we or our licensees will successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Failure of our potential milestone and royalty providers&#8217; product candidates to meet current Good Manufacturing Practices standards may cause delays in regulatory approval and penalties for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under cGMP to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our potential milestone and royalty providers&#8217; drug product candidates on the schedule required for clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our potential milestone and royalty providers or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our potential milestone and royalty providers&#8217; product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and standards. Any difficulties or delays in contractors&#8217; manufacturing and supply of our potential milestone and royalty providers&#8217; product candidates or any failure of our potential milestone and royalty providers&#8217; contractors to maintain compliance with the applicable regulations and standards could increase costs, reduce revenue, make our licensees postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our potential milestone and royalty providers&#8217; product candidates, or cause any of our potential milestone and royalty providers&#8217; products that may be approved for commercial sale to be recalled or withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, so our and our licensees&#8217; use of them may be restricted and subject to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees and collaborators&#8217; use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license, which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our and our licensees&#8217; ability to commercialize our technologies, products or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employees, Location, Data Integrity, and Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The loss of, COVID-19 related absence of, or changes in any of our key personnel, could delay or prevent achieving our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business efforts could be adversely affected by the loss or COVID-19 related absence of one or more key members of our staff. We currently do not have key person insurance on any of our employees. In addition, given our minimal employee base, a COVID-19 outbreak in our employee population could significantly hinder our ability to meet our operating objectives. Changes in management may cause disruption in our business, strategic and employee relationships, which may delay or prevent the achievement of our business objectives. During the transition periods, there may be uncertainty among investors, employees and others concerning our future direction and performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because we are a small biopharmaceutical focused company with limited resources, we may not be able to attract and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had 12 full-time employees and one part-time employee as of March 6, 2023. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. There is intense competition for the services of these personnel, especially in California. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, we expect the high cost of living in the San Francisco Bay Area, where our headquarters is located, may impair our ability to attract and retain employees in the future. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer, and we may be unable to implement our current initiatives or grow effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to our small number of employees, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain of our functions as a public company. We may have limited control over these third parties, and we cannot guarantee that they will perform their obligations in an effective and timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of system failures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and any future licensees, suppliers, contractors and consultants are vulnerable to damage from cyberattacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We could experience failures in our information systems and computer servers, which could be the result of a cyberattacks and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs and other business operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our information technology systems or data or those of our partners or contractors are or were compromised by security incidents, our sensitive information could be exposed or stolen and we could experience adverse consequences, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. Our computer systems, and those of our partners and contractors, are potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the ordinary course of our business, we maintain sensitive data on our networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our business partners. The secure maintenance and protection of this information is critical to our business and reputation. Threats to our systems and sensitive data can come from a variety of sources, ranging in sophistication from a person with authorized access to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">our network, to an individual hacker, to an organized threat actor organization, to a state-sponsored attack. Cyber threats also may be intentional or accidental. It is often difficult to anticipate or immediately detect cyber incidents and the damage caused by such incidents. Data breaches and any unauthorized access to our systems could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to exposure of personal information of our employees, legacy clinical trial patients, vendors and others, which could expose us to liability under foreign, federal, or state privacy laws. Theft of proprietary information could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Authorities worldwide have been warning businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. Moreover, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have implemented security measures that are intended to protect our data security and information technology systems, such measures may not prevent all such cyber incidents. Further, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Compliance with stringent and changing obligations related to data privacy and security protection is a rigorous and time-intensive process. Our actual or perceived failure to comply with any privacy or data security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states, countries and jurisdictions strictly regulate data privacy and protection and may impose significant penalties for failure to comply with these requirements. For example, in the U.S., the CCPA became effective on January 1, 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents and the CPRA which became effective on January 1, 2023, which expands upon the CCPA. The CCPA and CPRA give California residents expanded privacy rights, including the right to request correction, access and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their information is processed. The CCPA and CPRA include a framework with potentially severe statutory damages and private rights of action and will likely impact our business activities, along with increasing our compliance costs and potential liability. If we fail to comply with the CCPA and CPRA, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Other states are beginning to pass similar laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compliance with laws and regulations concerning privacy, cybersecurity, data governance and data protection is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the laws and regulations and incur substantial expenditures. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Further, data incidents experienced by us, our partners or collaborators could lead to significant fines, required corrective action, the loss of trade secrets or other intellectual property, public disclosure of sensitive clinical or commercial data, and the exposure of personally identifiable information (including sensitive personal information) of our employees, partners, and others. A data security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm to our reputation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines imposed on us by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional compliance obligations under federal, state or foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements for mandatory corrective action to be taken by us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, cyber incidents can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Lastly, we cannot guarantee that we are in compliance with all applicable data protection laws and regulations as they are enforced now or as they evolve. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn, or it may be removed voluntarily from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our potential royalty providers receive regulatory approval for our product candidates, they will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the EMA, or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials or obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for such products are subject to extensive regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such product may be withdrawn voluntarily by our potential royalty providers based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our potential royalty providers&#8217; ability to sell products in which we have ownership or<span style="letter-spacing:-0.1pt;"> </span>and royalty interests, if approved, profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which, among other things, substantially changed the way healthcare is financed by both governmental and private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been judicial, Congressional and executive branch challenges to the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. &#160;In addition, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. On August 16, 2022, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how other such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. In addition, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, <span style="background:#ffffff;">in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. In addition, beginning in 2023, Centers for Medicare &amp; Medicaid Services, or CMS, will require manufacturers to refund CMS for certain discarded amounts of single-dose container and single-use package drugs. </span>At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An expansion in the government&#8217;s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers, and reduced product utilization, any of which could adversely affect our business and results of operations. We expect that additional healthcare reform measures will be adopted in the future. We cannot know what form any such new legislation may take or the market&#8217;s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our potential royalty providers from being able to generate revenue, attain profitability, develop, or commercialize our current product candidates in which we have an ownership or royalty interest. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our potential milestone and royalty providers are subject to various state and federal healthcare-related laws and regulations that if violated may impact the commercialization of our product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing or arranging for the purchase, lease, or order of a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The ACA modified the federal Anti-Kickback Statute&#8217;s intent requirement so that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it to have committed a violation. In addition, several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, persons and entities from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Certain suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individual, commonly known as a &#8220;whistleblower&#8221;, or &#8220;relator&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend and/or settle a False Claims Act action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including a private payor, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information by entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only federal healthcare programs, such as the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government. Additionally, certain state and local laws require the registration of pharmaceutical sales representatives, restrict payments that may be made to healthcare providers and other potential referral sources, and require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers. Further, some states have laws governing the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA and differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws, and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our or our potential milestone and royalty providers&#8217; business activities could be subject to challenge under one or more of such laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our potential milestone and royalty providers are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we or our potential milestone and royalty providers may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, reputational harm, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our or our potential milestone and royalty providers&#8217; operations, any of which could have a material adverse effect on our business and results of operations. In addition, we and our licensees may be subject to certain analogous foreign laws and violations of such laws could result in significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. Our operations are subject to anti-corruption laws including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. We and the royalty agreement counterparties and licensees who generate our royalties operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anticorruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control laws by the United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the business practices of the royalty agreement counterparties and licensees who generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the royalty agreement counterparties and licensees who generate our royalties are found to be in violation of any of these laws or any other governmental regulations, we or the royalty agreement counterparties and licensees who generate our may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or the royalty agreement counterparties and licensees who generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">As we or our potential milestone and royalty providers do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our potential milestone and royalty providers may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities will be a significant part of future business activities and when and if we or our potential milestone and royalty providers are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States. Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate&#8217;s development. International sales may be limited or disrupted by many factors, including without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of government controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export license requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">political or economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in tariffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on repatriating profits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exchange rate fluctuations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withholding and other taxation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our share price may be volatile, and there may not be an active trading market for our common stock, Series A Preferred Stock or our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the market price of our common stock will not decline below its present market price. Additionally, there may not be an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our stock price or the existence of an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. We have experienced significant volatility in the price of our common stock. From January&#160;1, 2022, through March 6, 2023, the share price of our common stock has ranged from a high of $32.09 to a low of $15.68. From January&#160;1, 2022, through March 6, 2023, the share price of our Series A Preferred Stock has ranged from a high of $27.09 to a low of $22.14. From January&#160;1, 2022, through March 6, 2023, the share price of our Series B Preferred Stock has ranged from a high of $26.81 to a low of $21.75. Additionally, we have two significant holders of our common stock that could affect the liquidity of our stock and have a significant negative impact on our stock price if the holders were to quickly sell their ownership positions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future contribute to, increased volatility and diminished expectations for the economy and the markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.</p><a id="_Hlk69843796"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have issued equity securities and may issue additional equity securities from time to time, that materially and adversely affect the price of our common stock, including our Series X preferred stock, Series A Preferred Stock and depositary shares representing interests in our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in such a manner as we determine from time to time, including pursuant to our 2018 Common Stock ATM Agreement, as amended, and 2021 Series B Preferred Stock ATM Agreement. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. If we issue additional equity securities, the price of our existing securities may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, there were 5,003 shares of Series&#160;X preferred stock issued and outstanding. Each share of Series&#160;X preferred stock is convertible into 1,000 shares of registered common stock. The total number of shares of common stock issuable upon conversion of all issued Series&#160;X preferred stock would be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which was initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. A holder of Series X preferred shares may elect to increase or decrease the conversion blocker above or below 19.99% on 61 days&#8217; notice, provided the conversion blocker does not exceed the limits under Nasdaq Marketplace Rule 5635(b), to the extent then applicable. If holders of our Series X convertible preferred stock elect to convert their preferred shares into common stock such conversion would dilute our currently outstanding common stock both in number and in earnings per share. BVF (and its affiliates), as current holders of all shares of our Series X preferred stock, would, if they converted all such shares to common stock, obtain majority voting control of the Company. As of December 31, 2022, BVF owned approximately 31.5% of our total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own 52.3% of our total outstanding shares of common stock. Additionally, as of December 31, 2022, we had issued and outstanding 984,000 shares of Series A Preferred Stock and 1,600,000 depositary shares, each representing a 1/1000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> fractional interest in a share of our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our securities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to raise additional funds to support our operations, we may sell additional equity or convertible debt securities, which would result in dilution to our stockholders and/or debt securities which may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in additional dilution or result in other rights or obligations that adversely affect our stockholders. For example, holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Additionally, holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and by-laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our disclosure controls and internal controls over financial reporting are effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Companies that file reports with the SEC, including us, are subject to the requirements of Section&#160;404 of the SOX. Section&#160;404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form&#160;10-K filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to use our NOL carry-forwards and certain other tax attributes to offset taxable income or taxes may be limited. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and/or be unavailable to offset future income tax liabilities. &#160;As of December 31, 2022, we had U.S. federal NOL carryforwards of $108.8 million, of which $13.6 million will begin to expire in 2036. &#160;Under the federal income tax law, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the federal tax law. In addition, Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (or, the Code), and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an &#8220;ownership change&#8221; to utilize its NOL carry-forwards and certain other tax attributes against any taxable income in taxable periods after the ownership change. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change, by value, in a corporation&#8217;s equity ownership over a three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of Code, we experienced an ownership change in February 2017, that significantly limits the availability of our tax attributes to offset future income. To the extent that we do not utilize our carry forwards within the applicable statutory carry-forward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in tax laws or regulations</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">that</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">are applied</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">adversely</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to us may</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">have a material adverse</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">effect</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">on our business,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">cash flow, financial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">condition,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or results</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">of operations</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For instance, the recently enacted Inflation Reduction Act imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future tax expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities-related class action and stockholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is uncertain. We could be forced to expend significant time and resources in the defense of these suits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. Although we carry insurance to protect us from such claims, our insurance may not provide adequate coverage. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4fb88fdb_7ea2_4389_943b_fb2ba0750276"></a><a id="Item1BUnresolvedStaffComments_868310"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;<b style="font-weight:bold;white-space:pre-wrap;">1B.    Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_84fa0436_f883_4f2e_af8a_26fc130b1959"></a><a id="Item2Properties_752211"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We currently lease space in one building that houses our corporate headquarters in Emeryville, California. &#160;The lease was originally scheduled to expire in February 2023 and in January 2023, we extended the lease through July 2023. We believe our facilities are adequate to meet our requirements for the near term and we are currently evaluating our future office space needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_41c3946c_64cf_44b8_a1aa_c3e81bd01eeb"></a><a id="Item3LegalProceedings_945310"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">From time to time, we are involved in litigation, arbitration or other proceedings relating to claims arising out of our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are not currently involved in any legal proceedings that we believe to be material. We may, however, be involved in material legal proceedings in the future, and the potential impact on us of any on-going proceeding could change. Such matters are subject to significant uncertainties, and there can be no assurance that any legal proceedings in which we are or may become involved will not have a material adverse effect on our business, results of operations, financial position or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_da948956_66cd_44a4_bdb1_be3d0f38949d"></a><a id="Item4MineSafetyDisclosures_972169"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b78207a4_7152_4c4c_8e5b_e1c11129209a"></a><a id="PARTII_531471"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market for Registrant&#8217;s Common Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades on The Nasdaq Global Market tier of the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;XOMA.&#8221; On March&#160;6, 2023, there were 192 stockholders of record of our common stock, one of which was Cede&#160;&amp; Co., a nominee for Depository Trust Company (&#8220;DTC&#8221;). All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede&#160;&amp; Co. as one stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not paid dividends on our common stock. Holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year per share) per year. Holders of our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per year of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). We do not anticipate paying cash dividends on our common stock in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_23d667db_6547_4a7c_8c8a_9b1235ac2f9f"></a><a id="Item6SelectedConsolidatedFinancialData_8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;Reserved</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8113bc8c_b1e4_4f77_bc5c_83e2fb64aea2"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Our portfolio was built through licensing our proprietary products and platforms from our legacy discovery and development business, combined with the acquisition of rights to future milestones and royalties that we have made since our royalty aggregator business model was implemented in 2017. Our drug royalty aggregator business is focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Although we generated net income of $15.8 million and positive cash flows from operations of $22.7 million for the year ended December 31, 2021, we generated net loss of $17.1 million and negative cash flows from operations of $12.9 million for the year ended December 31, 2022 and we had an accumulated deficit of $1.2 billion as of December 31, 2022. The payment we received from Novartis pursuant to our Anti-TGF&#946; Antibody License Agreement in 2021 was a one-time milestone payment that does not represent recurring revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Significant Developments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Purchase of IP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">ObsEva Intellectual Property Acquisition Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we entered into the ObsEva IP Acquisition Agreement pursuant to which we acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. We also assumed ObsEva&#8217;s ongoing obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. &#160;If ebopiprant is successfully commercialized, we will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA. &#160;We paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what we will receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Commercial Payment Purchase Agreement with Affitech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize <span style="background:#ffffff;">VABYSMO </span>(faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. &#160;Pursuant to the Affitech CPPA, we paid Affitech a $5.0 million regulatory approval milestone tied to these U.S. marketing approvals. Under the terms of the Affitech CPPA, we are eligible to receive a 0.5% commercial payment stream on net sales of VABYSMO in each of certain regions where it is approved, for a ten-year period following its first commercial sale in such region.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">In September 2022, in connection with Roche receiving approval from the EC to commercialize VABYSMO for the treatment of neovascular or &#8216;wet&#8217; age-related macular degeneration and visual impairment due to diabetic macular edema, we made a $3.0 million milestone payment to Affitech pursuant to the terms of the Affitech CPPA. As a result of </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">the EC approvals, we will be eligible to receive a 0.5% commercial payment stream for ten years from the first commercial sale of VABYSMO in Europe.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">VABYSMO was previously approved by the FDA in January 2022 and by Japan&#8217;s Ministry of Health, Labour, and Welfare in March 2022. In August 2022, we received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022, and in February 2023 we received $2.4 million for sales of VABYSMO during the second half of 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In July 2022, we received $2.5 million pursuant to our Kuros RPA. This payment represents 50% of a milestone earned by Kuros upon the closing of Regeneron&#8217;s acquisition of Checkmate Pharmaceuticals on May 31, 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">License and Collaboration Agreements </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Compugen </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we earned a $0.8 million milestone payment under our license agreement with Compugen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Novartis &#8211; VPM087</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2023, Novartis notified us that based upon a strategic review of the development program, Novartis will not initiate further studies of gevokizumab in gastrointestinal cancers. &#160;Novartis&#8217; study to evaluate treatment with gevokizumab with standard of care anti-cancer therapies in patients with metastatic colorectal, gastroesophageal, and renal cancers will continue to primary analysis, which is anticipated later this year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Novartis &#8211; Anti-CD40 Antibody</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant. Novartis is continuing iscalimab studies in other indications such as Sj&#246;gren&#8217;s Syndrome, Lupus Nephritis and Hidradenitis Suppurativa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Sonnet Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, Sonnet dosed the first patient in its Phase 1 clinical trial for SON-1010, and we earned a development-related milestone payment of $0.5 million from Sonnet pursuant to our Sonnet Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Rezolute &#8211; RZ358 Antibody </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, we earned a $2.0 million milestone payment pursuant to our Rezolute License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Modification of Equity Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In November 2022, we entered into the November 2022 Letter Agreement with Thomas Burns. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remains employed by us for a twelve-month period beginning on November 1, 2022, he will be deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. Conditioned on his execution of a release in favor of us, Mr. Burns will also receive this benefit upon any involuntary termination for reasons other than cause. This modification resulted in an acceleration of the expense recognized related to Mr. Burns&#8217; stock options. During the year ended December 31, 2022, we recognized stock-based compensation expense of $0.6 million related to the Mr. Burns&#8217; option awards. As of December 31, 2022, there was $0.5 million total </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">unrecognized compensation expense related to Mr. Burns&#8217; stock options expected to be recognized through the earlier of the vesting date of the option or October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Employee Retention Bonus</span><span style="font-style:italic;font-weight:bold;background:#ffff00;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we approved the Amended Retention Plan that amended the Retention Plan to provide that each of our current employees, excluding the Chief Executive Officer (&#8220;CEO&#8221;), will be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. As of December 31, 2022, we expect to pay $0.8 million in 2023 related to employee retention bonuses under the Amended Retention Plan, of which $0.1 million was accrued in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">James R. Neal&#8217;s Departure and Continuity Incentive </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective December 31, 2022, James R. Neal retired as our Chief Executive Officer and, effective as of January 1, 2023, resigned as a member of our Board and Chairman of the Board. Pursuant to Mr. Neal&#8217;s &#160;Amended and Restated Employment Agreement, dated as of December 15, 2021, following his departure date, Mr. Neal is entitled to a cash payment of $1.2 million, which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. &#160;As of December 31, 2022, we accrued the full amount of Mr. Neal&#8217;s continuity incentive of $1.2 million in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;30, 2022, the Board appointed Owen Hughes as our Executive Chairman of the Board and Interim Chief Executive Officer (principal executive officer), effective as of January&#160;1, 2023. Mr. Hughes will receive an annual base salary of $125,000 and will be eligible to receive an annual discretionary cash bonus with a target amount equal to 55% of his annual base salary upon the achievement of annual performance milestones to be established by the Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December 30, 2022, the Board also appointed Bradley Sitko as our Chief Investment Officer, effective as of January&#160;3, 2023. Mr. Sitko will receive an annual base salary of $500,000, a signing bonus of $110,000 and will be eligible to receive an annual discretionary cash bonus with a target amount equal to 50% of his annual base salary upon the achievement of annual performance milestones to be established by the Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;"> </span><span style="background:#ffffff;">Mr. Hughes and Mr. Sitko were also granted non-qualified stock options </span>subject to the terms and conditions of the Company&#8217;s Amended and Restated 2010 Long Term Incentive and Stock Award Plan. The options were granted outside the Plan as an inducement material to Mr.&#160;Hughes and Mr. Sitko entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). &#160;Further details of the stock option grants can be found in our Form 8-K filed January 4, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Arbitration Proceeding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, we initiated an arbitration proceeding against one of our licensees (the &#8220;Licensee&#8221;) with the American Arbitration Association/International Centre for Dispute Resolution. &#160;We seek damages, plus interest, and fees and costs of the arbitration (which fees and costs are currently estimated to be in the mid-single-digit millions of U.S. dollars range). &#160;In response, the Licensee seeks declarations that the License Agreement, under our interpretation, is unlawful, void and unenforceable, and that the License Agreement has expired. &#160;To date, the Licensee has not filed any counterclaims against us. However, to the extent the Licensee is deemed to be the prevailing party, the arbitrators, in their discretion, may require us to pay the Licensee&#8217;s fees and costs of the arbitration (currently estimated to be in the mid-single-digit millions of U.S. dollars range). A hearing before a panel of arbitrators was held on this matter in November 2022, and the parties have submitted post-hearing briefs. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with generally accepted accounting principles, or GAAP, requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates that involve a significant level of judgment and/or estimation uncertainty and could have or are reasonably likely to have a material impact on our financial condition or results of operations. We believe the following critical accounting policies and estimates describe the more significant judgments and estimates used in the preparation of our consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, and royalties on sales of products currently in clinical development. We acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables. We have accounted for the purchased rights as a financial asset in accordance with ASC 310. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Receivables </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. Except for <span style="background:#ffffff;">VABYSMO</span>, these developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The related receivable balances are classified as noncurrent since no payments are probable to be received in the near term. <span style="background:#ffffff;">VABYSMO</span> received FDA approval in January 2022,<span style="background:#ffffff;"> was approved by Japan&#8217;s Ministry of Health, Labour, and Welfare in March 2022</span>, and was approved by the EU&#8217;s EC in September 2022 and we do not yet have a foundation upon which to estimate receipts expected to be collected in the near term; therefore, they remain classified as noncurrent until such time an estimate can be made. Under the cost recovery method, any milestone, royalty, or other payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected will be recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Contingent Payments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be obligated to make contingent payments related to certain product development and regulatory approval milestones and sales-based milestones. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, subject to remeasurement to fair value at the end of each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"><i style="font-weight:normal;">Impairment Assessment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review these balances for impairment on a quarterly basis using updates from our partners, press releases and public information on clinical trials. &#160;If we determine an impairment is necessary, the impairment recorded will be based on an estimate of discounted future cash flows, which will rely on assumptions including probability of technical success and discount rate. &#160;Changes to these assumptions could have a material impact on our financial statements. &#160;No impairment has been recorded as of December 31, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense for stock options and other stock awards is estimated at the grant date based on the award&#8217;s fair value-based measurement. The valuation of stock-based compensation awards is determined at the date of grant using the Black-Scholes Model. This model requires highly complex and subjective inputs, such as the expected term of the option and expected volatility. These inputs are subjective and generally require significant analysis and judgment to develop. Our current estimate of volatility is based on the historical volatility of our stock price. To the extent volatility in our stock price increases in the future, our estimates of the fair value of options granted in the future could increase, thereby increasing stock-based compensation cost recognized in future periods. To establish an estimate of expected term, we consider the vesting period and contractual period of the award and our historical experience of stock option exercises, post-vesting cancellations and volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues. Forfeitures are recognized as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We review our valuation assumptions quarterly and, as a result, we likely will update our valuation assumptions used to value stock-based awards granted in future periods utilizing current data. In the future, as additional empirical evidence regarding these input estimates becomes available, we may change or refine our approach of deriving these input estimates. These changes could impact our fair value-based measurement of stock options granted in the future. Changes in the fair value-based measurement of stock awards could materially impact our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenues </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Total revenues for the&#160;years ended December 31, 2022 and 2021, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,150</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,518</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,368)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,877</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,642</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 235</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,027</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,160</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (32,133)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue from contracts with customers includes upfront fees, annual license fees and milestone payments related to the out-licensing of our legacy product candidates and technologies. The primary components of revenue from contracts with customers in 2022 were due to milestones earned of $2.0 million pursuant to our Rezolute License Agreement, $0.8 million pursuant to the Takeda Collaboration Agreement, $0.8 million pursuant to our license agreement with Compugen and $0.5 million pursuant to our Sonnet Collaboration Agreement. The primary components of revenue from contracts with customers in 2021 were due to milestones earned of $35.0 million under our Anti-TGF&#946; Antibody License Agreement with Novartis, $0.5 million under our license agreement with Compugen and $0.7 million under our license agreement with Janssen. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue recognized under units-of-revenue method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues recognized under the units-of-revenue method include the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. The increase in 2022 compared with 2021 was due to increased sales of products underlying the agreements with HCRP. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">G&amp;A Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses include salaries and related personnel costs, professional fees, and facilities costs. In 2022, G&amp;A expenses were $23.2 million compared with $20.5 million in 2021. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net increase of $2.7 million in 2022 as compared with 2021 was primarily due a $2.6 million increase in salaries and related expenses<span style="background:#ffffff;"> including the </span>$1.2 million Continuity Incentive accrued in connection with the departure of Mr. Neal, a $0.7 million increase in salaries and wages due to increased headcount and general salary increases, $0.4 million related to bonus payments to Mr. Neal pursuant to his amended employment agreement, and $0.1 million accrued in connection with the employee retention bonus. A $2.3 million increase in consulting and legal costs also contributed to the overall increase. The increases in salaries and related expenses, consulting and legal costs were partially offset by a $2.6 million reduction in stock-based compensation expense for stock options. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Interest Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The $0.5 million interest expense reported for the year ended December 31, 2021 was related to our SVB Loan that was repaid in June 2021. There was no interest expense for the year ended December 31, 2022. We expect no interest expense in 2023 as we have no outstanding loan balances; however if we elect to obtain new debt financing, our interest expense may increase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Income (Expense), Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the activity in other income (expense), net for the&#160;years ended December 31, 2022 and 2021 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 659</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (439)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 480</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 295</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,174</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The change in fair value of equity securities is due to the change in market price of equity securities we own in shares of Rezolute&#8217;s common stock. Investment income increased $0.7 million compared with the same period in 2021 due to higher market interest rates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Provision for Income Taxes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded a $15,000 income tax benefit and a $0.1 million income tax expense for the years ended December 31, 2022 and 2021, respectively. We continue to maintain a full valuation allowance against our remaining net deferred tax assets. We had a total of $5.9 million of gross unrecognized tax benefits, none of which would impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our unrestricted cash, our working capital and our cash flow activities as of and for each of the periods presented (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 57,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 93,328</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,502)</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 84,006</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (29,571)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (12,879)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22,678</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,557)</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (20,221)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (26,500)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,279</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,451)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,835</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,286)</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (37,551)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,013</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (46,564)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk93561944"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for 2022 was primarily due to our operating expenses of $23.4 million, excluding non-cash expenses of $4.4 million including stock-based compensation of $3.6 million, partially offset by a $2.0 million milestone payment received from Rezolute, a $0.8 million milestone payment received from Takeda and a $0.8 million milestone payment received from Compugen. Our primary source of cash provided by operating activities in 2021 was the $35.0 million milestone payment received from Novartis, partially offset by our operating expenses of $20.6 million excluding non-cash expenses including stock-based compensation of $6.2 million. </p><a id="_Hlk53658901"></a><a id="_Hlk53658770"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Net cash used in investing activities </span>for the&#160;year ended December 31, 2022 <span style="background:#ffffff;">of $</span>20.2<span style="background:#ffffff;"> million was primarily due to the $15.2 million paid for the IP acquired pursuant to the ObsEva IP Acquisition Agreement </span>in November 2022<span style="background:#ffffff;"> and</span> <span style="background:#ffffff;">the $5.0 million and $3.0 million payments for regulatory milestones pursuant to the Affitech CPPA, partially offset by the $2.5 million milestone payment received from Kuros in July 2022 and the $0.5 million commercial payment received from Roche in August 2022</span>. <span style="background:#ffffff;">Net cash used in investing activities </span>for the&#160;year ended December 31, 2021, <span style="background:#ffffff;">of $26.5 million was due to our acquisitions under RPAs and a CPPA, including a $13.5 million payment pursuant to the Viracta RPA, a $7.0 million payment pursuant to the Kuros RPA and a $6.0 million payment pursuant to the Affitech CPPA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities for the&#160;year ended December&#160;31, 2022, of $4.5 million was primarily due to the payment of dividends on our Series A and Series B Preferred Stock of $5.5 million, partially offset by the receipt of net cash provided from the exercise of stock options after related tax payments of $1.0 million. Net cash provided by financing activities for the year ended December 31, 2021 of $12.8 million was primarily due to the receipt of net cash proceeds of $37.1 million from our public offering of Series B Preferred Stock, $1.1 million net cash provided from the exercise of stock options after related tax payments, partially offset by $4.3 million cash used in the principal payments of debt, $17.1 million cash used to extinguish outstanding loans and $3.5 million payment of dividends on our Series A Preferred Stock and Series B Preferred Stock. </p><a id="_Hlk95311840"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 21.3pt;"><span style="font-style:italic;font-weight:bold;">Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have incurred significant operating losses since our inception and as of December 31, 2022, we had an accumulated deficit of $1.2 billion. &#160;As of December 31, 2022, we had $57.8 million in cash and cash equivalents. Based on our current cash balance and our ability to control discretionary spending, such as royalty acquisitions, we have evaluated and concluded our financial condition is sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have primarily financed our operations and acquisitions through the issuance of our common stock, Series A and Series B Preferred Stock, and amounts received as milestone payments under our license agreements. &#160;The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Milestone payments earned in 2021 and 2022 are not indicative of anticipated milestones in future periods. We may seek additional capital through use of our 2018 Common Stock ATM Agreement or 2021 Series B Preferred Stock ATM Agreement (see Note 11 of the Consolidated Financial Statements), or through other public or private debt or equity transactions. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common and preferred stock, which are subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. &#160;If we are unable to raise additional funds when we need them, our business and operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="font-style:italic;font-weight:bold;">Material Cash Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our material cash requirements in the short and long term consist of the following expenditures:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Operating expenditures:</b> Our primary uses of cash and operating expenses relate to employee and related costs, consultants to support our administrative and business development efforts, legal and accounting services, insurance, investor relations and IT services. Our planned spending includes costs to satisfy the Continuity Incentive related to the departure of Mr. Neal as CEO in December 2022 and increased personnel-related costs starting in 2023 due to the appointment of our new Executive Chairman and Chief Investment Officer. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In response to our prior CEO&#8217;s intention to retire as announced in December 2021, we implemented a Retention Plan to encourage our employees to remain with the Company through and beyond the new CEO transition period. Our Retention Plan includes a cash &#8220;stay&#8221; bonus, effective November 1, 2022, as well as a policy defining benefits upon any involuntary termination for reasons other than cause, which includes minimum severance, COBRA benefits, outplacement services and certain modifications to option awards. We expect our operating expenses to increase as a result of this Retention Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To support our royalty aggregator business model, we engage third parties to assist in our evaluation of potential acquisitions of milestone and royalty streams. Additional operating expenses, including consulting and legal costs, may increase in 2023 in response to an anticipated increase in the volume of acquisition targets evaluated or completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our amended headquarters lease expires in July 2023, and we are currently evaluating our office space needs, however, due to our small staff and minimal operating space requirements, we do not expect to incur material incremental costs associated with our current or future building leases. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">RPAs, CPPAs and IP Acquisitions: </b>A significant component of our business model is to acquire rights to potential future milestone and royalty streams. &#160;We expect to continue deploying capital toward these acquisitions in the near and long term. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We also have potential contingent consideration of $0.1 million recorded on our consolidated balance sheets as of December 31, 2022, for development milestones due under our agreement with Bioasis. We paid Affitech a total of $8.0 million in 2022 for milestones tied to the achievement of &#160;regulatory approvals. We have evaluated and concluded our existing capital resources are adequate to meet those needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have potential sales-based milestones that may become due under our agreements with Aronora, Kuros and Affitech as well as non-sales-based milestones, sales-based milestones and sales-based royalty payments that may become due under our agreement with ObsEva. All of these milestones and royalty payments represent a portion of the funds we may receive in the future pursuant to these agreements, and therefore will be fully funded by the related royalty or commercial payment receipts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative Agreements, Royalties and Milestone Payments</b>: We have committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by our licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on our consolidated balance sheet as of December 31, 2022. We are unable to determine precisely when and if our payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. &#160;All payments due will be funded by a portion of the related milestone or royalty revenue we receive or will be reimbursed by our licensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Dividends</b>: Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per share of Series A Preferred Stock per year). Holders of Series B Depositary Shares are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">preference per share of Series B Preferred Stock ($25.00 per depositary share) per year, which is equivalent to $2,093.75 per year per share of Series B Preferred Stock ($2.09375 per year per depositary share). &#160;Dividends on the Series A and Series B Preferred Stock are payable in arrears on or about the 15th day of January, April, July and October of each year. &#160;Since original issuance, all dividends have been paid as scheduled. &#160;We expect to continue making these dividend payments as scheduled using our existing capital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 2 to the Consolidated Financial Statements for information regarding new accounting pronouncements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_40ce9f43_fcde_46c3_85d1_d21736515cb7"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e623879a_7a50_4a97_bb76_05a6586ca7b9"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following consolidated financial statements of the registrant, related notes and report of independent registered public accounting firm are set forth beginning on page&#160;F-1 of this report.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Deloitte_Audit_Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. 34)</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_29154"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"><span style="font-style:normal;font-weight:normal;">Notes&#160;to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0ad84c0c_02c2_48f1_9c7d_dda9fb8b562e"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6301e9c6_cffa_4ef9_8391_6320d4e8f4f8"></a><a id="Item9AControlsandProcedures_282993"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the supervision and with the participation of our management, including our Executive Chairman and our Senior Vice President, Finance and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule&#160;13a-15 promulgated under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this report. Our disclosure controls and procedures are intended to ensure that the information we are required to disclose in the reports that we file or submit under the Securities Exchange Act of 1934 is (i)&#160;recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms and (ii)&#160;accumulated and communicated to our management, including the Executive Chairman and Senior Vice President, Finance and Chief Financial Officer, as the principal executive and financial officers, respectively, to allow timely decisions regarding required disclosures. Based on this evaluation, our Executive Chairman and our Senior Vice President, Finance and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Management, including our Executive Chairman and Interim Chief Executive Officer (principal executive officer) and our Senior Vice President, Finance and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Exchange Act Rules&#160;13a-15(f)). The Company&#8217;s internal control system was designed to provide reasonable assurance to the Company&#8217;s management and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">board of directors regarding the preparation and fair presentation of published financial statements in accordance with accounting principles generally accepted in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control&#8212;<i style="font-style:italic;">Integrated Framework (2013 Framework)</i>. Based on our assessment we believe that, as of December 31, 2022, our internal control over financial reporting is effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report does not include an attestation report by our registered public accounting firm regarding internal control over financial reporting. Management&#39;s report is not subject to attestation by our registered public accounting firm under Section 404(b) of the Sarbanes-Oxley Act pursuant to the rules established by the Securities and Exchange Commission, which permit us to provide only our management report in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) under the Exchange Act during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_48bdb757_2e5c_4a25_bf74_29d592dc4e0d"></a><a id="Item9BOtherInformation_968719"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_a06d6d29_b98a_4487_b828_2534cde070cc"></a><a id="risk"></a><a id="Item9C"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdiction that Prevents Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ba6e1dcd_dbf9_46fa_9782_d20b5ac9da62"></a><a id="_Hlk91769520"></a><a id="PARTIII_322550"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersCorporat"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;10.&#160;Directors, Executive Officers, Corporate Governance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required by this Item will be included in the Company&#8217;s proxy statement for the 2023 Annual Meeting of Stockholders (&#8220;2023 Proxy Statement&#8221;), under the sections labeled &#8220;<i style="font-style:italic;">Proposal 1&#8212;Election of Directors,&#8221; &#8220;Information about our Executive Officers&#8221;</i> and <i style="font-style:italic;">&#8220;Delinquent Section 16(a) Reports&#8221;</i> and is incorporated by reference. The 2023 Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this report relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Code of Ethics applies to all employees, officers and directors including the Executive Chairman and Interim Chief Executive Officer (principal executive officer) and the Senior Vice President, Finance and Chief Financial Officer (principal financial and principal accounting officer) and is posted on the Company&#8217;s website at https://investors.xoma.com/corporate-governance. We intend to satisfy the applicable disclosure requirements regarding amendments to, or waivers from, provisions of our Code of Ethics by posting such information on our website.</p><a id="_a7f50166_3d9b_4b4a_ad1b_8cd34ae4cb35"></a><a id="_Hlk91769647"></a><a id="Item11ExecutiveCompensation_327220"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required by this Item will be included in the sections labeled <i style="font-style:italic;">&#8220;Compensation of Executive Officers,&#8221; &#8220;Summary Compensation Table,&#8221; &#8220;Outstanding Equity Awards as of December 31, 2022,&#8221; </i>and <i style="font-style:italic;">&#8220;Compensation of Directors&#8221;</i> appearing in our 2023 Proxy Statement and is incorporated by reference.</p><a id="_581069a1_74e9_4ff4_8374_fa4a7332ab25"></a><a id="_Hlk91769690"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required by this Item will be included in the sections labeled &#8220;<i style="font-style:italic;">Common Stock of Certain Beneficial Owners and Management</i>&#8221; and &#8220;Equity Compensation Plan Information&#8221; appearing in our 2023 Proxy Statement and is incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_efca729e_22ca_4ae3_ad01_a40845e57de3"></a><a id="_Hlk91769712"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required by this Item will be included in the section labeled &#8220;<i style="font-style:italic;">Transactions with Related Persons</i>&#8221; appearing in our 2023 Proxy Statement and is incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_f18b68ce_70b5_4ce2_b204_978e50c72dc4"></a><a id="_Hlk91769742"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required by this Item will be included in the section labeled <i style="font-style:italic;">&#8220;Proposal 3 &#8211; Ratification of Appointment of Independent Registered Public Accounting Firm&#8221;</i> appearing in our 2023 Proxy Statement and is incorporated by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b36e85a0_b6dd_4068_bbc7_8f9f4192b505"></a><a id="PARTIV_208578"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;Exhibits and Financial Statement Schedules</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following documents are included as part of this Annual Report on Form&#160;10-K:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All financial statements of the registrant referred to in Item&#160;8 of this Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 54pt;">All financial statements schedules have been omitted because the required information is included in the consolidated financial statements or the notes thereto or is not applicable or required.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K12G3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/31/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/28/2014</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/18/2016</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312520316015/d39862dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of 8.625% Series A Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/11/2020</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521110287/d123419dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex3d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock</span></a> </p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr style="height:12.7pt;"><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">By-laws of XOMA Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K12G3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.1</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.2</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.3</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.4</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.5</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312518348826/d677241dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.6</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312521110287/d123419dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.7</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex3d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.8</span></a><span style="background:#ffffff;">, </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.9</span></a><span style="background:#ffffff;"> and </span><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">3.10</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen of Common Stock Certificate</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521110287/d123419dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Deposit Agreement, dated effective April 9, 2021, by and among XOMA Corporation, American Stock Transfer &amp; Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunder</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018019989/xoma-ex46_73.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrants (May 2018 Warrants)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019016040/xoma-ex47_58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrants (March 2019 Warrants)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex4d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312519099177/d728455ddef14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DEF 14A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;">Appendix   A</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/07/2022</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036112015529/ex10_6a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement for Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6A</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/14/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459016017643/xoma-ex101_350.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2016 Non-Equity Incentive Compensation Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/04/2016</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000119312517181624/d402926dex102.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended 2015 Employee Share Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/24/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312515197056/d931351dex992.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Subscription Agreement and Authorization of Deduction under the 2015 Employee Stock Purchase Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-204367</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/21/2015</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022003022/tmb-20211231xex10d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated December 15, 2021, between XOMA Corporation and James R. Neal</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/8/2022</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex109_172.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Change of Control Severance Agreement, dated August 7, 2017, to the Change of Control Severance Agreement, dated January 3, 2011, between XOMA Corporation and James R. Neal</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex108_173.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated August 7, 2017, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#*</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022007241/tmb-20220331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Amendment to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/05/2022</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup>*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022007241/tmb-20220331xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Amendment to Officer Employment Agreement dated November 1, 2022, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex1010_171.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Change of Control Severance Agreement, dated August 7, 2017, to the Change of Control Severance Agreement, dated October 28, 2015, between XOMA Corporation and Thomas Burns</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d56.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Amended and Restated Indemnification Agreement for Directors and Officers</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.56</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup>*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022007241/tmb-20220331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The Retention and Severance Plan dated, March 31, 2022</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/05/2022</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+#*</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">The Amended Retention and Severance Plan dated, October 25, 2022</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Officer Employment Agreement, dated January 3, 2023, between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex992.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex993.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Owen Hughes</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.3</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex994.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.4</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20*</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523019130/d103142dex995.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Inducement Stock Option Agreement, by and between XOMA Corporation and Bradley Sitko</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">333-269459</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.5</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/30/2023</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d57.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited (&quot;XOMA&quot;) Sesen Bio, Inc. and (formerly Viventia Biotech Inc.)</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.57</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated July 24, 2020, to the Non-Exclusive License Agreement, dated November 30, 2001, between XOMA Ireland Limited (&quot;XOMA&quot;) and Sesen Bio, Inc</span></a>. </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.58</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016202001662/xoma10qa120402ex1043.txt"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement by and between XOMA Ireland Limited and MorphoSys AG, dated as of February 1, 2002</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/04/2002</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312507049517/dex1046.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration Agreement, dated as of November 1, 2006, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/08/2007</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016210000097/ex10_48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Collaboration Agreement, effective as of February 28, 2007, between Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/10/2007</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312509051006/dex1031b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Collaboration Agreement, effective as of February 9, 2009, among Takeda Pharmaceutical Company Limited and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31B</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/11/2009</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016210000099/ex10_35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Discovery Collaboration Agreement dated September 9, 2009, by and between XOMA Development Corporation and Arana Therapeutics Limited</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q/A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/05/2010</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312509051006/dex1024c.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Research, Development and Commercialization Agreement, executed November 7, 2008, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24C</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/11/2009</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036112015529/ex10_25b.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1 to Amended and Restated Research, Development and Commercialization Agreement, effective as of April 30, 2010, by and between Novartis Vaccines and Diagnostics, Inc. (formerly Chiron Corporation) and XOMA (US) LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25B</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/14/2012</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837020012713/tmb-20200930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Amended and Restated Research, Development and Commercialization Agreement, between the Company and Novartis Vaccine and</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Diagnostics, Inc., dated September 30, 2015 </span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2020</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.31</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000114036115030673/ex10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement, dated June 19, 2015, by and between XOMA (US) LLC and Novartis Vaccines and Diagnostics, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/10/2015</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.32<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837020012713/tmb-20200930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement between the Company and Novartis International Pharmaceutical Ltd., dated September 30, 2015 </span></a><span style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;"> </span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2020</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.33<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">IL-1b Target License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.34<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">License Agreement, dated August 24, 2017, by and between XOMA Corporation and Novartis Pharma AG</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.35&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018004731/xoma-ex1066_607.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.66</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.36&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018012453/xoma-ex101_237.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated March 30, 2018, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/09/2018</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.37&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019006621/xoma-ex1071_267.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2, dated January 7, 2019, to the License Agreement, dated December 6, 2017, between XOMA (US) LLC and Rezolute, Inc. (formerly AntriaBio)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.71</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/07/2019</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.38</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017021836/xoma-ex104_177.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement, dated November 4, 2015, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/06/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.39<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.40<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment and Restatement, dated February 2, 2017, to the Asset Purchase Agreement, dated November 4, 2015, and License Agreement, dated March 23, 2016, between XOMA Corporation and Ology Bioservices Inc. (formerly Nanotherapeutics </span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">001-39801</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">11/03/2022</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022016142/tmb-20220930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Inc., now a wholly owned subsidiary of National Resilience, Inc.)</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.41</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1060_339.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Protective Rights Agreement dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.60</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.42</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1061_1989.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Protective Rights Agreements dated December 21, 2016 by and between XOMA (US) LLC and HealthCare Royalty Partners II, L.P. relating to the Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P. and the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.61</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.43</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1062_340.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the Amended and Restated License Agreement, dated effective as of October 27, 2006, between XOMA (US) LLC and DYAX, Corp.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.62</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.44</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1063_1988.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Interest Acquisition Agreement dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P., relating to the License Agreement, dated effective as of August 18, 2005, between XOMA (US) LLC and Wyeth Pharmaceuticals</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.63</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.45</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459017004563/xoma-ex1064_1433.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment of Section 6.10(a) and (b), dated March 8, 2017, to Royalty Interest Acquisition Agreements dated December 20, 2016, by and between XOMA Corporation and HealthCare Royalty Partners II, L.P.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.64</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.46</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000119312518352159/d675667dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/18/2018</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.47<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021002676/tmb-20201231xex10d59.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated March 10, 2021, to the Common Stock Sales Agreement, dated December 18, 2018, by and between XOMA Corporation and H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.59</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/10/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.48<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">At Market Issuance Sales Agreement, dated August 5, 2021, by and between XOMA Corporation and B. Riley Securities, Inc.</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.49&#8224;</p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018027722/xoma-ex109_282.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated September 20, 2018, between XOMA Corporation and Agenus Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.50<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019029005/xoma-ex101_307.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated April 7, 2019, between XOMA (US) LLC and Aronora, Inc.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/06/2019</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.51<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019040075/xoma-ex101_227.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement dated September 26, 2019, between XOMA (US) LLC and Palobiofarma, S.L</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/05/2019</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.52<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021006088/tmb-20210331xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Royalty Purchase Agreement dated March 22, 2021 between XOMA (US) LLC and Viracta Therapeutics, Inc.</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.53<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021014454/tmb-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Royalty Purchase Agreement, dated July 14, 2021, by and among XOMA (US) LLC and Kuros Royalty Fund (US) LLC</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/04/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.54<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Settlement and Release Agreement, dated April 15, 2021, by and among XOMA (US) LLC and Affimed N.V., Affimed GmbH Affimed</span></a></p></td><td style="vertical-align:middle;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.55<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837022003022/tmb-20211231xex10d48.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial Payment Purchase Agreement, dated October 6, 2021, by and among XOMA (US) LLC and Affitech Research AS</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.48</p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.56<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d56.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Intellectual Property Acquisition Agreement, dated November 21, 2022 between XOMA Corporation and ObsEva, SA</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.57<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d57.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated July 26, 2021, between ObsEva, SA and Organon International GmbH</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.58<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">#</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex10d58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated June 10, 2015, between ObsEva, SA and Ares Trading S.A.</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Subsidiaries of the Company</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:47.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC&#160;File&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:42.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.78%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.14%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.58%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_975745"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature pages hereto)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Executive Chairman, as required by Rule 13a-14(a) or Rule 15d-14(a)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer, as required by Rule 13a 14(a) or Rule 15d 14(a)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+(1)</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Executive Chairman and Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</span></a> </p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Labels Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104 </p></td><td style="vertical-align:top;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Confidential treatment has been granted with respect to certain portions of this exhibit. This exhibit omits the information subject to this confidentiality request. Omitted portions have been filed separately with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;Indicates a management contract or compensation plan or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>&#160;&#160;&#160;&#160;&#160; Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;">#&#160;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted as the Registrant has determined that (i)&#160;the omitted information is not material and (ii)&#160;the omitted material is of the type that the Registrant treats as private or confidential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup>&#160;&#160;&#160;&#160;This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ed04f764_75ea_46a4_a2d4_b3582ae7bcfa"></a><a id="Item16Form10KSummary_564652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16.&#160;Form&#160;10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_81b823ee_dd39_459b_9e5f_057ac83b7ba9"></a><a id="SIGNATURES_975745"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day of March&#160;2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA Corporation</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ OWEN HUGHES</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:46.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3cd9e89b_6302_4aeb_b53d_f0511d3cac32"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Owen Hughes and Thomas Burns, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:56.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Owen Hughes</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Chairman of the Board of Directors and Interim Chief Executive Officer (Principal Executive Officer) </p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Owen Hughes)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Thomas Burns</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President, Finance and Chief Financial Officer</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Thomas Burns)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Principal Accounting Officer)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Heather L. Franklin</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Heather L. Franklin)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Natasha Hernday</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Natasha Hernday)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Barbara Kosacz</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Barbara Kosacz)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Joseph M. Limber</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Joseph M. Limber)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Matthew Perry</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Matthew Perry)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ W. Denman Van Ness</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(W. Denman Van Ness)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Jack L. Wyszomierski</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:22.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Jack L. Wyszomierski)</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:56.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ae04a47e_78ef_40f9_8b58_6c90a41202b8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Index to Consolidated Financial Statements</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Deloitte_Audit_Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:AuditorFirmId" id="Narr_FZUPeYKFr0adn0BVCCtpNQ">34</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDBALANCESHEETS_29154"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:93.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a50c8307_0c4c_4aaf_a523_1ebcd4518394"></a><a id="Deloitte_Audit_Report"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 9pt 0pt;">To the Stockholders and the Board of Directors of XOMA Corporation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We have audited the accompanying consolidated balance sheets of XOMA Corporation and subsidiaries (the &quot;Company&quot;) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive (loss) income, stockholders&#39; equity, and cash flows, for the each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &quot;financial statements&quot;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"></span>These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#39;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:9pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments &#8212; Refer to Notes 2 and 5 to the financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:9pt 0pt 0pt 0pt;"><i style="font-style:italic;">Critical Audit Matter Description</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The carrying value of the long-term royalty and commercial payment receivables (&#8220;milestone and royalty rights&#8221;) is $63.7 million as of December 31, 2022. The Company accounts for milestone and royalty rights on a non-accrual basis using the cost recovery method. The developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The commercial payment product has limited available historical sales information, and as such the Company is unable to reasonably estimate the amount and timing of the commercial </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">payments to be received. Management assesses any impairment indicators and changes in expected recoverability of the long-term royalty and commercial payment receivable assets regularly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">The determination of impairment indicators requires obtaining and assessing all available information regarding the developmental pipeline products and the commercial payment product as of the Company&#8217;s financial reporting dates. The Company obtains information through available sources including: 1) updates from the selling party of the milestone and royalty rights, 2) publicly available clinical trial data and news, and 3) public disclosures provided by the research companies developing the products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">We identified the accounting evaluation of impairment indicators as a critical audit matter, primarily due to the Company&#8217;s reliance on third parties to disclose updates to the Company timely for the Company&#39;s required financial reporting deadlines. &#160;The timing of disclosure to the Company of a change in the use, or intent for future use, of the licenses related to the milestone and royalty rights could have a significant impact on the fair value of milestone and royalty rights and a significant change in fair value could cause a significant impairment. Performing audit procedures to evaluate whether management had appropriately identified impairment indicators involved challenging and complex auditor judgment, including the need to involve more experienced auditors in assessing the completeness of available information and if any available public information represents an impairment indicator as of the Company&#8217;s financial reporting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">How the Critical Audit Matter Was Addressed in the Audit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:9pt 0pt 9pt 0pt;">Our audit procedures related to the evaluation of assumptions used in the impairment assessment of the long-term royalty receivables included, but were not limited to, the following: </p><a id="_Hlk96681587"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Considering the impact of changes in the regulatory environment on management&#8217;s impairment indicator conclusions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We evaluated the Company&#8217;s assessment of impairment indicators by developing an independent expectation of impairment indicators through research of third-party disclosures and clinical trial news for programs associated with the milestone and royalty rights and comparing such expectation to those included in the impairment analysis.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We inspected the Company&#8217;s documentation of inquiries and written correspondence to obtain program updates from the selling parties of the milestone and royalty rights throughout the year and through the Company&#8217;s reporting date. &#160;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Confirmed with the selling parties of the milestone and royalty rights that complete information known to the selling party regarding the associated research programs was provided timely, completely, and accurately to the Company. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;min-height:12.0pt;text-align:justify;margin:10pt 0pt 10pt 0pt;"><b style="font-size:10pt;font-weight:bold;">/s/ </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:AuditorName" id="Narr_WSSLJtjCuE-ilIBbTb3rnQ"><b style="font-size:10pt;font-weight:bold;">DELOITTE &amp; TOUCHE LLP</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="dei:AuditorLocation" id="Narr_d-lwLJD6D06esCHRdVSjPw">San Francisco, California</ix:nonNumeric>&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">March 9, 2023&#160;&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have served as the Company&#39;s auditor since 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_19ed6bd2_86f6_4dc2_9888_3fa1a241fd70"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><a id="CONSOLIDATEDBALANCESHEETS_29154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_ef4950f5_bd5f_4ba1_b800_cec20cab062d"></a><a id="Tc_1HlF0tz320Cb7QaIW775fg_1_2"></a><a id="Tc_xOh5ySncDkq-zFzs_qwL1g_1_5"></a><a id="Tc_3q2QUbNiVkKsipyNcsx1NA_2_2"></a><a id="Tc_MYtHKQE-LkyNl2NIZx9kQQ_2_5"></a><a id="Tc_aQ_CCyInUEKRSoM6-XFzXw_4_0"></a><a id="Tc_fMdrIrhVLE-hsOwrxqsJZg_5_0"></a><a id="Tc_MPnf3Mhnj0-9sQOz9bdClw_6_0"></a><a id="Tc_tGOf8ZvlVEmJmslRe6HFPw_6_2"></a><a id="Tc_GQ70Kgf-6UOtO1z87GbU0w_6_5"></a><a id="Tc_JM9Hk1FLD0aqYAZ4t82w_w_7_0"></a><a id="Tc_9CdLTuRSVU6ANqcyVqtX4g_7_3"></a><a id="Tc_p68QJBpmiEaiReUFeeHEGw_8_0"></a><a id="Tc_JPuFpCnVrky2oGnTPubCug_9_0"></a><a id="Tc_eu-dlu7tpkKwvxva1i0XrQ_10_0"></a><a id="Tc_6T18iYA8nUeVyUYICV_GVw_10_6"></a><a id="Tc_E_I6F8VbHEGzunXuBNA_LQ_11_0"></a><a id="Tc_XyvcSXPBC0-ZO-m1gIDMQA_12_0"></a><a id="Tc_B8lpXmxAwUy1zmCFpMbmlw_13_0"></a><a id="Tc_ZLgNhAwGYEuQHlDjjey49A_14_0"></a><a id="Tc_ZlYRn7y6oUK7JkykMa2F1g_15_0"></a><a id="Tc_ue9k8yttM0i70YhTA0FGwA_16_0"></a><a id="Tc_vYnM_NGIjE2krhiIOsDV-g_16_6"></a><a id="Tc_xxXV_GLe8EK6iaa2dyGbsg_17_0"></a><a id="Tc_YownkLvuB0ijtPVogAeP9Q_18_0"></a><a id="Tc_rnXi1UYLnUWmivoltMsaiw_18_2"></a><a id="Tc_Zk69ssHV4UOBY5JdYvl3cQ_18_5"></a><a id="Tc_pzSVTESi4EGvB2AifikjjA_20_0"></a><a id="Tc_g9UknrhboUay0-jNI0-XZQ_21_0"></a><a id="Tc_KfjnTJLPl0av-TbYeuJe8w_22_0"></a><a id="Tc_vsbU-yA810G0xg7ORsT3Yg_22_2"></a><a id="Tc_sd-vq7ZWcESS0zDF2IZjsA_22_5"></a><a id="Tc_BubUQc-fx0GDWNMTG7DVhw_23_0"></a><a id="Tc_0Yhi-C1MOEi3HwB0DpVXnQ_24_0"></a><a id="Tc_5rvcBHG-FEWEj2geiPoY6Q_24_3"></a><a id="Tc_TqpV8uAc4UaOODIVQB2stQ_25_0"></a><a id="Tc_T0kb3tBPrEqIFLGKvRAkTQ_26_0"></a><a id="Tc_AXJ0hiReL02CQOPl16IDrg_27_0"></a><a id="Tc_oVA-WPOeCU-yNmvGpY4uUg_28_0"></a><a id="Tc_8OmVNr13-kSyN6U2mU-VDw_29_0"></a><a id="Tc_xI3F5Tggq0SwxHaZOEbUfw_30_0"></a><a id="Tc_Vu7G0buizkezlVsIhpyZlQ_31_0"></a><a id="Tc__1ibkH4O70WWLxvcRu7n3g_31_3"></a><a id="Tc_xpyJAIdgKku_BRNTdRRdxA_32_0"></a><a id="Tc_Tp2W2ypmsEKcTse1I7gUtw_34_0"></a><a id="Tc_f0yE2ZjC1EiEietYWAQ6WA_36_0"></a><a id="Tc_NUrRrkc3L0OL1UNW_SPo0A_37_0"></a><a id="Tc_w-yfdWzn60-bGYmYG6SImw_38_0"></a><a id="Tc_zyVhqRNhJU-ltk1jT40eQw_39_0"></a><a id="Tc_NUzxR5S_BEGl9Y1TdcfX8w_39_3"></a><a id="Tc_tdBbwBg0RECvNIpir7BI9g_39_6"></a><a id="Tc_HzlX-CjJG0GMTrDU80YrkA_40_0"></a><a id="Tc_zOxJlzvOWU2p2jbJJLv_DA_40_3"></a><a id="Tc_khRdf17UZECN30QXsimtaA_40_6"></a><a id="Tc_XPwjfUxhSE-08JfZoaEDuw_41_0"></a><a id="Tc_U74jokUF30awt_NX4Z0TBw_42_0"></a><a id="Tc_CQ3TlLJ_8UKD1bruYq51Nw_43_0"></a><a id="Tc_78utSQbqq0-Mxbi9vyNLcA_44_0"></a><a id="Tc_MmCgKjUjcUaJn1ygRdYGOg_45_0"></a><a id="Tc_MrxP465Vu0Cl8-d4_PyQZQ_45_2"></a><a id="Tc_9zSGn2CnEkGTjPTJSt2Euw_45_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Current assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Cash and cash equivalents </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_je64Ng6DYUuTO26NhKRx7g_6_3">57,826</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_j_fqfIkV_UGfmwtPzz_OxA_6_6">93,328</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Restricted cash</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_bZMs2ILblUSHc0BOAJceGA_7_6">2,049</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Short-term equity securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_gd5_3ytlcECpYuZTcn3CWA_8_3">335</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_HaIA-5omhE2pYEMQ1rLcrA_8_6">774</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Trade and other receivables, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_j5iB-Is6G0e1YiPa5t9krw_9_3">1</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_43mFhAa2Tkyan7QAO5nSYA_9_6">209</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Short-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_dQRjLKvQm06aEpZ5_AjuVA_10_3">2,366</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_pn_z5o2WZUaiPE1PsUe0ig_11_3">725</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_vUyTIGVZskGzUhVtflKM3w_11_6">613</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_u72OOld1Ikqko2MdA-Z2tQ_12_3">61,253</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_aNB3WDuF2U2_Tw_w8gxM2A_12_6">96,973</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_1LwV4KIwh0eNb5S12XVJGA_13_3">7</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_4ycBcGcGlEa3McbbCLhJyg_13_6">13</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_TSD1oqLIkUyrvsH-WjPc_A_14_3">29</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_x6_OXW6v0kiPFMBUDRRSaQ_14_6">200</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_ARCdnafZyE2GRfkSxWJJKw_15_3">63,683</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_4cM-tjbf-U2U-H3iQpPDdg_15_6">69,075</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Intangible assets, net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_TA1Stwx_i0Wz4-9CKuSmTQ_16_3">15,150</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Other assets - long term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_rZuXeWNytkipeFnbI-IigA_17_3">260</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_9D9aPKGLVEu0cNE0Ip9-ag_17_6">301</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_bJaqHN44YEur2dLZ3kj_aw_18_3">140,382</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_8rlDrkAcl0mErUifQ5gSMw_18_6">166,562</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Current liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_P0GFh-W9TESzqxFkFoSp2Q_22_3">524</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_u-LugVfA3kWzf4xAAtXBnA_22_6">1,072</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accrued and other liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_29N-5jpYCEyV94AxoyzZzQ_23_3">2,918</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_CqndnxjKX0i3Ea9ZJZ4MhQ_23_6">525</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Income taxes payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="Tc_w5iFJfwogUqlSukIyahE-A_24_6">91</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Contingent consideration under RPAs and CPPAs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_es8cICEX-0ODK59lpti_CA_25_3">75</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_ZXUxVNSd7UKBUyoEPLA6ag_25_6">8,075</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_q37UCdcz2kywthaa4Itj7A_26_3">34</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_NS8n7UQ13keGLqsjGh58RA_26_6">195</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_69opIzDgwUKKy4pslJV9Eg_27_3">1,899</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_CjxxdSEHkkusxN7cZdrcIg_27_6">1,641</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Preferred stock dividend accrual </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_8ZTqXRUhnUKO13l4D649bA_28_3">1,368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_cmwzpimFxkCGANE1PVO3jg_28_6">1,368</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_tXXb0Jew5kSSdguGlCBmXA_29_3">6,818</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_qp6Gjf7oxkSRxrx7vcwV7w_29_6">12,967</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method &#8211; long-term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_cozs0VsSRkW95qWMCUKxPg_30_3">9,550</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_ZoTlaP5bz0-32LjiT2Btvg_30_6">11,685</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Long-term operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_TMQJgSdG5Eq0T6G8sBAEuA_31_6">34</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_1Uy3WWgLc0SDbNjcYltMzA_32_3">16,368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_RO0EOMPCu0GITbZWUayCNQ_32_6">24,686</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Commitments and Contingencies (Note 12)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">Stockholders&#8217; equity:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Preferred Stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_qs4f4Bk1k0WjhLJLjLWPCw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_s3Vc2hMm2UG1rYkyrsISzA">0.05</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_JeM2sHbMoE6hB2xjPqRYDg"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_qeOTFXBY6EWihpURbMdI6w">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_9kj8-UwNUEq2gYckdKv-Kw"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_ewfmbA5SIkKVmfdHL--dKg">8.625</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series A cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_GUKVgwwBpkeo8Zek90VKVA"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_3Pdx6mCQA0ay767FWEAT2g"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_cTPbbVNPRk2ZDO92qjyiOw"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_L0_-6EzEYEeQDYZCJxVq2Q">984,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2022 and December 31, 2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_WeQsrAQfDEWB6tr4gDqS2A_38_3">49</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_sPhEOUWAQEK5CPKsargrnQ_38_6">49</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_uKAWW8o2KEi3qJQwv2gq_g"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_8d_NJ05ZOUS7dbxE97wKsg">8.375</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series B cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_YEohLPJ-CUaqp1cfFvZAXg"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_PoMXYC_AZEaYWxCLP5mHBw"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Ais0yhna1km6IewkERGMfw"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_OVZ8PwBuvEuKdykyyPECKQ">1,600</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2022 and December 31, 2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Convertible preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_E6WT7qwQEEqghXRQwmSRAw"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_noAqZMeDUECA1NbYFdje_A"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_oy-chCQt6kOlSuyigxIlow"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_KXrM0GPNA0G4mSls3o7j_Q">5,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2022 and December 31, 2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Common stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_NM365T6-0Ue1l0tsCy_J1g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_xAv3JSzj7Euij8TRmg1T7A">0.0075</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_TlA5n7hsnUS-Harc8Dibew"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_sPQrKpcrBEyShhzItcoaTA">277,333,332</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr__wT63UZtWEeUzyULd07cxQ"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_oSC_qskqXE2T2WvP6oghDQ">11,454,025</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> and </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_fPuNBGXh30uwa4WNNqWMYA"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_puhPHqk-c02STrUp01qhCw">11,315,263</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at December&#160;31,&#160;2022 and December 31, 2021, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_coJMQUHlLEabqTpv2Ig4Hg_41_3">86</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_KLDEeYh1q0aNeoZfQnxsxQ_41_6">85</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_93cPf-s8Kk6JKlgeswEHyQ_42_3">1,306,271</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc__QsFFP7JoUWVoTjtoTDPeA_42_6">1,307,030</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7.5pt;">Accumulated deficit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_ej2Z-pf0WkmZ0X3TrRrPIw_43_3">1,182,392</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_vskXHShsokSwYKdLPChEEw_43_6">1,165,288</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:7.5pt;">Total stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_P1Djw1QfZEmso_CQycSLMg_44_3">124,014</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_zRGEMsrl2kGLGyay3_C2EA_44_6">141,876</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:middle;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:7.5pt;">Total liabilities and stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_3NQQv5AkZEex0tJ33NmSyA_45_3">140,382</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_8mVyVgfuKkCSAXXqJ41aKg_45_6">166,562</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6035e9f1_06f9_48cf_9f1b_bfb3245e681d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><a id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOM"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eb8df63f_dbff_41ae_acbd_8e3ae1506f69"></a><a id="_4db16b99_e128_4095_b1cc_b6d9215cb5ae"></a><a id="Tc_-SuEvCTu_0aGbDWTuOnGgQ_1_2"></a><a id="Tc_YPhgdf10lUOV_EvPSPaCIA_2_2"></a><a id="Tc_4uUVMwDvbkW6KtYibIlyZw_3_2"></a><a id="Tc_77lSTdmYT02876yB2jc21w_3_5"></a><a id="Tc_pIiIOTkjc0u4Lm2coQ0I5A_4_0"></a><a id="Tc_TCDlH0vZ0keJfNho-Co1QQ_5_0"></a><a id="Tc_e8m_ha_au0avFJb4PyC8EQ_5_2"></a><a id="Tc_otWlG0BMxEevI9w1J00pUQ_5_5"></a><a id="Tc_6_68SAdvNEanhu7IAMqM2A_6_0"></a><a id="Tc_86VfJXVPq0qR8rAbwMQVFQ_7_0"></a><a id="Tc_yVbjyRNzbUmbTmwRztUgzA_9_0"></a><a id="Tc_zPaIUpjVN0iR-ZRD3rLy2A_10_0"></a><a id="Tc_MdmyJzNKm0uMEuqzWinIaw_11_0"></a><a id="Tc_nOTx0EUXAEeuITmy37SJ3w_12_0"></a><a id="Tc_lAl7YCjJrk-rpSwDmbYfMA_12_6"></a><a id="Tc_14XnPrfv_kCUq6h0cnquxg_13_0"></a><a id="Tc_-dWEJ2vi4kCAe_LdFxnshw_15_0"></a><a id="Tc_fW4qQIC-r0imqEzSQ2Ssog_17_0"></a><a id="Tc_5tyCaE5bhUC8L1NiFtHcxg_18_0"></a><a id="Tc_s4ZGBEBug0GmkHejEmB6Jw_18_3"></a><a id="Tc_elpDA8Czvku1oVGvpedx7w_19_0"></a><a id="Tc_5bp-RgG120ySDCgkllTejg_19_3"></a><a id="Tc_Ap5j6PwKZE2uGLizIfl12w_20_0"></a><a id="Tc_hBBo01G-GUCVoC55PiVNtQ_21_0"></a><a id="Tc_P7z5fVkZHEK-zkM9n02aaA_22_0"></a><a id="Tc_ro-7HAvXTESxCy0qZ60wfA_23_0"></a><a id="Tc_wpaG9Bd7pk2gdczc__JxZQ_23_2"></a><a id="Tc_o8GRw7VFRkCM3Zbg8Epz3w_23_5"></a><a id="Tc_L_gbexM2A0aTUvBCw91m_g_24_0"></a><a id="Tc_MScGvXKdNUa01COLQj1rOQ_24_2"></a><a id="Tc_L6C8loRv1UK8RlqDeG3RzQ_24_5"></a><a id="Tc_hjtVc2YDFk22eP9ak1Rk0w_25_0"></a><a id="Tc_m_NrkKTSQkOwlOdF5gKT_g_25_2"></a><a id="Tc_uU5-SH4nbEC-Wfkvn_H7zg_25_5"></a><a id="Tc_Z6xpGYFyJEOZKfEZ2DVGuw_26_0"></a><a id="Tc_1SHzOQQPtUqOjciX1YQuHg_26_2"></a><a id="Tc_vTTzutdEFUOKooVHrOsOog_26_5"></a><a id="Tc_PIJQRsXS5US7XsdJOmh3tg_27_0"></a><a id="Tc_Z9Ry8c0itUyOvf-Gks8h3Q_27_2"></a><a id="Tc_QxYL3ZRhUUKhp-gcMP2Vaw_27_5"></a><a id="Tc_L7Mz7_YUDkqgpSSMNu9tvA_28_0"></a><a id="Tc_-PvfS5xYvU6l3oLtD9LYMQ_29_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_AfcYSGcJRUShJiSs_lVe2w_5_3">4,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_IR_lEfC56UeUaiofp1S4Uw_5_6">36,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_FisCD6CUSUKWinUDPrpAKA_6_3">1,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_p67YrCPWkUO381dA1-Adgg_6_6">1,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_AJLhfrwdh0uVsPTzpot-qw_7_3">6,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_eBO_VkXjrECg55hn1Yn2ZA_7_6">38,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_oJuDMX0zNUSwWH6iP0-iXQ_10_3">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Aum_luVR1EKdsvklq-gWtw_10_6">171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_-AB1TrGWKU6F8oxe64FUwA_11_3">23,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_zfHfuSSJi0GhgChqaRSdeQ_11_6">20,460</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_ZPENP58OYEO3_XZ62YEp9g_12_3">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_bxBcwoUKLEy6rIncOt_8VA_13_3">23,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_yKxJHKk6HUWZmn9BqPYQuQ_13_6">20,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">(Loss) income from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_KxAoRmvbSkW59kPqKMW3oQ_15_3">17,414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_tlhH64Ptsk6tqK7ltEmHbg_15_6">17,529</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense), net:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="Tc_g8s2ML_srkiGQpayWa0yDg_18_6">461</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_7AxuJNEcMkOUTLXSwECQ6g_19_6">300</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_wrt8fdkU9UKv_WmO-Kuoew_20_3">295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_ktBuud4qSES9TwB3-SHsYA_20_6">879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">(Loss) income before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_McbPCeux-kG51nDurAunog_21_3">17,119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_yodO-Zne5kqFTOsHwRPfVA_21_6">15,889</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_DrGtK3mRVU-0Ngzc-L5gwg_22_3">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_z5Lolm6esUGUlGRu8_0y-A_22_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net (loss) income and comprehensive (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_szOhLjMdFEiOKRGSTFBejA_23_3"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_szOhLjMdFEiOKRGSTFBejA_23_3_2">17,104</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_UQwW6XkLvUSYO6DKBgrTAQ_23_6"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="Tc_UQwW6XkLvUSYO6DKBgrTAQ_23_6_2">15,798</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net (loss) income and comprehensive (loss) income (attributable to) available to common stockholders (Note 10), basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_R16ZX2VluUeQ4h6CSK53kA_24_3">22,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_ZgxxlN1s2ku9vbGlmd55vQ_24_6">7,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net (loss) income and comprehensive (loss) income (attributable to) available to common stockholders (Note 10), diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_FDRKkNrYbkmyawEAm_Tegw_25_3">22,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_RVrJQoAdAUiPH5SytYxG5w_25_6">7,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_iE-1Fbj6-E6XhYxXOm_daQ_26_3">1.98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_A33QM__TAUa6xW0NxNXxXQ_26_6">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_oquLCoxMaE-gw90aL59rTA_27_3">1.98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_a2DGrW3GbE-fGuHhJv4iEQ_27_6">0.65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_7TDayCjMOki_MfYvseSQIw_28_3">11,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_5loauwCjqEm2WG9fAM7y9Q_28_6">11,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_1Gu_SCXK50WgP-FRdRYwHg_29_3">11,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_8Keb8gng1UCONHfUTCVFdA_29_6">12,192</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f7d9dee8_365c_449a_bea8_632cff6eb5ca"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><a id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b25a3d61_0084_4cc6_866a_1f280648c953"></a><a id="Tc_9h8zqXJRtk6tY2LpOaDfCQ_1_1"></a><a id="Tc_Ofr6NW18bECkEznmHqt63g_1_6"></a><a id="Tc_6vEenAyLGkinlIG4SgmXtQ_1_11"></a><a id="Tc_48nTGbVmLUCwL8Xh__IYwQ_1_21"></a><a id="Tc_6oup4NNJrEij1EgtLpQmoQ_1_27"></a><a id="Tc__ZPPYP3mAEWvQ6f2V2RA1g_2_1"></a><a id="Tc__NPS2vr_r0qeFh8VFN7KBw_2_6"></a><a id="Tc_YkyP6NADK0yq3GyHQ5L0vw_2_11"></a><a id="Tc_8UwpNKgYg0KaxHJk6X4M2w_2_16"></a><a id="Tc_0xc3AK7xBU2xKuKud8d8QQ_2_21"></a><a id="Tc_SO-07NQQTE-bacd90AAJKg_2_24"></a><a id="Tc_Q-L5hUWFLES9ciaKKEO0Uw_2_27"></a><a id="Tc_-weZDekLt0mjBIwZTHaSOg_3_1"></a><a id="Tc_3RlOj5u3T0OqasdOZ_gsGw_3_3"></a><a id="Tc_I7qwQ_io9EiURgH3Mu5M2w_3_6"></a><a id="Tc_5gA-QbBw4kCtHaxAJKoeUg_3_8"></a><a id="Tc_blK98fR8tkyzmxcCdDwUOQ_3_11"></a><a id="Tc_hKOOuaNrfkSg5KidxPyqsg_3_13"></a><a id="Tc__7iTIpB-Q0aHbR-Qv7MQ0g_3_16"></a><a id="Tc__3PJX3PajkaCPr1uTZeiuw_3_18"></a><a id="Tc_pFjAzU7HNUa3NgwrlrbIcw_3_21"></a><a id="Tc_RFGxjoebEk2pCQrKPbwmbg_3_24"></a><a id="Tc_Ee8PmdXjl0elOpLZQTXWqA_3_27"></a><a id="Tc_BVfoEwJsTUK86W7ctTTfBA_4_0"></a><a id="Tc_FiqRHjtp9UWpi1Pdd2fs9A_4_3"></a><a id="Tc_BRgPjW9HdUuzU4ON4Ubqhg_4_8"></a><a id="Tc_hNj1pxnkQUWx3oUnm8j7iw_4_9"></a><a id="Tc_76Sptpo430uPkn6hLP2Yrg_4_13"></a><a id="Tc_UFbEzewIrkWvQ4BnpHsjow_4_14"></a><a id="Tc_cu7W9Jj5kEmYQyeHTKn2Kg_4_18"></a><a id="Tc_IB1AwxtCgUGahRVHqgo-Hg_4_21"></a><a id="Tc_lYLMf89Bfkyo9Qcvkf_u9Q_4_24"></a><a id="Tc_pBu0so9kVE62IB3Dpd4eDw_4_27"></a><a id="Tc__FFBY37-MkizS4lUFuPC0A_5_0"></a><a id="Tc_atYLVrxYfUS_mXLKCdding_5_1"></a><a id="Tc_a0U5kyrBzEqnYKzy3asqXg_5_4"></a><a id="Tc_vgcD1tjBGEm-h41OzvDILA_5_6"></a><a id="Tc_fzJDw1WswUaMDNe9bKdNeA_5_9"></a><a id="Tc_morFyMOdY0aOGcUrrQfb9g_5_11"></a><a id="Tc_SCusQhDuC0epVw260iLwBA_5_14"></a><a id="Tc_zhyv_QKi4kes5Ldc0ce71w_5_25"></a><a id="Tc_Ds876t7Y5EyNBjq5d-NZqg_6_0"></a><a id="Tc_6iTXPwKD7Uevj6lrynGglQ_6_1"></a><a id="Tc_FAgXBDb9T0ytMAc8ZvTpDA_6_4"></a><a id="Tc_C44Znj4ytkqvsEkvpQXwvA_6_6"></a><a id="Tc_TKPgqF3ZAk-xTzoC4y6VrA_6_9"></a><a id="Tc_-oAC9BnyPUO_1tfMstoCAA_6_11"></a><a id="Tc_UHn9XTPoIUqcwUxDHFcqqA_6_14"></a><a id="Tc_SJXACbPT20GNvmyZIj3IHg_6_16"></a><a id="Tc_ER2AJBIFTEmsOXWiwQn6EA_6_19"></a><a id="Tc_op0dBF2I-UiL9-EWsT1RBg_6_25"></a><a id="Tc_GaFHe3fv1ESumn-172RdQw_7_0"></a><a id="Tc_NhUsfQ2mNU6KoKMJHLPSRQ_7_1"></a><a id="Tc_UifFsGB-mkmM0-fZiKW-BQ_7_4"></a><a id="Tc_lLpIv6GQ9ki_mrzKezT6KA_7_6"></a><a id="Tc_-ydNKAUL4EmbqOnjwQrNsw_7_9"></a><a id="Tc_2Ab8_T2MREG_siJawUxn4A_7_11"></a><a id="Tc_45HDBtp-PkCqDNAyPtEZQw_7_14"></a><a id="Tc_zMvPj0x6-UC_G2-bNae8Gg_7_19"></a><a id="Tc_nPzGfWBqEk2a0sP5emxKPQ_7_25"></a><a id="Tc_0_mCQxO-W0qKNKlNA8-2Rw_8_0"></a><a id="Tc_eOrOXQw0Mk2YCp9Xz4Fa9g_8_4"></a><a id="Tc_aPcIhklLjkObJZJWQTKSSA_8_9"></a><a id="Tc_2MfozIDoq0iLUgXNQ8AtOQ_8_14"></a><a id="Tc_o0KWZUOy-0aTrBvyjf4qaQ_8_16"></a><a id="Tc_4q3sLBdN8E6di_6c9P1HNw_8_19"></a><a id="Tc_GBILUVnQTU-1eiZ4dxCMcQ_8_25"></a><a id="Tc_Xff-7MwzIE200Kk8Eu5-vA_9_0"></a><a id="Tc_oy1k0-MipEStD8fdqxi5Pg_9_1"></a><a id="Tc_DH8Ljn9smEOWU5IXy0Ce-A_9_4"></a><a id="Tc_rrJvOi2aEk6Ne28f3y8beA_9_6"></a><a id="Tc_VMj1e6y_RU687EpsCFeakw_9_9"></a><a id="Tc_9jgBREhabEm69Dd6mvV6WQ_9_11"></a><a id="Tc_Jvd8awY37EOMoS7H6c__vQ_9_14"></a><a id="Tc_LoYlUOM11UC8XbkdVosRLg_9_16"></a><a id="Tc_DG0kX3C-EE65cJXlYOX7ew_9_19"></a><a id="Tc_b7si0e6AxE2fdiT2qSGeBw_9_22"></a><a id="Tc_5IvnR70110CcdN4EU2CsQA_10_0"></a><a id="Tc_dTwPuysElUKUG9iNg0lNfw_10_3"></a><a id="Tc_53lE8h7YvEqBDIZvmYn80Q_10_8"></a><a id="Tc_qqT1fOSi2Eu3JI2eL3RulA_10_9"></a><a id="Tc_wcIkti6EVEyl3Iq56emAUw_10_13"></a><a id="Tc_7UMt8XvU4EC5WOX-dN3UOQ_10_14"></a><a id="Tc_6i0V3ys0s06UknNebpXwaQ_10_18"></a><a id="Tc_ATjZjaxwI0eTmyMmFkazOQ_10_21"></a><a id="Tc_gec42dtH5kuCqnYt4SOlhw_10_24"></a><a id="Tc_hMycGBiyoUmJmtA8YQe5Ew_10_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_vQwMZUIjlkK21tVvAQmxiw_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZOzNI1DrZEGxVECSfnMO5w_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_KvTnTgWd0UW5Rjfacfj8TA_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_G_kWhrXNpEKAC_CxrE9pPg_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_CAH_AcX6CkCrAep7AqoovQ_4_16">11,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_N7qdQV4-4EKb_6sUEu6AXA_4_19">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RH9hqR8qmEylkS9dmwcVCA_4_22">1,307,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BnOCrJhW80iaq81uuV1DfA_4_25">1,165,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_liSMQo3fXEaIyT466QtrUg_4_28">141,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_z1ynA4I2ykqxBFXvfSU6QQ_5_16">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_01oeGB8Ohk6LqicO8ZPtFQ_5_19">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_4uJ6AivT3E-2WdF1IQm2wA_5_22">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_7rZrvhfO-0Oee_0yN3ZF8Q_5_28">930</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ZeFyjxw37kW3xQq30hD5Tw_6_22">3,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc__IbAJiunKkKHjUBrgBnsIw_6_28">3,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution and ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" scale="3" id="Tc_gAIWJ4Spi0es5vQk9FSk3g_7_16">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_LG0zJQ7iOkGlP9I_WimReg_7_22">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_0uI0y7YpZUyvNpX1awooqA_7_28">176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_Dcyv7i2IYkWjqZpv_qE21w_8_22">5,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_5qq5YBOVmEGEWpiAsuiuDQ_8_28">5,472</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTSoj4BvgUOQEPopJD5s6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8X3vlz6lMkiAyTymzCOocg_9_25">17,104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Nc1ySng0s0uJePV13g44KQ_9_28">17,104</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Kw6qb0Sfnk-G2qeKRBMjiA_10_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Qenev3yvV0SWLUoYoE6s_g_10_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zMpMm6r57kGoeIrwyong2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_M9OnCtkOk0Saw2wCdR-9oQ_10_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bnirjFhGZEq0-FJZJXu1DQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_js8vShVnOkOKWlXQEAwooA_10_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_6nlcAozO5E6px3sYRHV5eQ_10_16">11,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JolEGH37NkusDk0bLGi3jA_10_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHPRrMM4WkiFXB-GwNaVCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_cOILZtbtKku13wrUc3LrhQ_10_22">1,306,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RKKUO79jyUSa60B9WdlKKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ws0i1h4KVk-hMXCGmoGKSg_10_25">1,182,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r1AyXH-RQkWGefqgr9vAfQ_10_28">124,014</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><a id="_3bdc08a7_8b87_4788_a5c9_11d94525ad69"></a><a id="Tc_YWiEzPsYi0KKeRFmdeal8A_1_1"></a><a id="Tc_bDCxz2UBTU69b6fR29Csjg_1_6"></a><a id="Tc_WVwZ6agODUi59zc0Z4YhvA_1_11"></a><a id="Tc_9O_UpD2Nik6O1rqr3hWRyA_1_21"></a><a id="Tc_GoE3zcUISUqrHIOUzMMHMQ_1_27"></a><a id="Tc_TazBuToaj0ColDjfqk_eIg_2_1"></a><a id="Tc_FhDRhed8vUecClLonua4XA_2_6"></a><a id="Tc_Xx82Eg7hG0WCIHzO0gYf0Q_2_11"></a><a id="Tc_vrstx9RVm02IWF2zvgYqWg_2_16"></a><a id="Tc_psYJf7qYW0Sah-0rzS8WCQ_2_21"></a><a id="Tc_Os-zSUWM40OnhUu-cALG-Q_2_24"></a><a id="Tc_avoeJ87Vck63A6fcozT6Qg_2_27"></a><a id="Tc_0Cs3GduQEUajcP6KB-ELmQ_3_1"></a><a id="Tc_BuTUXLh7rkqtnnjPTGqsfQ_3_3"></a><a id="Tc_4Z88hg34_0KljdDI1zu2tA_3_6"></a><a id="Tc_EhRTi19zy0COetw7HPCnrw_3_8"></a><a id="Tc_B03gn-HRmUKWR2g69u17pg_3_11"></a><a id="Tc_mj5eMnl1V0Gvb2Y7198BFw_3_13"></a><a id="Tc_wYzA8BCdbEij51uOHYvIfQ_3_16"></a><a id="Tc_6-VHqCVAR0O03DXZDvvsiA_3_18"></a><a id="Tc_5GkQE08XmUeKFLWc-y1zNA_3_21"></a><a id="Tc_O3tuOSehzkKvgzwAtCfP0w_3_24"></a><a id="Tc_FRkXRW7hK0e-rg8zA_Pq5g_3_27"></a><a id="Tc_FPOllBYvyEGav-5jtZt-Bw_4_0"></a><a id="Tc_yUBP-6k0EESh1Feo7DBH7A_4_3"></a><a id="Tc_Zx8YyWiHE0WuCSyqk6Ya3g_4_6"></a><a id="Tc_624Ojx0tNU-OoFprfjrrIA_4_8"></a><a id="Tc_PuVo3_G5iUOVaVLsv0h5Aw_4_9"></a><a id="Tc_qhONA6PjnE-Eqy_Mus1Wzg_4_13"></a><a id="Tc_VTtDZhafjkqcOhDYYN8b6A_4_14"></a><a id="Tc_4BmIDjaHiUaAPqzN0hRtyA_4_18"></a><a id="Tc_VOsggXDvLkyKN-2_gIPwRg_4_21"></a><a id="Tc_MdMD3o-jAEqbEWWzri84Kw_4_24"></a><a id="Tc_rp0_qAqTE0K8hTbL1gEx1A_4_27"></a><a id="Tc_DVQUVZGKR0-xGsvvdlu3hw_5_0"></a><a id="Tc_mBihNDLBxkSTEHfsLKwYpQ_5_1"></a><a id="Tc_FMe206UhX0q62nC-tYIXEw_5_4"></a><a id="Tc_p6LvocSDzUWWBSRhrlS9zQ_5_9"></a><a id="Tc__KgqXP68a0-V0RVbLzY3dw_5_11"></a><a id="Tc__z0S3byugk6fXdsrad1JJQ_5_14"></a><a id="Tc_gehwAAn9G02vQ7Ytv4XHfQ_5_16"></a><a id="Tc_g8bQY_ypGUKyaKb-HAD-kg_5_19"></a><a id="Tc_IdC1wLb52kGWjzT4HohgpA_5_25"></a><a id="Tc_RnNQHtMDKEiCFJEotCBPRQ_6_0"></a><a id="Tc_WBwfYV8G_Eeavh_EIbaACA_6_1"></a><a id="Tc_qqWOw5daWk24Rk6qPPxIkQ_6_4"></a><a id="Tc_Fx4-Rr5nU0-AVqXaE6JcCA_6_6"></a><a id="Tc_s2t7qS7nf0CYlOTtrM_feA_6_9"></a><a id="Tc_BZ5SmpXrF0q16HoKa9LGLw_6_11"></a><a id="Tc_jSmcUdKovkOhynJsMspqMg_6_14"></a><a id="Tc_tD1NU2p8mkyn7llnOTFADA_6_25"></a><a id="Tc_sH6OU3xxeUakGfRuHtq9EQ_7_0"></a><a id="Tc_MIEZ5GOnx0iHfpLSnPb_Gg_7_1"></a><a id="Tc_sBAQaAUjQ06QG2fBxNGCFg_7_4"></a><a id="Tc_CKbGm7CD70SStx5-mZbHBg_7_6"></a><a id="Tc_15rxX72ZTkC2r4V8j20IaQ_7_9"></a><a id="Tc_XfFtONOBOkmFrVjCBX5ZhQ_7_11"></a><a id="Tc_iFZPBwXoskiZlHVc-oLuGQ_7_14"></a><a id="Tc_rNTMpH1rHE6dLSIeZWOfxQ_7_16"></a><a id="Tc_5Qb3l9-xpkCyrmY2BTtkYw_7_19"></a><a id="Tc_QX8UsiQEJkiP5VrgJ-EAig_7_25"></a><a id="Tc_j9SQtvyP9Uy_b8epWkpFBA_8_0"></a><a id="Tc_4LbWK_-f_0qBsbJZZVTlow_8_1"></a><a id="Tc_KLhki5al7UamhEQ3hS469g_8_4"></a><a id="Tc_xDtq051c6E257qKb0GI18g_8_6"></a><a id="Tc_2dT9UpNwZUyCZVfLpNwAoQ_8_9"></a><a id="Tc_1cY0U-y2zU2J-XGiSiLw9w_8_11"></a><a id="Tc_rsRGKwUaw0qrm0AjQOj3Wg_8_14"></a><a id="Tc_iwDxHkeXKEu8ZrzRm1fibQ_8_19"></a><a id="Tc_qFU1RaSw8E6bykJnYdZfXA_8_22"></a><a id="Tc__q83FXYBOka2GHOb4pkefQ_8_25"></a><a id="Tc_RPWMc9Y9_E6C2SKK3Zs8Sg_8_28"></a><a id="Tc_LUFvhNqNDUqqDA_-8h_ybQ_9_0"></a><a id="Tc_R4AFUuB610KstFMwK_a1jQ_9_1"></a><a id="Tc_v5Ygda1IgEykRuq24TmUyQ_9_4"></a><a id="Tc_v-URUG2jkUGLjOcHBsEaRQ_9_6"></a><a id="Tc_HUgRJzMD5UGQfzLFPu3txg_9_9"></a><a id="Tc_pAEo30BPw0-HleqsufWyQA_9_11"></a><a id="Tc_Ay95OAFVeUiyEcGFUJ6v_A_9_14"></a><a id="Tc_xBs_u8I6ZEGNRmrFBKWlCQ_9_19"></a><a id="Tc_kW_DlGnTeECuszEthDLxvA_9_25"></a><a id="Tc_GeCCweebGE2YihmZJ0Ll4Q_10_0"></a><a id="Tc_fDwHA0EyqEqMwtuh_DHPAg_10_1"></a><a id="Tc_z30tvfFIPkaGryMHHD6ajQ_10_4"></a><a id="Tc_-IPVmPHXBE6Ot1kY9mgLhg_10_6"></a><a id="Tc_hFZPd9lYYUClQBuSp7oY1A_10_9"></a><a id="Tc_ZwHz1kaoq0eeCaHA2RVSRw_10_11"></a><a id="Tc_McDtF3RftEuDav87mex0WA_10_14"></a><a id="Tc_v-DP2znTQk2QvUzOAU4WrA_10_16"></a><a id="Tc_w0PEkvWV_kqLQPn7VTEyLw_10_19"></a><a id="Tc_0rjsw6t4FU6P7FNFKO9ohw_10_25"></a><a id="Tc_0B6_c31XNUOzs_85GcEu9w_11_0"></a><a id="Tc_v1gxnDhc-0iQNkRR10P3hw_11_1"></a><a id="Tc_tIxZnJFjREmPgMWFn0JM6g_11_4"></a><a id="Tc__uP_QLme2063rcr6pdP0FQ_11_6"></a><a id="Tc_cETFnk_BE0ekrcLnic-tdg_11_9"></a><a id="Tc_ettVCkp6mUaVq3z8qR0FEA_11_11"></a><a id="Tc_Fz8fxM4J10-M_wFedUEQWw_11_14"></a><a id="Tc_s1XlLXS37U6otk1RvcqhsA_11_16"></a><a id="Tc_B7sVuzZFeEyPDfPvkg7sgw_11_19"></a><a id="Tc_Bac5uGyIBUmYrcTsJOsPHg_11_22"></a><a id="Tc_c_8pfwFJ6UuvtX16GKbcEA_12_0"></a><a id="Tc_OAjBWOTasEyrhD1EljWWkg_12_3"></a><a id="Tc_5TqBgqb1OkKt_djXPLmK_Q_12_8"></a><a id="Tc_rqb223nI7EyBGzbID9vpkQ_12_9"></a><a id="Tc_D-fdy7tU1kCr_--9DXvMFw_12_13"></a><a id="Tc_LvrCGXUDikuUI6iGBqi_MQ_12_14"></a><a id="Tc_nOuRiu-LjU2YIOIicObKFw_12_18"></a><a id="Tc_fa6ikGThfka4hfXjO3-_dg_12_21"></a><a id="Tc_K85P-zC6kkuN4B-B5P9pQw_12_24"></a><a id="Tc_nNrT0xMI_kmxdU5dJVpZkA_12_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_a3oi0WX4a0K70SSR78LuQQ_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4mvkXYIs-UyeGKROWIiCrw_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i9sxLuyDfkyzZdNDX8SCMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_1gVV6oZyA0GJChC5kgN76g_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_nxDXbxyTOEy94T1vySUmdg_4_16">11,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2HfeCbG150qTODEhtStwOA_4_19">84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9iAqnNnr4UCD-KQ4aTDILg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iJIvMM31Dk-qKT-nbWYcsw_4_22">1,267,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7mSqMJYiC0-QLMIxAQYuXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rGKQRctgiUulZnFgvHJ54A_4_25">1,181,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JgXlQ-gmyEupBWjz9Bf5hg_4_28">86,424</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ty0cbCyI1UahHddWl2YJhw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="Tc_9GdEmzSAg0KVXXdHi4GmhA_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_V6ftizE4GEuLav_6HaDKhw_5_22">37,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_JT66qvFEUkyoP0PVFeOxAA_5_28">37,140</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_srgr_IJESU26SJ3yRR-fmg_6_16">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_1YHnvxergEGaxHRwwLAVnw_6_19">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_fGeMj7EW_UOkIwvmxXWHbA_6_22">1,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_5p_m61aWfkCMnZ5Hu_U3vw_6_28">1,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_0xXKsFB7fUSjetFBI7EZ9A_7_22">6,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4OzBBLY2akWJhm_4bm2AEA_7_28">6,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of common stock warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="Tc_tY6A1TUQokGn8wlvsxxXEQ_8_16">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution and ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" scale="3" id="Tc_X1FuBj7DIkKSfHXh_psRfg_9_16">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_Sf4db39o1EurZIwIMVjHJQ_9_22">133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" scale="3" id="Tc_TP3C6azz2EehTBjbX0pZpQ_9_28">133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_x_inK-YxMkWBmimdfwMB3w_10_22">4,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_dQ5DhTGtMkybri91cyPfLw_10_28">4,867</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net income and comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wf94VZSnXU-Wpl7zah_jxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_xT-t6o2h-ke0df9Uh4nrWQ_11_25">15,798</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_INZBzDFj10mVN2-D8wKOyA_11_28">15,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:18.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Lq2yClLQeEaHLpyHu6hHxQ_12_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hwSMMTJ6L0ixjvyAgqwvNQ_12_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_MGWuKrxDSEWhsJaWdFDs5Q_12_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_ENQ73CanRUSKHC3GBxcfjA_12_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_stYnjBbz60awp1fVuAlISw_12_16">11,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AvIViKiMFUqF9FSb8LgIbA_12_19">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QrkbwE0_N0WZd1eohg5Ubg_12_22">1,307,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_sgN2xx0FCUiRS4vq9bwUag_12_25">1,165,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_hytxBFldUka6YPPaOai6uA_12_28">141,876</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1b5143f1_67b1_4f1a_bc38_dc1ca578126a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_524071"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_8d779f07_0503_4111_b4d6_eda4a9ab93a9"></a><a id="Tc_kaTp5yknR0eN_p2zaImlfg_1_2"></a><a id="Tc_0C_fTn6lgkivO3cb_TyGhA_2_2"></a><a id="Tc_slz5JTqjOEKZepxAX6RbuQ_2_5"></a><a id="Tc_j0yIgm1V8UWcWrrJ30g8PQ_3_0"></a><a id="Tc_fvuVmC3xdEygdBiFIxUd3A_4_0"></a><a id="Tc_TRs8CyShHkqfmoqX2-ek_g_4_2"></a><a id="Tc_qJ25027WEk6dcHNzZko0ag_4_5"></a><a id="Tc_W_Z48Vm7cE2lJcRI49-nBw_5_0"></a><a id="Tc_pxF4mp19YU6r-KMY3UcDIA_6_0"></a><a id="Tc_YCHvvWeKeEmdFm_cWx0XfQ_7_0"></a><a id="Tc_TvkXJmA_E0COf6Yb9SVMcw_8_0"></a><a id="Tc_WUXQvVun5kG06lhSRV8Kcg_9_0"></a><a id="Tc_Y3zQTptR40e1h6XUavOfdw_9_3"></a><a id="Tc_Le5at-GfOkung7IMvB_Efg_10_0"></a><a id="Tc_CNqHaEk7NU69gNPl3xDe2w_10_3"></a><a id="Tc_lAKYoRbULkGMCa15PYQwAQ_11_0"></a><a id="Tc_6La8zL6iNU-i6h6Zgxkp-w_11_3"></a><a id="Tc_b-6CwWvF70WWWfwxExC7uA_12_0"></a><a id="Tc_eco0JBPwSk-sCnJGiiYVmQ_13_0"></a><a id="Tc_PblkfbVp1kOBSl6DlFkUSQ_14_0"></a><a id="Tc_T_6T5CSlT0WWToh42-GsRg_14_6"></a><a id="Tc_JwOQSkW2P0K7-f4wjQEF-Q_15_0"></a><a id="Tc_zN-gUnCx30acrWer5SWjLA_16_0"></a><a id="Tc_0G5FrPcNjkCh7VEx4OcmqA_17_0"></a><a id="Tc_6T5n3h5ZpkysBLA8ImV-bw_17_3"></a><a id="Tc_ZwEY7b81b0O_S9z79xgA8w_18_0"></a><a id="Tc_xBLOk2EeuUuwCWaP1ge1Rw_19_0"></a><a id="Tc_v19VABdYTkqUHZHlXrK9sw_20_0"></a><a id="Tc_oQ3PFkr9D0qbZyVKAQDHkA_21_0"></a><a id="Tc_ycmP3nez9keedAk3FJL-sw_22_0"></a><a id="Tc_AQaf_oV48kunHrZjMiDO6Q_23_0"></a><a id="Tc_gj6fOJmMPkaL2Obw-pXuFw_23_3"></a><a id="Tc_6Zl_Z6FW2k65zXHT4hZagQ_24_0"></a><a id="Tc_hLHG4l0VfkeL5SiAr2UQ5Q_24_3"></a><a id="Tc_wp-iIqajvEqHB5DMKLTeBg_25_0"></a><a id="Tc_U8Nb_p0ar0Ga9GJfKTE6Fg_27_0"></a><a id="Tc_kfLkT7ocTEuAepW96vxqbQ_28_0"></a><a id="Tc_7m0JbuMAHE2EgShTonw0zg_29_0"></a><a id="Tc_jMrOVW8CRUyySo9h7FGnSw_29_6"></a><a id="Tc_lcli_hjpY0GZv5CW2q055w_30_0"></a><a id="Tc_qjyFZ66UtE6CNACkGJV7bg_30_6"></a><a id="Tc_eyt2QoGUtUO-bhN2W8xfQw_31_0"></a><a id="Tc_gzJZcK-PjUafhTvHL4zYbg_33_0"></a><a id="Tc_3eKXTC0F40mNyCcp23DsCg_34_0"></a><a id="Tc_P-WffXOIMEi4_VFjrc_YyA_34_3"></a><a id="Tc_xlg92s0nUEyrbUvDYFLaOA_35_0"></a><a id="Tc_VOoIY0RLMkWCM3EDGaHV2g_36_0"></a><a id="Tc_deEu6K_WhEGSPGZN72XY7A_36_3"></a><a id="Tc_Zd-VxjipP0Cwvqi-YUpkww_37_0"></a><a id="Tc_Ib2ppj_EMU6nnnrOMfjm_A_38_0"></a><a id="Tc_XKyJTYtlxkW7PQ12q55_9A_39_0"></a><a id="Tc_OqJpo_3_bEe0B--garroew_39_3"></a><a id="Tc_-5EuHTbPXU-sOR6C49ibgQ_40_0"></a><a id="Tc_LJfQ7CgpDEWhwKfDgkCiyg_40_3"></a><a id="Tc_NiBfCvOGcUahlG5GWa_zgg_41_0"></a><a id="Tc_SJ5IRl_1y0mdjcNCsFGyGw_41_3"></a><a id="Tc_cga7j85O6UWjpOoe4b4W7A_42_0"></a><a id="Tc_OPTGcPum80qk4tem1Te5gg_44_0"></a><a id="Tc_SggqbPlCR0-OMCcb9R238Q_45_0"></a><a id="Tc_XJv1verClEGqh9EAx_xxXg_46_0"></a><a id="Tc_MV3bqzwkTUSNjNt0pj0qiA_46_2"></a><a id="Tc_Swb1xCRPmkGT-bgw8QVcew_46_5"></a><a id="Tc_Gav4cFg5QkWaTmqeaoBDmA_48_0"></a><a id="Tc_wU--AMlI3UmdlEQilEu82w_49_0"></a><a id="Tc_7BVqTtzpjkybesBr-_owng_49_2"></a><a id="Tc_EbiTscii5E-bhyYlXQjUXw_49_5"></a><a id="Tc_sAKPl01eTU6NSSxOunLDbw_49_6"></a><a id="Tc_jjfagP_aZkCPJ8y7uM2_yw_50_0"></a><a id="Tc_T52s9GYxOEuQL3OdVjoiJw_50_2"></a><a id="Tc_eUGiaUE9gUavrD0gvZWuqQ_50_3"></a><a id="Tc_Tpd1Mapv006ymtvCIWrO9A_50_5"></a><a id="Tc_VOUoF1qFe0iRYNoqpsNQFQ_51_0"></a><a id="Tc_dwmGIEpi8kKvzSPgwGj1oA_52_0"></a><a id="Tc_oVBhJCVZNEyETvjrXLUJcA_52_2"></a><a id="Tc_TJ4_J48z_kGxSbkjXtJE9Q_52_3"></a><a id="Tc_nq-f06_N_Eq9u7_Sx3bLlQ_52_5"></a><a id="Tc_i6aouPKLYkGv7ZhjurAWTA_53_0"></a><a id="Tc_1ADoFRgv10KcxSioCka2kg_53_2"></a><a id="Tc_-5ynOc1zlEiQAsCZqGF-Jw_53_5"></a><a id="Tc_TtC1f5M_w0mcf0dGUTFagA_54_0"></a><a id="Tc_2vNXppUV_U2JS9YXq3SB6A_54_2"></a><a id="Tc_7A5eQF5yMEmunATTxOFKEg_54_5"></a><a id="Tc_NyreOdR7KUit-x0EHzqXjA_54_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net (loss) income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_k5UBGCmT00ex_rRTshxAjw_4_3">17,104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="Tc_QQsWsT0SnkO_-BF9_8BrGw_4_6">15,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_9i4VSiuAMEKo1C5XMawBAA_6_3">3,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_J4MMYUDs4Uu155NbGgl9_w_6_6">6,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Common stock contribution to 401(k)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_mllULS75Sk6572iyfNoY-Q_7_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_mKK5w8m8iUqQHCeZLwNQ1w_7_6">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_eKHcMKeY90aWQseOvI_yhg_8_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_ogxcar0Y30--ubdlUe8k_A_8_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of debt issuance costs, debt discount and final payment on debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_tuAXObJBQ0yjBCKFXk8MIQ_9_6">200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_XiuH8eBng0CYjCOw1pToRQ_10_6">300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Reduction of contingent NIH refund liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReductionOfContingentRefundLiability" scale="3" id="Tc_5LSyI3E9xE-pbtCdh2wnIw_11_6">105</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_iLpZS_O5iEq2RSSs-zjwxg_12_3">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_UASHHrSmjUyjpsMrYcd_0w_12_6">160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_0bCXZ6ZFd0C-u26jpgD_qA_13_3">439</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_Cwg7Q0WW4USLG4wB4HCzmg_13_6">919</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"> Amortization of intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_dhq0N5T7fUKfgSPoEyUl_w_14_3">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Trade and other receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_A00Nbfb-UkKfzAx12OLe0g_16_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_gte2zQB2EEyBN_N7jbDu3A_16_6">54</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Income tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" sign="-" scale="3" id="Tc_NVjlJ44DjU28XyudVhi9NA_17_6">1,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_WiKGoB-s3ku4ifc0Enjcog_18_3">71</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_PidSA5dzkkGzcIsU5dJ0fw_18_6">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_obSUTG7uXkC9khwqkbJAeg_19_3">1,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_OjjHrmwHqUOkCLPx9OCqmA_19_6">765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="3" id="Tc_SG2HGTjbK06nS55qQQOCfA_20_3">91</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="Tc_UQy92uI3vkmbDz7XieLJuw_20_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_DeO2_8eLCUepxCkl4hQD3g_21_3">195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_nv0waxqzzUarrbgRYaKzBg_21_6">179</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Unearned revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_Dyo4iBxEskeH9RSHNdxnrA_22_3">1,877</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_SP9SSYlZKkimyRg292quPA_22_6">1,642</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Contingent NIH refund liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:IncreaseDecreaseInRefundLiability" sign="-" scale="3" id="Tc_4MidNrVjmkanb71qY0mWtQ_23_6">1,305</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" sign="-" scale="3" id="Tc_g9vbbAxbmEqJ7IKMcoIZCg_24_6">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_67hi4SChf025rlRdolLwdg_25_3">12,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_gPmxJWYiok6q42E0VsZGZg_25_6">22,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payments of consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" scale="3" id="Tc_iKt9Sh_DMkykJ_pXUyVHyw_28_3">8,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" scale="3" id="Tc_W_764I0phUiYQyYqjiHQcQ_28_6">26,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Receipts under RPAs and CPPAs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="3" id="Tc_NVn-COJnNkGecl4IWQBN7w_29_3">3,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment for IP acquired under the ObsEva IP Acquisition Agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" id="Tc_SOll8gcOg0Ox1K2q2MNA1w_30_3">15,247</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Wk-RUr6r20GHFHIp6RtSTw_31_3">20,221</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc__uQBLdFKUkmJdf96Km36MQ_31_6">26,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="3" id="Tc_byxxEDjSDEGsVNx32NgyIw_34_6">40,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_hc5w6_ea7EiDpscBwTkcnw_35_3">5,472</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_qOdXYfS_0E-8KkEDthB1Pw_35_6">3,499</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of preferred and common stock issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_Syd0HZLqBEWR4Go_5A76PQ_36_6">3,385</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of options and other share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_gB6RXJDCSEuluQ-ivrG1Pg_37_3">2,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_zEsHHollL0GlSpid_jLo_A_37_6">1,584</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_LYlzXWrAkEuUTeE8wZ1kgQ_38_3">1,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_p9lRRcFEc0yhRiwl3Qq4_Q_38_6">488</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Principal payments &#8211; debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" scale="3" id="Tc_ypYsE3EDVEKDUY_Yo5Z1Lg_39_6">4,250</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment for extinguishment of debt </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:RepaymentsOfLongTermDebtExtinguishmentOfDebt" scale="3" id="Tc_9bwlEa8HRkmCRRndMSaxRQ_40_6">17,103</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment for debt modification fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtRestructuringCosts" scale="3" id="Tc_6kvFk2XWt0iAY_cdYHjFhg_41_6">24</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash (used in) provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_aycmOFsbwkCJmPZG50bvNw_42_3">4,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_w0NFkSj80kqJUW_ajnB71g_42_6">12,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net (decrease) increase in cash, cash equivalents and restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_kezfMCwzm0S_yvzqNNN_wQ_44_3">37,551</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_dlLbei7w7EysbYrZ8FYWqw_44_6">9,013</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash and restricted cash at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_b7J7HOLBNkOjG5JRFX83Ww_45_3">95,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_f_EI168Za06mTrelYGpdVg_45_6">86,364</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_IoA2M2oqFkqo3DksrY0Vvw_46_3">57,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZfTnxYgno0OP_JPq9c2SdQ_46_6">95,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental Cash Flow Information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash paid for taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_T2Sng-dxCEOawvEVlYlkGQ_49_3">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_01MAdoyVSUmusjprclNdug_50_6">311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Estimated fair value of contingent consideration under the Affitech CPPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="xoma:EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_8kUQDQXqM0yCNiyyJjKalg_52_6">8,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividend accrual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_GXMwYciDekqH0-0bqC-wtA_53_3">1,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_y43y8Yy__EWquCCn9jfBNA_53_6">1,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Accrued transaction costs in connection with ObsEva IP Acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedTransactionCostsRelatedToPurchaseAgreements" scale="3" id="Tc_vwR7xnUeFE6QFsrWdxemVw_54_3">122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1ceb0607_e8da_43bb_b2f2_4d2dff67047f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">XOMA Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><a id="NOTESTOCONSOLIDATEDFINANCIALSTATEMENTS_4"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:NatureOfOperations" id="Tb_EWxP8RXSO0i3BCC2Kcro9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with outlicensing its proprietary products and platforms from its legacy discovery and development business. The Company&#8217;s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_vh94xxn-2EW9OKIjdcYegQ">57.8</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" format="ixt:booleanfalse" name="us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear" id="Narr_F53THUMTCEG5Xwrvp2nwRA">one year</ix:nonNumeric> following the date that these consolidated financial statements are issued.</p></ix:nonNumeric><a id="_Hlk90551798"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_Cy5bZ2fPrk-j8cOsKbosQw" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_SVwVh-8bikeJBDMECUXFEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with GAAP in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:UseOfEstimates" id="Tb_Xm_35WxdbEKvxXQ8HjGmlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_OPysTSHEHUyxqpqODrkBrA" continuedAt="Tb_OPysTSHEHUyxqpqODrkBrA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2022, the Company had cash equivalent balances of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_KamTyFYl4k-t4xNuCz2k4Q">30.3</ix:nonFraction> million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ABiXQiESXUOCHu9nRRS_ig_1_1"></a><a id="Tc_441hsKqS70K47OlhdKdVkA_1_4"></a><a id="Tc_9CiMQrzhFUCITtz6SKmJSQ_2_1"></a><a id="Tc_2ubUckkp6kGXVupeMQWI6w_2_4"></a><a id="Tc_GJOwIZ8Or0KCsoi1Df7PLQ_4_0"></a><a id="Tc_IhkE7PWbEUiV_tFE-AXmrw_4_1"></a><a id="Tc_0JaIG0nbc0iUFP5GhcwjYQ_4_4"></a><a id="Tc_g8ws0TNmiESB-p-sTuzj9Q_5_0"></a><a id="Tc_vQ_ZFkOtK06gSRNwut4SiA_5_2"></a><a id="Tc_01JD--fzZkmmfpJ9cQFlAg_6_0"></a><a id="Tc_gcQPw3Sa5kWnbjjJNIEe1A_6_1"></a><a id="Tc_NKGHRur1skGh61Oug0fnWw_6_4"></a><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont1" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont2"><ix:continuation id="Tb_OPysTSHEHUyxqpqODrkBrA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_pkuu0t86uEuHLXNh4uS75A">no</ix:nonFraction>t have any cash equivalent balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company&#8217;s Series A and Series B Preferred Stock. As of December 31, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Group_tGEBuxCNEUKC1UVaCKlOTA" continuedAt="Group_tGEBuxCNEUKC1UVaCKlOTA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p></ix:nonNumeric><ix:continuation id="Group_tGEBuxCNEUKC1UVaCKlOTA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_DMt2wz3aD0SIo0sqYQ1DNA_4_2">57,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_c9xNFR63VEeFfNNCbSwWcw_4_5">93,328</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_90GZCpTsF0StQz95TJLETw_5_5">2,049</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_d4YdoIwz8UKWeH1blJ4wKw_6_2">57,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_-fZlXbVUv0C72_vhjMNSSw_6_5">95,377</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_1qmZW5H0RUuMhayR9Bmk-w" continuedAt="Tb_1qmZW5H0RUuMhayR9Bmk-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont2" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont3"><ix:continuation id="Tb_1qmZW5H0RUuMhayR9Bmk-w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock" id="Tb_uA7PJl2oe0GKxgQrKGkqMw" continuedAt="Tb_uA7PJl2oe0GKxgQrKGkqMw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93564945"></a><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont3" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont4"><ix:continuation id="Tb_uA7PJl2oe0GKxgQrKGkqMw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_qoqgKS59FEaTp-hX8597aQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:EquitySecuritiesPolicy" id="Tb_fIVhu7PGDECBbC_O40DMBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive (loss) income in the period of sale.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="Tb_nyx41DpeKEmjOOPVvs3vsg" continuedAt="Tb_nyx41DpeKEmjOOPVvs3vsg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_-X6iqpYqFkiyni-0GHPojA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_v5skynLYgkaCigj_RmC3MA">no</ix:nonFraction></ix:nonFraction> impairment was recorded as of December 31, 2022 and 2021.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk92310155"></a><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont4" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont5"><ix:continuation id="Tb_nyx41DpeKEmjOOPVvs3vsg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:AssetAcquisitionsPolicyPolicyTextBlock" id="Tb_RUNl7ioZn0uZBnCeBxJxtA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. Other contingent consideration payments are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statement of cash flows. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_wmQVw2riJkuB0m2LAmNgDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_Qy0R61UYDEOWWQR8GJxwCg" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_VtUksiKWokyeNFgf8E65-w">17 years</ix:nonNumeric>. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_eIX2ST9sgE-qBg6NwodDFw" continuedAt="Tb_eIX2ST9sgE-qBg6NwodDFw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont5" continuedAt="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont6"><ix:continuation id="Tb_eIX2ST9sgE-qBg6NwodDFw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_OpjRhELLuUiObw1yAmpDWw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_RXIKzFf980qbd0sROt55Sw">no</ix:nonFraction> interest or penalties charged in relation to the unrecognized tax benefits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_-28o8Woldke9CFfvfTAPiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net (Loss) Income per Share (Attributable to) Available to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted (loss) income per share (attributable to) available to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net (loss) income per share attributable to common stockholders is then calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_KAwjXEOuhkSnfS30GApabw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_9KSQOL4lzk-Mo-iVg1F8QQ" continuedAt="Tb_9KSQOL4lzk-Mo-iVg1F8QQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Cy5bZ2fPrk-j8cOsKbosQw_cont6"><ix:continuation id="Tb_9KSQOL4lzk-Mo-iVg1F8QQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company plans to adopt ASU 2016-13 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company plans to adopt ASU 2021-08 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_6728a778_0042_48e5_ab09_25e113f12110"></a><a id="Tc_ysi4pKj0T0G6HQvg4ZUhoA_1_5"></a><a id="Tc_gACiUhrhsUuqBlM8zxx8_w_1_8"></a><a id="Tc_xJMeM5zxgUOlHdvKwmSvHg_2_2"></a><a id="Tc_VH-s62SrqkaCH9J0LZAGHA_2_5"></a><a id="Tc_GazzLHfk8UKYqhY7avenmg_2_8"></a><a id="Tc_NqOBGK69BUGCRazlhMVR3w_3_0"></a><a id="Tc_RxjGLcXvMUC_GcfQc2yqFQ_4_0"></a><a id="Tc_qQHj6-p3vkashxuZQ2NcZA_4_2"></a><a id="Tc_5YtkWqB2FEWvnSUBZ4_nqg_4_5"></a><a id="Tc_jNVJaxo10Ey1r1EJ-Kuz_w_4_8"></a><a id="Tc_14R43NhuEUevVdRiW6jaEg_5_0"></a><a id="Tc_CLYMQ5qaJEOBKd7yn01hWQ_5_2"></a><a id="Tc_nrKoGMlC6k-Kz5VAoqWLeg_5_5"></a><a id="Tc_cSkm7beoj0qYCYGvsfzfpA_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_kmnyzOgTGUiJj5DCEuLfVg" continuedAt="Tb_kmnyzOgTGUiJj5DCEuLfVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Consolidated Financial Statement Detail</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, equity securities consisted of an investment in Rezolute&#8217;s common stock of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_tIDqLvdLRU-RDFaGl32d5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="Narr_icYQrOwPYE-DQ3V5SMtUUQ">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_mDszNS3HWE2vdHDJSeC0mw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="Narr_S8NeLlRgQUKHiluphVvJRw">0.8</ix:nonFraction> million, respectively (Note 4). For the years ended December 31, 2022 and 2021, the Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ObP3X6UuqEmc0v7i_E4cnQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_nZ7FcTbTeECrO-1Ia5F7ZQ">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_gA6KAG_rhUGJzhjdDOAkdA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_CPKxupGAd0eRoel8DKm6lQ">0.9</ix:nonFraction> million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Intangible assets, net</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_cYkmRm-iQEGtq_jFhccCdw" continuedAt="Tb_cYkmRm-iQEGtq_jFhccCdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_bw3_es1agU6CeEXTHR-l9w_4_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_kD8Xy66sp0m0kgf1lh9mPg_4_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_mtNaLcLAn0yJwlcQ00zqZg_4_9">15,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_4Cnu27BfqkK8hZJ0j9FOjQ_5_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_FQ6ShbJhOkqIWMw86EyXPw_5_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_HzQ9VT-Wg0Ci6pKVbYRaiQ_5_9">15,150</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_DmX5bVNScEqQDxiFoEP-GA_1_2"></a><a id="Tc_ikBrSqB1-UabTSFebTgMkA_2_2"></a><a id="Tc_fsTBEW5M3kat7rVS9hWznw_4_0"></a><a id="Tc_DOdS_x9bDE-ny97pMXn4CA_4_2"></a><a id="Tc_KaiTKmvjdECjaCvyusRFiA_5_0"></a><a id="Tc_nGzVFlNZnUyiHKKKr1eE4Q_6_0"></a><a id="Tc_WIOcwbU8VUyIW2vKBf9HBg_7_0"></a><a id="Tc__H0jokMMK06kpqKt9NBcPA_8_0"></a><a id="Tc_IlhJT5gvuk-yKjE8jJ6KlA_9_0"></a><a id="Tc_BFDAwp8Qk0iFZjNDhhLqgQ_9_2"></a><a id="_50ab1c9b_b1c0_4142_87b4_7bf42f962f0d"></a><a id="Tc_lbIIzzMRSk6AtKEC2pYHmg_1_2"></a><a id="Tc_3AAXD8ZPwE6cPdEOQzvmnw_1_5"></a><a id="Tc_fVbAelDnNUmjoTKZQ7rTfQ_2_2"></a><a id="Tc_I6zUhs5a30i1g-nwjVhc3w_2_5"></a><a id="Tc_LNLLg9jpkE6lpc7crA7oag_3_0"></a><a id="Tc_MaKlPuGy-kiiyTRCh3jOiw_4_0"></a><a id="Tc_MQ9XNtv-GEuGWsemArDZAA_5_0"></a><a id="Tc_pquQ1USMx0aQnAhMtclFPw_6_0"></a><a id="Tc_JKSnXspIv0CaOGrDiKsQXw_7_0"></a><a id="Tc_45GqXlxRF0qRbPsrHQ9w3w_7_2"></a><a id="Tc_rLKmOTZD1EyTWWfOUJ2t3w_7_5"></a><ix:continuation id="Tb_kmnyzOgTGUiJj5DCEuLfVg_cont1"><ix:continuation id="Tb_cYkmRm-iQEGtq_jFhccCdw_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:18pt;"></span><span style="display:inline-block;width:18pt;"></span>The remaining life of the intangible assets is <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_lFkrNxT43UKki83VfacoxA">16.9</ix:nonNumeric> years. <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Group_YymV6f6gkkuU2gKcFZEobA" continuedAt="Group_YymV6f6gkkuU2gKcFZEobA_2" escape="true">The following table presents the projected amortization expense for the next five years (in thousands): </ix:nonNumeric></p><ix:continuation id="Group_YymV6f6gkkuU2gKcFZEobA_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_C-SM891sf0uC-Y9OYz3kIg_4_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_03tQDPqDOkGttkL7M4kkxw_5_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_D0EzuYmmUk2U-8qHKSLK9Q_6_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_a_tA6csFO0uu0m0FcFhenQ_7_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="Tc_bTj03u6qy0Okrf_eSiL9iQ_8_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" scale="3" id="Tc_YqNo3mY2CUOiRXjAulR5KQ_9_3">4,485</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accrued and Other Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_-xO4HZj5tUKz7jVNt54hyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued payroll and benefits  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_6NOFpFV2kUqcmx0yWznaqg_3_3">1,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_eHrtFRqGF0G1E2RyoVIkAg_3_6">135</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_63DJA4ZJKU-dOzxACCUzLw_4_3">867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_x5Q-AYIXA0KYLy9FruCPdQ_4_6">295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_pxfXsPTMokWCs4b6lDIl-g_5_3">562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_XgJ1Xki7y065U0wHnolcVg_5_6">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_iuFlBM-dwUScjAmJBFlbgQ_6_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_nkpkQtRKWkSNWe05nPBHCg_6_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_bJuezVV100mF9_vHO2SyrA_7_3">2,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_BPm3TPJirEGPl4EzRd4aow_7_6">525</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:LicensingAndOtherArrangementsTextBlock" id="Tb_PNYAaApaoUiy4IK8-0w57A" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lLvvXbzgEakGtNGbJg_Ww" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" scale="6" id="Narr_AA1G-3oJekOOePSQ2g-yxw">475.0</ix:nonFraction> million in payments for ebopiprant development, commercialization and sales-based milestones. &#160;If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA. &#160;The Company paid ObsEva a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_x13qx5wL-kK-xVQb-PpI-Q">15.0</ix:nonFraction> million upfront payment at closing and will pay potential earn-out payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPayments" scale="6" id="Narr_CsfdCyMZ3EW55z9Ud9ZJjw">97.5</ix:nonFraction> million for development, regulatory and sales-based milestones, representing a portion of what the Company will receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#8217;s cost to acquire said intangible asset of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="Narr_axQwYI-vTE6P431wou4efQ">15.2</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_UFIXp2ohxkSl1qO2UxogcA">15.0</ix:nonFraction> million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="6" id="Narr_apzOHecpeUyQ0ZqrjVwyfA">0.2</ix:nonFraction> million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_bo2nVZP6rkeb0fDMrGiIoQ">17 years</ix:nonNumeric>. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_Ahe5QIsxxUizl2KrKGn_7g">0.1</ix:nonFraction> million of amortization expense in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022. No impairment indicators were identified, and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_9XTuiqDn8k-WxjXJbdzMeQ">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" scale="6" id="Narr_APjb8rJJb0WkHzAs-I-YJg">46.5</ix:nonFraction> million, sales-based milestones payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments" scale="6" id="Narr_h5rtTdjzREiskmVI-eH8lA">51.0</ix:nonFraction> million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk91748058"></a><a id="_Hlk93938130"></a><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont1" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_A1kCUnvEVkeIqfayjmaonA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_as3kJxdm2k2N9To8DQfWUQ">no</ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_H1WDisLgxkqIvK7clGpKEQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_-m16cPG_e0G0sqDYNO3t7w">No</ix:nonFraction> revenue was recognized related to this arrangement for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_QuNAM6UTBUi0dix_wZDOIw">one hundred eighty days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_kERFMM1IGkGqX-HRQc5VOQ">one</ix:nonFraction> combined performance obligation. The Company recognized the entire upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_oNHa2zwoIEe3d9OCtmTPKg"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_iJv1Ie6ugE-hMNuM9yQGOA">37.0</ix:nonFraction></ix:nonFraction> million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7DasBvaAtkS6lYyw7kjKSA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_pSt56gvjvUGTB7Xj2qxmEQ">480.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_G8esAtNmakKoYvkKmZ81HQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_7STsoBHNFEyiW0AtNw_SZA">10.0</ix:nonFraction> million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_9_1_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GF-6_dQKikmqEGqiVXM_qA" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_sxUK_zsWCUKwlx3CoAOOlQ">ten years</ix:nonNumeric> from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_1LZ3t2nkSEWe3SuWckVpsA">25.0</ix:nonFraction> million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_zysQ4yJds0Ce7B-RDefZXw">17.7</ix:nonFraction> million in cash, and the remaining balance of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_0HQ2F4usPUGiRtw00ne_tw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" sign="-" scale="6" id="Narr_Yh9uDECpxkOfNVaEBsjX0A">7.3</ix:nonFraction> million was recognized as a reduction to the Company&#39;s debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pQS3U8aNZU-yXj_-Ru7Piw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Of-57e0UA0OwTmEsrF4z7w">35.0</ix:nonFraction> million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1sPaZ1NGOUiQwEfq8TQ6mg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_EuYRerGYbk-z9SITiDYNAA">35.0</ix:nonFraction> million as revenue from contracts with </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95303077"></a><a id="_Hlk94259450"></a><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont2" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive remaining milestones up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_RJvrk0V6KESPsHjHA8ywIw">410.0</ix:nonFraction> million under the Anti-TGF&#946; Antibody License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_mUpfRhvkk0KZsrvoYgF1Cw"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_rWKiyUA6T0aAFlHkvFLYwQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_5SgqhQEjlkOv32eReShtDQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_anP1oMP0m0SNfn6pyDqBYA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_N6P_LIilFUyijP2yWXsWjQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_fUOxNf7PVkKeWhHzR6pvmw">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wmOMUEuzuk6yS0QoDP0Ysw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_j3BwY1d1B0SyWg8s0gv1Wg">No</ix:nonFraction> revenue was recognized related to this arrangement for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_LOXhb2YAVUiCSsgzV707tg">30.0</ix:nonFraction> million for the license and rights granted to Novartis. Of the total consideration, $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_I6pQyKLUkUuY5x7LOxlanA">15.7</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_KBknEIw28UqcAdm0ztzRzA">14.3</ix:nonFraction> million (equal to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_fwE8yWfrn0K-IqzRprsY2A" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_RGtbFuLmGUWEQv3eV3AbRA">12.0</ix:nonFraction> million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_zxnsIjh_CEWpIY4bqVxV7Q">5.0</ix:nonFraction> million cash related to the sale of <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5HV6RMbJ6kqeVqeUwpkS3g">539,131</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_jPTAzgIwzkuRGvLLLeWmUQ">9.2742</ix:nonFraction> per share. The fair market value of the common stock issued to Novartis was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw" decimals="-5" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock" scale="6" id="Narr_Vo6IJGTuVECdfmRH-OJwtg">4.8</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_O4qqeUXvRUOuXlgWB_pilg">8.93</ix:nonFraction> per share on August&#160;24, 2017, resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_K76MH7biSEC1Pe9Q8-s-Cw">0.2</ix:nonFraction> million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_9ni1jDQqGE2MNc84XrIr5g" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_4dU6Yr6XbkWGPOyxOwuAPQ">438.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_rJ-F8BD5CUu-Uk0PG_Pfyw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_PTXKBMTsfU6FkEhfEiWlwg">10.0</ix:nonFraction> million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The <ix:nonFraction unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreements" scale="0" id="Narr_PAUTxvkh1kmUsdEm1a0MCg">two</ix:nonFraction> agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_mKpLgvvU_ESS4rWpVijdiQ">six months</ix:nonNumeric>&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ArrangementsNumber" scale="0" id="Narr_BezZzAnZc0q5lv8nwbxmcQ">one</ix:nonFraction> arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont3" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_tcv9gnTwCUKECkDxfYg3Lg">no</ix:nonFraction> further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementTransactionPrice" scale="6" id="Narr_oufEjfcUPkiZNXdirvkCQg">40.2</ix:nonFraction> million, which consisted of the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_-QX8b6_AKE68rdeZBUEfGA">25.7</ix:nonFraction> million upfront cash payments, the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_1N_JNKJu7kSZU2GORTx2dQ">14.3</ix:nonFraction> million Servier Loan payoff and the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_RIZvTcOGwUKXPYUvOQ1nIA">0.2</ix:nonFraction> million premium on the sale of the common stock. The transaction price was allocated to the <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_dbRbQWs7-02MXgh7yBH72g">two</ix:nonFraction> performance obligations based on their standalone selling prices. The Company determined that the nature of the <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_px_56qjut0Sns8lermBa2Q">two</ix:nonFraction> performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_r11OGkPAXkWTZaN_G9-weg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_N8Dy_QCOIEmSUX21_KeCSw">40.2</ix:nonFraction> million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_7mfj_7ebGkGUh0k6xCo79g"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_UtuD8ct0kE6ZcmEGtFtJHA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_gro3K76bP0OQmWnemm-I-w"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_cQIm4Lti5k-PRwlP0kEKrg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_aMZBjU8EQ0Kgm-_wARFcmQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_U_TmjdUVK0KwRE_u1_RuLA">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_x7uVaLNyW025G4gxpaAXkQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_NiltdSfsZk-ZK1L_0_avbA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_kNUrGAqyEkalFB8W0WRezg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_UPLTthXsyUuUgXa9bzBhEw">no</ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_gb8Mq7RYNUyPvOuADsltaQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_KnEHTfppvk2dFzYQ2l4M2w">19.0</ix:nonFraction> million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of <ix:nonNumeric contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_daw_HrxdKUKz56KM-1KXIQ" format="ixt-sec:duryear" name="xoma:RoyaltiesPeriodMinimum" id="Narr_EukrVGVLYEuSI9z6J6k3kA">13.5</ix:nonNumeric>&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" scale="6" id="Narr_FIp5mhO8yUqHcvDXcXQJvg">3.3</ix:nonFraction> million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of <ix:nonNumeric contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_8lTCShzHaUKKjZmgyv0_Xg">10 years</ix:nonNumeric> from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_16_2020_To_11_16_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eC4aFolUA0GTxlIWZ6Cc1Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_PHbUYYF-FEeFP0aTcv-yrA">2.0</ix:nonFraction> million milestone payment from Takeda. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont4" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company earned a development milestone pursuant to the Takeda Collaboration Agreement and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_aQqKR6_fy0yZBwIQWrikJQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_tFiRVlUiAEKRMJaYR1JLoA">0.8</ix:nonFraction> million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income. The Company recognized annual license fee revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_7wxTmOyFPkGXQt3cSa57RA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_et-e7GgfWUiOwBMbFJUlPA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_EuXVMgiSQkKFYqjEXEEp2Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_2M1j78B2XkKk3bgov0AT-A">0.1</ix:nonFraction></ix:nonFraction> million from Takeda in the consolidated statement of operations and comprehensive (loss) income for the each of the years ended December 31, 2022 and 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_KVlM-TrrKkaytvD-T-MHoA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_Nu5yGJg4u0a4xpAMTVp3Rg"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_6q7rrgqGBkOnCvdN-oUk-w"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_7xl6kinD4kCita5IrTnhpA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_YZvYRbVzLECmq8sDVquTyw"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_0eq236-WtkGBmxQjnIQVVg">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_XYGKxv5BIUGLGdCmTAnZCg">16.0</ix:nonFraction> million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_DWIu-n3lPUiIYGcRZmhJLA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_gSk9xJXyMUqEAUPbQlUu5w">232.0</ix:nonFraction> million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_j83jgfg09UidGXoNWAtd8A" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_0eeoZie_V0-KiSnlJ8t0IA">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country. Rezolute&#8217;s future royalty obligations in the United States will be reduced by <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfDecreaseInFutureRoyaltyObligations" scale="-2" id="Narr_BKh8Usf07kap5QzW4E1AXA">20</ix:nonFraction>% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_I3wo0vb-CUixzfe_qIAyTg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_LbleYQ9Or02yDAUZOIg96w">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_WCMTJxnVkkyQwPrv8crMng">ninety days</ix:nonNumeric>&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk7587136"></a><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont5" continuedAt="Tb_PNYAaApaoUiy4IK8-0w57A_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_yjwNFP6S2U-RBHFsecGGDg">No</ix:nonFraction> consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" scale="6" id="Narr_XkeFsY6t7k229Or54IAf6w">6.0</ix:nonFraction> million upon Rezolute&#8217;s financing and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementInstallmentPaymentsReceived" scale="6" id="Narr_7bl7_omANE-4LXBtserg8g">8.5</ix:nonFraction> million in installment payments through October 2020. The Company also received <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_12_6_2017_To_10_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mfqGdjZYME-gcLNsUw5Lng" decimals="INF" format="ixt:numdotdecimal" name="xoma:LicenseAgreementSharesReceived" scale="0" id="Narr_vHTgM87plU6b5bajISbzHw">161,861</ix:nonFraction> shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden_osQASCJOc0aG36cPBan18A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1:50</span></span> reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_867K-w4nlkWwUkggr9tW3w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_A7vssnfNOUi9NdFa2QnS1w">2.0</ix:nonFraction> million milestone payment due to the Company pursuant to the Rezolute License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_8SsPA-cdo0K4zx7dDhkPMA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_AVqelqyyPk-kU35ev3nW5g">2.0</ix:nonFraction> million and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UWK0SRUsv06_NuNedSDLfQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_W0bkIcm1FE-rATTiX6cL0w">no</ix:nonFraction> revenue as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_dFE8e5qzOECln2Ps7eQaPg"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_X113JsXI70-ml5eAOvpXzg"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_dhVkumxt2U-3qp5zjfDtNQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_JuceBWqzaE2yAJJk8ekA3A">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_aFnHuC66l0uUMFI6UWbfjA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_U1G66e6H_0-BuOJHsyx6mg">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company and Janssen were parties to a license agreement which was terminated in 2017.</span> In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_Ju87qs_CPk6pc4jwWfrPPQ">2.5</ix:nonFraction> million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" scale="6" id="Narr_mXT7G1bnEU6g_-Z3RGvhtA">3.0</ix:nonFraction> million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization" scale="-2" id="Narr_gWGeTHxgy0qeL3EVJKaxZw">0.75</ix:nonFraction>% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U2mBKo7TtEGcPUHwD7IglQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_4zvYS7eywUq7BCGCiGE5dg">2.5</ix:nonFraction> million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_PL6qNM8JgkeHSr5yXfQ1uw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_ZBBREFKWiUCV7JQKQ47Q6g">0.5</ix:nonFraction> million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In December 2021, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_P4EQyfpsBUSEXZiG7S71Fw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_M6d-w5SrH0GSy4Ll3Lj0Ig">0.2</ix:nonFraction> million milestone pursuant to its agreement with Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_QHibXrOq0Uapn27emCVY5Q"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_P8SQebPFukSCFbOJ3i0dEA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_Jc-3J8t6ek-plJYbk6ebmA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_zqrxwfY-E0eBJbF-4cEnXQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_MB1k_FE490e3F6hITNFdoQ"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_2nHOGC5Ig0K4jqHxVKJ1gA">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company recognized <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xdeG_av2K0qt9xOQHo2aRg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_R9A_q1kv2ECnWTx0n3djeg">no</ix:nonFraction> revenue and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IXa196Wdf0SCxbIeQySyiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_V7EqN_pGN0OrmQQ3N3xnzA">0.7</ix:nonFraction> million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and 2021, respectively.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PNYAaApaoUiy4IK8-0w57A_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the commercial milestone payments are solely dependent on Affimed&#8217;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_fkbKOMO31E2L_JoljZNMpg"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_JPc2PX6ZN0uz4Hm8hpD69g"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_woVVlZFTpEib8T1ryZt1MA"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_nUDR9APUUUGizz9lHyrKsg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_WJishCjv0EKd5KvCF-PA1Q"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_ECqgzF21IEuKDArWEBESeA">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WMb-KT8So0uQN8syGEGdzg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_FQ4vqAqqJUqDq8ae5Xg__A"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_cenBgMUh9Uyccspm0H9hgA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_xiig2a_FsEqPdrr8Ckt4LA">No</ix:nonFraction></ix:nonFraction> revenue was recognized related to this arrangement for the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;21, 2016, the Company entered into <ix:nonFraction unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_RvEU-Ikvj0mht0fulYuqzw">two</ix:nonFraction> royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ugLN8Eo-O0CB7wwIKyDDpA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_8fdrxJMhp0uLYvtNvjcdDQ">6.5</ix:nonFraction> million, plus potential additional payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" scale="6" id="Narr_1Uex0FhJ0Eu0qF2Y_XkI0w">4.0</ix:nonFraction> million in the event <ix:nonFraction unitRef="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:MilestonePeriodsNumber" scale="0" id="Narr_IluBSZgUAUqCA1CX0m2nrA">three</ix:nonFraction> specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_aPOJphzjLkGSA83nJdzBJw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_qT3Ygo8rp0GypPSwstTlzQ">11.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="Narr_aPG3qxv3CEa-6nPHXFOX_g">18.0</ix:nonFraction> million as unearned revenue recognized the under units-of-revenue method. The Company allocated the total proceeds between the <ix:nonFraction unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_-RzU3nJgZkajpiPN1Pb64Q">two</ix:nonFraction> Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the &quot;units-of-revenue&quot; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_BsX5M1Uu6EOTSHfP8EnvNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_8SvB3dDCxEOzkp2n0kBY3w">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_aM7qfAJs_Ue2FngKRak2-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_vWFy-C4A60eA68eb5o5xWA">1.6</ix:nonFraction> million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2022 and 2021, respectively. As of December&#160;31, 2021, the Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_LgHnTr7tQUGlusKD_x4gBw">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_d43QRzRZM0KHRczmQKBKOg">11.7</ix:nonFraction> million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_TXegeEutYEOwrM0WLG6ppA">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_Ae3NIJA-Ykee7NBFk8bHcQ">9.6</ix:nonFraction> million, respectively. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93562407"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:RoyaltyPurchaseAgreementTextBlock" id="Tb_kOXxdNlkoEOsyJqaZo2Kpw" continuedAt="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of short-term royalty and commercial payment receivables was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_30eZjgFsLEaw_G0n6V204A">2.4</ix:nonFraction> million as of December 31, 2022. There was <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_HwI9NEJxgkqd_um2isqDhw">no</ix:nonFraction> balance of short-term royalty and commercial payment receivables as of December 31, 2021. The balance of long-term royalty and commercial payment receivables was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_JJHmjGixq02zDs_Qpvmj9w">63.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_VnH_PtYmxkCPztXdVqKM5g">69.1</ix:nonFraction> million as of December 31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_4-DsOA7VvEWZR9gX9CsQ6A">33</ix:nonFraction>% of the future royalties on <ix:nonFraction unitRef="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" scale="0" id="Narr_5vcuh6_8f0ahtGr3x9vu3w">six</ix:nonFraction> Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lP-1sgwP7kC3A25KNKaI5g" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_c0_yRHyDK0u-2CT3doMjIA">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen digit percentage of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_JQH3grFnSE2r2ZP0tfOL-A">33</ix:nonFraction>% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_p4dgpct0ik2knGpohVsu9Q" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_tTBqu7R9pUajOAXqJ-Msgg">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng" decimals="-5" format="ixt:numdotdecimal" name="xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_Kh-9_d_7_0aQQx_DveJmHA">59.5</ix:nonFraction> million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_j4ElNZhA0E-_JPRkD0IGeg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="6" id="Narr_WX0uziB3Sk6_TGOnGeu6Kg">15.0</ix:nonFraction> million. At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qccAUP40R0mSuKlRmGHvKA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_ZgT0XiAQEE6cTdaOTmtgXw">15.0</ix:nonFraction> million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CXsrLLVq5kSPUm74NYuFBA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_ULw8dyDdjk-zrRU4AzhBwA">10.0</ix:nonFraction> million clinical development milestone under its license agreement with Merck, of which the Company earned $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_Ly4atDKgw0upvsfHyN2RXQ">1.0</ix:nonFraction> million. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashReceivedForAchievementOfContractualMilestones" scale="6" id="Narr_yTJctROjQk-3IfwLtVMXzg">1.0</ix:nonFraction> million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessments and no impairment indicators have been identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_MAbD5nWZf0aUq7Ov_NLXRQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_XYYLTNy10kmhj0v-Y3KeNQ">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" scale="-2" id="Narr_6d-cdSLtZE-DXKAFC0pUdw">1</ix:nonFraction>% royalty right on the next <ix:nonFraction unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreementsFutureLicenseAgreements" scale="0" id="Narr_TLQ7hb81_EuLPLcDpGHLLA">two</ix:nonFraction> license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" scale="6" id="Narr_P2hCrAlYQkO-YKvRZLDW2g">0.3</ix:nonFraction> million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" scale="6" id="Narr_yw8Hq-BU7kSe_lBtMfW0_Q">0.4</ix:nonFraction> million per licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis RPA, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="6" id="Narr_PXeVh52tPUK_IDKzxYVSzw">0.3</ix:nonFraction> million and will make contingent future cash payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FwHL2hBqk0yF5G8wK5a2qg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr_O-To3VAQvEu3CDe1gOzevw">0.2</ix:nonFraction> million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;). </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk20239215"></a><a id="_Hlk93562521"></a><ix:continuation id="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont1" continuedAt="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_0gbuwiJPkkeQ96ZgoyPBQQ">0.4</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_8q4lNKGzV0ytGmrv4V-nXg">0.1</ix:nonFraction> million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income. As of December 31, 2022, there was <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_w99E8bZ4zUqbZLBCG0gtjQ">no</ix:nonFraction> change in the fair value of the contingent consideration from its initial value and <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:PaymentsOfContingentConsideration" scale="6" id="Narr_VOU6eoqF-EWDpyy74PZRKg">no</ix:nonFraction> amounts were paid during the year ended December 31, 2022. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_XCX-GXu_aUql7RsveubZrA">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_s6Xmk-SskE67Bmh6cHSc5g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="6" id="Narr_vMC5JMcovEyDqVJPkFMaKA">1.2</ix:nonFraction> million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_V_cdDAl530WO8X_Yw2S8dA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_C5JFS8lPCEKaM2Rj05xCvA">1.2</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_8Lp1iopY80moFAsWA0Oicw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_YxLfgNZs50OdaN0rhpzu-A">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_uCGbr5fahUmTsmM7d98Osg">five</ix:nonFraction> anti-thrombotic hematology drug candidates. <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_mFIhKUQDVkKe9JtFWKzj1g">Three</ix:nonFraction> candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber" scale="0" id="Narr_okNvQN8m8UKdxSetJqzwvQ">one</ix:nonFraction> which was subject to an exclusive license option by Bayer. The Company will receive <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw" decimals="INF" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_tC8XyNVia0q5MJokDP5RIg">100</ix:nonFraction>% of future royalties and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_TDeVtpuRPE-AumUx2VlfqA">10</ix:nonFraction>% of future Non-Royalties economics from these Bayer Products. The other <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_mII8YC2zjkiB0IKNOeOyDQ">two</ix:nonFraction> candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low single-digit percentage of net sales and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_5UjpruV03EikUQ_3xM5owA">10</ix:nonFraction>% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_FDbB1j8njUmZTjxG2xR7Lg">10</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="INF" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" scale="-2" id="Narr_Qg26j2I1W0Sac3Es0ym_RA">5</ix:nonFraction>% upon the Company&#8217;s receipt of <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementPaymentPercentageFactor" scale="0" id="Narr_C4534sMJeE-yB79LZPOl6g">two</ix:nonFraction> times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_m5f8jD6llUO8X0Wzxmyc9g">6.0</ix:nonFraction> million upfront payment at the close of the transaction. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_83JqH9MaqUu4NibTiAAyew" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_2cdif2Hf6EejCFFVcm28iQ">3.0</ix:nonFraction> million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPaymentsPerProduct" scale="6" id="Narr_UGrqzTO8TkyLln5PnDW2gg">1.0</ix:nonFraction> million for each of the <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_54LWm-iYUESIrWHsO7vyRA">three</ix:nonFraction> Bayer Products that were active on September 1, 2019 (up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr__S8RgYv01UO3gDRnoHx_Dw">3.0</ix:nonFraction> million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_wkab-DXxvECqI2EluVPvOQ">250.0</ix:nonFraction> million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesPaymentsToAggregateAmountOfPerProduct" scale="6" id="Narr_LAGUYSNkekisvCiSFJEUtQ">85.0</ix:nonFraction> million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_vDy71A6aIUOzYMrPc5_xXg">250.0</ix:nonFraction> million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_g1F0OBf7j0WjQWqPxwZK0w">250.0</ix:nonFraction> million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_saZIlH4B90CGfRJmvskgkA">9.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_UFUADyCv0UOL7ca-KcSTpQ">3.0</ix:nonFraction> million. In September 2019, the Company paid the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_jKmiP9r9_kuqlBxvTOdkgA" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsOfContingentConsideration" scale="6" id="Narr_XABpITpnQESxgwHnGeRdtw">3.0</ix:nonFraction> million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk20239517"></a><a id="_Hlk92457586"></a><ix:continuation id="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont2" continuedAt="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wVSdoYr4jUereb7ZG5cXaw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_1aId8b5t10C-6Wm6O1rVKg">no</ix:nonFraction> impairment was recorded as of December 31, 2022.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_DQz6gMlwmUizNRHwg5QyGA">six</ix:nonFraction> drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5i_Uy5BsyEObHFG9u5GxwQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="6" id="Narr_g2jmBdjmFECy9_w2abNx2A">10.0</ix:nonFraction> million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_eDWmuuCiJEKMe1ytakqnRA">10.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VbBrsLclIUqIJDiHDqkKUA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_hwbaTrVvXkypds8CCBy1rg">no</ix:nonFraction> impairment was recorded as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_qSi-FNKwOUyIYBhH2mNWuA">two</ix:nonFraction> clinical-stage drug candidates for $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_EbXYjQ5mzUCNFK-esz7zlw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" scale="6" id="Narr_MEHzLlJ2HkmAg8Vdgxr9oA">13.5</ix:nonFraction> million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum" scale="6" id="Narr_QgGY72jWI0yckroS_jbqcA">54.0</ix:nonFraction> million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumConsiderationRetained" scale="6" id="Narr_9BpXX7ddL0CuTirotEJa_Q">20.0</ix:nonFraction> million consideration retained by Viracta, and (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RegulatoryAndCommercialMilestonesReceivableMaximum" scale="6" id="Narr_s95A3ozzwEG8ObROWZoWYg">57.0</ix:nonFraction> million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_rFnK-vmXR0q6nG-2x7neUw">13.5</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_v4dNNnJyNk2mkUC5mofV7g" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_p2qhVL49i0KeWPhgsjU9RQ">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA" decimals="INF" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_GC1teheqTUyBM0UdNcMjyg">100</ix:nonFraction>% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" scale="6" id="Narr__gePlOh5pUOQfQTw3UpTMQ">25.5</ix:nonFraction> million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_JcwoIZoaJkyMEMgIAP0usQ">7.0</ix:nonFraction> million. The Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" scale="6" id="Narr_K8WSoyU0J0CtiVzVi_NwHQ">142.5</ix:nonFraction> million to Kuros in sales-based milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_c9juPFjI2UyPCCkvD4DUNA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_DO-2euXFHUqm4N26RIhVHg">7.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93563417"></a><ix:continuation id="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont3" continuedAt="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qkTeCxJPbk-sQaXhYuVwgg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivedCounterparty" scale="6" id="Narr_gv17kKdVXUeEmeuC7pzEmw">5.0</ix:nonFraction> million milestone payment to Kuros. &#160;Pursuant to the Kuros RPA, the Company is entitled to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA" decimals="INF" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivablePercentage" scale="-2" id="Narr_NgrbX__91U61m2ASeL_CXA">50</ix:nonFraction>% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_43509g1PLEqQVPLib8nQng" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_JOvfy0SbYUezR4UkXJWpag">2.5</ix:nonFraction> million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b>As of December 31, 2022, no payments are probable to be received under the Kuros RPA in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lVrv91FNZU23z9vv3AQpjg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_H30wB9zhs0ePZ6BTyBifsg">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_vMcVf9hnuUy7qgq2C52zmw">6.0</ix:nonFraction> million. The Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw" decimals="4" format="ixt:numdotdecimal" name="xoma:CommercialSalesReceivablePercentageOnNetSales" scale="-2" id="Narr_duHYrYRSXE2bejomMxNJsQ">0.50</ix:nonFraction>% of future net sales of faricimab for a <ix:nonNumeric contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw" format="ixt-sec:durwordsen" name="xoma:CommercialPaymentReceivableTerm" id="Narr_ooFi4ow-DUqgHa_5CbvaiA">ten-year</ix:nonNumeric> period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" scale="6" id="Narr_AhuzlSoWK0mZkFVm46f1eg">20.0</ix:nonFraction> million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_6l94mu3WR023CHJP8x84GQ">14.0</ix:nonFraction> million as long-term royalty receivables which includes the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw" decimals="-5" format="ixt:numdotdecimal" name="xoma:UpfrontPayment" scale="6" id="Narr_2eFlYPyUR0G9JtTbM8hZeQ">6.0</ix:nonFraction> million upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnRegulatoryMilestone" scale="6" id="Narr_LtzNz1d9_UOkM-mofiIwQQ">8.0</ix:nonFraction> million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_dL0biRcLQE2o79IGiJORGw">8.0</ix:nonFraction> million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_57EK_vMqWUmNmBpE0DQrcg">12.0</ix:nonFraction> million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonePayment" scale="6" id="Narr_DFmBEHTugUOio4mmb0kDRg">5.0</ix:nonFraction> million milestone tied to these U.S. marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, in connection with Roche receiving approval from the European Commission to commercialize VABYSMO for the treatment of neovascular or &#8216;wet&#8217; age-related macular degeneration and visual impairment due to diabetic macular edema, the Company made a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonePayment" scale="6" id="Narr_FwXu1oXt8UaNgv2uqSdq7g">3.0</ix:nonFraction> million milestone payment to Affitech pursuant to the terms of the Affitech CPPA. As a result of the EC Approval, XOMA is eligible to receive a <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w" decimals="INF" format="ixt:numdotdecimal" name="xoma:CommercialSalesReceivablePercentageOnNetSales" scale="-2" id="Narr_t3jsfAlmwUalXHIs1yudgA">0.5</ix:nonFraction>% commercial payment stream for <ix:nonNumeric contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w" format="ixt-sec:durwordsen" name="xoma:CommercialPaymentReceivableTerm" id="Narr_JvgOEUtqNkeS8e96_LLK2A">ten years</ix:nonNumeric> from the first commercial sale of VABYSMO in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qeDzPAJvEkG3H6Q0IdTsfg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashReceivedForAchievementOfContractualMilestones" scale="6" id="Narr_9fusWFK4WUOGFRUJxybphQ">0.5</ix:nonFraction> million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_SHL2DGznK0y-hmUTeZ2Q-A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_VZuWbdyx4kKN9RPgrzRGlA">0.5</ix:nonFraction> million received was recorded as a direct reduction of the long-term royalty receivable balance. In February 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_7_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4AJG2U9b-06BTayaXGugZA" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashReceivedForAchievementOfContractualMilestones" scale="6" id="Narr_P4ZimDNm5ECu3i8DsCMUgw">2.4</ix:nonFraction> million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was reclassified from long-term to short-term royalty and commercial payment receivables in the Company&#8217;s consolidated balance sheet as of December 31, 2022. Based upon limited available information, the Company is unable to reasonably estimate future net sales and the commercial payments to be received during the year ended December 31, 2023 and, as such, no additional amounts are reflected as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. &#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NqA3jpIWgUS-c7ELvkpPVA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ImpairmentOfLongTermRoyaltyReceivable" scale="6" id="Narr_MPNl3227WkOgktyd0DznxA">no</ix:nonFraction> impairment was recorded as of December 31, 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d7f3abe_a83b_45bd_ac07_93aee150d32b"></a><a id="Tc_uIPfQP35uE6pAwiznOednA_1_2"></a><a id="Tc_UA2OPBw_I0e85AUrvwZeZg_1_4"></a><a id="Tc_EDqVVQNbQEGmSnGC5EZZZA_2_0"></a><a id="Tc_sPyHEavJnEGZULOjXnjpfQ_2_2"></a><a id="Tc_skRpzSB2Hkm6mYdpE-6RAw_2_3"></a><a id="Tc_2-N6psInXU-3rx1DqO5tlw_2_4"></a><a id="Tc_fFDGl3dxw0KBRX0NZ6S9jQ_3_0"></a><a id="Tc_gcTAqI7hX0WZjtSw-Ayjbw_4_0"></a><a id="Tc_HHsE4RiJAESmorr_Jd09_Q_4_3"></a><a id="Tc_5Unb0kpjFkSF6uVHHXClwg_5_0"></a><a id="Tc_ihbsmEpNfkCxspmGcRC6ig_5_3"></a><a id="Tc_l-QYjS-mnUqpz0WpAh01Bg_6_0"></a><a id="Tc_cpLuCBHMLESrX4CwffnOPQ_6_3"></a><a id="Tc_ZziAg0Y_IEmbOay15Z6PhA_7_0"></a><a id="Tc_85dztHdZREatjMxxxR-01A_7_2"></a><a id="Tc_F4MBkzt9Ekiawfn1LJy4Vg_7_3"></a><a id="Tc_supJANsLOUu_OKPpnq2qBw_7_4"></a><a id="Tc_URn9DFtOGkSDCoAmwhgw8w_8_0"></a><a id="Tc_vzyTXUfvHk6sBFUpZCfN8A_9_0"></a><a id="Tc_J0jTfilnH0CIzLOEt1rFpw_9_3"></a><a id="Tc_BDOSlDXqHEqDNMdUgLz9Fw_10_0"></a><a id="Tc_L0fmJtBzJ0qllkUCalnqvg_10_3"></a><a id="Tc_wMgtQSKOn0SHgMrsUcywjw_11_0"></a><a id="Tc_KPGJ16Yz5k2KKISC1m0fiw_12_0"></a><a id="Tc_YNb7W7vkT0mlmn7kgFOgzw_13_0"></a><a id="Tc_tEcerL8ddUGAki1C2R12rg_13_2"></a><a id="Tc_TfdxdEXwbkCZ-hlOlt-Mlw_13_4"></a><ix:continuation id="Tb_kOXxdNlkoEOsyJqaZo2Kpw_cont4"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="Tb_a8SH7dVFiEKxwKBTsvE46w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty receivable activities during the years ended December 31, 2022 and 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_luvHZUi680KgF0_cQGAIGA_2_5">34,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_kB9yfId7VkK_kt3X391buA" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_ptOwam8W7EulDK87yn6QSQ_4_5">13,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_9IG6mnsXWkKJ-8l8yrS4Uw" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_HIbJytQOpE-UX-A_CYdfow_5_5">7,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_m0XXi-6V7kqy8Lqgpe0vfg" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_tMe4-bsZ0EORjp_8cPAQCg_6_5">14,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_1EFx1whi7UOdqgcw35RAmA_7_5">69,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_kQY9oDQ6-02HjwmVuO7AAQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_4BzmG0ArgEWpUPjUL0I3OQ_9_5">2,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_CwZO45sv6Uq0rXZHujiv9g_10_5">526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:ShortTermRightsReceivableReclassification" scale="3" id="Tc_DLPz9HlWp06o0MgeCbmlwQ_12_3">2,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableReclassification" scale="3" id="Tc_YVPN7sYtzEeQPj7_68vNng_12_5">2,366</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_BUzxMJfSsEOXjho7J0K2gA_13_3">2,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_Bzzrt1uTs0uFcieqx0EbCg_13_5">63,683</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_SW8cYPo8dU2pC4vXVhG9pA" continuedAt="Tb_SW8cYPo8dU2pC4vXVhG9pA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a684d925_6207_4a5f_98d1_8902732c11c5"></a><a id="Tc_Do0GrmTUQEurmSok1DstiQ_1_2"></a><a id="Tc_0mk1qa6wzk6j_Z1Mb7iiYA_2_2"></a><a id="Tc_EMSpvPBVOEKp3SzMUbagPw_2_5"></a><a id="Tc_DHyp_y66_EaR6C8YweU2mA_2_8"></a><a id="Tc_B7mMdToTckWiyf235kC7Qg_3_2"></a><a id="Tc_JoaaVHF10E6nnyXVqN7ZMg_3_5"></a><a id="Tc_teg1XnDa4UmJHt4nS7ybDQ_3_8"></a><a id="Tc_IJnI2oH-5k-8LNmACH5TpQ_4_2"></a><a id="Tc_NXsAmUZX60KTsi0VyODI_Q_4_5"></a><a id="Tc_jGSUBmL2lkWrPQ3t8nDBaw_4_8"></a><a id="Tc_U0WI5svn_0aO5Wb8-ckPYA_5_2"></a><a id="Tc_SG64CbjMV0u0yRoD-BJFhw_5_5"></a><a id="Tc_A4Ue1-tPw0eSMDWvdWBkIg_5_8"></a><a id="Tc_rffI00-0NUykbeHp92bYBQ_5_11"></a><a id="Tc_CtGXM8FGAUuPYbJLb2sKpg_6_0"></a><a id="Tc_iHs15FZ-3EiyatvGtZvNfw_7_0"></a><a id="Tc_ynJJmc5dsUCL2XDOS7UH4g_8_0"></a><a id="Tc_w6lKvgmgvUyxizLIrkY7yA_8_2"></a><a id="Tc_Rg_dGxvvzU2F42Iceepeig_8_5"></a><a id="Tc_ApqlgU6B50eCO9f_gZFJnw_8_6"></a><a id="Tc_v2wfFqt3wkShyohVzGYwog_8_8"></a><a id="Tc_6Ie0OugOIU6f2DA6khPqmQ_8_9"></a><a id="Tc_fRKx1l4ufkiOFVADwA1tNA_8_11"></a><a id="Tc_bQoaI-xJwUOiXNIFr5uu4w_9_0"></a><a id="Tc_gZHdNhC2Zk2tFjrYA74utw_9_6"></a><a id="Tc_A4oNNNzFpEOhIrlChSE6hg_9_9"></a><a id="Tc_9o-O0kD84EmqMjhlkxVQGw_10_0"></a><a id="Tc_1dbt-T_jbkWDaRyqYJzAbw_10_6"></a><a id="Tc_VeQUbmkqR0CwOD_479P45A_10_9"></a><a id="Tc_2OnyvF_1nEmVfU5vAnJG_A_11_0"></a><a id="Tc_CXP5lVIsskC6PGPHZON7cA_11_2"></a><a id="Tc_uhJHfV8U5EyVuoxkwUhzbQ_11_5"></a><a id="Tc_6SIzRHEYV0uEMVxjZhtKEw_11_6"></a><a id="Tc_cvuRD0pTkkei6ADJiorbqA_11_8"></a><a id="Tc_1ezDO8nCXEyiqpOaiQRyPw_11_9"></a><a id="Tc_DMfu05zQk0a1uvMva8eGsw_11_11"></a><a id="Tc_H1TlrgqkyEueHktn6Qtt1w_12_0"></a><a id="Tc_SIm3QBj3N0W_x4mAW74rjA_13_0"></a><a id="Tc_y9rWgWW_3k-r6izFj4sbIA_13_2"></a><a id="Tc_yZARPblaqECS5enIwvMyEQ_13_3"></a><a id="Tc_8VQ9p3ljW0WjV3vFlp6i8g_13_5"></a><a id="Tc_qLElPyzAnk-88kF-mEG3_A_13_6"></a><a id="Tc_d4TKdfAesEmfi7-qolQxyA_13_8"></a><a id="Tc_yWhbULsGpU2rsMRP8QV_Sw_13_11"></a><a id="_5fbc02ee_ff50_4f4a_935a_25385f33f519"></a><a id="Tc_t6qWmwBMC0-66LMThGZ3jA_1_2"></a><a id="Tc_bhsqvq2ul02kAa8zNLeM0A_2_2"></a><a id="Tc_un5GfxVkOUimPt2AEX1D2g_2_5"></a><a id="Tc_rTGTcMn1YES6Pf8bo0tLyA_2_8"></a><a id="Tc_KnoOgAfMj0qF3N0BP7YDNg_3_2"></a><a id="Tc_-oXNwSKKiU-Izz2kUFx3tw_3_5"></a><a id="Tc_AJSersviq0Wg82Vd1Ad2Eg_3_8"></a><a id="Tc_nmw3ND83y0S6PQlHB3f62Q_4_2"></a><a id="Tc_CXqKO9-4v0alaJJFN7yoBw_4_5"></a><a id="Tc_NJezUM8v20ChQutenY_0VA_4_8"></a><a id="Tc_OHS2uCgCP0euzOqj1kRuKw_5_2"></a><a id="Tc_i_mV94PGNEaWp7tKgFJHig_5_5"></a><a id="Tc_IHDED0wOI0aFo-tvBM2pIg_5_8"></a><a id="Tc_oaMIDVgqAUKJRQ4dCVq9RA_5_11"></a><a id="Tc_agp8wKFYukWslEVqlU0iqQ_6_0"></a><a id="Tc_InR0YO8YUk-ZscKQHDNJVQ_7_0"></a><a id="Tc_qsEChU570U6y_GmSaz7X2Q_7_2"></a><a id="Tc_yk6xrUjPU0ehMiPGjXx2hQ_7_5"></a><a id="Tc_K9Vzyak1J02elYlC2fqF7w_7_6"></a><a id="Tc_DXbpbfSBwEq1UYvON2e-Zw_7_8"></a><a id="Tc_tqO3urKB302pxZZAxN4a_Q_7_9"></a><a id="Tc_AFA_QLEtaEeOgYPqepkDUw_7_11"></a><a id="Tc_4fWoqvk6zE2qmuMD8Ov18A_8_0"></a><a id="Tc_NJaVCLwvq0WXuaAyhGPloQ_9_0"></a><a id="Tc_J_r_KxKWHEGW8ksE3KCIwg_9_2"></a><a id="Tc__d54ctBKska_aX5ELxXdfA_9_3"></a><a id="Tc_8U3hvRgVBkKZYixb_2zqGg_9_5"></a><a id="Tc_0XPbd4DwIUK8FXQgN-vi-Q_9_6"></a><a id="Tc_Y_U0yudKdU29p36esI_Hxw_9_8"></a><a id="Tc_erk-lZ0hgUWy2QPqSgArpg_9_11"></a><ix:continuation id="Tb_SW8cYPo8dU2pC4vXVhG9pA_cont1" continuedAt="Tb_SW8cYPo8dU2pC4vXVhG9pA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_XOgFj8vJqU-LK_O9WhjxCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rUQ9aQoP0UevSR54GD1sWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_1dT_fcbe_UOuiWVqqZY3gg_8_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wKH3zH90P0eBo19y-1AFvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_8BJ0JyUTnU-y-axeVEgBLA_8_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_mRH9FOSK6E204DyksHfdpA_9_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_cj4pgs6f5kugEZT380GTTw_9_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_CkaZcYAjOEu1iS4AIu0m8w_10_3">335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_GjtEX4whe0a3JUgivBcS2w_10_12">335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_pVdCLlK8v0WEaLWGLSw6lw_11_3">30,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_SmrCVSMjSEC9DdymsMPA8Q_11_12">30,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1cbEl4Re006vJtiqqHtFKA" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_ujds5pRPe0O7uDGNgO7OPg_13_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_AzwVq99w1UGt5n1zt0FmrA_13_12">75</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2021 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cxJRCFdTx0yjmZeqnao7Zg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_j5Vc5Att-kiFFqw0HEaySQ_7_3">774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_1vEjGPXT80KiOCUs4c3Plw_7_12">774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xgElIxuKbE-siKQSQ-ga1g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_wBMF1pg8G06iaTvIDrRrHg_9_9">8,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_MjAzO5PIVU6mLCv9YfOEIQ_9_12">8,075</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Securities</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Tb_r_2JErVgvE6xRp6r7DtTTw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2022 and 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. As of December 31, 2022 and 2021, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_wnnfQxVkw0W35DAttJy3RQ">2.07</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0k8XC5hhM0GGrBlYX_tVYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_3Nmh7TPV5UKdkUSUHydUNQ">4.78</ix:nonFraction>, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represented the future consideration that was contingent upon the achievement of specified regulatory milestones. The fair value measurement was based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones. During the year ended December 31, 2022, the estimated fair value of the contingent consideration recorded pursuant to the Affitech CPPA decreased from $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_FAnAp8a72E6w0d6JVWeLow" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_fEs5cLIFjk6V-U5fVvthaw">8.0</ix:nonFraction> million to <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4kBNFywoskiicslz4mbomw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_W9KA5hASrEuFBzdb1PChyQ">zero</ix:nonFraction> after the Company paid Affitech a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsOfContingentConsideration" scale="6" id="Narr_8PWVw2c9WUO8R-2NQSQFPA">5.0</ix:nonFraction> million for milestones tied to the achievement of U.S. marketing approvals in January 2022 and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsOfContingentConsideration" scale="6" id="Narr_ulvKIngzTk2Ba78Yf9RmBg">3.0</ix:nonFraction> million for milestones tied to the achievement of EC Approvals in September 2022 (Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income until settlement. As </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_SW8cYPo8dU2pC4vXVhG9pA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_JTi4wJhq2U663DBSLHd2Vw">no</ix:nonFraction> changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA from the initial value of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_r1ERX-00-kOo1Xhy1OfigQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_6IlBxBtkFkaju_9rdjEuDA">0.1</ix:nonFraction> million. &#160; </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bba066ec_68df_4ee6_9390_d1cb33a8ccce"></a><a id="Tc_6YAmt2IdzkGPhQRkOo96Qw_1_2"></a><a id="Tc_LGhb3FgqIkiuR94zbZOLhA_2_2"></a><a id="Tc_RP2pvISNjE-g4Je9Tw5BPQ_2_5"></a><a id="Tc_hHZ-SRO_jkm5CMRqCvJEaw_3_0"></a><a id="Tc_BHmrBlP8oUiFzRy-jryNwQ_4_0"></a><a id="Tc_k1fk8jYG60qucgVEJAl0cw_4_2"></a><a id="Tc_RWdSfqaPjUC7_rde3J_rEQ_4_5"></a><a id="Tc_rE1YT4uwcUSwfW0fGBQBkg_5_0"></a><a id="Tc_FpAd5whqHk677BDXHX8XtQ_6_0"></a><a id="Tc_OCy6H6ANPkyaN8vA3yQsRQ_6_2"></a><a id="Tc_v0cB-wj-5kmjzI7zVyQCaA_6_5"></a><a id="_c479213d_76c0_4907_86e5_b427db274a75"></a><a id="Tc_jeMgginGyU--VH98V0eBJw_1_2"></a><a id="Tc_e1xYyjfeA0e-7Ilcw5NOfQ_2_2"></a><a id="Tc_A3nIJwQoTUKM33ol0AxRsA_2_5"></a><a id="Tc_vbpLJ_SDQEyCul9TbraT0A_3_0"></a><a id="Tc_4dqy5QYt-06d0LtRYuiLBQ_4_0"></a><a id="Tc_egD6b7vEY0qS8VinxKTSqA_4_2"></a><a id="Tc_4hUV4pIlOkCR71kFAJjB7w_4_5"></a><a id="_Hlk95210281"></a><a id="Tc_ByRuIqRbJEmfhexV2jLwCg_1_2"></a><a id="Tc_Ab0xYAWgUEGe9puVjYSVaA_1_5"></a><a id="Tc_BUEy43SFe0-SZdAx5Mw6Aw_2_2"></a><a id="Tc_yKwe9PZ3RESTA3nAbxmPOw_2_5"></a><a id="Tc_h6JoY2XN6ku0U2QHW5MV1A_3_0"></a><a id="Tc_dRY46t4xWUONXYo6Ovinuw_3_2"></a><a id="Tc_w5iyOGvGqUqin67PgOsPTw_3_5"></a><a id="Tc_8N-F088Jt0mS7tDZtcAm8w_4_0"></a><a id="Tc_VHIlkCfLokqELPklgWpB3g_4_3"></a><a id="Tc_oI1PulAgfEyiX2zbAoIVuQ_4_6"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:LeaseDisclosureTextBlock" id="Tb_LfIqaDLZxUS4-IIygk7V5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Lease Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases <ix:nonFraction unitRef="Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesNumberOfLeasedFacilities" scale="0" id="Narr_tWRfXGNfsECYrGm5rTBZkA">one</ix:nonFraction> facility in Emeryville, California under an operating lease that expires in February 2023. As of December 31, 2022, the total net lease liability from January 2023 until expiration of the lease was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_JQNeN2TEeU24mxPrSn9wUg" decimals="-3" format="ixt:numdotdecimal" name="xoma:LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" scale="0" id="Narr_2lDg5YcKX0eL_0echm4coA">34,000</ix:nonFraction>. &#160;In January 2023, the Company amended the lease to extend the lease period through July 2023 (Note 14). </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_JZDuarbI2EOzPYvW1_osNg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the years ended December 31, 2022 and 2021, respectively (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_tSJsDqHR-kOOjeElXE6SUw_4_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_SgeIozfjCEmr-qJalSdZkw_4_6">177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_3mdANgfhyEmlTAgfTRRc-Q_5_3">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_8QV6AElEfUaVCUYTxaqF1w_5_6">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_Z4s839kttEO1K64EDfsT6g_6_3">189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_NCTGXAQu5Uqp6kmGxfFxRQ_6_6">185</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb_-33uM1VZKkabO9hKgld7Kw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_vvZ2xV9-H06w7fE4YQmCYw_4_3">202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_OPVWFuANYEyg-Du8et94bA_4_6">196</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s operating lease as of December 31, 2022 and 2021 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="Tb_EJUBfv24gEyq_5w2fovFbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_eZsBYo5TUE-pYHnd0jO8Sw">0.17</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_iCqOosI9Q0mgrB3X_bVSsQ">1.17</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Ma9p7xNYg0OCUKwZ1ILvDA_4_2">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_Y4PwaRILREev5MtZduV1Qw_4_5">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><a id="_8a1fe9a3_7d18_43ae_9426_fc68cba20308"></a><a id="Tc_EEHtHcKiw06wit-JIYdkqg_1_2"></a><a id="Tc_ZJ5Es1QcAUSY5Y2iZh4QoQ_2_2"></a><a id="Tc_JWOwiA_IFE6O0X4VCd7cGQ_2_5"></a><a id="Tc_z3BztXNJ40iXVX2mPgg7UQ_3_0"></a><a id="Tc_ZaUPaXpaaEa--LIvZNqDAA_3_2"></a><a id="Tc_lV4SvAZMCUm7-7erhz22YQ_3_5"></a><a id="Tc_JOgg8uhDLUmvlrL6oiXtmg_4_0"></a><a id="Tc_GL-rKe_sJUy81aM6ogJgkA_4_3"></a><a id="Tc_9qokMP2pdkuDPOFj2HQ6Xw_4_6"></a><a id="Tc_c6WMb8IRXUW4LCzBDAwbtA_5_0"></a><a id="Tc__MiPhHbubUKiew1aiLQx8g_5_2"></a><a id="Tc_c3ou9JiDT02Y4aFkmLMzFQ_5_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_RwA7k6GaDEaiT_6tTw4EYA" continuedAt="Tb_RwA7k6GaDEaiT_6tTw4EYA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has pre-tax book loss of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="6" id="Narr_tDzntQ8gcU6yBcgQxCN-zw">17.1</ix:nonFraction> million and pre-tax book income of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="Narr_PJT_07eS7US6eTnfJ0zdaA">15.9</ix:nonFraction> million for the years ended December 31, 2022 and 2021, respectively. &#160;The Company had a $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Narr_Ctae7y2gV0Oz4OYVhMhpyg">15,000</ix:nonFraction> income tax benefit and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_iNDgQJBLqUu6dZ2DBlbCiA">0.1</ix:nonFraction> million income tax expense for the&#160;years ended December&#160;31, 2022 and 2021, respectively. &#160;</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_wh-JIDaMhEuE0QsK33e5uQ" continuedAt="Tb_wh-JIDaMhEuE0QsK33e5uQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" sign="-" scale="3" id="Tc_bnwA7iRR70iGJn2HJAifsw_3_3">15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="3" id="Tc_QRB2zGeIoU2aQG_7rg_aGQ_3_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_4djSOyhNF0ytNhqMb1A9Ug_5_3">15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_H18YXWtLlU-hcdxFDg5tXA_5_6">91</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e913e8dc_7f27_459c_b914_8b006bb55fc5"></a><a id="Tc_LUr0f1LTuUKo8eSTyC_avA_1_2"></a><a id="Tc_vUhIZzuBk0eApJrmb5Gt7A_2_2"></a><a id="Tc_X3Qo0OFO5US-Jt1D4xSI9A_2_4"></a><a id="Tc_uswMVbnX5EqybVp16ykX0w_3_0"></a><a id="Tc_QsL-tiDzfE2SgasJeK2tWg_3_3"></a><a id="Tc_OW27AYm_Ukmf3M9rP9VrRg_3_5"></a><a id="Tc_p3bLdWRVpEqBEK1TAoJPPA_4_0"></a><a id="Tc_dXJL6KLPCEup9X3ZnOhjIw_4_3"></a><a id="Tc_KV0Xl9coeU6w8F0OFSctiA_4_5"></a><a id="Tc_qdgGgpwWa0-yzXTD7gWBxA_5_0"></a><a id="Tc_YkJGM7oyFEy4SLa7Wr1tgg_5_2"></a><a id="Tc_z4UfbO08x0CztXdmNy5t6g_5_3"></a><a id="Tc_YcQ9VOqzOEy61H2vrWHuyw_5_5"></a><a id="Tc_y8bWoS7isEuzMamiI8LPUg_6_0"></a><a id="Tc_Fob30KdaxkmGlwUQjCv0Ew_6_2"></a><a id="Tc_1YC_tDMOpEyQpJVZMakTag_6_3"></a><a id="Tc_J5ZCxUXtlky2vNmATPMLcQ_6_5"></a><a id="Tc_0SLgUu4nTEK8YzyYIu8e-Q_7_0"></a><a id="Tc_GQQUS_Ojd0qA_GaFbRlGOQ_7_3"></a><a id="Tc_R8v3ZIUttUewhWbYBfPEqQ_7_5"></a><a id="Tc_7tBuHk3Ork2IgQZU7DBn3Q_8_0"></a><a id="Tc_QMGsHKDsVk-_PLvKwWAZpw_8_2"></a><a id="Tc_xXaHlGMHkUub8hHiq_ZdYQ_8_3"></a><a id="Tc_PDGwnP8M8UaHFSnpHMov-g_8_5"></a><a id="_651c729e_3d16_42d0_b126_ba38ad169971"></a><a id="Tc_AvLNlaJ6MUWk5ukijnfUYA_1_2"></a><a id="Tc_63zwnqC2RES5mViHPta6FA_2_2"></a><a id="Tc_on7PTolUB0ePY_mwaL_ZdQ_2_5"></a><a id="Tc_GSXDWGAO8UK-fM_F2XKSKA_3_0"></a><a id="Tc_LYjtQd4PQUCwMTqzoszqqQ_3_2"></a><a id="Tc_nDEnTkE8Sk6OIbiBtnQfnA_3_5"></a><a id="Tc_2K9lsJznyEi4MncSrzTtfg_4_0"></a><a id="Tc_GbSPuCmRIkSrCOFxCqGtvw_5_0"></a><a id="Tc_J9cbG-378EKpnqdPXTlMVw_6_0"></a><a id="Tc_UwdB_XTFXkqI6lYRwVzz5A_7_0"></a><a id="Tc_mjodB2qIMkWaBfDv51RX6w_8_0"></a><a id="Tc_4mTGZmIWfk2yJCoXxWYtNA_9_0"></a><a id="Tc__WFvobepqkSLGPR4Gw-Bow_10_0"></a><a id="Tc_WkVJ3uSKhUeY0XkKh2F9xw_11_0"></a><a id="Tc_4cN26l2dL0uO9G6bOBCksg_11_2"></a><a id="Tc_juB9J9XTpEi7iecZ8Aj7Nw_11_5"></a><ix:continuation id="Tb_RwA7k6GaDEaiT_6tTw4EYA_cont1" continuedAt="Tb_RwA7k6GaDEaiT_6tTw4EYA_cont2"><ix:continuation id="Tb_wh-JIDaMhEuE0QsK33e5uQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_X7owPNiblkO0hceiB4hpCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#8217;s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_voblypEIDUOqQ92YjUQVZg_3_2">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Dj7tI91LKkiE0pQqqLn8lg_3_4">21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" sign="-" scale="-2" id="Tc_p5eUz-cYVkulFFV3CJowCQ_4_2">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" scale="-2" id="Tc_NAqXxPkXuEWX1WoZ38N7zA_4_4">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" scale="-2" id="Tc_q-tmErlBdUSeWV8LHd6CdQ_5_4">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to net operating loss carryforward utilization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="xoma:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" sign="-" scale="-2" id="Tc_6iH77blGzUyr54PYrmjDIg_6_4">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_28sXm-TZl0i3VB9Vm9Kanw_7_2">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_xo0iWUJsDkey-ce6J6npMw_7_4">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_YNb5lo8Xa0ScFJtDJBSU2w_8_4">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_7Oadxji5K0-eW3d3m83VDw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_jiCmhbyWy0W_l4_Yorn1zA_3_3">4,732</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_W6RxlG9Wg0SIcuWhOA4AIQ_3_6">7,822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_m-bc9oKI30C_hCwiuG5fWw_4_3">23,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_6Mo613Crv0mW7UecypWYrg_4_6">17,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_ghGhpsjtoUqXbsO6U3BJ_Q_5_3">13,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="Tc_HFsfJdwy3EeyvPQbUQuCZQ_5_6">13,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_U1SEF4INYUSngkmxQ69CqQ_6_3">4,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_IPNz5y1fEEiDyJFf-De92A_6_6">4,778</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_zKdaPcI4NUCwU2tXrH16pw_7_3">2,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="Tc_uzJMEkqkL0uu-_m1GAra3g_7_6">2,817</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_GZeKi18ou02RSge55gYtSg_8_3">1,324</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_2uIpSkuPbU6dDODRbHbMlQ_8_6">807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_EmeE-kgjgES063OWES3IgA_9_3">50,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_NzK7qtXq_EeXBAq0Umh38Q_9_6">47,006</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_qtqe7qanwUK3bvWm3TikMw_10_3">50,329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_08e1dt-Tnk2k4o0cZYrFkA_10_6">47,006</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SoJMkvQEd0GCqEyppA4jKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-opkpTvh2U-sJds8V7C3Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net increase (decrease) in the valuation allowance was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_pB1IY3fQBUmE7mM04T14Lw">3.3</ix:nonFraction> million and $(<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="6" id="Narr_PGzWBy6X4UuulkVDHzexMw">4.6</ix:nonFraction>) million, for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#8217;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2022 and 2021.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had federal NOL carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_lZol9zSOukOk2vDEppi06g">108.8</ix:nonFraction> million and state NOL carry-forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_I3IaD-K-xEGI556fraBoOA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_G1z36xkhc0Glld44O6yskQ">20.9</ix:nonFraction> million to offset future taxable income. $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw" decimals="-5" format="ixt:numdotdecimal" name="xoma:OperatingLossCarryForwardSubjectToExpiration" scale="6" id="Narr_ZXTIZE9G0UKrIeFMFC3HOg">13.6</ix:nonFraction> million of federal NOL carryforwards will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WnhYpE1OH0qWIIqY-1VSWQ" name="xoma:NetOperatingLossCarryforwardsExpirationYear" id="Narr_ud6dPF-hkEupDR_ykojUnQ">2036</ix:nonNumeric> and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ibRXt1hd3k63S2armpWFhg" name="xoma:NetOperatingLossCarryforwardsExpirationYear" id="Narr_WGxJt5ubfEyuRLQgId86GQ">2033</ix:nonNumeric>. The Company had federal orphan credit of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_bYn_MgYoV0WUzvqn6X6Z0w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_ORtf20ONP0OtHDYCdvguJQ">2.0</ix:nonFraction> million which if not utilized will expire in <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_T4pTOnp0j0KTjb2iHvM7fg" name="xoma:TaxCreditCarryForwardExpirationYear" id="Narr_geqv4f3Ic0SRlZzsSQk5uQ">2037</ix:nonNumeric>. The Company also had $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yTZvacgI1ke_u3yIpm8d6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_E0oPNBvusk2gJvMSwVO5Ww">19.8</ix:nonFraction> million of California research and development tax credits which have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_509a5efb_3441_4142_a766_0b3b25c7ba34"></a><a id="Tc_9IvcjP8VkkeTomfnujgOCw_1_2"></a><a id="Tc_u4elXI4mIEyO9Y6WBzx3SA_2_2"></a><a id="Tc_H5I3y3byWE2L1sCe6I-5_A_2_5"></a><a id="Tc_tWXWzqHZQU222fA7utmgNw_3_0"></a><a id="Tc_WaCG_MVJt0SNuE8cVNhtow_3_2"></a><a id="Tc_7l4EwNbQDk-SlUOnOeM9Rg_3_5"></a><a id="Tc_m0N8zwlOHEmBbTW27ux3xQ_4_0"></a><a id="Tc_Tyxk1DsGUUyJsmObuC9A0Q_5_0"></a><a id="Tc_tdvH9FBDpU2WWZ77bAI-Sg_5_3"></a><a id="Tc_U-7v6p0KbUeH01JJTurpyA_5_6"></a><a id="Tc_dGesT2P1bkaM-ckMsExhhw_6_0"></a><a id="Tc_z6nyas723U67Ph2cIvLMwQ_6_2"></a><a id="Tc_ZOHeKxZm2E2rh08KYlz42g_6_5"></a><ix:continuation id="Tb_RwA7k6GaDEaiT_6tTw4EYA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" scale="-2" id="Narr_mc4Qo1bX2k2xssqzxdU3DQ">80</ix:nonFraction>% of taxable income annually. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. &#160;The change in this US tax law did not have an impact on the Company&#39;s consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Act&#8221;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#8217;s consolidated financial statements and related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#8217;s federal income tax returns for tax&#160;years 2019 and beyond remain subject to examination by the Internal Revenue Service. The Company&#8217;s state income tax returns for tax&#160;years 2018 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Tb_HawNw5c3XEO5NuxtvpX8Yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_WmeKEvOJ9EWljngF5ZPC_A_3_3">5,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_F0QBiGQa-kWlGgiQlrad7g_3_6">5,938</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_MgyqPr65aEiXYyenxGZoGA_4_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="Tc_VfdCjdlB-kGgIDrIvQQDtA_4_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_OfwYngzPvUWJfI2UcXCqPA_6_3">5,938</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Tc_jFkVAvY8YUeadRTX26QqXg_6_6">5,938</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_eGP0rIdSSkGq_N0XvS_CYA">5.9</ix:nonFraction> million of gross unrecognized tax benefits, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_Fe9ZN3IWokW6RFpLVtIONg">none</ix:nonFraction> of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" scale="6" id="Narr_i13uCQL2W02-n-yF4xL0DA">no</ix:nonFraction>t expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2022, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_eKhiSt8xBEuMDOOe5AXGvw">no</ix:nonFraction>t accrued interest or penalties related to uncertain tax positions.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_2-OosS0mWEe-s3uFC2j1Xg" continuedAt="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stock Based Compensation and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_KkqFMkj5UEiv41z424bdcw">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May&#160;2015, the Company&#8217;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#8220;2015 ESPP&#8221;), which replaced the Company&#8217;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_mtNNjdSvqEOZFT5yUq0h2Q">15,000</ix:nonFraction> shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" scale="-2" id="Narr_dWNBHoyyHUaDA27HAS9umg">10</ix:nonFraction>% of their eligible compensation, subject </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont1" continuedAt="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to any plan limitations. The 2015 ESPP provides for <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="Narr_EShdbjmpXE231n2F6qI4zg">six-month</ix:nonNumeric> offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_Sg3GzIhQJUqUeFrzwKM4LA">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Compensation Committee and the Board of Directors adopted, and in May&#160;2017, the Company&#8217;s stockholders approved, an amendment to the Company&#8217;s 2015 ESPP. The amendment (a)&#160;increased by <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_s6BVPPFHj0adHDYlaZkYdw">250,000</ix:nonFraction> the shares of common stock (from <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gTYL1gbNEamV73yFBPD9w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_HjSluhsfwUGBQgUoutRcgw">15,000</ix:nonFraction> shares to a total of <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2Eq4oPH3-kmCmCEtd6jqOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_i7WWTQc-NEiNQNXTuTOAdw">265,000</ix:nonFraction> shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="Narr_Lf4tBCwjsU-ZqBA8hJeM1Q">2,500</ix:nonFraction>. As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_innzPLhQmEaLAZC2EVjFOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_a_0R528EmUeM5Dwnsi-TrA">230,937</ix:nonFraction> remaining authorized shares available for purchase under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2022 and 2021, employees purchased <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_1RsmLz3I-0-bqBfxeOniKA">6,090</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_mcDXIe1eeUuUz9qtOy-1xw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" id="Narr_ID7bV_2ESk6OVQHCbt1zWg">2,225</ix:nonFraction> shares of common stock, respectively, under the 2015 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Savings Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under section 401(k)&#160;of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June&#160;1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_KYyrLEuNPkOLRlX-KwrfUQ"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_MV3C44QZjkyCGn8CeQ99ZA">50</ix:nonFraction></ix:nonFraction>% of their eligible compensation per payroll period, up to a maximum for 2022 and 2021 of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_dqF-u1exn0eMTofXVXH82g" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_BPqfntYdbkGtLks2KCRbtw">20,500</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Bp0iF72XDUmK5_A2DxhSyQ" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_vNmUbbGrmk2xBC_lOZjZww">19,500</ix:nonFraction>, respectively (or $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_uQJXomIUj0Gu7qpcedCwyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_o-NMyVuCIESxX8n-SFNpRQ">27,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_-p2i8myCR0Cc2q5-v8T5eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="Narr_H4Zw1ej0x0u79RXgyHLp_A">26,000</ix:nonFraction>, respectively, for employees over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" format="ixt-sec:durwordsen" name="xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="Narr_6K8JG9qiHEK9h0uWxaS-ag"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" format="ixt-sec:durwordsen" name="xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="Narr_FXBG4BQMs0ScsRZGJwkLAQ">50 years</ix:nonNumeric></ix:nonNumeric> of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#8217;s common stock, in amounts which match up to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_9UQegpZ6pk6Io8imyOcdnw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_fXR7Jt3GZ0-ol-jf9nE0Vg"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_k3R6O4_a8E2Uzc-CrSZ8Zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_FNhmXGc_oUWuMKiglgPu0g">50</ix:nonFraction></ix:nonFraction>% of the salary deferred by the participants. The expense related to these contributions was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_L8iLUHcJZ0W2atms_c7k2A"><ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="Narr_6H0QwY3RwEekBQ47tubPmw">0.1</ix:nonFraction></ix:nonFraction> million for the&#160;years ended December 31, 2022 and 2021, and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="INF" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" scale="-2" id="Narr_aY5p4BSejEa-D2vckIotUQ"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" scale="-2" id="Narr_gXq02gpB2UmkOT3ljeQxPQ">100</ix:nonFraction></ix:nonFraction>% was paid in common stock for each&#160;year. The Company applies shares from plan forfeitures of terminated employees toward the Company&#8217;s matching contribution. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company&#8217;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_S_3GoTwkMUmL0YDsH6p4lA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__vqtkLVIfUWl9oF2oiWcmg">ten years</ix:nonNumeric> from the date of the grant or <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_4_yOcoEhi0evQ1_wlkZgQg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_1YKC94rNWkGKHnkUvmCT_Q">three months</ix:nonNumeric> from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_le_sU7N1A06C93O-_SOo1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_4g_yqEjCuESo6hV--xp4PQ">192,964</ix:nonFraction> shares available for grant under the 2010 Plan. As of December&#160;31, 2022, options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_c3q8pXA60E2IFa_nifIVng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_7SHcbLp8T0yOcTWfL2gHKQ">2,025,542</ix:nonFraction> shares of common stock were outstanding under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options generally vest&#160;monthly over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2rqqrvz1g0ady6TBHhDp8A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_VU9Zjz8weEOG6Z4f5KT8HQ">three years</ix:nonNumeric> for employees and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NmtXsMtquUe4CqwtZxHDmg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Mwzq3KGkME6YACmITEtPwQ">one year</ix:nonNumeric> for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="Narr_NAtNW4r-W0ChtjPN797bNg">55 years</ix:nonNumeric> of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="Narr_e30jInzoTEG6ir87vYhTzg">70 years</ix:nonNumeric>) vest on the earlier of scheduled vest date or the date of retirement.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_01d238c5_87e0_4308_bea6_681545e821bc"></a><a id="Tc_yTnpBEMkgUCVR8fpUCt08w_1_5"></a><a id="Tc_nwax7uU_BkituMAzGyGbmQ_1_8"></a><a id="Tc_hRF1HS-IwkGZ2E1M-jPeAg_2_5"></a><a id="Tc_9E1HxWwhykqGU-N2ln0G-Q_2_8"></a><a id="Tc_VYTYcFwUVkCsl14r8lBnMw_2_11"></a><a id="Tc_d8mCdTYhzkWlKzEgVZPnCA_3_5"></a><a id="Tc_hbS9v7h2UEGExuTPfNZKdA_3_8"></a><a id="Tc_iSyeRzwZmU-NBqZoKju5Pg_3_11"></a><a id="Tc_l-IBV_pQaUOxNOc1LQ5iyQ_4_2"></a><a id="Tc_h1inCzJzx0W_xV9T7KypDw_4_5"></a><a id="Tc_0bqrmTiJgEW0ym3klDdYzg_4_8"></a><a id="Tc_fTHst1vbkEGTSnib4Sl8JQ_4_11"></a><a id="Tc_v0RyM4wD10mox6mKUAJsuQ_5_2"></a><a id="Tc_Mfp_TcbbTUqCYj0LlZE71w_5_5"></a><a id="Tc_uMVhAHe70UOYuoJIY0pKQw_5_8"></a><a id="Tc_a7RJQnASlEmK8qY6izH2qQ_5_11"></a><a id="Tc__RRiKrHFYUOo8aozbVkfkw_6_0"></a><a id="Tc_j2U5X2lIJUC7Nwds7cXgJA_6_5"></a><a id="Tc_hya2STfGhEWBxlV7ITMHPw_6_11"></a><a id="Tc_u9e6ys5V20Gmts5sqGd_8g_7_0"></a><a id="Tc_3y_CA_lU3E6FMB5Ku7VTDw_8_0"></a><a id="Tc_9Qjhw47rZU-afvrFeavAUQ_9_0"></a><a id="Tc_FIFHm175J0ydElvXQcvAuQ_10_0"></a><a id="Tc_s-fRVRaJA0eg5gJqZMN2uw_10_5"></a><a id="Tc_oR0PGq_YcU6OCpS6OTBRIA_10_11"></a><a id="Tc_TYEbHpfk0k6ufXpExVO2nw_11_0"></a><a id="Tc_k-9p_uPq3Eu_PrZxdmpm-g_11_5"></a><a id="Tc_kASRn5AiMkSJt53febGxKA_11_11"></a><a id="_72a102a4_c93a_4af5_a3dc_2eff415e6766"></a><a id="Tc_6aZ2Kr3hB0ud2QsXn93zyg_1_2"></a><a id="Tc_IUrVpXfSakiYU_VbJsz_pg_2_2"></a><a id="Tc_s5cJlmM2PkyTstbs3gxguQ_2_4"></a><a id="Tc_0p4-T2HlOEKVlpMiGq_BBw_3_0"></a><a id="Tc_oz7bLvFuh0Glf4eUGZyeGQ_3_3"></a><a id="Tc_EEKEwJ2he0KZasQGclLiwg_3_5"></a><a id="Tc_5-D4x_kWN0CIhsjXuE-sEw_4_0"></a><a id="Tc_ZNV4QWX7eEyocsV7F_WEdg_4_3"></a><a id="Tc_z2XwoNfMEEeUTKZd9fdLrQ_4_5"></a><a id="Tc_kGwIv1isGUiXKid9QVWw3w_5_0"></a><a id="Tc_MUd9bxLR206YIOVaQI9z8g_5_3"></a><a id="Tc_hV2wbCer4UyskfK9jGtNRg_5_5"></a><a id="Tc_NeOhy6SgFUaDWGRACgNjkw_6_0"></a><a id="Tc_bmeaFPaCBUi6bBl_O6cXsA_6_2"></a><a id="Tc_nENMj2WE8021u1DusmkhiQ_6_4"></a><a id="_67e17c2c_1d2c_444e_b9f0_df2accb445d3"></a><a id="Tc_SGWM5eUaz0uFh9ZqF-uGiQ_1_2"></a><a id="Tc_Vi6F9TcMlEui83eqgt2xqA_2_2"></a><a id="Tc_jozYQ49a-UeraYDDFZqNLg_2_5"></a><a id="Tc_jL86PBLRpkOzUnSJ6zao5A_3_0"></a><a id="Tc_2shpGmAz_ky8wq0IUFoCrA_3_2"></a><a id="Tc_y_bX9V9-sUuRyd119IgB2w_3_5"></a><ix:continuation id="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont2" continuedAt="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans Summary </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_aOFoGW66UkWPiMDyKDwgxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_kCd8IcFWxUKqOWRoeCmgYw_6_3">1,911,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_af7vH3DwIUuittP9ETH2zw_6_6">20.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_z9_ytmsh60eQMHKD9u6ubQ_6_9"> 6.33</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Qm1uGevROUOW4OWxvMx03Q_6_12">15,103</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_HSBdF-aSm0uUIje4x85Ydw_7_3">292,972</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_DpXg_Ex_C0q5dPvoSGO2Uw_7_6">19.40</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_zcs1HVMs3kazdvn2FqOKgw_8_3">128,811</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_jKHHwZ4MjEunomNe6YTRfA_8_6">7.22</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_6yHZpFiJTE6ol54ElDunyQ_9_3">49,796</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vHz15McHf0udNFP8dNi0Tw_9_6">64.30</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_TeGtOQJ7s0qdoMfptC-1Dg_10_3">2,025,542</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_K0gOp4S7L0K53FKmAiRaqQ_10_6">20.24</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_N2ryq6zGkkCNDt3HoGOqGQ_10_9"> 6.10</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_6T4E0CCGh0u8AUFllzkJoQ_10_12">10,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_id8QDTvsZkGfqpbtSMKhFA_11_3">1,718,864</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_An7Wce-vxU2GVxtwtfKzqw_11_6">19.67</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_foMWzCh7oEKRm1K4VOv7WQ_11_9"> 5.56</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_sqCo1_OkQku8bWwzL0fg6Q_11_12">10,764</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised in 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_cAVLr9ZJJU-x7V389ZoFQw">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_uIuRYQ00q0Wc9NjUojgqSw">1.6</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted in 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_1qy_RSdmh0S_SANcm2VQNw">12.01</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_2jkjTkOgIEurqC10S4FlKA">22.23</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_v_hV0ir1cEWtoGOP-taG0g">4.0</ix:nonFraction> million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_XL41bSJFVk-NTU7inR_Opw">1.8</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_o6_fOevkt0KoQJ37nnxpxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021, was estimated based on the following weighted average assumptions for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_soxqdHr1tUufdGNmzGSLZA_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_8UcdzDADo0SJzPrerUxlYQ_3_4">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_0Vi4hmevc0OppcbpXyeEZg_4_2">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_eTOBDKrTIEWmXYHw-wT0mA_4_4">83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_ZZZAfxP-OEGB9ub1L51M4w_5_2">2.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_en-WFXkMLkiZ80qQnq7lsw_5_4">0.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_SSgtrUCvA0Wsdw9qvXpWkg">5.64</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_X6Zs57Mx0EicRlj1vyl2qg">5.66</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_YvDnfn-FxES-HArp-Rm71A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_DtxxwLR7u0SbwLsm60y1Bg_3_3">3,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvwASmfkaEWRGoQyRqS1Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_j8iLtyWWPUuh2fYqNGQTiw_3_6">6,195</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"> Thomas Burns Equity Awards Modification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remains employed by the Company for a <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_rAroNAm8f0G6gOtRf-Uv6Q" format="ixt-sec:durwordsen" name="xoma:EmploymentPeriodRetirementEligible" id="Narr_Gn2H34oitUeKwwP4IdYHZw">twelve-month</ix:nonNumeric> period beginning on November 1, 2022, he will be deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. Conditioned on his execution of a release in favor of the Company, Mr. Burns will also receive this benefit upon any involuntary termination for reasons other than cause. The unrecognized stock compensation cost for the unvested stock options as of November 1, 2022 will be recognized over the shorter of (1) <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_bdWwrZZvA0WUmM4wVRe4tw" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_OdFkX1SHG0SZMqWOZPT61A">twelve months</ix:nonNumeric> and (2) the remaining original vesting period (the &#8220;Revised Vesting </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2-OosS0mWEe-s3uFC2j1Xg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Term&#8221;). During the year ended December 31, 2022, the Company recognized stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_SwAbSDClgkW7N51ti2Pz6g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_3JiW2jQtbkm9W5KEeKZ9kQ">0.6</ix:nonFraction> million related to the Mr. Burns&#8217; option awards. As of December 31, 2022, there was $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_FLXGWQjtYkORU4sQnEG_vA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_DJOFLDW1Nk2Gjl8X1aTggg">0.5</ix:nonFraction> million total unrecognized compensation expense related to Mr. Burns&#8217; stock options expected to be recognized through the earlier of the vesting date of the option or October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 25, 2022, the Company approved the Amended Retention Plan which provides that each of its current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of <ix:nonFraction unitRef="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw" contextRef="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPeriodsCashRetentionBonus" scale="0" id="Narr_8DrJjy7VuEWk7OwTfB2ZSg">two</ix:nonFraction> periods: (1) the <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg" format="ixt-sec:durwordsen" name="xoma:PeriodOneRetentionBonusEligibility" id="Narr_NB6MfH57iEyCv49JRtmboQ">three-month</ix:nonNumeric> anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg" format="ixt-sec:durwordsen" name="xoma:PeriodTwoRetentionBonusEligibility" id="Narr_nVZYviua70qF_rtLTm5nPQ">nine-month</ix:nonNumeric> period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company will accrue and recognize the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. Pursuant to Amended Retention Plan, as of December 31, 2022, the Company expects to pay $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_cOp6nGVAs0WrsYuMFKEFVg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CashRetentionBonusExpectedPaymentNextTwelveMonths" scale="6" id="Narr_J-GV7gzSzUOF_3IoPmHONQ">0.8</ix:nonFraction> million in 2023 related to the cash retention bonuses. The Company accrued $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_e4kVRRL9ukOGf7-2PTwdVA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr_1GXqO9NY7kaH3_8Tubo4_A">0.1</ix:nonFraction> million for cash retention bonuses in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2022, the Company&#8217;s board of directors (&#8220;the Board&#8221;) appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer (&#8220;CEO&#8221;) effective January 1, 2023 and, in connection with Mr. Hughes&#8217; appointment, James R. Neal retired as the Company&#8217;s CEO effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedCompensationContinuityIncentive" scale="6" id="Narr_RFPrgkx33UKujCTA5NOs_A">1.2</ix:nonFraction> million (the &#8220;Continuity Incentive&#8221;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_q-sxs5W_mkKsWzMqNMcjqw" decimals="-5" format="ixt:numdotdecimal" name="xoma:CompensationExpenseEmploymentAgreement" scale="6" id="Narr_R7KaW5H0j0mC-mpncUVsfg">1.2</ix:nonFraction> million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3da5e197_ae40_490b_8e3a_c22fd0c57d05"></a><a id="Tc_4SsAJRK3M0eCufvhVNMO0g_1_2"></a><a id="Tc_TonbwwJT_kK7jaomoR4F9w_2_2"></a><a id="Tc_CqeiqccLcEanK-uoRClWJw_2_4"></a><a id="Tc__PwQCpnp3kqlPVQEeJBRSA_3_0"></a><a id="Tc_VSFtfyEnt0yelvVH2ES0tw_3_4"></a><a id="Tc_mTZ7sNiVlkKPcIfCE9yOiw_4_0"></a><a id="Tc_2V-5svt5pEyUtOyth9r7fg_5_0"></a><a id="Tc_FRVGuScYqke7U0HkEDMCQw_5_4"></a><a id="Tc_2UgQRNI3s0mwoIv_YXjQ3w_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:EarningsPerShareTextBlock" id="Tb_0hRYzVEgVk6elrzJODoWmg" continuedAt="Tb_0hRYzVEgVk6elrzJODoWmg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share (attributable to) available to common stockholders if their inclusion is anti-dilutive. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_qJG3o8Npek2J53VK3KBCtQ" continuedAt="Tb_qJG3o8Npek2J53VK3KBCtQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_5aGHU9JvxUq_BpGHRTnqYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_vtO9YHLJx0uC-Zn6vxL2Dg_3_2">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_q87bEsiOOE6OxrrZkp0I_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_iO2MwCo840WWn7jkEj_okQ_4_2">885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_gxn9ucloMEePqYe0bPpnKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Lii2LXtKMkaWa8VUutXRKg_4_4">479</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_u8nxMvP_akullwQz4lc9rA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_rUrf9vc4YE-Y04RPsoK3sg_5_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_H2bqQnhw9Ee5mJJDry_ixQ_6_2">5,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_jCXnTwWxnUauufebsPG_5w_6_4">479</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c42a741_2daf_4f9e_adff_42f67d57d4f1"></a><a id="Tc_H5U_kDevzEiLMRGUauwKJQ_1_2"></a><a id="Tc_B89f7Eyq1EKD_QBqGp6cHw_2_2"></a><a id="Tc_Xs3NypOs_kKFPHw4OwBOEw_2_5"></a><a id="Tc_Np8SZ46i506AIdmYiyBGMw_3_0"></a><a id="Tc_4PxfdFuK_kSQZUnXK1KNDg_4_0"></a><a id="Tc_XF2iQb9lgE2psD6W7Mrh3Q_4_2"></a><a id="Tc_3LvGan1UEEK7lm9-nUl-XQ_4_5"></a><a id="Tc_ONOaC7s8dUywRrIER5zCtA_5_0"></a><a id="Tc_fmk4MfUkW06AHaQfAEuIEg_6_0"></a><a id="Tc_1Bg4aX9q5ka71QtPJ48J6A_7_0"></a><a id="Tc_nvaEXGqx9UGFXq-G3ezV5Q_7_3"></a><a id="Tc__BLR_QgAUEmLT0Waljvsjg_8_0"></a><a id="Tc_pIf1djnd5kixKTpZ-jHqFQ_8_2"></a><a id="Tc_YWpD2bTlsU2AK9FbP1QFew_8_5"></a><a id="Tc_XAYou4kpzU2PmjIokXj0vA_9_0"></a><a id="Tc_EYx74Th5wUiN-FOuZPGrUA_9_3"></a><a id="Tc_1l_sxLhtHkq2LcnVXnjUiA_10_0"></a><a id="Tc_IlB8_thM4kaiIxqvvUQNBg_10_2"></a><a id="Tc_Hsxizb-sm0-duw7kc0ETjA_10_5"></a><a id="Tc_a4HtVID3mEKzBY5lm9_LGw_12_0"></a><a id="Tc_vLAwTTzem0aorHo1zi2MTA_13_0"></a><a id="Tc_-O7q7HCAM0m1GOej7ffNvQ_14_0"></a><a id="Tc_smEj35v3fESmtVhBYspqFA_14_3"></a><a id="Tc_eDigYbBZr0ivK5scT6J_Mg_15_0"></a><a id="Tc_PIGfTVGFbEesYuWGSUiI-A_15_3"></a><a id="Tc_XRGjG4is3ki8slo-fQW_MA_16_0"></a><a id="Tc_KMPEdqlbXEOB34Q4uAJLIw_17_0"></a><a id="Tc_Y6inkiwFr06AkukVFMJnVg_17_2"></a><a id="Tc_aD8kQFCQQ0CtyiSQ_uDDKQ_17_5"></a><a id="Tc_SWgWXHaUZkSED80x_CQflA_18_0"></a><a id="Tc_ajt_qWqGmEGc8p5V0jG_FQ_18_2"></a><a id="Tc_IRYGvRLmP0iy3mjOiCdB0g_18_5"></a><ix:continuation id="Tb_0hRYzVEgVk6elrzJODoWmg_cont1"><ix:continuation id="Tb_qJG3o8Npek2J53VK3KBCtQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_JS2kPqb0iUScxzaSuG822Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nG16MTMpLUOFs4MXPQ9N0w_4_3">17,104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_UyrERykj9E2UGIhul9Mkow_4_6">15,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_TQhoRVF410uclBhV1JhcMw_5_3">2,122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_KfANEcBXDEibQ6Xokccwrw_5_6">2,122</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_5G68eWW4cUq0JrTezzPpNw_6_3">3,350</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" scale="3" id="Tc_aRKLGQumhkC4C05LvvqTQg_6_6">2,438</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="Tc_8FdXX2zQrUKCVefYqJIfJw_7_6">3,451</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc__SGEsXUoe0-Be93Mn7dPew_8_3">22,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="Tc_bZkKXytphkyd0twGQSGgzQ_8_6">7,787</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" sign="-" scale="3" id="Tc_B9flZKBSUEKiFAmTY3QKeQ_9_6">181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_ufQ2YGAP6UK-UllAxC__Sg_10_3">22,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_3sKvQVBYUUCsmZsKXGBpSQ_10_6">7,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_3_wOjTxjYESxKzWsGzX8Dw_13_3">11,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_jL-YKfspDEa_chTaoFAXhA_13_6">11,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="Tc_L3ooPKk44kqQFYuKwoROkA_14_6">900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="3" id="Tc_xV_Jl6krLEi_vpK2w-iHMg_15_6">4</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_ovWvedT34UOqLfTdQ4wL6g_16_3">11,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="Tc_LelWU4JZIEetocEp-zkz0Q_16_6">12,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Nnq5AktYBEeaahU1A4iNlg_17_3">1.98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_q_t4SVnhQkO20fVuiiI35Q_17_6">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_4fkS154wHkmFg3Z-ktJqZA_18_3">1.98</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_GC9jrELtFkSzZ__vTBptfA_18_6">0.65</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_KwezC5x3qEKRq89sngjacQ" continuedAt="Tb_KwezC5x3qEKRq89sngjacQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series X and Series Y Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_UYkiYmAOIk2ogIy_KnYMTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_RAJIwkWOwk6mKoqkWc-Ljg">5,003</ix:nonFraction> shares of Series X convertible preferred stock in 2017 and <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_s24vGEKFqEy3_8cKQImkMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CWd4Pz7KK0KJe7gAItqccA">1,252.772</ix:nonFraction> shares of Series Y convertible preferred stock in 2018. There were <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_uxkL92PMnEKbjnT9gFRfjw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_9vQpbIReOEaZSD0AYkuISw">no</ix:nonFraction> shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_fRh-wLj3lEmlKOT8MGvVEA"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_F5l_KeqNjkiK_Ay-gH2Hmw"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_HfE9-E3YvUy2tEHofZIIig"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_PQC0hltvkUmOJlXURVJkKQ">5,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized and issued of Series X convertible preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series&#160;X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series Y is convertible into <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_mS1sKPw6CE2n0SBLlBsMLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_KkrIDe3vV0K3M2WUn59-LA"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_hxzif6f6wkKNy-S4FYzklQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_ID6yC1fAl02JvkVL5u0DyQ">1,000</ix:nonFraction></ix:nonFraction> shares of registered common stock based on a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_sp6WSCeDk02ydf80LtVc8g" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_HHF5meHFZEm_F3rj7CB4zQ">4.03</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_1HuefpXb_UKf4eNJQw4how" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockConversionPricePerShare" scale="0" id="Narr_ZMteAmfd3ESKy0w9JJIAZg">13.00</ix:nonFraction> per share of common stock respectively. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95476618"></a><a id="_Hlk95468970"></a><ix:continuation id="Tb_KwezC5x3qEKRq89sngjacQ_cont1" continuedAt="Tb_KwezC5x3qEKRq89sngjacQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series A Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2020, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sO-ZiH9JX0a2e36VG0bf-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_84kd6Pr5kkGU99zBRXyafA">984,000</ix:nonFraction> shares of its <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_c4lr6-vztku9OOl5VvIsvA">8.625</ix:nonFraction>% Series A cumulative, perpetual preferred stock at the price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_VF1XQaITcE-WO2mrHASYgQ">25.00</ix:nonFraction> per share, through a public offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_EoI-pQFWLkKUrtASgddEgw">24.6</ix:nonFraction> million. Total offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_T2zunOVqqk-ZQ4hfXgE_ag">2.0</ix:nonFraction> million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromIssuanceOrSaleOfEquityNet" scale="6" id="Narr_TD0HcEe2dkWwq1h-2KZMng">22.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_1RkD9Ss8B0-aazbjCUtXGQ"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_HvW4lsUBRUqNL9MuHbUxcA"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_Q5zKUQZlFEe0UC8VxAiQ8w"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_hLhJf8VDykajSJTceYjHTA">984,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized and issued of Series A Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212;&#160;</i>Holders of <span style="background:#ffffff;">the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_olg6QBxI6kCJV74oTu5KuA">8.625</ix:nonFraction>%</span><span style="background:#ffffff;"> per annum of the </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_f9OuiDSFEE-rdsinSagn6Q">25.00</ix:nonFraction></span><span style="background:#ffffff;"> liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the </span>Series<span style="background:#ffffff;"> A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodYearProrated" scale="0" id="Narr_djmpNBFem0K5p7CfWKTIjw">360</ix:nonFraction></span><span style="background:#ffffff;">-day&#160;year consisting of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:PreferredStockDividendPeriodProratedMonthsInYear" scale="0" id="Narr_o4Fm9KBa7EeU2u6wvpmFUg">twelve</ix:nonFraction></span><span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodMonth" scale="0" id="Narr_tcBoknTzZU6uzxqFRrtX5Q">30</ix:nonFraction></span><span style="background:#ffffff;">-day&#160;months.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212;&#160;</i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will <span style="background:#ffffff;">rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the </span>distribution<span style="background:#ffffff;"> of assets with the Company&#8217;s Series X Preferred Stock. </span>The Series A Preferred Stock have a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_L98IlhLzEkiWvyvWgexUvg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_lmlh4mhC0kaH47iao04EFg">0.05</ix:nonFraction></ix:nonFraction> per share and a liquidation preference of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_4ZyR6GLQ2E2lo01bmJTNLQ">25.00</ix:nonFraction> per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption&#8212;&#160;</i>The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EHfSyV3gW0yDNOYLjydoRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_TmbPq_Cmj0mCwhR7clGlcQ">26.00</ix:nonFraction> per share between December 15, 2021 and December 15, 2022, (ii) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_qfx1aT0hdUKuLGbIUvod5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_3_I6wqYInUO4IPNhHkUKbA">25.75</ix:nonFraction> per share between December 15, 2022 and December 15, 2023, (iii) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HvH-K2iJckyzvUJ368yfOA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_9_jJdFFO-0K54aikL5_lXg">25.50</ix:nonFraction> per share between December 15, 2023 and December 15, 2024 (iv) $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ECC3Oq74RkeaDZlwSNK7uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_1bi3yYH2jUa3RDTDlIft1Q">25.25</ix:nonFraction> per share between December 15, 2024 and December 15, 2025 and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_A1kceVHEZkC9lyFdU9dnZg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_SeHcwHDjCkybMVOuwzk6yw">25.00</ix:nonFraction> per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, <span style="background:#ffffff;">upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockRedemptionPricePerShareOptionalRedemption" scale="0" id="Narr_1ivimnCEgUuGtR_0TVLO7g">25.00</ix:nonFraction></span><span style="background:#ffffff;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Conversion&#8212;&#160;</i>The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KwezC5x3qEKRq89sngjacQ_cont2" continuedAt="Tb_KwezC5x3qEKRq89sngjacQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stock per share equal to the lesser of (A) (i) the sum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_8_6yrvA5BU2Lu_VjrEzy4w">25.00</ix:nonFraction> liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ" decimals="5" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_R7Zw_LFW4E6SBHkWXobmjg">1.46071</ix:nonFraction> (the &#8220;Share Cap&#8221;). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#8217;s common stock on the <ix:nonFraction unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ" contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays" scale="0" id="Narr_RT8c7wtqg0CnSFl_EdPAkA">10</ix:nonFraction> consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212;&#160;</i>Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212;</i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Depositary Shares Representing Interest in Series B Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 9, 2021, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CrcG42Lh2EGRKLf2sS1hBA">1,600,000</ix:nonFraction> Series B Depositary Shares, at the price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_HkTgX1UL_UypJujDv6S3SQ">25.00</ix:nonFraction> per Series B Depositary Share, through a public offering for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_U2KljEMoV0-XgVAtepgegw">40.0</ix:nonFraction> million. Each Series B Depositary Share represents <span style="-sec-ix-hidden:Hidden_bylnvwbfT0qC2wS2bhBX0Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/1000</span></span> interest in a share of Series B Preferred Stock. Total offering costs of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_K04wTa_lGUKOJDCrLewJ2A">2.9</ix:nonFraction> million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromIssuanceOfPreferredStockNet" scale="6" id="Narr_TAQDK5Shw02UgtnfBj7_6Q">37.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spouse of James Neal, then CEO and Chairman of the Board of Directors, purchased <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-IMfj84v-UCty8g7R2816g">8,000</ix:nonFraction> shares of the Series B Depositary Shares in the public offering at the public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ciJIa6qAFU2yV5PeZYq7oQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_YokCv8B2FkWjpjgmK4dzbQ">25.00</ix:nonFraction> per share for an aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_CwCdK2FP_kWGD02CAhsIXg">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_lLENuL8Pn0S6nRoPXCHv-w"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_fzv72Z5S_0qtN0EPdKWqAQ">3,600</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_ztdJVeXdtUCVEdwpOyt_Qg">1,600</ix:nonFraction> issued of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_WnDSCczp7UiwaFt1WW_DWA">8.375</ix:nonFraction>% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends</i>&#8212; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_aEbXM1cIrU2PQeJgezlG9w">8.375</ix:nonFraction>% per annum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_6K-iAzL3w0yH9H6hhnPEQg">25,000.00</ix:nonFraction> liquidation preference per share, which equals $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendAmountPerShare" scale="0" id="Narr_SzLLFTNCjkqcjrBYtlzzVQ">2,093.75</ix:nonFraction> per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a <ix:nonFraction unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="0" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodYearProrated" scale="0" id="Narr_vDEhNiq5rUeZUwa1-J2dXg">360</ix:nonFraction>-day year consisting of <ix:nonFraction unitRef="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:PreferredStockDividendPeriodProratedMonthsInYear" scale="0" id="Narr_2N9LhdA54kKY3_Bhc0oPVg">twelve</ix:nonFraction> <ix:nonFraction unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ" contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A" decimals="0" format="ixt:numdotdecimal" name="xoma:PreferredStockDividendPeriodMonth" scale="0" id="Narr__azsI86Sm06Eb4Efu_pGEg">30</ix:nonFraction>-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Preference</i> - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_HfMf4kCxKkGo_1QiyNzmCQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Dp4oCU6VzEKflvVR7yiSRw">0.05</ix:nonFraction></ix:nonFraction> per share and a liquidation preference of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_ryJ7TY4Gy0WdVYi_DYLoFw">25,000.00</ix:nonFraction> per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption</i> - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_10e0GTXDRUWaRkscI-rq2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_RsV_vGAp806DBLRwLslwhQ">26,000.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mxRsfmorrkSEqfBuonPH7g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_mRnUDfWaDEKpttSg2-ging">26.00</ix:nonFraction> per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_l3gJWyDRYUKye9TcMvxKkA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_zbTRyCOMPUKG4DYPF6amEg">25,750.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_DUPN51MSmkqx8eTsUOxe0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_freuayKpiESm9cCdNBuCjA">25.75</ix:nonFraction> per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_VF5VDW6QuUuc3CbbuaDBkw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_6jv8kaKAtkmvsy_kCwugiw">25,500.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_3Xidd4rXq0CdoCYMGseM6A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_NjkUhaXCPUu5zdqzMHVAbw">25.50</ix:nonFraction> per depositary share), (iv) between </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95224052"></a><a id="_021c2111_9592_41ad_b83a_57d4743d89c2"></a><a id="Tc_0T5EB8r9D0StJzi4YHjncg_1_2"></a><a id="Tc_0UQWwK9pnEGQBQ0vVi1Nzg_1_5"></a><a id="Tc_11szVijHLkqirnK2AOPvGw_2_2"></a><a id="Tc_DObxtVPEUUS_K2ioknCq_g_2_5"></a><a id="Tc_m2HyPeiLWkuYyO8cdaOCdg_3_0"></a><a id="Tc_ApXXe_wSW0aQUlmiJRAv4Q_3_2"></a><a id="Tc_V4vLTh_EUEeNMxK07A28JA_3_5"></a><a id="Tc_BV3hESp4WkCRKdeDHmVfAQ_3_8"></a><a id="Tc_DNJHrFuQZEeAQvXDnKFCJA_4_0"></a><a id="Tc_ljpoFczODEmR_ySD6WDgAA_4_8"></a><a id="Tc_l6Tye_eMkUuAc8n6kLbbUw_5_0"></a><a id="Tc_OocWGnvFfkaPngZddWWUPg_5_8"></a><a id="Tc_nbheZVF68UaleYS5paAZuA_6_0"></a><a id="Tc_EkYeIiTIP0WibXujqgZzGw_6_8"></a><a id="Tc_zA0X4_i19EyflUwx_x6vaQ_7_0"></a><a id="Tc_Vb4L1YN7ukORkaSv_f32Og_7_8"></a><a id="Tc_KMTgiY7BqEy9frht1XN4pw_8_0"></a><a id="Tc_rb4NKSxgH0a5X4C1WF0TMA_8_8"></a><ix:continuation id="Tb_KwezC5x3qEKRq89sngjacQ_cont3" continuedAt="Tb_KwezC5x3qEKRq89sngjacQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">April 15, 2025 to April 15, 2026, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_HlTz8mGzA0mZC7-lIrM7Uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_AIgzquZedEqTBk-EYemJUw">25,250.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ItyWObStzkWwMfLcO4SwBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_t-3dzaxNLkKE_bhn3aVDsg">25.25</ix:nonFraction> per depositary share), and (v) after April 15, 2026, at a redemption price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_PyU4HZ2-MUyl0mkJzT2hGg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_o5d86STOEUuH9g7oZYCL_Q">25,000.00</ix:nonFraction> per share ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_P9oH2exeW068heueh9jTxg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" id="Narr_5dDvhP5ddkiIQyXtUOjMjw">25.00</ix:nonFraction> per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockRedemptionPricePerShareOptionalRedemption" scale="0" id="Narr_SOtg8VwjfkaiFO80-j1FOw">25,000.00</ix:nonFraction> per share plus accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion </i>- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" id="Narr_1FWhhDEgUEWwjmCWNbBT8A">25,000.00</ix:nonFraction> per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#8220;Conversion Rate&#8221;); and (B) <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw" decimals="2" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_0dbhjPN-ZUK58lZHWLIu9g">1,253.13</ix:nonFraction> (<ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA" decimals="5" format="ixt:numdotdecimal" name="xoma:PreferredStockShareCap" scale="0" id="Narr_v1mqMXCz5EO1vWki-M8ZQA">1.25313</ix:nonFraction> per depositary share) (i.e., the &#8220;Share Cap&#8221;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>&#8212; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification</i>&#8212;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company&#8217;s Board of Directors declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:DividendsDeclaredTableTextBlock" id="Tb_13VIU7coJUybmctyZNnhTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 20, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cbQH9ljBJEebaeTjfrtxMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oU8u6lClxEOfghqL98sZqw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_e_wg_juxd0y7BimoFVPg8Q_4_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ns1YY3UqQkOJK6UyTHN1bg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_WrEKyI_BW0KQR6sl9XSdjg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_0PiitNbnlkOAAKi86QeTSw_4_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 18, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KkEuaC7pjUygw9Z4wgEdgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lbU7cay48kKD_gmRJwUG_g" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_bq2hc9Cvp0mbCYYt0BsYTQ_5_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z4eBHZawv0inBmuQccPnkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T3jnk2RjiUevKoKd9EnTqQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_GE4rEzuAn0uEwD1tdzGI3Q_5_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 18, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AffMX3HfskqqtMAs2dYFqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_9mhY0z8wFkeA-5k_gob2uw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_Vz1bpyK91kquvTfcBA9zHg_6_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rVEGkExq70yCFYYZq4K5yQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_uXlwrNWockK5GTzJTR4xtA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_zRliJZVZtkGXIRnj7zz3uA_6_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 20, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LQOgbcYcy0O5Ut6RtuujLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BeZq4eB_bk2TnmlVTH1lsQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_Zs5Cq37zQEOWgNUdM5IQ0Q_7_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Kelm5qnj-EOoeAXowZDZbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nnI_V8OIx0mQwuOLxFWnCw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_gyayY19G_kWpKIqCf-XwVg_7_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 17, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xxzwN1Kink2tMJX3CRXlnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_I6McfUQy7EyE3U2m-gNLig_8_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NoKAl2q6DEWcRsp0Y0mt6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CkHConVlPkaisM4vx4ktDA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_2dMfspLqQka_wGhTUUYDvw_8_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, BVF owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_vwURkgm0wUqLsLPF49LUsQ">31.5</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA" decimals="3" format="ixt:numdotdecimal" name="xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" scale="-2" id="Narr_VvEJFYZUzkmOEzCxgXQdyQ">52.3</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2022, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_RZm2Jy7FokSeaBcgqnJP7g_1_6"></a><a id="Tc_7RWhILnr4E-iwUImuwbSLA_1_9"></a><a id="Tc_MD-uJfK1q0yAs1CpgFqx6A_1_11"></a><a id="Tc__NUXoh0CUU6_v5EhYiSLmQ_2_0"></a><a id="Tc_uqBHk6_SVk-ypSXFFtLzKQ_2_2"></a><a id="Tc_WUcD_dnpeEimnTBOd3cQcA_2_4"></a><a id="Tc_8qQk-Lnff0K-ZEbYZewHxQ_2_6"></a><a id="Tc_vmi0POaXnUKYS6y_tR7omA_2_9"></a><a id="Tc_Uv3BzeRO8kS0deUJ2EWJOQ_2_11"></a><a id="Tc_NuWU6n8cp067xhB5OJdgag_3_0"></a><a id="Tc_B1-yaXIILUCka7CHUP5T5A_3_2"></a><a id="Tc_8LeI_zzQWEeyy873tr482A_3_4"></a><a id="Tc_z0xwVtJm4Ey_LYhSVYMCyA_3_6"></a><a id="Tc_V8szH560BEGrkoWDM9bUrg_4_0"></a><a id="Tc_1457TTUXAEe_WyFDJoYHFg_4_2"></a><a id="Tc_x6ngfuS610ivvLkJ374vEA_4_4"></a><a id="Tc_P1JXyrFHt0WQTZphTUmhFw_4_6"></a><ix:continuation id="Tb_KwezC5x3qEKRq89sngjacQ_cont4" continuedAt="Tb_KwezC5x3qEKRq89sngjacQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_p24xpBTiUk-dfPSrxHMCZw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfCommonStockToBeIssued" scale="6" id="Narr_5b1g8lthfk6kKmT9cHSr1Q">30.0</ix:nonFraction> million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_3Ps32ZWrf0q2EllGoG3fog" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" scale="-2" id="Narr_DNE-DNRynU-UzZNZttBQng">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_10_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_jfpTunIQFUqf7I8Jy9MJPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfCommonStockToBeIssued" scale="6" id="Narr_RS9j4a0rGUCivk3tV1fEZQ">50.0</ix:nonFraction> million. <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_12_18_2018_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_W-KLX26PfE2wxKbylONFcw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_FYH4jrnIoUW2iwmdByZ38g">No</ix:nonFraction> shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_yudqPJgz7UaaG7AG1-aQYw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_I1AmdCHpeEuV1AQQS30ZIA">50.0</ix:nonFraction> million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_HhSShoGRe0G87HW8PMEEcg" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares" scale="-2" id="Narr_OegX9qg3Z0-L5SMe9RHHQQ">3</ix:nonFraction>% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_8_5_2021_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_4s6qFO24NU6iO5tq9Aj0Nw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_UXldOYgoQ0Ko2Ukk92ZdGw">No</ix:nonFraction> shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2022 and 2021, the following common stock warrants were outstanding:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_Q4S3N-LVMUuHJn9I5NYMRA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_8NluGu-i-E-t31Iz2m1JSg_3_7"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_8NluGu-i-E-t31Iz2m1JSg_3_7_2">23.69</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_qnR6Lok3ukOjTlgnrtvYVQ_3_9">6,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_9Ubkbdbn40WGHaN41gA33Q_3_11">6,332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_7YLEteS7LEGf7RzWkm_plA_4_7"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_7YLEteS7LEGf7RzWkm_plA_4_7_2">14.71</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_CxolKg1aN0eGymToxxk_-g_4_9">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc__hjZwQcCR0e3ArABgZmbvQ_4_11">4,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_ev7B2tbFr0SXLy_9Jb4FQA_5_9">11,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_FXi2jE4XjE6TwFokSoBY1A_5_11">11,177</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_1g2-D6BSBkSLIamsMD7nMw">6,332</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Gsar_HhBCkar1MZx518Mqw">23.69</ix:nonFraction> per share. The warrant may be exercised on a cashless basis and is exercisable within <ix:nonNumeric contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_8nHUuSkvaUSLpkODfJC36A" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_Yx4Rhm0OzUuL0tE2daMq1Q">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr__AFbSpKVbEOn0NmO26fmGg">0.1</ix:nonFraction> million. The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_G4XzFg0O1EqCuRCZOQpB4w">4,845</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_Xo_nod8KyUauwrvQcg_9kg">14.71</ix:nonFraction> per share. The second warrant may be exercised on a cashless basis and is exercisable within <ix:nonNumeric contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_f0_HvkLSs0CosO5uys_l2Q" format="ixt-sec:durwordsen" name="xoma:ExercisablePeriodOfWarrants" id="Narr_z30aoHcAIEao_Vibyc21GQ">10 years</ix:nonNumeric> from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_-4qPEv7CvUe68NSbMiXAFA">0.1</ix:nonFraction> million.<span style="letter-spacing:-0.1pt;">&#160;As of December 31, 2022, both warrants are outstanding and </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AQY72CQvV02u0NTeC1tQxQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_gC19HApppEy4crFutzvGJQ">no</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares have been </span><span style="-sec-ix-hidden:Hidden_FXGxJuaD7Eqmui9GgIgKuw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">issued</span></span><span style="letter-spacing:-0.1pt;"> upon exercise of the warrants.</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KwezC5x3qEKRq89sngjacQ_cont5"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_KAp18D1mlUaqPQDG55dhmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContractualObligationEstimatedMilestonePayments" scale="6" id="Narr_v6wBrkm7bUu4Sa8415VQpQ">6.3</ix:nonFraction> million (assuming <ix:nonFraction unitRef="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" scale="0" id="Narr_8yvRxZTFHkeh8kOvpCdQpQ">one</ix:nonFraction> product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, and ObsEva the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, and the Merck KGaA royalties. The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_m-sihnkBl0O9A8sgQ_PEEg">0.1</ix:nonFraction> million for the Bioasis Contingent Consideration which, represents the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2022, there has been <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg" decimals="0" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="0" id="Narr_RreIGeWgZkS88dJFl-Ax5Q">no</ix:nonFraction> change in the estimated fair value of the Bioasis Contingent Consideration from the initial value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is recognized. As of December 31, 2022, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_k_sLWKXSlEu9WIjrFJoc0g" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr__aPcUlkacEyTG5zv3LirqQ">no</ix:nonFraction> liability was recorded on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Arbitration Proceeding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated an arbitration proceeding against <ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfArbitrationProceedingsInitiated" scale="0" id="Narr_Y1C8wFe-_UOpANI-O6zayg">one</ix:nonFraction> of its licensees (the &#8220;Licensee&#8221;) with the American Arbitration Association/International Centre for Dispute Resolution. &#160;XOMA seeks damages, plus interest, and fees and costs of the arbitration (which fees and costs are currently estimated to be in the mid-single-digit millions of U.S. dollars range). &#160;In response, the Licensee seeks declarations that the License Agreement, under XOMA&#8217;s interpretation, is unlawful, void and unenforceable, and that the License Agreement has expired. &#160;To date, the Licensee has not filed any counterclaims against XOMA. However, to the extent the Licensee is deemed to be the prevailing party, the arbitrators, in their discretion, may require XOMA to pay the Licensee&#8217;s fees and costs of the arbitration (currently estimated to be in the mid-single-digit millions of U.S. dollars range). A hearing before a panel of arbitrators was held on this matter in November 2022, and the parties have submitted post-hearing briefs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Tb_wIEG0q0x30-trTCNH5lU0Q" continuedAt="Tb_wIEG0q0x30-trTCNH5lU0Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Concentration of Risk, Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_A4To0NeQ0UybzQYa3NDSxg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_Idu8n98QRkawlM4Agxn2Mw">four</ix:nonFraction> partners represented&#160;<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pFFI1aKmY0-JrE7vjxLafg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_a7sVA1LUkEGnDhTg2MRDWA">33</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y18GrbyNrEilibNOBjl-og" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Lus4P_ME3UKAuHe_dDCYVA">31</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qy9rE8Y_SEaSHkgLxZXqAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_4WIMPbrtkESWs41Xz5iNkA">13</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hJHO8BzhGkm3pdbOfFsQrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_t9x1vl0MJkmlqS-5DOBMNg">12</ix:nonFraction>% of total revenues. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bf1c89fc_6fc5_4ea2_b38e_db68e7f160f9"></a><a id="Tc_GuyHE6p3T0m02LVzNbQHAg_1_2"></a><a id="Tc_BVJ8-18ZMkmY-2Y_0NoPww_2_2"></a><a id="Tc_Ci5YS24r5EepEeXJLxaJKA_2_5"></a><a id="Tc_QDXxyUUen0C-xPn5w5yeFw_3_0"></a><a id="Tc_oP8_Uaq4rUS4hj4_ZJEJ3A_3_2"></a><a id="Tc_Ub5M-xva-Ea9B97-30cchg_3_5"></a><a id="Tc_7DIt8iSRgUOSmJtLfpFsMQ_4_0"></a><a id="Tc_VRONy6yFfU2hFDHPVq5v7A_5_0"></a><a id="Tc_bNEkKtrCDkutvZ1bF_Tgvg_5_3"></a><a id="Tc_jvj6kKejtE-GUN1PEG4ubw_6_0"></a><a id="Tc_MnTxSxIUNkmEAFlj_JGhjA_6_2"></a><a id="Tc_sirsi8eNukyF2DYZqI8Mtw_6_5"></a><ix:continuation id="Tb_wIEG0q0x30-trTCNH5lU0Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Tuhk6nZzwk6xT736Ru4Zyw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_4R37DvmxvE2UUyD5SRMQLA">one</ix:nonFraction> partner represented&#160;<ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W069niAtjE6EsmPfY337qA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_ThMn-Ilz9km8e9IxYwhRYQ">92</ix:nonFraction>% of total revenues. As of December 31, 2022, there is <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_qX-duOd_ekSRDBb3-naLqQ">no</ix:nonFraction> trade receivables balance. As of December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qIclTWez7UKcmOfuHD_oAQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_FhMCBZV7AUGFFaXfr2I08g">one</ix:nonFraction> partner represented <ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_2vBGTX6yJEWsXPa205KCrg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_OHr5MnguJEGOvi5fbJzczA">100</ix:nonFraction>% of the trade receivables balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates in <ix:nonFraction unitRef="Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_vBSTkFr_Q0CEJ1_i6AFGlQ">one</ix:nonFraction> business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Geographic Information</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="Tb_6vbuUATA1Uuk83dSaEYcug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_BRZefaTLEE2Yy6v52PFdig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_o7GUcp_5F0-y_4ancj8SNQ_3_3">4,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_uq3xBIh_ZEu0t2lz65AnGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_iHLlh2lzlUSH_1vcprnfCQ_3_6">2,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_Dtmc_sm9HUOpkVYHoPRuoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_OZAylWdRGUK-EDCTOaxC-A_4_3">1,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember_OSUGOQpK0k66rX6ilVlChg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_q4lOh0CRKU-IqIXP0Tn8xA_4_6">550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember_kIunflkcykiOnsDFbUFC3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_PJWl1KpJekK3G1TAwFM2Ww_5_6">35,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_5py-pIk6zEiGaqdF69k_mg_6_3">6,027</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_YX81dCFjKUmOZHtlSnulDQ_6_6">38,160</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s property and equipment is held in the United States.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_5BSRf8KcLEurBMg0-ZgmjA" continuedAt="Tb_5BSRf8KcLEurBMg0-ZgmjA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emeryville Lease Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023, the Company entered into an amendment to extend the lease term of its corporate headquarters in Emeryville, California from its original expiration of February 2023 through July 2023. The total remaining undiscounted lease payments due in 2023 under the extended lease term is $<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="As_Of_1_13_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gX6CfAtkvUmCg-Bai3Zw_g" decimals="-5" format="ixt:numdotdecimal" name="xoma:LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" scale="6" id="Narr_a86GUBrlqESAxCGOfDA-BQ">0.1</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appointment of Owen Hughes as Executive Chairman of the Board of Directors and Interim CEO</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer), effective as of January&#160;1, 2023. Pursuant to Mr. Hughes&#8217; employment agreement, Mr. Hughes will receive an annual base salary of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA" decimals="-3" format="ixt:numdotdecimal" name="xoma:EmploymentAgreementAnnualSalary" scale="0" id="Narr_NDF-uFIUXk6LalbL2lYOIw">125,000</ix:nonFraction></span><span style="background:#ffffff;"> and be eligible to receive an annual discretionary cash bonus, with a target amount equal to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA" decimals="2" format="ixt:numdotdecimal" name="xoma:AnnualDiscretionaryCashBonusTargetPercentage" scale="-2" id="Narr_MEH-V5XSHk2I5WL9f_cvkA">55</ix:nonFraction>%</span><span style="background:#ffffff;"> of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of his employment agreement, on January 3, 2023, the Company granted Mr. Hughes </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Qzz2di3EtU2QVCStAbp7Gw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_arGW7-mq_EqvPZZEELZtcQ">two</ix:nonFraction></span><span style="background:#ffffff;"> separate non-qualified stock options to purchase: (i) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_jae3kNoSt0Gbm-t0wzlFkA">100,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_yWnl8fZSDEKzPW73ih-cIg">18.66</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;First Hughes Inducement Award&#8221;) and (ii) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_P2qSAMbeA0WKRTgF-bcGsw">75,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Y8Oc-S9Y7EWEVhxW9r5-Uw">30.00</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;Second Hughes Inducement Award&#8221; and together with the First Hughes Inducement Award, the &#8220;Hughes Inducement Awards&#8221;). The First Hughes Inducement Award will vest in a series of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kjZwwrEtk-QxVmWmdRujQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" scale="0" id="Narr_AO2rjcHowUCR4FPGtKg_Jw">four</ix:nonFraction></span><span style="background:#ffffff;"> equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. The Second Hughes Inducement Award will vest in a series of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qLzFyf8POkuPzS_GjeXV5Q" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_JSDyB7hhSUyWoNAz5Z6drw">36</ix:nonFraction></span><span style="background:#ffffff;"> successive equal monthly installments measured from January 1, 2023. The Hughes Inducement Awards are subject to the terms and conditions of the 2010 Plan but were granted outside the 2010 Plan as an inducement material to Mr. Hughes entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Appointment of Bradley Sitko as Chief Investment Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On December&#160;30, 2022, the Board appointed Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;3, 2023. Pursuant to Mr. Sitko&#8217;s employment agreement with the Company, he will receive an annual base </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5BSRf8KcLEurBMg0-ZgmjA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">salary of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:EmploymentAgreementAnnualSalary" scale="0" id="Narr_jixxdWBeW0uTi22CfW1Pbg">500,000</ix:nonFraction></span><span style="background:#ffffff;"> and a signing bonus of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:EmploymentAgreementSigningBonus" scale="0" id="Narr_wyPu4OsCkEyykJ-KL_cOcw">110,000</ix:nonFraction></span><span style="background:#ffffff;">. Mr. Sitko&#8217;s signing bonus will be paid within </span><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" format="ixt-sec:durwordsen" name="xoma:EmploymentAgreementSigningBonusPaymentPeriod" id="Narr_frIKYSQeH0SkXgnUO5VaeQ"><span style="background:#ffffff;">30 days</span></ix:nonNumeric><span style="background:#ffffff;"> after the effective date of his employment agreement and will be subject to standard deductions and withholdings. If Mr. Sitko resigns without good reason or is terminated for cause (each as defined in his employment agreement), in either case, within </span><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" format="ixt-sec:durwordsen" name="xoma:EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" id="Narr_NnOUGQH3KUmRBpTjLj7Q1g"><span style="background:#ffffff;">one year</span></ix:nonNumeric><span style="background:#ffffff;"> after the effective date of his employment agreement, then Mr. Sitko will be required to repay the signing bonus, based on the gross amount, but prorated on a daily basis for the time employed, to be paid within </span><ix:nonNumeric contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" format="ixt-sec:durwordsen" name="xoma:EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" id="Narr_T6cE-nu_sEmqOxL00Lw50A"><span style="background:#ffffff;">60 days</span></ix:nonNumeric><span style="background:#ffffff;"> after his termination date. Mr. Sitko will also be eligible to receive an annual discretionary cash bonus, with a target amount equal to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:AnnualDiscretionaryCashBonusTargetPercentage" scale="-2" id="Narr_cPykt4FXP0S6gAOD1_8lNQ">50</ix:nonFraction>%</span><span style="background:#ffffff;"> of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of his employment agreement, on January 3, 2023 the Company granted Mr. Sitko </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f4LrCv2BoEiulseA8lIUQA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_Gatna3HvsUiFc7TgJERrpQ">two</ix:nonFraction></span><span style="background:#ffffff;"> separate non-qualified stock options to purchase: (i) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_mlONrKgkrEmvVpBCyLUeig">300,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_gDchCGnT10G1dnlSL_6FpA">18.66</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;First Sitko Inducement Award&#8221;) and (ii) </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Q9g-Dwo8EUWv-7gJgtgC4Q">250,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_NDalSWOkMUqDfs95wNuibg">30.00</ix:nonFraction></span><span style="background:#ffffff;"> per share (together with the First Sitko Inducement Award, the &#8220;Sitko Inducement Awards&#8221;). </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_CSlIL-c4x0m_wb8XsqtBow">Twenty-five</ix:nonFraction></span><span style="background:#ffffff;"> percent of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable on </span><span style="-sec-ix-hidden:Hidden_292B7Rrmb0OIBzdjG3jt5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">January 3, 2024</span></span><span style="background:#ffffff;"> (the &#8220;Initial Vesting Date&#8221;), and the balance of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable in a series of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VTkPPsj7uUqml3L2CsbZfA" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_K9gc868HuU27amYGP56Lkw">36</ix:nonFraction></span><span style="background:#ffffff;"> successive equal monthly installments thereafter on the same day of the month as the Initial Vesting Date. The Sitko Inducement Awards are subject to the terms and conditions of the 2010 Plan, but were granted outside the 2010 Plan as an inducement material to Mr. Sitko entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>xoma-20221231xex4d6.htm
<DESCRIPTION>EX-04.6
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:right;margin:30pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.6</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF XOMA CORPORATION CAPITAL STOCK</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following is a description of the Common Stock, $0.0075 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), Preferred Stock, $0.05 par value (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and depositary shares of XOMA Corporation (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Company</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The Common Stock, 8.625% Series A Cumulative Perpetual Preferred Stock (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series A Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and the depositary shares (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series B Depositary Shares</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) representing the 8.375% Series B Cumulative Perpetual Preferred Stock (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Series B Preferred Stock</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) are the only securities of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common Stock</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General. </font><font style="font-family:'Times New Roman','Times','serif';">The Company is authorized to issue up to 277,333,332 shares of Common Stock. The following description is based on (i) the Company&#8217;s Certificate of Incorporation, as currently in effect (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Certificate of Incorporation</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), (ii) the Company&#8217;s By-laws, as currently in effect (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">By-laws</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and (iii) the Delaware General Corporation Law (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">DGCL</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The following summary description of the Common Stock of the Company is qualified in its entirety by reference to the provisions of the Certificate of Incorporation and By-laws, copies of which have been filed as exhibits to the Company&#8217;s Annual Report on Form 10-K filed herewith, and the applicable provisions of the DGCL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividend Rights. </font><font style="font-family:'Times New Roman','Times','serif';">The holders of our Common Stock have the right to receive dividends and distributions, whether payable in cash or otherwise, as may be declared from time to time by our board of directors, from legally available funds. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights. </font><font style="font-family:'Times New Roman','Times','serif';">Each holder of our Common Stock is generally entitled to one vote for each share of Common Stock owned of record on all matters submitted to a vote of our stockholders. Except as otherwise required by law, holders of Common Stock (as well as holders of any Preferred Stock entitled to vote with the common stockholders) will generally vote together as a single class on all matters presented to the stockholders for their vote or approval, including the election of directors. Any matter brought before the stockholders for a vote, other than the election of directors, will generally be decided by a majority of the votes cast on the matter, unless the matter is one in which an express provision of the DGCL, the Certificate of Incorporation, the By-laws, the rules or regulations of any stock exchange applicable to us, applicable law or pursuant to any regulation applicable to us or our securities requires a different vote, in which case the express provision will govern and control the decision of the matter. Directors will be elected by a plurality of the votes cast and entitled to vote generally on the election of directors. There are no cumulative voting rights with respect to the election of directors or any other matters.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">No Preemptive or Similar Rights. </font><font style="font-family:'Times New Roman','Times','serif';">Holders of our Common Stock have no redemption rights, conversion rights or preemptive rights to purchase or subscribe for our securities.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Right to Receive Liquidation Distributions. </font><font style="font-family:'Times New Roman','Times','serif';">In the event of our liquidation, dissolution or winding-up, holders of our Common Stock will be entitled to share equally in the assets available for distribution after payment of all creditors and the liquidation preferences of our Preferred Stock (if any).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The rights of the holders of our Common Stock are subject to, and may be adversely affected by, the rights of holders of shares of any Preferred Stock that we may designate and issue in the future.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:18pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">General.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">Under our Certificate of Incorporation, our board of directors is authorized to issue up to 1,000,000 shares of Preferred Stock, and, by resolution, to divide the Preferred Stock into series and, with respect to each series, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">to determine the designations and the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, including the dividend rights, conversion or exchange rights, voting rights, redemption rights and terms, liquidation preferences, sinking fund provisions and the number of shares constituting the series. Our board of directors can, without stockholder approval but subject to the terms of the Certificate of Incorporation and to any resolution of the stockholders approved by at least 75% of all issued shares entitled to vote in respect thereof, issue Preferred Stock with voting and other rights that could adversely affect the voting power of the holders of our Common Stock and which could have certain anti-takeover effects. Before we may issue any series of Preferred Stock, our board of directors will be required to adopt resolutions creating and designating such series of Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following summary description of the Preferred Stock of the Company, including the Series B Depositary Shares, is qualified in its entirety by reference to the provisions of the Certificate of Incorporation, By-laws and the certificates of designation of preferences, rights and limitations of each series of the Preferred Stock, copies of which have been filed as exhibits to the Company&#8217;s Annual Report on Form 10-K, and the applicable provisions of the DGCL. As of December 31, 2022, 5,003 shares of Series X Preferred Stock, 984,000 shares of Series A Preferred Stock and 1,600 shares of Series B Depositary Shares were issued and outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><a name="_Hlk65341734"></a><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The 8.625% Series A Cumulative Perpetual Preferred Stock.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 984,000 shares of our Preferred Stock as Series A Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Series A Preferred Stock will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:</font></p><div style="margin-top:12pt;"></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series A Preferred Stock;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock and on parity with any future class or series of our equity securities expressly designated as ranking on parity with the Series A Preferred Stock;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series A Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and;</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-top:0pt;min-height:11.9pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';min-width:18pt;white-space:nowrap;">&#9679;</font><font style="font-family:'Times New Roman','Times','serif';">effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We will pay cumulative cash dividends on the Series A Preferred Stock, when and as declared by our board of directors, at the rate of 8.625% of the $25.00 liquidation preference per share per year (equivalent to $2.15625 per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. The first dividend, which was paid on April 15, 2021 in the amount of $0.71875 per share of Series A Preferred Stock, was for more than a full quarter and covered the period from, and including, the first date we issued and sold the Series A Preferred Stock through, but not including, April 15, 2021. Dividends on the Series A Preferred Stock will continue to accumulate whether or not (i) any of our agreements prohibit the current payment of dividends, (ii) we have earnings or funds legally available to pay the dividends, or (iii) our board of directors does not declare the payment of the dividends.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The liquidation preference of each share of Series A Preferred Stock is $25.00. Upon liquidation, holders of our Series A Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series A Preferred Stock plus an amount equal to accumulated but unpaid dividends with respect to such shares. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Optional Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> On and after December 15, 2021, the first anniversary of December 15, 2020, to but excluding the second anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $26.00 per share, plus any accrued and unpaid dividends. On and after December 15, 2022, the second anniversary of December 15, 2020, to but excluding the third anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.75 per share, plus any accrued and unpaid dividends. On and after December 15, 2023, the third anniversary of December 15, 2020, to but excluding the fourth anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.50 per share, plus any accrued and unpaid dividends. On and after December 15, 2024, the fourth anniversary of December 15, 2020, to but excluding the fifth anniversary, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.25 per share, plus any accrued and unpaid dividends. On and after December 15, 2025, the fifth anniversary of December 15, 2020, the shares of Series A Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25.00 per share, plus any accrued and unpaid dividends.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Special Optional Redemption Upon a Change of Control or Delisting Event</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series A Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of Series A Preferred Stock, both (i) the shares of Series A Preferred Stock are no longer listed on Nasdaq, the New York Stock Exchange (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">NYSE</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) or the NYSE American LLC (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">NYSE AMER</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii) we are not subject to the reporting requirements of the Exchange Act, but any Series A Preferred Stock is still outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series A Preferred Stock, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25.00 per share, plus any accrued and unpaid dividends up to, but not including, the date of redemption.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series A Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of the Series A Preferred Stock, the following have occurred and are continuing:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition by any person, including any syndicate or group deemed to be a &#8220;person&#8221; under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our company entitling that person to exercise more than 50% of the total voting power of all shares of our company entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or ADRs representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We refer to redemption following a Delisting Event or Change of Control as a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">special optional redemption</font><font style="font-family:'Times New Roman','Times','serif';">.&#8221; If, prior to the Delisting Event Conversion Date (as defined below) or the Change of Control Conversion Date (as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series A Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of the Series A Preferred Stock will not have the conversion right described below.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series A Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series A Preferred Stock) to convert some or all of the Series A Preferred Stock held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, into a number of shares of our Common Stock (or equivalent value of alternative consideration) per share of Series A Preferred Stock equal to the lesser of:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quotient obtained by dividing (1) the sum of the $25.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series A Preferred Stock dividend payment and prior to the corresponding Series A Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined below); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.46071 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series A Preferred Stock will not have any right to convert the Series A Preferred Stock, and any Series A Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series A Preferred Stock cash in lieu of such fractional shares.</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series A Preferred Stock are not convertible into or exchangeable for any other securities or property.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Change of Control.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2) if the consideration to be received in the Change of Control by holders of our Common Stock is other than solely cash (x) the average of the closing prices for our Common Stock on the principal U.S. securities exchange on which our Common Stock is then traded (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y) the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then listed for trading on a U.S. securities exchange. The &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series A Preferred Stock, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide notice to the holders of the Series A Preferred Stock of a Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> Holders of Series A Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series A Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series A Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our board of directors to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series A Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series A Preferred Stock, voting as a separate class. In any matter in which the Series A Preferred Stock may vote, each share of Series A Preferred Stock shall be entitled to one vote.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The 8.375% Series B Cumulative Perpetual Preferred Stock and the Series B Depositary Shares.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 3,600 shares of our Preferred Stock as Series B Preferred Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The Series B Preferred Stock underlying the Series B Depositary Shares will rank, as to dividend rights and rights upon our liquidation, dissolution or winding up:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior to all classes or series of our Common Stock and to all other equity securities issued by us expressly designated as ranking junior to the Series B Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior with respect to the payment of dividends and on parity with respect to the distribution of assets upon our liquidation, dissolution or winding up with our Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity with our Series A Preferred Stock, and with any future class or series of our equity securities expressly designated as ranking on parity with the Series B Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">junior to all equity securities issued by us with terms specifically providing that those equity securities rank senior to the Series B Preferred Stock with respect to the payment of dividends and the distribution of assets upon our liquidation, dissolution or winding up, none of which exists on the date hereof; and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectively junior to all our existing and future indebtedness (including indebtedness convertible into our Common Stock or Preferred Stock) and to the indebtedness and other liabilities of (as well as any preferred equity interests held by others in) our existing or future subsidiaries.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We will pay cumulative cash dividends on the Series B Preferred Stock, when and as declared by our board of directors, at the rate of 8.375% of the $25,000.00 liquidation preference ($25.00 per depositary share) per year (equivalent to $2,093.75 per share or $2.09375 per depositary share per year). Dividends will be payable quarterly in arrears, on or about the 15th day of January, April, July and October; provided that if any dividend payment date is not a business day, then the dividend which would otherwise have been payable on that dividend payment date may be paid on the next succeeding business day, and no interest, additional dividends or other sums will accumulate. Dividends will accumulate and be cumulative from, and including, the date of original issuance. Dividends on the Series B Preferred Stock underlying the Series B Depositary Shares will continue to accumulate whether or not (i) any of our agreements prohibit the current payment of dividends, (ii) we have earnings or funds legally available to pay the dividends, or (iii) our board of directors does not declare the payment of the dividends.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The liquidation preference of each share of Series B Preferred Stock is $25,000.00 ($25.00 per depositary share). Upon liquidation, holders of our Series B Preferred Stock will be entitled to receive the liquidation preference with respect to their shares of Series B Preferred Stock plus an amount equal to accumulated but unpaid dividends with respect to such shares. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Optional Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> On and after April&#160;15, 2022, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $26,000.00 per share ($26.00 per depositary share), plus any accrued and unpaid dividends. On and after April&#160;15, 2023, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,750.00 per share ($25.75 per depositary share), plus any accrued and unpaid dividends. On and after April&#160;15, 2024, the shares of Series B Preferred </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,500.00 per share ($25.50 per depositary share), plus any accrued and unpaid dividends. On and after April&#160;15, 2025, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,250.00 per share ($25.25 per depositary share), plus any accrued and unpaid dividends. On and after April&#160;15, 2026, the shares of Series B Preferred Stock will be redeemable at our option, in whole or in part, at a redemption price equal to $25,000.00 per share ($25.00 per depositary share), plus any accrued and unpaid dividends. On or after the date fixed for redemption of shares of Series B Preferred Stock, each holder of Series B Depositary Shares to be redeemed must present and surrender the depositary receipts evidencing the Series B Depositary Shares to the depositary at the place designated in the notice of redemption. The redemption price of such Series B Depositary Shares will then be paid to or on the order of the person whose name appears on such depositary receipts as the owner thereof.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Special Optional Redemption Upon a Change of Control or Delisting Event</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event (as defined below), we may, at our option, redeem the Series B Preferred Stock, in whole or in part, within 90 days after the first date on which such Delisting Event occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per depositary share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series B Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of Series B Preferred Stock, both (i)&#160;the shares of Series B Preferred Stock (or the Series B Depositary Shares) are no longer listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER, and (ii)&#160;we are not subject to the Exchange Act, but any Series B Preferred Stock is still outstanding.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Upon the occurrence of a Change of Control (as defined below), we may, at our option, redeem the Series B Preferred Stock underlying the Series B Depositary Shares, in whole or in part within 120 days after the first date on which such Change of Control occurred, for cash, at a redemption price of $25,000.00 per share (equivalent to $25.00 per depositary share), plus any accrued and unpaid dividends up to, but not including, the date of redemption, and the depositary will redeem a proportional number of Series B Depositary Shares representing the shares redeemed.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">With respect to the Series B Preferred Stock, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; occurs when, after the original issuance of the Series B Preferred Stock, the following have occurred and are continuing:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the acquisition by any person, including any syndicate or group deemed to be a &#8220;person&#8221; under Section 13(d)(3) of the Exchange Act, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers or other acquisition transactions of shares of our company entitling that person to exercise more than 50% of the total voting power of all shares of our company entitled to vote generally in elections of directors (except that such person will be deemed to have beneficial ownership of all securities that such person has the right to acquire, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">following the closing of any transaction referred to in the bullet point above, neither we nor any acquiring or surviving entity (or if, in connection with such transaction shares of our Common Stock are converted into or exchanged for (in whole or in part) common equity securities of another entity), has a class of common securities (or ADRs representing such securities) listed on Nasdaq, the NYSE or the NYSE AMER, or listed or quoted on an exchange or quotation system that is a successor to Nasdaq, the NYSE or the NYSE AMER.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We refer to redemption following a Delisting Event or Change of Control as a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">special optional redemption</font><font style="font-family:'Times New Roman','Times','serif';">.&#8221; If, prior to the Delisting Event Conversion Date or the Change of Control Conversion Date (each as defined below), as applicable, we have provided or provide notice of exercise of any of our redemption rights relating to the Series B Preferred Stock (whether our optional redemption right or our special optional redemption right), the holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have the conversion right described below.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Upon the occurrence of a Delisting Event or a Change of Control, as applicable, each holder of Series B Depositary Shares representing interests in the Series B Preferred Stock will have the right (unless, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide notice of our election to redeem the Series B Preferred Stock) to direct the depositary, on such holder&#8217;s behalf, to convert some or all of the Series B Preferred Stock underlying the Series B Depositary Shares held by such holder on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable into a number of shares of our Common Stock (or equivalent value of alternative consideration) per depositary share equal to the lesser of:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quotient obtained by dividing (1) the sum of the $25.00 per depositary share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable (unless the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and unpaid dividend will be included in this sum) by (2) the Common Stock Price (as defined herein); and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.25313 (i.e., the Share Cap), subject to certain adjustments; and subject, in each case, to certain conditions, including, under specified circumstances, an aggregate cap on the total number of shares of our Common Stock issuable upon conversion and to provisions for the receipt of alternative consideration.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">If, prior to the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable, we have provided or provide a redemption notice, whether pursuant to our special optional redemption right or our optional redemption right, holders of Series B Depositary Shares representing interests in the Series B Preferred Stock will not have any right to direct the depositary to convert the Series B Preferred Stock, and any Series B Preferred Stock subsequently selected for redemption that has been tendered for conversion will be redeemed on the related date of redemption instead of converted on the Delisting Event Conversion Date or Change of Control Conversion Date, as applicable.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Because each depositary share represents a 1/1000th interest in a share of the Series B Preferred Stock, the number of shares of Common Stock ultimately received for each depositary share will be equal to the number of shares of Common Stock received upon conversion of each share of Series B Preferred Stock divided by 1000. In the event that the conversion would result in the issuance of fractional shares of Common Stock, we will pay the holder of Series B Depositary Shares cash in lieu of such fractional shares.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Except as provided above in connection with a Delisting Event or Change of Control, shares of the Series B Preferred Stock are not convertible into or exchangeable for any other securities or property.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Change of Control Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Change of Control will be: (1) if the consideration to be received in the Change of Control by the holders of our Common Stock is solely cash, the amount of cash consideration per share of Common Stock; and (2)&#160;if the consideration to be received in the Change of Control by holders of our Common Stock is other than solely cash (x)&#160;the average of the closing prices for our Common Stock on the principal U.S. securities exchange on which our Common Stock is then traded (or, if no closing sale price is reported, the average of the closing bid and ask prices per share or, if more than one in either case, the average of the average closing bid and the average closing ask prices per share) for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred as reported on the principal U.S. securities exchange on which our Common Stock is then traded, or (y)&#160;the average of the last quoted bid prices for our Common Stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the ten consecutive trading days immediately preceding, but not including, the date on which such Change of Control occurred, if our Common Stock is not then </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">listed for trading on a U.S. securities exchange. The &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Common Stock Price</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; for any Delisting Event will be the average of the closing price per share of our Common Stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the Delisting Event.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">For purposes of this description of the Series B Preferred Stock and the underlying Series B Depositary Shares, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delisting Event Conversion Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a business day fixed by our board of directors that is not fewer than 20 days nor more than 35 days after the date on which we provide the notice described above to the holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> Holders of the Series B Depositary Shares representing interests in the Series B Preferred Stock generally will have no voting rights. However, if we do not pay dividends on any outstanding shares of Series B Preferred Stock for six or more quarterly dividend periods (whether or not declared or consecutive), holders of Series B Preferred Stock (voting separately as a class with all other outstanding series of preferred stock upon which like voting rights have been conferred and are exercisable) will be entitled to elect two additional directors to our Board of Directors to serve until all unpaid dividends have been fully paid or declared and set apart for payment. In addition, certain material and adverse changes to the terms of the Series B Preferred Stock cannot be made without the affirmative vote of holders of at least 66 2/3% of the outstanding shares of Series B Preferred Stock, voting as a separate class. In any matter in which the Series B Preferred Stock may vote, each share of Series B Preferred Stock shall be entitled to one vote. As a result, each depositary share will be entitled to 1/1000th of a vote.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">The Series X Preferred Stock.</font><i style="font-family:'Times New Roman','Times','serif';font-style:italic;"> </i><font style="font-family:'Times New Roman','Times','serif';">We have designated 5,003 shares of our Preferred Stock as Series X Preferred Stock. The Series X Preferred Stock ranks: </font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">senior to any class or series of our capital stock created specifically ranking by its terms junior to the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity to our Common Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on parity to any class or series of our capital stock created specifically ranking by its terms on parity with the Series X Preferred Stock; and</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">junior to any class or series of our capital stock created specifically ranking by its terms senior to the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">in each case, as to distributions of assets upon our liquidation, dissolution or winding up whether voluntarily or involuntarily. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dividends</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> Holders of Series X Preferred Stock are entitled to receive dividends on shares of Series X Preferred Stock equal (on an as-converted basis) to and in the same form as dividends actually paid on our Common Stock or other junior securities. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Preference</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> In the event of our liquidation, dissolution, or winding up, holders of our Series X Preferred Stock will participate pari passu (on an as-converted basis, without regard to any blocker provisions) with any distribution of proceeds to holders of our Common Stock. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Redemption</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> We are not obligated to redeem or repurchase any shares of Series X Preferred Stock. Shares of Series X Preferred Stock are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> The Series X Preferred Stock is convertible at the option of the holders thereof at any time after issuance into the number of registered shares of Common Stock determined by dividing the aggregate stated value of the Series X Preferred Stock being converted by the conversion price then in effect. The initial conversion price is $4.03 and is subject to adjustment as described below. No holder may request a conversion of its Series X Preferred Stock to the extent such conversion would result in the holder and its affiliates beneficially owning more than a pre-</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">set conversion blocker threshold, which will initially be set at 19.99% of our Common Stock then outstanding (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). The amount of beneficial ownership of a holder and its affiliates will be determined in accordance with Section 13(d) of the Exchange Act, and the rules and regulations of that section.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Conversion Price Adjustment-Stock Dividends and Stock Splits</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b><font style="font-family:'Times New Roman','Times','serif';"> If we pay a stock dividend or otherwise make a distribution payable in Common Stock on our Common Stock or any Common Stock equivalents, subdivide or combine our outstanding Common Stock, or reclassify our Common Stock in such a way that we issue additional shares of our capital stock, the conversion price will be adjusted by multiplying the then-existing conversion price by a fraction, the numerator of which is the number of shares of Common Stock outstanding immediately before the distribution, dividend, adjustment or recapitalization and the denominator of which is the number of shares of Common Stock outstanding immediately after such action. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Fundamental Transaction.</font><font style="font-family:'Times New Roman','Times','serif';"> If we effect a &#8220;fundamental transaction&#8221; (as defined below), then upon any future conversion of the Series X Preferred Stock, the holders will have the right to receive, for each share of Common Stock they would have received upon such conversion, the same kind and amount of securities, cash or property as such holder would have been entitled to receive in the fundamental transaction had it been the holder of Common Stock immediately prior to the fundamental transaction. The term &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">fundamental transaction</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any of the following:</font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a merger or consolidation of the Company with or into another entity or any stock sale to, or other business combination in which the Company is not the surviving entity;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale of all or substantially all of our assets in one transaction or a series of related transactions;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any completed tender offer or exchange offer involving holders of Common Stock in which more than 50% of the Common Stock is converted or exchanged into other securities, cash or property, regardless of who makes such offer; or</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 56.25pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any reclassification of Common Stock or any compulsory share exchange by which our Common Stock is effectively converted into or exchanged for other securities, cash or property (but not a reverse stock split).</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">If the holders of Common Stock are given a choice as to the securities, cash or property to be received in a fundamental transaction, the holders of Series X Preferred Stock will be given the same choice on conversion of such holders&#8217; shares. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:12pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Voting Rights.</font><font style="font-family:'Times New Roman','Times','serif';"> The Series X Preferred Stock has no voting rights, except to the extent expressly provided in our Certificate of Incorporation or as otherwise required by law. However, so long as 2,502 shares of Series X Preferred Stock are outstanding, we may not take any of the following actions without the affirmative consent of holders of a majority of the outstanding Series X Preferred Stock: </font></p><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">amend our Certificate of Incorporation, By-laws or other charter documents so as to materially, specifically and adversely affect the preferences, rights, or privileges of the Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue additional shares of Series X Preferred Stock or increase or decrease the number of authorized shares of Series X Preferred Stock;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell, assign, monetize, pledge or otherwise divest or encumber our rights under any material license agreement, joint venture or other partnership agreement to which we are a party as of the date of this offering and involving any drug or drug candidate;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue or commit to issue any other equity securities, with certain exceptions;</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue any equity-based award or compensation to certain of our officers, unless the award has been unanimously approved by our compensation committee at a time when a designee appointed by the Series X Preferred holders is then serving on that committee; or</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.19;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enter into any agreement or understanding to take any of the actions listed above.</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;margin:18pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Anti-takeover Effects of Provisions of our Certificate of Incorporation and By-laws and Delaware Law</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Certificate of Incorporation and By-laws Provisions. </font><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation authorizes our board of directors to issue up to 1,000,000 shares of Preferred Stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the board of directors may determine. In addition, our By-laws require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings. Our By-laws also provide that our board of directors is able to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member. Provisions of Delaware law and our Certificate of Incorporation and By-laws could make the acquisition of our company through a tender offer, a proxy contest or other means more difficult and could make the removal of incumbent officers and directors more difficult. We expect these provisions to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of our company to first negotiate with our board of directors. We believe that the benefits provided by our ability to negotiate with the proponent of an unfriendly or unsolicited proposal outweigh the disadvantages of discouraging these proposals. We believe the negotiation of an unfriendly or unsolicited proposal could result in an improvement of its terms.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:18pt;margin:18pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Delaware Law. </font><font style="font-family:'Times New Roman','Times','serif';">We are subject to Section 203 of the DGCL, an anti-takeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the date the person became an interested stockholder, unless: </font></p><div style="margin-top:18pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:11.9pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66% of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.9pt;text-align:justify;text-indent:25pt;margin:12pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, beneficially owns, or is an affiliate of the corporation and within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s outstanding voting securities. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>xoma-20221231xex10d10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;min-height:11.9pt;text-align:right;margin:30pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.10</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">November 1, 2022 </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Thomas Burns </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">VIA EMAIL/DOCUSIGN </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Dear Thomas: </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">As you know, you are employed by XOMA Corporation (the &#8220;Company&#8221;) pursuant to the terms of an Officer Employment Agreement dated August 7, 2017, as amended on April 1, 2022 (the &#8220;Agreement&#8221;). You and the Company are hereby agreeing to amend the Agreement to modify the retention benefit contained therein, as set forth below (the &#8220;Amendment&#8221;). </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Under the existing terms of the Agreement, in order to be eligible for the retention benefit, you must remain employed by the Company for a twelve (12)-month period (the &#8220;Period&#8221;) following the first day of employment of the Company&#8217;s new Chief Executive Officer. By the terms of this Amendment, the Period shall be accelerated to start on November 1, 2022. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Other than set forth herein, the terms of the Agreement shall remain in full force and effect. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">This Amendment forms the complete and exclusive agreement between you and the Company with respect to this subject matter. It supersedes any other agreements or promises made to you by anyone, whether oral or written, with respect to such subject matter. Changes to the terms of this Amendment require a written modification signed by an officer of the Company. This Amendment may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Please sign and date this letter and return it to me. </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sincerely, </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Jim Neal </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">On behalf of the Board of Directors </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Understood and Accepted: </font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Thomas Burns</u><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:1.44pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u> </u><font style="display:inline-block;width:33.5pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;">              </font><font style="display:inline-block;width:1pt;"></font><font style="display:inline-block;width:36pt;"></font><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">November 1, 2022     </u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thomas Burns </font></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';">Date</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>xoma-20221231xex10d14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:31 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;min-height:46.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 10.14</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">XOMA</b><b style="font-variant:small-caps;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-variant:small-caps;font-weight:bold;">Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Amended and Restated</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt;"><b style="font-variant:small-caps;font-weight:bold;">Retention</b><b style="font-variant:small-caps;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-variant:small-caps;font-weight:bold;">and</b><b style="font-variant:small-caps;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-variant:small-caps;font-weight:bold;">Severance</b><b style="font-variant:small-caps;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-variant:small-caps;font-weight:bold;">Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Section</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.25pt;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">I</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">NTRODUCTION</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt;">This XOMA Corporation Retention and Severance Plan (the &#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;) is hereby established by the Board of Directors of XOMA Corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;) effective as of January<font style="letter-spacing:-0.75pt;"> </font>1,<font style="letter-spacing:-0.75pt;"> </font>2022.<font style="letter-spacing:1.35pt;"> </font>The<font style="letter-spacing:-0.75pt;"> </font>purpose<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Plan<font style="letter-spacing:-0.75pt;"> </font>is<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.7pt;"> </font>provide<font style="letter-spacing:-0.75pt;"> </font>for<font style="letter-spacing:-0.65pt;"> </font>retention<font style="letter-spacing:-0.7pt;"> </font>bonuses<font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.7pt;"> </font>severance<font style="letter-spacing:-0.75pt;"> </font>benefits to<font style="letter-spacing:-0.55pt;"> </font>eligible<font style="letter-spacing:-0.75pt;"> </font>employees<font style="letter-spacing:-0.65pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Company<font style="letter-spacing:-0.75pt;"> </font>under<font style="letter-spacing:-0.7pt;"> </font>certain<font style="letter-spacing:-0.75pt;"> </font>specified<font style="letter-spacing:-0.55pt;"> </font>conditions.<font style="letter-spacing:1.65pt;"> </font>This<font style="letter-spacing:-0.75pt;"> </font>Plan<font style="letter-spacing:-0.75pt;"> </font>document<font style="letter-spacing:-0.55pt;"> </font>also is<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Summary Plan<font style="letter-spacing:-0.05pt;"> </font>Description<font style="letter-spacing:-0.25pt;"> </font>for<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Plan.<font style="letter-spacing:-0.1pt;"> </font>Capitalized terms<font style="letter-spacing:-0.1pt;"> </font>used but not defined<font style="letter-spacing:-0.05pt;"> </font>herein<font style="letter-spacing:-0.25pt;"> </font>shall have the meanings given to them in the Equity Plan (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 10pt 72pt;">For<font style="letter-spacing:-0.05pt;"> </font>purposes<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Plan,<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>following<font style="letter-spacing:-0.25pt;"> </font>terms<font style="letter-spacing:-0.15pt;"> </font>are<font style="letter-spacing:-0.3pt;"> </font>defined<font style="letter-spacing:-0.1pt;"> </font>as<font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">follows:</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-size:12pt;">&#8221; means any corporation or limited liability company (other than the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company)</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">&#8220;unbroken</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">chain</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">corporations</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and/or</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">limited</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">liability</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">companies&#8221;</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">beginning with</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Company, if</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">each</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">corporations</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and/or limited</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">liability</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">than</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">last corporation</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">limited</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">liability</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">company</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">unbroken</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">chain</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">owns</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">stock</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">possessing</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">50%</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">more of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">total</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">combined</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">voting</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">power</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">classes</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">stock</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">limited</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">liability</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">company</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">membership interests in one of the other corporations and/or limited liability companies in such chain.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Base Salary</font><font style="font-size:12pt;">&#8221; means base pay (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect prior to any reduction that would give rise to an employee&#8217;s right to a resignation for Good Reason (if </font><font style="font-size:12pt;letter-spacing:-0.1pt;">applicable).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-size:12pt;">&#8221; means (1) willful material fraud or material dishonesty in connection with the employee&#8217;s performance of his or her duties to the Company; (2) failure by the employee to materially perform his or her duties; (3) material breach by the employee of his or her employment agreement with the Company or the Company&#8217;s Code of Ethics; (4) misappropriation</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">material</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">business</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">opportunity</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Company;</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">(5) misappropriation</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of any Company funds or property; or (6) conviction of, or the entering of a plea of guilty or no contest with respect to, a felony.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Code</font><font style="font-size:12pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;letter-spacing:-0.85pt;"> </font><font style="font-size:12pt;">means</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Compensation</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Committee</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Board </font>of<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.1pt;">Directors.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">means</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">XOMA</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Corporation</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">successor </font><font style="font-size:12pt;letter-spacing:-0.1pt;">company.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><font style="font-size:12pt;letter-spacing:-0.1pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Confidentiality Agreement</font><font style="font-size:12pt;letter-spacing:-0.1pt;">&#8221; </font><font style="font-size:12pt;letter-spacing:-0.2pt;">means </font><font style="font-size:12pt;letter-spacing:-0.25pt;">the </font><font style="font-size:12pt;letter-spacing:-0.1pt;">employee&#8217;s Proprietary </font>Information<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>Inventions<font style="letter-spacing:-0.4pt;"> </font>Agreement<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>any<font style="letter-spacing:-0.35pt;"> </font>similar<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>successor<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">document.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-size:0pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Covered Termination</font><font style="font-size:12pt;">&#8221; means, with respect to an employee, a Termination of Service that is due to (1) a termination by the Company without Cause (and other than as a result of the employee&#8217;s death or Disability) or (2) the employee&#8217;s resignation for Good Reason, and in either case of (1) or (2), results in such employee&#8217;s Separation from Service.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-size:12pt;">&#8221; means any physical or mental condition which renders an Eligible Employee incapable of performing the work for which he or she was employed by the Company or similar work offered by the Company and that results in a Termination of Service. The Disability of an Eligible Employee shall be established if such Eligible Employee is, by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of not less than twelve (12) consecutive months or more, unable to perform his or her usual duties for the Company or its Affiliates.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Eligible Employee</font><font style="font-size:12pt;">&#8221; means an employee of the Company that meets the requirements to be eligible to receive Plan benefits as set forth in Section 2.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Equity Plan</font><font style="font-size:12pt;">&#8221; means the XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-size:12pt;">&#8221; for an employee&#8217;s resignation means the occurrence of any of the following actions are undertaken by the Company without the employee&#8217;s prior written </font><font style="font-size:12pt;letter-spacing:-0.1pt;">consent:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:12pt;">a material reduction in such employee&#8217;s Base Salary (unless pursuant to a salary reduction program applicable generally to XOMA&#8217;s employees);</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:12pt;">a material reduction in such employee&#8217;s duties (including responsibilities</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and/or authorities), provided,</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">however, that</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">change</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">job</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">position</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">(including</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">a change</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in title) shall not be</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">deemed</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">&#8220;material reduction&#8221;</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in and of itself unless</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">employee&#8217;s new duties are materially reduced from the prior duties;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:12pt;">a material breach by</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the Company</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">any provision of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">this Plan or any</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">material</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">agreement</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">between</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">employee</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">concerning</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">terms</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and conditions of such employee&#8217;s employment with the Company; or</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(4)</font><font style="font-size:12pt;">a relocation of such employee&#8217;s principal place of employment with the Company (or successor to the Company, if applicable) to a place that increases such employee&#8217;s one-way commute by more than 30 miles as compared to such employee&#8217;s then- current principal place of employment immediately prior to such relocation (excluding regular travel</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">ordinary</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">course</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">business);</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">provided</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">1(l)(4)</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">apply</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">so</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">long as the employee remains eligible following</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">such relocation to live and work full-time outside of such 30 mile radius as long as such employee performs his or her duties in a timely fashion.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">3.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Notwithstanding<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>foregoing,<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>order<font style="letter-spacing:-0.45pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>employee&#8217;s<font style="letter-spacing:-0.4pt;"> </font>resignation<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>deemed<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>have<font style="letter-spacing:-0.35pt;"> </font>been for Good Reason, the employee must (a) provide written notice to the Company of such employee&#8217;s<font style="letter-spacing:-0.25pt;"> </font>intent<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>resign<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>Good<font style="letter-spacing:-0.15pt;"> </font>Reason<font style="letter-spacing:-0.1pt;"> </font>within<font style="letter-spacing:-0.1pt;"> </font>90 days<font style="letter-spacing:-0.4pt;"> </font>after<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>first<font style="letter-spacing:-0.3pt;"> </font>occurrence<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>event giving rise to Good Reason, which notice shall describe the event(s) the employee believes give rise to Good Reason; (b) allow the Company at least 60 days<font style="letter-spacing:-0.05pt;"> </font>from receipt of the written notice to cure<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>event<font style="letter-spacing:-0.55pt;"> </font>(such<font style="letter-spacing:-0.35pt;"> </font>period,<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Cure</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.4pt;"> </font><font style="font-style:italic;font-weight:bold;">Period</font>&#8221;),<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>(c)<font style="letter-spacing:-0.5pt;"> </font>if<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>event<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.45pt;"> </font>not<font style="letter-spacing:-0.55pt;"> </font>reasonably<font style="letter-spacing:-0.3pt;"> </font>cured<font style="letter-spacing:-0.35pt;"> </font>within the<font style="letter-spacing:0.45pt;"> </font>Cure<font style="letter-spacing:0.4pt;"> </font>Period,<font style="letter-spacing:0.35pt;"> </font>then<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>employee<font style="letter-spacing:0.45pt;"> </font>must<font style="letter-spacing:0.5pt;"> </font>resign<font style="letter-spacing:0.5pt;"> </font>from<font style="letter-spacing:0.5pt;"> </font>all<font style="letter-spacing:0.5pt;"> </font>positions<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>employee<font style="letter-spacing:0.45pt;"> </font>then<font style="letter-spacing:0.45pt;"> </font>holds<font style="letter-spacing:0.4pt;"> </font><font style="letter-spacing:-0.2pt;">with </font>the Company not later than one hundred eighty (180) days following the first occurrence of the event giving rise to Good Reason.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Participation</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">means</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">agreement</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">between</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">employee</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">and the Company in substantially the form of </font><b style="font-size:12pt;font-weight:bold;">A</b><b style="font-size:9.5pt;font-weight:bold;">PPENDIX </b><b style="font-size:12pt;font-weight:bold;">A </b><font style="font-size:12pt;">attached hereto, and which may include such</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">terms</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Committee</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">deems</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">necessary</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">advisable</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">administration</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Plan.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Administrator</font><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">means</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Committee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">&#8220;Section 409A&#8221; </font><font style="font-size:12pt;">means Section 409A of the Code and the treasury regulations and other guidelines thereunder and any state law of similar effect.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(p)</font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Separation from Service</font><font style="font-size:12pt;">&#8221; means a &#8220;separation from service&#8221; within the meaning</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Treasury</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">Regulations</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">1.409A-1(h),</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">without</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">regard</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">alternative</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">definition </font><font style="font-size:12pt;letter-spacing:-0.1pt;">thereunder.</font></div><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Section</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.25pt;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">E</b><b style="font-size:9.5pt;font-weight:bold;">LIGIBILITY</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">FOR</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">B</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ENEFITS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Eligible</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-size:12pt;font-weight:bold;">Employee</b><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">An</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">employee</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">eligible</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">participate in the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan if (i) the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Administrator has</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">designated such employee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">eligible</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to participate</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in the Plan by providing such employee a Participation Agreement; (ii) such employee has signed and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">returned</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Participation</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">required</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">therein; and (iii) such employee meets the other Plan eligibility requirements set forth in this Section 2. The determination of whether an employee is an Eligible Employee shall be made by the Plan Administrator,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">its</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">sole</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">discretion,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">determination</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">binding</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">conclusive</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">on</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">all </font><font style="font-size:12pt;letter-spacing:-0.1pt;">persons.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Release Requirement.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Except as otherwise provided in an individual Participation Agreement, in order to be eligible to receive benefits under the Plan, the employee also must execute a general waiver and release, in such a form as provided by the Company (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Release</font><font style="font-size:12pt;">&#8221;), within the applicable time period set forth therein, and such Release must become effective</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">accordance</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">its</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">terms, which</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">must</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">occur in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">event</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">more</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">than</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">60</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">days</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">following the date of the applicable Covered Termination.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">4.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Plan Benefits Provided In Lieu of Any Previous Benefits.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Except as otherwise provided in an individual Participation Agreement, this Plan shall supersede any severance benefit plan, policy or practice previously maintained by the Company with</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">respect to an Eligible Employee and any severance benefits in any individually negotiated employment contract</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">agreement</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">between</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Employee,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">excluding</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">terms of any equity</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">award grant</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">notices</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and agreements</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">governing the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">outstanding equity awards that may apply upon termination of such employee&#8217;s service.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For avoidance of doubt, the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Employee&#8217;s equity awards shall remain subject to the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">terms and conditions of the applicable equity plan or equity option or award agreement under which such awards were granted and no provision of this Plan</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">shall be construed as to limit the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">actions that may be</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">taken, or to violate the terms of such equity plan or equity option or award agreement.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Further notwithstanding the foregoing or any other provision of this Plan or the applicable Participation Agreement, no vesting and extension of time</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">for exercise of options or other equity awards upon the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">retirement</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">superseded</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or otherwise</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">adversely</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">affected</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;letter-spacing:-0.2pt;">this </font>Plan<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>applicable<font style="letter-spacing:-0.3pt;"> </font>Participation<font style="letter-spacing:-0.25pt;"> </font>Agreement<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>any<font style="letter-spacing:-0.35pt;"> </font>way<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>definition<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>Cause<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Plan shall supersede the definition of Cause in any applicable equity option or award agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Exceptions to Severance Benefit Entitlement.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">An employee who otherwise is an Eligible Employee will not receive benefits under the Plan in the following circumstances, as determined by the Plan Administrator in its sole discretion:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:12pt;">The employee is terminated by the Company for any reason (including due</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">death</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Disability) or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">voluntarily</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">terminates</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">with the Company in any manner, and in either case, such termination does not constitute a Covered Termination. Voluntary terminations include, but are not limited to, resignation or retirement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:12pt;">The employee voluntarily terminates employment with the Company in order to accept employment with another entity that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:12pt;">The employee</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">is offered</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">identical or</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">substantially equivalent</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or comparable position with the Company or an Affiliate.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For purposes of this Section 2(d), a &#8220;substantially</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">equivalent</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">comparable</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">position&#8221;</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">one</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">provides</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">employee</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">substantially the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">same</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">level</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">responsibility</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">compensation</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">would</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">give</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">rise</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">right to a resignation for Good Reason.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">5.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(4)</font><font style="font-size:12pt;">The employee is offered immediate reemployment in a substantially</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">equivalent</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or comparable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">position</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">successor</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Affiliate</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or by a purchaser of the Company&#8217;s assets, as the case may be, following a Change in Control and the terms of such reemployment would not give rise to the employee&#8217;s right to a resignation for Good Reason.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">For purposes of the foregoing, &#8220;immediate reemployment&#8221; means that the employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">successor</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Affiliate</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">purchaser</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">its assets, as the case may be, results in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">uninterrupted</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">employment such that the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">employee does not incur a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">lapse</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">pay</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or benefits</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">result</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the change</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">ownership</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">sale of its</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">assets. For the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">avoidance</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of doubt, an employee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">who</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">becomes</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">immediately reemployed as described</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">2(d)(4) by</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">successor to</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Affiliate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">purchaser of the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">assets, as</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">case</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">be, following a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Change</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in Control shall continue</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to be an Eligible Employee following the date of such reemployment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:45.7pt;text-indent:0pt;white-space:nowrap;">(5)</font><font style="font-size:12pt;">The employee is rehired by the Company or an Affiliate in a substantially equivalent or comparable position and recommences employment prior to the date severance benefits under the Plan are scheduled to commence.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-size:12pt;font-weight:bold;">Termination of Severance Benefits</b><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">An Eligible Employee&#8217;s right to receive severance benefits under this Plan shall terminate immediately if, at any time prior to or during the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">which the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">receiving severance</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">under the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan, the Eligible Employee willfully breaches any material statutory, common law, or contractual obligation to the Company or an Affiliate (including, without limitation, the contractual obligations</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">set</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">forth</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Confidentiality</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Agreement</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">confidentiality,</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">non-disclosure and developments agreement, non-competition, non-solicitation, or similar type agreement between the Eligible Employee and the Company, as applicable).</font></div><div style="margin-top:12pt;"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Section</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.25pt;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">R</b><b style="font-size:9.5pt;font-weight:bold;">ETENTION</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">B</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ONUSES</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Eligible<font style="letter-spacing:-0.35pt;"> </font>Employees<font style="letter-spacing:-0.15pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>receive<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.1pt;"> </font>cash<font style="letter-spacing:-0.3pt;"> </font>retention<font style="letter-spacing:-0.05pt;"> </font>bonus<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>event<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Eligible<font style="letter-spacing:-0.35pt;"> </font>Employee remains employed by the Company through the three (3)-month anniversary of November 1, 2022 (the &#8220;<font style="font-style:italic;font-weight:bold;">Initial Period</font>&#8221;).<font style="letter-spacing:2pt;"> </font>The cash bonus will be equal to 25% of the Base Salary paid to the Eligible Employee by the Company during the Initial Period, less any standard and customary payroll deductions and withholdings. This bonus will be paid on the first payroll date following the last day of the Initial Period.<font style="letter-spacing:2pt;"> </font>In order to earn<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>bonus, the<font style="letter-spacing:-0.1pt;"> </font>Eligible<font style="letter-spacing:-0.1pt;"> </font>Employee<font style="letter-spacing:-0.1pt;"> </font>must remain<font style="letter-spacing:-0.05pt;"> </font>employed through<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>last day<font style="letter-spacing:-0.05pt;"> </font>of the Initial Period; <font style="font-style:italic;font-weight:bold;">provided, however, </font>that if the Eligible Employee is terminated by the Company without<font style="letter-spacing:-0.5pt;"> </font>Cause<font style="letter-spacing:-0.6pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>resigns<font style="letter-spacing:-0.6pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>Good<font style="letter-spacing:-0.75pt;"> </font>Reason,<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.75pt;"> </font>either<font style="letter-spacing:-0.7pt;"> </font>case<font style="letter-spacing:-0.6pt;"> </font>during<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Initial<font style="letter-spacing:-0.75pt;"> </font>Period,<font style="letter-spacing:-0.45pt;"> </font>then<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Eligible Employee will remain eligible for the bonus payment as set forth in the Eligible Employee&#8217;s Participation Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">6.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Eligible Employees will receive a second cash retention bonus in the event the Eligible Employee remains employed by the Company through the nine (9)-month period immediately following<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Initial<font style="letter-spacing:-0.3pt;"> </font>Period<font style="letter-spacing:-0.25pt;"> </font>(the<font style="letter-spacing:-0.1pt;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Extended</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.3pt;"> </font><font style="font-style:italic;font-weight:bold;">Period</font>&#8221;).<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.35pt;"> </font>cash<font style="letter-spacing:-0.05pt;"> </font>bonus<font style="letter-spacing:-0.15pt;"> </font>will<font style="letter-spacing:-0.25pt;"> </font>be equal<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>25% of the Base Salary paid to the Eligible Employee by the Company during the Extended Period, less payroll deductions and withholdings.<font style="letter-spacing:2pt;"> </font>This bonus will be paid on the first payroll date following the<font style="letter-spacing:-0.55pt;"> </font>last<font style="letter-spacing:-0.5pt;"> </font>day<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Extended<font style="letter-spacing:-0.55pt;"> </font>Period.<font style="letter-spacing:1.8pt;"> </font>In<font style="letter-spacing:-0.55pt;"> </font>order<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>earn<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>bonus,<font style="letter-spacing:-0.65pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Eligible<font style="letter-spacing:-0.55pt;"> </font>Employee<font style="letter-spacing:-0.6pt;"> </font>must<font style="letter-spacing:-0.5pt;"> </font>remain actively employed through the last day of the Extended Period; <font style="font-style:italic;font-weight:bold;">provided, however, </font>that if the Eligible Employee is terminated by the Company without Cause or resigns for Good Reason, in either case during the Extended Period, then the Eligible Employee will remain eligible for the bonus payment as set forth in the Eligible Employee&#8217;s Participation Agreement.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Section</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.25pt;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">S</b><b style="font-size:9.5pt;font-weight:bold;">EVERANCE </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">B</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ENEFITS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Benefits in Participation Agreement.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Benefits under the Plan shall be provided to an Eligible Employee as set forth in the Participation Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Additional</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:12pt;font-weight:bold;">Benefits.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Notwithstanding the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">foregoing,</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the Committee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">may, in its sole discretion, provide benefits to Company employees who are not Eligible Employees (&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Non-Eligible Employees</font><font style="font-size:12pt;">&#8221;) chosen by the Plan Administrator, in its sole discretion, and the provision</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of any</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Non-Eligible</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">way</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">obligate</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company to provide such benefits to any other employee, even if similarly situated.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If benefits under the Plan</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">are</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">provided</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Non-Eligible</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Employee,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">references</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">&#8220;Eligible</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Employee&#8221;</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">(and similar references) shall be deemed to refer to such Non-Eligible Employee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Certain Reductions.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">In addition to Section 2(e) above, the Company, in its</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">sole</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">discretion,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">have</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">authority</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">reduce</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">severance</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">benefits,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">in whole or in part, by any other severance benefits, pay and benefits provided during a period following written notice of a business closing or mass layoff, pay and benefits in lieu of such notice, or other similar</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">payable</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">by the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or an Affiliate that become payable in connection with the Eligible Employee&#8217;s termination of employment pursuant to (i) any applicable legal requirement, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other similar state law or (ii) any Company policy</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">practice</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">providing</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">remain</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">on</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">payroll</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">limited</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">period </font>of time after being given notice of the termination of the Eligible Employee&#8217;s employment, and the<font style="letter-spacing:-0.7pt;"> </font>Plan<font style="letter-spacing:-0.75pt;"> </font>Administrator<font style="letter-spacing:-0.7pt;"> </font>shall<font style="letter-spacing:-0.5pt;"> </font>so<font style="letter-spacing:-0.75pt;"> </font>construe<font style="letter-spacing:-0.65pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>implement<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>terms<font style="letter-spacing:-0.6pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Plan.<font style="letter-spacing:1.55pt;"> </font>Any<font style="letter-spacing:-0.35pt;"> </font>such<font style="letter-spacing:-0.75pt;"> </font>reductions that the Company determines to make pursuant to this Section 4(c) shall be made such that any severance<font style="letter-spacing:-0.1pt;"> </font>benefit<font style="letter-spacing:-0.05pt;"> </font>under the<font style="letter-spacing:-0.3pt;"> </font>Plan<font style="letter-spacing:-0.3pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.3pt;"> </font>reduced<font style="letter-spacing:-0.05pt;"> </font>solely<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.25pt;"> </font>similar<font style="letter-spacing:-0.2pt;"> </font>type<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>benefit<font style="letter-spacing:-0.25pt;"> </font>under<font style="letter-spacing:-0.2pt;"> </font>such legal requirement, agreement, policy or practice (<i style="font-style:italic;">i.e</i>., any cash severance benefits under the Plan shall<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.15pt;"> </font>reduced<font style="letter-spacing:-0.1pt;"> </font>solely<font style="letter-spacing:-0.1pt;"> </font>by<font style="letter-spacing:-0.35pt;"> </font>any cash<font style="letter-spacing:-0.1pt;"> </font>payments<font style="letter-spacing:-0.2pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>severance<font style="letter-spacing:-0.15pt;"> </font>benefits<font style="letter-spacing:-0.2pt;"> </font>under<font style="letter-spacing:-0.05pt;"> </font>such<font style="letter-spacing:-0.1pt;"> </font>legal<font style="letter-spacing:-0.3pt;"> </font>requirement, agreement,<font style="letter-spacing:-0.45pt;"> </font>policy<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>practice).<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.6pt;"> </font>Company&#8217;s<font style="letter-spacing:-0.6pt;"> </font>decision<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>apply<font style="letter-spacing:-0.5pt;"> </font>such<font style="letter-spacing:-0.55pt;"> </font>reductions<font style="letter-spacing:-0.6pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>severance benefits<font style="letter-spacing:-0.1pt;"> </font>of one<font style="letter-spacing:-0.1pt;"> </font>Eligible<font style="letter-spacing:-0.1pt;"> </font>Employee<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>amount<font style="letter-spacing:-0.2pt;"> </font>of such<font style="letter-spacing:-0.05pt;"> </font>reductions<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>no<font style="letter-spacing:-0.05pt;"> </font>way<font style="letter-spacing:-0.05pt;"> </font>obligate<font style="letter-spacing:-0.1pt;"> </font>the Company<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>apply<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>same<font style="letter-spacing:-0.3pt;"> </font>reductions<font style="letter-spacing:-0.4pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>same<font style="letter-spacing:-0.1pt;"> </font>amounts<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>severance<font style="letter-spacing:-0.35pt;"> </font>benefits<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>other Eligible Employee.<font style="letter-spacing:2pt;"> </font>In the Company&#8217;s sole discretion, such reductions may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments pursuant to the Company&#8217;s statutory obligation.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">7.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Parachute Payments.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Except as otherwise provided in an individual Participation</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Agreement,</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">benefit</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">receive</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">from the Company or otherwise (a &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-size:12pt;">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-size:12pt;">&#8221;), then any such Payment shall be equal to the Reduced Amount.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Reduced Amount</font><font style="font-size:12pt;">&#8221; shall be either (x) the largest portion of the Payment</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">would</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">result</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">no</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">portion</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Payment</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">(after</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">reduction)</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">being</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">subject</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Excise Tax or (y)</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the largest portion, up to and including the total, of the Payment, whichever amount (i.e.,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">amount</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">determined</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">clause</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">(x)</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">clause</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">(y)),</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">after</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">taking</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">into</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">account</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">applicable federal, state and local employment taxes, income</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">taxes, and the Excise Tax (all computed at the highest</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">applicable</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">marginal</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">rate),</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">results</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Employee&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">receipt, on</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">after-tax</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If a reduction in a Payment is required pursuant to the preceding sentence</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Reduced</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Amount</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">determined</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">pursuant</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">clause</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">(x)</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">preceding</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">sentence, the reduction shall occur in the manner (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-size:12pt;">&#8221;) that results in the greatest economic benefit for the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Employee.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If more than one method of reduction will result in the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">same</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">economic</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">benefit,</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">items</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">so</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">reduced</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">reduced</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">pro</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">rata</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">(the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Pro</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Rata</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Reduction </font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Method</font><font style="font-size:12pt;letter-spacing:-0.1pt;">&#8221;).</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding any provisions in this Section above to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.1pt;"> </font>taxes<font style="letter-spacing:-0.2pt;"> </font>pursuant<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>Section<font style="letter-spacing:-0.3pt;"> </font>409A<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.1pt;"> </font>would<font style="letter-spacing:-0.1pt;"> </font>not<font style="letter-spacing:-0.3pt;"> </font>otherwise<font style="letter-spacing:-0.15pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>subject<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>taxes<font style="letter-spacing:-0.2pt;"> </font>pursuant<font style="letter-spacing:-0.1pt;"> </font>to Section<font style="letter-spacing:-0.35pt;"> </font>409A,<font style="letter-spacing:-0.5pt;"> </font>then<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Reduction<font style="letter-spacing:-0.35pt;"> </font>Method<font style="letter-spacing:-0.3pt;"> </font>and/or<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.4pt;"> </font>Pro<font style="letter-spacing:-0.6pt;"> </font>Rata<font style="letter-spacing:-0.4pt;"> </font>Reduction<font style="letter-spacing:-0.4pt;"> </font>Method,<font style="letter-spacing:-0.45pt;"> </font>as<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>case<font style="letter-spacing:-0.4pt;"> </font>may be,<font style="letter-spacing:0.35pt;"> </font>shall<font style="letter-spacing:0.25pt;"> </font>be<font style="letter-spacing:0.2pt;"> </font>modified<font style="letter-spacing:0.2pt;"> </font>so<font style="letter-spacing:0.2pt;"> </font>as<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.25pt;"> </font>avoid<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.2pt;"> </font>imposition<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>taxes<font style="letter-spacing:0.1pt;"> </font>pursuant<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>Section<font style="letter-spacing:0.2pt;"> </font>409A<font style="letter-spacing:0.2pt;"> </font>as<font style="letter-spacing:0.1pt;"> </font><font style="letter-spacing:-0.1pt;">follows: </font>(A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for the Eligible Employee as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (<i style="font-style:italic;">e.g.</i>, being terminated without Cause), shall<font style="letter-spacing:1.25pt;"> </font>be<font style="letter-spacing:1.2pt;"> </font>reduced<font style="letter-spacing:1.3pt;"> </font>(or<font style="letter-spacing:1.3pt;"> </font>eliminated)<font style="letter-spacing:1.05pt;"> </font>before<font style="letter-spacing:1pt;"> </font>Payments<font style="letter-spacing:1.15pt;"> </font>that<font style="letter-spacing:1.25pt;"> </font>are<font style="letter-spacing:1.25pt;"> </font>not<font style="letter-spacing:1.25pt;"> </font>contingent<font style="letter-spacing:1.05pt;"> </font>on<font style="letter-spacing:1.25pt;"> </font>future<font style="letter-spacing:1.2pt;"> </font>events;<font style="letter-spacing:1.3pt;"> </font><font style="letter-spacing:-0.25pt;">and </font>(C) as a third priority, Payments that are &#8220;deferred<font style="letter-spacing:-0.05pt;"> </font>compensation&#8221; within the meaning of Section 409A<font style="letter-spacing:-0.15pt;"> </font>shall<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.35pt;"> </font>reduced<font style="letter-spacing:-0.3pt;"> </font>(or<font style="letter-spacing:-0.2pt;"> </font>eliminated)<font style="letter-spacing:-0.25pt;"> </font>before<font style="letter-spacing:-0.35pt;"> </font>Payments<font style="letter-spacing:-0.15pt;"> </font>that<font style="letter-spacing:-0.1pt;"> </font>are<font style="letter-spacing:-0.35pt;"> </font>not<font style="letter-spacing:-0.3pt;"> </font>deferred<font style="letter-spacing:-0.3pt;"> </font>compensation<font style="letter-spacing:-0.1pt;"> </font>within the meaning of Section 409A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company shall appoint a nationally recognized accounting or law firm to make the determinations<font style="letter-spacing:-0.15pt;"> </font>required<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.3pt;"> </font>this<font style="letter-spacing:-0.15pt;"> </font>Section.<font style="letter-spacing:2.75pt;"> </font>The<font style="letter-spacing:-0.1pt;"> </font>Company<font style="letter-spacing:-0.05pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>bear all<font style="letter-spacing:-0.05pt;"> </font>expenses<font style="letter-spacing:-0.15pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>respect<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.25pt;">the </font>determinations by such accounting or law firm required to be made hereunder.<font style="letter-spacing:2pt;"> </font>If the Eligible Employee<font style="letter-spacing:-0.15pt;"> </font>receives<font style="letter-spacing:-0.1pt;"> </font>a<font style="letter-spacing:-0.05pt;"> </font>Payment for<font style="letter-spacing:0.1pt;"> </font>which the Reduced Amount<font style="letter-spacing:0.05pt;"> </font>was<font style="letter-spacing:-0.1pt;"> </font>determined<font style="letter-spacing:0.05pt;"> </font>pursuant to<font style="letter-spacing:0.05pt;"> </font><font style="letter-spacing:-0.1pt;">clause </font>(x)<font style="letter-spacing:-0.55pt;"> </font>above<font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Internal<font style="letter-spacing:-0.75pt;"> </font>Revenue<font style="letter-spacing:-0.6pt;"> </font>Service<font style="letter-spacing:-0.6pt;"> </font>determines<font style="letter-spacing:-0.65pt;"> </font>thereafter<font style="letter-spacing:-0.5pt;"> </font>that<font style="letter-spacing:-0.75pt;"> </font>some<font style="letter-spacing:-0.55pt;"> </font>portion<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Payment is subject to the Excise Tax, Eligible Employee agrees to promptly return to the Company a sufficient<font style="letter-spacing:-0.05pt;"> </font>amount<font style="letter-spacing:-0.05pt;"> </font>of the<font style="letter-spacing:-0.05pt;"> </font>Payment<font style="letter-spacing:-0.25pt;"> </font>(after<font style="letter-spacing:-0.2pt;"> </font>reduction<font style="letter-spacing:-0.25pt;"> </font>pursuant to clause<font style="letter-spacing:-0.05pt;"> </font>(x) above) so that no portion of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>remaining<font style="letter-spacing:-0.45pt;"> </font>Payment<font style="letter-spacing:-0.5pt;"> </font>is<font style="letter-spacing:-0.35pt;"> </font>subject<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Excise<font style="letter-spacing:-0.3pt;"> </font>Tax.<font style="letter-spacing:2pt;"> </font>For<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>avoidance<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.45pt;"> </font>doubt,<font style="letter-spacing:-0.4pt;"> </font>if<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Reduced Amount was determined pursuant to clause (y) above, the Eligible Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">8.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-size:12pt;font-weight:bold;">R</b><b style="font-size:9.5pt;font-weight:bold;">ETURN</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">OF</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-size:12pt;font-weight:bold;">C</b><b style="font-size:9.5pt;font-weight:bold;">OMPANY</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">P</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ROPERTY</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An Eligible Employee will not be entitled to any severance benefit under the Plan unless and until the Eligible Employee returns all material Company Property.<font style="letter-spacing:2pt;"> </font>For this purpose, &#8220;<font style="font-style:italic;font-weight:bold;">Company</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </font><font style="font-style:italic;font-weight:bold;">Property</font>&#8221;<font style="letter-spacing:-0.45pt;"> </font>means<font style="letter-spacing:-0.5pt;"> </font>all<font style="letter-spacing:-0.35pt;"> </font>paper<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.4pt;"> </font>electronic<font style="letter-spacing:-0.45pt;"> </font>Company<font style="letter-spacing:-0.4pt;"> </font>documents<font style="letter-spacing:-0.5pt;"> </font>(and<font style="letter-spacing:-0.4pt;"> </font>all<font style="letter-spacing:-0.4pt;"> </font>copies<font style="letter-spacing:-0.55pt;"> </font>thereof) and other Company<font style="letter-spacing:-0.05pt;"> </font>property which the<font style="letter-spacing:-0.05pt;"> </font>Eligible<font style="letter-spacing:-0.05pt;"> </font>Employee<font style="letter-spacing:-0.05pt;"> </font>had in his<font style="letter-spacing:-0.1pt;"> </font>or her possession or control at<font style="letter-spacing:-0.75pt;"> </font>any<font style="letter-spacing:-0.65pt;"> </font>time,<font style="letter-spacing:-0.7pt;"> </font>including,<font style="letter-spacing:-0.65pt;"> </font>but<font style="letter-spacing:-0.75pt;"> </font>not<font style="letter-spacing:-0.75pt;"> </font>limited<font style="letter-spacing:-0.75pt;"> </font>to,<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.75pt;"> </font>files,<font style="letter-spacing:-0.5pt;"> </font>notes,<font style="letter-spacing:-0.65pt;"> </font>drawings,<font style="letter-spacing:-0.65pt;"> </font>records,<font style="letter-spacing:-0.65pt;"> </font>plans,<font style="letter-spacing:-0.65pt;"> </font>forecasts, reports,<font style="letter-spacing:-0.55pt;"> </font>studies,<font style="letter-spacing:-0.35pt;"> </font>analyses,<font style="letter-spacing:-0.35pt;"> </font>proposals,<font style="letter-spacing:-0.55pt;"> </font>agreements,<font style="letter-spacing:-0.6pt;"> </font>financial<font style="letter-spacing:-0.45pt;"> </font>information,<font style="letter-spacing:-0.55pt;"> </font>research<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.7pt;"> </font>development information, sales and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment<font style="letter-spacing:-0.1pt;"> </font>(including,<font style="letter-spacing:-0.25pt;"> </font>but<font style="letter-spacing:-0.35pt;"> </font>not<font style="letter-spacing:-0.35pt;"> </font>limited<font style="letter-spacing:-0.35pt;"> </font>to,<font style="letter-spacing:-0.25pt;"> </font>computers, mobile<font style="letter-spacing:-0.35pt;"> </font>telephones),<font style="letter-spacing:-0.25pt;"> </font>credit<font style="letter-spacing:-0.3pt;"> </font>cards,<font style="letter-spacing:-0.25pt;"> </font>entry<font style="letter-spacing:-0.35pt;"> </font>cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.25pt;"> </font>confidential<font style="letter-spacing:-0.3pt;"> </font>information<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Company<font style="letter-spacing:-0.15pt;"> </font>(and<font style="letter-spacing:-0.3pt;"> </font>all<font style="letter-spacing:-0.3pt;"> </font>reproductions<font style="letter-spacing:-0.2pt;"> </font>thereof<font style="letter-spacing:-0.25pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>whole<font style="letter-spacing:-0.15pt;"> </font>or in<font style="letter-spacing:-0.2pt;"> </font>part).<font style="letter-spacing:2pt;"> </font>As<font style="letter-spacing:-0.35pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>condition<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.4pt;"> </font>receiving<font style="letter-spacing:-0.25pt;"> </font>benefits<font style="letter-spacing:-0.3pt;"> </font>under<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Plan,<font style="letter-spacing:-0.15pt;"> </font>an<font style="letter-spacing:-0.45pt;"> </font>Eligible<font style="letter-spacing:-0.5pt;"> </font>Employee<font style="letter-spacing:-0.25pt;"> </font>must<font style="letter-spacing:-0.2pt;"> </font>not<font style="letter-spacing:-0.2pt;"> </font>make or retain copies, reproductions or summaries of any such Company documents, materials or property.<font style="letter-spacing:2pt;"> </font>However, an Eligible Employee is not required to return his or her personal copies of documents<font style="letter-spacing:-0.75pt;"> </font>evidencing<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Eligible<font style="letter-spacing:-0.75pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.75pt;"> </font>hire,<font style="letter-spacing:-0.75pt;"> </font>termination,<font style="letter-spacing:-0.75pt;"> </font>compensation,<font style="letter-spacing:-0.75pt;"> </font>benefits<font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>stock options and any other documentation received as a stockholder of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-size:12pt;font-weight:bold;">T</b><b style="font-size:9.5pt;font-weight:bold;">IME</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">OF</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-size:12pt;font-weight:bold;">P</b><b style="font-size:9.5pt;font-weight:bold;">AYMENT</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;">F</b><b style="font-size:9.5pt;font-weight:bold;">ORM</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">OF</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">B</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ENEFITS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reserves the right in the Participation Agreement to specify whether payments under the<font style="letter-spacing:-0.05pt;"> </font>Plan<font style="letter-spacing:-0.05pt;"> </font>will be<font style="letter-spacing:-0.05pt;"> </font>paid in a<font style="letter-spacing:-0.05pt;"> </font>single sum, in installments, or in any other form and to determine the timing of such payments.<font style="letter-spacing:2pt;"> </font>All such payments under the Plan will be subject to applicable<font style="letter-spacing:-0.35pt;"> </font>withholding<font style="letter-spacing:-0.5pt;"> </font>for<font style="letter-spacing:-0.7pt;"> </font>federal,<font style="letter-spacing:-0.45pt;"> </font>state,<font style="letter-spacing:-0.45pt;"> </font>foreign,<font style="letter-spacing:-0.25pt;"> </font>provincial<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>local<font style="letter-spacing:-0.5pt;"> </font>taxes.<font style="letter-spacing:2pt;"> </font>All<font style="letter-spacing:-0.5pt;"> </font>benefits<font style="letter-spacing:-0.65pt;"> </font>provided under the Plan are intended to satisfy the requirements for an exemption from application of Section 409A to the maximum extent that an exemption is available and any ambiguities herein shall be interpreted accordingly; <i style="font-style:italic;">provided, however</i>, that to the extent such an exemption is not available, the benefits provided under the Plan are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">It<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.15pt;"> </font>intended<font style="letter-spacing:-0.3pt;"> </font>that<font style="letter-spacing:-0.3pt;"> </font>(i)<font style="letter-spacing:-0.2pt;"> </font>each<font style="letter-spacing:-0.05pt;"> </font>installment<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>benefits<font style="letter-spacing:-0.15pt;"> </font>payable<font style="letter-spacing:-0.1pt;"> </font>under<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Plan<font style="letter-spacing:-0.1pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>an<font style="letter-spacing:-0.55pt;"> </font>Eligible Employee be regarded as a separate &#8220;payment&#8221; for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), (ii) all payments of any such benefits under the Plan satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9)(iii), and (iii) any such <font style="letter-spacing:-0.1pt;">benefits</font><font style="letter-spacing:-0.45pt;"> </font><font style="letter-spacing:-0.1pt;">consisting</font><font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">of</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">COBRA</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">premiums</font><font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">also</font><font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">satisfy,</font><font style="letter-spacing:-0.2pt;"> </font><font style="letter-spacing:-0.1pt;">to</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.6pt;"> </font><font style="letter-spacing:-0.1pt;">greatest</font><font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">extent</font><font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;">possible,</font><font style="letter-spacing:-0.15pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">exemption </font>from the application of Section 409A provided under Treasury Regulations Section 1.409A- 1(b)(9)(v).<font style="letter-spacing:2pt;"> </font>However, if the Company determines that any severance benefits payable under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A and the Eligible Employee is a &#8220;specified employee&#8221; of the<font style="letter-spacing:-0.15pt;"> </font>Company, as such term is defined<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.1pt;"> </font>Section 409A(a)(2)(B)(i), then, solely to the extent necessary to avoid the imposition of the adverse personal tax consequences under Section<font style="letter-spacing:-0.05pt;"> </font>409A,<font style="letter-spacing:-0.2pt;"> </font>(A) the<font style="letter-spacing:-0.35pt;"> </font>timing<font style="letter-spacing:-0.05pt;"> </font>of such<font style="letter-spacing:-0.05pt;"> </font>severance<font style="letter-spacing:-0.1pt;"> </font>benefit<font style="letter-spacing:-0.05pt;"> </font>payments shall<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>delayed<font style="letter-spacing:-0.05pt;"> </font>until<font style="letter-spacing:-0.05pt;"> </font>the earlier<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>(1)<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>date<font style="letter-spacing:-0.45pt;"> </font>that<font style="letter-spacing:-0.45pt;"> </font>is<font style="letter-spacing:-0.5pt;"> </font>six<font style="letter-spacing:-0.4pt;"> </font>months<font style="letter-spacing:-0.55pt;"> </font>and<font style="letter-spacing:-0.45pt;"> </font>one<font style="letter-spacing:-0.5pt;"> </font>day<font style="letter-spacing:-0.25pt;"> </font>after<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.45pt;"> </font>Eligible<font style="letter-spacing:-0.7pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.55pt;"> </font>Separation<font style="letter-spacing:-0.45pt;"> </font>from Service and (2) the date of the Eligible Employee&#8217;s death (such applicable date, the &#8220;<font style="font-style:italic;font-weight:bold;">Delayed Initial Payment Date</font>&#8221;), and (B) the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee would otherwise have received through the Delayed </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">9.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Initial Payment Date if the commencement of the payment of the severance benefits had not been delayed pursuant to this paragraph and (2) commence<font style="letter-spacing:-0.1pt;"> </font>paying<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>balance, if any, of the<font style="letter-spacing:-0.1pt;"> </font>severance<font style="letter-spacing:-0.1pt;"> </font>benefits<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>accordance<font style="letter-spacing:-0.1pt;"> </font>with<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>applicable payment schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">In no event shall payment of any severance benefits under the Plan be made prior to an<font style="letter-spacing:-0.25pt;"> </font>Eligible<font style="letter-spacing:-0.25pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.35pt;"> </font>Separation<font style="letter-spacing:-0.25pt;"> </font>from<font style="letter-spacing:-0.25pt;"> </font>Service<font style="letter-spacing:-0.35pt;"> </font>or<font style="letter-spacing:-0.15pt;"> </font>prior<font style="letter-spacing:-0.15pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>effective<font style="letter-spacing:-0.3pt;"> </font>date<font style="letter-spacing:-0.3pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>Release.<font style="letter-spacing:2pt;"> </font>If the Company determines that any severance payments or benefits provided under the Plan constitute &#8220;deferred compensation&#8221; under Section<font style="letter-spacing:-0.3pt;"> </font>409A, and the<font style="letter-spacing:-0.1pt;"> </font>Eligible<font style="letter-spacing:-0.1pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.2pt;"> </font>Separation from Service occurs at a time during the calendar year when the Release could become effective in<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>calendar<font style="letter-spacing:-0.45pt;"> </font>year<font style="letter-spacing:-0.45pt;"> </font>following<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>calendar<font style="letter-spacing:-0.45pt;"> </font>year<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>which<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Eligible<font style="letter-spacing:-0.6pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.65pt;"> </font>Separation<font style="letter-spacing:-0.55pt;"> </font>from Service occurs, then regardless of when the Release is returned to the Company and becomes effective, the Release will not be deemed effective, solely for purposes of the timing of payment of severance benefits under this Plan, any earlier than the latest permitted effective date (the &#8220;<font style="font-style:italic;font-weight:bold;">Release Deadline</font>&#8221;).<font style="letter-spacing:2pt;"> </font>If the Company determines that any severance payments or benefits provided under the Plan constitute &#8220;deferred compensation&#8221; under Section 409A, then except to the<font style="letter-spacing:-0.75pt;"> </font>extent<font style="letter-spacing:-0.75pt;"> </font>that<font style="letter-spacing:-0.75pt;"> </font>severance<font style="letter-spacing:-0.75pt;"> </font>payments<font style="letter-spacing:-0.75pt;"> </font>may<font style="letter-spacing:-0.75pt;"> </font>be<font style="letter-spacing:-0.75pt;"> </font>delayed<font style="letter-spacing:-0.75pt;"> </font>until<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Delayed<font style="letter-spacing:-0.75pt;"> </font>Initial<font style="letter-spacing:-0.75pt;"> </font>Payment<font style="letter-spacing:-0.75pt;"> </font>Date<font style="letter-spacing:-0.75pt;"> </font>pursuant to the preceding paragraph, on the first regular payroll date following the effective date of an Eligible Employee&#8217;s Release, the Company shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee would otherwise have received through such payroll date but for the delay in payment related to the effectiveness<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Release<font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>(2)<font style="letter-spacing:-0.75pt;"> </font>commence<font style="letter-spacing:-0.75pt;"> </font>paying<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>balance,<font style="letter-spacing:-0.75pt;"> </font>if<font style="letter-spacing:-0.75pt;"> </font>any,<font style="letter-spacing:-0.75pt;"> </font>of<font style="letter-spacing:-0.7pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>severance<font style="letter-spacing:-0.75pt;"> </font>benefits in accordance with the applicable payment schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-size:12pt;font-weight:bold;">T</b><b style="font-size:9.5pt;font-weight:bold;">RANSFER</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">A</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">SSIGNMENT</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The<font style="letter-spacing:-0.05pt;"> </font>rights<font style="letter-spacing:-0.1pt;"> </font>and<font style="letter-spacing:-0.25pt;"> </font>obligations<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>an Eligible<font style="letter-spacing:-0.3pt;"> </font>Employee<font style="letter-spacing:-0.3pt;"> </font>under this<font style="letter-spacing:-0.35pt;"> </font>Plan<font style="letter-spacing:-0.05pt;"> </font>may<font style="letter-spacing:-0.05pt;"> </font>not<font style="letter-spacing:-0.25pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>transferred or assigned without the prior written consent of the Company.<font style="letter-spacing:2pt;"> </font>This Plan shall be binding upon any entity or person who is a successor by merger, acquisition, consolidation or otherwise to the business<font style="letter-spacing:-0.75pt;"> </font>carried<font style="letter-spacing:-0.6pt;"> </font>on<font style="letter-spacing:-0.75pt;"> </font>by<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>Company<font style="letter-spacing:-0.75pt;"> </font>without<font style="letter-spacing:-0.75pt;"> </font>regard<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.75pt;"> </font>whether<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.75pt;"> </font>not<font style="letter-spacing:-0.75pt;"> </font>such<font style="letter-spacing:-0.6pt;"> </font>entity<font style="letter-spacing:-0.55pt;"> </font>or<font style="letter-spacing:-0.75pt;"> </font>person<font style="letter-spacing:-0.6pt;"> </font>actively assumes<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>obligations<font style="letter-spacing:-0.75pt;"> </font>hereunder<font style="letter-spacing:-0.75pt;"> </font>as<font style="letter-spacing:-0.65pt;"> </font>required<font style="letter-spacing:-0.75pt;"> </font>under<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Equity<font style="letter-spacing:-0.75pt;"> </font>Plan<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.75pt;"> </font>without<font style="letter-spacing:-0.75pt;"> </font>regard<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>whether or not a Change in Control occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">M</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ITIGATION</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise specifically provided in the Plan, an Eligible Employee will not be required<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.55pt;"> </font>mitigate<font style="letter-spacing:0.5pt;"> </font>damages<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>amount<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.55pt;"> </font>any<font style="letter-spacing:0.5pt;"> </font>payment<font style="letter-spacing:0.5pt;"> </font>provided<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>Plan<font style="letter-spacing:0.5pt;"> </font>by<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">seeking </font>other employment or otherwise, nor will the amount of any payment provided<font style="letter-spacing:-0.1pt;"> </font>for under the Plan be reduced by any compensation earned by an Eligible Employee as a result of employment by another employer<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.1pt;"> </font>retirement benefits received by<font style="letter-spacing:-0.1pt;"> </font>such Eligible<font style="letter-spacing:-0.15pt;"> </font>Employee after<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>date of the Eligible Employee&#8217;s termination of employment with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">10.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">9.</b></font><b style="font-size:12pt;font-weight:bold;">C</b><b style="font-size:9.5pt;font-weight:bold;">LAWBACK</b><b style="font-size:12pt;font-weight:bold;">;</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.65pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">R</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ECOVERY</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All<font style="letter-spacing:-0.75pt;"> </font>payments<font style="letter-spacing:-0.75pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>severance<font style="letter-spacing:-0.65pt;"> </font>benefits<font style="letter-spacing:-0.75pt;"> </font>provided<font style="letter-spacing:-0.75pt;"> </font>under<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>Plan<font style="letter-spacing:-0.75pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>be<font style="letter-spacing:-0.75pt;"> </font>subject<font style="letter-spacing:-0.55pt;"> </font>to<font style="letter-spacing:-0.75pt;"> </font>recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for Good Reason, constructive termination, or any similar term under any plan of or agreement with the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">10.</b></font><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">R</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">IGHT</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">TO </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">I</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">NTERPRET</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">A</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">DMINISTER</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">P</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">LAN</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">;</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.9pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">A</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">MENDMENT</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.15pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">T</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ERMINATION</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Interpretation and Administration.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The Committee shall be the Plan Administrator and shall have the exclusive discretion and authority to establish rules, forms, and procedures for the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">administration of the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan and to construe and interpret the Plan</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">operation</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Plan,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">including,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">but</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">not</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">limited</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">eligibility</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">participate in the Plan and amount of benefits paid under the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The rules, interpretations, computations and other actions of the Committee shall be binding and conclusive on all persons.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Amendment.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Administrator</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">reserves</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">right</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">amend</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Plan at any time; </font><i style="font-size:12pt;font-style:italic;">provided, however, </i><font style="font-size:12pt;">that any amendment of the Plan will not be effective as to a particular</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">employee</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">who</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">adversely</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">impacted</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">amendment</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">has</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">effective Participation Agreement without the written consent of such employee.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Termination.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Unless</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">otherwise extended by</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">Committee, the</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Plan will automatically terminate following satisfaction of all the Company&#8217;s obligations under the Plan.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">11.</b></font><b style="font-size:12pt;font-weight:bold;">N</b><b style="font-size:9.5pt;font-weight:bold;">O</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:12pt;font-weight:bold;">I</b><b style="font-size:9.5pt;font-weight:bold;">MPLIED</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-size:12pt;font-weight:bold;">E</b><b style="font-size:9.5pt;font-weight:bold;">MPLOYMENT</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">C</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ONTRACT</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The<font style="letter-spacing:-0.1pt;"> </font>Plan<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.05pt;"> </font>not<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>deemed<font style="letter-spacing:-0.3pt;"> </font>(i)<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>give<font style="letter-spacing:-0.35pt;"> </font>any<font style="letter-spacing:-0.05pt;"> </font>employee<font style="letter-spacing:-0.1pt;"> </font>or other<font style="letter-spacing:-0.25pt;"> </font>person<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>right<font style="letter-spacing:-0.05pt;"> </font>to be retained in the employ of the Company or (ii) to interfere with the right of the Company to discharge any employee or other person at<font style="letter-spacing:-0.1pt;"> </font>any time, with<font style="letter-spacing:-0.1pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>without<font style="letter-spacing:-0.05pt;"> </font>cause, which<font style="letter-spacing:-0.1pt;"> </font>right is<font style="letter-spacing:-0.2pt;"> </font>hereby reserved.<font style="letter-spacing:2pt;"> </font>This Plan does not modify the at-will employment status of any Eligible Employee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">12.</b></font><b style="font-size:12pt;font-weight:bold;">L</b><b style="font-size:9.5pt;font-weight:bold;">EGAL</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">C</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ONSTRUCTION</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This Plan<font style="letter-spacing:-0.1pt;"> </font>is<font style="letter-spacing:-0.15pt;"> </font>intended to<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>governed<font style="letter-spacing:-0.05pt;"> </font>by<font style="letter-spacing:-0.05pt;"> </font>and shall<font style="letter-spacing:-0.25pt;"> </font>be construed in<font style="letter-spacing:-0.1pt;"> </font>accordance with the Employee Retirement Income Security Act of 1974 (&#8220;<font style="font-style:italic;font-weight:bold;">ERISA</font>&#8221;) and, to the extent not preempted by ERISA, the laws of the State of California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">13.</b></font><b style="font-size:12pt;font-weight:bold;">C</b><b style="font-size:9.5pt;font-weight:bold;">LAIMS</b><b style="font-size:12pt;font-weight:bold;">,</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.75pt;"> </b><b style="font-size:12pt;font-weight:bold;">I</b><b style="font-size:9.5pt;font-weight:bold;">NQUIRIES</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">A</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">PPEALS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Applications for Benefits and Inquiries.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Any application for benefits, inquiries</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">about</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">inquiries</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">about</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">present</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">future</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">rights</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">must</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">submitted to</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Administrator</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">writing</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">applicant</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">(or</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">his</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">her</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">authorized</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">representative).</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Plan Administrator is:</font></div><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">11.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">XOMA<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.1pt;">Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Compensation<font style="letter-spacing:-0.35pt;"> </font>Committee<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Attention to: Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2200<font style="letter-spacing:-0.25pt;"> </font>Powell<font style="letter-spacing:-0.1pt;"> </font>Street,<font style="letter-spacing:-0.2pt;"> </font>Suite<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.25pt;">310</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville,<font style="letter-spacing:-0.15pt;"> </font>CA <font style="letter-spacing:-0.1pt;">94608</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Denial of Claims.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">In the event that any application for benefits is denied in whole or in part, the Plan Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant&#8217;s right to review the denial.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Any electronic</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">notice</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">comply</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">regulations</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">U.S.</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Department</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Labor.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">notice</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of denial</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">set</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">forth</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">manner</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">designed</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">be</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">understood</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">applicant</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">include</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">the </font><font style="font-size:12pt;letter-spacing:-0.1pt;">following:</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">specific</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">reason</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">reasons</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">denial;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:12pt;">references</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">specific</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">provisions</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">upon</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">denial</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;letter-spacing:-0.25pt;">is </font><font style="letter-spacing:-0.1pt;">based;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">description</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">additional</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">information</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">material</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;letter-spacing:-0.2pt;">Plan </font>Administrator<font style="letter-spacing:1.85pt;"> </font>needs<font style="letter-spacing:1.7pt;"> </font>to<font style="letter-spacing:1.85pt;"> </font>complete<font style="letter-spacing:1.8pt;"> </font>the<font style="letter-spacing:1.55pt;"> </font>review<font style="letter-spacing:1.75pt;"> </font>and<font style="letter-spacing:1.55pt;"> </font>an<font style="letter-spacing:1.8pt;"> </font>explanation<font style="letter-spacing:1.8pt;"> </font>of<font style="letter-spacing:1.65pt;"> </font>why<font style="letter-spacing:1.8pt;"> </font>such<font style="letter-spacing:1.8pt;"> </font>information<font style="letter-spacing:1.85pt;"> </font>or material is necessary; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(4)</font><font style="font-size:12pt;">an explanation of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the Plan&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">review</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">procedures</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">and the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">limits applicable</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">such</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">procedures,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">including</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">statement</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">applicant&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">right</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">bring</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">civil</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">action under</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">502(a)</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">ERISA</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">following</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">denial</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">on</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">review</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">claim,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">described</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Section 13(d) below.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This notice of denial will be given to the applicant within 90 days after the Plan Administrator<font style="letter-spacing:-0.05pt;"> </font>receives<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.2pt;"> </font>application,<font style="letter-spacing:-0.05pt;"> </font>unless<font style="letter-spacing:-0.2pt;"> </font>special<font style="letter-spacing:-0.1pt;"> </font>circumstances<font style="letter-spacing:-0.2pt;"> </font>require<font style="letter-spacing:-0.15pt;"> </font>an<font style="letter-spacing:-0.1pt;"> </font>extension<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.05pt;"> </font>time, in which case, the Plan Administrator has up to an additional 90 days for processing the application.<font style="letter-spacing:2pt;"> </font>If<font style="letter-spacing:-0.25pt;"> </font>an<font style="letter-spacing:-0.35pt;"> </font>extension<font style="letter-spacing:-0.1pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>time<font style="letter-spacing:-0.35pt;"> </font>for<font style="letter-spacing:-0.25pt;"> </font>processing<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.2pt;"> </font>required,<font style="letter-spacing:-0.25pt;"> </font>written<font style="letter-spacing:-0.35pt;"> </font>notice<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>extension<font style="letter-spacing:-0.1pt;"> </font>will be furnished to the applicant before the end of the initial 90 day period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">This notice of extension will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render its decision on the <font style="letter-spacing:-0.1pt;">application.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Request for a Review.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">Any person (or that person&#8217;s authorized representative)</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">whom</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">application</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">denied,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">whole</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">part,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">appeal</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the denial by submitting a request for a review to the Plan Administrator within 60 days after the application is denied.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">A request for a review shall be in writing and shall be addressed to:</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">XOMA<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.1pt;">Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Compensation<font style="letter-spacing:-0.35pt;"> </font>Committee<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Attention to: Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2200<font style="letter-spacing:-0.25pt;"> </font>Powell<font style="letter-spacing:-0.1pt;"> </font>Street,<font style="letter-spacing:-0.2pt;"> </font>Suite<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.25pt;">310</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville,<font style="letter-spacing:-0.15pt;"> </font>CA <font style="letter-spacing:-0.1pt;">94608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">12.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A request for review must set forth all of the grounds on which it is based, all facts in support of the<font style="letter-spacing:-0.3pt;"> </font>request<font style="letter-spacing:-0.25pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>any<font style="letter-spacing:-0.3pt;"> </font>other<font style="letter-spacing:-0.2pt;"> </font>matters<font style="letter-spacing:-0.4pt;"> </font>that<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>applicant<font style="letter-spacing:-0.75pt;"> </font>feels<font style="letter-spacing:-0.4pt;"> </font>are<font style="letter-spacing:-0.35pt;"> </font>pertinent.<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.6pt;"> </font>applicant<font style="letter-spacing:-0.25pt;"> </font>(or<font style="letter-spacing:-0.45pt;"> </font>his<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.45pt;"> </font>her representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant to submit) written comments, documents, records, and other information relating<font style="letter-spacing:-0.05pt;"> </font>to his or her claim.<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.1pt;"> </font>applicant<font style="letter-spacing:-0.25pt;"> </font>(or his<font style="letter-spacing:-0.15pt;"> </font>or her<font style="letter-spacing:-0.2pt;"> </font>representative) shall<font style="letter-spacing:-0.05pt;"> </font>be<font style="letter-spacing:-0.1pt;"> </font>provided, upon<font style="letter-spacing:-0.25pt;"> </font>request<font style="letter-spacing:-0.05pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>free of charge, reasonable access to, and copies of, all documents, records and other information relevant<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>his<font style="letter-spacing:-0.15pt;"> </font>or<font style="letter-spacing:-0.2pt;"> </font>her<font style="letter-spacing:-0.2pt;"> </font>claim.<font style="letter-spacing:2pt;"> </font>The<font style="letter-spacing:-0.35pt;"> </font>review<font style="letter-spacing:-0.1pt;"> </font>shall<font style="letter-spacing:-0.25pt;"> </font>take<font style="letter-spacing:-0.35pt;"> </font>into<font style="letter-spacing:-0.05pt;"> </font>account<font style="letter-spacing:-0.3pt;"> </font>all<font style="letter-spacing:-0.25pt;"> </font>comments, documents,<font style="letter-spacing:-0.4pt;"> </font>records and<font style="letter-spacing:-0.65pt;"> </font>other<font style="letter-spacing:-0.7pt;"> </font>information<font style="letter-spacing:-0.75pt;"> </font>submitted<font style="letter-spacing:-0.55pt;"> </font>by<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>applicant<font style="letter-spacing:-0.75pt;"> </font>(or<font style="letter-spacing:-0.45pt;"> </font>his<font style="letter-spacing:-0.75pt;"> </font>or<font style="letter-spacing:-0.7pt;"> </font>her<font style="letter-spacing:-0.7pt;"> </font>representative)<font style="letter-spacing:-0.5pt;"> </font>relating<font style="letter-spacing:-0.75pt;"> </font>to<font style="letter-spacing:-0.75pt;"> </font>the<font style="letter-spacing:-0.75pt;"> </font>claim, without regard to whether such information was submitted or considered in the initial benefit <font style="letter-spacing:-0.1pt;">determination.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Decision on Review.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The Plan Administrator will act on each request for review within 60 days after receipt of the request, unless special circumstances require an extension</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">(not</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">exceed</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">additional</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">60</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">days),</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">processing</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">request</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">review.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If an extension for review is required, written notice of the extension will be furnished to the applicant within the initial 60 day period.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">This notice of extension will describe the special circumstances</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">necessitating</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">additional</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">date</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Administrator</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to render its decision on</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">review.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Plan Administrator will</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">give prompt, written or electronic notice of its decision to the applicant. Any electronic notice will comply with the regulations of the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">U.S. Department</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Labor.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">In</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">event</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Administrator</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">confirms</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">denial</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of the application for benefits in whole or in part, the notice will set forth, in a manner calculated to be understood by the applicant, the following:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">specific</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">reason</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">reasons</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">denial;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:12pt;">references</font><font style="font-size:12pt;letter-spacing:0.05pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">specific</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">provisions</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">upon</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">which</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:0.2pt;"> </font><font style="font-size:12pt;">denial</font><font style="font-size:12pt;letter-spacing:0.15pt;"> </font><font style="font-size:12pt;letter-spacing:-0.25pt;">is </font><font style="letter-spacing:-0.1pt;">based;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:1.15pt;"> </font><font style="font-size:12pt;">statement</font><font style="font-size:12pt;letter-spacing:1.25pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:1.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:1.2pt;"> </font><font style="font-size:12pt;">applicant</font><font style="font-size:12pt;letter-spacing:0.95pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:1.15pt;"> </font><font style="font-size:12pt;">entitled</font><font style="font-size:12pt;letter-spacing:0.95pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:1.25pt;"> </font><font style="font-size:12pt;">receive,</font><font style="font-size:12pt;letter-spacing:1.3pt;"> </font><font style="font-size:12pt;">upon</font><font style="font-size:12pt;letter-spacing:1pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">request </font>and<font style="letter-spacing:2pt;"> </font>free<font style="letter-spacing:2pt;"> </font>of<font style="letter-spacing:2pt;"> </font>charge,<font style="letter-spacing:2pt;"> </font>reasonable<font style="letter-spacing:2pt;"> </font>access<font style="letter-spacing:2pt;"> </font>to,<font style="letter-spacing:2pt;"> </font>and<font style="letter-spacing:2pt;"> </font>copies<font style="letter-spacing:2pt;"> </font>of,<font style="letter-spacing:2pt;"> </font>all<font style="letter-spacing:2pt;"> </font>documents,<font style="letter-spacing:2pt;"> </font>records<font style="letter-spacing:2pt;"> </font>and<font style="letter-spacing:2pt;"> </font>other<font style="letter-spacing:2pt;"> </font>information relevant to his or her claim; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(4)</font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:1.45pt;"> </font><font style="font-size:12pt;">statement</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:1.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">applicant&#8217;s</font><font style="font-size:12pt;letter-spacing:1.4pt;"> </font><font style="font-size:12pt;">right to bring a civil</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">action under Section 502(a) of ERISA.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-size:12pt;font-weight:bold;">Rules and Procedures.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The Plan Administrator will establish rules and procedures,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">consistent</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">ERISA,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">necessary</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">appropriate</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">carrying</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">out its responsibilities in reviewing</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">benefit claims.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Plan Administrator may</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">require</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">an applicant who wishes to submit additional information in connection with an appeal from the denial of benefits to do so at the applicant&#8217;s own expense.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">13.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-size:12pt;font-weight:bold;">Exhaustion</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-size:12pt;font-weight:bold;">of</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;"> </b><b style="font-size:12pt;font-weight:bold;">Remedies.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">No</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">legal</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">action</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">benefits</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">may be brought until the applicant (i) has submitted a written application for benefits in accordance with the procedures described by Section 13(a) above, (ii) has been notified by the Plan Administrator that the application is denied, (iii) has filed a written request for a review of the application</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">accordance</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">appeal</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">procedure</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">described</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Section</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">13(c)</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">above,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">(iv) has been notified that the Plan Administrator has denied the appeal.</font><font style="font-size:12pt;letter-spacing:3.7pt;"> </font><font style="font-size:12pt;">Notwithstanding the foregoing, if the Plan Administrator does not respond to an Eligible Employee&#8217;s claim or appeal within the relevant time</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">limits</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">specified</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">in this</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Section 13,</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Eligible</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">bring</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">legal action for benefits under the Plan pursuant to Section 502(a) of ERISA.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">14.</b></font><b style="font-size:12pt;font-weight:bold;">B</b><b style="font-size:9.5pt;font-weight:bold;">ASIS OF</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;">P</b><b style="font-size:9.5pt;font-weight:bold;">AYMENTS</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">TO</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">AND</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.1pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">FROM</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">P</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">LAN</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">The<font style="letter-spacing:-0.75pt;"> </font>Plan<font style="letter-spacing:-0.55pt;"> </font>shall<font style="letter-spacing:-0.75pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>unfunded,<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.55pt;"> </font>all<font style="letter-spacing:-0.75pt;"> </font>cash<font style="letter-spacing:-0.55pt;"> </font>payments<font style="letter-spacing:-0.75pt;"> </font>under<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>Plan<font style="letter-spacing:-0.75pt;"> </font>shall<font style="letter-spacing:-0.5pt;"> </font>be<font style="letter-spacing:-0.6pt;"> </font>paid<font style="letter-spacing:-0.75pt;"> </font>only from the general assets of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">15.</b></font><b style="font-size:12pt;font-weight:bold;">O</b><b style="font-size:9.5pt;font-weight:bold;">THER</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-size:12pt;font-weight:bold;">P</b><b style="font-size:9.5pt;font-weight:bold;">LAN</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:0.2pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">I</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">NFORMATION</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Employer and Plan Identification Numbers.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The Employer Identification</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Number</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">assigned</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">(which</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">&#8220;Plan</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Sponsor&#8221;</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">as</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">that</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">term</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">used in</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">ERISA)</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Internal</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Revenue</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Service</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">52-2154066.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">Number</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">assigned</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Plan by the Plan Sponsor pursuant to the instructions of the Internal Revenue Service is 510.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Ending</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-size:12pt;font-weight:bold;">Date</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-size:12pt;font-weight:bold;">for</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-size:12pt;font-weight:bold;">Plan&#8217;s</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-size:12pt;font-weight:bold;">Fiscal</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:12pt;font-weight:bold;">Year.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">date</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">end</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">fiscal</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">year for the purpose of maintaining the Plan&#8217;s records is December 31.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Agent</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:12pt;font-weight:bold;">for</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.4pt;"> </b><b style="font-size:12pt;font-weight:bold;">the</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-size:12pt;font-weight:bold;">Service</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-size:12pt;font-weight:bold;">of</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:12pt;font-weight:bold;">Legal</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.5pt;"> </b><b style="font-size:12pt;font-weight:bold;">Process.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">agent</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">service</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">legal process with respect to the Plan is:</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">XOMA<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.1pt;">Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Compensation<font style="letter-spacing:-0.3pt;"> </font>Committee<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Attention to: Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2200<font style="letter-spacing:-0.25pt;"> </font>Powell<font style="letter-spacing:-0.1pt;"> </font>Street,<font style="letter-spacing:-0.2pt;"> </font>Suite<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.25pt;">310</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville,<font style="letter-spacing:-0.15pt;"> </font>CA <font style="letter-spacing:-0.1pt;">94608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">In<font style="letter-spacing:-0.1pt;"> </font>addition,<font style="letter-spacing:0.05pt;"> </font>service<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>legal<font style="letter-spacing:-0.05pt;"> </font>process<font style="letter-spacing:-0.15pt;"> </font>may<font style="letter-spacing:-0.1pt;"> </font>be<font style="letter-spacing:-0.05pt;"> </font>made<font style="letter-spacing:-0.35pt;"> </font>upon<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font>Plan<font style="letter-spacing:-0.3pt;"> </font><font style="letter-spacing:-0.1pt;">Administrator.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Plan</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;">Sponsor.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2.9pt;"> </b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">&#8220;Plan</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Sponsor&#8221;</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;letter-spacing:-0.25pt;">is:</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">XOMA<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.1pt;">Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Compensation<font style="letter-spacing:-0.35pt;"> </font>Committee<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Attention to: Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2200<font style="letter-spacing:-0.25pt;"> </font>Powell<font style="letter-spacing:-0.1pt;"> </font>Street,<font style="letter-spacing:-0.2pt;"> </font>Suite<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.25pt;">310</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville,<font style="letter-spacing:-0.15pt;"> </font>CA <font style="letter-spacing:-0.1pt;">94608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">14.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:41.05pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-size:12pt;font-weight:bold;">Plan</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-size:12pt;font-weight:bold;">Administrator.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Administrator</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Committee.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Plan Administrator&#8217;s contact information is:</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">XOMA<font style="letter-spacing:-0.55pt;"> </font><font style="letter-spacing:-0.1pt;">Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Compensation<font style="letter-spacing:-0.35pt;"> </font>Committee<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Board<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">Attention to: Corporate Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2200<font style="letter-spacing:-0.25pt;"> </font>Powell<font style="letter-spacing:-0.1pt;"> </font>Street,<font style="letter-spacing:-0.2pt;"> </font>Suite<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.25pt;">310</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Emeryville,<font style="letter-spacing:-0.15pt;"> </font>CA <font style="letter-spacing:-0.1pt;">94608</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">The Plan Administrator is the named fiduciary charged with the responsibility for administering the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">16.</b></font><b style="font-size:12pt;font-weight:bold;">S</b><b style="font-size:9.5pt;font-weight:bold;">TATEMENT</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-size:9.5pt;font-weight:bold;">OF</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-size:12pt;font-weight:bold;">ERISA</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.75pt;"> </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">R</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">IGHTS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;">Participants in this Plan are entitled to certain rights and protections under ERISA. If you are an Eligible Employee, you are considered a participant in the Plan and, under ERISA, you are entitled to:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Receive</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.35pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Information</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">About</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.15pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Your</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.55pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Plan</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">and</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.45pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;">Benefits</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font><font style="font-size:12pt;">Examine, without</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">charge, at</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Administrator&#8217;s</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">office</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">at other specified locations, such as worksites, all documents governing the Plan and</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">a copy of the latest</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">annual</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">report</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">(Form</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">5500</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Series),</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">applicable,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">filed</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">the Plan</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">U.S.</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Administration;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font><font style="font-size:12pt;">Obtain, upon written request to the Plan Administrator, copies of documents</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">governing</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">operation</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">copies of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">latest</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">annual</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">report</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">(Form</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">5500 Series), if applicable, and an updated (as necessary) Summary Plan Description.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Administrator may make a reasonable charge for the copies; and</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(3)</font><font style="font-size:12pt;">Receive a summary of the Plan&#8217;s annual financial report, if applicable.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Plan Administrator is required by</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">law to furnish each Eligible</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Employee with a copy of this summary annual report.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Prudent Actions by Plan Fiduciaries.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">In addition to creating rights for Plan Eligible Employees, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">people who operate the Plan, called &#8220;fiduciaries&#8221; of the Plan, have a duty to do so prudently and in the interest of you and other Eligible Employees and</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">beneficiaries.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">No</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">one,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">including</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">employer,</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">union</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">other</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">person,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">fire</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">you or otherwise discriminate</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">against you in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">any way</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">to prevent you</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">from obtaining a</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Plan benefit or exercising your rights under ERISA.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Enforce</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.7pt;"> </b><b style="font-size:12pt;font-weight:bold;">Your</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-size:12pt;font-weight:bold;">Rights.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:1.85pt;"> </b><font style="font-size:12pt;">If</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">claim</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Plan</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">benefit</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">is</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">denied</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">decision</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">without</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">charge,</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">appeal</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">denial,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">all</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">within</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">certain</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">time</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">schedules.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">15.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">Under<font style="letter-spacing:-0.25pt;"> </font>ERISA,<font style="letter-spacing:-0.5pt;"> </font>there<font style="letter-spacing:-0.4pt;"> </font>are<font style="letter-spacing:-0.4pt;"> </font>steps<font style="letter-spacing:-0.5pt;"> </font>you<font style="letter-spacing:-0.35pt;"> </font>can<font style="letter-spacing:-0.2pt;"> </font>take<font style="letter-spacing:-0.4pt;"> </font>to<font style="letter-spacing:-0.3pt;"> </font>enforce<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>above<font style="letter-spacing:-0.4pt;"> </font>rights.<font style="letter-spacing:2pt;"> </font>For instance, if you request a copy of Plan documents or the latest annual report from the Plan, if applicable,<font style="letter-spacing:-0.15pt;"> </font>and<font style="letter-spacing:-0.2pt;"> </font>do<font style="letter-spacing:-0.25pt;"> </font>not<font style="letter-spacing:-0.15pt;"> </font>receive<font style="letter-spacing:-0.2pt;"> </font>them<font style="letter-spacing:-0.25pt;"> </font>within<font style="letter-spacing:-0.2pt;"> </font>30<font style="letter-spacing:-0.2pt;"> </font>days,<font style="letter-spacing:-0.15pt;"> </font>you<font style="letter-spacing:-0.2pt;"> </font>may<font style="letter-spacing:-0.25pt;"> </font>file<font style="letter-spacing:-0.25pt;"> </font>suit<font style="letter-spacing:-0.15pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>Federal<font style="letter-spacing:-0.15pt;"> </font>court.<font style="letter-spacing:2.5pt;"> </font>In<font style="letter-spacing:-0.2pt;"> </font>such<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.5pt;">a </font>case,<font style="letter-spacing:-0.4pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>court<font style="letter-spacing:-0.45pt;"> </font>may<font style="letter-spacing:-0.45pt;"> </font>require<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Plan<font style="letter-spacing:-0.5pt;"> </font>Administrator<font style="letter-spacing:-0.7pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>provide<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>materials<font style="letter-spacing:-0.6pt;"> </font>and<font style="letter-spacing:-0.5pt;"> </font>pay<font style="letter-spacing:-0.5pt;"> </font>you<font style="letter-spacing:-0.5pt;"> </font>up<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.45pt;"> </font>$110 a<font style="letter-spacing:-0.4pt;"> </font>day<font style="letter-spacing:-0.35pt;"> </font>until<font style="letter-spacing:-0.5pt;"> </font>you<font style="letter-spacing:-0.55pt;"> </font>receive<font style="letter-spacing:-0.55pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>materials,<font style="letter-spacing:-0.45pt;"> </font>unless<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>materials<font style="letter-spacing:-0.45pt;"> </font>were<font style="letter-spacing:-0.4pt;"> </font>not<font style="letter-spacing:-0.55pt;"> </font>sent<font style="letter-spacing:-0.3pt;"> </font>because<font style="letter-spacing:-0.4pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>reasons<font style="letter-spacing:-0.45pt;"> </font>beyond the control of the Plan Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">If you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a<font style="letter-spacing:-0.1pt;"> </font>Federal court.<font style="letter-spacing:2pt;"> </font>The court will decide who should<font style="letter-spacing:-0.05pt;"> </font>pay court<font style="letter-spacing:-0.05pt;"> </font>costs and legal fees.<font style="letter-spacing:2pt;"> </font>If you<font style="letter-spacing:-0.05pt;"> </font>are successful, the court<font style="letter-spacing:-0.05pt;"> </font>may order the<font style="letter-spacing:-0.05pt;"> </font>person you have sued to pay these costs<font style="letter-spacing:-0.05pt;"> </font>and fees.<font style="letter-spacing:2pt;"> </font>If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Assistance with Your Questions.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:2pt;"> </b><font style="font-size:12pt;">If you have any questions about the Plan, you should contact the Plan Administrator.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">If you have any questions about this statement or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">about</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">rights</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">ERISA,</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">if</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">you</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">need</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">assistance</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">obtaining</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">documents</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">from</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Assistance</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Inquiries,</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">Employee</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">Benefits</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Security</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">Administration,</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">U.S.</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Department of Labor, 200</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Constitution</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Avenue</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">N.W.,</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">Washington, D.C.</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">20210.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">You</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">may</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">also</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">obtain</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">certain publications</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">about</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="font-size:12pt;">rights</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">and</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">responsibilities</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">ERISA</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">by</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">calling</font><font style="font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">publications</font><font style="font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="font-size:12pt;">hotline of the Employee Benefits Security Administration.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">16.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:2.21;text-indent:41.5pt;margin:0pt 166.9pt 0pt 166.6pt;"><b style="font-variant:small-caps;font-weight:bold;">Appendix A Participation</b><b style="font-variant:small-caps;font-weight:bold;letter-spacing:-0.6pt;"> </b><b style="font-variant:small-caps;font-weight:bold;">Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">Name:</b><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:46.67pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>__________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Section</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;letter-spacing:-0.25pt;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">E</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">LIGIBILITY</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">You have been designated as eligible to participate in the XOMA Corporation Retention and<font style="letter-spacing:-0.05pt;"> </font>Severance<font style="letter-spacing:-0.1pt;"> </font>Plan<font style="letter-spacing:-0.25pt;"> </font>(the<font style="letter-spacing:-0.1pt;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Plan</font>&#8221;), a<font style="letter-spacing:-0.35pt;"> </font>copy<font style="letter-spacing:-0.05pt;"> </font>of which<font style="letter-spacing:-0.3pt;"> </font>is<font style="letter-spacing:-0.2pt;"> </font>attached<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>this<font style="letter-spacing:-0.4pt;"> </font>Participation<font style="letter-spacing:-0.3pt;"> </font>Agreement<font style="letter-spacing:-0.3pt;"> </font>(the &#8220;<font style="font-style:italic;font-weight:bold;">Participation Agreement</font>&#8221;).<font style="letter-spacing:2pt;"> </font>Capitalized terms not explicitly defined in this Participation Agreement<font style="letter-spacing:-0.25pt;"> </font>but<font style="letter-spacing:-0.2pt;"> </font>defined<font style="letter-spacing:-0.5pt;"> </font>in<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Plan<font style="letter-spacing:-0.25pt;"> </font>shall<font style="letter-spacing:-0.2pt;"> </font>have<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>same<font style="letter-spacing:-0.25pt;"> </font>definitions<font style="letter-spacing:-0.35pt;"> </font>as<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.25pt;"> </font>Plan.<font style="letter-spacing:2pt;"> </font>You<font style="letter-spacing:-0.5pt;"> </font>will<font style="letter-spacing:-0.45pt;"> </font>receive the benefits set forth below if you meet all the eligibility requirements set forth in the Plan, including,<font style="letter-spacing:-0.2pt;"> </font>without<font style="letter-spacing:-0.25pt;"> </font>limitation,<font style="letter-spacing:-0.25pt;"> </font>executing<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>required<font style="letter-spacing:-0.1pt;"> </font>Release<font style="letter-spacing:-0.15pt;"> </font>within<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>applicable<font style="letter-spacing:-0.35pt;"> </font>time<font style="letter-spacing:-0.35pt;"> </font>period<font style="letter-spacing:-0.3pt;"> </font>set forth therein and allowing such Release to become effective in accordance with its terms. Notwithstanding<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>schedule<font style="letter-spacing:-0.3pt;"> </font>for<font style="letter-spacing:-0.2pt;"> </font>provision<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>benefits<font style="letter-spacing:-0.4pt;"> </font>as<font style="letter-spacing:-0.4pt;"> </font>set<font style="letter-spacing:-0.25pt;"> </font>forth<font style="letter-spacing:-0.25pt;"> </font>below,<font style="letter-spacing:-0.2pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>schedule<font style="letter-spacing:-0.3pt;"> </font>and<font style="letter-spacing:-0.3pt;"> </font>timing of payment of any benefits under this Participant Agreement is subject to any delay in payment that may be required under the Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Section</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.25pt;">2.</b></font><b style="font-size:12pt;font-weight:bold;">S</b><b style="font-size:9.5pt;font-weight:bold;">EVERANCE </b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">B</b><b style="font-size:9.5pt;font-weight:bold;letter-spacing:-0.1pt;">ENEFITS</b><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">.</b><sup style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;vertical-align:top;">1</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">If<font style="letter-spacing:-0.25pt;"> </font>you<font style="letter-spacing:-0.6pt;"> </font>are<font style="letter-spacing:-0.65pt;"> </font>terminated<font style="letter-spacing:-0.6pt;"> </font>in<font style="letter-spacing:-0.55pt;"> </font>a<font style="letter-spacing:-0.4pt;"> </font>Covered<font style="letter-spacing:-0.6pt;"> </font>Termination,<font style="letter-spacing:-0.45pt;"> </font>you<font style="letter-spacing:-0.35pt;"> </font>will<font style="letter-spacing:-0.55pt;"> </font>receive<font style="letter-spacing:-0.35pt;"> </font>the<font style="letter-spacing:-0.6pt;"> </font>severance<font style="letter-spacing:-0.35pt;"> </font>benefits<font style="letter-spacing:-0.4pt;"> </font>set forth<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>this<font style="letter-spacing:-0.1pt;"> </font>Section<font style="letter-spacing:-0.05pt;"> </font>2.<font style="letter-spacing:2pt;"> </font>All<font style="letter-spacing:-0.05pt;"> </font>severance<font style="letter-spacing:-0.1pt;"> </font>benefits<font style="letter-spacing:-0.15pt;"> </font>described<font style="letter-spacing:-0.1pt;"> </font>herein<font style="letter-spacing:-0.05pt;"> </font>are<font style="letter-spacing:-0.1pt;"> </font>subject<font style="letter-spacing:-0.05pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>standard<font style="letter-spacing:-0.05pt;"> </font>deductions and withholdings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-size:12pt;font-weight:bold;">Base</b><b style="font-size:12pt;font-weight:bold;letter-spacing:1.5pt;"> </b><b style="font-size:12pt;font-weight:bold;">Salary.</b><b style="font-size:12pt;font-weight:bold;letter-spacing:4pt;"> </b><font style="font-size:12pt;">You</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">receive</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">a</font><font style="font-size:12pt;letter-spacing:1.5pt;"> </font><font style="font-size:12pt;">cash</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:1.8pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">an</font><font style="font-size:12pt;letter-spacing:1.55pt;"> </font><font style="font-size:12pt;">amount</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">equal</font><font style="font-size:12pt;letter-spacing:1.6pt;"> </font><font style="font-size:12pt;">to&#160;</font><font style="font-size:12pt;letter-spacing:-0.5pt;">[*] </font><font style="font-size:12pt;">months</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">(the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Period</font><font style="font-size:12pt;">&#8221;)</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">then-applicable</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Base</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Salary.</font><font style="font-size:12pt;letter-spacing:1.95pt;"> </font><font style="font-size:12pt;">The Base Salary payment will be paid to you in a lump sum cash payment no later than the second regular payroll date following the effective date of the Release, but in any event not later than March 15 of the year following the year in which your Separation from Service occurs.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:72pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-size:12pt;font-weight:bold;">Bonus Payment</b><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">You will be entitled to payment of [*] of your annual target cash bonus for the year in which your Covered Termination occurs (the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Annual Target Bonus Severance Payment</font><font style="font-size:12pt;">&#8221;).</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The Annual Target Bonus Severance Payment shall be paid in a lump sum cash payment no later than</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">the second regular payroll date</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">following the</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">effective</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">date of the Release, but in any event not later than March 15 of the year following the year in which your Separation from Service occurs.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.0pt;margin-top:0.2pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">1</sup> Severance<font style="letter-spacing:2pt;"> </font>benefits<font style="letter-spacing:2pt;"> </font>to<font style="letter-spacing:2pt;"> </font>be<font style="letter-spacing:2pt;"> </font>omitted<font style="letter-spacing:2pt;"> </font>from<font style="letter-spacing:2pt;"> </font>participation<font style="letter-spacing:2pt;"> </font>agreement<font style="letter-spacing:2pt;"> </font>for<font style="letter-spacing:2pt;"> </font>CFO,<font style="letter-spacing:2pt;"> </font>other<font style="letter-spacing:2pt;"> </font>than<font style="letter-spacing:2pt;"> </font>paragraph<font style="letter-spacing:2pt;"> </font>(c) (Retention Bonus Payment).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">17.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-size:12pt;font-weight:bold;">Retention Bonus Payment.</b><font style="font-size:12pt;"> If your Covered Termination occurs during the Initial Period (as such term is defined in the Plan), then you will receive payment of the retention bonus that you would have received had you remained employed through the last day of the Initial Period. And if your Covered Termination occurs during the Extended Period (as such term is defined in the Plan), then you will receive payment of the retention bonus that you would have received had you remained employed through the last day of the Extended Period. Any bonus paid to you under this Section will be paid to you at the same time as the severance payment set forth in Section 2(a) above.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-size:12pt;font-weight:bold;">Payment of Continued Group Health Plan Benefits</b><font style="font-size:12pt;">. If you timely elect continued group health plan continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">1985</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">(&#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">COBRA</font><font style="font-size:12pt;">&#8221;) following</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">Covered</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Termination</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">date, the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">Company shall pay directly to the carrier the full amount of your COBRA premiums on behalf of you for your continued coverage under the Company&#8217;s group health plans, including coverage for your eligible dependents, until the earliest of (i) the end of the Severance Period following the date of your Covered Termination, (ii) the expiration of your eligibility for the continuation coverage under COBRA, or (iii) the date when you become eligible for substantially equivalent health insurance</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">coverage</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">connection</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">with</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">new</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">employment</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">(such</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">from</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">your</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">termination</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">date through the earliest of (i) through (iii), the &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">COBRA Payment Period</font><font style="font-size:12pt;">&#8221;).</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Upon the conclusion of such period of insurance premium payments made by the Company, you will be responsible for the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">entire</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">premiums</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">(or</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">payment</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">for</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">cost</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">coverage)</font><font style="font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="font-size:12pt;">required</font><font style="font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="font-size:12pt;">under</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">COBRA</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">for the duration of your eligible COBRA coverage period, if any.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">You agree to promptly notify the Company as soon as you become eligible for health insurance coverage in connection with new employment or self-employment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the<font style="letter-spacing:-0.05pt;"> </font>Public<font style="letter-spacing:-0.3pt;"> </font>Health<font style="letter-spacing:-0.25pt;"> </font>Service<font style="letter-spacing:-0.35pt;"> </font>Act),<font style="letter-spacing:-0.2pt;"> </font>then<font style="letter-spacing:-0.3pt;"> </font>in<font style="letter-spacing:-0.25pt;"> </font>lieu<font style="letter-spacing:-0.25pt;"> </font>of<font style="letter-spacing:-0.2pt;"> </font>paying<font style="letter-spacing:-0.05pt;"> </font>COBRA<font style="letter-spacing:-0.05pt;"> </font>premiums<font style="letter-spacing:-0.35pt;"> </font>directly<font style="letter-spacing:-0.25pt;"> </font>to<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.3pt;"> </font>carrier<font style="letter-spacing:-0.2pt;"> </font>on your behalf, the Company will instead pay you on the last day of each remaining month of the COBRA<font style="letter-spacing:-0.55pt;"> </font>Payment<font style="letter-spacing:-0.55pt;"> </font>Period<font style="letter-spacing:-0.5pt;"> </font>a<font style="letter-spacing:-0.6pt;"> </font>fully<font style="letter-spacing:-0.55pt;"> </font>taxable<font style="letter-spacing:-0.55pt;"> </font>cash<font style="letter-spacing:-0.55pt;"> </font>payment<font style="letter-spacing:-0.55pt;"> </font>equal<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.5pt;"> </font>the<font style="letter-spacing:-0.55pt;"> </font>value<font style="letter-spacing:-0.55pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>monthly<font style="letter-spacing:-0.5pt;"> </font>COBRA premium for the first month of COBRA coverage, subject to applicable tax withholding (such amount,<font style="letter-spacing:-0.25pt;"> </font>the<font style="letter-spacing:-0.15pt;"> </font>&#8220;<font style="font-style:italic;font-weight:bold;">Special</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.3pt;"> </font><font style="font-style:italic;font-weight:bold;">Severance</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.15pt;"> </font><font style="font-style:italic;font-weight:bold;">Payment</font>&#8221;),<font style="letter-spacing:-0.25pt;"> </font>such<font style="letter-spacing:-0.35pt;"> </font>Special<font style="letter-spacing:-0.1pt;"> </font>Severance<font style="letter-spacing:-0.15pt;"> </font>Payment<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.35pt;"> </font>be<font style="letter-spacing:-0.4pt;"> </font>made<font style="letter-spacing:-0.45pt;"> </font>without regard<font style="letter-spacing:-0.35pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>your<font style="letter-spacing:-0.5pt;"> </font>election<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.25pt;"> </font>COBRA<font style="letter-spacing:-0.35pt;"> </font>coverage<font style="letter-spacing:-0.4pt;"> </font>or<font style="letter-spacing:-0.5pt;"> </font>payment<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.5pt;"> </font>COBRA<font style="letter-spacing:-0.35pt;"> </font>premiums<font style="letter-spacing:-0.45pt;"> </font>and<font style="letter-spacing:-0.35pt;"> </font>without<font style="letter-spacing:-0.55pt;"> </font>regard to your continued eligibility for COBRA coverage during the COBRA Payment Period.<font style="letter-spacing:2pt;"> </font>Such Special Severance Payment shall end upon expiration of the COBRA Payment Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:41.1pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-size:12pt;font-weight:bold;">Equity Acceleration</b><font style="font-size:12pt;">.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">The vesting and exercisability of each outstanding unvested stock option and other stock award, as applicable, that you hold covering Company common stock as of the date of your Covered Termination (each, an &#8220;</font><font style="font-size:12pt;font-style:italic;font-weight:bold;">Equity Award</font><font style="font-size:12pt;">&#8221;) that is subject to time-vesting shall be accelerated</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">full</font><font style="font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="font-size:12pt;">and any</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">reacquisition or</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">repurchase rights</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;">held by</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">respect</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">common</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">stock</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">issued</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">pursuant</font><font style="font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="font-size:12pt;">any</font><font style="font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="font-size:12pt;">time-vesting</font><font style="font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="font-size:12pt;">Equity Award</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">granted</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">you</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">shall</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">lapse</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">in</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">full.</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">In</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">addition, the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="font-size:12pt;">extend</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="font-size:12pt;">period</font><font style="font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="font-size:12pt;">of time in which you may exercise any vested outstanding and unexercised stock options or other equity awards (including those vested pursuant to the previous sentence) through the applicable expiration date(s) of your options.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">18.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:78.27%;border-width:0;"><div style="max-width:100%;padding-left:10.95%;padding-right:10.78%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:12pt;font-weight:bold;min-width:41.05pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">Outplacement. &#160;</b><font style="font-size:12pt;">The</font><font style="font-size:12pt;letter-spacing:2.5pt;"> </font><font style="font-size:12pt;">Company</font><font style="font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-size:12pt;">will</font><font style="font-size:12pt;letter-spacing:2.65pt;"> </font><font style="font-size:12pt;">pay</font><font style="font-size:12pt;letter-spacing:2.6pt;"> </font><font style="font-size:12pt;">(directly</font><font style="font-size:12pt;letter-spacing:2.65pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:2.65pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:2.55pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">outplacement </font>provider<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>your<font style="letter-spacing:-0.3pt;"> </font>choice)<font style="letter-spacing:-0.15pt;"> </font>up<font style="letter-spacing:-0.4pt;"> to [*] </font>in outplacement<font style="letter-spacing:-0.1pt;"> </font>assistance<font style="letter-spacing:-0.1pt;"> </font>for<font style="letter-spacing:-0.05pt;"> </font><font style="letter-spacing:-0.2pt;">you.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1pt;margin:0pt 0pt 0pt 158.5pt;"><font style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">To accept the terms of this Participation Agreement and participate in the Plan, please sign and <font style="letter-spacing:-0.2pt;">date this </font><font style="letter-spacing:-0.1pt;">Participation Agreement </font><font style="letter-spacing:-0.25pt;">in the </font><font style="letter-spacing:-0.1pt;">space provided below </font><font style="letter-spacing:-0.25pt;">and </font><font style="letter-spacing:-0.1pt;">return </font><font style="letter-spacing:-0.25pt;">it to </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:133.75pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>no later than <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:54.22pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:24.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="letter-spacing:-0.5pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt;">Eligible<b style="font-weight:bold;letter-spacing:-0.2pt;"> </b><b style="font-weight:bold;letter-spacing:-0.1pt;">Employee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;">[Insert</font><font style="font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="font-size:12pt;letter-spacing:-0.1pt;">Name]</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;letter-spacing:-0.1pt;">Date:</font></p></td><td style="vertical-align:bottom;width:43.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:13.0pt;margin-top:0.3pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">19.</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.95%;margin-right:10.78%;margin-top:30pt;page-break-after:avoid;width:78.27%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>xoma-20221231xex10d15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_mps009951520000000000000004054000000000"></a><a name="_mpv339064660000010000000000000000000000"></a><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk121483250"></a>Exhibit 10.15</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">OFFICER EMPLOYMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">This Officer Employment Agreement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) between Owen Hughes (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee</u>&#8221;) and XOMA Corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">the Company</u>&#8221;) (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221;) is effective as of January 1, 2023 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Effective Date</u>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u>. Employee&#8217;s employment with XOMA in the position of Executive Chairman and Interim Chief Executive Officer shall commence on the Agreement Effective Date. Employee&#8217;s employment with XOMA will be governed by the terms set forth in this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position and Responsibilities</u>. Employee shall be employed on a part-time basis, averaging approximately 30-40 hours per month, reporting to the Board of Directors (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;). &#160;While employed by XOMA, Employee may not accept consulting or other business or non-profit opportunities without first obtaining written approval from the Board. In addition, while employed by XOMA, except on behalf of XOMA, Employee will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by Employee to compete with XOMA (or that is planning or preparing to compete with XOMA), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by XOMA; <i style="font-style:italic;">provided, however,</i> that Employee may purchase or otherwise acquire up to (but not more than) five percent (5%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term of Employment</u>. The term of Employee&#8217;s employment with XOMA shall be the period from the Agreement Effective Date until Employee&#8217;s employment is terminated pursuant to Section 7. It is anticipated that Employee will serve as Interim Chief Executive Officer for a period of one (1) year while the Company recruits a new Chief Executive Officer. &#160;Upon the new Chief Executive Officer commencing employment with the Company, Employee&#8217;s employment will automatically terminate and Employee will cease serving as Executive Chair, however Employee will remain a member of the Board of Directors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation and Reimbursement of Expenses</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>. Employee will receive for services to be rendered hereunder a base salary paid at the rate of $125,000 per year, less applicable payroll deductions and withholdings (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>&#8221;), paid on XOMA&#8217;s ordinary payroll cycle. In addition, Employee shall be eligible to participate in XOMA&#8217;s Corporate Achievement Goals plan (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAGs</u>&#8221;), as it may be amended from time to time in accordance with its terms, with an initial target rate of 55% of Base Salary, which can be adjusted from time to time by the Board.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Awards</u>. &#160;Subject to approval by the Board, the Company will grant Employee a non-qualified option to purchase 100,000 shares of the Company&#8217;s common stock with an exercise price equal to the fair market value of the common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FMV Option</u>&#8221;). &#160;The FMV Option shall vest in four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 (subject to Employee&#8217;s continuous service). &#160;In addition, subject to approval by the Board, the Company will grant Employee a non-qualified </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps586101060000000000000004054000000000"></a>-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">option to purchase 75,000 shares of the Company&#8217;s common stock with an exercise price equal to $30 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Option</u>&#8221;). &#160;The Additional Option shall vest monthly over three years (subject to Employee&#8217;s continuous service). &#160;The FMV Option and the Additional Option shall be issued outside of, but subject in all respects to the terms and conditions of the Company&#8217;s Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;), and shall be governed in all respects by the terms of the Plan as if granted thereunder, the grant notice and the option agreement. The Company intends for the FMV Option and the Additional Option to each be a material inducement to Employee entering into employment with the Company within the meaning of Listing Rule 5635(c)(4) of The Nasdaq Stock Market LLC. &#160;Employee may be eligible for additional annual equity grants at the discretion of the Board. &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement of Expenses</u>. XOMA shall reimburse Employee for all reasonable travel and other expenses incurred in performing Employee&#8217;s obligations under this Agreement in a manner consistent with XOMA policies.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Benefit Plans</u>. Employee shall not be eligible for benefits under any employee benefit plan of XOMA due to his part-time status, except as required by law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Proprietary Information Agreement and XOMA Policies</u>. As a condition of employment with XOMA, Employee must sign and comply with the Employee Confidential Information and Inventions Assignment Agreement attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</u>&#8221;), which prohibits unauthorized use or disclosure of XOMA proprietary information, among other obligations. In addition, Employee is required to abide by XOMA&#8217;s policies and procedures (including but not limited to XOMA&#8217;s Employee Handbook), as adopted or modified from time to time within XOMA&#8217;s discretion; <i style="font-style:italic;">provided, however,</i> that in the event the terms of this Agreement differ from or are in conflict with XOMA&#8217;s general employment policies or practices, this Agreement shall control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Employment; Severance</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Consistent with XOMA policy, Employee&#8217;s employment relationship with XOMA is at-will. Accordingly, Employee may resign Employee&#8217;s employment with XOMA at any time and for any reason whatsoever simply by notifying XOMA; and XOMA may terminate Employee&#8217;s employment at any time, with or without cause or advance notice. &#160;Employee&#8217;s employment will automatically end upon a new Chief Executive Officer commencing employment with the Company (unless Employee and XOMA mutually agree otherwise).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance</u>. &#160;If Employee&#8217;s employment automatically terminates due to a new Chief Executive Officer commencing employment within one (1) year after the Agreement Effective Date, then provided that such termination of employment constitutes a &#8220;separation from service&#8221; under Treas. Reg. Section 1.409A-1(h), the Company will pay Employee severance in the form of Base Salary continuation at the rate then in effect through the one-year anniversary of the Agreement Effective Date. &#160;Such severance payments will be paid on the Company&#8217;s ordinary payroll dates (starting on the first payroll date after the Release Agreement (defined below) becomes effective) and will be subject to standard deductions and withholdings. &#160;As a condition receiving such severance benefits, Employee shall execute and deliver to XOMA a release of claims in favor of XOMA substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release </u></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) within the timeframe set forth in the Release Agreement, but not later than forty-five (45) days following Employee&#8217;s employment termination date, and allow the Release Agreement to become effective according to its terms (by not invoking any legal right to revoke it) within any applicable time period set forth in the Release Agreement. &#160;If the period during which Employee may elect to execute the Release and have it become effective may occur in more than one taxable year, then the first payroll date after the Release Agreement becomes effective will be deemed to occur in the second of such taxable years. &#160;Any such severance payments that would have been made from the date of such termination to the first payroll date following the effective date of the Release will be made on such first payroll date. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Agreement</u>. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective permitted successors and assigns.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Section 409A of the Code</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>It is intended that this Agreement will comply with Section 409A of the Code and its regulations and guidelines (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u>&#8221;), to the extent the Agreement is subject to Section 409A, and the Agreement shall be interpreted on a basis consistent with such intent. If an amendment of the Agreement is necessary in order for it to comply with Section 409A, the Parties will negotiate in good faith to amend the Agreement in a manner that preserves the original intent of the Parties to the extent reasonably possible. No action or failure to act under this Section 9 shall subject XOMA to any claim, liability, or expense, and XOMA shall not have any obligation to indemnify or otherwise protect Employee from the obligation to pay any taxes, interest or penalties under Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>With respect to any reimbursement or in-kind benefit arrangements of XOMA and its subsidiaries that constitute deferred compensation for purposes of Section 409A, except as otherwise permitted by Section 409A, the following conditions shall be applicable: (A) the amount eligible for reimbursement, or in-kind benefits provided, under any such arrangement in one calendar year may not affect the amount eligible for reimbursement, or in-kind benefits to be provided, under such arrangement in any other calendar year (except that the benefit plans may impose a limit on the amount that may be reimbursed or paid), (B) any reimbursement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (C) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. Whenever payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate payment for purposes of Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>If Employee is deemed on the date of &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)) to be a &#8220;specified employee&#8221; (under Treas. Reg. Section 1.409A-1(i)), then with regard to any payment or benefit that is considered deferred compensation under Section 409A of the Code payable on account of a &#8220;separation from service&#8221; that is required to be delayed under Section 409A(a)(2)(B) of the Code (after taking into account any applicable exceptions to such requirement), such payment or benefit shall be made or provided on the earlier of (i) the expiration of the six (6)-month period measured from the date of Employee&#8217;s &#8220;separation from service,&#8221; or (ii) the date of Employee&#8217;s death (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay Period</u>&#8221;). Upon expiration of the Delay Period, all payments and benefits delayed under this Section 9(c) shall be paid or reimbursed to </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Employee in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided on the payment dates specified. For purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment, references to Employee&#8217;s &#8220;termination of employment&#8221; (and corollary terms) shall be construed to refer to Employee&#8217;s &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given upon actual confirmed receipt by mail, courier or email. In the case of Employee, mailed notices shall be addressed to Employee at the home or personal email address that Employee most recently communicated to XOMA in writing. In the case of XOMA, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA&#8217;s Successors</u>. Any successor to XOMA (direct or indirect, by purchase, lease, merger, amalgamation, consolidation, liquidation or otherwise) to all or substantially all of XOMA&#8217;s business or assets shall assume XOMA&#8217;s obligations under this Agreement and agree expressly to perform XOMA&#8217;s obligations under this Agreement in the same manner and to the same extent as XOMA would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; shall include any successor to XOMA&#8217;s business or assets which executes and delivers the assumption agreement described in this Section 11(a) or which becomes bound by the terms of this Agreement by operation of law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee&#8217;s Successors</u>. Without the written consent of XOMA, Employee shall not assign or transfer this Agreement or any right or obligation under this Agreement to any other person or entity. However, except as otherwise set forth herein, the terms of this Agreement and all rights of Employee shall inure to the benefit of, and be enforceable by, Employee&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Agreement</u>. Changes in Employee&#8217;s employment terms, other than those changes expressly reserved to XOMA&#8217;s or the Board&#8217;s discretion in this Agreement, require a written modification approved by XOMA and signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. Any party&#8217;s failure to enforce any provision or provisions of the Agreement will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Agreement. The rights granted to the Parties herein are cumulative and will not constitute a waiver of any party&#8217;s right to assert all other legal remedies available to it under the circumstances.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Agreement and the provision in question shall be </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">16.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">17.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. &#160;To ensure the timely and economical resolution of disputes that may arise between Employee and the Company, both Employee and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, Employee will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or Employee&#8217;s employment with the Company (including but not limited to all statutory claims); or the termination of Employee&#8217;s employment with the Company (including but not limited to all statutory claims). &#160;BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EMPLOYEE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING. &#160;The Arbitrator will have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition. &#160;All claims, disputes, or causes of action under this section, whether by Employee or the Company, must be brought solely in an individual capacity, and will not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. &#160;The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. &#160;To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class will proceed in a court of law rather than by arbitration. &#160;Any arbitration proceeding under this Arbitration section will be presided over by a single arbitrator and conducted by JAMS, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JAMS</u>&#8221;) in San Francisco, CA under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at &#160;http://www.jamsadr.com/rules-employment-arbitration/). &#160;Employee and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense. &#160;The Arbitrator will: (a) have the authority to compel adequate discovery for the resolution of the dispute; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all remedies that Employee or the Company would be entitled to seek in a court of law. &#160;The Company </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;">will pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Employee if the dispute were decided in a court of law. &#160;This section will not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>&#8221;). &#160;In the event Employee brings multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. &#160;Nothing in this section is intended to prevent either Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">19.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. &#160;Employee shall execute the Company&#8217;s standard form of indemnification agreement provided herewith.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">20.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Complete Agreement</u>. This Agreement, together with Employee&#8217;s Confidentiality Agreement and the other agreements referenced herein, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter, and supersedes and replaces any other agreements or promises made to Employee by anyone, whether oral or written.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[signature page to follow]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_Hlk121483251"></a><b style="font-weight:bold;">COMPANY:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:46.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ W. Denman Van Ness</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 22pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:46.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">W. Denman Van Ness<font style="background:#ffff00;"> </font><br>Lead Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Owen Hughes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Owen Hughes</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EMPLOYEE CONFIDENTIAL INFORMATION AND <br>INVENTIONS ASSIGNMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM RELEASE OF CLAIMS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Release of Claims Agreement (&#8220;Release Agreement&#8221;) is entered into between XOMA Corporation (&#8220;XOMA&#8221;) and Owen Hughes (&#8220;Employee&#8221;). XOMA and Employee (collectively, the &#8220;Parties&#8221;) are parties to an Officer Employment Agreement (&#8220;Employment Agreement&#8221;) and agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Employee&#8217;s employment with XOMA terminated on _______, 20__.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims</u>. In exchange for the compensation, benefits and other consideration to be provided to Employee under the Employment Agreement that Employee is not otherwise entitled to receive, Employee hereby generally and completely releases XOMA and XOMA (US) LLC, and their past and present officers, agents, directors, employees, investors, shareholders, administrators, partners, attorneys, agents, insurers, affiliates, divisions, subsidiaries, parents, predecessor and successor corporations, and assigns (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Parties</u>&#8221;), from, and agrees not to sue or otherwise institute any legal or administrative proceedings concerning, any and all claims, duties, liabilities, obligations and causes of action, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring prior to or on the date Employee signs this Release Agreement (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Claims</u>&#8221;).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Released Claims include but are not limited to:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>all claims arising out of or in any way related to Employee&#8217;s employment with XOMA or the termination of that employment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>all claims related to compensation or benefits from XOMA, including salary, bonuses, commissions, vacation, paid time off, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity or profits interests in XOMA (including but not limited to any right to purchase, or actual purchase, of shares of stock of XOMA);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>all tort claims, including claims for fraud, defamation, emotional distress and discharge in violation of public policy;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>all federal, state and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees or other claims arising under the Federal Civil Rights Act of 1964, the federal Civil Rights Act of 1991, the federal Age Discrimination in Employment Act of 1967 (the &#8220;ADEA&#8221;), the federal Americans with Disabilities Act of 1990, the federal Fair Labor Standards Act, the federal the Employee Retirement Income Security Act of 1974, the federal Worker Adjustment and Retraining Notification Act, the California Fair Employment and Housing Act and the California Labor Code, and all amendments to and regulations issued under each such statute;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>all claims for violation of the federal or any state constitution;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font>all claims for attorneys&#8217; fees and costs.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment of Waiver of Claims under ADEA</u>. Employee acknowledges that Employee is knowingly and voluntarily waiving and releasing any rights Employee may have under the ADEA, and that the consideration given for the waiver and release in this Section 3 is in addition to anything of value to which Employee is already entitled. Employee further acknowledges that Employee has been advised, as required by the ADEA, that: (a) Employee&#8217;s waiver and release do not apply to any rights or claims that may arise after the date Employee signs this Release Agreement; (b) Employee should consult with an attorney prior to signing this Release Agreement (although Employee may choose voluntarily not to do so); (c) Employee has twenty-one (21) days to consider this Release Agreement (although Employee may choose voluntarily to sign it earlier); (d) Employee has seven (7) days following the date Employee signs this Release Agreement to revoke the Release Agreement (by providing written notice of Employee&#8217;s revocation to the Legal Department at XOMA); and (e) this Release Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after the date that this Release Agreement is signed by Employee provided that Employee does not revoke it (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Unknown Claims</u>. In giving the releases set forth in this Release Agreement, which include claims which may be unknown to Employee at present, Employee acknowledges that Employee has read and understands Section 1542 of the California Civil Code which reads as follows:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 72pt 12pt 72pt;"><b style="font-weight:bold;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Employee hereby expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to Employee&#8217;s release of claims herein, including but not limited to the release of unknown and unsuspected claims.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>. Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;Excluded Claims&#8221;): (a) any rights or claims for indemnification Employee may have pursuant to any written indemnification agreement with XOMA to which Employee is a party or under applicable law; (b) any rights which cannot be waived as a matter of law; (c) any rights Employee has to file or pursue a claim for workers&#8217; compensation or unemployment insurance; and (d) any claims for breach of the Employment Agreement or this Release Agreement. <b style="font-weight:bold;">In addition, nothing in this Release Agreement prevents Employee from filing, cooperating with or participating in any proceedings before the Equal Employment </b></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing or any analogous federal or state government agency, except that Employee acknowledges and agrees that Employee hereby waives Employee&#8217;s right to any monetary benefits in connection with any such claim, charge or proceeding.</b> Employee represents and warrants that, other than the Excluded Claims, Employee is not aware of any claims Employee has or might have against any of the Released Parties that are not included in the Released Claims.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</u>. Employee represents that Employee has been paid all compensation owed and for all time worked; Employee has received all the leave and leave benefits and protections for which Employee is eligible pursuant to the federal Family and Medical Leave Act, the California Family Rights Act, any applicable law or XOMA policy; and Employee has not suffered any on the job injury for which Employee has not already filed a workers&#8217; compensation claim.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nondisparagement</u>. Employee agrees not to disparage XOMA, and XOMA&#8217;s officers, directors, employees, shareholder, members and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation. Similarly, Employee understands that XOMA agrees to direct its directors and officers not to disparage Employee in any manner likely to be harmful to Employee&#8217;s business reputation or personal reputation. Nothing in this provision, however, shall prevent either Employee or XOMA from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Release Agreement is intended to prohibit or restrain Employee in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Voluntary Adverse Action</u>. Employee agrees that Employee will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against XOMA, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall Employee induce or encourage any person or entity to bring any such claims; <i style="font-style:italic;">provided, however,</i> that Employee must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of XOMA Property; Compliance with Proprietary Information Agreement</u>. Employee represents that Employee has complied fully with Section 7(g) of the Employment Agreement and the provisions of Employee&#8217;s Employee Confidential Information and Invention Assignment Agreement with XOMA (the &#8220;Confidentiality Agreement&#8221;), and further agrees to continue to abide by Employee&#8217;s continuing obligations under the Confidentiality Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Representations</u>. Employee represents that Employee has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">provisions of this Release Agreement. Neither Party has relied upon any representations or statements made by the other Party which are not specifically set forth in this Release Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Release Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Release Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Release Agreement, together with the Employment Agreement, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter. This Release Agreement may only be modified or amended in a writing signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Release Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Release Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ W. Denman Van Ness</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 22pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">W. Denman Van Ness<font style="background:#ffff00;"> </font><br>Lead Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Owen Hughes</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Owen Hughes</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>xoma-20221231xex10d16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:46 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><a name="_mps009951520000000000000004054000000000"></a><a name="_mpv339064660000010000000000000000000000"></a><font style="font-weight:bold;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk121483250"></a>Exhibit 10.16</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">OFFICER EMPLOYMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">This Officer Employment Agreement (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) between Bradley Sitko (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee</u>&#8221;) and XOMA Corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">the Company</u>&#8221;) (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>&#8221;) is effective as of January 3, 2023 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement Effective Date</u>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</u>. Employee&#8217;s employment with XOMA in the position of Chief Investment Officer shall commence on the Agreement Effective Date. Employee&#8217;s employment with XOMA will be governed by the terms set forth in this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Position and Responsibilities</u>. Employee shall devote reasonable best efforts and substantially all of Employee&#8217;s working time and attention to employment with XOMA. Employee shall perform those duties and responsibilities associated with Chief Investment Officer and as may be directed by the Executive Chairman (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chairman</u>&#8221;), to whom Employee will report. While employed by XOMA, Employee may not accept consulting or other business or non-profit opportunities without first obtaining written approval from the Chairman. In addition, while employed by XOMA, except on behalf of XOMA, Employee will not directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venturer, associate, representative or consultant of any other person, corporation, firm, partnership or other entity whatsoever known by Employee to compete with XOMA (or that is planning or preparing to compete with XOMA), anywhere in the world, in any line of business engaged in (or planned to be engaged in) by XOMA; <i style="font-style:italic;">provided, however,</i> that Employee may purchase or otherwise acquire up to (but not more than) five percent (5%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. Notwithstanding the foregoing, Employee is permitted to provide consulting services to his former employer during the first thirty (30) days of Employee&#8217;s employment with the Company provided such consulting services are limited to ten (10) hours per week and do not otherwise interfere with Employee&#8217;s legal and contractual obligations to the Company in any material respect. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term of Employment</u>. The term of Employee&#8217;s employment with XOMA shall be the period from the Agreement Effective Date until Employee&#8217;s employment is terminated pursuant to Section 7. Consistent with XOMA policy, Employee&#8217;s employment relationship with XOMA is at-will. Accordingly, Employee may resign Employee&#8217;s employment with XOMA at any time and for any reason whatsoever simply by notifying XOMA; and XOMA may terminate Employee&#8217;s employment at any time, with or without Cause (as defined in Section 7(d)) or advance notice, subject to the provisions of Sections 7, 8 and 9.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation and Reimbursement of Expenses</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u>. Employee will receive for services to be rendered hereunder a base salary paid at the rate of $500,000 per year, less applicable payroll deductions and withholdings (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Salary</u>&#8221;), paid on XOMA&#8217;s ordinary payroll cycle. In addition, Employee shall be eligible to participate in XOMA&#8217;s Corporate Achievement Goals plan (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAGs</u>&#8221;), as it may be amended from time to time in accordance with its terms, with an initial target rate of 50% of Base Salary (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Target Bonus</u>&#8221;), which can be adjusted from time to time by the Board of Directors (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Board</u>&#8221;). &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps586101060000000000000004054000000000"></a>-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Awards</u>. &#160;On the Agreement Effective Date, the Company will grant Employee a non-qualified option to purchase 300,000 shares of the Company&#8217;s common stock with an exercise price equal to the fair market value of the common stock (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FMV Option</u>&#8221;). &#160;The FMV Option shall vest over a four-year period, with one-quarter of the shares vesting on the one-year anniversary of the Agreement Effective Date, and then equal monthly installments thereafter (subject to Employee&#8217;s continuous service). &#160;On the Agreement Effective Date, the Company will also grant Employee a non-qualified option to purchase 250,000 shares of the Company&#8217;s common stock with an exercise price of $30 per share (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Option</u>&#8221;). &#160;The Additional Option shall vest over a four-year period, with one-quarter of the shares vesting on the one-year anniversary of the Agreement Effective Date, and then equal monthly installments thereafter (subject to Employee&#8217;s continuous service). &#160;The FMV Option and the Additional Option shall be issued outside of, but subject in all respects to the terms and conditions of the Company&#8217;s Equity Incentive Plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;), and shall be governed in all respects by the terms of the Plan as if granted thereunder, the grant notice and the option agreement. The Company intends for the FMV Option and the Additional Option each to be a material inducement to Employee entering into employment with the Company within the meaning of Listing Rule 5635(c)(4) of The Nasdaq Stock Market LLC. &#160;Employee may be eligible for additional annual equity grants at the discretion of the Board. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signing Bonus</u>. &#160;The Company will pay Employee a signing bonus equal to $110,000. &#160;This amount will be paid within thirty (30) days after the Agreement Effective Date and will be subject to standard deductions and withholdings. &#160;If Employee resigns without Good Reason (as defined herein) or if Employee is terminated for Cause (as defined herein), in either case, within one (1) year after the Agreement Effective Date, then Employee will be required to repay the signing bonus to the Company, based on the gross amount, but prorated on a daily basis for the time employed, to be paid to the Company within sixty (60) days after Employee&#8217;s termination date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reimbursement of Expenses</u>. XOMA shall reimburse Employee for all reasonable travel and other expenses incurred in performing Employee&#8217;s obligations under this Agreement in a manner consistent with XOMA policies.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Participation in Benefit Plans</u>. The payments provided in Section 4 are in addition to benefits Employee is entitled to under any employee benefit plan of XOMA for which Employee is or becomes eligible. The Employee shall be entitled to participate in any benefit plan for which key executives of the Company are eligible. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Proprietary Information Agreement and XOMA Policies</u>. As a condition of employment with XOMA, Employee must sign and comply with the Employee Confidential Information and Inventions Assignment Agreement attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality Agreement</u>&#8221;), which prohibits unauthorized use or disclosure of XOMA proprietary information, among other obligations. In addition, Employee is required to abide by XOMA&#8217;s policies and procedures (including but not limited to XOMA&#8217;s Employee Handbook), as adopted or modified from time to time within XOMA&#8217;s discretion; <i style="font-style:italic;">provided, however,</i> that in the event the terms of this Agreement differ from or are in conflict with XOMA&#8217;s general employment policies or practices, this Agreement shall control.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Employment</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by Employee</u>. As provided in Section 3, Employee may resign Employee&#8217;s employment with XOMA at any time and for any reason. Employee will not be entitled to any of the severance benefits set forth in Section 8 or 9 if Employee resigns, unless such resignation is for Good Reason. For purposes of this Agreement, Employee shall have &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Reason</u>&#8221; for resignation from employment with XOMA if any of the following actions are taken by XOMA without Employee&#8217;s prior express written consent: <a name="_Hlk122431114"></a>(i) a reduction in Employee&#8217;s Target Bonus unless consistent to target bonus reductions for all other member of XOMA&#8217;s senior management team, (ii) a reduction in Employee&#8217;s Base Salary or Target Bonus, in each case, by more than 10%; (iii) a material reduction in Employee&#8217;s title or duties (including responsibilities and/or authorities); (iv) a required relocation of Executive&#8217;s principal place of employment to a location outside of the New York City metropolitan area; or (v) any other material breach of this Agreement. &#160;In order for Employee to resign for Good Reason, each of the following requirements must be met: (A) Employee must provide written notice to the Board within ninety (90) days after the occurrence of the event giving rise to Good Reason setting forth the basis for Employee&#8217;s resignation, (B) Employee must allow XOMA at least thirty (30) days from receipt of such written notice to cure such event, (C) such event is not reasonably cured by XOMA within such thirty (30) day period (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cure Period</u>&#8221;), and (D) Employee must resign from all positions Employee then holds with XOMA not later than thirty (30) days after the expiration of the Cure Period. If Employee resigns for Good Reason, Employee shall be entitled to the severance benefits set forth in Section&#160;8 or 9, as applicable. <i style="font-style:italic;"> </i></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by XOMA Without Cause</u>. Employee may be terminated by XOMA without Cause, but in such case, Employee shall be entitled to the severance benefits set forth in Section 8 or 9, as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Upon Death or Permanent Disability</u>. Except as required by law and as provided in Section 8, all benefits and other rights of Employee under this Agreement shall be terminated by Employee&#8217;s death or Permanent Disability. For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permanent Disability</u>&#8221; is defined as Employee being incapable of performing duties to XOMA by reason of any medically determined physical or mental impairment that can be expected to last for a period of more than six (6) consecutive months from the first date of Employee&#8217;s absence due to the disability. XOMA will give Employee at least four (4) weeks written notice of termination due to such disability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination by XOMA for Cause</u>. XOMA may terminate Employee&#8217;s employment for Cause, in which case, Employee will not be entitled to any severance benefits under Section 8 or 9. &#160;For purposes of this Agreement, XOMA will have Cause to terminate Employee&#8217;s employment as the result of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>willful material fraud or material dishonesty in connection with Employee&#8217;s performance under this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>material breach of this Agreement or of XOMA&#8217;s Code of Ethics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>misappropriation of a material business opportunity of XOMA ;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>misappropriation of any XOMA funds or property ; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>conviction of, or the entering of a plea of guilty or no contest with respect to, a felony.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice and Opportunity to Cure</u>. It shall be a condition precedent to XOMA&#8217;s right to terminate Employee&#8217;s employment for the reasons set forth in Section 7(d)(ii) of this Agreement that (i) XOMA shall first have given Employee written notice stating with specificity the reason for the termination (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Breach</u>&#8221;) and (ii) if such Breach is capable of cure or remedy, Employee will have a period of thirty (30 days after the notice is given to remedy the Breach. <i style="font-style:italic;"> </i></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resignation from any XOMA Boards</u>. Upon termination of employment for any reason, and as a precondition to Employee&#8217;s receipt of the severance benefits set forth in Section 8 or 9, Employee shall resign from any and all positions Employee holds with any board of any XOMA entity, including any XOMA subsidiaries, to be effective no later than the date of Employee&#8217;s employment termination (or such other date requested or permitted by the Chairman).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of XOMA Property</u>. Upon termination of employment for any reason, and as a precondition to Employee&#8217;s receipt of the severance benefits set forth in Section 8 or 9, Employee shall immediately return to XOMA all documents, telephones, computers, keys, credit cards, other property and records of XOMA, and shall return or destroy all copies, within Employee&#8217;s possession, custody or control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims</u>. As a condition of entering into this Agreement and receiving the severance benefits set forth in Section 8 or 9, Employee shall execute and deliver to XOMA a release of claims in favor of XOMA substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release Agreement</u>&#8221;) within the timeframe set forth in the Release Agreement, but not later than forty-five (45) days following Employee&#8217;s employment termination date, and allow the Release Agreement to become effective according to its terms (by not invoking any legal right to revoke it) within any applicable time period set forth in the Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Benefits Outside of Change of Control Protection Period</u>. Subject to Sections 7(f), 7(g) and 7(h) and Employee&#8217;s continued compliance with the terms of this Agreement, the following provisions of this Section 8 shall apply upon the occurrence of an event of termination of Employee&#8217;s employment with XOMA as provided in Section 7(a) for Good Reason outside of a Change of Control Protection Period, Section 7(b) for termination without Cause outside of a Change of Control Protection Period, or Section 7(c) due to death or Permanent Disability at any time (whether inside or outside of a Change of Control Protection Period), in each case, provided that the termination of Employee&#8217;s employment with XOMA constitutes a &#8220;separation from service&#8221; as provided in Treas. Reg. Section 1.409A-1(h).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Severance</u>. XOMA shall pay Employee, or in the event of Employee&#8217;s death or Permanent Disability, Employee&#8217;s beneficiaries, as severance pay: (i) one (1x) times Employee&#8217;s Base Salary in effect as of Employee&#8217;s employment termination date <a name="_Hlk121740495"></a>(disregarding any reduction in the Employee&#8217;s Base Salary that would give rise to Employee&#8217;s </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">right to resign with Good Reason); and (ii) a prorated portion of Employee&#8217;s Target Bonus for the fiscal year in which the termination occurs, calculated by multiplying the annual Target Bonus by a fraction, the numerator of which shall be the number of months (including a portion of a month) of the fiscal year during which Employee was employed prior to the occurrence of the termination, and the denominator of which shall be twelve (12). In addition, if Employee is terminated without Cause after the completion of any fiscal year for which Employee was eligible to receive a bonus payment under CAGs, but before such CAGs payment is made, Employee shall be entitled to receive a bonus payment for such year consistent with Employee&#8217;s performance against CAGs objectives and the good faith determination by the Board that CAGs bonuses are payable for such year. The severance payment described in Section 8(a)(i) shall be paid in monthly installments over twelve (12) months, with the first two (2) of such monthly installments being paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date, and the remaining installments being paid monthly thereafter until fully paid. The severance payments described in Section 8(a)(ii) shall be paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group Health Coverage and Certain Other Benefits</u>. For a period of twelve (12) months following an event of termination under Section 7(a) for Good Reason or under Section 7(b) without Cause (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Premium Period</u>&#8221;), XOMA shall pay the full cost of COBRA continuation coverage (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA Premiums</u>&#8221;) of Employee and Employee&#8217;s spouse and eligible dependents (collectively &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Covered Persons</u>&#8221;), <i style="font-style:italic;">provided, however,</i> that (A)&#160;each Covered Person constitutes a qualified beneficiary, as defined in Section 4980B(g)(1) of the Internal Revenue Code of 1986, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221;); and (B)&#160;Employee elects continuation coverage within the prescribed time period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COBRA</u>&#8221;). The payments by XOMA for such group health coverage shall cease prior to the expiration of the twelve (12) month period in this Section 8(b), upon commencement of substantially similar coverage for all Covered Persons as a result of the employment of Employee by another employer, or when Employee ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. Notwithstanding the foregoing, if XOMA determines, in its sole discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Covered Persons elect or are eligible for COBRA coverage, XOMA instead shall pay to Employee, on the first day of each calendar month following Employee&#8217;s employment termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including the amount of COBRA premiums for all Covered Persons and an additional amount to pay for the taxes on all such amounts), less required payroll deductions and withholdings (such amount, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Special Cash Payment</u>&#8221;), for the remainder of the COBRA Premium Period. Employee may, but is not obligated to, use such Special Cash Payments toward the cost of COBRA premiums.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Program</u>. Upon the occurrence of an event of termination under Section 7(a) for Good Reason only or under Section 7(b) without Cause, Employee will be entitled to participate in a twelve (12)-month executive outplacement program provided by an executive coaching or outplacement service, at XOMA&#8217;s expense not to exceed $15,000 and paid directly to the coach or outplacement service (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Services</u>&#8221;). The Outplacement Services will commence after the Effective Date of the Release Agreement (as defined therein).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance Benefits During a Change of Control Protection Period</u>. Subject to Sections 7(f), 7(g) and 7(h) and Employee&#8217;s continued compliance with the terms of this Agreement, the following provisions of this Section 9 shall apply upon the occurrence of an event of termination of Employee&#8217;s employment with XOMA as provided in Section 7(a) for Good Reason during a Change of Control Protection Period or Section 7(b) for termination without Cause during a Change of Control Protection Period, in each case, provided that the termination of Employee&#8217;s employment with XOMA constitutes a &#8220;separation from service&#8221; as provided in Treas. Reg. Section 1.409A-1(h).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash Severance</u>. &#160;Employee shall be entitled to receive a severance payment of (i) one and a half (1.5) times Employee&#8217;s Base Salary in effect immediately prior to termination of employment (disregarding any reduction in the Employee&#8217;s Base Salary that would give rise to Employee&#8217;s right to resign with Good Reason), (ii) one and a half (1.5) times Employee&#8217;s Target Bonus in effect for the fiscal year in which the termination occurs; <a name="_Hlk121867246"></a>and (iii) any earned but unpaid bonus for any prior performance period. &#160;The severance payment shall be paid in a lump sum sixty (60) days after Employee&#8217;s employment termination date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Group Health Coverage and Certain Other Benefits</u>. For a period of eighteen (18) months, XOMA shall pay the full cost of the COBRA Premiums of the Covered Persons, subject to the same terms and conditions set forth in Section 8(b).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outplacement Program</u>. Employee will be entitled to the Outplacement Services for twelve (12) months, subject to the same terms and conditions set forth in Section 8(c).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equity Acceleration and Extended Option Exercise Period</u>. &#160;The vesting of all time-based equity awards granted to Employee by XOMA (including any such options granted or assumed by the surviving or continuing entity of the Change of Control) and still outstanding (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time-Based Awards</u>&#8221;) shall automatically be accelerated so that all the Time-Based Awards may be exercised (if applicable) immediately upon Employee&#8217;s termination date for any or all of the subject shares, and the post-termination exercise period of each Time-Based Award (if applicable) shall be extended to the earlier of sixty (60) months after the date of such termination and the remainder of the maximum term of such Time-Based Award); and (B) with respect to any performance-based stock awards (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance Awards</u>&#8221;) at the time of such termination, the Board (or its Compensation Committee) will assess in good faith the level of achievement of any performance goals for such Performance Awards and will determine in its sole discretion the degree of achievement of the performance goal(s) underlying such Performance Awards and accelerate a pro rata portion of such Performance Awards based on (x) the number of days that have elapsed during the applicable performance period divided by the total number of days in the performance period and (y) the deemed level of achievement of such performance goal(s). The Time-Based Awards and Performance Awards shall continue to be subject to all other terms and conditions of the applicable equity incentive or share option plans and the applicable award agreements between the Parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</u>&#8221; means the occurrence of any of the following events:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i) <font style="display:inline-block;width:21.67pt;"></font>a merger, amalgamation or acquisition in which XOMA is not the surviving or continuing entity, except for a transaction the principal purpose of which is to change the jurisdiction of XOMA&#8217;s organization;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii) <font style="display:inline-block;width:18.34pt;"></font>the sale, transfer or other disposition of all or substantially all of the assets of XOMA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii) <font style="display:inline-block;width:15.01pt;"></font>any other reorganization or business combination in which fifty percent (50%) or more of XOMA&#8217;s outstanding voting securities are transferred to different holders in a single or series of related transactions;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv) <font style="display:inline-block;width:15.67pt;"></font>approval by the shareholders of XOMA of a plan of complete liquidation of XOMA;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(v) <font style="display:inline-block;width:19.01pt;"></font>any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becoming the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of XOMA representing more than fifty percent (50%) of the total voting power represented by XOMA&#8217;s then outstanding voting securities; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(vi) <font style="display:inline-block;width:15.67pt;"></font>a change in the composition of the Board, as a result of which fewer than a majority of directors are Incumbent Directors. &#8220;Incumbent Directors&#8221; shall mean directors who (A) are directors of XOMA as of the date hereof, (B) are elected, or nominated for election, to the Board with the affirmative votes of the directors of XOMA as of the date hereof, or (C) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of those directors whose election or nomination was not in connection with any transaction described in subsections (i) through (v) or in connection with an actual or threatened proxy contest relating to the election of directors of XOMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(f)</font></font>For purposes of this Agreement, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control Protection Period</u>&#8221; means the period commencing two (2) months prior to the execution of the definitive agreement for a Change of Control and terminating twelve (12) months following the closing of a Change of Control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(g)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(i)<font style="display:inline-block;width:24.67pt;"></font>In the event that the benefits provided for in this Section 9 would constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excise Tax</u>&#8221;)(a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">280G Payment</u>&#8221;), then any such 280G Payment (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment</u>&#8221;) shall be equal to the Reduced Amount. The &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduced Amount</u>&#8221; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Employee&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reduction Method</u>&#8221;) that results in the greatest economic benefit for Employee. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pro Rata Reduction Method</u>&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(ii)<font style="display:inline-block;width:21.34pt;"></font>Notwithstanding any provision to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Employee as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iii)<font style="display:inline-block;width:18pt;"></font>Unless Employee and XOMA agree on an alternative accounting firm, the accountants shall perform the foregoing calculations. &#160;If the accountants are serving as accountant or auditor for the individual, entity or group effecting the Change of Control transaction, XOMA shall appoint a nationally recognized accounting firm to make the determinations required by this Section. &#160;For purposes of making the calculations required by this Section, the accountants may make reasonable assumptions and approximations and may rely on interpretations concerning the application of the Code for which there is a &#8220;substantial authority&#8221; tax reporting position. The Parties shall furnish such information and documents as the accountants may reasonably request in order to make a determination under this Section. &#160;XOMA shall bear all reasonable costs the accountants incur in connection with calculations contemplated by this Section. &#160;XOMA shall use commercially reasonable efforts to cause the accountants to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Employee and XOMA within fifteen (15) calendar days after the date on which Employee&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Employee or XOMA) or such other time as requested by Employee or XOMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;">(iv)<font style="display:inline-block;width:18.67pt;"></font>If Employee receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 9(g)(i) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Employee agrees to promptly return to XOMA a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 9(g)(i)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y), Employee shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Agreement</u>. This Agreement shall be binding upon, and inure to the benefit of, the Parties and their respective permitted successors and assigns.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-8-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Section 409A of the Code</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>It is intended that this Agreement will comply with Section 409A of the Code and its regulations and guidelines (collectively, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A</u>&#8221;), to the extent the Agreement is subject to Section 409A, and the Agreement shall be interpreted on a basis consistent with such intent. If an amendment of the Agreement is necessary in order for it to comply with Section 409A, the Parties will negotiate in good faith to amend the Agreement in a manner that preserves the original intent of the Parties to the extent reasonably possible. No action or failure to act under this Section 11 shall subject XOMA to any claim, liability, or expense, and XOMA shall not have any obligation to indemnify or otherwise protect Employee from the obligation to pay any taxes, interest or penalties under Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>With respect to any reimbursement or in-kind benefit arrangements of XOMA and its subsidiaries that constitute deferred compensation for purposes of Section 409A, except as otherwise permitted by Section 409A, the following conditions shall be applicable: (A) the amount eligible for reimbursement, or in-kind benefits provided, under any such arrangement in one calendar year may not affect the amount eligible for reimbursement, or in-kind benefits to be provided, under such arrangement in any other calendar year (except that the benefit plans may impose a limit on the amount that may be reimbursed or paid), (B) any reimbursement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (C) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. Whenever payments under this Agreement are to be made in installments, each such installment shall be deemed to be a separate payment for purposes of Section 409A.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>If Employee is deemed on the date of &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)) to be a &#8220;specified employee&#8221; (under Treas. Reg. Section 1.409A-1(i)), then with regard to any payment or benefit that is considered deferred compensation under Section 409A of the Code payable on account of a &#8220;separation from service&#8221; that is required to be delayed under Section 409A(a)(2)(B) of the Code (after taking into account any applicable exceptions to such requirement), such payment or benefit shall be made or provided on the earlier of (i) the expiration of the six (6)-month period measured from the date of Employee&#8217;s &#8220;separation from service,&#8221; or (ii) the date of Employee&#8217;s death (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay Period</u>&#8221;). Upon expiration of the Delay Period, all payments and benefits delayed under this Section 11(c) shall be paid or reimbursed to Employee in a lump sum and any remaining payments and benefits due under this Agreement shall be paid or provided on the payment dates specified. For purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment, references to Employee&#8217;s &#8220;termination of employment&#8221; (and corollary terms) shall be construed to refer to Employee&#8217;s &#8220;separation from service&#8221; (under Treas. Reg. Section 1.409A-1(h)).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given upon actual confirmed receipt by mail, courier or email. In the case of Employee, mailed notices shall be addressed to Employee at the home or personal email address that Employee most recently communicated to XOMA in writing. In the case of XOMA, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-9-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA&#8217;s Successors</u>. Any successor to XOMA (direct or indirect, by purchase, lease, merger, amalgamation, consolidation, liquidation or otherwise) to all or substantially all of XOMA&#8217;s business or assets shall assume XOMA&#8217;s obligations under this Agreement and agree expressly to perform XOMA&#8217;s obligations under this Agreement in the same manner and to the same extent as XOMA would be required to perform such obligations in the absence of a succession. For all purposes under this Agreement, the term &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">XOMA</u>&#8221; shall include any successor to XOMA&#8217;s business or assets which executes and delivers the assumption agreement described in this Section 13(a) or which becomes bound by the terms of this Agreement by operation of law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employee&#8217;s Successors</u>. Without the written consent of XOMA, Employee shall not assign or transfer this Agreement or any right or obligation under this Agreement to any other person or entity. However, except as otherwise set forth herein, the terms of this Agreement and all rights of Employee shall inure to the benefit of, and be enforceable by, Employee&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment of Agreement</u>. Changes in Employee&#8217;s employment terms, other than those changes expressly reserved to XOMA&#8217;s or the Board&#8217;s discretion in this Agreement, require a written modification approved by XOMA and signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. Any party&#8217;s failure to enforce any provision or provisions of the Agreement will not in any way be construed as a waiver of any such provision or provisions, nor prevent any party from thereafter enforcing each and every other provision of the Agreement. The rights granted to the Parties herein are cumulative and will not constitute a waiver of any party&#8217;s right to assert all other legal remedies available to it under the circumstances.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">16.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">17.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">19.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-10-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">20.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration</u>. &#160;To ensure the timely and economical resolution of disputes that may arise between Employee and the Company, both Employee and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, Employee will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to: the negotiation, execution, interpretation, performance, breach or enforcement of this Agreement; or Employee&#8217;s employment with the Company (including but not limited to all statutory claims); or the termination of Employee&#8217;s employment with the Company (including but not limited to all statutory claims). &#160;BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH EMPLOYEE AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN ADMINISTRATIVE PROCEEDING. &#160;The Arbitrator will have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition. &#160;All claims, disputes, or causes of action under this section, whether by Employee or the Company, must be brought solely in an individual capacity, and will not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. &#160;The Arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. &#160;To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class will proceed in a court of law rather than by arbitration. &#160;Any arbitration proceeding under this Arbitration section will be presided over by a single arbitrator and conducted by JAMS, Inc. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JAMS</u>&#8221;) in San Francisco, CA under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at &#160;http://www.jamsadr.com/rules-employment-arbitration/). &#160;Employee and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense. &#160;The Arbitrator will: (a) have the authority to compel adequate discovery for the resolution of the dispute; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award; and (c) be authorized to award any or all remedies that Employee or the Company would be entitled to seek in a court of law. &#160;The Company will pay all JAMS arbitration fees in excess of the amount of court fees that would be required of Employee if the dispute were decided in a court of law. &#160;This section will not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>&#8221;). &#160;In the event Employee brings multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. &#160;Nothing in this section is intended to prevent either Employee or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-11-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">21.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>. &#160;Employee shall execute the Company&#8217;s standard form of indemnification agreement provided herewith. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">22.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Complete Agreement</u>. This Agreement, together with Employee&#8217;s Confidentiality Agreement and the other agreements referenced herein, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter, and supersedes and replaces any other agreements or promises made to Employee by anyone, whether oral or written.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">[signature page to follow]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-12-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_Hlk121483251"></a><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ W. Denman Van Ness</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 22pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">W. Denman Van Ness<font style="background:#ffff00;"> </font><br>Lead Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Bradley Sitko</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Bradley Sitko</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><a name="_mps490873670000000000000004054000000000"></a>-13-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EMPLOYEE CONFIDENTIAL INFORMATION AND <br>INVENTIONS ASSIGNMENT AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM RELEASE OF CLAIMS AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Release of Claims Agreement (&#8220;Release Agreement&#8221;) is entered into between XOMA Corporation (&#8220;XOMA&#8221;) and Bradley Sitko (&#8220;Employee&#8221;). XOMA and Employee (collectively, the &#8220;Parties&#8221;) are parties to an Officer Employment Agreement (&#8220;Employment Agreement&#8221;) and agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination</u>. Employee&#8217;s employment with XOMA terminated on _______, 20__.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Claims</u>. In exchange for the compensation, benefits and other consideration to be provided to Employee under the Employment Agreement that Employee is not otherwise entitled to receive, Employee hereby generally and completely releases XOMA and XOMA (US) LLC, and their past and present officers, agents, directors, employees, investors, shareholders, administrators, partners, attorneys, agents, insurers, affiliates, divisions, subsidiaries, parents, predecessor and successor corporations, and assigns (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Parties</u>&#8221;), from, and agrees not to sue or otherwise institute any legal or administrative proceedings concerning, any and all claims, duties, liabilities, obligations and causes of action, both known and unknown, that arise out of or are in any way related to events, acts, conduct or omissions occurring prior to or on the date Employee signs this Release Agreement (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Claims</u>&#8221;).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Released Claims include but are not limited to:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>all claims arising out of or in any way related to Employee&#8217;s employment with XOMA or the termination of that employment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>all claims related to compensation or benefits from XOMA, including salary, bonuses, commissions, vacation, paid time off, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity or profits interests in XOMA (including but not limited to any right to purchase, or actual purchase, of shares of stock of XOMA);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>all claims for breach of contract, wrongful termination and breach of the implied covenant of good faith and fair dealing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>all tort claims, including claims for fraud, defamation, emotional distress and discharge in violation of public policy;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>all federal, state and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees or other claims arising under the Federal Civil Rights Act of 1964, the federal Civil Rights Act of 1991, the federal Age Discrimination in Employment Act of 1967 (the &#8220;ADEA&#8221;), the federal Americans with Disabilities Act of 1990, the federal Fair Labor Standards Act, the federal the Employee Retirement Income Security Act of 1974, the federal Worker Adjustment and Retraining Notification Act, the California Fair </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Employment and Housing Act and the California Labor Code, and all amendments to and regulations issued under each such statute;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>all claims for violation of the federal or any state constitution;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>all claims arising out of any other laws and regulations relating to employment or employment discrimination; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font>all claims for attorneys&#8217; fees and costs.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgment of Waiver of Claims under ADEA</u>. Employee acknowledges that Employee is knowingly and voluntarily waiving and releasing any rights Employee may have under the ADEA, and that the consideration given for the waiver and release in this Section 3 is in addition to anything of value to which Employee is already entitled. Employee further acknowledges that Employee has been advised, as required by the ADEA, that: (a) Employee&#8217;s waiver and release do not apply to any rights or claims that may arise after the date Employee signs this Release Agreement; (b) Employee should consult with an attorney prior to signing this Release Agreement (although Employee may choose voluntarily not to do so); (c) Employee has twenty-one (21) days to consider this Release Agreement (although Employee may choose voluntarily to sign it earlier); (d) Employee has seven (7) days following the date Employee signs this Release Agreement to revoke the Release Agreement (by providing written notice of Employee&#8217;s revocation to the Legal Department at XOMA); and (e) this Release Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth (8th) day after the date that this Release Agreement is signed by Employee provided that Employee does not revoke it (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Unknown Claims</u>. In giving the releases set forth in this Release Agreement, which include claims which may be unknown to Employee at present, Employee acknowledges that Employee has read and understands Section 1542 of the California Civil Code which reads as follows:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 72pt 12pt 72pt;"><b style="font-weight:bold;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Employee hereby expressly waives and relinquishes all rights and benefits under that section and any law or legal principle of similar effect in any jurisdiction with respect to Employee&#8217;s release of claims herein, including but not limited to the release of unknown and unsuspected claims.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Claims</u>. Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;Excluded Claims&#8221;): (a) any rights or claims for indemnification Employee may have pursuant to any written indemnification agreement with XOMA to which Employee is a party or under applicable law; (b) any rights which cannot be waived as a matter of law; (c) any rights Employee has to file or pursue a claim for workers&#8217; compensation or </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">unemployment insurance; and (d) any claims for breach of the Employment Agreement or this Release Agreement. <b style="font-weight:bold;">In addition, nothing in this Release Agreement prevents Employee from filing, cooperating with or participating in any proceedings before the Equal Employment Opportunity Commission, the Department of Labor, the California Department of Fair Employment and Housing or any analogous federal or state government agency, except that Employee acknowledges and agrees that Employee hereby waives Employee&#8217;s right to any monetary benefits in connection with any such claim, charge or proceeding.</b> Employee represents and warrants that, other than the Excluded Claims, Employee is not aware of any claims Employee has or might have against any of the Released Parties that are not included in the Released Claims.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations</u>. Employee represents that Employee has been paid all compensation owed and for all time worked; Employee has received all the leave and leave benefits and protections for which Employee is eligible pursuant to the federal Family and Medical Leave Act, the California Family Rights Act, any applicable law or XOMA policy; and Employee has not suffered any on the job injury for which Employee has not already filed a workers&#8217; compensation claim.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nondisparagement</u>. Employee agrees not to make any statement intending disparage XOMA, and XOMA&#8217;s officers, directors, employees, shareholder, members and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation. XOMA agrees that its directors and officers will not make any statements intending to disparage Employee in any manner likely to be harmful to Employee&#8217;s business reputation or personal reputation. Nothing in this provision, however, shall prevent either Employee or XOMA from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Release Agreement is intended to prohibit or restrain Employee in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Voluntary Adverse Action</u>. Employee agrees that Employee will not voluntarily provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other formal proceeding of any kind brought against XOMA, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall Employee induce or encourage any person or entity to bring any such claims; <i style="font-style:italic;">provided, however,</i> that Employee must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of XOMA Property; Compliance with Proprietary Information Agreement</u>. Employee represents that Employee has complied fully with Section 7(g) of the Employment Agreement and the provisions of Employee&#8217;s Employee Confidential Information and Invention Assignment Agreement with XOMA (the &#8220;Confidentiality Agreement&#8221;), and further agrees to continue to abide by Employee&#8217;s continuing obligations under the Confidentiality Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u>. The Parties shall each bear their own costs, expert fees, attorneys&#8217; fees and other fees incurred in connection with this Release Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Representations</u>. Employee represents that Employee has had the opportunity to consult with an attorney, and has carefully read and understands the scope and effect of the provisions of this Release Agreement. Neither Party has relied upon any representations or statements made by the other Party which are not specifically set forth in this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. In the event any provision of this Release Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any remaining part of such provision or any other provision of this Release Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the Parties insofar as possible under applicable law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Release Agreement, together with the Employment Agreement, forms the complete and exclusive embodiment of the entire agreement between the Parties with regard to this subject matter. This Release Agreement may only be modified or amended in a writing signed by Employee and a duly authorized officer of XOMA other than Employee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. This Release Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. Employee expressly consents to personal jurisdiction and venue in the state and federal courts for Alameda County, California for any lawsuit filed there against Employee by XOMA arising from or related to this Release Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Release Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and electronic signatures shall be equivalent to original signatures.</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">COMPANY:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">XOMA CORPORATION</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ W. Denman Van Ness</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 22pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">W. Denman Van Ness<font style="background:#ffff00;"> </font><br>Lead Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;">EMPLOYEE:</b></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Bradley Sitko</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Bradley Sitko</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.56
<SEQUENCE>7
<FILENAME>xoma-20221231xex10d56.htm
<DESCRIPTION>EX-10.56
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:49 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 30pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Execution Version</i></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-size:16pt;font-weight:bold;"><a name="a1031741"></a><a name="_Hlk119310978"></a></b>Exhibit 10.56</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="font-weight:normal;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">IP ACQUISITION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This <b style="font-weight:bold;">IP ACQUISITION AGREEMENT</b> (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;), dated as of November 21, 2022 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), is made by and between <b style="font-weight:bold;">OBSEVA, SA</b>, a Swiss corporation having its principal place of business at Chemin des Aulx, 12, 1228 Plan-les-Ouates, Geneva, Switzerland (&#8220;<b style="font-weight:bold;">Seller</b>&#8221;), and <b style="font-weight:bold;">XOMA (US) LLC</b>, a Delaware limited liability company having its principal place of business at 2200 Powell Street, Suite 310, Emeryville, CA 94608 (&#8220;<b style="font-weight:bold;">Buyer</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">WHEREAS, Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, all of Seller&#8217;s right, title, and interest in and to certain Acquired Patents (as defined below) and Acquired Know-How (as defined below) and obtain an assignment of the Licenses (as defined below), in each case, subject to the terms and conditions set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><a name="a542939"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Purchase </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">of Assets and Assumption of Licenses</u>. Subject to the terms and conditions set forth herein, Seller hereby irrevocably sells, assigns, transfers, and conveys to Buyer, and Buyer hereby accepts, all right, title, and interest in and to the following (collectively, the &#8220;<b style="font-weight:bold;">Acquired Rights</b>&#8221;):</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a1008872"></a>the patents and patent applications listed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u>, and all patents that issue from such patent applications, and all continuations, and continuations-in-part, and divisionals, and extensions, and substitutions, and reissues, and re-examinations, and renewals, of any of the foregoing, and rights to apply for new patents with respect to any of the foregoing (&#8220;<b style="font-weight:bold;">Patents</b>&#8221;), and any other patents or patent applications that claim a benefit or priority from any Patents, and inventions disclosed and claimed in any of the foregoing (collectively, the &#8220;<b style="font-weight:bold;">Acquired</b> <b style="font-weight:bold;">Patents</b>&#8221;);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Hlk118010184"></a><a name="a964954"></a>all Know-How as defined in the Organon License (as defined below) that is owned or has been developed by Obseva relating to the subject matter of the Organon License and/or the Merck Serono License (as defined below), including, but not limited to the general description of same set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2</u> (collectively, the &#8220;<b style="font-weight:bold;">Acquired Know-How</b>&#8221;); </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>those certain license agreements listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 3</u> (individually, the <b style="font-weight:bold;">&#8220;Organon License&#8221; </b>and the &#8220;<b style="font-weight:bold;">Merck Serono License&#8221;</b>) and all other licenses and similar contractual rights reasonably necessary for the use, exploitation, or commercialization of the Acquired Patents (collectively with the Organon License and Merck Serono License, the &#8220;<b style="font-weight:bold;">Licenses</b>&#8221;);</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:10pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="a1031746"></a>all milestones, royalties, fees, income, payments, and other proceeds now or hereafter due or payable to Seller under the Licenses; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="a685842"></a>all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for past, present, and future infringement, misappropriation, violation, breach, or default; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="a425445"></a>all other rights, privileges, and protections of any kind whatsoever of Seller accruing under any of the foregoing provided by any applicable law, treaty, or international convention throughout the world.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><a name="a916786"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assumption of Licenses/No Liabilities</u>. Subject to the terms and conditions set forth herein, Buyer hereby accepts Seller&#8217;s assignment of the Licenses, assumes all of Seller&#8217;s duties and obligations under the Licenses, and agrees to pay, perform, and discharge, as and when due, all of the liabilities and obligations of Seller under the Licenses accruing after the Effective Date, but only to the extent that such liabilities and obligations do not relate to any breach, default, or violation by Seller on or prior to the Effective Date (the &#8220;<b style="font-weight:bold;">Assumed Liabilities</b>&#8221;). Other than the Assumed Liabilities, Buyer neither assumes nor is otherwise liable for any obligations, claims, or liabilities of Seller of any kind, whether known or unknown, contingent, matured, or otherwise, whether currently existing or hereafter arising (collectively, &#8220;<b style="font-weight:bold;">Excluded Liabilities</b>&#8221;), including, for the avoidance of doubt, any obligations, claims, or liabilities arising from or in connection with any circumstances, causes of action, breach, violation, default, or failure to perform by or of Seller with respect to the Licenses on or prior to the Effective Date. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><a name="a00012"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a00013"></a>The aggregate purchase price for the Acquired Rights shall be FIFTEEN MILLION US Dollars (US$15,000,000) (the &#8220;<b style="font-weight:bold;">Purchase Price</b>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref117764129"></a><a name="a00014"></a>At Closing, Buyer shall pay, or cause to be paid, the Purchase Price, minus the Expense Reimbursement Amount in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u>, to Seller. Payment shall be made in US dollars by wire transfer of immediately available funds to Seller&#8217;s bank account identified in the wire transfer instructions previously provided to Buyer.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><a name="a00015"></a>If Buyer fails to make timely and proper payment of the Purchase Price, Seller may terminate this Agreement effective immediately on written notice to Buyer.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Earn-out Payments.</b> As additional consideration for Buyer&#8217;s purchase of the Acquired Rights, at such times as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(d)</u>, Buyer (or, at the direction</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:10pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">of Buyer, a designee of Buyer so long as Buyer remains an obligor thereof) shall pay to Seller during the term of the Licenses the following amounts (each, an &#8220;<b style="font-weight:bold;">Earn-Out Payment</b>&#8221; and collectively, the &#8220;<b style="font-weight:bold;">Earn-Out Payments</b>&#8221;):</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>[*] of all future Non-Sales Milestones payable to Buyer under section 7.2(a) of the Organon License; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>[*] of all future Sales-Based Milestones #[*] and #[*] payable to Buyer under section 7.3(a) of the Organon License (i.e., the Sales Milestones payable upon Net Sales in a given calendar year equaling or exceeding [*] and the Sales Milestones payable upon Net Sales in a given calendar year exceeding [*]).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(c)</u>, terms used and not otherwise defined herein shall have the meanings set forth in the Organon License. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Timing of Payment of Earn-out Payments.</b> Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(e)</u>, each Earn-out Payment that Buyer is required to make pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(c)</u> hereof shall be paid in full no later than [*] business days following the date upon which Buyer receives any of the payments specified therein pursuant to the Organon License. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Right of Set-off</b>. Buyer shall have the right to withhold and set off against any amount otherwise due to be paid pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u>, the amount of any Losses of a Buyer Indemnified Party that are determined by a final and enforceable decision to be due and payable to such Buyer Indemnified Party by Seller in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-weight:bold;">No Security.</b> The parties hereto understand and agree that (i) the contingent rights to receive any Earn-out Payment shall not be represented by any form of certificate or other instrument, are not transferable and do not constitute an equity or ownership interest in Buyer or any of its affiliates, (ii) Seller shall not have any rights as a securityholder of Buyer or any of its affiliates as a result of Seller&#8217;s contingent right to receive any Earn-out Payment hereunder, and (iii) no interest is payable with respect to any Earn-out Payment. <a name="_Ref54607579"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><b style="font-weight:bold;">Interest on Late Payments.</b> If Seller does not receive payment of any sum due to it on or before the due date, interest shall thereafter accrue on the sum due to Seller until the date of payment at the per annum rate of [*] over the then-current prime rate reported in The Wall Street Journal or the maximum rate allowable by applicable laws, whichever is lower, with such interest compounded quarterly. </div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">3</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Audit Rights.</b> Following the Effective Time and continuing thereafter through the term of the Licenses, Buyer shall maintain reasonably complete and accurate records in sufficient detail to permit Seller to confirm the receipt of the milestone events under the Organon License. Upon reasonable prior written notice, in any event no less than [*] days prior written notice, such records shall be available for examination during regular business hours and in a manner that does not interfere with Buyer&#8217;s business activities for a period of [*] years from the end of the calendar year to which they pertain, and not more often than once each calendar year, by an internationally-recognized independent certified public accountant selected by Seller and reasonably acceptable to Buyer, for the sole purpose of verifying the accuracy of any payments due under this Agreement. Once examined, such records shall no longer be subject to further examination. Any such auditor shall not disclose Buyer&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the amount of payments due under this Agreement. Any amounts shown to be owed but unpaid shall be paid within [*] days from the accountant&#8217;s report, plus interest (as set forth in Section 3(f)) from the original due date. Seller shall bear the full cost of such audit unless such audit discloses a failure by Buyer to pay any amount due for the audited period, in which case Buyer shall bear the full cost of such audit.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><a name="a00016"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing and Deliverables</u>. Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the &#8220;<b style="font-weight:bold;">Closing</b>&#8221;) will occur on the date hereof, immediately after the execution of this Agreement, and will take place by the exchange and release of pdfs of manually executed signature pages delivered by e-mail or other electronic means.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>At or prior to the Closing, Seller shall deliver to Buyer the following:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="a00017"></a>an assignment in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> (the &#8220;<b style="font-weight:bold;">Assignment</b>&#8221;) and duly executed by Seller, transferring all of Seller&#8217;s right, title, and interest in and to the Acquired Rights to Buyer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="a00018"></a>the complete prosecution files, including original granted patents, for all Acquired Patents in such form and medium as reasonably requested by Buyer, together with a list of local prosecution counsel contacts, and all such other documents, correspondence, and information as are reasonably requested by Buyer to register, prosecute to issuance, own, enforce, or otherwise use the Acquired Rights, including any maintenance fees due and deadlines for actions to be taken concerning prosecution and maintenance of all Acquired Patents in the [*] period following the date hereof; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>all documents and files (whether paper or stored electronically) in Seller&#8217;s possession that describe, contain or reflect (x) the Acquired Know-How</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">4</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">and (y) the Merck Serono Know-How as defined in the Merck Serono License, including writings, drawings, graphs, charts, photographs, sound recordings, images, and other data or data compilations experimental data and results, assay protocols, designs, formulas, experimental procedures and specifications; and </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>a consent in the form of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> and duly executed by JGB (Cayman) Port Ellen Ltd. with respect to the consummation of the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Substantially simultaneously with the Closing, and in any event, no later than by the end of the business day on which the Closing occurs, Seller shall deliver to Buyer evidence reasonably satisfactory to Buyer that Seller has paid each payee of an account payable the amount set out opposite its name in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 4</u>, unless otherwise noted therein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>At the Closing, Buyer shall pay to Seller the Purchase Price, minus the Expense Reimbursement Amount, in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><a name="a1031747"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances; Recordation; Covenants</u>.<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a1031748"></a>From and after the date hereof, each of the parties hereto shall, at their own expense, execute and deliver such additional documents, instruments, conveyances, and assurances, and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the documents to be delivered hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>No later than the end of the business day on which the Closing occurs, <a name="_Hlk119861236"></a>Seller shall pay each payee of an account payable the amount set out opposite its name in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 4</u> (unless otherwise noted therein) and provide confirmation of each such payoff, as applicable, to Buyer in a form acceptable to Buyer in its reasonable judgment.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="a1031749"></a>Without limiting the foregoing, and without limiting <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4(a)</u>, Seller shall execute and deliver to Buyer, such assignments and other documents, certificates, and instruments of conveyance in a form satisfactory to Buyer and suitable for filing with the United States Patent and Trademark Office (&#8220;<b style="font-weight:bold;">USPTO</b>&#8221;) and the registries and other recording governmental authorities in all applicable jurisdictions (including with respect to legalization, notarization, apostille, certification, and other authentication) as reasonably necessary to record and perfect the Assignment, and to vest in Buyer all right, title, and interest in and to the Acquired Rights in accordance with applicable law. As between Seller and Buyer, Buyer shall be responsible, at Buyer&#8217;s expense, for filing the Assignment, and other documents, certificates, and instruments of conveyance with the applicable governmental authorities; provided that, upon Buyer&#8217;s reasonable request,</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">5</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">Seller shall take such steps and actions, and provide such cooperation and assistance, at Seller&#8217;s expense, to Buyer and its successors, assigns, and legal representatives, including the execution and delivery of any affidavits, declarations, oaths, exhibits, assignments, powers of attorney, or other documents, as may be reasonably necessary to effect, evidence, or perfect the assignment of the Acquired Rights to Buyer, or any of Buyer&#8217;s successors or assigns.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Seller acknowledges that under the terms and conditions of the Licenses, Buyer, as the assignee thereof, is obligated to be a member of and participate in joint advisory committees, to have alliance managers, and to otherwise have skilled and knowledgeable representation with respect to its activities with its counterparties under and in furtherance of the Licenses (collectively, the &#8220;<b style="font-weight:bold;">Representative Activities</b>&#8221;). As such, to assist Buyer in the performance and assumption of the Representative Activities, Seller shall, at no charge to Buyer, make available to Buyer on a transition basis those of Seller&#8217;s personnel who have represented Seller in connection with the Representative Activities, and, if requested by Buyer, such personnel shall represent Buyer in connection with such Representative Activities for a period of not more than [*] following the Effective Date (as may be shortened or lengthened as mutually agreed upon by the parties). In all cases such personnel shall represent Buyer in good faith, to the best of their abilities, and in the same manner as such personnel represented Seller in connection with the Representative Activities prior to the Effective Date. Such personnel shall work in conjunction and consult with Buyer in connection with their participation in all Representative Activities and will strictly follow any feedback or instructions given by Buyer with respect to the Representative Activities. Such personnel shall not undertake any activities which would cause Buyer to breach any License. Buyer shall transition all Representative Activities to personnel of Buyer within [*] after the Effective Date. All information learned or observed by Seller&#8217;s personnel in the course of performing the Representative Activities is and will be deemed to be Buyer&#8217;s confidential information. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>Within [*] after the Effective Date, Seller shall, and shall cause its affiliates to, without additional compensation, disclose and make available to Buyer or its designee, in electronic or hard copy form, as Buyer may reasonably request, all Acquired Know-How and Merck Serono Know-How to the extent not already delivered at Closing pursuant to Section 4(a)(iii). In connection with such transfer, Seller, in a timely manner and at no charge to Buyer, shall assist Buyer in the use and understanding of the Acquired Know-How and Merck Serono Know-How, including providing technical assistance and making its technical personnel available to Buyer or its designee. Without prejudice to the generality of the foregoing, if visits of Seller&#8217;s representatives to Buyer&#8217;s or its designee&#8217;s facilities are reasonably requested by Buyer for purposes of transferring the Acquired Know-How and Merck Serono Know-How or for purposes of Buyer acquiring expertise on the practical application of such Acquired Know-How and Merck Serono Know-How or assisting on issues arising during the exploitation of any Acquired Know-How and Merck Serono Know-How, Seller shall send appropriate representatives to Buyer&#8217;s or its designee&#8217;s facilities [*]. Notwithstanding the foregoing, Seller&#8217;s</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">6</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">assistance shall not exceed [*] during such [*] period without Seller&#8217;s prior consent (which consent shall not be unreasonably withheld, conditioned or delayed).</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Hlk118738732"></a>Notwithstanding the transfer and assignment of the Acquired Rights from Seller to Buyer, Seller shall, [*], <a name="_Hlk118738768"></a>perform any and all [*] obligations applicable to or binding on Buyer under the Licenses, including, without limitation, [*] (as such terms are defined in the Organon License) in accordance with all of the terms and conditions set forth in the Organon License as if Seller continued to be a party thereto. Seller shall continue to fulfill all of its obligations under, and shall not breach, that certain [*] Agreement between Seller and Organon International GmbH (&#8220;<b style="font-weight:bold;">Organon</b>&#8221;) dated [*] (the &#8220;<b style="font-weight:bold;">Organon [*] Agreement</b>&#8221;). In connection with Seller&#8217;s obligation to [*], Buyer hereby grants to Seller a royalty-free, fully paid-up, worldwide, non-exclusive license, with the right to grant sublicenses, under the Acquired Rights solely for [*] pursuant to the Organon License [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><a name="a737477"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties of Seller</u>. Seller represents and warrants to Buyer that the statements contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u> are true and correct as of the date hereof, except as set forth in the correspondingly numbered sections of the Seller disclosure schedules, attached hereto. For purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6</u>, &#8220;Seller&#8217;s knowledge,&#8221; &#8220;knowledge of Seller,&#8221; and similar phrases shall mean the actual or constructive knowledge of any director or officer of Seller, after due inquiry.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a159489"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u><font style="text-decoration-line:none;">. Seller </font>is a corporation duly organized, validly existing and in good standing under the laws of Switzerland and has all necessary power and authority, and all licenses, permits, franchises, authorizations, consents and approvals, required to own its property and conduct its business as now conducted. Seller is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification or good standing is required by all applicable laws, rules, regulations and orders of any governmental authority applicable to Seller or any of its properties or assets.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority of Seller; Enforceability</u>. Seller has the full right, power, and authority to enter into this Agreement and perform its obligations hereunder. The execution, delivery, and performance of this Agreement by Seller has been duly authorized by all necessary organizational action of Seller and no other act or proceeding on the part of Seller is necessary to authorize the execution, delivery, or performance by Seller of this Agreement or any other agreement contemplated hereby or thereby. <a name="a1031754"></a>This Agreement has been duly executed and delivered by Seller and, assuming the due execution and delivery of this Agreement and the other agreements contemplated hereby by the other parties hereto and thereto, this Agreement constitutes, and the other agreements contemplated hereby upon execution and delivery by Seller will each constitute, a valid and binding obligation of Seller, enforceable against Seller in accordance with its and their terms.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">7</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts; Consents</u>. The execution, delivery, and performance by Seller of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (i) violate or conflict with the certificate of incorporation, by-laws, or other organizational documents of Seller; (ii) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule, or regulation; (iii) conflict with, or result in (with or without notice or lapse of time or both), any violation of or default under, or give rise to a right of termination, acceleration, or modification of any obligation or loss of any benefit under, any contract or other instrument to which this Agreement or any of the Acquired Rights are subject (including any License); or (iv) result in the creation or imposition of any encumbrances on the Acquired Rights. No consent, approval, waiver, or authorization is required to be obtained by Seller from its stockholders or any other person, group of persons, or entity (including any legal or governmental authority) in connection with the execution, delivery, and performance by Seller of this Agreement, or to enable Buyer to register, own, and use the Acquired Rights.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="a1031755"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership</u>. Except as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u>, Seller is the exclusive owner of all right, title, and interest in and to the Acquired Patents and Acquired Know-How, free and clear of all title defects or objections, liens, security interests, and other encumbrances. Seller is in full compliance with all legal requirements applicable to the Acquired Rights and Seller&#8217;s ownership and use thereof. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="a1031756"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patents and Applications</u>. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u> contains a correct, current, and complete list of all patents and patent applications related to the Licenses, including the Acquired Patents and the Merck Serono Patents (as defined in the Merck Serono License), specifying as to each, as applicable, the title, the record owner, the jurisdiction in which it has been issued or filed, the patent number or application serial or publication number, and the issue or application filing date. All required filings and fees related to the Acquired Patents listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1</u> have been timely filed with and paid to the USPTO and other relevant governmental authorities and authorized registrars, and all such patents and patent applications have at all times been and remain in good standing. Seller has provided Buyer with true and complete copies of all documents, certificates, office actions, responses, correspondence, and other filings and materials related to all such Acquired Patents. Seller has satisfied, and will continue to satisfy, all of its obligations to the inventors of the Acquired Patents (if any).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="a939225"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Know-How</u>. Seller has taken commercially reasonable steps to protect the rights of Seller in the Acquired Know-How and, except under confidentiality obligations contained in the Licenses, there has not been any disclosure by Seller of any Acquired Know-How to any third party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Validity and Enforceability</u>. No claim in any of the Acquired Patents has been deemed invalid by a court of competent jurisdiction, and the Acquired Patents are subsisting, and enforceable by Seller in all applicable jurisdictions. The Acquired Patents </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">8</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">are not subject to any pending or threatened (in writing) challenge or claim to their validity, subsistence, or enforceability. Without limiting the foregoing, neither the inventors of the Acquired Patents nor their counsel (i) intentionally failed to disclose any material, non-cumulative prior art references to the United States Patent and Trademark Office (the &#8220;<b style="font-weight:bold;">PTO</b>&#8221;) or any foreign patent offices requiring such disclosure in connection with the prosecution of any Acquired Patents, (ii) made any material misstatements or misrepresentations to the PTO or any foreign patent offices in connection with the prosecution of any of the Acquired Patents, or (iii) engaged in any act or omission inconsistent with the duty of candor to the PTO. The inventions and discoveries described in the Acquired Patents were made solely by the inventors named in the Acquired Patents, without misappropriation of any trade secrets, confidential information, or other rights of any person. The inventors named in the Acquired Patents that are employees or agents of Seller had no obligation to assign the inventions claimed by the Acquired Patents to any third party based on any form of employment and/or consulting agreement or relationship. Seller is not aware of any prior art that must be disclosed to any governmental office in which a given patent application has been filed (based on relevant disclosure obligations). Seller and those authorized by Seller to make, offer for sale, sell or import into the United States any article covered by the Acquired Patents have complied with the marking provisions of 35 U.S.C. section 287(a) with respect to the Acquired Patents.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="a494317"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Actions</u>. There are no actions (including any US Patent Trial and Appeal Board proceedings or European Opposition Proceedings) settled, pending, or threatened in writing (including in the form of offers to obtain a license): (i) alleging any infringement, misappropriation, or other violation of the intellectual property rights of any third party based on the use or exploitation of any Acquired Rights; (ii) challenging the validity, patentability, enforceability, issuance, inventorship or ownership of any Acquired Patents or Acquired Know-How or Seller&#8217;s rights with respect thereto; or (iii) by Seller alleging any infringement, misappropriation, or other violation by any third party of any Acquired Rights. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="a1031757"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licenses</u>. Seller has provided Buyer with true and complete copies of all Licenses (or in the case of any oral agreements, a complete and accurate written description thereof), including all modifications, amendments, and supplements thereto and waivers thereunder. Each License is valid, binding, in full force and effect, and enforceable between Seller and the other parties thereto, and neither Seller nor, to Seller&#8217;s knowledge, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under) any License, or has provided or received any written notice of breach of, default under, or any actual or intended termination of any License, nor to Seller&#8217;s knowledge, is there any basis to provide or receive any such notice. Seller has not received any written notice from Organon or any affiliate thereof that Organon intends to wind-down, limit, or suspend its commercialization activities under the Organon License or otherwise take any action that would adversely effect the sale of Licensed Products (as defined in the Organon License), nor is Seller aware of any basis </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">9</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">for such conduct or any such notice. Seller has not waived or relinquished any rights under any License. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accounts Payable</u>. There are no liabilities, debts, claims or obligations of any nature of Seller, whether known, unknown, accrued, absolute, direct or indirect, contingent, determined, determinable or otherwise, whether due or to become due, except (i) the convertible notes issued to JGB (Cayman) Port Ellen Ltd. and (ii) the accounts payable set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 4</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><a name="a778459"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Representations and Warranties of Buyer</u>. Buyer represents and warrants to Seller that the statements contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7</u> are true and correct as of the date hereof, except as set forth in the correspondingly numbered sections of the Buyer disclosure schedules, attached hereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a00035"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Organization</u><font style="text-decoration-line:none;">. </font>Purchaser is a limited liability company, duly organized, validly existing and in good standing under the laws of the State of Delaware, and has all powers and authority, and all licenses, permits, franchises, authorizations, consents and approvals of all applicable governmental authorities, required to own its property and conduct its business as now conducted.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority of Buyer; Enforceability</u>. Buyer has the full right, power, and authority to enter into this Agreement and perform its obligations hereunder. The execution, delivery, and performance of this Agreement by Buyer have been duly authorized by all necessary organizational action of Buyer, and no other act or proceeding on the part of Buyer is necessary to authorize the execution, delivery, or performance by Buyer of this Agreement or any other agreement contemplated hereby or thereby. This Agreement has been duly executed and delivered by Buyer and, assuming the due execution and delivery of this Agreement and the other agreements contemplated hereby by the other parties hereto and thereto, this Agreement constitutes, and the other agreements contemplated hereby upon execution and delivery by Buyer will each constitute, a valid and binding obligation of Buyer, enforceable against Buyer in accordance with its and their terms.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="a00072"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts; Consents</u>. The execution, delivery, and performance by Buyer of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not: (i) violate or conflict with the certificate of incorporation, by-laws, or other organizational documents of Buyer; (ii) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule, or regulation; or (iii) conflict with, or result in (with or without notice or lapse of time, or both), any violation of or default under, or give rise to a right of termination, acceleration, or modification of, any obligation or loss of any benefit under, any contract or other instrument to which this Agreement is subject. No consent, approval, waiver, or authorization is required to be obtained by Buyer from </div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">10</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">any person or entity (including any governmental authority) in connection with the execution, delivery, and performance by Buyer of this Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">8.</font><a name="a1031758"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Indemnification</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a1031759"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(a)(i)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8(a)(ii)</u> hereto, all representations and warranties contained herein and all related rights to indemnification shall continue in full force and effect until 11:59 p.m. (Eastern time) on the date that is [*] from Closing. The covenants and agreements contained in this Agreement shall survive the Closing until fully performed in accordance with their respective terms.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>The representations and warranties of Seller in [*] shall survive [*] following the Closing; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>The representations and warranties of Buyer in [*] shall survive [*] following the Closing.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 36pt;">Notwithstanding the foregoing or anything to the contrary in this Agreement, (i) if an indemnification claim is made prior to the expiration of the applicable survival period in accordance with the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u>, then such applicable representation, warranty, covenant or agreement shall survive as to such claim until all Losses (as defined below) arising out of or resulting from such claim have been fully paid in accordance with the terms of this Agreement, and (ii) none of the survival periods or limitations contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> shall apply to any claims relating to fraud or intentional misrepresentation.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="a00042"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement to Indemnify</u>. Each party (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) shall defend, indemnify, and hold harmless the other party, its affiliates, and their respective shareholders, directors, officers, and employees (each, an &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) from and against all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, fees, costs, or expenses of whatever kind, including reasonable attorneys&#8217; fees, the cost of enforcing any right to indemnification hereunder, and the cost of pursuing any insurance providers (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;) arising out of or in connection with (i) any breach or alleged breach of any representation, warranty or certification made by the Indemnifying Party in, or pursuant to, this Agreement, <font style="color:#010000;">(ii) </font>any breach or default by the Indemnifying Party in respect of any covenant or agreement made by the Indemnifying Party in this Agreement, (iii) any Excluded Liabilities, <font style="color:#010000;">and (iv) </font>any third-party claim, suit, action, or proceeding (each, a &#8220;<b style="font-weight:bold;">Third-Party Claim</b>&#8221;) arising on or after the date hereof and asserted against the Indemnified Party relating to the transactions contemplated in this Agreement, as applicable.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">11</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations</u>. Notwithstanding anything in this Agreement to the contrary, the aggregate amount required to be paid by the Indemnifying Party to the Indemnified Party under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(b)(i)</u> for any breach or alleged breach of any representation, warranty or certification, or pursuant to, this Agreement shall not exceed an amount equal to [*], provided, however, that the limitation set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(c)</u> shall not be applicable to claims for fraud or intentional misrepresentation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="a1031760"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification Procedures</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Claim</u>. An Indemnified Party may assert a claim for indemnification, whether for its own Losses or for Losses incurred by any other Indemnified Party by giving the Indemnifying Party written notice thereof (&#8220;<b style="font-weight:bold;">Notice of Claim</b>&#8221;). Each Notice of Claim given pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(d)</u> shall contain a description, in reasonable detail to the extent known to the Indemnified Party, of the facts, circumstances or events giving rise to such claim, together with (to the extent in the Indemnified Party&#8217;s possession and permitted by applicable law) copies of any formal written demand or complaint from any third party claimant and an estimate of the amount, if reasonably practicable, of the Losses that have been or may be sustained by the Indemnified Party. No failure or delay on the part of the Indemnified Party in giving the Indemnifying Party a Notice of Claim shall relieve, waive or otherwise release Seller from any of its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> unless (and then only to the extent that) the Indemnifying Party is adversely and materially prejudiced thereby in terms of the amount of Losses for which such Indemnifying Party is obligated to indemnify the Indemnified Party, and then, only to the extent of such prejudice. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Direct Claims</u>. Any claim by an Indemnified Party on account of Losses which do not result from a Third-Party Claim (a &#8220;<b style="font-weight:bold;">Direct Claim</b>&#8221;) shall be asserted by the Indemnified Party giving the Indemnifying Party Notice of Claim with respect thereto. The Indemnifying Party shall have [*] days after its receipt of such Notice of Claim to respond in writing to such Direct Claim. During such [*]-day period, the Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim and whether and to what extent any amount is payable in respect of the Direct Claim, and the Indemnified Party shall reasonably cooperate with the Indemnifying Party&#8217;s investigation by giving such information and assistance (including the right to examine any documents or records exclusively related to such Direct Claim) as the Indemnifying Party or any of its professional advisors may reasonably request. If Seller does not so respond within such [*]-day period, the Indemnifying Party shall be deemed to have rejected such Direct Claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement. To object to all or a portion of any Direct Claim </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">12</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 72pt;">made in a Notice of Claim, the Indemnifying Party must deliver a written objection to the Buyer Indemnified Party within [*] business days after receipt of such Notice of Claim expressing such objection and explaining in reasonable detail and in good faith the basis therefor (an &#8220;<b style="font-weight:bold;">Objection Notice</b>&#8221;). Following receipt by the Indemnified Party of the Objection Notice, if any, the Indemnified Party and the Indemnifying Part shall promptly, and within [*] business days, meet to attempt to resolve the rights of the respective parties that is the subject of the Objection Notice. If the Indemnifying Part and the Indemnified Party resolve the dispute, then as promptly as practicable (and in any event within [*] Business Days) following the resolution of the Direct Claim, the Indemnified Party and the Indemnifying Part shall execute and deliver a memorandum setting forth the aggregate Dollar amount of such Losses payable to the Indemnified Party (the &#8220;<b style="font-weight:bold;">Stipulated Amount</b>&#8221;), and such Stipulated Amount shall be paid in the manner set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(e)</u>. <a name="_Ref516090371"></a>In the event that the Indemnified Party and the Indemnifying Part do not execute a memorandum as contemplated above within [*] business days of receipt by the Indemnified Party of the Objection Notice, then the Buyer Indemnified Party may commence an action to resolve such dispute and enforce its rights with respect thereto in any court available therefor (such action, a &#8220;<b style="font-weight:bold;">Litigated Dispute</b>&#8221;). Upon the resolution of a Litigated Dispute, the amount awarded to the Indemnified Party, if any, in such Litigated Dispute (the &#8220;<b style="font-weight:bold;">Award Amount</b>&#8221;) shall be paid in the manner set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(e)</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third-Party Claims</u>. Any claim by an Indemnified Party on account of Losses resulting from a Third-Party Claim shall be asserted by the Indemnified Party giving the Indemnifying Part a Notice of Claim with respect thereto. The Indemnifying Part shall promptly assume control of the defense and investigation of the Third-Party Claim, with counsel reasonably acceptable to the Indemnified Party, and the Indemnified Party shall fully cooperate with the Indemnified Party in connection therewith, in each case at the Indemnified Party&#8217;s sole cost and expense. The Indemnified Party may participate in the defense of such Third-Party Claim, with counsel of its own choosing and at its own cost and expense. the Indemnifying Party shall not settle any Third-Party Claim without the Indemnified Party&#8217;s prior written consent (which consent shall not be unreasonably withheld, conditioned, or delayed). If the Indemnifying Part fails or refuses to assume control of the defense of such Third-Party Claim, the Indemnified Party shall have the right, but no obligation, to defend against such Third-Party Claim, including settling such Third-Party Claim after giving notice to Seller, in each case in such manner and on such terms as the Indemnified Party may deem appropriate. Neither the Indemnified Party&#8217;s failure to perform any obligation under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(d)</u>, nor any act or omission of the Indemnified Party in the defense or settlement of any Third-Party Claim shall relieve Seller of its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u>, including with respect to any Losses, except to the extent that Seller can demonstrate that it has been materially prejudiced as a result thereof.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">13</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Losses</u>. <a name="_Ref49947554"></a>With respect to any Losses for which an Indemnified Party is entitled to indemnification, any and all payments in respect of such Losses shall be satisfied, in whole or in part and at such Indemnified Party&#8217;s election, by: (i) in the case of the Seller, setting off such Losses against any Earn-out Payments that become payable to Seller in accordance with the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(e)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, as applicable</u>, or (ii) wire transfer of immediately available funds from the Indemnifying Party within ten (10) business days after such amounts are finally determined to be due and payable to such Indemnified Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">9.</font><a name="a00003"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Equitable Remedies</u>. Each party acknowledges that (a) a breach or threatened breach by such party of any of its obligations under this Agreement would give rise to irreparable harm to the other party for which monetary damages would not be an adequate remedy; and (b) if a breach or a threatened breach by each party of any such obligations occurs, the other party will, in addition to any and all other rights and remedies that may be available to such party at law, at equity, or otherwise in respect of such breach, be entitled to equitable relief, including a restraining order, an injunction, specific performance, and any other relief that may be available from a court of competent jurisdiction, without any requirement to (i) post a bond or other security; or (ii) prove actual damages or that monetary damages will not afford an adequate remedy.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">10.</font><a name="a00048"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Confidentiality</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a00073"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality and Use</u>. Seller agrees: (i) not to use any information that is of a sensitive, proprietary, or confidential nature, whether written or oral, concerning the Acquired Rights, other than as strictly necessary to exercise its rights or perform its obligations under this Agreement; (ii) not to use any such information, directly or indirectly, in any manner to the detriment of Buyer or to obtain any competitive advantage relative to Buyer; and (iii) to maintain such information in strict confidence, and not to disclose such information without Buyer&#8217;s prior written consent. Both parties agree to comply with the confidentiality obligations contained in the Licenses. The Mutual Non-Disclosure Agreement between Buyer and Seller dated [*], is hereby superseded in its entirety by the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="a00074"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compelled Disclosures</u>. If either party is compelled to disclose any information with respect to the financial terms of this Agreement, or Seller is compelled to disclose any information that is of a sensitive, proprietary, or confidential nature concerning the Acquired Rights, by judicial or administrative process or by other requirements of law, such party shall: (i) promptly notify the other party in writing; (ii) disclose only that portion of such information that it is advised by counsel in writing is legally required to be disclosed; and (iii) use reasonable best efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">14</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Disclosures</u>. Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10</u>, each party shall be permitted to disclose any information with respect to this Agreement (i) to the extent required by applicable law, applicable regulations, or applicable rules of any stock exchange or quotation system on which Buyer, Seller, or any of their respective affiliates lists or trades securities from and after the date hereof, and (ii) to their respective representatives as necessary in the ordinary course of business (as long as such persons agree to or are bound by contract or professional obligation to keep the terms of this Agreement confidential and not use any such terms except as necessary in connection with such ordinary conduct).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">11.</font><a name="a681472"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Miscellaneous</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="a163962"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interpretation</u>. For purposes of this Agreement, (i) the words &#8220;include,&#8221; &#8220;includes,&#8221; and &#8220;including&#8221; are deemed to be followed by the words &#8220;without limitation&#8221;; (ii) the word &#8220;or&#8221; is not exclusive; and (iii) the words &#8220;herein,&#8221; &#8220;hereof,&#8221; &#8220;hereby,&#8221; &#8220;hereto,&#8221; and &#8220;hereunder&#8221; refer to this Agreement as a whole. Unless the context otherwise requires, references herein: (x) to Sections, Schedules, and Exhibits refer to the Sections of, and Schedules and Exhibits attached to, this Agreement; (y) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement is intended to be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Schedules and Exhibits referred to herein are intended to be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="a00049"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. All notices, requests, consents, claims, demands, waivers, and other communications hereunder shall be in writing and shall be deemed to have been given: (i) when delivered by hand (with written confirmation of receipt); (ii) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (iii) on the date sent by facsimile or email of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient; and (iv) on the day after the date mailed, by certified or registered mail (in each case, return receipt requested, postage prepaid). Such communications must be sent to the respective parties at the following addresses or at such other address for a party as shall be specified in a notice given in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11(b)</u>:</div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;">If to Seller:</p></td><td style="vertical-align:top;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Address:</font></p></td><td style="vertical-align:top;width:34.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Chemin des Aulx, 12, 1228<br>Plan-les-Outes, Geneva, Switzerland</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">15</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><a name="a00050"></a><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:15.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:34.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-bottom:5pt;margin-left:0pt;margin-top:6pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Facsimile:</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Email:</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Attention:</font></p></td><td style="vertical-align:top;width:34.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">+41 (0)22 884 1556 <br>[*]<br>Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;">If to Buyer:</p></td><td style="vertical-align:top;width:15.89%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Address:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Email:</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Attention:</font></p></td><td style="vertical-align:top;width:34.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">2200 Powell Street, Suite 310</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">[*]<br>Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. This Agreement, together with Licenses and the documents to be delivered hereunder, and all related exhibits and schedules, constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="a00051"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="a362862"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Successors and Assigns</u>. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><a name="a1031740"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; Venue</u>. All matters arising out of or relating to this Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule. Any legal suit, action, or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby shall be instituted in the federal courts of the United States of America or the courts of the State of New York in each case located in the Borough of Manhattan and County of New York, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such legal suit, action, or proceeding.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="a00052"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Modification</u>. This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party hereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><a name="a00053"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver</u>. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. Except as otherwise set forth in this Agreement, no failure to exercise, or delay in exercising, any right, remedy, power, or privilege arising from this Agreement shall operate or be construed as a waiver thereof; and any single or partial exercise of any right, remedy, power, or privilege hereunder shall not preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="margin-bottom:12pt;margin-top:6pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">16</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="a1025104"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email, or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expense Reimbursement</u>. Seller agrees to reimburse Buyer for up to [*] of expenses incurred by Buyer in connection with the transactions contemplated by this Agreement (the &#8220;<b style="font-weight:bold;">Expense Reimbursement Amount</b>&#8221;). Such Expense Reimbursement Amount shall be set off from the Purchase Price in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3(b)</u>.</div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;text-transform:uppercase;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[signature page follows]</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;text-transform:uppercase;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">17</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">IN WITNESS WHEREOF, Seller and Buyer have caused this Agreement to be executed as of the date first written above by their respective duly authorized officers.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">OBSEVA S.A.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ Will Brown </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Will Brown</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Chief Financial Officer</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">XOMA (US) LLC</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">/s/ James R. Neal</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Name:</font></p></td><td style="vertical-align:top;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">James R. Neal </font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Chief Executive Officer </font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">18</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.57
<SEQUENCE>8
<FILENAME>xoma-20221231xex10d57.htm
<DESCRIPTION>EX-10.57
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:51 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Exhibit 10.57</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></p><p style="font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">LICENSE AGREEMENT<br>(EBOPIPRANT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This License Agreement (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is entered into as of July 26, 2021 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;), by and between ObsEva SA, having an address at Chemin des Aulx 12, 1228 Plan-Les-Ouates, Switzerland (&#8220;<b style="font-weight:bold;">ObsEva</b>&#8221;) and Organon International GmbH, having an address at Weystrasse 20, 6006 Lucerne, Switzerland (&#8220;<b style="font-weight:bold;">Organon</b>&#8221;). &#160;ObsEva and Organon may be referred to herein individually as a &#8220;<b style="font-weight:bold;">Party</b>&#8221; or collectively as the &#8220;<b style="font-weight:bold;">Parties</b>.&#8221;</p><p style="font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">RECITALS</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Whereas</b>, ObsEva Controls (as defined below) certain patents, know-how and other intellectual property rights relating to Licensed Compound and Licensed Products (as such terms are defined below);</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Whereas</b>, Organon possesses resources and expertise in the development and commercialization of pharmaceutical products;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Whereas</b>, Organon desires to obtain an exclusive license and sublicense to Develop, Manufacture, Commercialize and otherwise Exploit the Licensed Compounds and Licensed Products in the Field in the Territory (as such terms are defined below) and ObsEva desires to grant to Organon such license and sublicense.</p><p style="font-family:'Times New Roman Bold';font-size:11pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-variant:small-caps;font-weight:bold;">Now, Therefore</b>, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Organon and ObsEva hereby agree as follows:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DEFINITIONS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.1</font>&#8220;<b style="font-weight:bold;">Acceptance</b>&#8221; means, with respect to a Drug Approval Application, receipt of written notice from the applicable Regulatory Authority indicating that such Drug Approval Application has been accepted for filing and further Regulatory Authority review.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.2</font>&#8220;<b style="font-weight:bold;">Accounting Standards</b>&#8221; means United States Generally Accepted Accounting Principles (GAAP) or International Financial Reporting Standards (IFRS), as consistently applied by Organon or its Affiliates or Sublicensees, as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.3</font>&#8220;<b style="font-weight:bold;">Action</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(e)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.4</font>&#8220;<b style="font-weight:bold;">Affiliate</b>&#8221; means a Person or entity that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. For the purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.4</u>, the word &#8220;<b style="font-weight:bold;">control</b>&#8221; (including, with correlative meaning, the terms &#8220;<b style="font-weight:bold;">controlled by</b>&#8221; or &#8220;<b style="font-weight:bold;">under the common control with</b>&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to </div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:45.75pt;"></font><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. The Parties acknowledge that in the case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or policies of such entity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.5</font>&#8220;<b style="font-weight:bold;">Alliance Manager</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.5</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.6</font>&#8220;<b style="font-weight:bold;">Anti-Corruption Laws</b>&#8221; means any Applicable Laws regarding corruption, bribery, ethical business conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to Public Officials or private persons, agency relationships, commissions, lobbying, books and records, and financial controls, including the United States Foreign Corrupt Practices Act, 15 U.S.C. &#167;78-dd-1, et seq., the Bribery Act 2010, the Criminal Law and Anti-Unfair Competition Law of the People&#8217;s Republic of China, and laws implementing the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions; each as may be amended or supplemented from time to time</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.7</font>&#8220;<b style="font-weight:bold;">Applicable Laws</b>&#8221; means applicable laws, statutes, ordinances, rules, regulations, guidances and orders of any Governmental Authority (including court orders) having jurisdiction over or related to the subject item.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.8</font>&#8220;<b style="font-weight:bold;">Bankruptcy Event</b>&#8221; means: (a) voluntary or involuntary proceedings by or against a Party instituted in bankruptcy under any insolvency law, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing; (b) a receiver or custodian is appointed for a Party; (c) proceedings are instituted by or against a Party for corporate reorganization, dissolution, liquidation or winding-up of such Party, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing; or (d) substantially all of the assets of a Party are seized or attached and not released within sixty (60) days thereafter.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.9</font>&#8220;<b style="font-weight:bold;">Bayh-Dole Act</b>&#8221; means the Patent and Trademark Law Amendments Act of 1980 codified at 35 U.S.C. &#167;&#167; 200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. Part 401.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.10</font>&#8220;<b style="font-weight:bold;">Business Day</b>&#8221; means a day other than a Saturday or Sunday on which banking institutions in Lucerne, Switzerland and New York, New York are open for business.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.11</font>&#8220;<b style="font-weight:bold;">Calendar Quarter</b>&#8221; means each three (3) month period commencing January 1, April 1, July 1 or October 1, provided however that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the expiration of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.12</font>&#8220;<b style="font-weight:bold;">Calendar Year</b>&#8221; means the period beginning on the 1st of January and ending on the 31st of December of the same year, provided however that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31, 2021 and (b) the last Calendar Year of the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and ends on the date of termination or expiration of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.13</font>&#8220;<b style="font-weight:bold;">Change of Control</b>,&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.1(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.14</font>&#8220;<b style="font-weight:bold;">China</b>&#8221; means the People&#8217;s Republic of China, which includes mainland China, [*].</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.15</font>&#8220;<b style="font-weight:bold;">Claim</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.16</font>&#8220;<b style="font-weight:bold;">Clinical Trial</b>&#8221; means a clinical trial of a pharmaceutical product in humans which has been approved by a Regulatory Authority to be commenced and is designed to (a) establish that such pharmaceutical product is reasonably safe for continued testing; (b) investigate the safety and efficacy of such pharmaceutical product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with such pharmaceutical product in the dosage range to be prescribed; (c) investigate the safety/tolerability, pharmacokinetics and pharmacodynamics of such pharmaceutical product; (d) support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical product; or (e) obtain, support or maintain Regulatory Approval, including any post-marketing commitments.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.17</font>&#8220;<b style="font-weight:bold;">CMOs</b>&#8221; means Third Party contract manufacturers.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.18</font>&#8220;<b style="font-weight:bold;">Combination Product</b>&#8221; means a product containing a Licensed Compound together with one or more active ingredients, or with one or more products, devices, equipment or components (each, an &#8220;<b style="font-weight:bold;">Other Product</b>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.19</font>&#8220;<b style="font-weight:bold;">Commercialization</b>&#8221; or &#8220;<b style="font-weight:bold;">Commercialize</b>&#8221; means any and all activities undertaken prior to and after receipt of Regulatory Approval for a particular Licensed Product and that relate to the pricing and reimbursement (including obtaining and maintaining Reimbursement Approval), marketing, promoting, distributing, importing for sale, offering for sale, and selling of the Licensed Product, including Phase 4 Trials that are voluntarily undertaken and are not mandated by a Regulatory Authority as a condition of receiving or maintaining Regulatory Approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.20</font>&#8220;<b style="font-weight:bold;">Commercially Reasonable Efforts</b>&#8221; means, (a) with respect to the efforts to be expended by a Party with respect to any objective, such reasonable, diligent, and good faith efforts as [*] Party would normally use to accomplish a similar objective under similar circumstances, and (b) with respect to any obligation relating to Development or Commercialization of a Licensed Product by Organon, the application by [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.21</font>&#8220;<b style="font-weight:bold;">Confidential Information</b>&#8221; of a Party means (a) the terms of this Agreement and (b) with respect to each Party, any information relating to the business, operations and products of a Party or any of its Affiliates, including any technical information, Know-How, trade secrets, or inventions (whether patentable or not), not known or generally available to the public, that such Party discloses to the other Party under this Agreement (including information disclosed prior to the Effective Date pursuant to that certain letter agreement between the Parties or their respective Affiliates dated March 8, 2021), or otherwise becomes known to the other Party by virtue of this Agreement. Notwithstanding the foregoing, all Regulatory Documentation owned by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.6(b)</u> shall be deemed to be the Confidential Information of Organon, and Organon shall be deemed to be the disclosing Party and ObsEva shall be deemed to be the receiving Party with respect thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.22</font>&#8220;<b style="font-weight:bold;">Consent</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1(g)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.23</font>&#8220;<b style="font-weight:bold;">Control</b>&#8221; (including any variations such as &#8220;<b style="font-weight:bold;">Controlled</b>&#8221; and &#8220;<b style="font-weight:bold;">Controlling</b>&#8221;) means, with respect to a Party and (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that such Party or one of its Affiliates owns or has a license or sublicense to such right, item, or material (or in the case of material, has the right to physical possession of such material, and, in each case of the foregoing, other than by operation of the license and other grants in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>) and the ability to grant a </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">license or sublicense to, or assign its right, title and interest in and to, such right, item or material as provided for in this Agreement, without breaching the terms of any then-existing agreement with a Third Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.24</font>&#8220;<b style="font-weight:bold;">Controlling Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.25</font>&#8220;<b style="font-weight:bold;">Cover</b>,&#8221; &#8220;<b style="font-weight:bold;">Covering</b>&#8221; or &#8220;<b style="font-weight:bold;">Covered</b>&#8221; means, with respect to a Licensed Product and a country, that the making, using, selling, or offering for sale of such Licensed Product would, but for a license granted in this Agreement under the Licensed Patents, infringe a Valid Claim of the Licensed Patents in the country in which the activity occurs.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.26</font>&#8220;<b style="font-weight:bold;">Development</b>&#8221; or &#8220;<b style="font-weight:bold;">Develop</b>&#8221; means, with respect to Licensed Compound or a Licensed Product, all research and development activities, including the performance of pre-clinical and clinical development (including toxicology, pharmacokinetic and pharmacological studies, statistical analyses, protocol design, test method development and stability testing, process development, formulation development, and quality control development), Clinical Trials, Phase 4 Trials that are mandated by Regulatory Authority as a condition of receiving or maintaining Regulatory Approval (but no other Phase 4 Trials or Clinical Trials conducted after receipt of Regulatory Approval) and all regulatory affairs related to any of the foregoing, including regulatory activities that are required to obtain Regulatory Approval of the Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.27</font>&#8220;<b style="font-weight:bold;">Development Plan</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.28</font>&#8220;<b style="font-weight:bold;">Dispute</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.29</font>&#8220;<b style="font-weight:bold;">Dollar</b>&#8221; or &#8220;<b style="font-weight:bold;">$</b>&#8221; means U.S. dollars.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.30</font>&#8220;<b style="font-weight:bold;">Drug Approval Application</b>&#8221; means (a) Marketing Authorization Application (&#8220;<b style="font-weight:bold;">MAA</b>&#8221;) submitted to EMA for the purpose of obtaining European Commission approval for the marketing of the Licensed Product for the countries located within the European Union, (b) a New Drug Application (&#8220;<b style="font-weight:bold;">NDA</b>&#8221;) or a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in the FFDCA, or (c) any equivalent registration application filed to the applicable Regulatory Authority for approval to market the Licensed Product in any country other than the European Union or the United States, in each case, including all additions, deletions or supplements thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.31</font>&#8220;<b style="font-weight:bold;">EMA</b>&#8221; means the European Medicines Agency, or any successor thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.32</font>&#8220;<b style="font-weight:bold;">Enforcing Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.33</font>&#8220;<b style="font-weight:bold;">European Union</b>&#8221; or &#8220;<b style="font-weight:bold;">E.U.</b>&#8221; means the economic, scientific, and political organization of member states known as the European Union, as its membership may be altered from time to time, and any successor thereto; provided that for the purposes of this Agreement, the European Union shall be deemed to include the United Kingdom.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.34</font>&#8220;<b style="font-weight:bold;">Executive Officer</b>&#8221; means, with respect to ObsEva, the Chief Executive Officer of ObsEva or his or her designee and, with respect to Organon, the Executive Vice President, Head of Research and Development of Organon or his or her designee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.35</font>&#8220;<b style="font-weight:bold;">Existing INDs</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.6(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.36</font>&#8220;<b style="font-weight:bold;">Existing Know-How</b>&#8221; means the Licensed Know-How existing as of the Effective Date.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.37</font>&#8220;<b style="font-weight:bold;">Existing Patents</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1(d)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.38</font>&#8220;<b style="font-weight:bold;">Exploit</b>&#8221; means to Develop, make, have made and otherwise Manufacture, import, export, use, have used, register, sell, offer for sale, distribute, promote, market, have sold and otherwise Commercialize, modify, enhance, improve, or keep (whether for disposal or otherwise), transport or otherwise dispose of. &#8220;<b style="font-weight:bold;">Exploitation</b>&#8221; has correlative meaning.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.39</font>&#8220;<b style="font-weight:bold;">FDA</b>&#8221; means the United States Food and Drug Administration, or any successor thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.40</font>&#8220;<b style="font-weight:bold;">FFDCA</b>&#8221; means, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq., and the Public Health Service Act, 42 U.S.C. &#167;&#167; 262 et seq., as amended from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.41</font>&#8220;<b style="font-weight:bold;">Field</b>&#8221; means all therapeutic, prophylactic, palliative and diagnostic uses in humans and animals.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.42</font>&#8220;<b style="font-weight:bold;">First Commercial Sale</b>&#8221; means the first sale for monetary value to a Third Party for use or consumption of the Licensed Product by Organon or its Affiliate(s) or Sublicensee(s). For the avoidance of doubt, a First Commercial Sale may only occur after the Licensed Product has received Regulatory Approval for the country in which the First Commercial Sale occurs, and First Commercial Sale excludes any sale or other distribution of a Licensed Product for Clinical Trial or other Development purposes or for early access programs (such as pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or any similar use, in each case to provide patients with such Licensed Product prior to Regulatory Approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.43</font>&#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.13</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.44</font>&#8220;<b style="font-weight:bold;">Generic Product</b>&#8221; means, with respect to a Licensed Product and a country in the Territory, any product that (a) is approved for use in an indication that is the same as an indication for such Licensed Product in such country by a Regulatory Authority in reliance, in whole or in part, on the Regulatory Approval (or on safety or efficacy data submitted in support of the Regulatory Approval) of such Licensed Product in such country, (b) contains the Licensed Compound as an active ingredient, and (c) is sold in such country by a Third Party that is not a Sublicensee and did not purchase such product or Licensed Compound from Organon or its Affiliates or Sublicensees.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.45</font>&#8220;<b style="font-weight:bold;">Governmental Authority</b>&#8221; means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, representative, organization, unit, body or entity and any court or other tribunal); (d) multinational or supranational organization or body; or (e) individual, entity, or body, including any court, exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.46</font>&#8220;<b style="font-weight:bold;">GxP</b>&#8221; means, collectively, all relevant good practice quality guidelines and regulations, encompassing such internationally recognized standards as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP), and Good Review Practice (GRP), in each case (a) as such terms are defined from time to time by the FDA and other applicable Governmental Authorities pursuant to its regulations, guidelines or otherwise and (b) applicable </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">from time to time to the Development or Manufacturing of a Licensed Compound or Licensed Product or any intermediate thereof pursuant to Applicable Law.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.47</font>&#8220;<b style="font-weight:bold;">IND</b>&#8221; means an investigational new drug application filed with the FDA or the equivalent application or filing filed with any equivalent agency or Governmental Authority outside the United States (including any supra-national entity such as in the European Union) for approval to commence Clinical Trials in such jurisdiction such as a clinical trial application or a clinical trial notification, and including all regulations at Title 21 of the Code of Federal Regulations Part 312 et seq. and equivalent foreign regulations.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.48</font>&#8220;<b style="font-weight:bold;">IND Acceptance</b>&#8221; means, with respect to a particular Licensed Product, that the IND for the Clinical Trial for such Licensed Product filed hereunder by Organon with the FDA was accepted by the FDA, as evidenced by no objection by the FDA within thirty (30) days after the date of the IND submission (or any amended submission if the initial IND-filing was not accepted and such amendment restarted the applicable 30-day period).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.49</font>&#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.50</font>&#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.51</font>&#8220;<b style="font-weight:bold;">Infringing Licensed Product</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(v)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.52</font>&#8220;<b style="font-weight:bold;">Initiation</b>&#8221; means, with respect to a Clinical Trial, the first dosing of the first (1st) human subject in such Clinical Trial.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.53</font>&#8220;<b style="font-weight:bold;">Inventions</b>&#8221; means all inventions, whether or not patentable, discovered, made, developed, generated, conceived or reduced to practice in the course of conducting activities under this Agreement or through the exercise of a license granted in this Agreement, together with all intellectual property rights therein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.54</font>&#8220;<b style="font-weight:bold;">Joint Advisory Committee</b>&#8221; or &#8220;<b style="font-weight:bold;">JAC</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.55</font>&#8220;<b style="font-weight:bold;">Know-How</b>&#8221; means all present and future scientific, technical, or commercial information, results and data of any type whatsoever that is not in the public domain or otherwise publicly known, including databases, inventions, improvements, practices, research, methods, discoveries, developments, technology, protocols, specifications, formulae, software, algorithms, knowledge, know-how, trade secrets, processes, assays, skills, experience, chemical or biological materials, reagents, formulations, expertise, techniques, results of experimentation and testing, data (including pharmacological, biological, chemical, biochemical, toxicological, pre-clinical and clinical data and analytical and quality control data, stability data and other study data), CMC information, manufacturing process and development, and results in all cases, whether or not patentable, in written, electronic, tangible, intangible or any other form now known or hereafter developed, but excluding any Patent Rights and Trademarks.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.56</font>&#8220;<b style="font-weight:bold;">Knowledge</b>&#8221; means, with respect to a particular fact or matter, the knowledge, following reasonable inquiry, of any [*] of ObsEva who has responsibility for such fact or matter; provided that such reasonable inquiry shall not require ObsEva or [*] to perform any freedom to operate analysis with respect to any Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.57</font>&#8220;<b style="font-weight:bold;">Legal Action</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(b)</u>.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.58</font>&#8220;<b style="font-weight:bold;">Licensed Compound(s)</b>&#8221; means the compound known as Ebopiprant [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.59</font>&#8220;<b style="font-weight:bold;">Licensed Know-How</b>&#8221; means Know-How Controlled by ObsEva or any of its Affiliates as of the Effective Date or at any time during the Term that is necessary or reasonably useful for the Development, Manufacture, Commercialization or other Exploitation of a Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.60</font>&#8220;<b style="font-weight:bold;">Licensed Patents</b>&#8221; means Patent Rights Controlled by ObsEva or any of its Affiliates as of the Effective Date or at any time during the Term that claim [*]. &#160;The Licensed Patents existing as of the Effective Date are set forth on Schedule 1.60 and include the Merck Serono Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.61</font>&#8220;<b style="font-weight:bold;">Licensed Product</b>&#8221; means any product that contains, comprises or incorporates a Licensed Compound, whether alone or in combination with other active ingredients, in all current and future formulations, and in any dosage form, presentation or package configuration, and for any mode of administration.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.62</font>&#8220;<b style="font-weight:bold;">Licensed Product CMO</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.63</font>&#8220;<b style="font-weight:bold;">Licensed Technology</b>&#8221; means, collectively, the Licensed Know-How and the Licensed Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.64</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.65</font>&#8220;<b style="font-weight:bold;">Losses</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.66</font>&#8220;<b style="font-weight:bold;">MAA</b>&#8221; has the meaning set forth in the definition of &#8220;Drug Approval Application.&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.67</font>&#8220;<b style="font-weight:bold;">Major Market</b>&#8221; means each of [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.68</font>&#8220;<b style="font-weight:bold;">Manufacture</b>&#8221; and &#8220;<b style="font-weight:bold;">Manufacturing</b>&#8221; means all activities related to the synthesis, making, production, processing, purifying, formulating, filling, finishing, packaging, labelling, shipping, and holding of a Licensed Compound or Licensed Product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial production and analytic development, product characterization, supply chain, stability testing, quality assurance testing and release, investigations, risk assessments, corrective actions, and quality control.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.69</font>&#8220;<b style="font-weight:bold;">Manufacturing Process</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.70</font>&#8220;<b style="font-weight:bold;">Manufacturing Technology Transfer</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.71</font>&#8220;<b style="font-weight:bold;">Manufacturing Transfer Plan</b>&#8221; means the plan covering the Manufacturing Technology Transfer to Organon which the Parties shall agree upon as promptly as practicable after the Effective Date, but in no event longer than [*] days after the Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.72</font>&#8220;<b style="font-weight:bold;">Merck Serono</b>&#8221; has the meaning set forth in the definition of &#8220;Merck Serono Agreement.&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.73</font>&#8220;<b style="font-weight:bold;">Merck Serono Agreement</b>&#8221; means the License Agreement dated June 10, 2015 by and between Ares Trading S.A. (&#8220;Merck Serono&#8221;) and ObsEva, as amended by the First Amendment to the License Agreement dated July 8, 2016.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.74</font>&#8220;<b style="font-weight:bold;">Merck Serono Confidential Information</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.75</font>&#8220;<b style="font-weight:bold;">Merck Serono Patent Infringement</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.76</font>&#8220;<b style="font-weight:bold;">Merck Serono Patents</b>&#8221; means the Patent Rights listed on Schedule 1.60.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.77</font>&#8220;<b style="font-weight:bold;">NDA</b>&#8221; has the meaning set forth in the definition of &#8220;Drug Approval Application.&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.78</font>&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221; means the amounts invoiced by Organon or its Affiliates or Sublicensees for sales of Licensed Products to a Third Party (other than a Sublicensee) (whether a sales agent, a service provider, a hospital, an end user, a distributor, a pharmacy or otherwise), less the following:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>[*];</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>[*];</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>[*];</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>[*].</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">[*]. For the avoidance of doubt, Net Sales may only occur after the Licensed Product has received Regulatory Approval for the country in which the Net Sales occur.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>[*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.79</font>&#8220;<b style="font-weight:bold;">NMPA</b>&#8221; means the National Medical Licensed Products Administration in China, and local counterparts thereto, or any successor entity thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.80</font>&#8220;<b style="font-weight:bold;">ObsEva Indemnitee</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.81</font>&#8220;<b style="font-weight:bold;">ObsEva Patent Infringement</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.82</font>&#8220;<b style="font-weight:bold;">ObsEva Patents</b>&#8221; means all Licensed Patents in the Territory other than the Merck Serono Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.83</font>&#8220;<b style="font-weight:bold;">Organon Improvement Know-How</b>&#8221; means any and all Know-How (including any improvement, Invention or discovery) that is Controlled by Organon or its Affiliates that is discovered, made, developed, generated, conceived or reduced to practice by one or more employees of Organon or its Affiliates or Sublicensees (or a Third Party acting on its or their behalf) in the course of conducting activities under this Agreement and that relates solely to a Licensed Compound or Licensed Product [*], including new or improved methods of manufacture, formulas, uses, indications, delivery methods or dosage forms thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.84</font>&#8220;<b style="font-weight:bold;">Organon Improvement Patents</b>&#8221; means any and all Patent Rights Controlled by Organon or its Affiliates that claim (a) any Organon Improvement Know-How, (b) a Licensed Compound, or (c) any Licensed Product (or, with respect to Patent applications, would claim any of the foregoing if such Patent applications were to issue as Patents).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.85</font>&#8220;<b style="font-weight:bold;">Organon Improvement Technology</b>&#8221; means, collectively, the Organon Improvement Know-How and the Organon Improvement Patents.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.86</font>&#8220;<b style="font-weight:bold;">Organon Indemnitee</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.87</font>&#8220;<b style="font-weight:bold;">Organon Know-How</b>&#8221; means any Know-How that is (a) Controlled by Organon or any of its Affiliates as of the effective date of the applicable termination of this Agreement, (b) actually used by Organon or its Affiliates or Sublicensees in the Exploitation of or otherwise with respect to or incorporated in a Licensed Compound or any Licensed Product as it exists as of such effective date of termination, and (c) necessary to Develop, have Developed, Manufacture, have Manufactured, Commercialize or otherwise Exploit any Licensed Product as it exists as of such effective date of termination, but in each case (i) solely with respect to any such Licensed Product that is the subject of Development or Commercialization in the Territory as of the effective date of such termination, and (ii), if such Licensed Product is a Combination Product [*], excluding any such Know-How related to any such Other Product, including any active ingredient other than the Licensed Compound, in such Combination Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.88</font>&#8220;<b style="font-weight:bold;">Organon Patents</b>&#8221; means any Patents that (a) are Controlled by Organon or any of its Affiliates as of the effective date of the applicable termination of this Agreement, and (b) either (i) include one (1) or more claim(s) that claim or cover Organon Know-How or (ii) are actually used by Organon or its Affiliates or Sublicensees in the Exploitation of any Licensed Product as it exists as of such effective date of termination and are necessary to Develop, have Developed, Manufacture, have Manufactured, Commercialize or otherwise Exploit any Licensed Product as it exists as of such effective date of termination, but in each case (A) solely with respect to any such Licensed Product that is the subject of Development or Commercialization in the Territory as of the effective date of such termination, and (B), if such Licensed Product is a Combination Product [*], excluding any such Patents that cover any such Other Product, including any active ingredient other than the Licensed Compound, in such Combination Product, and in all cases, in no event shall Organon Patents include any Patent Controlled by Organon or any of its Affiliates that claims or covers the composition of any Other Product in a Combination Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.89</font>&#8220;<b style="font-weight:bold;">Organon Technology</b>&#8221; means, collectively, the Organon Know-How and the Organon Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.90</font>&#8220;<b style="font-weight:bold;">Other Product</b>&#8221; has the meaning set forth in the definition of &#8220;Combination Product.&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.91</font>&#8220;<b style="font-weight:bold;">Patent</b>&#8221; or &#8220;<b style="font-weight:bold;">Patent Right(s)</b>&#8221; means: (a) an issued or granted patent, including any extension, supplementary protection certificate, registration, confirmation, reissue, reexamination, extension or renewal thereof; (b) a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.92</font>&#8220;<b style="font-weight:bold;">Patent Challenge</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.93</font>&#8220;<b style="font-weight:bold;">Person</b>&#8221; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any Governmental Authority, government or agency or political subdivision thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.94</font>&#8220;<b style="font-weight:bold;">Phase 3 Trial</b>&#8221; means a Clinical Trial of a Licensed Product which Clinical Trial the FDA permits to be conducted under an open IND, and which is designed to: (a) establish that the Licensed Product is safe and efficacious for its intended use; (b) define warnings, precautions, and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c) enable the submission of an NDA to the FDA for the Licensed Product, and that satisfies the requirements of U.S. federal regulation 21 C.F.R. &#167; 312.21(c) and its successor regulation.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.95</font>&#8220;<b style="font-weight:bold;">Phase 4 Trial</b>&#8221; means a study of the Licensed Product conducted after Regulatory Approval: (a) due to a request or requirement of a Regulatory Authority as a condition of receiving or maintaining such Regulatory Approval; or (b) voluntarily by a Party to enhance marketing or scientific knowledge of the Licensed Product (including, for clarity, any post-marketing surveillance studies and registries sponsored by a Party, epidemiological models, or pharmacoeconomic studies).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.96</font>&#8220;<b style="font-weight:bold;">Privacy Laws</b>&#8221; means any Applicable Laws regarding the collection, use, transfer, storage, protection, deletion, processing (both by computer and manually), combination, or other use of Clinical Trial subject or patient data (sometimes referred to as protected health information) or other personal data.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.97</font>&#8220;<b style="font-weight:bold;">Product Trademarks</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.8</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.98</font>&#8220;<b style="font-weight:bold;">Prosecution</b>&#8221; means, with respect to any Patent, the preparation, filing, prosecution and maintenance (including any interferences, reissue proceedings, reexaminations, inter partes review, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of such Patent.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.99</font>&#8220;<b style="font-weight:bold;">Public Official</b>&#8221; means (a) any elected or appointed officer, employee or representative of any regional, federal, state, provincial, county or municipal Governmental Authority, agency or other division; (b) any officer, employee or representative of any commercial enterprise that is owned or controlled by a Governmental Authority, including any state-owned or controlled veterinary, laboratory research or medical facility; (c) any political party officer, candidate for public office, or political party employees or individuals acting for or on behalf of a political party or candidate for public office; (d) any officer, employee or representative of any public international organization, such as the African Union, the International Monetary Fund, the United Nations or the World Bank; and (e) any person acting in an official capacity for any Government Authority, enterprise or organization identified above. For clarity, healthcare providers employed by government-owned or -controlled hospitals, or a person serving on a healthcare committee that advises a Governmental Authority, will be considered Public Officials.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.100</font>&#8220;<b style="font-weight:bold;">Reduction Circumstances</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(iii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.101</font>&#8220;<b style="font-weight:bold;">Regulatory Approval</b>&#8221; means approval of a Drug Approval Application by the applicable Regulatory Authority for marketing and sale of a Licensed Product in the Territory. For clarity, Regulatory Approval does not include Reimbursement Approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.102</font>&#8220;<b style="font-weight:bold;">Regulatory Authority</b>&#8221; means (a) the FDA, (b) the EMA or the European Commission, (c) the NMPA, or (d) any regulatory body with similar regulatory authority over pharmaceutical or biotechnology products in any other jurisdiction anywhere in the world.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.103</font>&#8220;<b style="font-weight:bold;">Regulatory Documentation</b>&#8221; means (a) all Regulatory Filings, (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint files, and (c) data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to a Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.104</font>&#8220;<b style="font-weight:bold;">Regulatory Exclusivity</b>&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product, other than Patents, including rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">pediatric exclusivity), or rights similar thereto outside the U.S., such as Directive 2001/83/EC (as amended) in the European Union.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.105</font>&#8220;<b style="font-weight:bold;">Regulatory Filing</b>&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, Manufacture, or Commercialization of any Licensed Product made to or received from any Regulatory Authority in a given country, including INDs, Drug Approval Applications, Regulatory Approvals and Reimbursement Approvals.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.106</font>&#8220;<b style="font-weight:bold;">Reimbursement Approval</b>&#8221; means any governmental approval, agreement, determination, or decision establishing prices for a Licensed Product that can be charged or reimbursed in regulatory jurisdictions where the applicable Regulatory Authorities approve or determine the price or reimbursement of pharmaceutical products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.107</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.108</font>&#8220;<b style="font-weight:bold;">Reversion Licenses</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.109</font>&#8220;<b style="font-weight:bold;">Reversion Royalty Dispute</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.110</font>&#8220;<b style="font-weight:bold;">Royalty Term</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.111</font>&#8220;<b style="font-weight:bold;">Rules</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.112</font>&#8220;<b style="font-weight:bold;">Safety Concern</b>&#8221; means, with respect to a Licensed Product, (a) any safety concern required to be reported under 21 C.F.R. &#167; 312.32(c)(1)(iii) or the equivalent in any non-U.S. jurisdiction, or (b) a material toxicity or material drug safety issue or a Serious Adverse Event reasonably related to a Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.113</font>&#8220;<b style="font-weight:bold;">Safety Reason</b>&#8221; means that there is an unacceptable risk for harm in humans based upon (a) preclinical safety data, including data from animal toxicology studies, (b) the observation of serious adverse effects in humans after the Licensed Product has been administered to humans, such as during a Clinical Trial of a Licensed Product, or (c) other Safety Concerns.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.114</font>&#8220;<b style="font-weight:bold;">Step-In Prosecuted Patent</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(iv)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.115</font>&#8220;<b style="font-weight:bold;">Sublicensee</b>&#8221; means a Third Party to whom Organon grants a sublicense under any of the Licensed Technology licensed under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>, as permitted in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>, excluding contract research organizations, CMOs and similar service providers, and wholesalers, distributors and similar physical distributors that do not promote the sale of the Licensed Product. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.116</font>&#8220;<b style="font-weight:bold;">Supply Agreements</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.117</font>&#8220;<b style="font-weight:bold;">Supply Period</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.118</font>&#8220;<b style="font-weight:bold;">Term</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.1(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.119</font>&#8220;<b style="font-weight:bold;">Territory</b>&#8221; means all of the countries in the world, and their territories and possessions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.120</font>&#8220;<b style="font-weight:bold;">Third Party</b>&#8221; shall mean any Person that is not a Party or an Affiliate of a Party.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.121</font>&#8220;<b style="font-weight:bold;">Third Party Action</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.122</font>&#8220;<b style="font-weight:bold;">Third Party License</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(v)</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.123</font>&#8220;<b style="font-weight:bold;">Third Party License Agreement</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.7</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.124</font>&#8220;<b style="font-weight:bold;">Trademarks</b>&#8221; means any word, name, symbol, color, designation or device or any combination thereof that functions as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain names, whether or not registered.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.125</font>&#8220;<b style="font-weight:bold;">United States</b>&#8221; or &#8220;U.S.&#8221; means the United States of America, including its territories and possessions.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.126</font>&#8220;<b style="font-weight:bold;">Upfront Payment</b>&#8221; has the meaning set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.127</font>&#8220;<b style="font-weight:bold;">Valid Claim</b>&#8221; means any claim in any [*] unexpired and issued Licensed Patent that has not been disclaimed, revoked or held invalid by a final non-appealable decision of a court or other governmental agency of competent jurisdiction [*].</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">LICENSE GRANTS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.1</font><b style="font-weight:bold;">License Grant to Organon</b>. &#160;Subject to the terms and conditions of this Agreement, ObsEva (on behalf of itself and its Affiliates) hereby grants to Organon and its Affiliates an exclusive (even as to ObsEva and its Affiliates, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.5</u>), sublicensable (solely in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>), non-transferable (except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9</u>) license and sublicense under the Licensed Technology to Develop, Manufacture, have Manufactured, Commercialize and otherwise Exploit Licensed Compound and Licensed Products in the Field and in the Territory.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.2</font><b style="font-weight:bold;">Sublicenses</b>. &#160;Organon shall have the right to grant sublicenses under the license granted in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u>, subject to ObsEva being duly informed in writing by Organon in advance of the execution of any sublicense agreement by Organon with each Sublicensee; provided, however, that, [*]. &#160;Each sublicense granted by Organon pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u> shall be consistent with the terms and conditions of this Agreement and shall include obligations of confidentiality and non-use applicable to the Confidential Information of ObsEva that are substantially similar to those set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>, and include the applicable reporting and record keeping requirements set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u>. &#160;The granting by Organon of a sublicense to a Sublicensee shall not relieve Organon of its obligations hereunder and Organon shall remain directly liable to ObsEva with respect to the performance of its obligations under, and Organon&#8217;s compliance with all provisions of, this Agreement, including ensuring that the performance by any of its Sublicensees of such obligations is in accordance with the applicable terms of this Agreement. Organon shall promptly provide ObsEva with a copy of each fully executed sublicense agreement executed by Organon with each Sublicensee, provided that the commercial and financial terms of such sublicense may be redacted, and ObsEva hereby undertakes to treat such redacted sublicense agreement as Confidential Information of Organon. &#160;For the avoidance of doubt, (i) Organon may grant sublicenses on a country-by-country basis or worldwide and (ii) contract research organizations, CMOs and similar service providers, and wholesalers, distributors and similar physical distributors that do not promote the sale of the Licensed Product shall not need a sublicense and shall be handled in accordance with the subcontracting provision of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.6.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.3</font><b style="font-weight:bold;">Merck Serono Agreement</b>. &#160;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>The Parties acknowledge and agree that the sublicense granted under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 2</u> under certain Licensed Technology that is not owned by ObsEva or its Affiliates are subject to the limitations, obligations, and reservations imposed on ObsEva or its Affiliates in the Merck Serono Agreement. &#160;[*]. Organon acknowledges that it has received a copy of the Merck Serono Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>ObsEva represents and warrants to Organon, as of the Effective Date, that (i) Schedule 2.3 contains a complete and accurate list of all requirements applicable to Organon of the Merck Serono Agreement, and (ii) a copy of the Merck Serono Agreement and all associated amendments related to the performance of obligations thereunder was included in the electronic data room that has been made available to Organon.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>With respect to the Merck Serono Agreement, ObsEva represents and warrants to Organon, as of the Effective Date, that: (i) it is in full force and effect; (ii) neither ObsEva nor any of its Affiliates is in material breach thereof; (iii) neither ObsEva nor any of its Affiliates has received any notice from Merck Serono of any material breach or notice of threatened material breach thereof; (iv) neither ObsEva nor any of its Affiliates has received any notice from Merck Serono of any intent to reduce the scope of the field thereunder or render any of the licenses thereunder non-exclusive or otherwise terminate the Merck Serono Agreement, and, to ObsEva&#8217;s Knowledge no event, act or omission has occurred which would reasonably give rise to the right of Merck Serono to reduce the scope of the field thereof or render any of the licenses thereunder non-exclusive or otherwise terminate such agreement or any licenses thereunder (including with respect to any particular Patents or other intellectual property); (v) neither ObsEva nor any of its Affiliates have waived or relinquished any rights thereunder; and (vi) entering into this Agreement and granting the rights and licenses granted (or purported to be granted) to Organon hereunder complies with and will not result in a breach of the terms and conditions of the Merck Serono Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>ObsEva will inform Organon of any action it may take under the Merck Serono Agreement to the extent such action may impact Organon&#8217;s interest hereunder and will consult with Organon with respect thereto. &#160;Without limiting the foregoing, ObsEva shall: (i) fulfill in all material respects all of its obligations, including its payment obligations, under, and shall not otherwise breach in any material respect, the Merck Serono Agreement and shall maintain same in full force and affect; (ii) not assign (except an assignment to a party to which this Agreement has been assigned as permitted under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9</u>), amend, restate, amend and restate, terminate in whole or in part, or otherwise modify the Merck Serono Agreement, or otherwise waive any rights under the Merck Serono Agreement, in each case, without the prior written consent of Organon, such consent not to be unreasonably withheld, conditioned or delayed; (iii) provide Organon with prompt notice of any claim by Merck Serono or ObsEva, respectively, of ObsEva&#8217;s or Merck Serono&#8217;s breach under the Merck Serono Agreement or notice from Merck Serono or ObsEva of termination of the Merck Serono Agreement; (iv) promptly send to Organon copies of all other material correspondence from ObsEva to Merck Serono or from Merck Serono to ObsEva with respect to the Merck Serono Agreement. Without limiting any other right or remedy of Organon under this Agreement and in order to prevent, ameliorate, mitigate or cure a breach of the Merck Serono Agreement, in the event that ObsEva becomes aware (either on its own, or by notice from Merck Serono) of its material failure to perform any of its obligations under the Merck Serono Agreement (including where a breach or alleged breach by Organon of its obligations under this Agreement or any other act or omission by Organon prevents such performance by ObsEva or is the cause of ObsEva&#8217;s failure to perform such obligation), it shall so promptly notify Organon in writing. &#160;Except to the extent that a breach or alleged breach by Organon (or its Affiliate or Sublicensee) of its obligations under this Agreement or any other act or omission by Organon or its Affiliate or Sublicensee prevents such performance by ObsEva or is the cause of ObsEva&#8217;s failure to perform such obligation, ObsEva&#8217;s notice shall include ObsEva&#8217;s proposed plan to remediate or cure such material failure for Organon&#8217;s review and approval, and if such failure is not cured </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">within [*] days after written notice to Organon, Organon shall have the right, but not the obligation, to perform such obligation on behalf of ObsEva [*] For clarity, if and to the extent ObsEva is prevented from performing any of its obligations under the Merck Serono Agreement as a result of, or ObsEva&#8217;s material failure to perform any of its obligations under the Merck Serono Agreement is caused by, a breach or alleged breach by Organon (or its Affiliate or Sublicensee) of its obligations under this Agreement or any other act or omission by Organon or its Affiliate or Sublicensee, the preceding sentence shall not apply.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>Without limiting the provisions of the foregoing clause (d), ObsEva will enforce (or otherwise take the actions necessary to enable Organon to enforce) ObsEva&#8217;s rights and benefits under the Merck Serono Agreement, and the obligations of Merck Serono under the Merck Serono Agreement, in each case, that may impact the rights, benefits and obligations of Organon hereunder, including taking such actions and exercising such rights under the Merck Serono Agreement as Organon may reasonably request. &#160;ObsEva shall provide notice to Organon of any discussions or other interactions with Merck Serono related to any Licensed Compound or Licensed Product, or the Merck Serono Agreement, and allow Organon to participate in such discussions and interactions, and will not make any decisions with Merck Serono with respect to any Licensed Compound or Licensed Product without the prior consent of Organon, such consent not to be unreasonably withheld, conditioned or delayed.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>If Organon reasonably requests amendments to the Merck Serono Agreement that are reasonably necessary to facilitate Development and Commercialization of Licensed Compounds and Licensed Products, &#160;ObsEva shall, together with Organon, negotiate with Merck Serono to enter into an appropriate amendment to implement the requested modifications to the Merck Serono Agreement. For clarity, Organon shall participate, and at ObsEva&#8217;s request take the lead, in such negotiations, and any such amendments shall be subject to the approval of Organon and ObsEva, which approval shall not be unreasonably withheld, conditioned or delayed by either Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>ObsEva will bear and will be responsible for all of its payment obligations, including royalty payments to Merck Serono, under the Merck Serono Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.4</font><b style="font-weight:bold;">Additional In-License Agreements</b>. During the Term, neither ObsEva nor any of its Affiliates shall, without Organon&#8217;s prior written consent, enter into any agreement with a Third Party related to Know-How, Regulatory Documentation, material, Patents, or other intellectual property rights directed primarily to a Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.5</font><b style="font-weight:bold;">Reserved Rights</b>. &#160;Notwithstanding the exclusive licenses granted to Organon hereunder, ObsEva hereby reserves the right to practice, and to grant licenses under, the Licensed Technology to perform its obligations under this Agreement and any ancillary agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.6</font><b style="font-weight:bold;">No Implied Licenses</b>. &#160;Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">GOVERNANCE</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.1</font><b style="font-weight:bold;">Joint Advisory Committee</b>. &#160;Within [*], the Parties shall establish a Joint Advisory Committee (the &#8220;Joint Advisory Committee&#8221; or the &#8220;JAC&#8221;) to act as a consultative body, and provide input and oversight, with respect to the Development of the Licensed Product in the Territory. &#160;In particular, the JAC shall:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>review and discuss the Development Plan and amendments thereto;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>oversee the Development activities performed pursuant to the Development Plan;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>facilitate the transfer of Licensed Know-How to Organon under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4</u>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>review and discuss draft protocols or synopses of protocols for Clinical Trials and Phase 4 Trials; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>perform such other functions as the Parties may mutually agree in writing from time to time, except where in conflict with any provisions of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.2</font><b style="font-weight:bold;">JAC Membership and Meetings</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">JAC Representatives</b>. &#160;The JAC shall be comprised of an equal number of up to three (3) representatives from each Party. Each Party&#8217;s JAC representatives will have appropriate scientific, clinical, regulatory or commercial expertise and ongoing familiarity with the activities hereunder as are required to fulfill their obligations as members of the JAC. Each Party may replace its representatives on the JAC on written notice to the other Party. &#160;Organon shall appoint the chairperson of the JAC. &#160;The chairperson shall prepare and circulate agendas to JAC members at least five (5) days before each JAC meeting and shall direct the preparation of reasonably detailed minutes for each JAC meeting, which shall be approved by the chairperson and circulated to JAC members within thirty (30) days after such meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Meetings</b>. &#160;The JAC shall hold meetings at such times as it elects to do so, but no less frequently than once per Calendar Year. &#160;Notwithstanding the foregoing, either Party may request that a special ad hoc meeting of the JAC be convened to address matters that cannot reasonably be postponed until the next scheduled meeting of the JAC, and the Parties may mutually agree upon alternative meeting schedules, including less frequently. &#160;Meetings may be conducted in person or by teleconference, videoconference or other similar communications equipment. &#160;In-person meetings shall be held at locations alternately selected by the Parties. &#160;Each Party shall be responsible for its own expenses of participating in any JAC meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Non-Member Attendance</b>. &#160;Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the JAC meetings; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party. &#160;The Party inviting a Third Party to attend a JAC meeting shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.3</font><b style="font-weight:bold;">Limitations on Authority</b>. The JAC shall be an advisory body, and its decisions will not be binding on or enforceable against either Party, and each Party shall remain responsible for such Party&#8217;s decisions relating to the conduct of those activities for which it has a performance or other obligation hereunder, in each case in a manner consistent with the terms and conditions of this Agreement. Notwithstanding the foregoing, if [*], then, within [*] days after the applicable meeting of the JAC, ObsEva may submit such matter to the Party&#8217;s respective Executive Officers who shall discuss such matter in good faith as soon as practicable; provided that, if the Executive Officers are unable to reach agreement after such good faith discussions within a period of [*] days after such matter is so submitted, then Organon&#8217;s Executive Officer shall have the final decision-making authority with respect to such matter. Without limiting the generality of the foregoing, (a) the JAC shall not have the power to amend this Agreement, (b) no decision by the JAC or by either Party may be in contravention of any terms or conditions of this Agreement, and (c) neither the JAC nor a Party will have the authority to (i) amend or modify, or waive compliance with this Agreement, (ii) obligate either Party to violate Applicable Law, the requirements of </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">any Regulatory Authority or any agreement with any Third Party, or (iii) impose any obligation on either Party that would be in violation of such Party&#8217;s written standard operating procedures, written business policies, or written compliance policies or procedure.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.4</font><b style="font-weight:bold;">Discontinuation of the JAC</b>. &#160;The activities of the JAC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. &#160;Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.1(b)</u>, the JAC shall continue to exist until the earlier of (a) the Parties mutually agreeing to disband the JAC, (b) ObsEva&#8217;s election to withdraw its participation and remove its members from the JAC, or (c) [*]. At such time, the JAC shall automatically dissolve and have no further responsibilities under this Agreement, and each Party shall designate a contact person for the exchange of information under this Agreement. Following discontinuation of the JAC, any information, documents or reports that a Party is otherwise required to provide to the JAC pursuant to this Agreement shall be provided directly to the other Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.5</font><b style="font-weight:bold;">Alliance Managers</b>. &#160;Promptly after the Effective Date, each Party shall appoint an individual who shall serve as the main point of contact for each Party to exchange information, facilitate communication and coordinate the Parties&#8217; activities hereunder (each, an &#8220;<b style="font-weight:bold;">Alliance Manager</b>&#8221;). &#160;The Alliance Managers shall oversee communications between the Parties for all matters between meetings of the JAC and after the JAC is discontinued, and shall have such other responsibilities as the Parties may agree in writing after the Effective Date. Each Party may replace its Alliance Manager at any time by providing prior written notice (which may be by email) to the other Party. &#160;Each Party shall bear the costs of its Alliance Manager.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DEVELOPMENT; REGULATORY</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.1</font><b style="font-weight:bold;">General</b>. &#160;Subject to the terms and conditions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u>, Organon shall have sole right and responsibility, at its sole cost and expense, to Develop the Licensed Compounds and Licensed Products in the Territory, including, for clarity, formulation development, GMP manufacturing, regulatory dossier development, non-clinical studies, Clinical Trial development and execution, quality control and quality management, submission of Regulatory Filings, and interactions with relevant Regulatory Authorities.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.2</font><b style="font-weight:bold;">Development Plan; Performance</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Organon shall prepare, and shall provide to the JAC for review and discussion, a plan setting forth the Development activities (including regulatory activities) to be undertaken by Organon or its Affiliates or Sublicensees and intended to achieve Regulatory Approval of the Licensed Products in the Field in the Major Markets (&#8220;Development Plan&#8221;). Organon shall prepare an update to the Development Plan at least [*], and shall provide such amended Development Plan to the JAC for review and discussion.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Organon shall perform, and will ensure that its Affiliates, Sublicensees and Third Party contractors perform, all Development activities under this Agreement in sound scientific manner, in material compliance with all Applicable Laws, and in accordance with, as applicable, ICH and GxP</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.3</font><b style="font-weight:bold;">Development Reports</b>. &#160;In advance of each regularly scheduled JAC meeting, or in writing provided to ObsEva&#8217;s Alliance Manager at least [*] if the JAC is discontinued, Organon shall provide ObsEva with a high-level report (by means of a slide presentation or otherwise) summarizing Organon&#8217;s and its Affiliates and Sublicensees&#8217; significant Development activities in the Major Markets, and the results of such activities, during the period since the previous such report. At each meeting of the JAC, Organon will present and the Parties will discuss such report and a summary of Organon&#8217;s and its Affiliates&#8217; and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Sublicensees&#8217; significant Development efforts and updates on their Development progress with respect to the Licensed Compounds and the Licensed Products in the Major Markets during the period since the previous JAC meeting. In addition, Organon will promptly provide ObsEva, through the JAC or ObsEva&#8217;s Alliance Manager if the JAC is discontinued, with written notice and a reasonably detailed description of any significant Development events (e.g., Clinical Trial Initiation, termination or completion, clinical holds, Safety Concerns or receipt of Regulatory Approvals) arising in the course of Organon&#8217;s or its Affiliate&#8217;s or Sublicensee&#8217;s Development of Licensed Products in the Major Markets. Without limiting the foregoing, [*], Organon shall provide ObsEva a written report summarizing its Development activities [*], in the format reasonably requested by ObsEva, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.4</font><b style="font-weight:bold;">Technology Transfer</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Within [*] after the Effective Date, to the extent not done so already, ObsEva shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to Organon, in electronic or hard copy form, as Organon may reasonably request, Licensed Know-How and any other Know-How claimed or Covered by any Licensed Patent or otherwise relating to any Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>In connection with such transfer, ObsEva, in a timely manner, shall assist Organon in the use and understanding of such Licensed Know-How, including providing technical assistance and making its technical personnel available to Organon. Without prejudice to the generality of the foregoing, if visits of ObsEva&#8217;s representatives to Organon&#8217;s facilities are reasonably requested by Organon for purposes of transferring the Licensed Know-How or other Know-How to Organon or for purposes of Organon acquiring expertise on the practical application of such Know-How or assisting on issues arising during the Exploitation of any Licensed Compound or any Licensed Product, ObsEva shall send appropriate representatives to Organon&#8217;s facilities.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>In addition, in accordance with the Manufacturing Transfer Plan, ObsEva shall effect a full transfer to Organon or its designee (which designee may be an Affiliate or a CMO) of all Licensed Know-How relating to the then-current process for the Manufacture of the Licensed Compounds and Licensed Products (the &#8220;<b style="font-weight:bold;">Manufacturing Process</b>&#8221;) and to implement the Manufacturing Process at facilities designated by Organon (such transfer and implementation, as more fully described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>, the &#8220;<b style="font-weight:bold;">Manufacturing Technology Transfer</b>&#8221;). ObsEva shall provide, and shall [*] cause its CMOs to provide, all assistance requested by Organon to enable Organon (or its Affiliate or designated CMO, as applicable) to implement the Manufacturing Process at the facilities designated by Organon. &#160;If requested by Organon, such assistance shall include providing an introduction to ObsEva&#8217;s CMOs and facilitating the entering into of agreements with applicable Third Party suppliers relating to the Licensed Compounds and Licensed Products. Without limitation to the foregoing, in connection with the Manufacturing Technology Transfer:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>ObsEva shall make available, [*], to Organon (or its Affiliate or designated CMO, as applicable) from time to time as Organon may reasonably request during the period of the Manufacturing Technology Transfer (as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(d)</u>), all Manufacturing-related Licensed Know-How and materials relating to the Manufacturing Process, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to materials to be used and control methods, that are necessary or reasonably useful to enable Organon (or its Affiliate or designated CMO, as applicable) to use and practice the Manufacturing Process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>ObsEva shall cause all appropriate employees and representatives of ObsEva and its Affiliates to meet with, [*] cause all appropriate employees and representatives of its CMOs </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">to meet with, employees or representatives of Organon (or its Affiliate or designated CMO, as applicable) at the applicable manufacturing facility at mutually convenient times during the period of the Manufacturing Technology Transfer (as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(d)</u>) to assist with the working up and use of the Manufacturing Process and with the training of the personnel of Organon (or its Affiliate or designated CMO, as applicable) to the extent necessary or reasonably useful (as reasonably requested by Organon) to enable Organon (or its Affiliate or designated CMO, as applicable) to use and practice the Manufacturing Process; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Without limiting the generality of clause (ii) above, during the period of the Manufacturing Technology Transfer (as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(d)</u>), ObsEva shall cause all appropriate analytical and quality control laboratory employees and representatives of ObsEva and its Affiliates to meet with, [*] cause all appropriate analytical and quality control employees and representatives of its CMOs to meet with, employees or representatives of Organon (or its Affiliate or designated CMO, as applicable) at the applicable manufacturing facility and make available all necessary equipment, at mutually convenient times, to support and execute the transfer of all applicable analytical methods and the validation thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>ObsEva&#8217;s obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4</u>, including its obligations to provide support or assistance pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(b)</u> and to carry out the Manufacturing Technology Transfer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>, shall terminate on the earlier of (i) completion of the Manufacturing Technology Transfer in accordance with the Manufacturing Transfer Plan or (ii) the date that is [*] after the Effective Date. &#160;ObsEva shall provide up to an aggregate of [*] full-time equivalent hours of ObsEva (or its Affiliate(s)) employees to support and assist pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(b)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u> without additional compensation, [*]. Thereafter, Organon shall reimburse ObsEva for its full-time equivalent costs of ObsEva (or its Affiliate(s)) (at an hourly rate of [*] per hour) (where such full-time equivalent costs are in excess of the [*] full-time equivalent hours set forth in the preceding sentence) and any reasonable and verifiable out-of-pocket costs incurred by ObsEva in providing such support and assistance; [*] Organon shall reimburse all documented and verifiable out-of-pocket costs paid by ObsEva to CMOs in connection with the Manufacturing Technology Transfer, including during the period in which ObsEva provides full-time equivalent hours free of charge to Organon pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>. &#160;ObsEva shall invoice Organon for amounts owed by Organon pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u>, together with supporting documentation, once per Calendar Quarter, which invoiced amounts shall be payable by Organon within [*] days after its receipt of such invoice.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>Without limiting the foregoing, in the event that ObsEva makes any invention, discovery, or improvement relating to the Manufacture of a Licensed Compound or a Licensed Product during the Term, ObsEva shall promptly disclose such invention, discovery, or improvement to Organon, and shall, at Organon&#8217;s request, perform technology transfer with respect to such invention, discovery, or improvement in the same manner as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(d)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>Nothing in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4</u> shall obligate ObsEva to (i) create any new invention, discovery, improvement or other Know-How, (ii) purchase, lease or otherwise procure any additional equipment, software or other resources, or (iii) take any actions that would result in the breach of any agreement with a Third Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.5</font><b style="font-weight:bold;">Inventory</b>. ObsEva shall, at Organon&#8217;s request, transfer, assign and deliver to Organon any remaining inventory (as and to the extent requested by Organon) of GMP and non-GMP Licensed Product and bulk Licensed Compound in ObsEva&#8217;s (or its Affiliates&#8217; or its Third Party contract manufacturer&#8217;s) inventory as of the Effective Date, [*]. &#160;ObsEva hereby represents to Organon that Schedule 4.5 sets forth a complete and accurate list of the total quantities of such inventory as of the Effective Date (and indicating whether such inventory is GMP or non-GMP). ObsEva shall make available to Organon, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">directly or by enabling Organon to conduct an on-site or direct inspection of, documentation demonstrating that all such inventory to be provided to Organon was Manufactured in accordance with GMPs. &#160;ObsEva shall and hereby does, represent to Organon that such inventory was Manufactured in accordance with GMPs, Applicable Laws and the specifications therefor. &#160;In furtherance of and without limiting the foregoing, ObsEva shall provide to Organon, as soon as reasonably practicable following the Effective Date (but in all cases, within [*] days thereafter), reasonable supporting documentation with respect to such inventory, including batch records, release records and other documentation demonstrating the quality of such inventory. Organon may elect to take possession of less than the inventory remaining at the Effective Date for any reason, including if Organon or its Affiliates believes that any such inventory was not (and at all times up until delivery of such inventory to Organon hereunder did not remain) Manufactured in accordance with all Applicable Laws (including, as applicable, GMPs), and the specifications therefor, or that such inventory were adulterated or misbranded within the meaning of the FFDCA or any similar Applicable Laws of any applicable jurisdiction or were articles that could not, under the provisions of the Applicable Law, be introduced into interstate commerce. &#160;If Organon elects to take possession of less than the remaining inventory, Organon shall so notify ObsEva and ObsEva shall transfer, assign and deliver to Organon only such inventory as requested by Organon. Except as otherwise set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.5</u>, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.6</font><b style="font-weight:bold;">Regulatory Responsibilities</b>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Subject to the terms and conditions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u>, Organon shall have the sole right and responsibility, at its sole cost and expense, to seek to obtain and to maintain Regulatory Approvals for the Licensed Products in the Field in the Territory and to conduct all related regulatory affairs, including communications with Regulatory Authorities in the Territory relating to the Licensed Compounds and Licensed Products. ObsEva shall support Organon, as may be reasonably necessary, in obtaining all Regulatory Approval for the Licensed Products, and in the activities in support thereof, including providing necessary documents or other materials required by Applicable Law to obtain all Regulatory Approval.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Organon (or its Affiliate or Sublicensee) shall be the holder of and shall own all Regulatory Filings, including INDs, Drug Approval Applications and Regulatory Approvals, for the Licensed Products in the Territory in the name of Organon (or its Affiliate or Sublicensee, as applicable). Upon the request of Organon, ObsEva shall execute all documents and take all actions as are necessary or reasonably requested by Organon to transfer and vest title to Organon in all Regulatory Filings for a Licensed Compound or Licensed Product owned or controlled by ObsEva (or any of its Affiliates), including the INDs set forth on Schedule 4.6(a) (collectively, the &#8220;<b style="font-weight:bold;">Existing INDs</b>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.7</font><b style="font-weight:bold;">Adverse Event Reporting</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Following the transfer of any Existing IND from ObsEva to Organon hereunder, or if there are no Existing INDs to transfer then on and after the Effective Date, Organon shall be solely responsible for the collection, review, assessment, tracking, submission, and filing of information related to adverse events (&#8220;AEs&#8221;) and serious adverse events (&#8220;SAEs&#8221;) associated with the Licensed Compounds and Licensed Products, in accordance with 21 CFR 312.32, 314.80 and comparable regulations, guidance, directives and the like governing AEs/SAEs associated with such Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Within [*] of the Effective Date, ObsEva will provide Organon with all legacy AE and SAE reports in the form of a mutually agreed format (electronic copy of CIOMS I form or E2B format).</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>Following receipt, and completion of processing, by Organon of all AE and SAE reports required to be provided under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.7(b),</u> Organon will assume the role of global safety database holder, and shall be responsible for maintaining, at its sole cost and expense, the global safety database, for the Licensed Compounds and Licensed Products. &#160;</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">COMMERCIALIZATION; MANUFACTURE; SUBCONTRACTING</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.1</font><b style="font-weight:bold;">Commercialization</b>. &#160;Subject to the terms and conditions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u>, Organon shall have the sole right and responsibility, at its sole cost and expense, to Commercialize the Licensed Products in the Territory and to conduct market access activities relating to the Licensed Products, including: (a) developing and executing a commercial launch and pre-launch plan; (b) negotiating Reimbursement Approvals with Governmental Authorities; (c) marketing, advertising and promotion; (d) distribution and performance of related services; (e) handling order processing, invoicing and collection, inventory and receivables; (f) determining pricing and terms of sale of Licensed Product; and (g) providing customer support.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.2</font><b style="font-weight:bold;">Medical Affairs</b>. &#160;Subject to the terms and conditions of this Agreement, including <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u>, Organon shall have the sole right and responsibility, at its sole cost and expense, to conduct medical affairs relating to Licensed Products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.3</font><b style="font-weight:bold;">Manufacture</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Supply of Licensed Compounds and Licensed Products Prior to Manufacturing Technology Transfer</b>. During the period beginning on the Effective Date and ending on the date that is [*] after the Effective Date or, if earlier, ending on the date the facilities designated by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(c)</u> are fully qualified and validated following completion of Manufacturing Technology Transfer (the &#8220;<b style="font-weight:bold;">Supply Period</b>&#8221;), pursuant to supply agreements and associated quality agreements (collectively, &#8220;<b style="font-weight:bold;">Supply Agreements</b>&#8221;) &#160;to be entered into by the Parties [*] as soon as practicable (with a goal of no later than [*] days) after the Effective Date, unless otherwise agreed to in writing by the Parties, ObsEva shall have Manufactured and supplied to Organon or its designee, through ObsEva&#8217;s existing CMO that manufactures Licensed Compound and Licensed Products (&#8220;<b style="font-weight:bold;">Licensed Product CMO</b>&#8221;), the Licensed Compound and the Licensed Products [*] for Development purposes throughout the Territory. [*] The Supply Agreements will include the terms set forth on Schedule 5.3(a) (as applicable to Manufacture and supply of the Licensed Compound and/or the Licensed Product) and other terms customary for supply arrangements between partners. ObsEva shall use [*] to ensure that ObsEva&#8217;s agreements with the Licensed Product CMO are consistent with such terms, provided that in the event ObsEva and the Licensed Product CMO are unable to mutually agree to include such terms, the Parties will discuss in good faith any necessary amendments to Schedule 5.3(a) prior to ObsEva entering into an agreement or work order or similar arrangement with any such Licensed Product CMO. The Supply Agreements will provide (i) that ObsEva&#8217;s agreements with the Licensed Product CMO will require such CMO to Manufacture the Licensed Compounds and Licensed Products in accordance with GMPs and the specifications therefor and [*] &#160;In all cases, the price for the supply shall be [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Supply of Licensed Compounds and Licensed Products after the Supply Period</b>. As between the Parties, following expiration of the Supply Period, Organon shall have the sole right and responsibility to Manufacture the Licensed Compounds and Licensed Products for all purposes under this Agreement, including supply of Licensed Compound and Licensed Product to Organon&#8217;s Affiliates and Sublicensees.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.4</font><b style="font-weight:bold;">Reports</b>. Once per Calendar Year, in advance of a regularly scheduled JAC meeting, or in writing to ObsEva&#8217;s Alliance Manager if the JAC is discontinued, Organon shall provide ObsEva with (a) a high-level report (by means of a slide presentation or otherwise) summarizing Organon&#8217;s and its Affiliates and Sublicensees&#8217; significant Commercialization and medical affairs activities in the Major Markets during the period since the previous such report, and (b) [*]. At such JAC meeting or through the Parties&#8217; Alliance Managers, Organon will present and the Parties will discuss such report and a summary of Organon&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; significant Commercialization and medical affairs activities with respect to the Licensed Products in the Territory. &#160;Further, on or before June 1st of each Calendar Year, Organon shall provide ObsEva a written report summarizing its Manufacturing and as applicable Commercialization activities in the Territory during the preceding Calendar Year, in the format reasonably requested by ObsEva, [*]. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.5</font><b style="font-weight:bold;">Performance</b>. Organon shall perform, and will ensure that its Affiliates, Sublicensees and Third Party contractors perform, all Commercialization, medical affairs and Manufacturing activities under this Agreement in compliance with all Applicable Laws, including, as applicable, GxP standards.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.6</font><b style="font-weight:bold;">Subcontracting</b>. Organon shall have the right to engage any Third Party subcontractor to perform any or all of its obligations hereunder, including contract research organizations, contract manufacturing organizations and similar service providers. The applicable provisions of each agreement between Organon and a Third Party subcontractor shall be materially consistent with the corresponding provisions of this Agreement and shall include confidentiality and non-use provisions at least as stringent as those set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>. Organon&#8217;s engagement of any subcontractor pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.6</u> shall not relieve Organon of its obligations under this Agreement and Organon shall be fully responsible for any acts or omissions of its subcontractors, including compliance by such subcontractors with Anti-Corruption Laws, Privacy Laws and GxP standards, as applicable, and for compliance with all provisions of this Agreement.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">DILIGENCE &#160;</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.1</font><b style="font-weight:bold;">Development Diligence</b>. &#160;Organon, itself or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.2</font><b style="font-weight:bold;">Commercialization Diligence</b>. &#160;Organon, itself or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to (a) [*].</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">7.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">FINANCIAL PROVISIONS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.1</font><b style="font-weight:bold;">Upfront Payment</b>. Organon shall pay to ObsEva a one-time, non-refundable, noncreditable payment equal to Twenty-Five Million Dollars ($25,000,000) (the &#8220;<b style="font-weight:bold;">Upfront Payment</b>&#8221;), payable within [*] after the Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.2</font><b style="font-weight:bold;">Non-Sales Milestones Payments</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Non-Sales Milestones</b>. &#160;Subject to the remainder of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u>, Organon shall pay to ObsEva the one-time, non-refundable, non-creditable milestone payments set forth in the table below upon the first achievement of the applicable milestone event by the first Licensed Product (whether by or on behalf of Organon or its Affiliates or Sublicensees):</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.89%;"><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Non-Sales Milestone Event</b></p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Non-Sales Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.89%;"><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Non-Sales Milestone Cap</b>. Each milestone payment in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u> shall be payable one time only upon the first achievement of such milestone by the first Licensed Product and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Licensed Compound or Licensed Product. &#160;The maximum aggregate amount payable by Organon pursuant to this Section is [*]. [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Notice and Payment</b>. &#160;Organon shall notify ObsEva in writing and pay to ObsEva the applicable development milestone payment within [*]. &#160;If, notwithstanding the fact that Organon has not provided ObsEva notice of the achievement of any milestone event set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u>, ObsEva believes that any such milestone event has been achieved, it shall so notify Organon in writing and the Parties shall promptly meet and discuss in good faith whether such milestone has been achieved. &#160;Any dispute under this this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u> regarding whether or not such a milestone event has been achieved shall be subject to resolution in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.3</font><b style="font-weight:bold;">Sales-Based Milestones Payments</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Sales Milestones</b>. &#160;Subject to the remainder of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u>, in the event the aggregate Net Sales of all Licensed Products made by Organon or any of its Affiliates or Sublicensees in the Territory in a given Calendar Year first exceeds each of the sales milestone events set forth in the left-hand column of the table immediately below, Organon shall pay to ObsEva the sales milestone payment in the corresponding amount set forth in the right-hand column of the table within [*].</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.89%;"><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Sales Milestone Event</b></p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Sales Milestone Payment</b></p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Sales Milestone Cap</b>. Each milestone payment in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> shall be payable only upon the first achievement of such milestone in a Calendar Year, and no amounts shall be due for subsequent or repeated achievements of such milestone in subsequent Calendar Years, whether for the same or a different Licensed Compound or Licensed Product. &#160;The maximum aggregate amount payable by Organon pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> is [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Expiration of Royalty Term</b>. With respect to each Licensed Product in each country in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country, Net Sales of such Licensed Product in such country shall be excluded for purposes of </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">calculating the Net Sales thresholds set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u>. &#160;Following the expiration of the final Royalty Term, Organon will have no obligation to pay any milestone payments pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Notice and Payment</b>. &#160;As part of the report in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u>, Organon shall provide written notice to ObsEva upon the annual Net Sales of the Licensed Products reaching the values set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3(a)</u> above. &#160;If, notwithstanding the fact that Organon has not provided ObsEva notice of the achievement of any milestone event set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u>, ObsEva believes that any such milestone event has been achieved, it shall so notify Organon in writing and the Parties shall promptly meet and discuss in good faith whether such milestone has been achieved. &#160;Any dispute under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.3</u> regarding whether or not such a milestone event has been achieved shall be subject to resolution in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.4</font><b style="font-weight:bold;">Royalty Payments</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Royalty Rate</b>. &#160;Subject to the remainder of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u>, during the Royalty Term, Organon shall make quarterly non-refundable, non-creditable royalty payments to ObsEva on the aggregate Net Sales of all Licensed Products made by Organon or any of its Affiliates or Sublicensees in the Territory (excluding Net Sales of each Licensed Product in any country in the Territory for which the Royalty Term for such Licensed Product in such country has expired) in a Calendar Year on a tiered basis at the applicable incremental royalty rate set forth in the table below.</div><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.89%;"><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Portion of Aggregate Net Sales of all Licensed Products in the Territory in a Calendar Year</b></p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:3pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Royalty Rate</b></p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr><tr><td style="vertical-align:top;width:55.77%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">[*]</p></td><td style="vertical-align:top;width:44.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">[*]</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Royalty Term</b>. &#160;The royalties set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u> shall be paid on a Licensed Product-by-Licensed Product and country-by-country basis from the First Commercial Sale of such Licensed Product in such country by or on behalf of Organon, its Affiliates, or Sublicensees, until the last to occur of [*] (the &#8220;<b style="font-weight:bold;">Royalty Term</b>&#8221;). With respect to each Licensed Product in each country in the Territory, from and after the expiration of the Royalty Term for such Licensed Product in such country, Net Sales of such Licensed Product in such country shall be excluded for purposes of calculating the Net Sales thresholds and ceilings set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Royalty Reductions</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">After Expiration of Royalty Term</b>. Organon shall have no obligation to pay any royalty with respect to Net Sales of any Licensed Product in any country after the Royalty Term for such Licensed Product in such country has expired.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><b style="font-weight:bold;">Generic Product Sales</b>. On a Licensed Product-by-Licensed Product and country-by-country basis during the Royalty Term, and subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(vi)</u>, if one or more Generic Products is sold in such country and (A) if the aggregate [*] of all such Generic Products sold in such country in a Calendar Year exceed [*] of all such Generic Products and Licensed Product sold in such country in such Calendar Year, then commencing at the beginning of the Calendar Quarter in which such [*] of Generic Products sold exceed [*], the royalty rates set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u> for such Licensed Product shall be reduced in such country by [*] for the remainder of the Royalty Term. &#160;[*] Notwithstanding the foregoing, [*].</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><b style="font-weight:bold;">Reduction Circumstances</b>. Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(vi)</u>, on a Licensed Product-by-Licensed Product and country-by-country basis, if during any Calendar Quarter within the applicable Royalty Term for such Licensed Product in such country, [*] (the &#8220;<b style="font-weight:bold;">Reduction Circumstances</b>&#8221;), then, [*], the royalty rates set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u> applicable to the Net Sales of such Licensed Product in such country will be reduced by [*]; <i style="font-style:italic;">provided that</i>, [*], then [*]. For clarity, the maximum reduction in the royalty rates under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(iii)</u> is [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><b style="font-weight:bold;">Step-In Prosecuted Patent</b>. If, during the Royalty Term, Organon assumes the Prosecution of an ObsEva Patent pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4(b)(i)</u> or assumes the Prosecution of a Merck Serono Patent pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.4(b)(ii)</u> (each, a &#8220;<b style="font-weight:bold;">Step-In Prosecuted Patent</b>&#8221;), then on a Licensed Product-by-Licensed Product and country-by-country basis, such Step-In Prosecuted Patent shall cease to be included in the Licensed Patents for purposes of determining the Royalty Term applicable to such Licensed Product in such country.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><b style="font-weight:bold;">Third Party Payments</b>. In the event that Organon enters into a Third Party License Agreement pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.7</u> in order to obtain a license under [*] (in each case of clause (A) and (B), an &#8220;<b style="font-weight:bold;">Infringing Licensed Product</b>&#8221; and such Third Party License Agreement, a &#8220;<b style="font-weight:bold;">Third Party License</b>&#8221;), then, subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(vi)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.5</u>, on an Infringing Licensed Product-by-Infringing Licensed Product and country-by-country or jurisdiction-by-jurisdiction basis, Organon shall be entitled to deduct from any royalties payable hereunder with respect to that Infringing Licensed Product and country or other jurisdiction [*] actually paid to such Third Party under such Third Party License directly as a result of the Development, Manufacture or Commercialization of such Infringing Licensed Product in such country or jurisdiction; provided that, the royalty rate that otherwise would be applicable under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u> to Net Sales of such Infringing Licensed Product in such country or jurisdiction in a Calendar Quarter may not be reduced by more than [*] as a result of any deduction under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(v)</u>; provided further that, Organon may carry forward any such deductions permitted under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(v)</u> that are incurred or accrued in a Calendar Quarter but are not deducted from royalties due to ObsEva in such Calendar Quarter as a result of the foregoing proviso and apply such amounts against royalties due to ObsEva in any subsequent Calendar Quarter (subject to the minimum floor set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(c)(vi)</u>) until the amount of such permitted deduction has been fully applied against royalties due to ObsEva.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font><b style="font-weight:bold;">Royalty Floor</b>. Notwithstanding the above, on a Licensed Product-by-Licensed Product and country-by-country basis during the Royalty Term, in no event will (A) the royalty rate that otherwise would be applicable under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u> to such Licensed Product in such country in a Calendar Quarter be reduced by more than [*] as a result of the operation of subclauses (ii), (iii), and (v) above, individually or in combination and (B) [*]. For clarity, on a Licensed Product-by-Licensed Product and country-by-country basis, in no event will ObsEva receive less than [*] of the amount of royalties that otherwise would have been due and payable to ObsEva for such Licensed Product in such country in any Calendar Quarter at the royalty rates applicable under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4(a)</u>).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.5</font>[*].</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">8.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">PAYMENT; RECORDS; AUDITS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.1</font><b style="font-weight:bold;">Payment; Reports</b>. &#160;Royalty payments due from Organon to ObsEva under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4</u> shall be calculated and reported for each Calendar Quarter during the Term. &#160;Royalty payments due under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.4</u> shall be paid within [*] days after the end of each Calendar Quarter and shall be accompanied by a report setting forth [*].</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.2</font><b style="font-weight:bold;">Exchange Rate; Manner and Place of Payment</b>. &#160;The Upfront Payment and all milestone payments to be made by Organon to ObsEva under this Agreement shall be made in Dollars, and all royalty payments to be made by Organon to ObsEva under this Agreement shall be made in Euros, and each shall be made by bank wire transfer in immediately available funds to the bank account set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 8.2</u>. &#160;In the case of sales that are not in Dollars or Euros (as applicable), the rate of exchange to be used in computing the monthly amount of currency equivalent in Dollars or Euros (as applicable) due ObsEva shall be made at the monthly rate of exchange utilized by Organon in its worldwide accounting system consistent with Accounting Standards and Organon&#8217;s conversion procedures used in preparing its financial statements applied on a consistent basis.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.3</font><b style="font-weight:bold;">Taxes</b>. Organon shall inform ObsEva of any withholding tax obligation imposed by taxing authorities on payments due to ObsEva under this Agreement. &#160;The Parties agree to cooperate in good faith to provide one another with such documents and certifications as are reasonably necessary to enable the Parties to minimize or recover any withholding tax payment. &#160;If any Applicable Laws require that taxes be deducted and withheld from royalties or other payments payable by Organon to ObsEva under this Agreement, Organon shall (a) deduct those taxes from the payment owed by Organon hereunder; (b) pay those taxes to the proper Governmental Authority; (c) send evidence of the obligation together with proof of payment to ObsEva within thirty (30) days following such payment; (d) remit the net amount, after deductions or withholding made under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u>; and (e) cooperate with ObsEva in any way reasonably requested by ObsEva to obtain available reductions, credits or refunds of such taxes. For clarity, Organon shall be solely responsible for (i) [*] (and related tax returns) applicable to payments and transactions under this Agreement and (ii) all customs duties, import tariffs, taxes, freight, insurance, inspection costs and the like attributed to or for the transport and importation of any Licensed Product under this Agreement or the Supply Agreements. Notwithstanding the foregoing, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.4</font><b style="font-weight:bold;">Records; Audit</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Organon shall keep, and shall require its Affiliates and Sublicensees (as provided below) to keep, complete and accurate records pertaining to the sale or other disposition of Licensed Products in sufficient detail to permit ObsEva to confirm the accuracy of any sales milestone or royalty payment due hereunder. &#160;Organon will keep, and shall require its Affiliates and Sublicensees (as provided below) to keep, such books and records for [*] following the Calendar Year to which they pertain, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Upon the written request of ObsEva and not more than once in each Calendar Year, Organon shall permit an independent certified public accounting firm of nationally recognized standing selected by ObsEva [*] and reasonably acceptable to Organon, at ObsEva&#8217;s expense (except as set forth below), to have access during normal business hours to such of the records of Organon as may be reasonably necessary to verify the accuracy of the reports under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u> pertaining to the [*] preceding the date of such request. &#160;The accounting firm shall disclose to ObsEva [*] only whether the reports under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u> are correct or incorrect and the amount of any discrepancy. &#160;No other information shall be provided to ObsEva [*]. If such accounting firm correctly identifies a discrepancy made during such period, then (i) in the case of an underpayment, Organon shall pay the underpaid amount within [*] of the date ObsEva delivers to Organon such accounting firm&#8217;s written report so correctly concluding, or as otherwise agreed upon by the Parties, and (ii) in the case of an overpayment, the overpaid amount shall be credited against amounts payable by Organon in subsequent payment periods, or if there are no subsequent payment periods at that time, shall be reimbursed to Organon by ObsEva within [*] days of the date ObsEva delivers to Organon such accounting firm&#8217;s written report so correctly concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by ObsEva unless the accounting firm identifies an underpayment by Organon of [*] or more for the audited period, in which case Organon shall reimburse ObsEva for the reasonable fees charged by such accounting firm.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>Organon shall include in each sublicense granted by it to a Sublicensee a provision requiring the Sublicensee to make reports to Organon, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by ObsEva&#8217;s independent accountant to the same extent required of Organon under this Agreement. ObsEva shall treat all financial information subject to review under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u> or under any sublicense agreement with a Sublicensee in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with Organon, its Affiliates or Sublicensees obligating it to retain all such information in confidence pursuant to such confidentiality agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Late Payments</b>. &#160;If any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement (including any underpayments of royalties found during an audit under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u>), such payment shall accrue interest from [*]. &#160;</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">9.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">INTELLECTUAL PROPERTY</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.1</font><b style="font-weight:bold;">Ownership of Inventions</b>. &#160;Inventorship of all Inventions shall be determined in accordance with U.S. patent laws without regard to conflict of law, irrespective of where or when such Invention occurs. &#160;Subject to the license grants and other rights herein, as between the Parties, each Party shall own and retain all right, title and interest in and to any and all Inventions that are discovered, made, developed, generated, conceived or reduced to practice solely by or on behalf of such Party (or its Affiliates or its or their (sub)licensees), whether or not patented or patentable, and any and all Patents and other intellectual property rights with respect thereto. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.2</font><b style="font-weight:bold;">Certification Under Drug Price Competition and Patent Restoration Act</b>. Each Party shall immediately give written notice to the other Party of any certification of which they become aware filed pursuant to 21 U.S. Code Section 355(b)(2)(A) in the U.S. or any comparable law or regulation in any jurisdiction in the Territory other than the U.S. (or any amendment or successor thereto) claiming that any Licensed Patents in the Territory Covering the Licensed Compounds or Licensed Products, or the manufacture or use thereof, are invalid or unenforceable, or that infringement will not arise from the manufacture, use or sale of a product by a Third Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.3</font><b style="font-weight:bold;">Listing of Patents</b>. [*] shall determine which of the [*] Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S. Code Section 355 in the U.S. or any comparable law or regulation in any jurisdiction in the Territory other than the U.S. (or any amendment or successor thereto). [*] shall have the right to propose to [*] any [*] Patents for such listing and [*] shall propose such [*] Patents to [*] for such listing, provided that [*] shall have the right to determine whether any [*] Patents will be listed.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.4</font><b style="font-weight:bold;">Patent Prosecution</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Prosecution of [*] Patents and [*] Patents</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>As between the Parties, [*] shall have the first right, but not the obligation, to control Prosecution of the Licensed Patents in the Territory [*]. With respect to Prosecution of [*] Patents, [*] shall keep [*] fully informed of all steps with regard to the preparation, filing, prosecution, and maintenance of [*] Patents, including by providing [*] with a copy of material communications to and from any patent authority in the Territory regarding such [*] Patents, and by providing [*] drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for [*] to review and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">comment thereon. [*] shall consider in good faith the requests and suggestions of [*] with respect to such [*] drafts and with respect to strategies for filing and prosecuting the [*] Patents in the Territory.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>[*] shall keep [*] informed of the course of the Prosecution of [*] Serono Patents or related proceedings (e.g., interferences, oppositions, reexaminations, releases, revocations or nullifications) [*]. With respect to each [*] Patent [*] shall keep [*] fully informed of all steps with regard to the preparation, filing, prosecution, and maintenance of such [*] Patent, including by providing [*] with a copy of material communications to and from any patent authority in the Territory regarding such [*] Patent, and by providing [*] drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for [*] to review and comment thereon. [*] shall consider in good faith the requests and suggestions of [*] with respect to such [*] drafts and with respect to strategies for filing and prosecuting such [*] in the Territory.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Abandonment of [*] Patents and [*] Patents</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>If [*] desires to irrevocably abandon or cease prosecution or maintenance of any [*] Patent, it shall provide reasonable prior written notice to [*] of such intention to abandon [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>If [*] receives written notice [*] that [*]. &#160; </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Patent Term Extensions</b>. &#160;[*] shall have the right to make decisions regarding, and to file for and seek to obtain, [*], patent term extensions or supplementary protection certificates or their equivalents and any other extensions that are now or become available in the future, in any country in the Territory with respect to the [*]. [*] shall keep [*] reasonably informed of its efforts to obtain such extension or supplementary protection certificate. &#160;[*] shall provide prompt and reasonable assistance, as requested by [*], including by taking such action as patent holder as is required under any Applicable Laws to obtain such patent extension or supplementary protection certificate. &#160;With respect to [*], [*] shall be responsible for obtaining patent term extensions wherever available and [*] shall provide [*], in order for [*] to provide [*], with all relevant information and documentation in this respect, and all such information and documentation shall be provided by [*] promptly and in a manner that will ensure all such patent term extensions are obtained wherever legally permissible and to the maximum extent available. In the event any election with respect to obtaining patent term extensions is to be made for any [*], [*] shall have the right to make such elections and shall inform [*] of such elections in order for [*] to inform [*] of such elections as if such elections were made by [*] pursuant to the [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Organon Improvement Patents</b>. As between the Parties, [*] shall have the sole right, but not the obligation, to control Prosecution of Organon Improvement Patents [*]. &#160;[*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.5</font><b style="font-weight:bold;">Patent Enforcement</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Notice</b>. &#160;Each Party shall promptly notify the other Party after becoming aware of any alleged or threatened infringement by a Third Party of any [*] Patents in the Territory, which infringement adversely affects or is expected to adversely affect any Licensed Product in the Field in the Territory, including any such alleged or threatened infringement by reason of the Third Party making, using, offering to sell, selling or importing any product that is competitive with a Licensed Product in the Field in the Territory (collectively, &#8220;<b style="font-weight:bold;">[*] Patent Infringement</b>&#8221;). In addition, if either Party believes a [*] Patent is being infringed by a Third Party or if a Third Party claims that any [*] Patent is invalid or unenforceable (&#8220;<b style="font-weight:bold;">[*] Patent Infringement</b>&#8221;), such Party shall notify the other Party and provide details of such [*] Patent Infringement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Enforcement Right</b>. &#160;[*] shall have the first right, but not the obligation, to bring and control any legal action with respect to an [*] Patent Infringement in the Territory (&#8220;<b style="font-weight:bold;">Legal Action</b>&#8221;) [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Collaboration</b>. &#160;Each Party shall provide to the Party that brings a Legal Action pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.5(b)</u> (the &#8220;<b style="font-weight:bold;">Enforcing Party</b>&#8221;) reasonable assistance, and shall cooperate fully, in such Legal Action, [*], including to be named in such action if required by Applicable Laws to pursue such action. &#160;The Enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts and shall reasonably consider the other Party&#39;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the court. &#160;The non-enforcing Party shall be entitled to separate representation in such Legal Action by counsel of its own choice [*], but such Party shall at all times cooperate fully with the Enforcing Party. [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Expense and Recovery</b>. &#160;[*] incurred by such Party as a result of a Legal Action with respect to an ObsEva Patent Infringement. &#160;If the Enforcing Party recovers monetary damages in such Legal Action, such recovery shall be allocated [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">[*] Patent Infringement</b>. &#160;The Parties acknowledge [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.6</font><b style="font-weight:bold;">Infringement of Third Party Rights</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Notice</b>. If either Party becomes aware of any claim or action by a Third Party against either Party, its Affiliates or sublicensees that claims that the Licensed Product, or its use, Development, Manufacture, importation or sale infringes such Third Party&#39;s intellectual property rights in a jurisdiction in the Territory (&#8220;<b style="font-weight:bold;">Third Party Action</b>&#8221;), such Party shall promptly notify the other Party and shall provide all details regarding the Third Party Action that is reasonably available to such Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Right to Defend</b>. The Parties acknowledge that, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Consultation</b>. As between the Parties, the Party defending a Third Party Action pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9.6(b)</u> shall be the &#8220;<b style="font-weight:bold;">Controlling Party</b>.&#8221; The Controlling Party shall consult with the non-Controlling Party on all material aspects of the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in decision-making and formulation of defense strategy. The Parties shall reasonably cooperate with each other in all such actions or proceedings. The non-Controlling Party will be entitled to be represented by independent counsel of its own choice at its own expense.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Appeal</b>. In the event that a judgment in a Third Party Action is entered against the Controlling Party and an appeal is available, the Controlling Party shall have the first right, but not the obligation, to file such appeal [*]. If the Controlling Party does not desire to file such an appeal, it will promptly, in a reasonable time period (i.e., with sufficient time for the non-Controlling Party to take whatever action may be necessary) prior to the date on which such right to appeal will lapse or otherwise diminish, permit the non-Controlling Party to pursue such appeal [*]. The non-Controlling Party shall then become the Controlling Party. If Applicable Law requires the non-Controlling Party&#39;s involvement in an appeal, the non-Controlling Party shall be a nominal party of the appeal and shall provide reasonable cooperation to the Controlling Party at the Controlling Party&#39;s expense.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">No Settlement Without Consent</b>. No Controlling Party shall settle or otherwise compromise any Third Party Action by admitting that any Licensed Patent is invalid or unenforceable without the non-Controlling Party&#39;s [*] prior written consent.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.7</font><b style="font-weight:bold;">Third Party License Agreements. [*]</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.8</font><b style="font-weight:bold;">Product Trademarks</b>. Organon shall have the sole right to determine and own the Trademark(s) to be used for the Licensed Products in the Territory, including a global unitary Trademark for each Licensed Product and any other Trademarks to be used for the Licensed Products in any country in the Territory (the &#8220;<b style="font-weight:bold;">Product Trademarks</b>&#8221;). Organon shall have the sole right, at its cost and expense, for the filing, prosecution, registration and maintenance (including the defense of any opposition proceeding or equivalent proceeding) of the Product Trademarks throughout the Territory and for enforcement of the Product Trademarks against any known or suspected infringement or unauthorized use or misappropriation by a Third Party of any Product Trademarks in the Territory. &#160;</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">10.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">CONFIDENTIALITY</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.1</font><b style="font-weight:bold;">Confidential Information</b>. &#160;Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [*] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>, shall not publish or otherwise disclose the terms of this Agreement. &#160;Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, licensees, sublicensees, and other representatives do not disclose or make any unauthorized use of the other Party&#8217;s Confidential Information. &#160;Each Party will promptly notify the other upon discovery of any loss or unauthorized use or disclosure of the other Party&#8217;s Confidential Information. The terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u> through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3</u>, inclusive, shall apply to and be binding on Organon with respect to any Merck Serono Confidential Information (as defined below), and Organon shall be deemed the receiving Party of any such Merck Serono Confidential Information. &#8220;<b style="font-weight:bold;">Merck Serono Confidential Information</b>&#8221; means any information relating to the business, operations and products of Merck Serono or any of its Affiliates, including any technical information, Know-How, trade secrets or inventions (whether patentable or not), not known or generally available to the public, that is disclosed to Organon pursuant to this Agreement and identified as Merck Serono Confidential Information at the time of such disclosure. &#160;ObsEva shall use reasonable, good faith efforts to determine and identify as Merck Serono Confidential Information only that information relating to the business, operations and products of Merck Serono or any of its Affiliates that was disclosed to ObsEva by Merck Serono pursuant to the Merck Serono Agreement or that otherwise became known to ObsEva by virtue of the Merck Serono Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.2</font><b style="font-weight:bold;">Exceptions</b>. &#160;The obligations of confidentiality and restriction on use under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.1</u> will not apply to any information that the receiving Party can prove by competent written evidence:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; provided that the foregoing exception shall not apply with respect to Regulatory Documentation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>is independently discovered or developed by the receiving Party without the use of the disclosing Party&#8217;s Confidential Information; provided that the foregoing exception shall not apply with respect to Regulatory Documentation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.3</font><b style="font-weight:bold;">Authorized Disclosure</b>. &#160;Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>to a patent authority in connection with filing, prosecuting, and maintaining Patents, in each case as contemplated by, and in accordance with the terms of, this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>to Governmental Authorities in connection with filing Regulatory Filings and seeking Regulatory Approval for Licensed Products in accordance with this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>prosecuting or defending litigation as permitted by this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>disclosure as required to comply with Applicable Law (including regulations promulgated by securities exchanges) or court or administrative orders;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>disclosure of the financial terms of this Agreement to actual and bona fide potential investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, or collaboration, in each case under written obligations of confidentiality and non-use at least as stringent as those herein;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>disclosure by Organon or its Affiliates or Sublicensees to its or their employees, consultants, contractors, agents, licensees, sublicensees or other Third Parties, in each case as may be necessary or useful in connection with the Development, Manufacture, Commercialization or other Exploitation of the Licensed Compounds and Licensed Products in accordance with the terms of this Agreement or otherwise in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein; provided that disclosure pursuant to this clause (f) shall not be permitted with respect to Merck Serono Confidential Information except to the extent such disclosure is reasonably necessary in connection with conducting pre-clinical studies or Clinical Trials of Licensed Products or seeking Regulatory Approval of Licensed Products; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>disclosure made by ObsEva or its Affiliates after receiving advanced approval from Organon, to its employees, consultants, contractors, agents, licensees, or sublicensees to the extent necessary in assisting with ObsEva&#8217;s activities contemplated by this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3(c)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3(d)</u>, it will, except to the extent prohibited by Applicable Law or judicial or administrative process, give advance notice as promptly as reasonably practicable (and to the extent possible, at least [*] notice) to the other Party of such disclosure and provide a draft of the disclosure to the other Party reasonably in advance of such filing or disclosure to give the other Party a reasonable opportunity to take whatever action available to it under Applicable Law that it deems necessary to protect its Confidential Information (for example, quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by the applicable court or governmental body or, if disclosed, be used only for the purposes for which the order was issued). &#160;The other Party will provide any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">comments as soon as practicable, in no event later than [*] from such notice, and such Party will consider in good faith any timely comments provided by the other Party, but without any obligation to accept such comments. In any event, the Party required to make such disclosure will use efforts to secure confidential treatment of such Confidential Information at least as diligent as such Party would use to protect its own confidential information of a similar nature, but in no event less than reasonable efforts, and the Parties agree to take all reasonable action to avoid disclosure of Confidential Information, and in the event that no protective order or other remedy is obtained, or the disclosing Party waives compliance with the terms of this Agreement, the receiving Party shall furnish only that portion of Confidential Information which the receiving Party is advised by counsel is legally required to be disclosed. &#160;Any information disclosed pursuant to any of the foregoing subsections shall remain Confidential Information and subject to the foregoing provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.4</font><b style="font-weight:bold;">Licensed Know-How</b>. ObsEva agrees to keep all Licensed Know-How confidential subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.2</u> except for disclosures (a) reasonably necessary in connection with filing, prosecuting and maintaining Patents as contemplated by, and in accordance with the terms of, this Agreement and the Merck Serono Agreement and (b) as required to comply with Applicable Law (including regulations promulgated by securities exchanges) or court or administrative orders, provided that the terms of the last paragraph of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3</u> will apply to such disclosures, mutatis mutandis.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.5</font><b style="font-weight:bold;">Publications</b>. &#160;[*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.6</font><b style="font-weight:bold;">Clinical Trial Registration</b>. &#160;In all cases, Organon shall have the right to register Clinical Trials and publish the results or summaries of results of any Clinical Trials conducted hereunder with respect to Licensed Compound or Licensed Product on clinicaltrials.gov or other similar registry.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.7</font><b style="font-weight:bold;">Disclosures to Merck Serono</b>. Notwithstanding anything to the contrary herein, ObsEva shall be entitled to provide a copy of this Agreement to Merck Serono, subject to redaction of the financial terms set forth herein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.8</font><b style="font-weight:bold;">Press Releases and Public Disclosures</b>. &#160;The Parties have agreed on a joint press release announcing the execution of this Agreement as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 10.8</u>. Subject to obtaining consent from Merck Serono in accordance with the Merck Serono Agreement, the Parties shall issue such joint press release on the date and at the time(s) agreed by the Parties. &#160;Other than such initial joint press release, except as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section &#160;10.8</u>, neither Party may make any press release or public announcements regarding any matter covered by this Agreement, including the Development or Commercialization of Licensed Products, without the prior written consent of the other Party and Merck Serono (which consent shall not be unreasonably withheld). Organon shall provide a draft of any such proposed press release or public announcement to ObsEva at least [*] prior to the desired date of issuance. ObsEva will promptly submit such press release or public announcement to Merck Serono, and ObsEva will notify Organon if Merck Serono objects. If neither ObsEva nor Merck Serono objects to such press release or public announcement within the [*] deadline, such press release or public announcement shall be deemed to be approved by ObsEva and Merck Serono. If Organon is a publicly-traded company and believes it is required to issue a press release or make any other public announcement to comply with applicable law as a publicly-traded company, Organon may issue such press release or public announcement, provided that, if time allows, Organon shall submit the proposed press release or public announcement in writing to ObsEva no less than [*] prior to the anticipated date of disclosure so as to provide ObsEva and Merck Serono a reasonable opportunity to comment thereon. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.9</font><b style="font-weight:bold;">Equitable Relief</b>. &#160;Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>. &#160;In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">11.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">REPRESENTATIONS, WARRANTIES AND COVENANTS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.1</font><b style="font-weight:bold;">ObsEva Representations and Warranties</b>. ObsEva represents and warrants to Organon as of the Effective Date that:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>ObsEva has the full power, authority and right to enter into this Agreement and to perform its obligations hereunder in accordance with the terms and conditions hereof, and all requisite corporate action has been taken to authorize ObsEva&#39;s execution, delivery and performance of this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>The execution, delivery and performance of this Agreement by ObsEva does not breach, violate, contravene or constitute a default under any contract, arrangement or commitment to which ObsEva is a party or by which it is bound, or violate any statute, law or regulation or any order, writ, judgement, injunction, decree, determination, or award of any court, governmental body or administrative or other agency having jurisdiction over ObsEva;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by ObsEva in connection with the execution, delivery and performance of this Agreement have been obtained;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>All Licensed Patents existing as of the Effective Date are listed on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.60</u> (the &#8220;<b style="font-weight:bold;">Existing Patents</b>&#8221;). The Existing Patents are subsisting and, to ObsEva&#8217;s Knowledge, are not invalid or unenforceable, in whole or in part; to ObsEva&#8217;s Knowledge, the Existing Patents are being diligently prosecuted in the respective patent offices in the Territory in accordance with Applicable Law; the Existing Patents have been filed and maintained properly and correctly and all applicable fees have been paid on or before the due date for payment;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>ObsEva is the sole owner or exclusive licensee under the Merck Serono Agreement of the Licensed Technology; ObsEva is entitled to grant the rights and licenses it grants to Organon under this Agreement with respect to the Licensed Technology, free and clear of any rights therein granted to any Third Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>[*], neither ObsEva nor any of its Affiliates has previously entered into any agreement, whether written or oral, with respect to the assignment, transfer, license, conveyance or encumbrance of, or otherwise assigned, transferred, licensed, conveyed or encumbered its right, title, or interest in or to the Licensed Technology, the Licensed Compounds, or the Licensed Products (including by granting any covenant not to sue with respect thereto) or any Patent or other intellectual property or proprietary right or Know-How that would be an Existing Patent or Existing Know-How but for such assignment, transfer, license, conveyance, or encumbrance and it will not enter into any such agreements or grant any such right, title, or interest to any Person that is inconsistent with the rights and licenses granted to Organon under this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(1)</font>[*]</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(2)</font>[*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:144pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(3)</font>[*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>The Merck Serono Agreement is the only agreement between ObsEva (or its Affiliate) and a Third Party entered into prior to the Effective Date pursuant to which ObsEva (or its Affiliate) Controls any Patents or Know-How included within the Licensed Patents or Licensed Know-How (other than (i) agreements with ObsEva&#8217;s (or its Affiliate&#8217;s) employees and agreements with independent contractors and service providers entered into in the ordinary course of ObsEva&#8217;s (or its Affiliate&#8217;s) business, in each case, pursuant to which such employee, independent contractor or service provider, as applicable, assigns its right, title and interest to such Patents and Know-How to ObsEva (or its Affiliate), and (ii) agreements entered into in the ordinary course of business with service providers under which ObsEva (or its Affiliate) is granted customary licenses to the provider&#8217;s proprietary technology);</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font>Except for (A) the Merck Serono Agreement [*], the Development or Commercialization of a Licensed Compound or Licensed Product by or on behalf of Organon or its Affiliates will not require or result in any financial payment by ObsEva, Organon or any of their respective Affiliates under any agreement or other arrangement by which ObsEva or any of its Affiliates is bound; except for the Merck Serono Agreement, ObsEva is not obligated under any contract or other agreement to make any payments by way of royalties, fees, or otherwise to any owner or licensor of, or other claimant to, any Patent or other intellectual property or proprietary right or Know-How;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>To ObsEva&#8217;s Knowledge, no Person is infringing or threatening to infringe or misappropriating or threatening to misappropriate the Existing Patents or Existing Know-How;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font>ObsEva has not received any written notice from a Third Party that the Development of any Licensed Compound or Licensed Product conducted prior to the Effective Date has infringed any Patents or misappropriated any Know-How of any Third Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(k)</font>There are no claims, judgments, or settlements against, or amounts with respect thereto, owed by ObsEva or any of its Affiliates relating to the Existing Patents or the Existing Know-How. No claim or action has been brought or, to ObsEva&#8217;s Knowledge as of the Effective Date, threatened, by any Third Party alleging that (i) any of the Existing Patents are invalid or unenforceable, or (ii) the Existing Patents or the Existing Know-How, or the disclosing, copying, making, assigning, licensing or use of the Existing Patents or Existing Know-How, or the Development, Commercialization or other Exploitation of the Licensed Compounds or Licensed Products as contemplated herein, does or will infringe or misappropriate, or would infringe or misappropriate, any Patent or other intellectual property right of any Third Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(l)</font>To ObsEva&#8217;s Knowledge, other than the Merck Serono Patents, ObsEva is not aware of any Third Party Patent that claims (i) the composition of matter of any Licensed Compound, or (ii) a method of use of any Licensed Compound, as such method is described in the Existing Patents;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(m)</font>To ObsEva&#8217;s Knowledge, other than the Merck Serono Patents, ObsEva is not aware of any Third Party Patent or Know-How that is used in the Manufacture of Licensed Compound or Licensed Product;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(n)</font>There are no Trademarks Controlled by ObsEva or any of its Affiliates that have been used by ObsEva or any of its Affiliates in connection with Licensed Compound or Licensed Product or the Development thereof;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(o)</font>To ObsEva&#8217;s Knowledge, the practice by Organon under the Licensed Technology or the Exploitation by Organon (or its Affiliates or Sublicensees) of any Licensed Compound or Licensed Product, in each case, as contemplated under this Agreement, does not and will not infringe, misappropriate, or otherwise violate &#160;any intellectual property of any Third Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(p)</font>ObsEva and its Affiliates have generated, prepared, maintained, and retained all Regulatory Documentation that is required to be maintained or retained prior to the Effective Date pursuant to and in accordance with GLP and GCP and Applicable Laws;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(q)</font>Each Existing IND is in full force and good standing, and neither ObsEva nor any of its Affiliates has received any notice in writing, or otherwise has Knowledge of any facts, which have, or reasonably could have, led ObsEva (or its Affiliate) to believe that any Existing IND is not currently in, or may not remain in, good standing with the FDA or other applicable Regulatory Authority;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(r)</font>The Existing Know-How has been kept confidential or has been disclosed to Third Parties only under terms of confidentiality. &#160;To the Knowledge of ObsEva, no breach of such confidentiality has been committed by any Third Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(s)</font>To ObsEva&#8217;s Knowledge (i) ObsEva has made (and will make) available to Organon all Regulatory Documentation and Licensed Know-How and other information in its possession or Control regarding or related to the Licensed Compounds or the Licensed Products, and (ii) all such Regulatory Documentation and Licensed Know-How and other information are (and, if made available after the Effective Date, will be) true, complete, and correct. ObsEva has provided Organon with the opportunity to review all written material data in ObsEva&#8217;s possession relating to the subject matter of this Agreement, and has not intentionally concealed from Organon any such material data;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(t)</font>to ObsEva&#8217;s Knowledge: (i) there are no scientific or technical facts or circumstances that have not been disclosed to Organon, and that would materially adversely affect the scientific, therapeutic, or commercial potential of the Licensed Products; and (ii) there is nothing within ObsEva&#8217;s control that has not been disclosed to Organon and that could materially adversely affect the acceptance, or the subsequent approval, by any Regulatory Authority of any Regulatory Submissions with respect to any Licensed Product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(u)</font>ObsEva has provided to Organon true, complete, and correct (redacted) copies of all material agreements relating to the Licensed Technology or the Development of the Licensed Compounds and Licensed Products and components thereof (as applicable) that are in effect as of the Effective Date;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>ObsEva has provided Organon access to all material correspondence between ObsEva (or any of its Affiliates) and the FDA (or other Governmental Authority) regarding the Licensed Compounds and Licensed Products in ObsEva&#8217;s possession or control or of which ObsEva is aware, including (i) reports of inspection observations from any Governmental Authority related to Manufacturing facilities where the Licensed Compounds or any Licensed Product is being Manufactured, (ii) establishment inspection reports from any Governmental Authority, (iii) any FDA Form 483s relating to the Licensed Compounds or Licensed Products or any equivalent thereto from any Governmental Authority in any applicable jurisdiction, (iv) safety inquiries from any Governmental Authority, (v) any input from any </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Governmental Authority related to trial approvability, post-approval obligations, and notice of clinical hold, and (v) any notice, warning letter, regulatory letter, Section 305 notice, or any other similar communication to ObsEva or any of the Affiliates stating that their businesses were or are in material violation of any Applicable Law, or were or are the subject of any material pending, threatened or anticipated administrative agency or governmental or regulatory authority investigation, proceeding, review or inquiry; in each case ((i) through (v)), with respect to the Licensed Compounds or Licensed Products;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(w)</font>The Licensed Technology has not been created pursuant to, and is not subject to, any funding agreement with any Governmental Authority or any Third Party, and is not subject to the requirements of the Bayh-Dole Act or any similar provision of any Applicable Laws;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(x)</font>Other than as provided under the Merck Serono Agreement, the process used by ObsEva to Manufacture the Licensed Compounds or Licensed Products (as applicable) as of the Effective Date does not require the use of any Third Party intellectual property right;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(y)</font>ObsEva has provided to Organon true, complete, and correct (redacted) copies of all agreements relating to the Manufacture or supply of the Licensed Compounds and Licensed Products and components thereof (as applicable) that are in effect as of the Effective Date, a complete list of which appears on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 11.1(z)</u>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(z)</font>Neither ObsEva nor any of its Affiliates, and, to ObsEva&#8217;s Knowledge, none of its or their respective officers, employees, or agents, has made an untrue statement of material fact or fraudulent statement to the FDA or any other Regulatory Authority with respect to the Development of the Licensed Compounds or the Licensed Products, failed to disclose a material fact required to be disclosed to the FDA or any other Regulatory Authority with respect to the Development of the Licensed Compounds or the Licensed Products, or committed an act, made a statement, or failed to make a statement with respect to the Development of the Licensed Compounds or the Licensed Products that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or any analogous laws or policies in the Territory;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(aa)</font>ObsEva and its Affiliates have conducted, and, to ObsEva&#8217;s Knowledge, their respective contractors and consultants have conducted, all Manufacture and Development of the Licensed Compounds or the Licensed Products that they have conducted prior to the Effective Date in accordance with GxP and Applicable Law. &#160;ObsEva has conducted, and has caused its contractors and consultants to conduct, any and all pre-clinical and Clinical Trials related to the Licensed Compounds and Licensed Products in accordance with GxP and Applicable Law, and, to ObsEva&#8217;s Knowledge, all Licensed Compounds and Licensed Products used in Clinical Trials conducted by or on behalf of ObsEva or its Affiliates prior to the Effective Date were Manufactured in accordance with all Applicable Laws (including GMPs);</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(bb)</font>To ObsEva&#8217;s Knowledge, no investigation or proceedings have been carried out by Regulatory Authorities with respect to the Licensed Product or any ObsEva facilities and the facilities of its CMOs; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(cc)</font>ObsEva represents and warrants that it and its Affiliates have not ever been, are not currently, nor are they the subject of a proceeding that could lead to it or its Affiliates becoming a Debarred Entity, Excluded Entity or Convicted Entity and it and its Affiliates will not use in any capacity, in connection with the obligations to be performed under this Agreement, any person who is a Debarred </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Individual, Excluded Individual or a Convicted Individual. For purposes of this provision, the following definitions shall apply:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>A &#8220;<b style="font-weight:bold;">Debarred Individual</b>&#8221; is an individual who has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from providing services in any capacity to a Person that has an approved or pending drug or biological product application.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>A &#8220;<b style="font-weight:bold;">Debarred Entity</b>&#8221; is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. &#167;335a (a) or (b) from submitting or assisting in the submission of any abbreviated drug application, or a subsidiary or affiliate of a Debarred Entity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>An &#8220;<b style="font-weight:bold;">Excluded Individual</b>&#8221; or &#8220;<b style="font-weight:bold;">Excluded Entity</b>&#8221; is (A) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (B) is an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in U.S. federal procurement and non-procurement programs, including those produced by the U.S. General Services Administration (GSA).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>A &#8220;<b style="font-weight:bold;">Convicted Individual</b>&#8221; or &#8220;<b style="font-weight:bold;">Convicted Entity</b>&#8221; is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 21 U.S.C. &#167;335a (a) or 42 U.S.C. &#167;1320a - 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.2</font><b style="font-weight:bold;">Organon Representations and Warranties</b>. Organon represents and warrants to ObsEva as of the Effective Date that:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Organon has the full power, authority and right to enter into this Agreement and to perform its obligations hereunder in accordance with the terms and conditions hereof, and all requisite corporate action has been taken to authorize Organon&#39;s execution, delivery and performance of this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>The execution, delivery and performance of this Agreement by Organon does not breach, violate, contravene or constitute a default under any contract, arrangement or commitment to which Organon is a party or by which it is bound, or violate any statute, law or regulation or any order, writ, judgement, injunction, decree, determination, or award of any court, governmental body or administrative or other agency having jurisdiction over Organon;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by Organon in connection with the execution, delivery and performance of this Agreement have been obtained;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>it and its Affiliates are not currently, nor are they the subject of a proceeding that could lead to it or its Affiliates becoming, a Debarred Entity, Excluded Entity or Convicted Entity. For purposes of this provision, the definitions in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1(dd)</u> shall apply; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>Organon has (either itself or through Third Parties) the ability, capacity, knowledge, resources and experience to use, import, Develop, register, Manufacture, market, promote, distribute, offer for sale, Commercialize and otherwise Exploit the Licensed Product in the Field in the Major Markets.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.3</font><b style="font-weight:bold;">Covenants</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Each Party hereby covenants to the other Party that, in the performance of its obligations under this Agreement, such Party shall comply, and shall cause its and its Affiliates&#8217; and sublicensees&#8217; and its and their employees and subcontractors to comply, with all Applicable Laws, including (i) all Anti-Corruption Laws, (ii) all Privacy Laws, (iii) all current governmental regulations concerning GxP, as applicable, and (iv) national and international pharmaceutical industry codes of practice.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Each Party hereby covenants to the other Party that it and its Affiliates&#8217; employees and contractors shall not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, and shall not directly or indirectly promise, offer, or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or any other person in connection with the performance of its obligations under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>Each Party hereby covenants to the other Party that it shall immediately notify the other Party if such Party has any information or suspicion that there may be a violation of any Anti-Corruption Laws, any Privacy Laws, or any other Applicable Laws in connection with its performance of this Agreement or its or its Affiliates&#8217; or sublicensees&#8217; Development, Manufacture, Commercialization or other Exploitation of any Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>Organon hereby covenants to ObsEva that (i) it and its Affiliates shall, at all times during the Term, maintain and enforce a compliance and ethics program containing adequate systems, policies and procedures for the detection, investigation, documentation, and remediation of any allegations, reports or findings related to a potential violation of Applicable Laws, including Anti-Corruption Laws, with respect to the Licensed Products and payments and activities under this Agreement, (ii) such policies and procedures will set out rules governing interactions with healthcare providers, Public Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the investigation, documentation and remediation of any allegations, reports or findings related to a potential violation of Applicable Laws, and (iii) Organon shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all such policies and procedures in connection with the performance of its obligations under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font>ObsEva hereby covenants to Organon that it shall, at all times during the Term, maintain a Code of Business Conduct and Ethics approved by its Board of Directors of a scope substantially equivalent to, and in any event no less stringent than, ObsEva&#8217;s Code of Business Conduct and Ethics that is in effect as of the Effective Date and, in the performance of its obligations under this Agreement, ObsEva shall comply and shall require its and its Affiliates&#8217; employees and contractors to comply with such Code of Business Conduct and Ethics.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font>During the Term, ObsEva will not enter into any assignment, transfer, license, conveyance or encumbrance of, or otherwise assign, transfer, license, convey or encumber, its right, title, or interest in or to the Licensed Technology or grant to any Person any such right, title, or interest, in each case that is inconsistent with the rights and licenses granted to Organon under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font>During the Term, Organon and it and its Affiliates will not knowingly use in any capacity, in connection with the obligations to be performed under this Agreement, any person who is a </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Debarred Individual, Excluded Individual or a Convicted Individual. &#160;For purposes of this provision, the definitions in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11.1(dd)</u> shall apply.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font>[*]</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Within [*], ObsEva will, together with Organon, negotiate with Merck Serono to enter into a side letter agreement or other agreement to amend Section 6.1 of the Merck Serono Agreement in order to permit disclosures of Merck Serono Confidential Information consistent with the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3(f)</u> of this Agreement (excluding the proviso therein), and following execution of such an agreement between ObsEva and Merck Serono, the Parties will enter into an amendment to this Agreement to amend applicable terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>, including to remove or amend the proviso in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3(f)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.4</font><b style="font-weight:bold;">Disclaimer</b>. &#160;EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE, OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO. &#160;NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT ANY OF THE DEVELOPMENT, MANUFACTURING, OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY LICENSED COMPOUND OR LICENSED PRODUCT WILL BE SUCCESSFUL.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">12.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">INDEMNIFICATION</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.1</font><b style="font-weight:bold;">Indemnification by Organon</b>. &#160;Organon shall defend, indemnify, and hold harmless ObsEva and its Affiliates and their respective directors, officers, employees, and agents (each, an &#8220;<b style="font-weight:bold;">ObsEva Indemnitee</b>&#8221;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;<b style="font-weight:bold;">Losses</b>&#8221;), to which any ObsEva Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party (each, a &#8220;<b style="font-weight:bold;">Claim</b>&#8221;) to the extent such Losses arise out of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>the Development, use, Manufacture, Commercialization, or other Exploitation of any Licensed Compound or Licensed Product by Organon or its Affiliates or Sublicensees [*];</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>the negligence or willful misconduct of any Organon Indemnitee; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>the breach by Organon of any warranty, representation, covenant, or agreement made by Organon in this Agreement;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">except, in each case (a)-(c), to the extent such Losses arise out of any activities set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.2</u> for which ObsEva is obligated to indemnify any Organon Indemnitee under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.2</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.2</font><b style="font-weight:bold;">Indemnification by ObsEva</b>. &#160;ObsEva shall defend, indemnify, and hold harmless Organon and its Affiliates and their respective directors, officers, employees, and agents (each, an &#8220;<b style="font-weight:bold;">Organon Indemnitee</b>&#8221;) from and against any and all Losses to which any Organon Indemnitee may become subject as a result of any Claim to the extent such Losses arise out of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>the negligence or willful misconduct of any ObsEva Indemnitee;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>the breach by ObsEva of any warranty, representation, covenant, or agreement made by ObsEva in this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>the Development or Manufacture of the Licensed Products or Licensed Compounds by or on behalf of, or for, ObsEva or its Affiliates anywhere in the world prior to the Effective Date; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>the Development, Commercialization, Manufacture, or other Exploitation of any Licensed Products or Licensed Compound by or on behalf of, or for, ObsEva or its Affiliates or (sub)licensees anywhere in the world after the Term, for clarity, excluding Development, Commercialization, Manufacture, or other Exploitation conducted by, on behalf of, or for Organon or its Affiliates or Sublicensees as permitted hereunder;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">except, in each case (a)-(d), to the extent such Losses arise out of any activities set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1</u> for which Organon is obligated to indemnify any ObsEva Indemnitee under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.1</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.3</font><b style="font-weight:bold;">Indemnification Procedure</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>The Party claiming indemnity under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 12</u> (the &#8220;<b style="font-weight:bold;">Indemnified Party</b>&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;<b style="font-weight:bold;">Indemnifying Party</b>&#8221;) promptly after learning of such Claim.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought. &#160;The Indemnified Party may participate in and monitor such defense with counsel of its own choice at its own expense; provided, however, that the Indemnifying Party shall have the right to assume and conduct the defense of the Claim with counsel of its choice. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, unless the settlement involves only the payment of money, no admission of wrong-doing or fault by the Indemnified Party, and no restriction on the future actions or activities of the Indemnified Party. &#160;So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle such Claim without the prior written consent of the Indemnifying Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against and consent to the entry of any judgment, or enter into any settlement with respect to, the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (ii) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 12</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.4</font><b style="font-weight:bold;">Insurance</b>. &#160;Each Party, at its own expense, shall maintain insurance (or self-insurance), including commercial general liability insurance, product liability insurance and other appropriate insurance, in amounts consistent with sound business practice and reasonable in light of its obligations under this Agreement. &#160;Each Party shall maintain such insurance for the period commencing on the Effective Date until [*] after expiration or termination of this Agreement. &#160;Each Party shall provide a certificate of insurance evidencing such coverage to the other Party upon request. &#160;It is understood that such insurance shall not be construed to create any limit of either Party&#8217;s obligations or liabilities with respect to its indemnification obligations under this Agreement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">12.5</font><b style="font-weight:bold;">Limitation of Liability</b>. &#160;EXCEPT FOR DAMAGES THAT (A) ARISE IN CONNECTION WITH A PARTY&#8217;S (I) WILLFUL MISCONDUCT OR FRAUD, (II) BREACH OF ITS OBLIGATIONS UNDER <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE 10</u>, [*] (B) ARE SUBJECT TO INDEMNIFICATION UNDER <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 12.1</u> OR <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION 12.2</u>, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE FOR ANY SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY (OR ITS AFFILIATES OR (SUB)LICENSEES), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">13.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">TERM AND TERMINATION</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.1</font><b style="font-weight:bold;">Term</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 13</u>, shall continue in force and effect until the date of expiration of the last Royalty Term for the last Licensed Product (the &#8220;<b style="font-weight:bold;">Term</b>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>Following the expiration of the Term, the grants in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u> shall become fully-paid, royalty-free and irrevocable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.2</font><b style="font-weight:bold;">Termination for Breach</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>Either Party may terminate this Agreement in its entirety at any time upon written notice to the other Party if the other Party is in material breach of this Agreement and such material breach is not cured within [*] (in the case of a payment breach) or [*] days (in the case of all other breaches) after written notice thereof is delivered to the defaulting or breaching Party; provided, however, if such breach (other than a payment breach) is not reasonably curable within [*] days and if the breaching Party is making a bona fide effort to cure such breach, such termination shall be delayed for a time period to be agreed by the Parties in order to permit the breaching Party a reasonable period of time to cure such breach (but in no event will such additional time period be more than [*] days). &#160;Any notice provided pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> shall identify with particularity the alleged breach and state the non-breaching Party&#8217;s intent to terminate this Agreement if such breach is not cured.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>If the allegedly breaching Party disputes in good faith the allegation that there has been a material breach, then such Party may contest the allegation in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u> and, provided that the allegedly breaching Party gives written notice to the other Party of such dispute and initiates dispute resolution procedures under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u> during the applicable cure period, such cure period will toll upon the initiation of such dispute resolution procedures. &#160;If, as a result of such dispute resolution process, it is finally determined pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u> that the breaching Party committed a material breach of this Agreement, then the applicable cure period will resume and if the breaching Party does not cure such material breach within the remainder of such cure period (as such cure period may be extended pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2(a)</u>), then this Agreement will terminate effective as of the expiration of such cure period. &#160;This Agreement will remain in full force and effect during the pendency of any such dispute resolution proceeding and the applicable cure period. &#160;Any such dispute resolution proceeding will not suspend any obligations of either Party hereunder and each Party will use reasonable efforts to mitigate any damages. If, as a result of such dispute resolution proceeding, it is determined that the breaching Party did not commit such material breach (or such material breach was cured in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2(a)</u>), then no termination of this Agreement will be effective, and this Agreement will continue in full force and effect.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.3</font><b style="font-weight:bold;">Termination by ObsEva</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Termination for Patent Challenge</b>. &#160;In the event that Organon or any of its Affiliates or Sublicensees, anywhere in the world, institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment, injunction or any other equitable remedy, including any interference, reexamination, opposition or any similar proceeding, alleging that any claim in a Licensed Patent is invalid, unenforceable or otherwise not patentable (&#8220;<b style="font-weight:bold;">Patent Challenge</b>&#8221;), [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Termination for [*] Commercialization. [*]</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.4</font><b style="font-weight:bold;">Termination by Organon</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">For Cause</b>. Organon may terminate this Agreement in its entirety effective immediately upon written notice to ObsEva if Organon reasonably believes in good faith, after due inquiry and in a manner consistent with Organon&#8217;s then-current decision-making process with respect to such a determination, that Development or Commercialization of Licensed Compounds and Licensed Products should be terminated due to a Safety Reason; provided that [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">For Convenience</b>. Organon shall have the right to terminate this Agreement in its entirety, for any or no reason, at any time prior to First Commercial Sale of the first Licensed Product, upon [*] prior written notice to ObsEva.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.5</font><b style="font-weight:bold;">No Immediate Termination on Bankruptcy</b>. To the extent permitted by Applicable Law, all rights and licenses granted pursuant to this Agreement by a Party to the other Party shall not be terminated upon a Bankruptcy Event of such Party or its Affiliates, and each Party hereby claims the benefit of any Applicable Law which may enable it to prevent such termination, provided that such a Bankruptcy Event shall not bring material adverse effect to the transactions contemplated hereunder. In the event of a Bankruptcy Event of Organon, Organon shall, during the [*] period following such Bankruptcy Event, seek to enter into one or several sublicenses for each of [*]. Any such sublicense shall be subject to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u>. If, upon expiry of the [*] period Organon has failed to enter into a definitive sublicense agreement [*], ObsEva shall have the right to terminate this Agreement with respect to [*] immediately upon written notice. In the event of a termination of this Agreement [*] by ObsEva pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.5</u>, all rights and licenses granted by ObsEva hereunder (i) shall [*] and (ii) shall [*]. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.6</font><b style="font-weight:bold;">Effects of Termination</b>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-weight:bold;">General Consequences</b>. In the event of termination of this Agreement for any reason prior to expiration of the Term, except for the surviving provisions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.11</u>, the rights, licenses and obligations of the Parties hereunder shall terminate and be of no further force or effect as of the effective date of such termination and the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6</u> shall apply.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Confidential Information</b>. Upon termination of this Agreement in its entirety, either Party may request in writing, and the other Party shall either promptly return to the first Party, or as soon as reasonably practicable delete or destroy, all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party to which such first Party does not retain rights under the surviving provisions of this Agreement; provided that a Party may keep one copy </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">of such materials for legal archival purposes subject to continuing confidentiality obligations. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such Confidential Information that have been created solely by such Party&#8217;s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party&#8217;s standard archiving and back-up procedures, but not for any other use or purpose.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Sublicenses</b>. In the event of termination of this Agreement prior to expiration of the Term, at the request of a Sublicensee within [*] days after the effective date of termination, provided such Sublicensee is not then in default of its obligations under its sublicense agreement, such sublicense agreement will survive in accordance with its terms for such period of [*] days during which period ObsEva shall negotiate and enter into a continuing license with such Sublicensee granting such Sublicensee rights under the Licensed Technology (or the subset of the Licensed Technology that was sublicensed to such Sublicensee) on reasonable terms that (i) do not impose any additional obligations on ObsEva to those obligations contained in this Agreement and (ii) fully preserve ObsEva&#8217;s rights under this Agreement, including ObsEva&#8217;s rights to receive payments under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 7</u> on terms that are at least as favorable as those herein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Commercial Inventory</b>. &#160;In the event of termination of this Agreement by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> prior to expiration of the Term and after First Commercial Sale of a Licensed Product, Organon and its Affiliates shall be entitled, during the [*] period following the effective date of termination, to sell any commercial inventory of Licensed Products which remains on hand as of the effective date of the termination, so long as Organon pays to ObsEva the royalties applicable to such post-termination sales in accordance with the terms and conditions set forth in this Agreement. In the event of termination of this Agreement prior to expiration of the Term by ObsEva pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u> or by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(b)</u>, any commercial inventory of Licensed Products which remains on hand as of the effective date of the termination shall be offered for sale to ObsEva, to the extent licensed under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u>, at a price to be mutually agreed upon between the Parties in good faith [*]; provided that, if ObsEva elects not to purchase the entire commercial inventory, Organon shall be entitled, for a period of [*], to sell any unpurchased commercial inventory of Licensed Products so long as Organon pays to ObsEva the royalties applicable to such post-termination sales in accordance with the terms and conditions set forth in this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-weight:bold;">License to Organon</b>. &#160;In the event of termination of this Agreement prior to expiration of the Term, the license granted by ObsEva to Organon under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1</u> shall automatically terminate, provided that ObsEva grants to Organon, its Affiliates and Sublicensees (as the case may be) any licenses or rights of reference to any Licensed Technology reasonably necessary for Organon, its Affiliates or Sublicensees to exercise its rights or fulfill its obligations set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Reversion License</b>. In the event of termination of this Agreement prior to the expiration of the Term by ObsEva pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u> or by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(b)</u>, Organon shall, and hereby does, grant to ObsEva, effective on the effective date of termination, [*] (the license grants under clauses (i) and (ii), the &#8220;<b style="font-weight:bold;">Reversion Licenses</b>&#8221;). In all cases, the Reversion Licenses exclude [*]. The royalty(ies) to be paid under the Reversion Licenses shall be commercially reasonable taking into account the relative value of the Organon Improvement Technology and the Organon Technology. If the Parties are unable to agree upon such commercially reasonable royalty(ies) within [*] days after the effective date of termination (or such longer period as the Parties may agree) (&#8220;<b style="font-weight:bold;">Reversion Royalty Dispute</b>&#8221;), the Reversion Royalty Dispute shall be resolved in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u>. With respect to any Organon Technology that is licensed by Organon from Third Parties, (A) Organon shall notify ObsEva (which notice shall describe the terms and conditions of the Third Party </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">agreement that are applicable to the grant to ObsEva of the Reversion License under such Organon Technology or to the exercise of such Reversion License by ObsEva or any of its Affiliates or sublicensees, including payment terms), (B) ObsEva shall be responsible for (x) making any payments (including royalties, milestones and other amounts) that are payable by Organon to the Third Parties under any Third Party agreements with respect to and allocable to the Organon Technology that is the subject of such Reversion License by making such payments directly to Organon and, in each instance, ObsEva shall make the requisite payments to Organon and provide the necessary reporting information to Organon in sufficient time to enable Organon to comply with its obligations under such Third Party agreements (provided Organon has notified ObsEva of such obligations), and (y) complying with any other obligations included in such Third Party agreements that are applicable to the grant to ObsEva of the Reversion License under the applicable Organon Technology or to the exercise of such Reversion License by ObsEva or any of its Affiliates or sublicensees (provided Organon has notified ObsEva of such obligations), and the granting by ObsEva of a sublicense under the Reversion Licenses shall not relieve ObsEva of its obligations under this subclause (B); and (C) Organon shall timely pay and provide to such Third Parties all payments and reports made or provided by ObsEva under subclause (B).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><b style="font-weight:bold;">Assignments</b>. &#160;In the event of termination of this Agreement prior to expiration of the Term by ObsEva pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u> or by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(b)</u>, Organon shall promptly (i) where permitted by Applicable Law [*] then owned by Organon or its Affiliates and in its or their name solely relating to the Licensed Compounds or Licensed Products in the Territory that are subject of the license grant in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u>, including [*], (ii) [*], (iii) at ObsEva&#8217;s option, transfer to ObsEva any and all chemical, biological and other physical materials solely relating to or comprising the Licensed Products that are subject of the license grant in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u>, including clinical supplies of Licensed Products, that are in Organon&#8217;s or its Affiliates&#8217; possession or control, and (iv) assign to ObsEva or its designee all of Organon&#8217;s and its Affiliates&#8217; rights, title, and interest in and to all Product Trademarks and all domain names associated with the Product Trademarks, in each case solely relating to the Licensed Products in the Territory that are subject of the license grant in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u> (if any). [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(h)</font><b style="font-weight:bold;">Ongoing Clinical Trials</b>. Unless expressly prohibited by any Regulatory Authority or Applicable Law, if any Clinical Trials involving Licensed Products sponsored by Organon or its Affiliate or Sublicensee are being conducted by Organon as of the effective date of termination, at ObsEva&#8217;s reasonable written request made within [*] days after the effective date of termination (i) Organon shall, and shall cause its Affiliates and Sublicensees to, wind down such Clinical Trials in accordance with Applicable Law (provided that such winding down would not be inconsistent with Organon&#8217;s ethical obligations or reasonable internal policies), or (ii) [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><b style="font-weight:bold;">Organon Improvement Know-How</b>. In the event of termination of this Agreement prior to expiration of the Term by ObsEva pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u> or by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(b)</u>, Organon shall disclose and transfer to ObsEva (to the extent included in the Reversion Licenses) (i) all Organon Know-How and (ii) any Organon Improvement Know-How that is necessary to Develop, have Developed, Manufacture, have Manufactured, Commercialize or otherwise Exploit any Licensed Compound or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(j)</font><b style="font-weight:bold;">Supply Obligation</b>. Unless otherwise agreed by both Parties, Organon will have no obligation to Manufacture or supply to ObsEva Licensed Compound or Licensed Product for ObsEva&#8217;s continued Development and Commercialization of such Licensed Compounds and Licensed Products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.7</font><b style="font-weight:bold;">Transition Agreement</b>. In the event of termination of this Agreement in its entirety by ObsEva pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.2</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.3</u> or by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(b)</u>, unless ObsEva informs Organon that ObsEva will not (itself or with or through its Affiliates or a Third Party) continue </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Development, Commercialization or other Exploitation of any Licensed Product in the Territory, ObsEva and Organon shall negotiate in good faith the terms and conditions of a written transition agreement pursuant to which Organon and ObsEva will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to ObsEva as reasonably necessary for ObsEva to exercise its license pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.6(f)</u> with respect to the Licensed Products after termination of this Agreement as and to the extent set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 13</u>, which terms and conditions shall be consistent with those set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 13</u> and include duration and full time equivalent limits for the services to be provided to the extent not set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 13</u>. [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.8</font><b style="font-weight:bold;">Termination for Safety Reasons</b>. Notwithstanding the foregoing, if this Agreement is terminated by Organon pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13.4(a)</u>, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.9</font><b style="font-weight:bold;">Remedies</b>. Except as otherwise expressly provided herein, termination of this Agreement in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.10</font><b style="font-weight:bold;">Milestone Payments</b>. Notwithstanding anything to the contrary contained herein, if notice of termination of this Agreement is given prior to achievement of a given milestone set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u>, Organon shall not be obligated to make any milestone payment in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.2</u> to ObsEva with respect to any milestone achieved following the notice of such termination; provided that, [*].</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">13.11</font><b style="font-weight:bold;">Survival; Accrued Rights</b>. &#160;The obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: 2.6, 8.1 (with respect to payment obligations accruing during the Term), 8.2 through 8.5, 9.1, 11.4, 13.6 through 13.11, 14.2, 14.3, 14.4, 14.5, 14.7, 14.9, 14.10, 14.11, 14.12, 14.14, 14.15 and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 1</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 12</u>. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">In any event, expiration or termination of this Agreement will not relieve the Parties of any liability that accrued hereunder prior to the effective date of such expiration or termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice either Party&#8217;s right to obtain performance of any obligation that accrued hereunder prior to the effective date of such expiration or termination (including the rights to receive payments accrued or due prior to the effective date of such termination). &#160;</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;width:36pt;padding:0pt;">14.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">GENERAL PROVISIONS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.1</font><b style="font-weight:bold;">Change of Control of ObsEva</b>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>ObsEva (or its successor) shall provide Organon with written notice of any Change of Control of ObsEva within [*] following the closing date of such transaction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>In the event of a Change of Control of ObsEva: all Licensed Technology Controlled by ObsEva immediately before such Change of Control shall continue to be Licensed Technology but ObsEva and its Affiliates will not be deemed to &#8220;Control&#8221; any Know-How or Patent that, prior to the closing date of such Change of Control is owned, in-licensed or otherwise controlled by a Third Party (and such Third Party&#8217;s Affiliates that existed prior to such closing date), that becomes an Affiliate of ObsEva after the Effective Date as a result of such Change of Control unless such Know-How or Patent was so included in or subject to this Agreement prior to the closing date of such Change of Control or is used by such acquired Party or any of its Affiliates after the closing date of such Change of Control in the Development, Manufacture, Commercialization or other Exploitation of Licensed Products pursuant to this </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Agreement, in which case such Know-How or Patent will be &#8220;Controlled&#8221; by ObsEva for purposes of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font>In the event of a Change of Control of ObsEva or other assignment of this Agreement by ObsEva to a Third Party pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9(a)</u> that involves [*], then (i) at the request of Organon, (x) the JAC shall be disbanded, (y) any or all provisions of this Agreement providing for any delivery by Organon to ObsEva of information relating to activities contemplated by this Agreement shall terminate, save only for the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</u>, and (z) ObsEva and its acquirer in the Change of Control will adopt reasonable procedures to be agreed upon in writing to prevent disclosure of Confidential Information of Organon to such acquirer; and (ii) any information, documents or reports provided by Organon that ObsEva is otherwise required to provide to Merck Serono pursuant to this Agreement shall be provided directly to Merck Serono by Organon. &#160;As used herein, &#8220;<b style="font-weight:bold;">Change of Control</b>&#8221; means, with respect to ObsEva, a transaction with a Third Party(ies) involving, (A) the acquisition, merger or consolidation, directly or indirectly, of ObsEva, and, immediately following the consummation of such transaction, the shareholders or other owners of ObsEva, immediately prior thereto hold, directly or indirectly, as applicable, shares of capital stock of the surviving company representing less than fifty percent (50%) of the outstanding shares of such surviving or continuing company, (B) the sale of all or substantially all of the assets or business of ObsEva, or (C) a Person, or group of Persons acting in concert, acquire more than fifty percent (50%) of the voting equity securities or management control of ObsEva.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font>For clarity, a Change of Control does not include (i) an internal consolidation, merger, share exchange or other reorganization of ObsEva between it and one or more of its Affiliates, (ii) a sale of assets, merger, or other transaction effected with an Affiliate of ObsEva exclusively for the purpose of changing domicile of ObsEva, (iii) a transfer or assignment of any Patents or other intellectual property rights to a wholly-owned subsidiary of ObsEva; or (iv) any public offering of ObsEva&#8217;s equity securities or other issuance of stock by ObsEva in an equity financing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.2</font><b style="font-weight:bold;">Governing Law</b>. This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.3</font><b style="font-weight:bold;">Dispute Resolution</b>. Any dispute between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a &#8220;<b style="font-weight:bold;">Dispute</b>&#8221;) shall first be referred to the Executive Officers of the Parties, who shall confer in good faith on the resolution of the Dispute. &#160;Any final decision mutually agreed upon by the Executive Officers shall be conclusive and binding on the Parties. &#160;If the Executive Officers are not able to agree on the resolution of a Dispute within [*] (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then such Dispute shall be resolved by binding arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce in force on the date on which the Notice of Arbitration is submitted (the &#8220;<b style="font-weight:bold;">Rules</b>&#8221;). The arbitration will be conducted by a panel of three (3) arbitrators appointed in accordance with the Rules; provided that each Party will, [*] after the institution of the arbitration proceedings, appoint an arbitrator, and such arbitrators will together, within [*], select a third (3rd) arbitrator as the chairperson of the arbitration panel. &#160;The seat of the arbitration shall be Geneva. The arbitral proceedings shall be conducted in English. Except as may be required by Applicable Law or to protect or pursue a legal right, neither a Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both Parties. Each Party shall bear its own legal costs for its counsel and other expenses, and the Parties shall equally share the costs of the arbitration; provided that the arbitral tribunal shall have the discretion to provide that the losing Party is responsible for all or a portion of such arbitration and legal costs, and in such case the arbitral award will so provide. &#160;The arbitrators shall have no power to award damages excluded pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 12.5</u>. &#160;The </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">arbitral award shall be final and binding on the Parties and the Parties shall carry out the award without delay. &#160;Judgment on the award so rendered may be entered in any court of competent jurisdiction. Notwithstanding anything to the contrary herein, nothing in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.3</u> shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction, or other interim equitable relief concerning a Dispute in any court of competent jurisdiction before or after the initiation of an arbitration as set forth herein, if necessary to protect the interests of such Party. The Parties agree that any dispute concerning the propriety of the commencement of the arbitration or the scope and applicability of the agreement to arbitrate shall be determined by the arbitrators. &#160;Notwithstanding the foregoing, the Parties agree that a Reversion Royalty Dispute shall be resolved by arbitration administered by the International Centre for Dispute Resolution in accordance with its International Arbitration Rules and the Final Offer Supplementary Arbitration Rules, and the number of arbitrators in such arbitration shall be one (1).</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.4</font><b style="font-weight:bold;">Entire Agreement; Modification</b>. &#160;This Agreement, including the Schedules hereto, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to all of its terms. &#160;This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein (including [*]. &#160;This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.5</font><b style="font-weight:bold;">Relationship Between the Parties</b>. &#160;The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors. &#160;This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties. &#160;Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.6</font><b style="font-weight:bold;">Performance by Affiliates</b>. &#160;Organon may discharge any obligations and exercise any right under this Agreement through any of its Affiliates, and such Organon Affiliates are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of Organon and, subject to an assignment to such Affiliate pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9</u>, Organon shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.7</font><b style="font-weight:bold;">Waiver</b>. &#160;The waiver by either Party of any right under this Agreement or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. &#160;Any waiver by a Party of a particular term or condition will be effective only if set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.8</font><b style="font-weight:bold;">Further Assurances</b>. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.9</font><b style="font-weight:bold;">Assignment</b>. &#160;Except as expressly provided herein, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party, in whole or in part, without the prior written consent of the other Party (which consent shall not be unreasonably withheld or delayed); except that each Party may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent as follows:</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font>in connection with a sale of all or substantially all of the business or assets of such Party to which this Agreement relates, whether by merger, consolidation, divesture, sale of stock, sale of assets, or otherwise; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font>to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, this Agreement shall be automatically assigned back to the assigning Party or its successor. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9</u>. &#160;Any assignment not in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.9</u> shall be null and void and of no legal force or effect.</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.10</font><b style="font-weight:bold;">Accounting Standards</b>. &#160;Each Party shall calculate all amounts hereunder and perform other accounting procedures required hereunder applicable to it in accordance with the Accounting Standards normally used by such Party to calculate its financial position, in each case consistently applied by such Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.11</font><b style="font-weight:bold;">Severability</b>. &#160;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. &#160;The Parties will in such an instance use their best efforts to replace the invalid, unenforceable, or illegal provision(s) with valid, enforceable, and legal provision(s) that best implement the original intent of the Parties and purposes of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.12</font><b style="font-weight:bold;">Notices</b>. &#160;Any notice to be given under this Agreement must be in writing and delivered either in person, or by registered or certified mail (postage prepaid) requiring return receipt, or by internationally recognized overnight delivery service, in each case to the Party to be notified at its address given below, or at any other address such Party may designate by prior written notice to the other in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.12</u>. &#160;Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) if personally delivered, the date of actual receipt; (b) if delivered by registered or certified mail, five (5) Business Days after the date of postmark; or (c) if delivered by overnight delivery service, the next day the overnight delivery service regularly makes deliveries.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">If to ObsEva, notices must be addressed to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">ObsEva SA</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Chemin des Aulx 12,</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">1228 Plan-Les-Ouates, Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Attention: Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">with a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">ObsEva SA</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Chemin des Aulx 12,</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">1228 Plan-Les-Ouates, Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Attention: Chief Administrative Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">If to Organon, notices must be addressed to:</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Organon International GmbH</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Weystrasse 20,</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">6006 Lucerne, Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">Attention: [*]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">with a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Organon LLC</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">30 Hudson Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">33rd Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Jersey City, NJ (USA) 07302</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;">Attention: SVP, Head of Business Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 36pt;">Attention: Officer of the Secretary</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.13</font><b style="font-weight:bold;">Force Majeure</b>. &#160;Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, epidemics, pandemics, the spread of infectious diseases, quarantines, failure or delay of transportation, default by suppliers or unavailability of raw materials, governmental acts or restrictions or any other reason which is beyond the control of the respective Party (&#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221;). A Force Majeure may include reasonable measures affirmatively taken by a Party or its Affiliates to respond to any epidemic, pandemic, or spread of infectious disease, such as requiring employees to stay home, closures of facilities, delays of Clinical Trials, or cessation of activities in response to an epidemic or other Force Majeure event, to the extent such measures cause a failure or delay in the performance of a Party&#8217;s obligations under this Agreement. The Party affected by Force Majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations hereunder as soon as practicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.14</font><b style="font-weight:bold;">Interpretation</b>. &#160;The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. &#160;All references in this Agreement to the singular shall include the plural where applicable. &#160;Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. &#160;The word &#8220;<b style="font-weight:bold;">including</b>&#8221; and similar words means including without limitation. &#160;The word &#8220;<b style="font-weight:bold;">or</b>&#8221; means &#8220;<b style="font-weight:bold;">and/or</b>&#8221; unless the context dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive. &#160;The words &#8220;<b style="font-weight:bold;">herein</b>&#8221;, &#8220;<b style="font-weight:bold;">hereof</b>&#8221;, and &#8220;<b style="font-weight:bold;">hereunder</b>&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. &#160;All references to days in this Agreement mean calendar days, unless otherwise specified. &#160;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. &#160;This Agreement has been prepared in the English language and the English language shall control its interpretation. &#160;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding or pursuant to this Agreement (including the disclosure of Know-How, notices, and reports and documents submitted to the JAC) shall be in the English language.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.15</font><b style="font-weight:bold;">Counterparts; Electronic Signatures</b>. &#160;This Agreement may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same agreement. &#160;The Parties agree that execution of this Agreement by industry standard electronic signature software or by exchanging executed signature pages in .pdf format via e-mail shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or related to this Agreement, each Party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed agreement electronically.</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">{</b><b style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:bold;">Signature Page Follows</b><b style="font-weight:bold;">}</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 18pt 0pt;"><font style="font-variant:small-caps;">In Witness Whereof</font>, the Parties hereto have caused this Agreement to be executed and entered into by their duly authorized representatives as of the Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 42pt 0pt;"><b style="font-weight:bold;">ObsEva SA</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 42pt 0pt;"><b style="font-weight:bold;">Organon International GmbH</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">By:  </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Brian O&#8217;Callaghan</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">Name: Brian O&#8217;Callaghan</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="white-space:pre-wrap;">Title:  Chief Executive Officer</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Thomas Morlet</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">Name: Thomas Morlet</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;">Title: Managing Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;">{Signature Page to License Agreement}</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.58</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Description of Licensed Compounds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.60</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">[*] Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 2.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">[*]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;font-weight:bold;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 4.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Existing Inventory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 4.6(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Existing INDs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[None]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 5.3(a)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Key Terms of Supply Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 8.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">ObsEva Bank Account Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">[*]</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 10.8</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Joint Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><i style="font-style:italic;">Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i ; agent is being studied in an area of significant unmet need</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women&#8217;s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women&#8217;s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2&#945; (PGF2&#945;) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatment of preterm labor in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;This development-stage asset is being studied in one of the most crucial unmet needs for women globally. As we build Organon&#8217;s women&#8217;s health research and development portfolio, the agreement strengthens our path to long term growth,&#8221; said Kevin Ali, Organon&#8217;s Chief Executive Officer. &#8220;Organon and ObsEva share a commitment to improve the lives of women around the world. Through Organon&#8217;s strong development, scientific and medical capabilities, our goal is to change the future for millions of mothers and babies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Organon intends to work with the scientific and medical communities and regulatory authorities in major markets, including the United States, to advance the clinical development and registration of ebopiprant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Brian O&#8217;Callaghan, CEO of ObsEva, commented, &quot;Organon is the ideal partner for the development and commercialization of ebopiprant and we see this agreement as an important step in advancing this investigational agent. Although preterm birth rates are on the rise, there are currently no other known compounds in development. That is why we are focused on evaluating this agent in an important area of unmet need. Together with the data generated to date, this agreement underscores the value of our program, and we look forward to executing on our shared vision.&quot;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the terms of the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant. ObsEva is entitled to receive tiered double-digit royalties on commercial sales as well as up to $500 million in upfront and milestone payments including $25 million to be paid at signing, up to $90 million in development and regulatory milestones and up to $385 million sales based milestones. Goldman Sachs acted as exclusive financial advisor to ObsEva.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Ebopiprant</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">In November 2020, ObsEva announced positive results from PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of ebopiprant in preterm labor. In this study, 113 women with spontaneous preterm labor (gestational age between 24 and 34 weeks) were randomized and treated with atosiban (ex-U.S. standard of care) plus ebopiprant or atosiban plus placebo for 7 days. There were 83 </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">(73%) women with singleton pregnancies and 30 (27%) with twin pregnancies. One hundred and forty-one neonates were born.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the PROLONG study, ebopiprant reduced delivery in singleton pregnancies at 48 hours after the start of dosing by 55% compared to atosiban alone. Overall, 7/56 (12.5%) of women receiving ebopiprant delivered within 48 hours of starting treatment compared to 12/55 (21.8%) receiving placebo (OR 90% CI: 0.52 (0.22, 1.23)). In singleton pregnancies, 5/40 (12.5%) of women receiving ebopiprant delivered within 48 hours compared to 11/41 (26.8%) receiving placebo (OR 90% CI: 0.39 (0.15, 1.04)). &#160;A modest effect on delivery at 7 days was seen in the singletons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">The incidence of maternal, fetal and neonatal adverse events were comparable between subjects in the ebopiprant group and the placebo group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Ebopiprant (OBE022) was licensed from Merck KGaA, Darmstadt, Germany, in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About ObsEva</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women&#8217;s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is<b style="font-weight:bold;"> </b>traded under the ticker symbol &#8220;OBSV&#8221; and on the SIX Swiss Exchange where it is traded under the ticker symbol &#8220;OBSN&#8221;. For more information, please visit <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.ObsEva.com</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Organon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon&#8217;s products produce strong cash flows that will support investments in future growth opportunities in women&#8217;s health, including business development like recently acquired Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with its headquarters located in Jersey City, New Jersey. For more information, visit <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.organon.com</u> and connect with us on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LinkedIn</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Instagram</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statement of Organon &amp; Co.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Except for historical information herein, this news release of Organon &amp; Co. (the &#8220;company&#8221;) includes &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about ebopiprant as a potential treatment for preterm labor, Organon&#8217;s and ObsEva&#8217;s ability to improve the lives of women, Organon&#8217;s ability to advance the clinical development of ebopiprant, and the potential benefits of the license. Forward-looking statements may be identified by words such as &#8220;potential,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;will&#8221; or words of similar meaning. These </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">statements are based upon the current beliefs and expectations of Organon&#8217;s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including the impact of the recent global outbreak of novel coronavirus<b style="font-weight:bold;"> </b>disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Organon&#8217;s ability to accurately predict its future financial results and performance; Organon&#8217;s ability to accurately predict future market conditions; manufacturing difficulties or delays; dependence on the effectiveness of Organon&#8217;s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Organon does not undertake any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including its registration statement on Form 10, available at the SEC&#8217;s Internet site (www.sec.gov).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cautionary Note Regarding Forward Looking Statements of ObsEva SA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 18pt 0pt;">Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, and similar expressions, and are based on ObsEva&#8217;s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva&#8217;s product candidates, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva&#8217;s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva&#8217;s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the<b style="font-weight:bold;"> </b>SEC. These documents are available on the Investors page of ObsEva&#8217;s website at <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.ObsEva.com</u>. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Media Contacts Organon:</p></td><td style="vertical-align:top;width:25.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Karissa Peer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(614) 314-8094</p></td><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investor Contacts:</p></td><td style="vertical-align:top;width:26.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Jennifer Halchak</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 18pt 0pt;">(201) 275-2711</p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Kate Vossen</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">(732) 675-8448</p></td><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:26.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Edward Barger</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 24pt 0pt;">(267) 614-4669</p></td></tr><tr><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">CEO Office Contact Obseva:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:25.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Shauna Dillon</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+41 22 552 1550</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shauna.Dillon@obseva.ch</u></p></td><td style="vertical-align:top;width:24.06%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Investor Contacts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:26.79%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Joyce Allaire</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">+1(617) 435 6602</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">jallaire@lifesciadvisors.com</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 11.1(z)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">CMO Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">[*]</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.58
<SEQUENCE>9
<FILENAME>xoma-20221231xex10d58.htm
<DESCRIPTION>EX-10.58
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:16:54 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 10.58</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 36pt 0pt;"><a name="_mps218258980000000000000003929000000000"></a><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:36pt 0pt 0pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Dated June 10, 2015</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">By and Between</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">ARES TRADING S.A.</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">And</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">OBSEVA S.A.</b></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">This License Agreement&#160;</b><font style="font-family:'Times New Roman','Times','serif';">(the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) is dated as of June&#160;10, 2015 (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) by and between&#160;</font><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Ares Trading </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SA</b><font style="font-family:'Times New Roman','Times','serif';">, a Swiss corporation with registered offices at Zone Industrielle de l&#8217;Ouriettaz, 1108 Aubonne, Switzerland (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and&#160;</font><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Obseva </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">S.A.</b><font style="font-family:'Times New Roman','Times','serif';">, a Swiss corporation with registered offices at 12, Chemin des Aulx, 1228 Plan-Les-Ouates, Geneva (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Merck Serono and Licensee may be referred to herein as a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Party</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; or, collectively, as &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Parties</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Witnesseth</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-family:'Times New Roman','Times','serif';">, Licensee is active in the field of reproductive health and medicine;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-family:'Times New Roman','Times','serif';">, Merck Serono is engaged, among other activities, in the development of pharmaceutical products; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-family:'Times New Roman','Times','serif';">, Merck Serono wishes to license to Licensee, on an exclusive worldwide basis, the right to research, develop, manufacture and commercialize products comprising the Licensed Compounds in the Field (as hereinafter defined); and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><font style="font-family:'Times New Roman','Times','serif';">, Licensee wishes to obtain, and Merck Serono is willing to grant a license to the Merck Serono Technology upon the terms and conditions set forth herein; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Now, Therefore</b><font style="font-family:'Times New Roman','Times','serif';">, in consideration of the promises and mutual covenants contained herein, the parties agree to as follows:</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEFINITIONS</b></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following terms shall have the following respective definitions:</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Affiliate</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a Person or entity that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. For the purposes of this Section&#160;1.1, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of at least fifty percent (50%)&#160;of the voting stock of such entity, or by contract or otherwise.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Bankruptcy Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means: (a)&#160;voluntary or involuntary proceedings by or against a Party instituted in bankruptcy under any insolvency law, which proceedings, if involuntary, shall not have been dismissed within sixty (60)&#160;days after the date of filing; (b)&#160;a receiver or custodian is appointed for a Party; (c)&#160;proceedings are instituted by or against a Party for corporate reorganization, dissolution, liquidation or winding-up of such Party, which proceedings, if involuntary, shall not have been dismissed within sixty (60)&#160;days after the date of filing; or (d)&#160;substantially all of the assets of a Party are seized or attached and not released within sixty (60)&#160;days thereafter.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Calendar Quarter</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means each three (3)&#160;month period commencing January&#160;1,&#160;April&#160;1,&#160;July&#160;1 or October&#160;1, provided however that (i)&#160;the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (ii)&#160;the last Calendar Quarter of the Term shall end upon the expiration of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Calendar Year</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means the period beginning on the 1</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">st</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;of January and ending on the 31</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">st</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;of December of the same year, provided however that (i)&#160;the first Calendar Year of the Term shall commence on the Effective Date and end on December&#160;31, 2015 and (ii)&#160;the last Calendar Year of the Term shall commence on </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;"><a name="_Hlk128076743"></a></font><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">January&#160;1 of the Calendar Year in which this Agreement terminates or expires and ends on the date of termination or expiration of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Clinical Trial</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a clinical trial in human subjects that has been approved by a Regulatory Authority and is designed to measure the safety and/or efficacy of a Licensed Product. Clinical Trials shall include Phase I Trials, Phase II Trials and Phase III Trials.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Combination Product</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a product containing the Licensed Product together with one or more active ingredient, or with one or more product, device, equipment or component.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.7</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Commercialization</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221; or &#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Commercialize</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means any and all activities undertaken prior to and after Regulatory Approval of an NDA for a particular Licensed Product and that relate to the marketing, promoting, distributing, importing for sale, offering for sale, and selling of the Licensed Product.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.8</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Commercially Reasonable Efforts</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means, (a)&#160;with respect to the efforts to be expended by any Party with respect to any objective, such reasonable, diligent, and good faith efforts as such Party would normally use to accomplish a similar objective under similar circumstances, and (b)&#160;with respect to any obligation relating to research, Development or Commercialization of a Licensed Product by Licensee, the application by Licensee of the level of efforts required to carry out such obligation in a sustained manner consistent with the efforts a similarly situated biopharmaceutical company or pharmaceutical company, as the case may be, devotes to a product of similar market potential, profit potential or strategic value resulting from its own research efforts.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.9</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Confidential Information</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;of a Party means information relating to the business, operations and products of a Party or any of its Affiliates, including but not limited to, any technical information, Know-How, trade secrets, or inventions (whether patentable or not), not known or generally available to the public, that such Party discloses to the other Party under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.10</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Controlled</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to (a)&#160;Patent Rights, (b)&#160;Know-How or (c)&#160;biological, chemical or physical material, that a Third Party or a Party or one of its Affiliates owns or has a license or sublicense to such right, item, or material (or in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to, such right, item or material as provided for in this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.11</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Cover</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;, &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Covering</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; or &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Covered</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Licensed Product, that the using, selling, or offering for sale of such Licensed Product would, but for a license granted in this Agreement under the Merck Serono Patents, infringe a Valid Claim of the Merck Serono Patents in the country in which the activity occurs.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.12</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Development</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to a Licensed Product, the performance of all pre-clinical and clinical development (including toxicology, pharmacology, test method development and stability testing, process development, formulation development, quality control development, statistical analysis), Clinical Trials (excluding clinical trials conducted after Regulatory Approval of an NDA), manufacturing and regulatory activities that are required to obtain Regulatory Approval of the Licensed Product in the Territory.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.13</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Executive Officers</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, together, a member of the senior management of the pharmaceutical division of Merck Serono and the Chief Executive Officer of Licensee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.14</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">EMA</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means the European Medicines Agency or any successor agency.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.15</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">FDA</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means the United States Food and Drug Administration, or a successor federal agency thereto.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.16</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Field</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means all prophylactic, palliative, therapeutic or diagnostic uses in humans and animals.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.17</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">First Commercial Sale</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall mean, on a country-by-country basis, the first sale for monetary value to a Third Party for use or consumption of the Licensed Product, by Licensee, its Affiliate(s) or Sublicensees. For the avoidance of doubt, a First Commercial Sale may only occur after the Licensed Product has received Regulatory Approval valid for the country in which the First Commercial Sale occurs.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.18</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Governmental Body</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means any: (a)&#160;nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&#160;federal, state, local, municipal, foreign or other government; (c)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d)&#160;multi-national or supranational organization or body; or (e)&#160;individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.19</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">IND</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means an investigational new drug application filed with the FDA or the equivalent application or filing filed with any equivalent agency or Governmental Body outside the United States (including any supra-national entity such as in the European Union) for approval to commence Clinical Trials in such jurisdiction, and including all regulations at 21 CFR &#167; 312 Et. Seq. and equivalent foreign regulations.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.20</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Initiation</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;of a Clinical Trial means the [*] patient with a Licensed Product in such Clinical Trial.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.21</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Know-How</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means any scientific or technical information, results and data of any type whatsoever, in any tangible form, that is not in the public domain or otherwise publicly known, including, without limitation, discoveries, inventions, trade secrets, databases, practices, protocols, regulatory filings, methods, processes, techniques, biological and other materials, reagents, specifications, formulations, formulae, data (including pharmacological, biological, chemical, toxicological and clinical information, analytical, quality control and stability data, studies and procedures), manufacturing process and development information, results and data, whether or not patentable, all to the extent not claimed or disclosed in a patent. &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Know How</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; excludes Patent Rights.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.22</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensed Compound(s)</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Merck Serono&#8217;s proprietary compounds known as [*] and which are listed on Schedule 1.23. For the avoidance of doubt, Licensed Compounds are prostaglandin F2 receptors antagonists.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.23</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensed Product(s)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means any pharmaceutical product, in any dosage form, formulation, presentation or package configuration that is commercialized or undergoing research or pre-clinical or clinical development that contains or comprises, in part or in whole, a Licensed Compound.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.24</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee Know-How</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all Know-How that is owned or Controlled by Licensee or its Affiliates after the Effective Date and is necessary in the research, Development, manufacture, use, or Commercialization of the Licensed Products.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.25</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Major Market</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the United States, Germany, France, Italy, the United Kingdom and Spain.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.26</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Know-How</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means all Know-How that is owned or Controlled by Merck Serono as of the Effective Date and is necessary in the research, Development, manufacture, use, or Commercialization of the Licensed Products. The Know-How set forth on Schedule 1.27 constitutes all of such Know-How owned or Controlled by Merck Serono on the Effective Date.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.27</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Materials</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means all chemical, biological or physical materials that are owned or Controlled by Merck Serono or any of its Affiliates as of the Effective Date and that are necessary in the research, Development, manufacture, use or Commercialization of the Licensed Products. The Merck Serono Materials are set forth on Schedule 1.28.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.28</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Patents</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Patent Rights listed on Schedule 1.29.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.29</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Technology</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means the Merck Serono Know-How, the Merck Serono Patents and the Merck Serono Materials, collectively.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.30</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">NDA</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a New Drug Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR.&#167;&#160;314.3 et seq, a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR &#167;&#160;601, and any equivalent application filed in any country in the Territory, together, in each case, with all additions, deletions or supplements thereto.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.31</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Net Sales</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means, with respect to each country of the Territory, the amounts invoiced by Licensee or its Affiliates or Sublicensees for all sales of Licensed Products to a Third Party (whether an end user, a distributor or otherwise), less the following:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-family:'Times New Roman','Times','serif';">trade, cash and quantities discounts, rebates (including rebates similar to Medicare or other government rebates), reimbursements, allowances and credits for expired Licensed Products;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-family:'Times New Roman','Times','serif';">sales, use or similar taxes (including duties or other governmental charges levied or otherwise imposed on the sale or use of such Licensed Product, including, without limitation, value added taxes or other governmental charges otherwise measured by the billing amount, but only to the extent such amount(s) is (are) included in the billing);</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-family:'Times New Roman','Times','serif';">freight, postage, shipping, customs duties and insurance charges, but only to the extent such amount(s) is (are) included in the billing;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><font style="font-family:'Times New Roman','Times','serif';">any other specifically identified amounts included in the Licensed Product invoice price that should be credited for reasons substantially equivalent to those listed above or as determined in accordance with Licensee&#8217;s usual and customary accounting methods which are in accordance with International Accounting Standards or equivalent.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Net Sales shall not include credits or allowances actually granted for damaged goods, returns or rejections of previously sold Licensed Products and retroactive price reductions for wastage replacement, indigent patients and similar programs.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For the avoidance of doubt, Net Sales may only occur after the Licensed Product has received Regulatory Approval valid for the country in which the Net Sales occur.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In the event that a Licensed Product is sold in the form of a Combination Product, Net Sales for such Combination Product will be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where A is the invoice price of the Licensed Product containing a Compound as the only active ingredient if sold separately, and B is the invoice price of any other active ingredient(s) or other products, devices, equipment or components in the Combination Product if sold separately. In the event that the Licensed Product or one or more of such active ingredients or other products, devices, equipment or components in the Combination Product are not sold separately, then the Net Sales for such Combination Product shall be determined by the Parties in good faith.</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.32</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Patent Right(s)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means: (a)&#160;an issued or granted patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination, extension or renewal thereof; (b)&#160;a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c)&#160;all counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.33</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Person</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any Governmental Body, government or agency or political subdivision thereof.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.34</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Phase I Trial</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means a Clinical Trial in which the Licensed Product is administered to human subjects at multiple dose levels with the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the Licensed Product, and consistent with 21 CFR &#167; 312.21(a).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.35</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Phase II Trial</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a Clinical Trial of the Licensed Product in human patients, the principal purposes of which are to make a preliminary determination that the Licensed Product is safe for its intended use, to determine its optimal dose, and to obtain sufficient information about the Licensed Product&#8217;s efficacy to permit the design of Phase III Trials, and consistent with 21 CFR 312.21(b).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.36</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Phase III Trial</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a human Clinical Trial of the Licensed Product, which trial is designed (a)&#160;to establish that the Licensed Product is safe and efficacious for its intended use; (b)&#160;to define warnings, precautions and adverse reactions that are associated with the Licensed Product in the dosage range to be prescribed; and (c)&#160;consistent with 21 CFR &#167; 312.21(c).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.37</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Preferred Equity</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means, with respect to shares, equity with rights identical to existing Series A Preferred shares.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.38</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Regulatory Authority</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means (a)&#160;the FDA, (b)&#160;the EMA or the European Commission, or (c)&#160;any regulatory body with similar regulatory authority over pharmaceutical or biotechnology products in any other jurisdiction anywhere in the world.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.39</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Regulatory Approval</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means the receipt from a Regulatory Authority by Licensee, its Affiliates, or Sublicensees of approval to lawfully market a Licensed Product in the corresponding jurisdiction in the Territory.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.40</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Sublicensee</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means a Person other than an Affiliate of Licensee to which Licensee (or its Affiliate) has, pursuant to Section&#160;2.2, granted sublicense rights under any of the Merck Serono Technology licensed under Section&#160;2.1. &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Sublicense</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; shall be construed accordingly. For the avoidance of doubt, a Third Party contract manufacturer of Licensed Products on behalf of Licensee shall not be considered a Sublicensee for the purpose of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.41</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Territory</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;means all the countries in the world.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.42</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Third Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;shall mean any Person that is not a Party, an Affiliate of a Party, or a Sublicensee of Licensee hereunder.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.43</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Third Party License Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any agreement entered into by Licensee with a Third Party, or any amendment or supplement thereto, in each case following the Effective Date, whereby royalties, fees or other payments are to be made by Licensee to such Third Party in connection with the grant of rights under intellectual property rights Controlled by such Third Party, which rights are necessary to research or Develop the Licensed Compounds or Licensed Products.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.44</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Valid Claim</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; means any claim in any (i)&#160;unexpired and issued patent that has not been disclaimed, revoked or held invalid by a final nonappealable decision of a court or other governmental agency of competent jurisdiction or any (ii)&#160;patent application [*].</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.45</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Other Terms.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">The definition of each of the following terms is set forth in the section of the Agreement indicated below:</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Action</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;5.5 (b).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Controlling Party</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;5.6 (c).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Disputes</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section&#160;10.9.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee Indemnitees</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;8.1.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee Patents</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section&#160;5.4 (a).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Losses</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;8.1.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Indemnitees</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;8.2.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Royalty Term</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; has the meaning set forth in Section&#160;4.2 (d).</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Term</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;9.1.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8220;</b><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Upfront Payment</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;has the meaning set forth in Section&#160;4.1.</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">GRANT OF LICENSE</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Grant of License</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to the terms and conditions of this Agreement, Merck Serono hereby grants to Licensee an exclusive (even as to Merck Serono), worldwide, royalty-bearing right and license (with the right to sublicense subject to the provisions of Section&#160;2.2) under the Merck Serono Technology to research, Develop, make, have made, import, export, use and Commercialize the Licensed Products in the Field in the Territory.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Grant of Sublicense by Licensee</b><font style="font-family:'Times New Roman','Times','serif';">. The Licensee shall have the right to grant Sublicenses under the license granted in Section&#160;2.1, subject to Merck Serono being duly informed in writing by Licensee in advance of the execution of any Sublicense agreement. The Sublicense agreement shall be consistent with the terms and conditions of this Agreement. The granting by Licensee of a Sublicense shall not relieve Licensee of its obligations hereunder. Licensee shall promptly provide Merck Serono with a copy of the fully executed Sublicense agreement, which shall be redacted from its commercial terms, and Merck Serono hereby undertakes to treat such redacted Sublicense agreement as Confidential Information. For the avoidance of doubt, Licensee may grant Sublicenses to Sublicensees on a country-by-country basis or worldwide.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">2.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transfer.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Merck Serono shall use Commercially Reasonable Efforts to transfer to Licensee the Merck Serono Know-How and the Merck Serono Materials within thirty (30)&#160;days following the Effective Date. If within sixty (60)&#160;days after the initial transfer Licensee identifies specific items within the Merck Serono Know-How that were not transferred to Licensee, then Merck Serono will use reasonable efforts to provide the same to Licensee upon request. In addition, at Licensee&#8217;s reasonable request, Merck Serono shall provide access to any raw data or report directly and exclusively related to the Licensed Product which may become necessary for the Licensee to research, manufacture and Develop any Licensed Product in the Field. Each Party hereby designates a contact person as indicated below whose responsibility it will be to oversee the transfer described in this Section&#160;2.3:</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For Licensee: [*]</u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">For Merck Serono: [*]</u></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DEVELOPMENT AND COMMERCIALIZATION</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Development and Commercialization of the Licensed Products by Licensee</b><font style="font-family:'Times New Roman','Times','serif';">. Licensee shall have the exclusive right and responsibility to research and Develop the Licensed Products and to conduct (either itself or through its Affiliates, agents, subcontractors and/or Sublicensees) all Clinical Trials and non-clinical studies Licensee believes appropriate to obtain Regulatory Approval for the Licensed Products in any indication. In addition, Licensee shall have the exclusive right to Commercialize the Licensed Products itself or through one or more Third Parties and/or Sublicensees selected by Licensee, and shall have the responsibility in all matters relating to the Commercialization of the Licensed Products.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Manufacturing and Supply.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Subject to the terms and conditions of this Agreement, Licensee shall have the exclusive right to manufacture the Licensed Compounds and the Licensed Products itself or through one or more Third Party subcontractor(s) selected by Licensee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Regulatory Filings.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee shall be responsible for and shall own and maintain all regulatory filings and Regulatory Approvals for the Licensed Products, including all INDs and NDAs.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Diligence by Licensee.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee shall use Commercially Reasonable Efforts to (a)&#160;research and Develop at least one Licensed Product, in accordance with its development plan as updated and/or amended from time to time and (b)&#160;launch and Commercialize at least one Licensed Product in each Major Market within [*] after receiving Regulatory Approval (which for the purpose of this clause 3.4 shall include approval of pricing and reimbursement) in such Major Market.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reporting.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee (or its Sublicensee, as applicable) shall, on each anniversary of the Effective Date, provide Merck Serono with a written report summarizing its research, Development, manufacturing and as applicable Commercialization activities in the Territory during the preceding Calendar Year.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Trademarks.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee shall have the sole authority to select trademarks for the Licensed Products and shall own all such trademarks.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FINANCIAL TERMS</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Upfront Payment.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;In partial consideration for the grant of the rights hereunder, Licensee shall assign 25&#8217;000 Preferred Equity shares (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Upfront Payment</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to Merck Serono within thirty (30)&#160;days after the Initiation of the first Phase I Trial (&#8216;&#8216;Phase I Equity Event&#8217;&#8217;), it being specified that Merck Serono will subscribe to such Preferred Equity shares at the nominal value of CHF 1,-. In the event of any liquidation, dissolution, winding-up, sale or merger of Obseva (a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Liquidation Event</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), irrespective of its legal qualification, before the occurrence of the Phase I Equity Event, Licensee shall automatically assign the 25&#8217;000 Preferred Equity shares to Merck Serono, it being specified that Merck Serono will subscribe to such Preferred Equity shares at the nominal value of CHF 1,- and such assignment shall take place immediately before the Liquidation Event. If additional securities are issued or sold by ObsEva prior to the occurrence of the Phase I Equity Event, Merck Serono shall have the right to maintain a percentage ownership on an as converted basis through the purchase of its pro rata share of such securities on the same terms as such securities are offered to other purchasers (&#8220;the pre-Phase I Equity Event Pre-emptive Rights&#8221;). For the calculation of the pro-rata share purchase under such &#8220;pre-Phase I Equity Event Pre-emptive Right&#8221;, the 25&#8217;000 Preferred Equity Shares shall be counted as if they have been assigned to Merck Serono on the Effective Date.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Payments</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Rate.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;As further consideration for Merck Serono&#8217;s grant of the rights and licenses to the Licensee hereunder, the Licensee shall, during each applicable Royalty Term (i.e. on a country-by-country basis), pay to Merck Serono a royalty on aggregate annual worldwide Net Sales of each Licensed Product for each Calendar Year, at the percentage rate set forth below:</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Royalty Rate for Annual Net Sales of Licensed Products Net Sales per Calendar Year</b></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">[*]</font></font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Know-How Royalty.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;The royalty rate set forth in Section&#160;4.2 (a)&#160;applicable to the Net Sales of a Licensed Product in a country will be reduced by [*] during any period there exists no Valid Claim of a Merck Serono Patent in such country that Covers such Licensed Product in such country. For the avoidance of doubt, no Know-How Royalties shall be due in any country after the end of the Royalty Term pursuant to Section&#160;4.2 (d)&#160;in such country.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party License Agreements.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Subject to the terms and conditions of this Agreement, if Licensee enters into one or more Third Party License Agreement(s), Licensee will be entitled to deduct from any royalties payable to Merck Serono under Section&#160;4.2 (from the amount calculated by consideration of the then </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">applicable royalty rate), an amount equal to not more than [*] of any amounts paid by Licensee pursuant to such Third Party License Agreement(s) in respect of the Licensed Product which gave rise to the payment obligation under Section&#160;4.2. Notwithstanding the foregoing, under no circumstances shall the deductions under this Section&#160;4.2 (c)&#160;result in the amount payable to Merck Serono being reduced by more than [*] compared with the amount otherwise payable under Section&#160;4.2. In the event that Licensee is not able to deduct the full amount of the permitted deduction from the amount due to Merck Serono due to the [*] minimum amount, Licensee shall be entitled to deduct any undeducted excess amount from subsequent amounts owed to Merck Serono (subject always to Merck Serono receiving a minimum of [*] of the amount owed).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Term.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Royalties shall be payable on a Licensed Product-by-Licensed Product and country-by-country basis from the period from the First Commercial Sale of Licensed Product in such country until the latest of (a)&#160;the last date on which such Licensed Product is Covered by a Valid Claim within a Merck Serono Patent in such country, or (b)&#160;ten (10)&#160;years after such First Commercial Sale of Licensed Product in such country (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Royalty Term</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Payment of Royalties.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Nothing herein contained shall obligate Licensee and/or its Sublicensees to pay or cause to be paid to Merck Serono more than one royalty on any unit of Licensed Product. Simultaneous with the delivery of the report described in Section&#160;4.2 (f)&#160;hereof, Licensee shall pay, or cause to be paid, to Merck Serono at such place as Merck Serono may from time to time designate in writing, all royalties earned pursuant to this Section&#160;4.2 in the preceding Calendar Quarter. All such payments shall be made in Euros.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Royalty Reports; Currency Conversion.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Commencing with the Calendar Quarter in which the First Commercial Sale of a Licensed Product is made by the Licensee or its Affiliate or Sublicensee, Licensee shall submit to Merck Serono with each royalty payment a report detailing its computation of royalties due on Net Sales in each country during each Calendar Quarter within sixty (60)&#160;days after the end of such Calendar Quarter (and Licensee shall cause its Sublicensees to submit royalty reports containing the same level of detail). All payments to Merck Serono hereunder shall be made by deposit of Euros in the requisite amount to such bank account as Merck Serono may from time to time designate by written notice to Licensee. With respect to sales not denominated in Euros, royalty amounts owed shall first be calculated in the currency of sale, and then such amounts shall be converted into Euro using the exchange rate of the European Central Bank on the last day of the Calendar Quarter to which the report relates. For accounting and documentation purposes, the Parties may vary the method of payment set forth herein at any time upon mutual agreement, and any change shall be consistent with the local law at the place of payment or remittance.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(g)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Record Retention, Inspection.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Licensee shall keep or cause its Affiliates and Sublicensee to keep complete and accurate records in sufficient detail to enable Net Sales and royalties payable under Section&#160;4.2 to be established for a period of sixty (60)&#160;months after the date that such royalties were payable. Such records shall be consistent with Licensee&#8217;s normal accounting principles. At the request and cost of Merck Serono (but not more frequently than once each Calendar Year) an independent chartered or certified public accountant chosen by Merck Serono but approved by the Licensee (which approval shall not be unreasonably withheld or delayed) shall be allowed access during ordinary business hours to such records pertaining to the preceding two (2)&#160;Calendar Year solely to verify the accuracy of any payments made to Merck Serono under Section&#160;4.2. The accountant shall not disclose to Merck Serono any information other than that which should properly be contained in a report of matters relevant to Net Sales and royalty calculation and payment arising under Section&#160;4.2 above. Licensee shall make Sublicensee records available to Merck to the same extent as set forth in this Section&#160;4.2 (g).</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Tax.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;If applicable law requires that taxes be deducted and withheld from royalties or any other payments paid under this Agreement by either Party, said Party shall (i)&#160;deduct those taxes and interests and penalties assessed thereon from the payment or from any other payment owed by said Party hereunder; (ii)&#160;pay the taxes to the proper Governmental Body; (iii)&#160;send evidence of the obligation together with proof of payment to the other Party within three (3)&#160;months following such payment; (iv)&#160;remit the net amount, after deductions or withholding made under this Section&#160;4.3 and (v)&#160;cooperate with other Party in any way reasonably requested by said other Party, to obtain available reductions, credits or refunds of such taxes; provided, however, that the other Party shall reimburse said Party for said Party&#8217;s out-of-pocket expenses incurred in providing such assistance. It is understood and agreed between the Parties that any payments made by either Party under this Agreement are exclusive of any value added or similar tax imposed upon such payment.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Late Payment.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Payments not paid when due shall bear interest at a rate of [*] per annum above the three-month EURO LIBOR which applied on the day when the payment was due. Calculation of interest will be made for the exact number of days in the interest period based on a year of three hundred and sixty (360)&#160;days.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INVENTIONS AND PATENTS</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification Under Drug Price Competition and Patent Restoration Act.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Each Party shall immediately give written notice to the other Party of any certification of which they become aware filed pursuant to 21 U.S.C. Section&#160;355(b)(2)(A) (or any amendment or successor statute thereto) claiming that any Merck Serono Patents covering Licensed Compounds or Licensed Products, or the manufacture or use of each of the foregoing, are invalid or unenforceable, or that infringement will not arise from the manufacture, use or sale of a product by a Third Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Listing of Patents</b><font style="font-family:'Times New Roman','Times','serif';">. Merck Serono shall determine which of the Merck Serono Patents, if any, shall be listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section&#160;355, or any successor law in the United States, together with any comparable laws or regulations in any other country in the Territory. Licensee shall have the right to propose Merck Serono Patents for such listing and Merck Serono shall not unreasonably reject any such proposal.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Title to Inventions.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">All inventions having as inventors solely employees or independent contractors of one Party in the course of the Parties&#8217; performance under this Agreement, and all intellectual property rights pertaining to such inventions shall be the property of such Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patent Prosecution and Maintenance</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Licensee Patents</b><font style="font-family:'Times New Roman','Times','serif';">. Licensee shall have the right to file, prosecute and maintain the Patent Rights owned by Licensee pursuant to Section&#160;5.3 or otherwise (such Patent Rights, the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee Patents</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Licensee shall bear all costs and expenses of filing, prosecuting and maintaining Licensee Patents in the Territory. For the avoidance of doubt, Merck Serono shall have no right whatsoever regarding any Licensee Patents, including if such Licensee Patents are entirely or partially based on Merck Serono Know-How.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merck Serono Patents</b><font style="font-family:'Times New Roman','Times','serif';">. Merck Serono shall have the first right, and the obligation, to file, prosecute and maintain Merck Serono Patents. Merck Serono shall bear all costs and expenses of filing, prosecuting and maintaining Merck Serono Patents in the Territory. Merck Serono shall keep Licensee informed of the course of the filing and prosecution of Merck Serono Patents or related proceedings (e.g. interferences, oppositions, reexaminations, reissues, revocations or nullifications) in the United States, the European Union, Japan, China, Canada and Australia in a timely manner, and shall take into consideration the advice and recommendations of Licensee in that respect. At Merck Serono&#8217;s request, Licensee will provide Merck Serono with reasonable assistance in prosecuting Merck Serono Patents to the extent possible, including providing such data in Licensee&#8217;s control that is, in Merck Serono&#8217;s reasonable judgment, needed to support the prosecution of a Merck Serono Patent; provided, however, that Merck Serono shall reimburse Licensee for Licensee&#8217;s out-of-pocket expenses incurred in providing such assistance.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Election not to file and prosecute Merck Serono Patents</b><font style="font-family:'Times New Roman','Times','serif';">. If Merck Serono elects not to file, prosecute or maintain a Merck Serono Patent in a country or possession in the Territory, then it shall notify Licensee in writing at least ninety (90)&#160;days before any deadline applicable to the filing, prosecution or maintenance of such Merck Serono Patent, as the case may be, or any other date by which an action must be taken to establish or preserve such Merck Serono Patent in such country or possession. In such case, Licensee shall have the right, but not the obligation, to pursue the filing or support the continued prosecution or maintenance of such Merck Serono Patent. If Licensee does elect to take such action in a country in the Territory, then it shall notify Merck Serono of such election, and Merck Serono shall reasonably cooperate with Licensee in this regard. If Licensee does elect to take such action in a country in the Territory, it shall also notify Merck Serono, at the time of such election, whether Licensee requests from Merck Serono the assignment of all its right, title and interest in and to any such Merck Serono Patent in such country. If Licensee does not request from Merck Serono such assignment of a Merck Serono Patent, Merck Serono shall file, prosecute or maintain a Merck Serono Patent in a country or possession in the Territory and such </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merck Serono Patent shall remain a Merck Patent under which royalty payments shall be due by Licensee under Article 4 of this Agreement. If Licensee does request from Merck Serono the assignment of Merck Serono Patent in a country or possession in the Territory, such Merck Serono Patent shall become a Licensee Patent under which no royalty payments in such country or possession in the Territory shall be due by Licensee under this Agreement, and Licensee shall thereupon be responsible for all costs of filing, prosecution and maintenance of such new Licensee Patent for aforesaid country or possession in the Territory.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patent Term Extension</b><font style="font-family:'Times New Roman','Times','serif';">. Merck Serono shall be responsible for obtaining patent term extensions wherever available for Merck Serono Patents, at Merck Serono costs. Licensee shall provide Merck Serono with all relevant information, documentation and assistance in this respect. Any such assistance, supply of information and consultation shall be provided promptly and in a manner that will ensure that all patent term extensions for Licensed Products are obtained wherever legally permissible, and to the maximum extent available. In the event that any election with respect to obtaining patent term extensions is to be made, Licensee shall have the right to make such elections, and Merck Serono shall abide by all such elections.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Enforcement of Patents</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Notice.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;If either Party believes that a Merck Serono Patent is being infringed by a Third Party or if a Third Party claims that any Merck Serono Patent is invalid or unenforceable, the Party possessing such knowledge or belief shall notify the other Party and provide it with details of such infringement or claim that are known by such Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Right to bring an Action.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Merck Serono shall have the exclusive right to attempt to resolve such infringement or claim pertaining to a Merck Serono Patent, including by filing an infringement suit, defending against such claim or taking other similar action (each, an &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Action</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and to compromise or settle such infringement or claim. If Merck Serono does not intend to prosecute or defend an Action, Merck Serono shall promptly inform Licensee in writing and Licensee shall have the right to initiate an Action. If Licensee does not initiate an Action with respect to such an infringement or claim within one hundred and eighty (180)&#160;days following notice thereof, Merck Serono shall have the right to attempt to resolve such infringement or claim. The Party initiating the Action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to this Section&#160;5.5. Each Party shall have the right to join an Action relating to a Merck Serono-Patent taken by the other Party, at its own expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Costs of an Action.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Subject to the respective indemnity obligations of the Parties set forth in Article 8, the Party taking an Action under Section&#160;5.5 (b)&#160;shall pay all costs associated with such Action, other than the expenses of the other Party if the other Party elects to join such Action.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Settlement</b><font style="font-family:'Times New Roman','Times','serif';">. Neither Party shall settle or otherwise compromise any Action by admitting that any Merck Serono Patent is invalid or unenforceable without the other Party&#8217;s prior written consent, and, in the case of Licensee, Licensee may not settle or otherwise compromise an Action in a way that adversely affects or would be reasonably expected to adversely effect Merck Serono&#8217;s rights or benefits hereunder with respect to the Licensed Product, without Merck Serono&#8217;s prior written consent. The settlement will be treated in accordance with the law of the country to which the settlement relates.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reasonable Assistance</b><font style="font-family:'Times New Roman','Times','serif';">. The Party not enforcing or defending Merck Serono-Patents shall provide reasonable assistance to the other Party, including providing access to relevant documents and other evidence and making its employees available, subject to the other Party&#8217;s reimbursement of any out-of-pocket expenses incurred by the non-enforcing or non-defending Party in providing such assistance.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Distribution of Amounts Recovered.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Any amounts recovered by the Party taking an Action pursuant to this Section&#160;5.5, whether by settlement or judgment, shall be allocated in the following order: (i)&#160;to reimburse the Party taking such Action for any costs incurred, (ii)&#160;to reimburse the Party not taking such Action for its costs incurred in such Action, if it joins such Action; and (iii)&#160;the remaining amount of such recovery shall be attributed to Licensee (as if it were Net Sales), and Licensee shall pay to Merck Serono a royalty on such remaining amount based on the royalty rates set forth in Section&#160;4.2.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Third Party Actions Claiming Infringement.</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Notice</b><font style="font-family:'Times New Roman','Times','serif';">. If a Party becomes aware of any claim or action by a Third Party against either Party that claims that the Licensed Product, or its use, Development, manufacture or sale infringes such Third Party&#8217;s intellectual property rights (each, a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Third Party Action</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), such Party shall promptly notify the other Party of all details regarding such Third Party Action that is reasonably available to such Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Right to Defend.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Merck Serono shall have the right, at its sole expense, but not the obligation, to defend a Third Party Action through counsel of its choosing. If Merck Serono declines or fails to assert its intention to defend such Third Party Action within sixty (60)&#160;days of receipt/sending of notice under Section&#160;5.6 (a), then Licensee shall have the right to defend such Third Party Action. The Party defending such Third Party Action shall have the sole and exclusive right to select counsel for such Third Party Action. Each Party shall have the right to join any Third Party Action defended by the other Party, at its own expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consultation.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;The Party defending a Third Party Action pursuant to Section&#160;5.6 (b)&#160;shall be the&#160;&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Controlling Party.</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">&#160;The Controlling Party shall consult with the non-Controlling Party on all material aspects of the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in decision-making and formulation of defense strategy. The Parties shall reasonably cooperate with each other in all such actions or proceedings. The non-Controlling Party will be entitled to be represented by independent counsel of its own choice at its own expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Appeal</b><font style="font-family:'Times New Roman','Times','serif';">. In the event that a judgment in a Third Party Action is entered against the Controlling Party and an appeal is available, the Controlling Party shall have the first right, but not the obligation, to file such appeal. In the event the Controlling Party does not desire to file such an appeal, it will promptly, in a reasonable time period (i.e., with sufficient time for the non-Controlling Party to take whatever action may be necessary) prior to the date on which such right to appeal will lapse or otherwise diminish, permit the non-Controlling Party to pursue such appeal at such non-Controlling Party&#8217;s own cost and expense. The non-Controlling Party shall then become the Controlling Party. If applicable law requires the non-Controlling Party&#8217;s involvement in an appeal, the non-Controlling Party shall be a nominal party of the appeal and shall provide reasonable cooperation to the Controlling Party at the Controlling Party&#8217;s expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Costs of an Action</b><font style="font-family:'Times New Roman','Times','serif';">. Subject to the respective indemnity obligations of the Parties set forth in Article 8, the Controlling Party shall pay all costs associated with such Third Party Action other than the expenses of the other Party if the other Party elects to join such Action.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">No Settlement Without Consent.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;No Controlling Party shall settle or otherwise compromise any Third Party Action by admitting that any Merck Serono Patent is invalid or unenforceable without the non-Controlling Party&#8217;s prior written consent.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CONFIDENTIALITY</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Confidentiality Obligations.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Each Party agrees that, for the Term and for [*] years thereafter, such Party shall, and shall ensure that its officers, directors, employees, agents and Sublicensees shall keep completely confidential and not publish or otherwise disclose and not use for any purpose, except as expressly permitted hereunder, any Confidential Information disclosed to it by the other Party pursuant to this Agreement. The foregoing obligations shall not apply to any Confidential Information disclosed by a Party hereunder to the extent that the receiving Party can demonstrate that such Confidential Information:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">was already known to the receiving Party or its Affiliates, other than under an obligation of confidentiality, at the time of disclosure;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';">was subsequently lawfully disclosed to the receiving Party or its Affiliates by a Third Party without an obligation of confidentiality other than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">was developed or discovered by employees or agents of the receiving Party or its Affiliates who had no access to the Confidential Information of the disclosing Party.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Notwithstanding the above obligations of confidentiality and non-use, a Party may disclose information to the extent that such disclosure is reasonably necessary in connection with:</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="font-family:'Times New Roman','Times','serif';">filing or prosecuting patent applications, subject to the terms of Section&#160;5.3;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="font-family:'Times New Roman','Times','serif';">prosecuting or defending litigation;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="font-family:'Times New Roman','Times','serif';">conducting pre-clinical studies or Clinical Trials;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><font style="font-family:'Times New Roman','Times','serif';">seeking Regulatory Approval of the Licensed Product; or</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><font style="font-family:'Times New Roman','Times','serif';">complying with applicable law, including securities law and the rules of any securities exchange or market on which a Party&#8217;s securities are listed or traded;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font><font style="font-family:'Times New Roman','Times','serif';">due diligence performed by a Third Party in connection with either Party&#8217;s business development activities, subject to such Third Parties being bound by written obligations of confidentiality that are at least as stringent as the ones herein.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In addition, in connection with any permitted filing by either Party of this Agreement with any Governmental Body, included but not limited to the U.S. Securities and Exchange Commission Agreement, the filing Party shall endeavor to obtain confidential treatment of economic, trade secret information and such other information as may be requested by the other Party, and shall provide the other Party with the proposed confidential treatment request with reasonable time for such other Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the other Party. The filing Party shall, where reasonably practicable, give such advance notice to the other Party of such disclosure requirement as is reasonable under the circumstances and will use its reasonable efforts to cooperate with the other Party in order to secure confidential treatment of such Confidential Information required to be disclosed.</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Publications.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee shall not publish any information relating to the Licensed Compounds or the Licensed Products without the written consent of Merck Serono, which consent shall not be unreasonably withheld. Licensee shall submit to Merck Serono for Merck Serono&#8217;s written consent any publication, presentation or abstract of information related to the Licensed Product for review and approval at least thirty (30)&#160;days prior to submission. In case Merck Serono does not object to said proposed publication, presentation or abstract within said thirty (30)&#160;day deadline, Merck Serono shall be deemed to have approved said publication, presentation or abstract.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Press Releases and Disclosure.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Licensee may not make any subsequent press release or public announcements regarding this Agreement or any matter covered by this Agreement, including the Development or Commercialization of Licensed Products, without the prior written consent of Merck Serono (which consent shall not be unreasonably withheld). In case Merck Serono does not object to said press release within ten (10)&#160;business days&#8217; deadline, Merck Serono shall be deemed to have approved the said Press Release. In the event that Licensee believes it is required to issue a press release or make an other public announcement to comply with applicable law as a publicly-traded company and Merck Serono does not believe such public announcement is so required, Licensee may only issue such press release if (a)&#160;it obtains an opinion of legal counsel, from a reputable law firm approved by Merck Serono, that it is required to make such disclosure to comply with applicable law and (b)&#160;after receiving such opinion, </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';">provides the text of such planned disclosure to Merck Serono no less than seven (7)&#160;days prior to disclosure, and has incorporated all reasonable comments of Merck Serono regarding such disclosure.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 7</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merck Serono representations and warranties.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Merck Serono represents and warranties to the Licensee that:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">Merck Serono has the full power, authority and right to enter into this Agreement and to perform its obligations hereunder in accordance with the terms and conditions hereof, and all requisite corporate action has been taken to authorize Merck Serono&#8217;s execution, delivery and performance of this Agreement;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">The execution, delivery and performance of this Agreement by Merck Serono does not breach, violate, contravene or constitute a default under any contract, arrangement or commitment to which Merck Serono is a party or by which it is bound, or violate any statute, law or regulation or any court, governmental body or administrative or other agency having jurisdiction over Merck Serono; and</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by Merck Serono in connection with the execution, delivery and performance of this Agreement have been obtained.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';">Merck Serono has all right, title and interest in and to the Merck Serono Technology, and Merck Serono has not previously licensed, assigned, transferred, or otherwise conveyed any right, title or interest in and to the Merck Serono Technology to any Third Party, including but not limited to any rights to any Licensed Compounds and Licensed Products; the Merck Serono Technology is free and clear of any liens, charges, encumbrances or rights of others to possession or use.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">No claims have been asserted, or, to Merck Serono&#8217;s knowledge, threatened by any Person, nor are there any valid grounds for any claim of any such kind (i)&#160;challenging the validity, effectiveness, or ownership of Merck Serono Technology, and/or (ii)&#160;to the effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale or any other exercise of rights in any of Merck Serono Technology infringes or will infringe on any intellectual property right of any Person. No such claims have been asserted or, to the knowledge of Merck Serono, are threatened.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(f)</font><font style="font-family:'Times New Roman','Times','serif';">MERCK SERONO DISCLAIMS ALL OTHER WARRANTIES EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES TO TITLE OR NON-INFRINGEMENT, TO FREEDOM TO OPERATE, OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS OF LICENSED COMPOUND/LICENSED PRODUCT FOR A PARTICULAR PURPOSE.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Licensee representations and warranties.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Licensee represents and warranties to Merck Serono that:</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee has the full power, authority and right to enter into this Agreement and to perform its obligations hereunder in accordance with the terms and conditions hereof, and all requisite corporate action has been taken to authorize Licensee&#8217;s execution, delivery and performance of this Agreement;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">The execution, delivery and performance of this Agreement by Licensee does not breach, violate, contravene or constitute a default under any contract, arrangement or commitment to which Licensee is a party or by which it is bound, or violate any statute, law or regulation or any court, governmental body or administrative or other agency having jurisdiction over Licensee; and</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">All consents, approvals and authorizations from all governmental authorities or other Third Parties required to be obtained by Licensee in connection with the execution, delivery and performance of this Agreement have been obtained.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 8</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">INDEMNIFICATION</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnification by Merck Serono.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Merck Serono shall defend, indemnify and hold harmless Licensee, its Affiliates, directors, employees and agents (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee Indemnitees</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) from and against any and all liability, damage, loss, cost or expense (including reasonable attorney&#8217;s fees and expenses of litigation) (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Losses</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) arising or resulting from any claims made or suits brought by Third Parties to the extent such Losses arise or result from the breach of any provision of this Agreement by Merck Serono, including a breach of any of the Merck Serono representations and warranties set forth in Section&#160;7.1 of this Agreement. In the event of a claim against the Licensee Indemnitees which may be subject to the foregoing indemnification obligation, the Licensee Indemnitees agree to notify Merck Serono promptly of such claim and Merck Serono shall provide Licensee Indemnitees with any assistance Licensee Indemnitees may reasonably require in the defense of such action, at Merck Serono&#8217;s cost and expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Indemnification by Licensee.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Licensee shall defend, indemnify and hold harmless Merck Serono, its Affiliates, directors, employees and agents (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono Indemnitees</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) from and against any and all Losses arising or resulting from any claims made or suits brought by Third Parties to the extent such Losses arise or result from (i)&#160;the breach of any provision of this Agreement by Licensee, including a breach of any of the Licensee representations and warranties set forth in Section&#160;7.2 of this Agreement, and (ii)&#160;a product liability claim relating to the Licensed Product. In the event of a claim against the Merck Serono Indemnitees which may be subject to the foregoing indemnification obligation, the Merck Serono Indemnitees agree to notify Licensee promptly of such claim and Licensee shall provide Merck Serono Indemnitees with any assistance Merck Serono Indemnitees may reasonably require in the defense of such action, at Licensee&#8217;s cost and expense.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 9</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">TERM AND TERMINATION</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Term of Agreement.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;This Agreement shall come into force on the Effective Date and shall continue in full force and effect until the end of the last-to-expire Royalty Term in any country with respect to a Licensed Product, unless the Agreement is terminated at an earlier date pursuant to Article 9.2 to 9.6 below ( the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Term</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). As of the effective date of expiration of the Royalty Term in any country of the Territory, the license from Merck Serono to Licensee under Article 2 in such country shall convert to a fully paid, royalty free, irrevocable, perpetual, exclusive, and sublicensable license under the Merck Serono Technology to research, Develop, manufacture, make, have made, use, import, export, Commercialize, offer for sale and sell the Licensed Products in said country.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Termination of the Agreement by Licensee for convenience.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">At any time during the Term, Licensee may, at its convenience, terminate this Agreement in its entirety upon ninety (90)&#160;days prior written notice to Merck Serono.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Termination for Non-Payment.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;If Licensee has not paid the Upfront Payment or a royalty payment by the required respective payment dates set forth in Section&#160;4.1 and 4.2, Merck Serono shall have the right to terminate this Agreement with ninety (90)&#160;days prior notice to Licensee, unless Licensee has proceeded to payment within the period of such notice. Such termination shall be in addition to and not in lieu of any other remedies available to Merck Serono, at law and in equity.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Termination for Breach</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Either Party may terminate this Agreement, and the rights and licenses granted hereunder, with ninety (90)&#160;days prior notice to the other Party if the other Party breaches any material provision of this Agreement, unless the other Party cures such breach within the period of such notice.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">No Immediate Termination on Bankruptcy</b><font style="font-family:'Times New Roman','Times','serif';">. To the extent permitted by applicable law, all rights and licenses granted pursuant to this Agreement by a Party to the other Party shall not be terminated upon a Bankruptcy Event of such Party or its Affiliates, and each Party hereby claims the benefit of any applicable law which may enable it to prevent such termination. In the event of a Bankruptcy Event of Licensee, the Licensee shall, during the 24-month period following such Bankruptcy Event, seek to enter into one or several Sublicense agreements for the Territory with one or several Sublicensees. Any such Sublicense shall be subject to the terms of Section&#160;2.2. If, upon expiry of the 24-month period Licensee has failed to enter into one or more definitive Sublicense agreement(s), Merck Serono shall have the right to terminate this Agreement and to exercise its rights under Section&#160;9.7. During the aforementioned 24-month period, Licensee shall continue to prosecute and maintain the Licensee Patents, if any, and shall use appropriate safeguards in order for the value and usefulness of the Licensee Know-How to be preserved.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">No Challenge.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;In the event that Licensee or any of its Affiliates or Sublicensee, anywhere in the world, institutes, prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, opposition or any similar proceeding, alleging that any claim in a Merck Serono Patent is invalid, unenforceable or otherwise not patentable, except in the case where asserted as a defense or counterclaim to an action brought by Merck Serono against Licensee or any of its Affiliates or Sublicensee, Merck Serono shall have the right (i)&#160;to terminate this Agreement as a whole or (ii)&#160;to terminate the license granted to Licensee or Sublicensee under such challenged Merck Serono Patent on a patent-by-patent basis.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.7</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effects of Termination</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accrued Rights and Obligations.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Termination of this Agreement shall not release either Party from its obligations accrued prior to the effective date of termination nor deprive either Party from any rights that this Agreement provides shall survive termination. The provisions of Article 6 (Confidentiality), Article 8 (Indemnification), Section&#160;9.6 (No Challenge) and 9.7 (Effects of Termination) shall survive any termination of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Termination by Licensee pursuant to Section&#160;9.2 or by Merck Serono pursuant to Sections 9.3, 9.4, 9.5 or 9.6.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Upon any termination of this Agreement by Licensee pursuant to Section&#160;9.2 or by Merck Serono pursuant to Sections 9.3, 9.4, 9.5 or 9.6 (being understood that the effects mentioned below will occur only to the extent permitted by applicable law if the termination results from the application of Section&#160;9.5 on bankruptcy):</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(1)</font><font style="font-family:'Times New Roman','Times','serif';">all licenses granted to Licensee under Section&#160;2.1 shall terminate;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(2)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall return to Merck Serono (or at Merck Serono&#8217;s request, destroy) all relevant records and materials (including Merck Serono Materials) in its possession or control containing or comprising the Merck Serono Know-How or such other Confidential Information of Merck Serono.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(3)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall automatically grant Merck Serono an exclusive, sublicensable, royalty-free license under the Licensee Patents and the Licensee Know-How, if any, to research, Develop, make, have made, import, export, use and Commercialize the Licensed Products in the Field in the Territory.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(4)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall promptly and fully disclose and transfer to Merck Serono the Licensee Know How;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(5)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall, upon written request by Merck Serono and subject to Merck Serono assuming legal responsibility for any Clinical Trials of the Licensed Product then ongoing, transfer to Merck Serono, at Licensee&#8217;s cost and expense, all regulatory documentation and Regulatory Approvals prepared or obtained by or on behalf of Licensee prior to the date of such termination, to the extent solely related to Licensed Products and transferable;</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(6)</font><font style="font-family:'Times New Roman','Times','serif';">To the extent not prohibited by law, Licensee shall either wind down any ongoing Clinical Trials with respect to the Licensed Product, or at Merck Serono&#8217;s option, transfer such Clinical Trials to Merck Serono at Licensee&#8217;s cost;</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(7)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall, at Merck Serono&#8217;s option, transfer to Merck Serono free of charge any and all chemical, biological or physical materials relating to or comprising the Licensed Products, including clinical supplies of Licensed Products, that are owned or Controlled by Licensee.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(8)</font><font style="font-family:'Times New Roman','Times','serif';">Licensee and its Affiliates and Sublicensees shall be entitled, during the eighteen (18)&#160;month period following such termination, to sell any commercial inventory of Licensed Products which remains on hand as of the date of the termination, so long as Licensee pays to Merck Serono the royalties applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement. Any commercial inventory remaining following such eighteen (18)&#160;month period shall be offered for sale to Merck Serono, at a price equal to be mutually agreed upon between the Parties in good faith.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">Save as set forth in Section&#160;9.7 and to the extent permitted by applicable law, upon any termination of this Agreement, each of Licensee&#8217;s Sublicensees shall continue to have the rights and license set forth in their respective Sublicense agreements, which agreements shall be automatically assigned to Merck Serono, provided however, that such Sublicensee is not then in breach of any of its material obligations under its Sublicense agreement and provided further that the terms of the Sublicense are at least as favourable as the ones herein and do not impose any obligations on Merck Serono that are not expressly set forth herein.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:baseline;white-space:nowrap;">Article 10</font><font style="font-family:'Times New Roman','Times','serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">MISCELLANEOUS</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.1</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Relationship of the Parties.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.2</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Assignment</b><font style="font-family:'Times New Roman','Times','serif';">.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(a)</font><font style="font-family:'Times New Roman','Times','serif';">Except as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable, nor any other obligation delegable, by Licensee without the prior written consent of Merck Serono (not to be unreasonably withheld or delayed). Notwithstanding the foregoing, Licensee may assign this Agreement in whole without the consent of Merck Serono to (a)&#160;any Affiliate or (b)&#160;a successor to substantially all of the business of the Licensee to which this Agreement relates, in connection with any company merger, company trade sale, sale of stock, sale of assets or other similar transaction.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(b)</font><font style="font-family:'Times New Roman','Times','serif';">Merck Serono may assign this Agreement, in whole or in part, to any Affiliate or a successor in interest without the consent of Licensee. Merck Serono shall give written notice to Licensee promptly following any such assignment.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(c)</font><font style="font-family:'Times New Roman','Times','serif';">No assignment under this Section&#160;10.2 shall relieve the assigning party of any of its responsibilities or obligations hereunder and provided, further, that as a condition of such assignment, the assignee shall agree to be bound by all obligations of the assigning Party hereunder.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(d)</font><font style="font-family:'Times New Roman','Times','serif';">This Agreement shall be binding upon the successors and permitted assigns of the Parties.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(e)</font><font style="font-family:'Times New Roman','Times','serif';">Any assignment not in accordance with this Section&#160;10.2 shall be void.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.3</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Further Actions.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.4</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Accounting Procedures.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Each Party shall calculate all amounts hereunder and perform other accounting procedures required hereunder and applicable to it in accordance with either, as applicable (a)&#160;United States generally accepted accounting principles (US GAAP) or (b)&#160;International Financial Reporting Standard (IFRS), whichever is normally used by such Party to calculate its financial position, and in each case consistently applied by such Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.5</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Force Majeure.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, default by suppliers or unavailability of raw materials, governmental acts or restrictions or any other reason which is beyond the control of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations hereunder as soon as practicable.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.6</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">No Trademark Rights.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">No right, express or implied, is granted by this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the performance of this Agreement or otherwise</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">.</b></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.7</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Entire Agreement of the Parties; Amendments.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">This Agreement and the schedules and exhibits hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.8</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Captions.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.9</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Disputes</b><font style="font-family:'Times New Roman','Times','serif';">. If a dispute or difference arises under or in connection with this Agreement or hereunder between Merck Serono and the Licensee, including but not limited to any dispute or difference as to its interpretation, validity or termination (a &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Dispute</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) the Parties agree first to use all reasonable endeavours in good faith to settle the Dispute. A Party claiming that a Dispute has arisen must give notice to the other Party specifying the nature of the Dispute and requesting that the Dispute be resolved by the Executive Officers within fifteen (15)&#160;days of their first consideration of such dispute. If the Executive Officers cannot resolve such dispute within fifteen (15)&#160;days of their first consideration of such dispute, then, at any time after such fifteen (15)&#160;days period, either Party may proceed to enforce any and all of its rights with respect to such dispute.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.10</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Governing Law.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">This Agreement shall be governed by and interpreted in accordance with the laws of Switzerland, and will be subject to the exclusive jurisdiction of the courts of competent jurisdiction located in the Canton of Geneva.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.11</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Notices and Deliveries</b><font style="font-family:'Times New Roman','Times','serif';">. Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express courier service (signature required) to the Party to which it is directed at its address or facsimile number shown below or such other address or facsimile number as such Party shall have last given by notice to the other Party.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Merck Serono, addressed to:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">ARES TRADING SA</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Zone Industrielle de l&#8217;Ouriettaz</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">1170 Aubonne</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Switzerland</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile: [*]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">With a copy to:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Merck Serono S.A.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Zone Industrielle de l&#8217;Ouriettaz</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">1170 Aubonne</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Switzerland</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: Legal Department</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Facsimile: [*]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">If to Licensee, addressed to:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">OBSEVA S.A.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">12, Chemin des Aulx</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">1228 Plan-Les-Ouates, Geneva</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Switzerland</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">Attn: [*]</font></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.12</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Waiver.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.13</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Severability.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-weight:bold;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.14</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Counterparts.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.</font></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 36pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">{Signature page to follow}</i></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">In Witness Whereof</b><font style="font-family:'Times New Roman','Times','serif';">, the parties hereto have caused this Agreement to be executed and delivered in duplicate by their duly authorized representatives with legal and binding effect as of the date first above written.</font></p><div style="margin-left:-4.75pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">OBSEVA S.A.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Ernest Loumaye</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:109.28pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Ernest Loumaye</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:108.48pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  CEO</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:159.29pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">ARES TRADING SA</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ James Singleton</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:109.29pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  James Singleton</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:109.02pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Authorized Representative</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:72.39pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt 0pt 0pt 16.95pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">10.06.2015</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Fabien de Ladonchamps</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:75.68pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Fabien de Ladonchamps</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:76.55pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Finance Director</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:111.82pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Cedric Hyde</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:123.74pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Cedric Hyde</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:123.48pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Authorized Representative</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:72.39pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;"><a name="_Hlk128076743"></a></font><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 1.23</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Licensed Compounds</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</font></font><font style="font-family:'Times New Roman','Times','serif';">[*] Thiazolidine Carboxamide Derivatives as Modulators of the Prostaglandin F Receptor</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;">&#9679;</font></font><font style="font-family:'Times New Roman','Times','serif';">[*] Thiazolidine Carboxamide Derivatives as Modulators of the Prostaglandin F Receptor</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-size:10pt;"><a name="_Hlk128076743"></a></font><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 1.27</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merck Serono Know-How</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 1.28</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merck Serono Materials</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Schedule 1.29</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Merck Serono Patents</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*]</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">FIRST AMENDMENT TO THE</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"><br></b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">This Amendment N&#176;1 To The License Agreement&#160;</b><font style="font-family:'Times New Roman','Times','serif';">(&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">First Amendment</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), effective as of July&#160;8, 2016 (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">First Amendment Effective Date</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;), is made and entered into by and between&#160;</font><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Ares Trading </b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SA</b><font style="font-family:'Times New Roman','Times','serif';">, a Swiss corporation with registered offices at Zone Industrielle de l&#8217;Ouriettaz, 1170 Aubonne, Switzerland (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Serono</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and&#160;</font><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Obseva</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;"> S.A.</b><font style="font-family:'Times New Roman','Times','serif';">, a Swiss corporation with registered offices at Chemin des Aulx, 12, 1228 Plan-les-Ouates, Geneva, Switzerland (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Licensee</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;). Merck Serono and Licensee may be referred to herein as the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Party</font><font style="font-family:'Times New Roman','Times','serif';">&#8221; or, collectively, as the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Parties</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,&#160;</b><font style="font-family:'Times New Roman','Times','serif';">the Parties entered into a License Agreement on 10&#160;June 2015 (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">License Agreement</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">)&#160;</b><font style="font-family:'Times New Roman','Times','serif';">concerning Merck Serono&#8217;s proprietary compounds known as [*];</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><font style="font-family:'Times New Roman','Times','serif';">&#160;[*], is not claimed by and not specifically disclosed in the Merck Serono Patents listed on Schedule 1.29 of the License Agreement;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Licensee wishes and Merck Serono agrees to seek patent protection for [*] and Licensee instructed Clark and Elbing LLP, a law firm with registered offices at 101 Federal Street Fl, 1500 Boston, MA02110, US (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">C&amp;E</font><font style="font-family:'Times New Roman','Times','serif';">&#8221;) to prepare and file two new US patent applications covering [*] which were agreed upon by the Parties and of which the abstracts are attached hereto as Exhibit A;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><font style="font-family:'Times New Roman','Times','serif';">&#160;the two patent applications were filed on 4&#160;January 2016 and the U.S. Patent Application No.: [*] under attorney docket [*] contains only Merck Serono Know-How and compounds and the U.S. Patent Application No.: [*] under attorney docket [*] contains both, Merck Serono Know-How and Licensee Know-How;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">WHEREAS,</b><font style="font-family:'Times New Roman','Times','serif';">&#160;the Parties agree that the patent application [*] shall be a Merck Serono Patent according to Section&#160;5.3 of the License Agreement and that the patent application [*] shall be a Licensee Patent according to Section&#160;5.4(a) of the License Agreement; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Whereas</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,</b><font style="font-family:'Times New Roman','Times','serif';">&#160;the Parties therefore wish to amend the License Agreement as set forth herein.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">Now, Therefore</b><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">,&#160;</b><font style="font-family:'Times New Roman','Times','serif';">in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the License Agreement.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Modification of Schedule 1.29.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;The following patent application shall be added to the Merck Serono Patents in Schedule 1.29 of the License Agreement:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';">[*]</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">II.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reimbursement.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;According to Section&#160;5.4(b) of the License Agreement Merck Serono shall reimburse Licensee $8&#8217;989.75 for patent expenses incurred by Licensee in the preparation and filing of the patent application [*] and Merck shall bear all further costs and expenses of filing, prosecution and maintaining this patent application in the Territory.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For the avoidance of doubt and in accordance with Section&#160;5.4(a) of the License Agreement, Licensee shall solely bear all costs and expenses of filing, prosecution and maintaining the patent application [*] in the Territory.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">III.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Patent Maintenance.</b><font style="font-family:'Times New Roman','Times','serif';">&#160;Contrary to what is provided by Section&#160;5.4(b) of the License Agreement, Merck Serono agrees that the filing, prosecution, and maintenance of patent application [*] shall be under the responsibility of Licensee, provided that (i)&#160;Licensee coordinates all responses to office actions, country selection, filing strategy, enforcement activities and any other matter related to patent application [*] with the Merck Patent </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Department in Darmstadt (hereinafter&#160;&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-style:italic;font-weight:bold;">Merck Patent GmbH</font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#8221;</b><font style="font-family:'Times New Roman','Times','serif';">) and (ii)&#160;Merck Serono via Merck Patent GmbH shall reimburse Licensee for all reasonable costs and out-of-pocket expenses related to the filing, prosecution, and maintenance of patent application [*] after approval by a Merck Patent GmbH patent attorney, it being specified that such approval shall not unreasonably be withheld. Invoices can only be processed if they are addressed to Merck Patent GmbH.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For the coordination activities described in the preceding paragraph:</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-family:'Times New Roman','Times','serif';">Merck Patent GmbH&#8217;s contact person is [*], it being specified that Merck Patent GmbH shall be allowed to change such contact person provided that (i)&#160;it informs Licensee in a written notice prior to such change and (ii)&#160;the newly appointed contact person shall have the same skills and competences as the previous contact person; and</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-family:'Times New Roman','Times','serif';">Licensee shall inform Merck Patent GmbH about the coordination activities and Merck shall participate in the coordination activities, both in a timely manner (in particular in view of any relevant process timelines); in the event Merck Patent GmbH fails to do so, it is understood by the Parties that Licensee shall have the right to proceed further in such relevant process.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For the avoidance of doubt, Licensee is solely responsible for filing, prosecution, maintaining and enforcement of the patent application [*] in the Territory.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">IV.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Effectiveness.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">This First Amendment shall become effective as of the First Amendment Effective Date.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">V.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Counterparts; Fax; Signatures.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">This First Amendment may be executed in two (2)&#160;counterparts, including by facsimile or PDF, each of which, when signed and executed, shall be deemed to be an original and both of which together shall constitute the one and same document.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">VI.</b></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Full Force and Effect.&#160;</b><font style="font-family:'Times New Roman','Times','serif';">Except as set forth in this First Amendment, the License Agreement shall remain unchanged. This First Amendment, including its Exhibit A, shall be incorporated into and deemed part of the License Agreement from the First Amendment Effective Date on, and any future reference to the License Agreement shall include the terms and conditions of this First Amendment.</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-variant:small-caps;font-weight:bold;">In Witness Whereof</b><font style="font-family:'Times New Roman','Times','serif';">, the Parties have caused this First Amendment to be executed by their duly authorized representatives.</font></p><div style="margin-left:-4.75pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.89%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">OBSEVA S.A.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Ernest Loumaye</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:109.28pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Ernest Loumaye</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:108.48pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  CEO</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:159.29pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;">ARES TRADING SA</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Cedric Hyde</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:123.74pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Cedric Hyde</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:123.48pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Authorized Representative</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:72.39pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Fabien de Ladonchamps</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:75.68pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Fabien de Ladonchamps</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:76.55pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  VP Finance</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:132.35pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">By:</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  /s/ Sebastien Boutte</i><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:107.62pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Name:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Sebastien Boutte</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:106.8pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;">Title:</font><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  Authorized Representative</u><u style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:72.39pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">[*]</b></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>xoma-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:17:05 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 21.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="clear:left;float:left;margin-bottom:1em;margin-right:1.92%;width:99.89%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subsidiaries of the Company </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction of Organization </b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA Technology Ltd.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Bermuda</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA (US) LLC</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Delaware</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">XOMA UK Limited</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">United Kingdom</font></p></td></tr></table></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>xoma-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:17:07 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;background:#ffffff;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'TimesNewRomanPS-BoldMT';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'TimesNewRomanPS-BoldMT';font-size:8pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'TimesNewRomanPS-BoldMT';font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:8pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">We consent to the incorporation by reference in Registration Statement Nos. 333-269459, 333-151416, 333-171429, 333-174730, 333-181849, 333-198719, 333-204367, 333-212238, 333-218378, 333-232398 and 333-265248 on Form S-8 and Registration Statement No. 333-254073 on Form S-3 of our report dated March 9, 2023, relating to the consolidated financial statements of XOMA Corporation, appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';font-size:8pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">/s/ Deloitte &amp; Touche LLP</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'TimesNewRomanPSMT';">San Francisco, California</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'TimesNewRomanPSMT';">March 9, 2023</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>xoma-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:17:11 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Owen Hughes, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this annual report on Form 10-K of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 9, 2023</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>xoma-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:17:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Thomas Burns, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this annual report on Form 10-K of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: March 9, 2023</font></p></td><td style="vertical-align:top;width:57.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>xoma-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/8/2023 08:17:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Owen Hughes, Executive Chairman of the Board of Directors and Interim Chief Executive Officer of XOMA Corporation (the &#8220;Company&#8221;), and Thomas Burns, Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in Exhibit 32.1 fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 9</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;day of March, 2023</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;width:54.61%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></td></tr></table><div style="margin-top:8pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>xoma-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2023 8:16:50 PM-->
<!--Modified on: 3/8/2023 8:16:50 PM-->
<xsd:schema targetNamespace="http://www.xoma.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xoma="http://www.xoma.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" id="DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails">
        <link:definition>40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails">
        <link:definition>40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" id="DisclosureLeaseAgreementsLeaseCostsDetails">
        <link:definition>40702 - Disclosure - Lease Agreements - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesProvisionForIncomeTaxesDetails">
        <link:definition>40801 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" id="DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails">
        <link:definition>40802 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails">
        <link:definition>40803 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" id="DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails">
        <link:definition>41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" id="DisclosureLeaseAgreementsTables">
        <link:definition>30703 - Disclosure - Lease Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails">
        <link:definition>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" id="DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails">
        <link:definition>40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" id="DisclosureLicensingAndOtherArrangementsObsevaDetails">
        <link:definition>40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" id="DisclosureLicensingAndOtherArrangementsNovartisNis793Details">
        <link:definition>40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" id="DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails">
        <link:definition>40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" id="DisclosureLicensingAndOtherArrangementsTakedaDetails">
        <link:definition>40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteDetails">
        <link:definition>40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" id="DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails">
        <link:definition>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" id="DisclosureLicensingAndOtherArrangementsAffimedDetails">
        <link:definition>40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" id="DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails">
        <link:definition>40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails">
        <link:definition>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails">
        <link:definition>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails">
        <link:definition>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails">
        <link:definition>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails">
        <link:definition>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails">
        <link:definition>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails">
        <link:definition>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails">
        <link:definition>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails">
        <link:definition>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" id="DisclosureFairValueMeasurementsEquitySecuritiesDetails">
        <link:definition>40603 - Disclosure - Fair Value Measurements - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" id="DisclosureFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" id="DisclosureLeaseAgreementsLeasedFacilitiesDetails">
        <link:definition>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" id="DisclosureLeaseAgreementsAdditionalInformationDetails">
        <link:definition>40703 - Disclosure - Lease Agreements - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" id="DisclosureIncomeTaxesNolDetails">
        <link:definition>40804 - Disclosure - Income Taxes - NOL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" id="DisclosureIncomeTaxesTaxCreditCarryforwardDetails">
        <link:definition>40805 - Disclosure - Income Taxes - Tax credit carryforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>40806 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails">
        <link:definition>40901 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails">
        <link:definition>40902 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails">
        <link:definition>40903 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails">
        <link:definition>40904 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails">
        <link:definition>40905 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails">
        <link:definition>40906 - Disclosure - Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails">
        <link:definition>40907 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails">
        <link:definition>40908 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails">
        <link:definition>40909 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" id="DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails">
        <link:definition>40910 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" id="DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails">
        <link:definition>41001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" id="DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails">
        <link:definition>41101 - Disclosure - Capital Stock - Series X Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" id="DisclosureCapitalStockSeriesPreferredStockDetails">
        <link:definition>41102 - Disclosure - Capital Stock - Series A Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" id="DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails">
        <link:definition>41103 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" id="DisclosureCapitalStockDividendsDetails">
        <link:definition>41104 - Disclosure - Capital Stock - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" id="DisclosureCapitalStockBvfOwnershipDetails">
        <link:definition>41105 - Disclosure - Capital Stock - BVF Ownership (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" id="DisclosureCapitalStockAtmAgreementsDetails">
        <link:definition>41106 - Disclosure - Capital Stock - ATM Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" id="DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails">
        <link:definition>41107 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" id="DisclosureCapitalStockCommonStockWarrantsDetails">
        <link:definition>41108 - Disclosure - Capital Stock - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" id="DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails">
        <link:definition>41201 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" id="DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails">
        <link:definition>41202 - Disclosure - Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails">
        <link:definition>41301 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails">
        <link:definition>41303 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" id="DisclosureConsolidatedFinancialStatementsDetails">
        <link:definition>10301 - Disclosure - Consolidated Financial Statements Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" id="DisclosureLicensingAndOtherArrangements">
        <link:definition>10401 - Disclosure - Licensing and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements">
        <link:definition>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10601 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" id="DisclosureLeaseAgreements">
        <link:definition>10701 - Disclosure - Lease Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" id="DisclosureStockBasedCompensationAndOtherBenefitPlans">
        <link:definition>10901 - Disclosure - Stock Based Compensation and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders" id="DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders">
        <link:definition>11001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStock" id="DisclosureCapitalStock">
        <link:definition>11101 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11201 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformation">
        <link:definition>11301 - Disclosure - Concentration of Risk, Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" id="DisclosureConsolidatedFinancialStatementsDetailsTables">
        <link:definition>30303 - Disclosure - Consolidated Financial Statements Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables">
        <link:definition>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30603 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" id="DisclosureStockBasedCompensationAndOtherBenefitPlansTables">
        <link:definition>30903 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables" id="DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables">
        <link:definition>31003 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>31103 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables">
        <link:definition>31303 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" id="DisclosureDescriptionOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - Description of Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" id="DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails">
        <link:definition>41203 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" id="DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails">
        <link:definition>41302 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20221231_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20221231_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20221231_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20221231_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:element name="AccruedAndOtherLiabilitiesCurrent" id="xoma_AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" id="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConsolidatedFinancialStatementDetailAbstract" id="xoma_ConsolidatedFinancialStatementDetailAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsTextBlock" id="xoma_LicensingAndOtherArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsAbstract" id="xoma_LicensingAndOtherArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementTextBlock" id="xoma_RoyaltyPurchaseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" id="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognitionDeferredRevenuePolicyTextBlock" id="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquitySecuritiesPolicy" id="xoma_EquitySecuritiesPolicy" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ImpairmentOfLongTermRoyaltyReceivable" id="xoma_ImpairmentOfLongTermRoyaltyReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RezoluteIncMember" id="xoma_RezoluteIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceived" id="xoma_LicenseAgreementConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromUpfrontPayment" id="xoma_ProceedsFromUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockPremium" id="xoma_CommonStockPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NovartisPharmaAGMember" id="xoma_NovartisPharmaAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="XOMA052LicenseAgreementMember" id="xoma_XOMA052LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IL1TargetLicenseAgreementMember" id="xoma_IL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMember" id="xoma_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisInternationalPharmaceuticalLtdMember" id="xoma_NovartisInternationalPharmaceuticalLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfLicenseAgreements" id="xoma_NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementTerminationPriorWrittenNoticePeriod" id="xoma_AgreementTerminationPriorWrittenNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPerformanceObligations" id="xoma_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementTransactionPrice" id="xoma_LicenseAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" id="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfRoyaltyInterestAcquisitionAgreements" id="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchasedPercentageOfMilestones" id="xoma_PurchasedPercentageOfMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" id="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" id="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementMember" id="xoma_RoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgenusIncMember" id="xoma_AgenusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SiliconValleyBankMember" id="xoma_SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisNoteMember" id="xoma_NovartisNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyReceivablePercentageOnNetSales" id="xoma_RoyaltyReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExercisablePeriodOfWarrants" id="xoma_ExercisablePeriodOfWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FederalOrphanCreditMember" id="xoma_FederalOrphanCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" id="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetOperatingLossCarryforwardsExpirationYear" id="xoma_NetOperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" id="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandFifteenEmployeeStockPurchasePlanMember" id="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" id="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" id="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" id="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" id="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" id="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BiotechnologyValueFundLPMember" id="xoma_BiotechnologyValueFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockConversionPricePerShare" id="xoma_PreferredStockConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandEighteenAtMarketAgreementMember" id="xoma_TwoThousandEighteenAtMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TenYearWarrantsIssuedThirdRangeMember" id="xoma_TenYearWarrantsIssuedThirdRangeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractualObligationEstimatedMilestonePayments" id="xoma_ContractualObligationEstimatedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="xoma_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="xoma_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasesNumberOfLeasedFacilities" id="xoma_OperatingLeasesNumberOfLeasedFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner1Member" id="xoma_Partner1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner2Member" id="xoma_Partner2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner3Member" id="xoma_Partner3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfMajorPartners" id="xoma_NumberOfMajorPartners" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BioasisTechnologiesIncMember" id="xoma_BioasisTechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" id="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementAndCommonStockPurchaseAgreementMember" id="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasePaymentsNonCash" id="xoma_OperatingLeasePaymentsNonCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfDecreaseInFutureRoyaltyObligations" id="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" id="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfRoyaltyOnNetSalesUponCommercialization" id="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AronoraIncMember" id="xoma_AronoraIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PalobiofarmaSLMember" id="xoma_PalobiofarmaSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BayerProductsMember" id="xoma_BayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonBayerProductsMember" id="xoma_NonBayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentFutureCashPayments" id="xoma_ContingentFutureCashPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ChangesInEstimatedFairValueOfContingentConsideration" id="xoma_ChangesInEstimatedFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsOfContingentConsideration" id="xoma_PaymentsOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPayment" id="xoma_UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="MilestonesPaymentsToAggregateAmountOfPerProduct" id="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ContingentConsiderationFairValueDisclosure" id="xoma_ContingentConsiderationFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" id="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceivedDebtRepayment" id="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueNewIssuesCommonStock" id="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" id="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ArrangementsNumber" id="xoma_ArrangementsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesPeriodMinimum" id="xoma_RoyaltiesPeriodMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementRz358Member" id="xoma_LicenseAgreementRz358Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyInterestAcquisitionAgreementsMember" id="xoma_RoyaltyInterestAcquisitionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FirstRoyaltyInterestAcquisitionAgreementMember" id="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecondRoyaltyInterestAcquisitionAgreementMember" id="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HealthCareRoyaltyPartnersTwoLimitedPartnersMember" id="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePeriodsNumber" id="xoma_MilestonePeriodsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLicenseAgreementsFutureLicenseAgreements" id="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncyteImmunoOncologyAssetsMember" id="xoma_IncyteImmunoOncologyAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MerckImmunoOncologyProductMember" id="xoma_MerckImmunoOncologyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" id="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" id="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesNumber" id="xoma_AgreementDrugCandidatesNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" id="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EmployeeMember" id="xoma_EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeUnderAgeFiftyMember" id="xoma_EmployeeUnderAgeFiftyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAgeFiftyOrOverMember" id="xoma_EmployeeAgeFiftyOrOverMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeasedFacilitiesEmeryvilleCaliforniaMember" id="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantExercisePrice14.71Member" id="xoma_CommonStockWarrantExercisePrice14.71Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumValueOfCommonStockToBeIssued" id="xoma_MaximumValueOfCommonStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="XomaCorporationMember" id="xoma_XomaCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" id="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" id="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="JanssenBiotechInc.Member" id="xoma_JanssenBiotechInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesExclusiveLicenseOptionNumber" id="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="EmployeeTerminatedMember" id="xoma_EmployeeTerminatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentFutureCashPaymentsPerProduct" id="xoma_ContingentFutureCashPaymentsPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AgreementPaymentPercentageFactor" id="xoma_AgreementPaymentPercentageFactor" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseDisclosureTextBlock" id="xoma_LeaseDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsExercised" id="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementNonRz358ProductsMember" id="xoma_LicenseAgreementNonRz358ProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMember" id="xoma_CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MezagitamabMember" id="xoma_MezagitamabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" id="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAchieved" id="xoma_MilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementTwoMember" id="xoma_RoyaltyPurchaseAgreementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CashReceivedForAchievementOfContractualMilestones" id="xoma_CashReceivedForAchievementOfContractualMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseInRefundLiability" id="xoma_IncreaseDecreaseInRefundLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceOrSaleOfEquityNet" id="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodYearProrated" id="xoma_PreferredStockDividendPeriodYearProrated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodMonth" id="xoma_PreferredStockDividendPeriodMonth" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockDividendPeriodProratedMonthsInYear" id="xoma_PreferredStockDividendPeriodProratedMonthsInYear" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredStockRedemptionPricePerShareOptionalRedemption" id="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockShareCap" id="xoma_PreferredStockShareCap" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" id="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" id="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TaxCreditCarryForwardExpirationYear" id="xoma_TaxCreditCarryForwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLossCarryForwardSubjectToExpiration" id="xoma_OperatingLossCarryForwardSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockConvertibleThresholdConsecutiveTradingDays" id="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAntibodiesMember" id="xoma_OtherAntibodiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ViractaTherapeuticsInc.Member" id="xoma_ViractaTherapeuticsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedPreferredStockDividendCurrent" id="xoma_AccruedPreferredStockDividendCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ProceedsFromIssuanceOfPreferredStockNet" id="xoma_ProceedsFromIssuanceOfPreferredStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DepositarySharesRatioToPreferredStock" id="xoma_DepositarySharesRatioToPreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MilestonesReceivableExcludingConsiderationRetainedMaximum" id="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MaximumConsiderationRetained" id="xoma_MaximumConsiderationRetained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RegulatoryAndCommercialMilestonesReceivableMaximum" id="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PreferredStockDividendAmountPerShare" id="xoma_PreferredStockDividendAmountPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepaymentsOfLongTermDebtExtinguishmentOfDebt" id="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" id="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AffimedMember" id="xoma_AffimedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" id="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementInstallmentPaymentsReceived" id="xoma_LicenseAgreementInstallmentPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" id="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementSharesReceived" id="xoma_LicenseAgreementSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AtMarketIssuanceSalesAgreement2021Member" id="xoma_AtMarketIssuanceSalesAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumValueOfStockToBeIssued" id="xoma_MaximumValueOfStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TakedaPharmaceuticalCompanyLimitedMember" id="xoma_TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesXAndSeriesYConvertiblePreferredStockMember" id="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesXConvertiblePreferredStockMember" id="xoma_SeriesXConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesYConvertiblePreferredStockMember" id="xoma_SeriesYConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentPurchaseAgreementMember" id="xoma_CommercialPaymentPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialSalesReceivablePercentageOnNetSales" id="xoma_CommercialSalesReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AffitechResearchAsMember" id="xoma_AffitechResearchAsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReductionOfContingentRefundLiability" id="xoma_ReductionOfContingentRefundLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" id="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentReceivableTerm" id="xoma_CommercialPaymentReceivableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPayableOnRegulatoryMilestone" id="xoma_MaximumPayableOnRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumPayableOnSalesMilestone" id="xoma_MaximumPayableOnSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" id="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" id="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePayment" id="xoma_MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AccruedSalariesAndEmployeeBenefitsCurrent" id="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ContingentConsiderationUnderPurchaseAgreements" id="xoma_ContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LongTermRightsReceivableNonCurrent" id="xoma_LongTermRightsReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" id="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" id="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightsReceivableCurrent" id="xoma_RightsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MilestonePaymentReceivedCounterparty" id="xoma_MilestonePaymentReceivedCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentReceivablePercentage" id="xoma_MilestonePaymentReceivablePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner4Member" id="xoma_Partner4Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermRightsReceivableReclassification" id="xoma_LongTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialAssetsFairValueDisclosure" id="xoma_FinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShortTermRightsReceivableReclassification" id="xoma_ShortTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" id="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FaricimabSvoaVabysmoProductMember" id="xoma_FaricimabSvoaVabysmoProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" id="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPeriodsCashRetentionBonus" id="xoma_NumberOfPeriodsCashRetentionBonus" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PeriodOneRetentionBonusEligibility" id="xoma_PeriodOneRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodTwoRetentionBonusEligibility" id="xoma_PeriodTwoRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmploymentPeriodRetirementEligible" id="xoma_EmploymentPeriodRetirementEligible" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" id="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentEmployeesExcludingChiefExecutiveOfficerMember" id="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialRightsAcquiredNonCurrent" id="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ObsevaIntellectualPropertyRightsMember" id="xoma_ObsevaIntellectualPropertyRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OrganonMember" id="xoma_OrganonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" id="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" id="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationExpenseEmploymentAgreement" id="xoma_CompensationExpenseEmploymentAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedCompensationContinuityIncentive" id="xoma_AccruedCompensationContinuityIncentive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChiefExecutiveOfficerRetiredMember" id="xoma_ChiefExecutiveOfficerRetiredMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiefExecutiveOfficerInterimMember" id="xoma_ChiefExecutiveOfficerInterimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiefInvestmentOfficerMember" id="xoma_ChiefInvestmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmploymentAgreementAnnualSalary" id="xoma_EmploymentAgreementAnnualSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AnnualDiscretionaryCashBonusTargetPercentage" id="xoma_AnnualDiscretionaryCashBonusTargetPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSigningBonus" id="xoma_EmploymentAgreementSigningBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSigningBonusPaymentPeriod" id="xoma_EmploymentAgreementSigningBonusPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" id="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedPaymentArrangementNumberOfAwardsGrants" id="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedPaymentArrangementExercisePrice18.66Member" id="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementExercisePrice30.00Member" id="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" id="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RetentionBonusExpenseAccrued" id="xoma_RetentionBonusExpenseAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedTransactionCostsRelatedToPurchaseAgreements" id="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" id="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CashRetentionBonusExpectedPaymentNextTwelveMonths" id="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AronoraKurosAffitechObsevaAndMerckKgaaMember" id="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" id="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfArbitrationProceedingsInitiated" id="xoma_NumberOfArbitrationProceedingsInitiated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumEarnOutPayments" id="xoma_MaximumEarnOutPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" id="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumEarnOutPaymentsSalesBasedMilestonePayments" id="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionsPolicyPolicyTextBlock" id="xoma_AssetAcquisitionsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>xoma-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2023 8:16:50 PM-->
<!--Modified on: 3/8/2023 8:16:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638139034061867541" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034061867541" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="us-gaap_RestrictedCashCurrent_638139034061867541" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="us-gaap_EquitySecuritiesFvNi_638139034061867541" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638139034061867541" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="xoma_RightsReceivableCurrent_638139034061867541" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139034061867541" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139034061867541" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638139034061867541" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638139034061867541" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139034061877542" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034061877542" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638139034061877542" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638139034061877542" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638139034061877542" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139034061877542" xlink:to="us-gaap_LiabilitiesCurrent_638139034061877542" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638139034061877542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="us-gaap_AccountsPayableCurrent_638139034061877542" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638139034061887542" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638139034061887542" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034061887542" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638139034061887542" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="us-gaap_DeferredIncomeCurrent_638139034061887542" order="6" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139034061877542" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638139034061887542" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139034061877542" xlink:to="us-gaap_DeferredIncomeNoncurrent_638139034061887542" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638139034061887542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139034061877542" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638139034061887542" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638139034061897542" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638139034061897542" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139034061897542" xlink:to="us-gaap_PreferredStockValue_638139034061897542" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139034061897542" xlink:to="us-gaap_CommonStockValue_638139034061897542" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139034061897542" xlink:to="us-gaap_AdditionalPaidInCapital_638139034061897542" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638139034061897542" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139034061897542" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638139034061897542" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638139034061907543" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" xlink:to="us-gaap_OperatingIncomeLoss_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638139034061907543" xlink:to="us-gaap_Revenues_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638139034061907543" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638139034061907543" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638139034061907543" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638139034061907543" xlink:to="us-gaap_OperatingExpenses_638139034061907543" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638139034061907543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139034061907543" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638139034061907543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139034061907543" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638139034061917543" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139034061907543" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638139034061917543" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" xlink:to="us-gaap_InterestExpenseDebt_638139034061917543" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034061917543" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034061907543" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638139034061917543" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638139034061907543" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139034061917543" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638139034061917543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_ProfitLoss_638139034061917543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_ShareBasedCompensation_638139034061927543" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638139034061927543" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_DepreciationNonproduction_638139034061927543" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638139034061927543" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034061927543" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReductionOfContingentRefundLiability" xlink:label="xoma_ReductionOfContingentRefundLiability_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="xoma_ReductionOfContingentRefundLiability_638139034061927543" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="xoma_OperatingLeasePaymentsNonCash_638139034061927543" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034061927543" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638139034061927543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638139034061927543" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638139034061937543" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638139034061937543" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139034061937543" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139034061937543" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638139034061937543" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638139034061937543" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034061937543" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncreaseDecreaseInRefundLiability" xlink:label="xoma_IncreaseDecreaseInRefundLiability_638139034061937543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="xoma_IncreaseDecreaseInRefundLiability_638139034061937543" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034061917543" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638139034061947545" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638139034061947545" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" xlink:to="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034061947545" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638139034061947545" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034061947545" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034061947545" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034061957544" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034061957544" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_PaymentsOfDividends_638139034061957544" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638139034061957544" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638139034061957544" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638139034061957544" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_638139034061957544" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_638139034061957544" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_638139034061967540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_638139034061967540" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_638139034061967540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034061947545" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_638139034061967540" order="9" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034061967540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034061967540" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638139034061967540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent_638139034061967540" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139034061967540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139034061967540" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139034061977540" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139034061977540" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139034061977540" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139034061977540" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638139034061977540" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139034061977540" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="AccruedAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_638139034061977540" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638139034061977540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638139034061977540" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638139034061987540" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638139034061987540" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="FinancialAssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638139034061987540" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638139034061987540" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638139034061987540" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638139034061987540" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638139034061987540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638139034061987540" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139034061997540" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638139034061997540" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_638139034061997540" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_638139034061997540" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139034061997540" order="5" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638139034061997540" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638139034061997540" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638139034061997540" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139034062007546" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638139034062007546" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638139034062007546" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638139034062007546" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139034061997540" xlink:to="us-gaap_DeferredTaxAssetsOther_638139034062007546" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638139034062007546" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_638139034062007546" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034062007546" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034062007546" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034062007546" xlink:to="us-gaap_NetIncomeLoss_638139034062017543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034062007546" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638139034062017543" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034062007546" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_638139034062017543" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034062017543" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638139034062017543" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638139034062017543" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638139034062017543" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>xoma-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2023 8:16:50 PM-->
<!--Modified on: 3/8/2023 8:16:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsAffimedDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesNolDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesTaxCreditCarryforwardDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSeriesPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashCurrent" xlink:title="definition: AssetsAbstract to RestrictedCashCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="definition: AssetsAbstract to RestrictedCashNoncurrent" use="optional" priority="0" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsAxis" xlink:label="DividendsAxis" xlink:title="DividendsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDomain" xlink:label="DividendsDomain" xlink:title="DividendsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DividendsAxis" xlink:to="DividendsDomain" xlink:title="definition: DividendsAxis to DividendsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="definition: EquityMethodInvestmentNonconsolidatedInvesteeAxis to EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="PortionAtFairValueFairValueDisclosureMember" xlink:title="PortionAtFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="PortionAtFairValueFairValueDisclosureMember" xlink:title="definition: FairValueByMeasurementBasisAxis to PortionAtFairValueFairValueDisclosureMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedPreferredStockDividendCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_DividendsPreferredStockStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_OrganonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReductionOfContingentRefundLiability" xlink:label="xoma_ReductionOfContingentRefundLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_ReductionOfContingentRefundLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisPharmaAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ArrangementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MezagitamabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_OtherAntibodiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementRz358Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementSharesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_JanssenBiotechInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffimedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePeriodsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_IncyteImmunoOncologyAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MerckImmunoOncologyProductMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestoneAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashReceivedForAchievementOfContractualMilestones" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CashReceivedForAchievementOfContractualMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_BayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_NonBayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementPaymentPercentageFactor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumConsiderationRetained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivedCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivablePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_FaricimabSvoaVabysmoProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_UpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentReceivableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePayment" xlink:label="xoma_MilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashReceivedForAchievementOfContractualMilestones" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CashReceivedForAchievementOfContractualMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ShortTermRightsReceivableReclassification" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableReclassification" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="xoma_FinancialAssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="xoma_ContingentConsiderationFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_PaymentsOfContingentConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - NOL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Income Taxes - Tax credit carryforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="xoma_FederalOrphanCreditMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_TaxCreditCarryForwardExpirationYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeUnderAgeFiftyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeAgeFiftyOrOverMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeTerminatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="xoma_EmploymentPeriodRetirementEligible" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="40909 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodOneRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodTwoRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_RetentionBonusExpenseAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="40910 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_AccruedCompensationContinuityIncentive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_CompensationExpenseEmploymentAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Capital Stock - Series X Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesXConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="xoma_SeriesYConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockConversionPricePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Capital Stock - Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodYearProrated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockShareCap" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_DepositarySharesRatioToPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendAmountPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodYearProrated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockDividendPeriodMonth" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PreferredStockShareCap" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_BiotechnologyValueFundLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="xoma_XomaCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_MaximumValueOfStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_DepositarySharesRatioToPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41107 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xlink:type="extended" xlink:title="41108 - Disclosure - Capital Stock - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="xoma_ExercisablePeriodOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" xlink:label="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner4Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xoma_NumberOfMajorPartners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_AsiaPacificMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerInterimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefInvestmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementAnnualSalary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonus" xlink:label="xoma_EmploymentAgreementSigningBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementSigningBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusPaymentPeriod" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementSigningBonusPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AnnualDiscretionaryCashBonusTargetPercentage" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_AnnualDiscretionaryCashBonusTargetPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>xoma-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2023 8:16:50 PM-->
<!--Modified on: 3/8/2023 8:16:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Class Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.625% Series A Cumulative, Perpetual Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Depositary Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation State Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address City Or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security12b Title</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RightsReceivableCurrent" xlink:to="xoma_RightsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rights Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrent" xlink:to="xoma_LongTermRightsReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty and commercial rights receivables, non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets - long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued And Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Income Taxes, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, current</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedPreferredStockDividendCurrent" xlink:to="xoma_AccruedPreferredStockDividendCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Preferred Stock Dividend, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method - long-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (Note 12)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,454,025 and 11,315,263 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.375% Series B Cumulative, Perpetual Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) income from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains Losses On Extinguishment Of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Loss) income before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income (attributable to) available to common stockholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income (attributable to) available to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income (attributable to) available to common stockholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income (attributable to) available to to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Stockholders Equity Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Benefit Plan and Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution and ESPP</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Benefit Plan and Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock, Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (loss) income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined contribution plan issuance of Common stock for services or claims.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Issuance Of Common Stock For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock contribution to 401(k)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization Of Financing Costs And Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt issuance costs, debt discount and final payment on debt</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReductionOfContingentRefundLiability" xlink:label="xoma_ReductionOfContingentRefundLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReductionOfContingentRefundLiability" xlink:to="xoma_ReductionOfContingentRefundLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReductionOfContingentRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reduction in contingent refund liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReductionOfContingentRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of Contingent Refund Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReductionOfContingentRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of contingent NIH refund liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReductionOfContingentRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction of contingent refund liability</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasePaymentsNonCash" xlink:to="xoma_OperatingLeasePaymentsNonCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease payments, non cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments Non Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of equity securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) recognized due to change in fair value of investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncreaseDecreaseInRefundLiability" xlink:label="xoma_IncreaseDecreaseInRefundLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncreaseDecreaseInRefundLiability" xlink:to="xoma_IncreaseDecreaseInRefundLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncreaseDecreaseInRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in contingent refund liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncreaseDecreaseInRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Refund Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_IncreaseDecreaseInRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent NIH refund liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Contingent Consideration Liability, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of consideration under RPAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:to="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts related to purchase of royalty rights and other commercial payment rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts Related To Purchase Of Royalty Rights And Other Commercial Payment Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts under RPAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for IP acquired under the ObsEva IP Acquisition Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment to acquire assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to purchase of royalty rights and other commercial payment rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to purchase of royalty rights and other commercial payment rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments related to purchase of royalty rights and other commercial payment rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of preferred and common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options and other share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" xlink:to="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, excluding extinguishment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt, Excluding Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments - debt</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" xlink:to="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, considered extinguishment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt, Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for extinguishment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtRestructuringCosts" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Restructuring Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for debt modification fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (decrease) increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and restricted cash at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value Of Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under the Affitech CPPA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:to="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued transaction costs in connection with acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Transaction Costs Related To Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued transaction costs in connection with ObsEva IP Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated financial statement detail.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Financial Statements Detail</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Financial Statements Detail</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsTextBlock" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing And Other Arrangements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTextBlock" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeaseDisclosureTextBlock" xlink:to="xoma_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation and Other Benefit Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risk segment and geographic information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk, Segment and Geographic Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk, Segment and Geographic Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for sale of future revenue streams.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Deferred Revenue Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Future Revenue Streams</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesPolicy" xlink:to="xoma_EquitySecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Policy for future milestones, royalties purchase rights and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for asset acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leases Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net (Loss) Income per Share (Attributable to) Available to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive (Loss) Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of of cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost, accumulated amortization, and net carrying value of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of projected amortization expense for next five years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding securities considered anti-dilutive</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the changes in royalty and commercial payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of royalty receivable activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Changes in Estimated Fair Value of Level 3 Financial Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost components of operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental cash flows information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of supplemental cash flow information related to operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of present value assumptions used in calculating the present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Provision for Income Taxes (All Current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Net Deferred Tax Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Unrecognized Tax Benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDeclaredTableTextBlock" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Declared [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of declared and paid cash dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Common Stock Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue by Geographical Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year [true false]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Substantial Doubt about Going Concern, within One Year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:to="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of Rights to Future Milestones and Royalties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of Rights to Future Milestones and Royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment Of Long Term Royalty Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-term royalty receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life of intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax penalties or interest charged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RezoluteIncMember" xlink:to="xoma_RezoluteIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Equity Securities, FV-NI [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ebopiprant IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected amortization expense for the next five years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Through Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total for next five years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities And Other Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries and Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued legal and accounting fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued incentive compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ObsevaIntellectualPropertyRightsMember" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva intellectual property rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OrganonMember" xlink:to="xoma_OrganonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organon</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset acquisition</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Development, Commercialization And Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPayments" xlink:to="xoma_MaximumEarnOutPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for various milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost to acquire assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes In Estimated Fair Value Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Contract Cost Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized contract costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible asset</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Development And Regulatory Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Sales-Based Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract With Customer Asset Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract With Customer Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International Pharmaceutical Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisNoteMember" xlink:to="xoma_NovartisNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured note agreement and subsequent amendments with Novartis referred to as the "Note Agreement".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Termination Prior Written Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPerformanceObligations" xlink:to="xoma_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromUpfrontPayment" xlink:to="xoma_ProceedsFromUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payment received</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimum" xlink:to="xoma_RoyaltiesPeriodMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties, Period, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in debt obligation</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisPharmaAGMember" xlink:to="xoma_NovartisPharmaAGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XOMA-052 license agreement and IL1 target license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement and IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XOMA052LicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 target license agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementTransactionPrice" xlink:to="xoma_LicenseAgreementTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceived" xlink:to="xoma_LicenseAgreementConsiderationReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of license agreement consideration received as repayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Debt Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received, repayment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing stock price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockPremium" xlink:to="xoma_CommonStockPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium received on sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArrangementsNumber" xlink:to="xoma_ArrangementsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements the agreements are accounted for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining performance obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda Pharmaceutical Company Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CollaborationAgreementMember" xlink:to="xoma_CollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about collaboration agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MezagitamabMember" xlink:to="xoma_MezagitamabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MezagitamabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mezagitamab antibody (TAK-079).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MezagitamabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TAK-079</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OtherAntibodiesMember" xlink:to="xoma_OtherAntibodiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibody technologies.  Excludes TAK-079 (mezagitamab).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibodies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Per Discovery Product Candidate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement and common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement and Common Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementRz358Member" xlink:to="xoma_LicenseAgreementRz358Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with RZ358.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, RZ358</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementNonRz358ProductsMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with non-RZ358 products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Non-RZ358 products</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Decrease In Future Royalty Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payments received upon achievement of financing activities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Achievement of Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments received upon achievement of financing activities</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of installment payments received during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Installment Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Installment payments received</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementSharesReceived" xlink:to="xoma_LicenseAgreementSharesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of counterparty's common stock entity received under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Shares Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_JanssenBiotechInc.Member" xlink:to="xoma_JanssenBiotechInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech Inc.</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales upon commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalty On Net Sales Upon Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on worldwide net sales of each product upon commercialization</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AffimedMember" xlink:to="xoma_AffimedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AffimedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affimed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AffimedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affimed</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P (HCRP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Interest Acquisition Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Sale Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of royalty interest acquisition agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Royalty Interest Acquisition Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePeriodsNumber" xlink:to="xoma_MilestonePeriodsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Periods, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgenusIncMember" xlink:to="xoma_AgenusIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BioasisTechnologiesIncMember" xlink:to="xoma_BioasisTechnologiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis Technologies Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraIncMember" xlink:to="xoma_AronoraIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora [Member]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PalobiofarmaSLMember" xlink:to="xoma_PalobiofarmaSLMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palobiofarma, S.L.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palobiofarma, S.L {Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palo</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ViractaTherapeuticsInc.Member" xlink:to="xoma_ViractaTherapeuticsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta Therapeutics, Inc. ("Viracta").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros [Member]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AffitechResearchAsMember" xlink:to="xoma_AffitechResearchAsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech Research AS, a Norwegian biotech company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncyteImmunoOncologyAssetsMember" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte immuno-oncology assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte Immuno-Oncology Assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MerckImmunoOncologyProductMember" xlink:to="xoma_MerckImmunoOncologyProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck immuno-oncology product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck Immuno-Oncology Product</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyReceivablePercentageOnNetSales" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has the right to receive as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has right to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestones and royalties purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Licensed Products Related To Milestones And Royalties Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestone and royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfMilestones" xlink:to="xoma_PurchasedPercentageOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestoneAchieved" xlink:to="xoma_MilestoneAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone achieved</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashReceivedForAchievementOfContractualMilestones" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashReceivedForAchievementOfContractualMilestones" xlink:to="xoma_CashReceivedForAchievementOfContractualMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash receipts for achievement of contractual milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Received for Achievement of Contractual Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash receipts for achievement of contractual milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTwoMember" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A second royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty rights entity has option to  purchase in future license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Optional Royalty Rights Purchase On Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of option to purchase royalty right on future license agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of future license agreements under optional purchase right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of License Agreements, Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of future license agreements under optional purchase right</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Be Made Upon Exercise Of Option, Second License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation upon exercise of options per licensed product, second agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Be Made Upon Exercise Of Option, Third License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation upon exercise of options per licensed product, third agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPayments" xlink:to="xoma_ContingentFutureCashPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential future cash payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsOfContingentConsideration" xlink:to="xoma_PaymentsOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BayerProductsMember" xlink:to="xoma_BayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NonBayerProductsMember" xlink:to="xoma_NonBayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_SiliconValleyBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Loan</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesNumber" xlink:to="xoma_AgreementDrugCandidatesNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Exclusive License Option, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of non-royalties on net sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-royalties to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementPaymentPercentageFactor" xlink:to="xoma_AgreementPaymentPercentageFactor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier used in determining change in payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Payment Percentage, Factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier for cumulative amount of consideration paid</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_UpfrontPayment" xlink:to="xoma_UpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for initial payment under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_UpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPaymentsPerProduct" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contingent future cash payment for each product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Future Cash Payments, Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future cash payment for each product</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Royalties On Net Sales Per Product, Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Payments To Aggregate Amount Of Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate milestones payments per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Receivable, Excluding Consideration Retained, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones and other payments receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumConsiderationRetained" xlink:to="xoma_MaximumConsiderationRetained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Consideration Retained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory and Commercial Milestones Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commercial milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential future sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivedCounterparty" xlink:to="xoma_MilestonePaymentReceivedCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Received, Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received by Kuros</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivablePercentage" xlink:to="xoma_MilestonePaymentReceivablePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by counterparty entity is entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Receivable, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by Kuros that company is entitled to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long-term rights receivable due to receipt of royalty and commercial payment receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of Royalty and Commercial Payment Receivable Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of royalty and commercial payments, Long-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in long-term royalty receivable balance due to receipt of payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentPurchaseAgreementMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FaricimabSvoaVabysmoProductMember" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab-svoa, (VABYSMO) products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VABYSMO</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments entity eligible to receive as a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Sales, Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments eligible to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentReceivableTerm" xlink:to="xoma_CommercialPaymentReceivableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Receivable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment receivable term</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of sales and/or regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Regulatory and Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional payments upon achievement of regulatory and sales milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPayableOnRegulatoryMilestone" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount payable on regulatory milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payable on Regulatory Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payable on regulatory milestone</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPayableOnSalesMilestone" xlink:to="xoma_MaximumPayableOnSalesMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount payable on sales milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payable on Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payable on sales milestone</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePayment" xlink:label="xoma_MilestonePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePayment" xlink:to="xoma_MilestonePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and commercial payment rights acquired, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty And Commercial Rights Acquired, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of royalty and commercial payment rights, Long-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShortTermRightsReceivableReclassification" xlink:to="xoma_ShortTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in short term rights receivable due to reclassification from long-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to short-term royalty and commercial payment receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableReclassification" xlink:to="xoma_LongTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long term rights receivable due to reclassification to short-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to long-term royalty and commercial payment receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets for Identical Assets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FinancialAssetsFairValueDisclosure" xlink:to="xoma_FinancialAssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationFairValueDisclosure" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Common Stock Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Fv Ni Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities in Emeryville, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities, Emeryville, California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Number Of Leased Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's net lease liability until expiration of operating lease to be paid in next fiscal year following current fiscal year. Excludes payments after  extension of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One, Prior To Expiration of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net lease liability until expiration of lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Remaining Lease Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Discount Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense Benefit Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax at statutory rate</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation and other permanent differences</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal orphan drug credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Orphan Drug Credit, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal orphan drug credit</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense (benefit) related to net operating loss carryforward utilization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Net Operating Loss Carryforward Utilization, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax benefit related to net operating loss carryforward utilization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets In Process Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development and other tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Deferred Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry-forwards</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carry forward that is subject to expiration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carry Forward Subject To Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forward subject to expiration</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carryforwards Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards expiration year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FederalOrphanCreditMember" xlink:to="xoma_FederalOrphanCreditMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FederalOrphanCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal orphan tax credit carryforward.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FederalOrphanCreditMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Orphan Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward amount</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TaxCreditCarryForwardExpirationYear" xlink:to="xoma_TaxCreditCarryForwardExpirationYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward expiration year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carry Forward Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward expiration year</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards offset of taxable income percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards Offset Of Taxable Income Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforward offset (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase related to current year tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that would impact effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits expected to change significantly over the next twelve months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Employee Stock Purchase Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Offering Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage related to employees to purchase shares at the lower fair market value at offering period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in aggregate number of shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum shares per employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares purchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relationship to Entity</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeUnderAgeFiftyMember" xlink:to="xoma_EmployeeUnderAgeFiftyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeUnderAgeFiftyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity under 50 years old.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeUnderAgeFiftyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Under Age Fifty</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeAgeFiftyOrOverMember" xlink:to="xoma_EmployeeAgeFiftyOrOverMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity age 50 or over.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee, Age Fifty or Over</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Savings Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual contribution per employee (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Maximum Annual Contributions Per Employee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual contribution per employee</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Age Required For Catch Up Contribution Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Age requirement for participant to be eligible for a catch-up contribution, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer matching contribution (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Cost Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of defined contribution plan expense paid through the issuance of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred savings plan expense paid in common shares (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Long Term Incentive and Share Award Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeTerminatedMember" xlink:to="xoma_EmployeeTerminatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeTerminatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terminated employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeTerminatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terminated employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to stock options (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which unrecognized compensation expense is expected to be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which unrecognized compensation expense is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Vice President, Finance and Chief Financial Officer of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Vice President, Finance and Chief Financial Officer, Thomas Burns</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentPeriodRetirementEligible" xlink:to="xoma_EmploymentPeriodRetirementEligible_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Period, Retirement Eligible</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentPeriodRetirementEligible_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which individual will be deemed retirement eligible for purposes of equity award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees of entity, excluding Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees, excluding Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Departure and Continuity Incentive</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPeriodsCashRetentionBonus" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Periods, Cash Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which employees will be eligible to receive cash retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodOneRetentionBonusEligibility" xlink:to="xoma_PeriodOneRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodTwoRetentionBonusEligibility" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RetentionBonusExpenseAccrued" xlink:to="xoma_RetentionBonusExpenseAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recorded as expense during the period for cash retention bonuses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retention Bonus, Expense Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recorded as expense for cash retention bonuses</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" xlink:to="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash retention bonus expected to be paid in next fiscal year following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Retention Bonus, Expected Payment, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash retention bonuses expected to be paid in 2023</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerRetiredMember" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of chief executive officer prior to retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, Retired, James R. Neal</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedCompensationContinuityIncentive" xlink:to="xoma_AccruedCompensationContinuityIncentive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Compensation, Continuity Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued cash payment related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CompensationExpenseEmploymentAgreement" xlink:to="xoma_CompensationExpenseEmploymentAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense, Employment Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net income loss available to common stockholders basic and diluted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends and Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated preferred dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undistributed Earnings Loss Allocated To Participating Securities Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Allocation of undistributed earnings to participating securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undistributed Earnings Loss Allocated To Participating Securities Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Add: Adjustments to undistributed earnings allocated to participating securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of dilutive stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of dilutive warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X and series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X And Series Y Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesXConvertiblePreferredStockMember" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series X Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SeriesYConvertiblePreferredStockMember" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Y convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Y Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for each share of convertible preferred stock that is converted</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockConversionPricePerShare" xlink:to="xoma_PreferredStockConversionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock conversion price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock conversion price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodYearProrated" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Year Prorated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days in year over which dividend will be prorated and computed</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Prorated Months in Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of months in year over which dividend will be prorated and compute</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendPeriodMonth" xlink:to="xoma_PreferredStockDividendPeriodMonth_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Period, Month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendPeriodMonth_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days in month over which dividend will be prorated and computed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Redemption Price Per Share, Optional Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockShareCap" xlink:to="xoma_PreferredStockShareCap_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Share Cap</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockShareCap_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share cap (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Threshold Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions By Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spouse of James Neal, then CEO and Chairman of the Board of Directors</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DepositarySharesRatioToPreferredStock" xlink:to="xoma_DepositarySharesRatioToPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents depositary share's fractional interest in share of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depositary Shares, Ratio To Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DepositarySharesRatioToPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depositary share's fractional interest in share of preferred stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Preferred Stock, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PreferredStockDividendAmountPerShare" xlink:to="xoma_PreferredStockDividendAmountPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The dividend amount per share based on the dividend rate on preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividend Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PreferredStockDividendAmountPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend amount (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_DividendsPayableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend declared (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends, Per Share, Cash Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend paid (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BiotechnologyValueFundLPMember" xlink:to="xoma_BiotechnologyValueFundLPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biotechnology Value Fund, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BVF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XomaCorporationMember" xlink:to="xoma_XomaCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest, if shares are converted (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the Market Agreement, 2018 in which the company may sell common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 ATM Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Common Stock ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumValueOfCommonStockToBeIssued" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum value of common stock to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common shares to be issued</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumValueOfStockToBeIssued" xlink:to="xoma_MaximumValueOfStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of stock to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of shares to be issued</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction, preferred stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten Year Warrants Issued in May 2018</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantExercisePrice14.71Member" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $14.71 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of unregistered shares of common stock called by warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ExercisablePeriodOfWarrants" xlink:to="xoma_ExercisablePeriodOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable Period Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ExercisablePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable period of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable In Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="xoma_CommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePayments" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation Estimated Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Estimated Milestone Payments, Number Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" xlink:label="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" xlink:to="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty milestones, sales milestones, non-sales milestones, and royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty milestones, sales milestones, non-sales milestones, and royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfArbitrationProceedingsInitiated" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated by entity against one of its licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Arbitration Proceedings Initiated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner1Member" xlink:to="xoma_Partner1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 1</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner2Member" xlink:to="xoma_Partner2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 2</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner3Member" xlink:to="xoma_Partner3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 3</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner4Member" xlink:to="xoma_Partner4Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 4</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfMajorPartners" xlink:to="xoma_NumberOfMajorPartners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Major Partners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Revenues From External Customers And Long Lived Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaPacificMember" xlink:to="srt_AsiaPacificMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaPacificMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asia Pacific</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues From External Customers And Long Lived Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues from External Customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerInterimMember" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of interim chief executive officer and Executive Chairman of the Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Chairman of the Board and Interim CEO, Owen Hughes</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefInvestmentOfficerMember" xlink:to="xoma_ChiefInvestmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of  chief investment officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Investment Officer, Bradley Sitko</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation award with exercise price of $18.66 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price, $18.66 per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation award with exercise price of $30.00 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price, $30.00 per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid under extended lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Under Extended Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining undiscounted lease payments under extended lease term</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementAnnualSalary" xlink:to="xoma_EmploymentAgreementAnnualSalary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of annual base salary pursuant to employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Annual Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementAnnualSalary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of annual base salary</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonus" xlink:label="xoma_EmploymentAgreementSigningBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementSigningBonus" xlink:to="xoma_EmploymentAgreementSigningBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementSigningBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount of signing bonus pursuant to employment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementSigningBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Signing Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementSigningBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of signing bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusPaymentPeriod" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementSigningBonusPaymentPeriod" xlink:to="xoma_EmploymentAgreementSigningBonusPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents period within which signing bonus will be paid pursuant to employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Signing Bonus, Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period within which signing bonus will be paid</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" xlink:to="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Signing Bonus, Resignation Or Termination, Period Requiring Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" xlink:to="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents period within which signing bonus would need to be repaid upon resignation or termination for cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreement, Signing Bonus, Repayment Period Upon Resignation Or Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period within which signing bonus would need to be repaid upon resignation or termination</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AnnualDiscretionaryCashBonusTargetPercentage" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AnnualDiscretionaryCashBonusTargetPercentage" xlink:to="xoma_AnnualDiscretionaryCashBonusTargetPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual discretionary cash bonus target as a percentage of current annual base salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Discretionary Cash Bonus, Target Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual discretionary cash bonus target (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Number of Awards Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal quarterly vesting installments</label>
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of successive equal monthly vesting installments</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>xoma-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/8/2023 8:16:50 PM-->
<!--Modified on: 3/8/2023 8:16:50 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureDescriptionOfBusiness" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangements" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreements" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlans" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStock" roleURI="http://www.xoma.com/role/DisclosureCapitalStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformation" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.xoma.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsTables" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockTables" roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureDescriptionOfBusinessLiquidityDetails" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsAffimedDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureLeaseAgreementsAdditionalInformationDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesNolDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesTaxCreditCarryforwardDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" roleURI="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSeriesPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCapitalStockCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" roleURI="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="us-gaap_StatementTable_638139034063727568" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063727568" xlink:to="us-gaap_StatementClassOfStockAxis_638139034063727568" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063727568" xlink:to="us-gaap_ClassOfStockDomain_638139034063727568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063727568" xlink:to="us-gaap_CommonStockMember_638139034063727568" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063727568" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034063727568" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063727568" xlink:to="dei_AdrMember_638139034063727568" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063727568" xlink:to="us-gaap_StatementLineItems_638139034063727568" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638139034063727568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentType_638139034063727568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentAnnualReport_638139034063737569" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentPeriodEndDate_638139034063737569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentTransitionReport_638139034063737569" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityFileNumber_638139034063737569" order="5" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityRegistrantName_638139034063737569" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityIncorporationStateCountryCode_638139034063737569" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityTaxIdentificationNumber_638139034063737569" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityAddressAddressLine1_638139034063737569" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityAddressAddressLine2_638139034063737569" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityAddressCityOrTown_638139034063737569" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638139034063737569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityAddressStateOrProvince_638139034063737569" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityAddressPostalZipCode_638139034063747568" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_CityAreaCode_638139034063747568" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_LocalPhoneNumber_638139034063747568" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_Security12bTitle_638139034063747568" order="16" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_TradingSymbol_638139034063747568" order="17" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_SecurityExchangeName_638139034063747568" order="18" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityWellKnownSeasonedIssuer_638139034063747568" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityVoluntaryFilers_638139034063747568" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638139034063747568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityCurrentReportingStatus_638139034063747568" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityInteractiveDataCurrent_638139034063757569" order="22" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityFilerCategory_638139034063757569" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntitySmallBusiness_638139034063757569" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityEmergingGrowthCompany_638139034063757569" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_IcfrAuditorAttestationFlag_638139034063757569" order="26" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityShellCompany_638139034063757569" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityPublicFloat_638139034063757569" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638139034063757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityCommonStockSharesOutstanding_638139034063757569" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_AuditorFirmId_638139034063767568" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_AuditorName_638139034063767568" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_AuditorLocation_638139034063767568" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_EntityCentralIndexKey_638139034063767568" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_CurrentFiscalYearEndDate_638139034063767568" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638139034063767568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentFiscalYearFocus_638139034063767568" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_DocumentFiscalPeriodFocus_638139034063777569" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063727568" xlink:to="dei_AmendmentFlag_638139034063777569" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638139034063777569" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063777569" xlink:to="us-gaap_StatementClassOfStockAxis_638139034063777569" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063777569" xlink:to="us-gaap_ClassOfStockDomain_638139034063777569" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063777569" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034063777569" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063777569" xlink:to="us-gaap_StatementLineItems_638139034063777569" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638139034063777569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063777569" xlink:to="us-gaap_AssetsAbstract_638139034063777569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_AssetsCurrentAbstract_638139034063787570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034063787570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_RestrictedCashCurrent_638139034063787570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_EquitySecuritiesFvNi_638139034063787570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638139034063787570" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="xoma_RightsReceivableCurrent_638139034063787570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139034063787570" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139034063787570" xlink:to="us-gaap_AssetsCurrent_638139034063787570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638139034063787570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139034063787570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034063787570" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638139034063787570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638139034063787570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_OtherAssetsNoncurrent_638139034063797570" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139034063777569" xlink:to="us-gaap_Assets_638139034063797570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063777569" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="us-gaap_AccountsPayableCurrent_638139034063797570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638139034063797570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638139034063797570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034063797570" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638139034063797570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638139034063797570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="us-gaap_DeferredIncomeCurrent_638139034063807569" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638139034063807569" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139034063797570" xlink:to="us-gaap_LiabilitiesCurrent_638139034063807569" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_DeferredIncomeNoncurrent_638139034063807569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638139034063807569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_Liabilities_638139034063807569" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_CommitmentsAndContingencies_638139034063807569" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638139034063807569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139034063797570" xlink:to="us-gaap_StockholdersEquityAbstract_638139034063807569" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139034063807569" xlink:to="us-gaap_PreferredStockValue_638139034063817566" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139034063807569" xlink:to="us-gaap_CommonStockValue_638139034063817566" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139034063807569" xlink:to="us-gaap_AdditionalPaidInCapital_638139034063817566" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139034063807569" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638139034063817566" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139034063807569" xlink:to="us-gaap_StockholdersEquity_638139034063817566" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638139034063817566" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063777569" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638139034063817566" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638139034063827570" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063827570" xlink:to="us-gaap_StatementClassOfStockAxis_638139034063827570" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063827570" xlink:to="us-gaap_ClassOfStockDomain_638139034063827570" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063827570" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034063827570" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063827570" xlink:to="us-gaap_SeriesBPreferredStockMember_638139034063827570" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034063827570" xlink:to="us-gaap_ConvertiblePreferredStockMember_638139034063827570" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063827570" xlink:to="us-gaap_StatementLineItems_638139034063827570" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638139034063827570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139034063827570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638139034063827570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_PreferredStockSharesIssued_638139034063827570" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638139034063827570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_PreferredStockSharesOutstanding_638139034063827570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638139034063837570" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_CommonStockSharesAuthorized_638139034063837570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_CommonStockSharesIssued_638139034063837570" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063827570" xlink:to="us-gaap_CommonStockSharesOutstanding_638139034063837570" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenuesAbstract_638139034063837570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638139034063837570" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034063837570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638139034063837570" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638139034063837570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638139034063837570" xlink:to="us-gaap_Revenues_638139034063837570" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638139034063837570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139034063837570" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638139034063837570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638139034063837570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139034063837570" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638139034063837570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139034063837570" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638139034063847576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139034063837570" xlink:to="us-gaap_OperatingExpenses_638139034063847576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638139034063847576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638139034063847576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139034063847576" xlink:to="us-gaap_InterestExpenseDebt_638139034063847576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139034063847576" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034063847576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139034063847576" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638139034063847576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034063847576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139034063847576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638139034063847576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638139034063847576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034063847576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034063847576" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638139034063857571" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638139034063857571" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638139034063857571" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034063857571" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139034063857571" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638139034063857571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063857571" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034063857571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638139034063857571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034063857571" xlink:to="us-gaap_PreferredStockMember_638139034063857571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034063857571" xlink:to="us-gaap_CommonStockMember_638139034063867571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034063857571" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638139034063867571" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034063857571" xlink:to="us-gaap_RetainedEarningsMember_638139034063867571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034063857571" xlink:to="us-gaap_EquityComponentDomain_638139034063867571" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063857571" xlink:to="us-gaap_StatementClassOfStockAxis_638139034063867571" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063867571" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034063867571" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063867571" xlink:to="us-gaap_SeriesBPreferredStockMember_638139034063867571" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063867571" xlink:to="us-gaap_ConvertiblePreferredStockMember_638139034063867571" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034063867571" xlink:to="us-gaap_ClassOfStockDomain_638139034063867571" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034063857571" xlink:to="us-gaap_StatementLineItems_638139034063867571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034063867571" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_StockholdersEquity_638139034063867571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638139034063867571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_SharesOutstanding_638139034063867571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638139034063877571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638139034063877571" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034063877571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638139034063877571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638139034063877571" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139034063877571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638139034063877571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_638139034063877571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan" xlink:label="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638139034063877571" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans" xlink:label="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan_638139034063877571" xlink:to="xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans_638139034063877571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_DividendsPreferredStockStock_638139034063877571" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139034063877571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_NetIncomeLoss_638139034063877571" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_StockholdersEquity_638139034063887571" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638139034063867571" xlink:to="us-gaap_SharesOutstanding_638139034063887571" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_ProfitLoss_638139034063887571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_ShareBasedCompensation_638139034063887571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638139034063887571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_DepreciationNonproduction_638139034063887571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638139034063887571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_638139034063887571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638139034063897570" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReductionOfContingentRefundLiability" xlink:label="xoma_ReductionOfContingentRefundLiability_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="xoma_ReductionOfContingentRefundLiability_638139034063897570" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="xoma_OperatingLeasePaymentsNonCash_638139034063897570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034063897570" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638139034063897570" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638139034063897570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638139034063897570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_638139034063907583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139034063907583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139034063907583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638139034063907583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638139034063907583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034063907583" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncreaseDecreaseInRefundLiability" xlink:label="xoma_IncreaseDecreaseInRefundLiability_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="xoma_IncreaseDecreaseInRefundLiability_638139034063907583" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139034063897570" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_638139034063907583" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034063907583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139034063887571" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139034063907583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_638139034063917573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" xlink:to="xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034063917573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638139034063917573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034063917573" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139034063917573" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034063927572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034063927572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentsOfDividends_638139034063927572" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638139034063927572" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638139034063927572" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638139034063927572" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_638139034063927572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt_638139034063927572" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt" xlink:label="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_638139034063937575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt_638139034063937575" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtRestructuringCosts" xlink:label="us-gaap_PaymentsOfDebtRestructuringCosts_638139034063937575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_PaymentsOfDebtRestructuringCosts_638139034063937575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034063937575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139034063917573" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139034063937575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638139034063937575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638139034063937575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139034063937575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139034063937575" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381390340639375751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381390340639375751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638139034063947570" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638139034063947570" xlink:to="us-gaap_IncomeTaxesPaidNet_638139034063947570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638139034063947570" xlink:to="us-gaap_InterestPaidNet_638139034063947570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139034063947570" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139034063947570" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements_638139034063947570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_638139034063947570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139034063947570" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_638139034063947570" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedTransactionCostsRelatedToPurchaseAgreements" xlink:label="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_638139034063957567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139034063947570" xlink:to="xoma_AccruedTransactionCostsRelatedToPurchaseAgreements_638139034063957567" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638139034063957567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638139034063957567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation and Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638139034063957567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638139034063957567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails" xlink:type="extended" xlink:title="10301 - Disclosure - Consolidated Financial Statements Details" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638139034063967568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638139034063967568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xlink:type="extended" xlink:title="10401 - Disclosure - Licensing and Other Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_638139034063967568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_638139034063967568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xlink:type="extended" xlink:title="10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_638139034063967568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_638139034063967568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10601 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638139034063977567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638139034063977567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreements" xlink:type="extended" xlink:title="10701 - Disclosure - Lease Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock_638139034063977567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LeaseDisclosureTextBlock_638139034063977567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638139034063977567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638139034063977567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans" xlink:type="extended" xlink:title="10901 - Disclosure - Stock Based Compensation and Other Benefit Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638139034063987568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638139034063987568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders" xlink:type="extended" xlink:title="11001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638139034063987568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638139034063987568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStock" xlink:type="extended" xlink:title="11101 - Disclosure - Capital Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638139034063987568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638139034063987568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11201 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638139034063997567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638139034063997567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation" xlink:type="extended" xlink:title="11301 - Disclosure - Concentration of Risk, Segment and Geographic Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_638139034063997567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_638139034063997567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638139034063997567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638139034063997567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638139034064007568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638139034064007568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638139034064007568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638139034064007568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638139034064007568" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638139034064007568" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_EquitySecuritiesPolicy_638139034064007568" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638139034064007568" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638139034064007568" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638139034064007568" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638139034064007568" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638139034064007568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638139034064007568" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638139034064017567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638139034064017567" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638139034064017567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638139034064017567" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638139034064017567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638139034064017567" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638139034064017567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638139034064017567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Consolidated Financial Statements Details (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638139034064027568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638139034064027568" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638139034064027568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638139034064027568" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638139034064027568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638139034064027568" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638139034064027568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638139034064027568" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638139034064027568" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638139034064027568" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638139034064087573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638139034064087573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638139034064097574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_638139034064097574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Lease Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638139034064097574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638139034064097574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638139034064097574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638139034064097574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638139034064097574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638139034064107574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638139034064107574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_638139034064107574" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables" xlink:type="extended" xlink:title="30903 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638139034064107574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638139034064107574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638139034064107574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638139034064107574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638139034064107574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638139034064117573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638139034064117573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockTables" xlink:type="extended" xlink:title="31103 - Disclosure - Capital Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_638139034064117573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_638139034064117573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638139034064117573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638139034064117573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables" xlink:type="extended" xlink:title="31303 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_638139034064117573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_638139034064117573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034064127573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_638139034064127573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638139034064127573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139034064127573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashCurrent_638139034064127573" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139034064127573" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract" xlink:label="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_638139034064127573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract_638139034064127573" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064127573" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638139034064127573" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638139034064127573" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638139034064137574" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638139034064137574" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638139034064137574" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638139034064137574" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638139034064137574" xlink:to="srt_EquityMethodInvesteeNameDomain_638139034064137574" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638139034064137574" xlink:to="xoma_RezoluteIncMember_638139034064137574" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638139034064137574" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638139034064137574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638139034064137574" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_638139034064137574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638139034064137574" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638139034064137574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract_1" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638139034064137574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139034064137574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638139034064137574" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139034064137574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139034064137574" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139034064147575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139034064147575" xlink:to="us-gaap_IntellectualPropertyMember_638139034064147575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638139034064137574" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638139034064147575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638139034064147575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638139034064147575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139034064147575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638139034064147575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638139034064147575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139034064147575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139034064147575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139034064147575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139034064147575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139034064147575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139034064157576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638139034064147575" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_638139034064157576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638139034064157576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638139034064157576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" xlink:to="us-gaap_AccruedBonusesCurrent_638139034064157576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638139034064157576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638139034064157576" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638139034064157576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638139034064157576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract_1" xlink:to="us-gaap_AssetAcquisitionTable_638139034064157576" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638139034064157576" xlink:to="us-gaap_AssetAcquisitionAxis_638139034064167575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638139034064167575" xlink:to="us-gaap_AssetAcquisitionDomain_638139034064167575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638139034064167575" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_638139034064167575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638139034064157576" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064167575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064167575" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064167575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064167575" xlink:to="xoma_LicenseAgreementMember_638139034064167575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638139034064157576" xlink:to="srt_CounterpartyNameAxis_638139034064167575" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064167575" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064167575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064167575" xlink:to="xoma_OrganonMember_638139034064167575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638139034064157576" xlink:to="us-gaap_AssetAcquisitionLineItems_638139034064167575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_638139034064167575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638139034064167575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments_638139034064167575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_MaximumEarnOutPayments_638139034064167575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638139034064177576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638139034064177576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064177576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064177576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReductionOfContingentRefundLiability" xlink:label="xoma_ReductionOfContingentRefundLiability_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_ReductionOfContingentRefundLiability_638139034064177576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638139034064177576" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638139034064177576" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139034064177576" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638139034064177576" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638139034064177576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638139034064177576" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064187575" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064187575" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638139034064167575" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064187575" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" xlink:to="srt_CounterpartyNameAxis_638139034064187575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064187575" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064187575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064187575" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_638139034064187575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064187575" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064187575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064187575" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064187575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064187575" xlink:to="xoma_LicenseAgreementMember_638139034064197576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" xlink:to="us-gaap_DebtInstrumentAxis_638139034064197576" order="3" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638139034064197576" xlink:to="us-gaap_DebtInstrumentNameDomain_638139034064197576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139034064197576" xlink:to="xoma_NovartisNoteMember_638139034064197576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064187575" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064197576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="xoma_NumberOfPerformanceObligations_638139034064197576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="xoma_ProceedsFromUpfrontPayment_638139034064197576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064197576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064197576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="xoma_RoyaltiesPeriodMinimum_638139034064197576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638139034064197576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638139034064197576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064207577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064207577" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064197576" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064207577" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" xlink:to="srt_CounterpartyNameAxis_638139034064207577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064207577" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064207577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064207577" xlink:to="xoma_NovartisPharmaAGMember_638139034064207577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064207577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064207577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064207577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064207577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064207577" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638139034064217576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638139034064217576" xlink:to="xoma_XOMA052LicenseAgreementMember_638139034064217576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638139034064217576" xlink:to="xoma_IL1TargetLicenseAgreementMember_638139034064217576" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064217576" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064217576" xlink:to="us-gaap_EquityComponentDomain_638139034064217576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064217576" xlink:to="us-gaap_CommonStockMember_638139034064217576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064207577" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_LicenseAgreementTransactionPrice_638139034064217576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_LicenseAgreementConsiderationReceived_638139034064217576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_ProceedsFromUpfrontPayment_638139034064217576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638139034064217576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034064217576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638139034064217576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064227575" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_SharesIssuedPricePerShare_638139034064227575" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638139034064227575" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_SharePrice_638139034064227575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_CommonStockPremium_638139034064227575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064227575" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_NumberOfLicenseAgreements_638139034064227575" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064227575" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_ArrangementsNumber_638139034064227575" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638139034064227575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="xoma_NumberOfPerformanceObligations_638139034064227575" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_638139034064237577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_638139034064237577" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064237577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064237577" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064237577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064237577" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064237577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064237577" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064237577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064217576" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064237577" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" xlink:to="srt_CounterpartyNameAxis_638139034064247577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064247577" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064247577" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064247577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064247577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064247577" xlink:to="xoma_CollaborationAgreementMember_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064247577" xlink:to="xoma_LicenseAgreementMember_638139034064247577" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" xlink:to="srt_ProductOrServiceAxis_638139034064247577" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139034064247577" xlink:to="srt_ProductsAndServicesDomain_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064247577" xlink:to="xoma_MezagitamabMember_638139034064247577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064247577" xlink:to="xoma_OtherAntibodiesMember_638139034064247577" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064247577" xlink:to="us-gaap_LicenseMember_638139034064247577" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064247577" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064257576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638139034064257576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="xoma_RoyaltiesPeriodMinimum_638139034064257576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064257576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064257576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064257576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064247577" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064257576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064257576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064257576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064257576" xlink:to="srt_CounterpartyNameAxis_638139034064267583" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064267583" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064267583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064267583" xlink:to="xoma_RezoluteIncMember_638139034064267583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064257576" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064267583" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064267583" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064267583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064267583" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638139034064267583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638139034064267583" xlink:to="xoma_LicenseAgreementMember_638139034064267583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638139034064267583" xlink:to="xoma_LicenseAgreementRz358Member_638139034064267583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638139034064267583" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_638139034064267583" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064257576" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638139034064267583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_RoyaltiesPeriodMinimum_638139034064267583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638139034064267583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064267583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638139034064267583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_LicenseAgreementConsiderationReceived_638139034064277577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064277577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638139034064277577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_638139034064277577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="xoma_LicenseAgreementSharesReceived_638139034064277577" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638139034064277577" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064277577" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064277577" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064277577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064267583" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064277577" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064287576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064287576" xlink:to="srt_CounterpartyNameAxis_638139034064287576" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064287576" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064287576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064287576" xlink:to="xoma_JanssenBiotechInc.Member_638139034064287576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064287576" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064287576" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064287576" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064287576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064287576" xlink:to="xoma_LicenseAgreementMember_638139034064287576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064287576" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="xoma_ProceedsFromUpfrontPayment_638139034064287576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_638139034064287576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638139034064287576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064287576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064287576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064297861" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064297861" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064287576" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064297861" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064297861" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064297861" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064297861" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064297861" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064297861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064297861" xlink:to="xoma_LicenseAgreementMember_638139034064297861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064297861" xlink:to="srt_CounterpartyNameAxis_638139034064297861" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064297861" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064297861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember_638139034064297861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064297861" xlink:to="xoma_AffimedMember_638139034064297861" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064297861" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" xlink:to="us-gaap_ContractWithCustomerAssetNet_638139034064307578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" xlink:to="us-gaap_ContractWithCustomerLiability_638139034064307578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" xlink:to="us-gaap_CapitalizedContractCostNet_638139034064307578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064307578" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638139034064307578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064307578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064307578" xlink:to="srt_CounterpartyNameAxis_638139034064307578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064307578" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064307578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064307578" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638139034064307578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064307578" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064307578" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064307578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064307578" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064307578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064307578" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_638139034064317576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638139034064317576" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638139034064317576" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638139034064317576" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638139034064317576" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064307578" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_638139034064317576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="xoma_ProceedsFromUpfrontPayment_638139034064317576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638139034064317576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="xoma_MilestonePeriodsNumber_638139034064317576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638139034064317576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638139034064317576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="us-gaap_DeferredIncomeCurrent_638139034064317576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638139034064317576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064317576" xlink:to="us-gaap_DeferredIncomeNoncurrent_638139034064317576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064327577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064327577" xlink:to="srt_CounterpartyNameAxis_638139034064327577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064327577" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_AgenusIncMember_638139034064327577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_BioasisTechnologiesIncMember_638139034064327577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_AronoraIncMember_638139034064327577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_PalobiofarmaSLMember_638139034064327577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_ViractaTherapeuticsInc.Member_638139034064327577" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064327577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064327577" xlink:to="xoma_AffitechResearchAsMember_638139034064327577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064327577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064327577" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064327577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064327577" xlink:to="xoma_RightsReceivableCurrent_638139034064337578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064327577" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064337578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" xlink:to="srt_CounterpartyNameAxis_638139034064337578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064337578" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064337578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064337578" xlink:to="xoma_AgenusIncMember_638139034064337578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064337578" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064337578" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064337578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064337578" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064337578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" xlink:to="srt_ProductOrServiceAxis_638139034064337578" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139034064337578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139034064337578" xlink:to="srt_ProductsAndServicesDomain_638139034064337578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064337578" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_638139034064347580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064337578" xlink:to="xoma_MerckImmunoOncologyProductMember_638139034064347580" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" xlink:to="dei_LegalEntityAxis_638139034064347580" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638139034064347580" xlink:to="dei_EntityDomain_638139034064347580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638139034064347580" xlink:to="xoma_AgenusIncMember_638139034064347580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064337578" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064347580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638139034064347580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_PurchasedPercentageOfMilestones_638139034064347580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638139034064347580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064347580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064347580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064357577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064357577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_MilestoneAchieved_638139034064357577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashReceivedForAchievementOfContractualMilestones" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_CashReceivedForAchievementOfContractualMilestones_638139034064357577" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064347580" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064357577" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" xlink:to="srt_CounterpartyNameAxis_638139034064357577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064357577" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064357577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638139034064357577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064357577" xlink:to="xoma_BioasisTechnologiesIncMember_638139034064357577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064367580" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064367580" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064367580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064367580" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064367580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064367580" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember_638139034064367580" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" xlink:to="srt_RangeAxis_638139034064367580" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064367580" xlink:to="srt_RangeMember_638139034064367580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064367580" xlink:to="srt_MaximumMember_638139034064367580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064357577" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_638139034064367580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_638139034064367580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_638139034064367580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_638139034064367580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_638139034064367580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064377577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_ContingentFutureCashPayments_638139034064377577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064377577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064377577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064377577" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_PaymentsOfContingentConsideration_638139034064377577" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064367580" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064377577" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="srt_CounterpartyNameAxis_638139034064387577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064387577" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064387577" xlink:to="xoma_AronoraIncMember_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064387577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064387577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064387577" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="srt_ProductOrServiceAxis_638139034064387577" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139034064387577" xlink:to="srt_ProductsAndServicesDomain_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064387577" xlink:to="xoma_BayerProductsMember_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064387577" xlink:to="xoma_NonBayerProductsMember_638139034064387577" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="us-gaap_DebtInstrumentAxis_638139034064387577" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638139034064387577" xlink:to="us-gaap_DebtInstrumentNameDomain_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139034064387577" xlink:to="xoma_SiliconValleyBankMember_638139034064387577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064387577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="srt_RangeAxis_638139034064387577" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064387577" xlink:to="srt_RangeMember_638139034064397578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064397578" xlink:to="srt_MaximumMember_638139034064397578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064377577" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_AgreementDrugCandidatesNumber_638139034064397578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638139034064397578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064397578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638139034064397578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638139034064397578" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_AgreementPaymentPercentageFactor_638139034064397578" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment_638139034064397578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_UpfrontPayment_638139034064397578" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_638139034064407579" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_ContingentFutureCashPayments_638139034064407579" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638139034064407579" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638139034064407579" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064407579" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064407579" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_PaymentsOfContingentConsideration_638139034064407579" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064407579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064407579" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064397578" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064417578" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064417578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064417578" xlink:to="srt_CounterpartyNameAxis_638139034064417578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064417578" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064417578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064417578" xlink:to="xoma_PalobiofarmaSLMember_638139034064417578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064417578" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064417578" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064417578" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064417578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064417578" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064417578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064417578" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" xlink:to="xoma_AgreementDrugCandidatesNumber_638139034064427575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064427575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064427575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064417578" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064427575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064427575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064427575" xlink:to="srt_CounterpartyNameAxis_638139034064427575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064427575" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064427575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064427575" xlink:to="xoma_ViractaTherapeuticsInc.Member_638139034064427575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064427575" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064427575" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064427575" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064427575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064427575" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064427575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064427575" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_AgreementDrugCandidatesNumber_638139034064437575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights" xlink:label="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights_638139034064437575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638139034064437575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_MaximumConsiderationRetained_638139034064437575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638139034064437575" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064437575" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064427575" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064437575" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064437575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064437575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064437575" xlink:to="srt_CounterpartyNameAxis_638139034064437575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064437575" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064447577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064447577" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064447577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064437575" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064447577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064447577" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064447577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064447577" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064447577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064437575" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638139034064447577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638139034064447577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_UpfrontPayment_638139034064447577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones_638139034064447577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064447577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_MilestonePaymentReceivedCounterparty_638139034064447577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage_638139034064447577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_MilestonePaymentReceivablePercentage_638139034064447577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_RightsReceivableCurrent_638139034064457575" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064457575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064447577" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064457575" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" xlink:to="srt_CounterpartyNameAxis_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064457575" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064457575" xlink:to="xoma_AffitechResearchAsMember_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064457575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064457575" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638139034064457575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064457575" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638139034064457575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" xlink:to="srt_ProductOrServiceAxis_638139034064467577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139034064467577" xlink:to="srt_ProductsAndServicesDomain_638139034064467577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139034064467577" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_638139034064467577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064457575" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_UpfrontPayment" xlink:label="xoma_UpfrontPayment_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_UpfrontPayment_638139034064467577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_638139034064467577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_CommercialPaymentReceivableTerm_638139034064467577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones_638139034064467577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064467577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone_638139034064467577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_MaximumPayableOnSalesMilestone_638139034064467577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064467577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064467577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MilestonePayment" xlink:label="xoma_MilestonePayment_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_MilestonePayment_638139034064477574" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashReceivedForAchievementOfContractualMilestones" xlink:label="xoma_CashReceivedForAchievementOfContractualMilestones_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_CashReceivedForAchievementOfContractualMilestones_638139034064477574" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064477574" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ImpairmentOfLongTermRoyaltyReceivable" xlink:label="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064467577" xlink:to="xoma_ImpairmentOfLongTermRoyaltyReceivable_638139034064477574" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064477574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064477574" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064477574" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064477574" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064477574" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064477574" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064477574" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064477574" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064477574" xlink:to="srt_CounterpartyNameAxis_638139034064477574" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064477574" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064487575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064487575" xlink:to="xoma_ViractaTherapeuticsInc.Member_638139034064487575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064487575" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638139034064487575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064487575" xlink:to="xoma_AffitechResearchAsMember_638139034064487575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638139034064477574" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_RightsReceivableCurrent_638139034064487575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_6381390340644875751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_RightsReceivableCurrent_6381390340644875751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638139034064487575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638139034064487575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638139034064487575" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_6381390340644875751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_LongTermRightsReceivableNonCurrent_6381390340644875751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification_638139034064487575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_ShortTermRightsReceivableReclassification_638139034064487575" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638139034064487575" xlink:to="xoma_LongTermRightsReceivableReclassification_638139034064497577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638139034064497577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638139034064497577" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638139034064497577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638139034064497577" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638139034064497577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638139034064497577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638139034064497577" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638139034064497577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638139034064497577" xlink:to="us-gaap_FairValueInputsLevel1Member_638139034064497577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638139034064497577" xlink:to="us-gaap_FairValueInputsLevel3Member_638139034064497577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638139034064497577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638139034064497577" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638139034064497577" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638139034064547579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638139034064547579" xlink:to="us-gaap_MoneyMarketFundsMember_638139034064547579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638139034064497577" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064547579" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064547579" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638139034064547579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638139034064547579" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638139034064547579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638139034064547579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638139034064547579" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638139034064547579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638139034064547579" xlink:to="xoma_FinancialAssetsFairValueDisclosure_638139034064557580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064547579" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638139034064557580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638139034064557580" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_638139034064557580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064557580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064557580" xlink:to="us-gaap_MeasurementInputTypeAxis_638139034064557580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638139034064557580" xlink:to="us-gaap_MeasurementInputTypeDomain_638139034064557580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638139034064557580" xlink:to="us-gaap_MeasurementInputSharePriceMember_638139034064557580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064557580" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638139034064557580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_638139034064557580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638139034064557580" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_638139034064557580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_5" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064567586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064567586" xlink:to="srt_CounterpartyNameAxis_638139034064567586" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064567586" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064567586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064567586" xlink:to="xoma_BioasisTechnologiesIncMember_638139034064567586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064567586" xlink:to="xoma_AffitechResearchAsMember_638139034064567586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064567586" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064567586" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064567586" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064567586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064567586" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064567586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064567586" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638139034064567586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638139034064567586" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064567586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064567586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064567586" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064567586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064567586" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064577595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PaymentsOfContingentConsideration" xlink:label="xoma_PaymentsOfContingentConsideration_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638139034064567586" xlink:to="xoma_PaymentsOfContingentConsideration_638139034064577595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638139034064577595" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139034064577595" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034064577595" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034064577595" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034064577595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034064577595" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638139034064577595" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139034064577595" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638139034064577595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139034064577595" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_638139034064577595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_638139034064577595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139034064577595" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease_638139034064577595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_638139034064587583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638139034064587583" xlink:to="us-gaap_OperatingLeaseCost_638139034064587583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638139034064587583" xlink:to="us-gaap_VariableLeaseCost_638139034064587583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638139034064587583" xlink:to="us-gaap_LeaseCost_638139034064587583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreements - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments_638139034064587583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638139034064587583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638139034064587583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes - Provision for Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139034064587583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638139034064587583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139034064587583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139034064587583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139034064597581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent_638139034064597581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent_638139034064597581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent" xlink:label="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent_638139034064597581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139034064597581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064597581" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638139034064597581" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638139034064597581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139034064597581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139034064597581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638139034064607580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638139034064607580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_638139034064607580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther_638139034064607580" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross_638139034064607580" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638139034064607580" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet_638139034064607580" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638139034064607580" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - NOL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638139034064607580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139034064607580" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638139034064607580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638139034064607580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638139034064607580" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638139034064607580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139034064607580" xlink:to="us-gaap_DomesticCountryMember_638139034064617580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139034064607580" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638139034064617580" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139034064607580" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638139034064617580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064617580" xlink:to="us-gaap_OperatingLossCarryforwards_638139034064617580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryForwardSubjectToExpiration" xlink:label="xoma_OperatingLossCarryForwardSubjectToExpiration_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064617580" xlink:to="xoma_OperatingLossCarryForwardSubjectToExpiration_638139034064617580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetOperatingLossCarryforwardsExpirationYear" xlink:label="xoma_NetOperatingLossCarryforwardsExpirationYear_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064617580" xlink:to="xoma_NetOperatingLossCarryforwardsExpirationYear_638139034064617580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails" xlink:type="extended" xlink:title="40805 - Disclosure - Income Taxes - Tax credit carryforward (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638139034064617580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139034064617580" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638139034064617580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638139034064617580" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638139034064617580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139034064617580" xlink:to="stpr_CA_638139034064617580" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638139034064617580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139034064617580" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638139034064617580" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638139034064617580" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638139034064627582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_FederalOrphanCreditMember" xlink:label="xoma_FederalOrphanCreditMember_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638139034064627582" xlink:to="xoma_FederalOrphanCreditMember_638139034064627582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638139034064627582" xlink:to="us-gaap_ResearchMember_638139034064627582" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139034064617580" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638139034064627582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064627582" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638139034064627582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TaxCreditCarryForwardExpirationYear" xlink:label="xoma_TaxCreditCarryForwardExpirationYear_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064627582" xlink:to="xoma_TaxCreditCarryForwardExpirationYear_638139034064627582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage" xlink:label="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139034064627582" xlink:to="xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage_638139034064627582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" xlink:title="40806 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_UnrecognizedTaxBenefits_638139034064627582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638139034064627582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_638139034064627582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6381390340646275821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_UnrecognizedTaxBenefits_6381390340646275821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638139034064637581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638139034064637581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_638139034064627582" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638139034064637581" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064637581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064637581" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064637581" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064637581" xlink:to="us-gaap_EquityComponentDomain_638139034064637581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064637581" xlink:to="us-gaap_CommonStockMember_638139034064637581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064637581" xlink:to="us-gaap_PlanNameAxis_638139034064637581" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638139034064637581" xlink:to="us-gaap_PlanNameDomain_638139034064637581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139034064637581" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638139034064637581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638139034064647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638139034064647583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_638139034064647583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638139034064647583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638139034064647583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638139034064647583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638139034064647583" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638139034064647583" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638139034064647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064637581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_638139034064647583" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638139034064657582" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139034064657582" xlink:to="srt_TitleOfIndividualAxis_638139034064657582" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064657582" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064657582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064657582" xlink:to="xoma_EmployeeMember_638139034064657582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeUnderAgeFiftyMember" xlink:label="xoma_EmployeeUnderAgeFiftyMember_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EmployeeMember_638139034064657582" xlink:to="xoma_EmployeeUnderAgeFiftyMember_638139034064657582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeAgeFiftyOrOverMember" xlink:label="xoma_EmployeeAgeFiftyOrOverMember_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_EmployeeMember_638139034064657582" xlink:to="xoma_EmployeeAgeFiftyOrOverMember_638139034064657582" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139034064657582" xlink:to="srt_RangeAxis_638139034064657582" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064657582" xlink:to="srt_RangeMember_638139034064657582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064657582" xlink:to="srt_MaximumMember_638139034064657582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139034064657582" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638139034064657582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_638139034064657582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum" xlink:label="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_638139034064657582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum_638139034064657582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638139034064667581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638139034064667581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage" xlink:label="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139034064657582" xlink:to="xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage_638139034064667581" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="us-gaap_PlanNameAxis_638139034064667581" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638139034064667581" xlink:to="us-gaap_PlanNameDomain_638139034064667581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139034064667581" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638139034064667581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064667581" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064667581" xlink:to="us-gaap_EquityComponentDomain_638139034064667581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064667581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064667581" xlink:to="us-gaap_CommonStockMember_638139034064667581" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="us-gaap_AwardTypeAxis_638139034064677582" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064677582" xlink:to="us-gaap_EmployeeStockOptionMember_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="srt_RangeAxis_638139034064677582" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064677582" xlink:to="srt_RangeMember_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064677582" xlink:to="srt_MinimumMember_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="srt_TitleOfIndividualAxis_638139034064677582" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064677582" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeTerminatedMember" xlink:label="xoma_EmployeeTerminatedMember_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064677582" xlink:to="xoma_EmployeeTerminatedMember_638139034064677582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064667581" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638139034064677582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638139034064677582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638139034064677582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_638139034064687588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638139034064687588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638139034064687588" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064677582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139034064687588" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064687588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064687588" xlink:to="us-gaap_AwardTypeAxis_638139034064687588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139034064687588" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064687588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139034064687588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064687588" xlink:to="us-gaap_EmployeeStockOptionMember_638139034064687588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064687588" xlink:to="srt_TitleOfIndividualAxis_638139034064697582" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064697582" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064697582" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064697582" xlink:to="xoma_EmployeeMember_638139034064697582" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064697582" xlink:to="srt_DirectorMember_638139034064697582" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064687588" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064697582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064697582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139034064697582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064697582" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638139034064697582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064697582" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638139034064697582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails" xlink:type="extended" xlink:title="40905 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064697582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139034064697582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064697582" xlink:to="us-gaap_AwardTypeAxis_638139034064697582" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139034064697582" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064707583" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064707583" xlink:to="us-gaap_EmployeeStockOptionMember_638139034064707583" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064697582" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139034064707583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034064707583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139034064707583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638139034064707583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381390340647075831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381390340647075831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638139034064707583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139034064707583" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139034064707583" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638139034064707583" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638139034064707583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638139034064707583" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139034064717586" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638139034064717586" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638139034064717586" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638139034064717586" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139034064717586" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638139034064717586" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638139034064717586" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139034064717586" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139034064717586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139034064717586" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064707583" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139034064727580" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails" xlink:type="extended" xlink:title="40906 - Disclosure - Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064727580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064727580" xlink:to="us-gaap_AwardTypeAxis_638139034064727580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064727580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034064727580" xlink:to="us-gaap_EmployeeStockOptionMember_638139034064727580" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064727580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139034064727580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139034064727580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139034064727580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638139034064737579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638139034064727580" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139034064737579" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638139034064727580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034064737579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40907 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064737579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064737579" xlink:to="us-gaap_IncomeStatementLocationAxis_638139034064737579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638139034064737579" xlink:to="us-gaap_IncomeStatementLocationDomain_638139034064737579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638139034064737579" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638139034064737579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064737579" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064737579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638139034064737579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064737579" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638139034064737579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails" xlink:type="extended" xlink:title="40908 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064747579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064747579" xlink:to="srt_TitleOfIndividualAxis_638139034064747579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064747579" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064747579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember" xlink:label="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064747579" xlink:to="xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_638139034064747579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064747579" xlink:to="srt_RangeAxis_638139034064747579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064747579" xlink:to="srt_RangeMember_638139034064747579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064747579" xlink:to="srt_MaximumMember_638139034064747579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638139034064747579" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentPeriodRetirementEligible" xlink:label="xoma_EmploymentPeriodRetirementEligible_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" xlink:to="xoma_EmploymentPeriodRetirementEligible_638139034064747579" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638139034064747579" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139034064747579" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139034064747579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638139034064747579" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139034064747579" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="40909 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064757583" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064757583" xlink:to="srt_TitleOfIndividualAxis_638139034064757583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064757583" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064757583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064757583" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638139034064757583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064757583" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638139034064757583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_638139034064757583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="xoma_PeriodOneRetentionBonusEligibility_638139034064757583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_638139034064757583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="xoma_RetentionBonusExpenseAccrued_638139034064757583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths" xlink:label="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_638139034064757583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064757583" xlink:to="xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths_638139034064757583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="40910 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_4" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064767584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064767584" xlink:to="srt_TitleOfIndividualAxis_638139034064767584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034064767584" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064767584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034064767584" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_638139034064767584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638139034064767584" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064767584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064767584" xlink:to="xoma_AccruedCompensationContinuityIncentive_638139034064767584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement_638139034064767584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638139034064767584" xlink:to="xoma_CompensationExpenseEmploymentAgreement_638139034064767584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638139034064777584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638139034064777584" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139034064777584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139034064777584" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638139034064777584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638139034064777584" xlink:to="us-gaap_PreferredStockMember_638139034064777584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638139034064777584" xlink:to="us-gaap_StockCompensationPlanMember_638139034064777584" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638139034064777584" xlink:to="us-gaap_WarrantMember_638139034064777584" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638139034064777584" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638139034064777584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638139034064777584" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638139034064777584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable_638139034064777584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034064777584" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064777584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064777584" xlink:to="us-gaap_ClassOfStockDomain_638139034064777584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034064777584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064777584" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034064777584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064777584" xlink:to="us-gaap_SeriesBPreferredStockMember_638139034064787586" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139034064777584" xlink:to="us-gaap_StatementLineItems_638139034064787586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract" xlink:label="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034064787586" xlink:to="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_NetIncomeLoss_638139034064787586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_638139034064787586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_638139034064787586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139034064787586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_638139034064787586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract_638139034064787586" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638139034064787586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139034064787586" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139034064787586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638139034064787586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638139034064787586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_638139034064787586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139034064797585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_EarningsPerShareBasic_638139034064797585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638139034064787586" xlink:to="us-gaap_EarningsPerShareDiluted_638139034064797585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Capital Stock - Series X Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064797585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064797585" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064797585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064797585" xlink:to="us-gaap_ClassOfStockDomain_638139034064797585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXAndSeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064797585" xlink:to="xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_638139034064797585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesXConvertiblePreferredStockMember" xlink:label="xoma_SeriesXConvertiblePreferredStockMember_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064797585" xlink:to="xoma_SeriesXConvertiblePreferredStockMember_638139034064797585" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SeriesYConvertiblePreferredStockMember" xlink:label="xoma_SeriesYConvertiblePreferredStockMember_638139034064797585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064797585" xlink:to="xoma_SeriesYConvertiblePreferredStockMember_638139034064797585" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064797585" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064807584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="us-gaap_PreferredStockSharesOutstanding_638139034064807584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139034064807584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="us-gaap_PreferredStockSharesIssued_638139034064807584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638139034064807584" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConversionPricePerShare" xlink:label="xoma_PreferredStockConversionPricePerShare_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064807584" xlink:to="xoma_PreferredStockConversionPricePerShare_638139034064807584" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Capital Stock - Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064807584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064807584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064807584" xlink:to="us-gaap_EquityComponentDomain_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064817584" xlink:to="us-gaap_CommonStockMember_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064817584" xlink:to="us-gaap_PreferredStockMember_638139034064817584" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" xlink:to="srt_StatementScenarioAxis_638139034064817584" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139034064817584" xlink:to="srt_ScenarioUnspecifiedDomain_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139034064817584" xlink:to="srt_ScenarioForecastMember_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064817584" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064817584" xlink:to="us-gaap_ClassOfStockDomain_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064817584" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034064817584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064807584" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064817584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638139034064817584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638139034064817584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_SharesIssuedPricePerShare_638139034064817584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034064827583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638139034064827583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOrSaleOfEquityNet" xlink:label="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_ProceedsFromIssuanceOrSaleOfEquityNet_638139034064827583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139034064827583" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockSharesIssued_638139034064827583" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockLiquidationPreference_638139034064827583" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_638139034064827583" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638139034064827583" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockDividendPeriodMonth_638139034064827583" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638139034064827583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638139034064827583" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_638139034064837584" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638139034064837584" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockShareCap_638139034064837584" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays" xlink:label="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064817584" xlink:to="xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays_638139034064837584" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064837584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064837584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064837584" xlink:to="us-gaap_ClassOfStockDomain_638139034064837584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064837584" xlink:to="us-gaap_SeriesBPreferredStockMember_638139034064847585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064837584" xlink:to="dei_AdrMember_638139034064847585" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638139034064847585" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638139034064847585" xlink:to="us-gaap_RelatedPartyDomain_638139034064847585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638139034064847585" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_638139034064847585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" xlink:to="srt_StatementScenarioAxis_638139034064847585" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139034064847585" xlink:to="srt_ScenarioUnspecifiedDomain_638139034064847585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139034064847585" xlink:to="srt_ScenarioForecastMember_638139034064847585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064837584" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064847585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_SharesIssuedPricePerShare_638139034064847585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638139034064847585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock_638139034064847585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_DepositarySharesRatioToPreferredStock_638139034064847585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139034064857585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockSharesIssued_638139034064857585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638139034064857585" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ProceedsFromIssuanceOfPreferredStockNet" xlink:label="xoma_ProceedsFromIssuanceOfPreferredStockNet_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_ProceedsFromIssuanceOfPreferredStockNet_638139034064857585" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638139034064857585" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockLiquidationPreference_638139034064857585" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendAmountPerShare" xlink:label="xoma_PreferredStockDividendAmountPerShare_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockDividendAmountPerShare_638139034064857585" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodYearProrated" xlink:label="xoma_PreferredStockDividendPeriodYearProrated_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockDividendPeriodYearProrated_638139034064857585" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodProratedMonthsInYear" xlink:label="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638139034064857585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockDividendPeriodProratedMonthsInYear_638139034064857585" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockDividendPeriodMonth" xlink:label="xoma_PreferredStockDividendPeriodMonth_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockDividendPeriodMonth_638139034064867587" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638139034064867587" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockRedemptionPricePerShareOptionalRedemption" xlink:label="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockRedemptionPricePerShareOptionalRedemption_638139034064867587" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_638139034064867587" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PreferredStockShareCap" xlink:label="xoma_PreferredStockShareCap_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064847585" xlink:to="xoma_PreferredStockShareCap_638139034064867587" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsPayableTable_638139034064867587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638139034064867587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638139034064867587" xlink:to="us-gaap_SubsequentEventTypeAxis_638139034064867587" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638139034064867587" xlink:to="us-gaap_SubsequentEventTypeDomain_638139034064877585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638139034064877585" xlink:to="us-gaap_SubsequentEventMember_638139034064877585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638139034064867587" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064877585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064877585" xlink:to="us-gaap_ClassOfStockDomain_638139034064877585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064877585" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034064877585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064877585" xlink:to="dei_AdrMember_638139034064877585" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638139034064867587" xlink:to="us-gaap_DividendsPayableLineItems_638139034064877585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638139034064877585" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638139034064877585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638139034064877585" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_638139034064877585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41105 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" xlink:to="dei_LegalEntityAxis_638139034064887585" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638139034064887585" xlink:to="dei_EntityDomain_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638139034064887585" xlink:to="xoma_BiotechnologyValueFundLPMember_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" xlink:to="srt_OwnershipAxis_638139034064887585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638139034064887585" xlink:to="srt_OwnershipDomain_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638139034064887585" xlink:to="xoma_XomaCorporationMember_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064887585" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064887585" xlink:to="us-gaap_EquityComponentDomain_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064887585" xlink:to="us-gaap_CommonStockMember_638139034064887585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064877585" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638139034064887585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064887585" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638139034064887585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638139034064887585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064887585" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638139034064887585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41106 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" xlink:to="us-gaap_StatementEquityComponentsAxis_638139034064897584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139034064897584" xlink:to="us-gaap_EquityComponentDomain_638139034064897584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638139034064897584" xlink:to="us-gaap_CommonStockMember_638139034064897584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638139034064897584" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638139034064897584" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638139034064897584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638139034064897584" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_638139034064897584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638139034064897584" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_638139034064897584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" xlink:to="srt_RangeAxis_638139034064897584" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139034064897584" xlink:to="srt_RangeMember_638139034064897584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139034064897584" xlink:to="srt_MaximumMember_638139034064897584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfCommonStockToBeIssued" xlink:label="xoma_MaximumValueOfCommonStockToBeIssued_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="xoma_MaximumValueOfCommonStockToBeIssued_638139034064907585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139034064907585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="xoma_MaximumValueOfStockToBeIssued_638139034064907585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_DepositarySharesRatioToPreferredStock" xlink:label="xoma_DepositarySharesRatioToPreferredStock_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="xoma_DepositarySharesRatioToPreferredStock_638139034064907585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638139034064907585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638139034064897584" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638139034064907585" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638139034064897584" xlink:to="us-gaap_StatementClassOfStockAxis_638139034064907585" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139034064907585" xlink:to="us-gaap_ClassOfStockDomain_638139034064907585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064907585" xlink:to="us-gaap_SeriesAPreferredStockMember_638139034064907585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064907585" xlink:to="us-gaap_SeriesBPreferredStockMember_638139034064907585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638139034064907585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139034064907585" xlink:to="dei_AdrMember_638139034064907585" order="3" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails" xlink:type="extended" xlink:title="41107 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638139034064917586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638139034064917586" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638139034064917586" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638139034064917586" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638139034064917586" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638139034064917586" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_638139034064917586" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638139034064917586" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_638139034064917586" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638139034064917586" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638139034064917586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064917586" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638139034064917586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638139034064917586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064917586" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638139034064917586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails" xlink:type="extended" xlink:title="41108 - Disclosure - Capital Stock - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638139034064927588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638139034064927588" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638139034064927588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638139034064927588" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638139034064927588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638139034064927588" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_638139034064927588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638139034064927588" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_638139034064927588" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638139034064927588" xlink:to="us-gaap_DebtInstrumentAxis_638139034064927588" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638139034064927588" xlink:to="us-gaap_DebtInstrumentNameDomain_638139034064927588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139034064927588" xlink:to="xoma_SiliconValleyBankMember_638139034064927588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638139034064927588" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638139034064927588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638139034064927588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ExercisablePeriodOfWarrants" xlink:label="xoma_ExercisablePeriodOfWarrants_638139034064927588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" xlink:to="xoma_ExercisablePeriodOfWarrants_638139034064927588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_638139034064937586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638139034064927588" xlink:to="xoma_StockIssuedDuringPeriodSharesWarrantsExercised_638139034064937586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_638139034064937586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638139034064937586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_CommitmentsAndContingenciesTable_638139034064937586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638139034064937586" xlink:to="us-gaap_TypeOfArrangementAxis_638139034064937586" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064937586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638139034064937586" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064937586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064937586" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638139034064947586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638139034064937586" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638139034064947586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638139034064937586" xlink:to="srt_CounterpartyNameAxis_638139034064947586" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638139034064947586" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064947586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064947586" xlink:to="xoma_BioasisTechnologiesIncMember_638139034064947586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638139034064947586" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_638139034064947586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638139034064937586" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638139034064947586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638139034064947586" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638139034064947586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember" xlink:label="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638139034064947586" xlink:to="xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_638139034064947586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638139034064937586" xlink:to="xoma_CommitmentsAndContingenciesLineItems_638139034064947586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638139034064947586" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638139034064947586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064947586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638139034064947586" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638139034064947586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_638139034064957587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638139034064957587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638139034064957587" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638139034064957587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638139034064957587" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638139034064957587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638139034064957587" xlink:to="us-gaap_CustomerConcentrationRiskMember_638139034064957587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638139034064957587" xlink:to="us-gaap_CreditConcentrationRiskMember_638139034064957587" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638139034064957587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638139034064957587" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638139034064957587" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638139034064957587" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638139034064967585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638139034064967585" xlink:to="us-gaap_SalesRevenueNetMember_638139034064967585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638139034064967585" xlink:to="us-gaap_AccountsReceivableMember_638139034064967585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638139034064957587" xlink:to="srt_MajorCustomersAxis_638139034064967585" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638139034064967585" xlink:to="srt_NameOfMajorCustomerDomain_638139034064967585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139034064967585" xlink:to="xoma_Partner1Member_638139034064967585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139034064967585" xlink:to="xoma_Partner2Member_638139034064967585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139034064967585" xlink:to="xoma_Partner3Member_638139034064967585" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139034064967585" xlink:to="xoma_Partner4Member_638139034064967585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638139034064957587" xlink:to="us-gaap_ConcentrationRiskLineItems_638139034064967585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638139034064967585" xlink:to="xoma_NumberOfMajorPartners_638139034064967585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638139034064967585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638139034064967585" xlink:to="us-gaap_ConcentrationRiskPercentage1_638139034064967585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638139034064977587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638139034064967585" xlink:to="us-gaap_AccountsReceivableNetCurrent_638139034064977587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638139034064977587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638139034064977587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:label="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfRiskSegmentAndGeographicInformationAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638139034065027588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638139034065027588" xlink:to="srt_StatementGeographicalAxis_638139034065027588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638139034065027588" xlink:to="srt_SegmentGeographicalDomain_638139034065027588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139034065027588" xlink:to="country_US_638139034065027588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember" xlink:label="srt_AsiaPacificMember_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139034065027588" xlink:to="srt_AsiaPacificMember_638139034065027588" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139034065027588" xlink:to="srt_EuropeMember_638139034065027588" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_638139034065027588" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638139034065027588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638139034065027588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_638139034065027588" xlink:to="us-gaap_Revenues_638139034065027588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_638139034065037587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_SubsequentEventTypeAxis_638139034065037587" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638139034065037587" xlink:to="us-gaap_SubsequentEventTypeDomain_638139034065037587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638139034065037587" xlink:to="us-gaap_SubsequentEventMember_638139034065037587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034065037587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139034065037587" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034065037587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139034065037587" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638139034065037587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="srt_TitleOfIndividualAxis_638139034065037587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139034065037587" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034065037587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_638139034065037587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034065037587" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_638139034065037587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139034065037587" xlink:to="xoma_ChiefInvestmentOfficerMember_638139034065047660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_AwardTypeAxis_638139034065047660" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139034065047660" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139034065047660" xlink:to="us-gaap_EmployeeStockOptionMember_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139034065047660" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139034065047660" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice18.66Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139034065047660" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementExercisePrice30.00Member" xlink:label="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139034065047660" xlink:to="xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_638139034065047660" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_VestingAxis_638139034065047660" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638139034065047660" xlink:to="us-gaap_VestingDomain_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638139034065047660" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139034065047660" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638139034065047660" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139034065047660" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638139034065057589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638139034065037587" xlink:to="us-gaap_SubsequentEventLineItems_638139034065057589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm" xlink:label="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm_638139034065057589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementAnnualSalary" xlink:label="xoma_EmploymentAgreementAnnualSalary_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_EmploymentAgreementAnnualSalary_638139034065057589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonus" xlink:label="xoma_EmploymentAgreementSigningBonus_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_EmploymentAgreementSigningBonus_638139034065057589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusPaymentPeriod" xlink:label="xoma_EmploymentAgreementSigningBonusPaymentPeriod_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_EmploymentAgreementSigningBonusPaymentPeriod_638139034065057589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment" xlink:label="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment_638139034065057589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination" xlink:label="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination_638139034065057589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_AnnualDiscretionaryCashBonusTargetPercentage" xlink:label="xoma_AnnualDiscretionaryCashBonusTargetPercentage_638139034065057589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_AnnualDiscretionaryCashBonusTargetPercentage_638139034065057589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638139034065067588" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139034065067588" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139034065067588" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638139034065067588" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139034065067588" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638139034065067588" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20221231.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638139034065067588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638139034065057589" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638139034065067588" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911321088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 06, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XOMA CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2154066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">2200 Powell Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line2</a></td>
<td class="text">Suite 310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">204-7200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,564,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,460,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DELOITTE & TOUCHE LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000791908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0075 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912693776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="nump">$ 93,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Short-term equity securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">61,253<span></span>
</td>
<td class="nump">96,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">69,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">15,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets - long term</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">140,382<span></span>
</td>
<td class="nump">166,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">8,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedPreferredStockDividendCurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,818<span></span>
</td>
<td class="nump">12,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method - long-term</a></td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">11,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,368<span></span>
</td>
<td class="nump">24,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,454,025 and 11,315,263 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,306,271<span></span>
</td>
<td class="nump">1,307,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,182,392)<span></span>
</td>
<td class="num">(1,165,288)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">124,014<span></span>
</td>
<td class="nump">141,876<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">140,382<span></span>
</td>
<td class="nump">166,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedPreferredStockDividendCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedPreferredStockDividendCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914294448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0075<span></span>
</td>
<td class="nump">$ 0.0075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">277,333,332<span></span>
</td>
<td class="nump">277,333,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,454,025<span></span>
</td>
<td class="nump">11,315,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,454,025<span></span>
</td>
<td class="nump">11,315,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912046704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">6,027<span></span>
</td>
<td class="nump">38,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,191<span></span>
</td>
<td class="nump">20,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,441<span></span>
</td>
<td class="nump">20,631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operations</a></td>
<td class="num">(17,414)<span></span>
</td>
<td class="nump">17,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax</a></td>
<td class="num">(17,119)<span></span>
</td>
<td class="nump">15,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">15<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(17,104)<span></span>
</td>
<td class="nump">15,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">(17,104)<span></span>
</td>
<td class="nump">15,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income (attributable to) available to common stockholders, basic</a></td>
<td class="num">(22,576)<span></span>
</td>
<td class="nump">7,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income (attributable to) available to to common stockholders, diluted</a></td>
<td class="num">$ (22,576)<span></span>
</td>
<td class="nump">$ 7,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">11,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">12,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911547024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>8.625% Series A Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>8.375% Series B Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 1,267,377<span></span>
</td>
<td class="num">$ (1,181,086)<span></span>
</td>
<td class="nump">$ 86,424<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan', window );">Issuance of common stock related to 401(k) contribution and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans', window );">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,798<span></span>
</td>
<td class="nump">15,798<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">1,307,030<span></span>
</td>
<td class="num">(1,165,288)<span></span>
</td>
<td class="nump">141,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan', window );">Issuance of common stock related to 401(k) contribution and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans', window );">Issuance of common stock related to 401(k) contribution and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
<td class="num">(17,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,306,271<span></span>
</td>
<td class="num">$ (1,182,392)<span></span>
</td>
<td class="nump">$ 124,014<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911352528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (17,104)<span></span>
</td>
<td class="nump">$ 15,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,608<span></span>
</td>
<td class="nump">6,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims', window );">Common stock contribution to 401(k)</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs, debt discount and final payment on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReductionOfContingentRefundLiability', window );">Reduction of contingent NIH refund liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasePaymentsNonCash', window );">Non-cash lease expense</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables, net</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,845<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(91)<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="num">(1,877)<span></span>
</td>
<td class="num">(1,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_IncreaseDecreaseInRefundLiability', window );">Contingent NIH refund liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(12,879)<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payments of consideration under RPAs and CPPAs</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(26,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Receipts under RPAs and CPPAs</a></td>
<td class="nump">3,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payment for IP acquired under the ObsEva IP Acquisition Agreement</a></td>
<td class="num">(15,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(20,221)<span></span>
</td>
<td class="num">(26,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of preferred stock dividends</a></td>
<td class="num">(5,472)<span></span>
</td>
<td class="num">(3,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of preferred and common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of options and other share-based compensation</a></td>
<td class="nump">2,419<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt', window );">Principal payments - debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt', window );">Payment for extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtRestructuringCosts', window );">Payment for debt modification fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(4,451)<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(37,551)<span></span>
</td>
<td class="nump">9,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at the beginning of the period</a></td>
<td class="nump">95,377<span></span>
</td>
<td class="nump">86,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">57,826<span></span>
</td>
<td class="nump">95,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements', window );">Estimated fair value of contingent consideration under the Affitech CPPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">$ 1,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedTransactionCostsRelatedToPurchaseAgreements', window );">Accrued transaction costs in connection with ObsEva IP Acquisition</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedTransactionCostsRelatedToPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued transaction costs in connection with acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedTransactionCostsRelatedToPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan issuance of Common stock for services or claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_IncreaseDecreaseInRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in contingent refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_IncreaseDecreaseInRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasePaymentsNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments, non cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasePaymentsNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receipts related to purchase of royalty rights and other commercial payment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReductionOfContingentRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in contingent refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReductionOfContingentRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, excluding extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, considered extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911317936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Description of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with outlicensing its proprietary products and platforms from its legacy discovery and development business. The Company&#8217;s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2022, the Company had cash and cash equivalents of $57.8 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690997239888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with GAAP in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2022, the Company had cash equivalent balances of $30.3 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company&#8217;s Series A and Series B Preferred Stock. As of December 31, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive (loss) income in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. Other contingent consideration payments are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net (Loss) Income per Share (Attributable to) Available to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted (loss) income per share (attributable to) available to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net (loss) income per share attributable to common stockholders is then calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company plans to adopt ASU 2016-13 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company plans to adopt ASU 2021-08 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914436656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Consolidated Financial Statements Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Consolidated Financial Statements Detail</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Consolidated Financial Statement Detail</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, equity securities consisted of an investment in Rezolute&#8217;s common stock of $0.3 million and $0.8 million, respectively (Note 4). For the years ended December 31, 2022 and 2021, the Company recognized a loss of $0.4 million and $0.9 million, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Intangible assets, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:18pt;"/><span style="display:inline-block;width:18pt;"/>The remaining life of the intangible assets is 16.9 years. The following table presents the projected amortization expense for the next five years (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,485</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accrued and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued payroll and benefits  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140691003083296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsAbstract', window );"><strong>Licensing and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsTextBlock', window );">Licensing and Other Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. &#160;If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA. &#160;The Company paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company will receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#8217;s cost to acquire said intangible asset of $15.2 million, consisting of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented 17 years. The Company recognized $0.1 million of amortization expense in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. No revenue was recognized related to this arrangement for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. The Company recognized $35.0 million as revenue from contracts with </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGF&#946; Antibody License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized related to this arrangement for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#8364;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#8217;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company earned a development milestone pursuant to the Takeda Collaboration Agreement and recognized $0.8 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income. The Company recognized annual license fee revenue of $0.1 million from Takeda in the consolidated statement of operations and comprehensive (loss) income for the each of the years ended December 31, 2022 and 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute&#8217;s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#8217;s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden_osQASCJOc0aG36cPBan18A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1:50</span></span> reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $2.0 million and no revenue as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and December 31, 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company and Janssen were parties to a license agreement which was terminated in 2017.</span> In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized no revenue and $0.7 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the commercial milestone payments are solely dependent on Affimed&#8217;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized related to this arrangement for the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized the under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $1.9 million and $1.6 million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2022 and 2021, respectively. As of December&#160;31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140691003083296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyPurchaseAgreementTextBlock', window );">Royalty and Commercial Payment Purchase Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The balance of short-term royalty and commercial payment receivables was $2.4 million as of December 31, 2022. There was no balance of short-term royalty and commercial payment receivables as of December 31, 2021. The balance of long-term royalty and commercial payment receivables was $63.7 million and $69.1 million as of December 31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen digit percentage of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessments and no impairment indicators have been identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income. As of December 31, 2022, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2022. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#8217;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. &#160;Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b>As of December 31, 2022, no payments are probable to be received under the Kuros RPA in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Affitech Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, in connection with Roche receiving approval from the European Commission to commercialize VABYSMO for the treatment of neovascular or &#8216;wet&#8217; age-related macular degeneration and visual impairment due to diabetic macular edema, the Company made a $3.0 million milestone payment to Affitech pursuant to the terms of the Affitech CPPA. As a result of the EC Approval, XOMA is eligible to receive a 0.5% commercial payment stream for ten years from the first commercial sale of VABYSMO in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $0.5 million received was recorded as a direct reduction of the long-term royalty receivable balance. In February 2023, the Company received $2.4 million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was reclassified from long-term to short-term royalty and commercial payment receivables in the Company&#8217;s consolidated balance sheet as of December 31, 2022. Based upon limited available information, the Company is unable to reasonably estimate future net sales and the commercial payments to be received during the year ended December 31, 2023 and, as such, no additional amounts are reflected as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. &#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty receivable activities during the years ended December 31, 2022 and 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,575</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,500</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,000</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,000</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690997610784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2021 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,075</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2022 and 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. As of December 31, 2022 and 2021, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $2.07 and $4.78, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contingent Consideration </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represented the future consideration that was contingent upon the achievement of specified regulatory milestones. The fair value measurement was based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones. During the year ended December 31, 2022, the estimated fair value of the contingent consideration recorded pursuant to the Affitech CPPA decreased from $8.0 million to zero after the Company paid Affitech a total of $5.0 million for milestones tied to the achievement of U.S. marketing approvals in January 2022 and $3.0 million for milestones tied to the achievement of EC Approvals in September 2022 (Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income until settlement. As </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of December 31, 2022, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA from the initial value of $0.1 million. &#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916042384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LeaseDisclosureTextBlock', window );">Lease Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Lease Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. As of December 31, 2022, the total net lease liability from January 2023 until expiration of the lease was $34,000. &#160;In January 2023, the Company amended the lease to extend the lease period through July 2023 (Note 14). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the years ended December 31, 2022 and 2021, respectively (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s operating lease as of December 31, 2022 and 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914661696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has pre-tax book loss of $17.1 million and pre-tax book income of $15.9 million for the years ended December 31, 2022 and 2021, respectively. &#160;The Company had a $15,000 income tax benefit and $0.1 million income tax expense for the&#160;years ended December&#160;31, 2022 and 2021, respectively. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#8217;s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to net operating loss carryforward utilization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,822</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,657</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,125</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,778</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,817</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 807</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,006</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,006)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SoJMkvQEd0GCqEyppA4jKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-opkpTvh2U-sJds8V7C3Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The net increase (decrease) in the valuation allowance was $3.3 million and $(4.6) million, for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#8217;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2022 and 2021.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had federal NOL carry-forwards of approximately $108.8 million and state NOL carry-forwards of approximately $20.9 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. &#160;The change in this US tax law did not have an impact on the Company's consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;Inflation Act&#8221;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#8217;s consolidated financial statements and related notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#8217;s federal income tax returns for tax&#160;years 2019 and beyond remain subject to examination by the Internal Revenue Service. The Company&#8217;s state income tax returns for tax&#160;years 2018 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2022, the Company has not accrued interest or penalties related to uncertain tax positions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914696976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Based Compensation and Other Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stock Based Compensation and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May&#160;2015, the Company&#8217;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#8220;2015 ESPP&#8221;), which replaced the Company&#8217;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2017, the Compensation Committee and the Board of Directors adopted, and in May&#160;2017, the Company&#8217;s stockholders approved, an amendment to the Company&#8217;s 2015 ESPP. The amendment (a)&#160;increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2022, the Company had 230,937 remaining authorized shares available for purchase under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2022 and 2021, employees purchased 6,090 and 2,225 shares of common stock, respectively, under the 2015 ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Savings Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under section 401(k)&#160;of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June&#160;1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50% of their eligible compensation per payroll period, up to a maximum for 2022 and 2021 of $20,500 and $19,500, respectively (or $27,000 and $26,000, respectively, for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#8217;s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the&#160;years ended December 31, 2022 and 2021, and 100% was paid in common stock for each&#160;year. The Company applies shares from plan forfeitures of terminated employees toward the Company&#8217;s matching contribution. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company&#8217;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three months from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had 192,964 shares available for grant under the 2010 Plan. As of December&#160;31, 2022, options to purchase 2,025,542 shares of common stock were outstanding under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options generally vest&#160;monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans Summary </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,103</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 292,972</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.40</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,811)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.22</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,796)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64.30</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,718,864</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.67</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.56</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,764</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised in 2022 and 2021 was $2.8 million and $1.6 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted in 2022 and 2021 was $12.01 and $22.23, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, $4.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 1.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021, was estimated based on the following weighted average assumptions for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"> Thomas Burns Equity Awards Modification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remains employed by the Company for a twelve-month period beginning on November 1, 2022, he will be deemed &#8220;retirement eligible&#8221; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. Conditioned on his execution of a release in favor of the Company, Mr. Burns will also receive this benefit upon any involuntary termination for reasons other than cause. The unrecognized stock compensation cost for the unvested stock options as of November 1, 2022 will be recognized over the shorter of (1) twelve months and (2) the remaining original vesting period (the &#8220;Revised Vesting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Term&#8221;). During the year ended December 31, 2022, the Company recognized stock-based compensation expense of $0.6 million related to the Mr. Burns&#8217; option awards. As of December 31, 2022, there was $0.5 million total unrecognized compensation expense related to Mr. Burns&#8217; stock options expected to be recognized through the earlier of the vesting date of the option or October 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 25, 2022, the Company approved the Amended Retention Plan which provides that each of its current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company will accrue and recognize the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. Pursuant to Amended Retention Plan, as of December 31, 2022, the Company expects to pay $0.8 million in 2023 related to the cash retention bonuses. The Company accrued $0.1 million for cash retention bonuses in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2022, the Company&#8217;s board of directors (&#8220;the Board&#8221;) appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer (&#8220;CEO&#8221;) effective January 1, 2023 and, in connection with Mr. Hughes&#8217; appointment, James R. Neal retired as the Company&#8217;s CEO effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of $1.2 million (the &#8220;Continuity Incentive&#8221;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full $1.2 million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916223728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share (attributable to) available to common stockholders if their inclusion is anti-dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,798</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,438)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,451)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,787</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,968</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,288</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,192</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914670080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series X and Series Y Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were 5,003 shares authorized and issued of Series X convertible preferred stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series&#160;X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212; </i>Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212; </i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion&#8212; </i>Each share of Series&#160;X and Series Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212; </i>Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212; </i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#8217;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Series A Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were 984,000 shares authorized and issued of Series A Preferred Stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends&#8212;&#160;</i>Holders of <span style="background:#ffffff;">the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of </span><span style="background:#ffffff;">8.625%</span><span style="background:#ffffff;"> per annum of the </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the </span>Series<span style="background:#ffffff;"> A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a&#160;</span><span style="background:#ffffff;">360</span><span style="background:#ffffff;">-day&#160;year consisting of </span><span style="background:#ffffff;">twelve</span><span style="background:#ffffff;">&#160;</span><span style="background:#ffffff;">30</span><span style="background:#ffffff;">-day&#160;months.&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Rights&#8212;&#160;</i>In the event of the Company&#8217;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will <span style="background:#ffffff;">rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the </span>distribution<span style="background:#ffffff;"> of assets with the Company&#8217;s Series X Preferred Stock. </span>The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption&#8212;&#160;</i>The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, <span style="background:#ffffff;">upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of </span><span style="background:#ffffff;">$25.00</span><span style="background:#ffffff;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Conversion&#8212;&#160;</i>The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) 1.46071 (the &#8220;Share Cap&#8221;). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#8217;s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights&#8212;&#160;</i>Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification&#8212;</i>The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Depositary Shares Representing Interest in Series B Preferred Stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Each Series B Depositary Share represents <span style="-sec-ix-hidden:Hidden_bylnvwbfT0qC2wS2bhBX0Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/1000</span></span> interest in a share of Series B Preferred Stock. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The spouse of James Neal, then CEO and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dividends</i>&#8212; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals $2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Liquidation Preference</i> - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">Redemption and Special Optional Redemption</i> - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion </i>- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#8220;Conversion Rate&#8221;); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the &#8220;Share Cap&#8221;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Voting Rights</i>&#8212; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Classification</i>&#8212;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2022, the Company&#8217;s Board of Directors declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 20, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cbQH9ljBJEebaeTjfrtxMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ns1YY3UqQkOJK6UyTHN1bg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 18, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KkEuaC7pjUygw9Z4wgEdgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z4eBHZawv0inBmuQccPnkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 18, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AffMX3HfskqqtMAs2dYFqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rVEGkExq70yCFYYZq4K5yQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 20, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LQOgbcYcy0O5Ut6RtuujLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Kelm5qnj-EOoeAXowZDZbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 17, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xxzwN1Kink2tMJX3CRXlnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NoKAl2q6DEWcRsp0Y0mt6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, BVF owned approximately 31.5% of the Company&#8217;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2022, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December&#160;31, 2022 and 2021, the following common stock warrants were outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders&#8217; equity on the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.<span style="letter-spacing:-0.1pt;">&#160;As of December 31, 2022, both warrants are outstanding and </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.1pt;"> shares have been </span><span style="-sec-ix-hidden:Hidden_FXGxJuaD7Eqmui9GgIgKuw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">issued</span></span><span style="letter-spacing:-0.1pt;"> upon exercise of the warrants.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914759776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contingent Consideration </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, and ObsEva the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, and the Merck KGaA royalties. The Company recorded $0.1 million for the Bioasis Contingent Consideration which, represents the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2022, there has been no change in the estimated fair value of the Bioasis Contingent Consideration from the initial value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is recognized. As of December 31, 2022, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Arbitration Proceeding</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated an arbitration proceeding against one of its licensees (the &#8220;Licensee&#8221;) with the American Arbitration Association/International Centre for Dispute Resolution. &#160;XOMA seeks damages, plus interest, and fees and costs of the arbitration (which fees and costs are currently estimated to be in the mid-single-digit millions of U.S. dollars range). &#160;In response, the Licensee seeks declarations that the License Agreement, under XOMA&#8217;s interpretation, is unlawful, void and unenforceable, and that the License Agreement has expired. &#160;To date, the Licensee has not filed any counterclaims against XOMA. However, to the extent the Licensee is deemed to be the prevailing party, the arbitrators, in their discretion, may require XOMA to pay the Licensee&#8217;s fees and costs of the arbitration (currently estimated to be in the mid-single-digit millions of U.S. dollars range). A hearing before a panel of arbitrators was held on this matter in November 2022, and the parties have submitted post-hearing briefs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914580208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Concentration of Risk, Segment and Geographic Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Concentration of Risk, Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2022, four partners represented&#160;33%, 31%, 13% and 12% of total revenues. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, one partner represented&#160;92% of total revenues. As of December 31, 2022, there is no trade receivables balance. As of December 31, 2021, one partner represented 100% of the trade receivables balance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,610</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,160</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s property and equipment is held in the United States.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911242976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Emeryville Lease Extension</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 13, 2023, the Company entered into an amendment to extend the lease term of its corporate headquarters in Emeryville, California from its original expiration of February 2023 through July 2023. The total remaining undiscounted lease payments due in 2023 under the extended lease term is $0.1 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Appointment of Owen Hughes as Executive Chairman of the Board of Directors and Interim CEO</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer), effective as of January&#160;1, 2023. Pursuant to Mr. Hughes&#8217; employment agreement, Mr. Hughes will receive an annual base salary of </span><span style="background:#ffffff;">$125,000</span><span style="background:#ffffff;"> and be eligible to receive an annual discretionary cash bonus, with a target amount equal to </span><span style="background:#ffffff;">55%</span><span style="background:#ffffff;"> of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of his employment agreement, on January 3, 2023, the Company granted Mr. Hughes </span><span style="background:#ffffff;">two</span><span style="background:#ffffff;"> separate non-qualified stock options to purchase: (i) </span><span style="background:#ffffff;">100,000</span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$18.66</span><span style="background:#ffffff;"> per share (the &#8220;First Hughes Inducement Award&#8221;) and (ii) </span><span style="background:#ffffff;">75,000</span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$30.00</span><span style="background:#ffffff;"> per share (the &#8220;Second Hughes Inducement Award&#8221; and together with the First Hughes Inducement Award, the &#8220;Hughes Inducement Awards&#8221;). The First Hughes Inducement Award will vest in a series of </span><span style="background:#ffffff;">four</span><span style="background:#ffffff;"> equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. The Second Hughes Inducement Award will vest in a series of </span><span style="background:#ffffff;">36</span><span style="background:#ffffff;"> successive equal monthly installments measured from January 1, 2023. The Hughes Inducement Awards are subject to the terms and conditions of the 2010 Plan but were granted outside the 2010 Plan as an inducement material to Mr. Hughes entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Appointment of Bradley Sitko as Chief Investment Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On December&#160;30, 2022, the Board appointed Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;3, 2023. Pursuant to Mr. Sitko&#8217;s employment agreement with the Company, he will receive an annual base </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">salary of </span><span style="background:#ffffff;">$500,000</span><span style="background:#ffffff;"> and a signing bonus of </span><span style="background:#ffffff;">$110,000</span><span style="background:#ffffff;">. Mr. Sitko&#8217;s signing bonus will be paid within </span><span style="background:#ffffff;">30 days</span><span style="background:#ffffff;"> after the effective date of his employment agreement and will be subject to standard deductions and withholdings. If Mr. Sitko resigns without good reason or is terminated for cause (each as defined in his employment agreement), in either case, within </span><span style="background:#ffffff;">one year</span><span style="background:#ffffff;"> after the effective date of his employment agreement, then Mr. Sitko will be required to repay the signing bonus, based on the gross amount, but prorated on a daily basis for the time employed, to be paid within </span><span style="background:#ffffff;">60 days</span><span style="background:#ffffff;"> after his termination date. Mr. Sitko will also be eligible to receive an annual discretionary cash bonus, with a target amount equal to </span><span style="background:#ffffff;">50%</span><span style="background:#ffffff;"> of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Pursuant to the terms of his employment agreement, on January 3, 2023 the Company granted Mr. Sitko </span><span style="background:#ffffff;">two</span><span style="background:#ffffff;"> separate non-qualified stock options to purchase: (i) </span><span style="background:#ffffff;">300,000</span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$18.66</span><span style="background:#ffffff;"> per share (the &#8220;First Sitko Inducement Award&#8221;) and (ii) </span><span style="background:#ffffff;">250,000</span><span style="background:#ffffff;"> shares of the Company&#8217;s common stock at an exercise price of </span><span style="background:#ffffff;">$30.00</span><span style="background:#ffffff;"> per share (together with the First Sitko Inducement Award, the &#8220;Sitko Inducement Awards&#8221;). </span><span style="background:#ffffff;">Twenty-five</span><span style="background:#ffffff;"> percent of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable on </span><span style="-sec-ix-hidden:Hidden_292B7Rrmb0OIBzdjG3jt5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">January 3, 2024</span></span><span style="background:#ffffff;"> (the &#8220;Initial Vesting Date&#8221;), and the balance of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable in a series of </span><span style="background:#ffffff;">36</span><span style="background:#ffffff;"> successive equal monthly installments thereafter on the same day of the month as the Initial Vesting Date. The Sitko Inducement Awards are subject to the terms and conditions of the 2010 Plan, but were granted outside the 2010 Plan as an inducement material to Mr. Sitko entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911395584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with GAAP in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2022, the Company had cash equivalent balances of $30.3 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company&#8217;s Series A and Series B Preferred Stock. As of December 31, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock', window );">Sale of Future Revenue Streams</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EquitySecuritiesPolicy', window );">Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive (loss) income in the period of sale.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock', window );">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. Other contingent consideration payments are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s consolidated statement of cash flows. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the consolidated statement of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive (loss) income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (Loss) Income per Share (Attributable to) Available to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Net (Loss) Income per Share (Attributable to) Available to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted (loss) income per share (attributable to) available to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net (loss) income per share attributable to common stockholders is then calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (Loss) Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Comprehensive (Loss) Income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;">Recent Accounting Pronouncements Not Yet Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company plans to adopt ASU 2016-13 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company plans to adopt ASU 2021-08 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AssetAcquisitionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policy for future milestones, royalties purchase rights and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sale of future revenue streams.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914636368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of cash and cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93,328</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,049</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,377</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690917073024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Consolidated Financial Statements Detail</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of cost, accumulated amortization, and net carrying value of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of projected amortization expense for next five years</a></td>
<td class="text">The following table presents the projected amortization expense for the next five years (in thousands): <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,485</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Accrued payroll and benefits  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 135</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 295</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 525</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,798</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,438)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,451)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,787</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,968</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,288</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,192</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding securities considered anti-dilutive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914631888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock', window );">Summary of royalty receivable activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty receivable activities during the years ended December 31, 2022 and 2021 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,575</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment rights:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Viracta</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,500</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,000</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,000</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,075</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Kuros</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,500)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td></tr><tr><td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in royalty and commercial payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914529088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2021 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,075</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Estimated Fair Value of Level 3 Financial Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916963312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of cost components of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the years ended December 31, 2022 and 2021, respectively (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 185</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock', window );">Summary of supplemental cash flow information related to operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 196</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock', window );">Schedule of present value assumptions used in calculating the present value of lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914291360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes (All Current)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#8217;s actual effective income tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock compensation and other permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal orphan drug credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax benefit related to net operating loss carryforward utilization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The significant components of net deferred tax assets at December&#160;31, 2022 and 2021 were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,732</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,822</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,974</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,657</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development and other tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,125</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,778</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unearned revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,817</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,324</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 807</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,006</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (47,006)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SoJMkvQEd0GCqEyppA4jKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-opkpTvh2U-sJds8V7C3Yw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s activity related to its unrecognized tax benefits (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to current year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Increase related to prior year tax position</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,938</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914479968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Based Compensation and Other Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average Assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021, was estimated based on the following weighted average assumptions for:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.64 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.66 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity for the&#160;year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,911,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,103</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 292,972</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.40</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (128,811)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.22</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,796)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64.30</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,718,864</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.67</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.56</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,764</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based Compensation Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive (loss) income (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,195</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914590528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding securities considered anti-dilutive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 479</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,798</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,122)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,438)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Allocation of undistributed earnings to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,451)</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,787</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Add: Adjustments to undistributed earnings allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 181</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net (loss) income (attributable to) available to common stockholders, diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22,576)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,968</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,288</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 900</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of dilutive warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,192</p></td></tr><tr><td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net (loss) income per share (attributable to) available to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.98)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.65</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916002928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of declared and paid cash dividends</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 20, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_cbQH9ljBJEebaeTjfrtxMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ns1YY3UqQkOJK6UyTHN1bg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 18, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">March 17, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_KkEuaC7pjUygw9Z4wgEdgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Z4eBHZawv0inBmuQccPnkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">April 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">May 18, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AffMX3HfskqqtMAs2dYFqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rVEGkExq70yCFYYZq4K5yQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 15, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">July 20, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_LQOgbcYcy0O5Ut6RtuujLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Kelm5qnj-EOoeAXowZDZbA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 17, 2022</p></td></tr><tr><td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_xxzwN1Kink2tMJX3CRXlnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NoKAl2q6DEWcRsp0Y0mt6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">January 17, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Common Stock Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914613520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Revenue by Geographical Region</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,477</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,610</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Asia Pacific</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 550</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Europe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,160</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912028912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="nump">$ 93,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear', window );">Substantial Doubt about Going Concern, within One Year</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=116846462&amp;loc=SL51888449-203568<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912654608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 30,300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">57,826<span></span>
</td>
<td class="nump">93,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 57,826<span></span>
</td>
<td class="nump">$ 95,377<span></span>
</td>
<td class="nump">$ 86,364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911519808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract', window );"><strong>Purchase of Rights to Future Milestones and Royalties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax penalties or interest charged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914232256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="num">$ (439)<span></span>
</td>
<td class="num">$ (919)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Long-term equity securities</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="num">$ (400)<span></span>
</td>
<td class="num">$ (900)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912701392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Intangible assets, net (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 15,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 15,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, useful life</a></td>
<td class="text">16 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Projected amortization expense for the next five years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive', window );">Total for next five years</a></td>
<td class="nump">4,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">15,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 15,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911493696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Financial Statements Details - Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued and other liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">$ 1,449<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">867<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentive compensation</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,918<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedSalariesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908812400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - ObsEva (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront cash payment to acquire assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReductionOfContingentRefundLiability', window );">Reduction of contingent refund liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones</a></td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember', window );">ObsEva IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront cash payment to acquire assets</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire assets</a></td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember', window );">ObsEva IP | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPayments', window );">Maximum earn-out payments</a></td>
<td class="nump">$ 97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments', window );">Maximum earn-out payments for development and regulatory milestones</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments', window );">Maximum earn-out payments for sales-based milestones</a></td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for various milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReductionOfContingentRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction in contingent refund liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReductionOfContingentRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908827680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - NIS793 (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Reduction in debt obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908248944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>USD ($) </div>
<div>item </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>EUR (&#8364;) </div>
<div>item </div>
<div>agreement </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreements', window );">Number of license agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ArrangementsNumber', window );">Number of arrangements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">&#8364; 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">539,131<span></span>
</td>
<td class="nump">539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.2742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Issuance of common stock, fair value</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ArrangementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arrangements the agreements are accounted for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ArrangementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock premium received on sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license agreement consideration received as repayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908104352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Nov. 01, 2006</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement | TAK-079</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement | Other antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate', window );">Maximum eligible milestone payments receivable per discovery product candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable per discovery product candidate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MezagitamabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MezagitamabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908503680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2">35 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities', window );">Payments received upon achievement of financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementInstallmentPaymentsReceived', window );">Installment payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementSharesReceived', window );">Number of shares received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations', window );">Percentage of decrease in future royalty obligations</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, RZ358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, Non-RZ358 products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments received upon achievement of financing activities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementInstallmentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment payments received during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementInstallmentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's common stock entity received under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfDecreaseInFutureRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908836272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,150<span></span>
</td>
<td class="nump">$ 36,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen Biotech Inc. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents', window );">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization', window );">Percentage of royalty on worldwide net sales of each product upon commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales upon commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914233104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Affimed (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 4,150,000<span></span>
</td>
<td class="nump">$ 36,518,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | Affimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffimedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffimedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690909146128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>period</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,877)<span></span>
</td>
<td class="num">$ (1,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">11,685<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | Royalty Sale Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 11,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | First Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones', window );">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePeriodsNumber', window );">Number of milestone periods | period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | Second Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePeriodsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePeriodsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of royalty interest acquisition agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfRoyaltyInterestAcquisitionAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690917042800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911371872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Payments related to purchase of royalty rights and other commercial payment rights</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased', window );">Number of licensed products related to milestone and royalties | product</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones', window );">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</a></td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CashReceivedForAchievementOfContractualMilestones', window );">Cash receipts for achievement of contractual milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CashReceivedForAchievementOfContractualMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts for achievement of contractual milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CashReceivedForAchievementOfContractualMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products related to milestones and royalties purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights and other commercial payment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908865872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683,000<span></span>
</td>
<td class="nump">$ 69,075,000<span></span>
</td>
<td class="nump">$ 34,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">8,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements', window );">Percentage of option to purchase royalty right on future license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements', window );">Number of future license agreements under optional purchase right | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement', window );">Obligation upon exercise of options per licensed product, second agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement', window );">Obligation upon exercise of options per licensed product, third agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Payments related to purchase of royalty rights and other commercial payment rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Second Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Payments related to purchase of royalty rights and other commercial payment rights</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of future license agreements under optional purchase right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreementsFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights and other commercial payment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rights entity has option to  purchase in future license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908342960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 07, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">8,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage', window );">Future non-royalty payments to be received (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementPaymentPercentageFactor', window );">Multiplier for cumulative amount of consideration paid | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount', window );">Threshold amount of cumulative royalties on net sales per product</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct', window );">Aggregate milestones payments per product</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber', window );">Number of drug candidates subject to exclusive license option | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPaymentsPerProduct', window );">Contingent future cash payment for each product</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Non-Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates subject to exclusive license option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementPaymentPercentageFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiplier used in determining change in payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementPaymentPercentageFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent future cash payment for each product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesPaymentsToAggregateAmountOfPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of non-royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for initial payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_BayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_BayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_NonBayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_NonBayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914407888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Palo (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683,000<span></span>
</td>
<td class="nump">$ 69,075,000<span></span>
</td>
<td class="nump">$ 34,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember', window );">Palo | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Payments related to purchase of royalty rights and other commercial payment rights</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights and other commercial payment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914427152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights', window );">Payments related to purchase of royalty rights and other commercial payment rights</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum', window );">Maximum amount of potential milestones and other payments receivable</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumConsiderationRetained', window );">Amount of maximum consideration retained</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum', window );">Maximum amount of potential regulatory and commercial milestones receivable</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumConsiderationRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumConsiderationRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments related to purchase of royalty rights and other commercial payment rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RegulatoryAndCommercialMilestonesReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908100928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones', window );">Pre-commercial milestone payments</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones', window );">Potential future sales milestone payments</a></td>
<td class="nump">142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivedCounterparty', window );">Milestone payment received by Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivablePercentage', window );">Percentage of milestone payment received by Kuros that company is entitled to receive</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestone payment received by counterparty entity is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivedCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivedCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for initial payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908419616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="nump">$ 69,075<span></span>
</td>
<td class="nump">$ 34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">8,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialSalesReceivablePercentageOnNetSales', window );">Payments eligible to receive (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentReceivableTerm', window );">Commercial payment receivable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones', window );">Maximum additional payments upon achievement of regulatory and sales milestones</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnRegulatoryMilestone', window );">Maximum payable on regulatory milestone</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum payable on sales milestone</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRoyaltyReceivable', window );">Impairment of long-term royalty receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | VABYSMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialSalesReceivablePercentageOnNetSales', window );">Payments eligible to receive (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentReceivableTerm', window );">Commercial payment receivable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CashReceivedForAchievementOfContractualMilestones', window );">Cash receipts for achievement of contractual milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CashReceivedForAchievementOfContractualMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts for achievement of contractual milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CashReceivedForAchievementOfContractualMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialSalesReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments entity eligible to receive as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialSalesReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of sales and/or regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRoyaltyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRoyaltyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for initial payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908247680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,075<span></span>
</td>
<td class="nump">34,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">69,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShortTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableReclassification', window );">Reclassification to long-term royalty and commercial payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long term rights receivable due to reclassification to short-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShortTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in short term rights receivable due to reclassification from long-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShortTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908479696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 30,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">$ 774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">30,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">8,075<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">30,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 8,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911311376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Equity Securities (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Closing Common Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="nump">2.07<span></span>
</td>
<td class="nump">4.78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908916896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Consideration (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 8,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsOfContingentConsideration', window );">Payments of contingent consideration</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690997253056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Leased facilities (Details) - Leased facilities, Emeryville, California<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>facility</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasesNumberOfLeasedFacilities', window );">Operating leases, number of leased facilities | facility</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease', window );">Net lease liability until expiration of lease | $</a></td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's net lease liability until expiration of operating lease to be paid in next fiscal year following current fiscal year. Excludes payments after  extension of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasesNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases, number of leased facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasesNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911404016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914324672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">2 months 1 day<span></span>
</td>
<td class="text">1 year 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914290368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax</a></td>
<td class="num">$ (17,119)<span></span>
</td>
<td class="nump">$ 15,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision (benefit)</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690912728080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation between statutory rate and effective rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent', window );">Stock compensation and other permanent differences</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent', window );">Federal orphan drug credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent', window );">Tax benefit related to net operating loss carryforward utilization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20.00%)<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal orphan drug credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense (benefit) related to net operating loss carryforward utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911396016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">$ 4,732<span></span>
</td>
<td class="nump">$ 7,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">23,974<span></span>
</td>
<td class="nump">17,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research and development and other tax credit carryforwards</a></td>
<td class="nump">13,176<span></span>
</td>
<td class="nump">13,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">4,715<span></span>
</td>
<td class="nump">4,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Unearned revenue</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">2,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">50,329<span></span>
</td>
<td class="nump">47,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(50,329)<span></span>
</td>
<td class="num">(47,006)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in the valuation allowance</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="num">$ (4,600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690917016304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - NOL (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 108.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLossCarryForwardSubjectToExpiration', window );">Net operating loss carry forward subject to expiration</a></td>
<td class="nump">$ 13.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry-forwards</a></td>
<td class="nump">$ 20.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetOperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NetOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NetOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLossCarryForwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carry forward that is subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLossCarryForwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908932864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax credit carryforward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage', window );">Operating loss carryforward offset (as a percent)</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember', window );">Federal Orphan Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_TaxCreditCarryForwardExpirationYear', window );">Tax credit carry forward expiration year</a></td>
<td class="text">2037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California | Research</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forward amount</a></td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards offset of taxable income percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_TaxCreditCarryForwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carry forward expiration year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_TaxCreditCarryForwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=xoma_FederalOrphanCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690915949600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">5,938<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Unrecognized tax benefits expected to change significantly over the next twelve months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908709136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - ESPP (Details) - 2015 ESPP - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th"><div>May 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions', window );">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage related to employees to purchase shares at the lower fair market value at offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,090<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in aggregate number of shares authorized for issuance</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum shares per employee</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914256832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contribution per employee (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum', window );">Age requirement for participant to be eligible for a catch-up contribution, minimum</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage', window );">Deferred savings plan expense paid in common shares (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember', window );">Employee, Under Age Fifty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee</a></td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="nump">$ 19,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember', window );">Employee, Age Fifty or Over</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Deferred Savings Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Maximum annual contribution per employee</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of defined contribution plan expense paid through the issuance of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeUnderAgeFiftyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeAgeFiftyOrOverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916984672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,025,542<span></span>
</td>
<td class="nump">1,911,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,025,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Minimum | Terminated employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">192,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911844880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock Options (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward', window );">Minimum age required for employees to qualify for immediate vesting of award</a></td>
<td class="text">55 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge', window );">Threshold years required for retirement age</a></td>
<td class="text">70 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum age required for employees to qualify for immediate vesting of award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908773952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="nump">1,911,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="nump">292,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(128,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited, expired or cancelled</a></td>
<td class="num">(49,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">2,025,542<span></span>
</td>
<td class="nump">1,911,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable at end of period</a></td>
<td class="nump">1,718,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</a></td>
<td class="nump">$ 20.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">19.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</a></td>
<td class="nump">64.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at end of period</a></td>
<td class="nump">20.24<span></span>
</td>
<td class="nump">$ 20.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable at end of period</a></td>
<td class="nump">$ 19.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Remaining Term, Outstanding</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Remaining Term, Exercisable</a></td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 10,804<span></span>
</td>
<td class="nump">$ 15,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">10,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised, aggregate intrinsic value</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 12.01<span></span>
</td>
<td class="nump">$ 22.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908588960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">292,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.68%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916289744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,608<span></span>
</td>
<td class="nump">$ 6,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908087856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember', window );">Senior Vice President, Finance and Chief Financial Officer, Thomas Burns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentPeriodRetirementEligible', window );">Period for which individual will be deemed retirement eligible for purposes of equity award</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember', window );">Senior Vice President, Finance and Chief Financial Officer, Thomas Burns | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentPeriodRetirementEligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentPeriodRetirementEligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690915809872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details) - Current employees, excluding Chief Executive Officer<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>period</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Employee Retention Bonus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPeriodsCashRetentionBonus', window );">Number of periods in which employees will be eligible to receive cash retention bonus | period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodOneRetentionBonusEligibility', window );">Initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodTwoRetentionBonusEligibility', window );">Period following initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RetentionBonusExpenseAccrued', window );">Amount recorded as expense for cash retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths', window );">Cash retention bonuses expected to be paid in 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash retention bonus expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPeriodsCashRetentionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPeriodsCashRetentionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodOneRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodOneRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodTwoRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodTwoRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RetentionBonusExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recorded as expense during the period for cash retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RetentionBonusExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690916013472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details) - Chief Executive Officer, Retired, James R. Neal<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Departure and Continuity Incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedCompensationContinuityIncentive', window );">Accrued cash payment related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CompensationExpenseEmploymentAgreement', window );">Compensation expense related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedCompensationContinuityIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedCompensationContinuityIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CompensationExpenseEmploymentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CompensationExpenseEmploymentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908839968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,894<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690909052128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (17,104)<span></span>
</td>
<td class="nump">$ 15,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Allocation of undistributed earnings to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,451)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net (loss) income (attributable to) available to common stockholders, basic</a></td>
<td class="num">(22,576)<span></span>
</td>
<td class="nump">7,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Add: Adjustments to undistributed earnings allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net (loss) income (attributable to) available to common stockholders, diluted</a></td>
<td class="num">$ (22,576)<span></span>
</td>
<td class="nump">$ 7,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">11,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Effect of dilutive warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders</a></td>
<td class="nump">11,413<span></span>
</td>
<td class="nump">12,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share (attributable to) available to common stockholders (in dollars per share)</a></td>
<td class="num">$ (1.98)<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Accumulated preferred dividends</a></td>
<td class="num">$ (2,122)<span></span>
</td>
<td class="num">$ (2,122)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: Accumulated preferred dividends</a></td>
<td class="num">$ (3,350)<span></span>
</td>
<td class="num">$ (2,438)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2740-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net income loss available to common stockholders basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908804176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Series X Convertible Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember', window );">Series X And Series Y Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember', window );">Series Y Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="nump">1,252.772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConversionPricePerShare', window );">Preferred stock conversion price per share</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXAndSeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=xoma_SeriesYConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690907533216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Series A Preferred Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2020 </div>
<div>USD ($) </div>
<div>D </div>
<div>M </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds from issuance of preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromIssuanceOrSaleOfEquityNet', window );">Net proceeds from issuance of stock | $</a></td>
<td class="nump">$ 22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodYearProrated', window );">Number of days in year over which dividend will be prorated and computed | D</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear', window );">Number of months in year over which dividend will be prorated and compute | M</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodMonth', window );">Number of days in month over which dividend will be prorated and computed | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.75<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption', window );">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1.46071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays', window );">Trading days | D</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | 8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | 8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodProratedMonthsInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodYearProrated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodYearProrated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockRedemptionPricePerShareOptionalRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockShareCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockShareCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromIssuanceOrSaleOfEquityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromIssuanceOrSaleOfEquityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690907012496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 09, 2021 </div>
<div>USD ($) </div>
<div>M </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2026 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendAmountPerShare', window );">Preferred stock, dividend amount (in dollars per share)</a></td>
<td class="nump">$ 2,093.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodYearProrated', window );">Number of days in year over which dividend will be prorated and computed | D</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear', window );">Number of months in year over which dividend will be prorated and compute | M</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockDividendPeriodMonth', window );">Number of days in month over which dividend will be prorated and computed | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption', window );">Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)</a></td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1,253.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000.00<span></span>
</td>
<td class="nump">$ 25,250.00<span></span>
</td>
<td class="nump">$ 25,500.00<span></span>
</td>
<td class="nump">$ 25,750.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DepositarySharesRatioToPreferredStock', window );">Depositary share's fractional interest in share of preferred stock | shares</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromIssuanceOfPreferredStockNet', window );">Net proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 37,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PreferredStockShareCap', window );">Share cap (in shares) | shares</a></td>
<td class="nump">1.25313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 25.25<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="nump">$ 25.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares | Spouse of James Neal, then CEO and Chairman of the Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share)</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock | $</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DepositarySharesRatioToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents depositary share's fractional interest in share of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DepositarySharesRatioToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The dividend amount per share based on the dividend rate on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodProratedMonthsInYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodProratedMonthsInYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockDividendPeriodYearProrated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockDividendPeriodYearProrated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockRedemptionPricePerShareOptionalRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockRedemptionPricePerShareOptionalRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PreferredStockShareCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PreferredStockShareCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromIssuanceOfPreferredStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromIssuanceOfPreferredStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908632992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Jul. 20, 2022</div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>May 18, 2022</div></th>
<th class="th"><div>Apr. 15, 2022</div></th>
<th class="th"><div>Mar. 17, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Oct. 20, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911534128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - BVF Ownership (Details) - BVF - Xoma Corporation - Common Stock<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest (as a percent)</a></td>
<td class="nump">31.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted', window );">Ownership interest, if shares are converted (as a percent)</a></td>
<td class="nump">52.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=xoma_XomaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=xoma_XomaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911384768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - ATM Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Apr. 09, 2021</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DepositarySharesRatioToPreferredStock', window );">Depositary share's fractional interest in share of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfCommonStockToBeIssued', window );">Maximum amount of common shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares', window );">Sales commission paid per transaction (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfStockToBeIssued', window );">Maximum amount of shares to be issued</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares', window );">Sales commission paid per transaction, preferred stock (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | 2018 Common Stock ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DepositarySharesRatioToPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents depositary share's fractional interest in share of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DepositarySharesRatioToPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumValueOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of common stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumValueOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumValueOfStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumValueOfStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690908223072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Summary of Common Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">11,177<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Ten Year Warrants Issued in May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690907001424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Common Stock Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Ten Year Warrants Issued in May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Ten Year Warrants Issued in May 2018 | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019 | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate number of unregistered shares of common stock called by warrants (in shares)</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ExercisablePeriodOfWarrants', window );">Exercisable period of warrants</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated fair value of warrants</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ExercisablePeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ExercisablePeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914545568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePayments', window );">Estimate of milestone payments | $</a></td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts', window );">Assumed number of products per contract | product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911859024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 8,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember', window );">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA | Royalty milestones, sales milestones, non-sales milestones, and royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140691003207088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Arbitration Proceeding (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfArbitrationProceedingsInitiated', window );">Number of arbitration proceedings initiated</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfArbitrationProceedingsInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arbitration proceedings initiated by entity against one of its licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfArbitrationProceedingsInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690907523312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables balance | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfMajorPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfMajorPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690914755312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract', window );"><strong>Concentration of Risk, Segment and Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of risk segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690911452080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,027<span></span>
</td>
<td class="nump">$ 38,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,477<span></span>
</td>
<td class="nump">2,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140690907872960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2023 </div>
<div>USD ($) </div>
<div>item </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 13, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementAnnualSalary', window );">Amount of annual base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AnnualDiscretionaryCashBonusTargetPercentage', window );">Annual discretionary cash bonus target (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes | Exercise price, $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes | Exercise price, $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted | shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes | Stock Options | Exercise price, $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments', window );">Number of equal quarterly vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Executive Chairman of the Board and Interim CEO, Owen Hughes | Stock Options | Exercise price, $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementAnnualSalary', window );">Amount of annual base salary | $</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementSigningBonus', window );">Amount of signing bonus | $</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementSigningBonusPaymentPeriod', window );">Period within which signing bonus will be paid</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment', window );">Maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination', window );">Period within which signing bonus would need to be repaid upon resignation or termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AnnualDiscretionaryCashBonusTargetPercentage', window );">Annual discretionary cash bonus target (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko | Exercise price, $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko | Exercise price, $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko | Stock Options | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chief Investment Officer, Bradley Sitko | Stock Options | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Leased facilities, Emeryville, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm', window );">Remaining undiscounted lease payments under extended lease term | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AnnualDiscretionaryCashBonusTargetPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual discretionary cash bonus target as a percentage of current annual base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AnnualDiscretionaryCashBonusTargetPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of annual base salary pursuant to employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementSigningBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of signing bonus pursuant to employment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementSigningBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementSigningBonusPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period within which signing bonus will be paid pursuant to employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementSigningBonusPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents period within which signing bonus would need to be repaid upon resignation or termination for cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid under extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=xoma_ShareBasedPaymentArrangementExercisePrice18.66Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=xoma_ShareBasedPaymentArrangementExercisePrice18.66Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=xoma_ShareBasedPaymentArrangementExercisePrice30.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=xoma_ShareBasedPaymentArrangementExercisePrice30.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>xoma-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xoma="http://www.xoma.com/20221231"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xoma-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_83JqH9MaqUu4NibTiAAyew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_T4pTOnp0j0KTjb2iHvM7fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_qrhyGaKdHU2y0jcE4pD9zA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AQY72CQvV02u0NTeC1tQxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f4LrCv2BoEiulseA8lIUQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Qzz2di3EtU2QVCStAbp7Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kjZwwrEtk-QxVmWmdRujQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VTkPPsj7uUqml3L2CsbZfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qLzFyf8POkuPzS_GjeXV5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_kB9yfId7VkK_kt3X391buA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_9IG6mnsXWkKJ-8l8yrS4Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_m0XXi-6V7kqy8Lqgpe0vfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_j83jgfg09UidGXoNWAtd8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_I3wo0vb-CUixzfe_qIAyTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GF-6_dQKikmqEGqiVXM_qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_daw_HrxdKUKz56KM-1KXIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-11-01</startDate>
            <endDate>2006-11-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_e4kVRRL9ukOGf7-2PTwdVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_SHL2DGznK0y-hmUTeZ2Q-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_43509g1PLEqQVPLib8nQng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_kQY9oDQ6-02HjwmVuO7AAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_p4dgpct0ik2knGpohVsu9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lP-1sgwP7kC3A25KNKaI5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_rJ-F8BD5CUu-Uk0PG_Pfyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_aPOJphzjLkGSA83nJdzBJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ugLN8Eo-O0CB7wwIKyDDpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_1HuefpXb_UKf4eNJQw4how">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_sp6WSCeDk02ydf80LtVc8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_HhSShoGRe0G87HW8PMEEcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_3Ps32ZWrf0q2EllGoG3fog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_EbXYjQ5mzUCNFK-esz7zlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_s6Xmk-SskE67Bmh6cHSc5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5i_Uy5BsyEObHFG9u5GxwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_j4ElNZhA0E-_JPRkD0IGeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_jKmiP9r9_kuqlBxvTOdkgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_A4To0NeQ0UybzQYa3NDSxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Tuhk6nZzwk6xT736Ru4Zyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qIclTWez7UKcmOfuHD_oAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ibRXt1hd3k63S2armpWFhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WnhYpE1OH0qWIIqY-1VSWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qkTeCxJPbk-sQaXhYuVwgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CXsrLLVq5kSPUm74NYuFBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_yudqPJgz7UaaG7AG1-aQYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="As_Of_3_10_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_jfpTunIQFUqf7I8Jy9MJPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-10</instant>
        </period>
    </context>
    <context id="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_p24xpBTiUk-dfPSrxHMCZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_c9juPFjI2UyPCCkvD4DUNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_V_cdDAl530WO8X_Yw2S8dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qccAUP40R0mSuKlRmGHvKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_10_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mfqGdjZYME-gcLNsUw5Lng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2020-10-30</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_JQNeN2TEeU24mxPrSn9wUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_13_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gX6CfAtkvUmCg-Bai3Zw_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_v4dNNnJyNk2mkUC5mofV7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VbBrsLclIUqIJDiHDqkKUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lVrv91FNZU23z9vv3AQpjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_8Lp1iopY80moFAsWA0Oicw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wVSdoYr4jUereb7ZG5cXaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_MAbD5nWZf0aUq7Ov_NLXRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NqA3jpIWgUS-c7ELvkpPVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_f0_HvkLSs0CosO5uys_l2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_8nHUuSkvaUSLpkODfJC36A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_rAroNAm8f0G6gOtRf-Uv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-21</instant>
        </period>
    </context>
    <context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_DWIu-n3lPUiIYGcRZmhJLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-06</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_9ni1jDQqGE2MNc84XrIr5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7DasBvaAtkS6lYyw7kjKSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_gb8Mq7RYNUyPvOuADsltaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lLvvXbzgEakGtNGbJg_Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-02-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FwHL2hBqk0yF5G8wK5a2qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_r1ERX-00-kOo1Xhy1OfigQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_k_sLWKXSlEu9WIjrFJoc0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraKurosAffitechObsevaAndMerckKgaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4kBNFywoskiicslz4mbomw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_FAnAp8a72E6w0d6JVWeLow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1cbEl4Re006vJtiqqHtFKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xgElIxuKbE-siKQSQ-ga1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_q-sxs5W_mkKsWzMqNMcjqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_cOp6nGVAs0WrsYuMFKEFVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qeDzPAJvEkG3H6Q0IdTsfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4AJG2U9b-06BTayaXGugZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-30</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-22</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yTZvacgI1ke_u3yIpm8d6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_bYn_MgYoV0WUzvqn6X6Z0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">xoma:FederalOrphanCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_4s6qFO24NU6iO5tq9Aj0Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ty0cbCyI1UahHddWl2YJhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sO-ZiH9JX0a2e36VG0bf-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_W-KLX26PfE2wxKbylONFcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_s24vGEKFqEy3_8cKQImkMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_UYkiYmAOIk2ogIy_KnYMTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_V62nRCE_MUKPRncFNFDb4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RKKUO79jyUSa60B9WdlKKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHPRrMM4WkiFXB-GwNaVCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7mSqMJYiC0-QLMIxAQYuXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9iAqnNnr4UCD-KQ4aTDILg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zMpMm6r57kGoeIrwyong2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bnirjFhGZEq0-FJZJXu1DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i9sxLuyDfkyzZdNDX8SCMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ciJIa6qAFU2yV5PeZYq7oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_mcDXIe1eeUuUz9qtOy-1xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_c3q8pXA60E2IFa_nifIVng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice30.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">xoma:ShareBasedPaymentArrangementExercisePrice18.66Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_le_sU7N1A06C93O-_SOo1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_innzPLhQmEaLAZC2EVjFOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2Eq4oPH3-kmCmCEtd6jqOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gTYL1gbNEamV73yFBPD9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-30</instant>
        </period>
    </context>
    <context id="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_4_yOcoEhi0evQ1_wlkZgQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_S_3GoTwkMUmL0YDsH6p4lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2rqqrvz1g0ady6TBHhDp8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NmtXsMtquUe4CqwtZxHDmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_Dtmc_sm9HUOpkVYHoPRuoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_BRZefaTLEE2Yy6v52PFdig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember_kIunflkcykiOnsDFbUFC3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember_OSUGOQpK0k66rX6ilVlChg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_uq3xBIh_ZEu0t2lz65AnGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_BsX5M1Uu6EOTSHfP8EnvNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_aM7qfAJs_Ue2FngKRak2-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_aQqKR6_fy0yZBwIQWrikJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_7wxTmOyFPkGXQt3cSa57RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_8SsPA-cdo0K4zx7dDhkPMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_H1WDisLgxkqIvK7clGpKEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_kNUrGAqyEkalFB8W0WRezg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wmOMUEuzuk6yS0QoDP0Ysw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xdeG_av2K0qt9xOQHo2aRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_cenBgMUh9Uyccspm0H9hgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_867K-w4nlkWwUkggr9tW3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_P4EQyfpsBUSEXZiG7S71Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pQS3U8aNZU-yXj_-Ru7Piw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_PL6qNM8JgkeHSr5yXfQ1uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_EuXVMgiSQkKFYqjEXEEp2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UWK0SRUsv06_NuNedSDLfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_x7uVaLNyW025G4gxpaAXkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1sPaZ1NGOUiQwEfq8TQ6mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IXa196Wdf0SCxbIeQySyiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WMb-KT8So0uQN8syGEGdzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eC4aFolUA0GTxlIWZ6Cc1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U2mBKo7TtEGcPUHwD7IglQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_r11OGkPAXkWTZaN_G9-weg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_G8esAtNmakKoYvkKmZ81HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_uxkL92PMnEKbjnT9gFRfjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_PyU4HZ2-MUyl0mkJzT2hGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_P9oH2exeW068heueh9jTxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_A1kceVHEZkC9lyFdU9dnZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_HlTz8mGzA0mZC7-lIrM7Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ItyWObStzkWwMfLcO4SwBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ECC3Oq74RkeaDZlwSNK7uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_VF5VDW6QuUuc3CbbuaDBkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_3Xidd4rXq0CdoCYMGseM6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HvH-K2iJckyzvUJ368yfOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_l3gJWyDRYUKye9TcMvxKkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_DUPN51MSmkqx8eTsUOxe0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_qfx1aT0hdUKuLGbIUvod5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_10e0GTXDRUWaRkscI-rq2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mxRsfmorrkSEqfBuonPH7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-15</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EHfSyV3gW0yDNOYLjydoRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-09</instant>
        </period>
    </context>
    <context id="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CkHConVlPkaisM4vx4ktDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BeZq4eB_bk2TnmlVTH1lsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nnI_V8OIx0mQwuOLxFWnCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-20</startDate>
            <endDate>2022-07-20</endDate>
        </period>
    </context>
    <context id="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_9mhY0z8wFkeA-5k_gob2uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_uXlwrNWockK5GTzJTR4xtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lbU7cay48kKD_gmRJwUG_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T3jnk2RjiUevKoKd9EnTqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oU8u6lClxEOfghqL98sZqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-20</startDate>
            <endDate>2021-10-20</endDate>
        </period>
    </context>
    <context id="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_WrEKyI_BW0KQR6sl9XSdjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-20</startDate>
            <endDate>2021-10-20</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iqfNwPqtQUKQ72qNgqgT2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e-eX2y3du0SjIMU4Khgc_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_RCbYz-Iv-Ee2b0eoyibbgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ZexR-kNri0e-hmnNihJ6mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_s2s7EUHKIU-1G1XKSBWUDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_HMDAQklqkUG0fZ521YdL4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_6oBXO6b-I0mpgNiU83WWgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yz_sn-UE30-ULY9heqfBuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Ud1xPuhf60KUwxKzTrATfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_SNdPlNffB0uww3AF1AK5Yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-09</startDate>
            <endDate>2021-04-09</endDate>
        </period>
    </context>
    <context id="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_I3IaD-K-xEGI556fraBoOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTSoj4BvgUOQEPopJD5s6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wf94VZSnXU-Wpl7zah_jxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cxJRCFdTx0yjmZeqnao7Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ObP3X6UuqEmc0v7i_E4cnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_gA6KAG_rhUGJzhjdDOAkdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_tIDqLvdLRU-RDFaGl32d5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_mDszNS3HWE2vdHDJSeC0mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0k8XC5hhM0GGrBlYX_tVYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_FLXGWQjtYkORU4sQnEG_vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_bdWwrZZvA0WUmM4wVRe4tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_dqF-u1exn0eMTofXVXH82g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_uQJXomIUj0Gu7qpcedCwyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Bp0iF72XDUmK5_A2DxhSyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeUnderAgeFiftyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_-p2i8myCR0Cc2q5-v8T5eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeAgeFiftyOrOverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_k3R6O4_a8E2Uzc-CrSZ8Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_9UQegpZ6pk6Io8imyOcdnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_0HQ2F4usPUGiRtw00ne_tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_mS1sKPw6CE2n0SBLlBsMLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_hxzif6f6wkKNy-S4FYzklQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">xoma:SeriesXAndSeriesYConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hJHO8BzhGkm3pdbOfFsQrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qy9rE8Y_SEaSHkgLxZXqAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y18GrbyNrEilibNOBjl-og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pFFI1aKmY0-JrE7vjxLafg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W069niAtjE6EsmPfY337qA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_2vBGTX6yJEWsXPa205KCrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rUQ9aQoP0UevSR54GD1sWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wKH3zH90P0eBo19y-1AFvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_u8nxMvP_akullwQz4lc9rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_q87bEsiOOE6OxrrZkp0I_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_5aGHU9JvxUq_BpGHRTnqYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_gxn9ucloMEePqYe0bPpnKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_SwAbSDClgkW7N51ti2Pz6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:SeniorVicePresidentFinanceAndChiefFinancialOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvwASmfkaEWRGoQyRqS1Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_Qy0R61UYDEOWWQR8GJxwCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_LRJ7NhbvUk6MDLLl-Q0iCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_6_2023_36F4JsyQ5kOhUztw-GFovQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-03-06</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ">
        <measure>xoma:agreement</measure>
    </unit>
    <unit id="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw">
        <measure>xoma:customer</measure>
    </unit>
    <unit id="Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg">
        <measure>xoma:facility</measure>
    </unit>
    <unit id="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">
        <measure>xoma:D</measure>
    </unit>
    <unit id="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ">
        <measure>xoma:M</measure>
    </unit>
    <unit id="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ">
        <measure>xoma:installment</measure>
    </unit>
    <unit id="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A">
        <measure>xoma:segment</measure>
    </unit>
    <unit id="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">
        <measure>xoma:item</measure>
    </unit>
    <unit id="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ">
        <measure>xoma:product</measure>
    </unit>
    <unit id="Unit_Standard_EUR_fwE8yWfrn0K-IqzRprsY2A">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw">
        <measure>xoma:period</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_Ko6kHFVqW0K7Y9zR34NSIA_2_1">0000791908</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_Vp2cTCW2UEOI1rglQ3PKLA_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_ppEdwEOXIkuf8uhxQIQGDQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_WOONeeSf8UujfskMw0Mqdg_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      id="Hidden_QTvgDvLQpk2h-LwDeIqFAg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      id="Hidden_MXTd9XYspk-r4SDqONPKow"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ"
      xsi:nil="true"/>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Hidden_wmlnCmGi9UaTuKy0fPEZIA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Hidden_etWwIGkuCUidf1uC_QoY1A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Hidden_m7mbWAfU6ka4R4vo0FBMHw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Hidden_MWtPRgmjjkCHN97YCziAHw">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_V62nRCE_MUKPRncFNFDb4Q"
      decimals="2"
      id="Hidden_osQASCJOc0aG36cPBan18A"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      id="Hidden_SoJMkvQEd0GCqEyppA4jKg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      id="Hidden_-opkpTvh2U-sJds8V7C3Yw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ"
      xsi:nil="true"/>
    <xoma:DepositarySharesRatioToPreferredStock
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA"
      decimals="INF"
      id="Hidden_bylnvwbfT0qC2wS2bhBX0Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0.001</xoma:DepositarySharesRatioToPreferredStock>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Ud1xPuhf60KUwxKzTrATfQ"
      decimals="5"
      id="Hidden_cbQH9ljBJEebaeTjfrtxMg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_18_2022_To_1_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_SNdPlNffB0uww3AF1AK5Yg"
      decimals="5"
      id="Hidden_Ns1YY3UqQkOJK6UyTHN1bg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_6oBXO6b-I0mpgNiU83WWgA"
      decimals="5"
      id="Hidden_KkEuaC7pjUygw9Z4wgEdgA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_15_2022_To_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yz_sn-UE30-ULY9heqfBuw"
      decimals="5"
      id="Hidden_Z4eBHZawv0inBmuQccPnkA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_s2s7EUHKIU-1G1XKSBWUDA"
      decimals="5"
      id="Hidden_AffMX3HfskqqtMAs2dYFqA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_15_2022_To_7_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_HMDAQklqkUG0fZ521YdL4A"
      decimals="5"
      id="Hidden_rVEGkExq70yCFYYZq4K5yQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_RCbYz-Iv-Ee2b0eoyibbgw"
      decimals="5"
      id="Hidden_LQOgbcYcy0O5Ut6RtuujLg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_10_17_2022_To_10_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ZexR-kNri0e-hmnNihJ6mg"
      decimals="5"
      id="Hidden_Kelm5qnj-EOoeAXowZDZbA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iqfNwPqtQUKQ72qNgqgT2g"
      decimals="5"
      id="Hidden_xxzwN1Kink2tMJX3CRXlnA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_e-eX2y3du0SjIMU4Khgc_w"
      decimals="5"
      id="Hidden_NoKAl2q6DEWcRsp0Y0mt6g"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <xoma:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_qrhyGaKdHU2y0jcE4pD9zA"
      decimals="INF"
      id="Hidden_FXGxJuaD7Eqmui9GgIgKuw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0</xoma:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A"
      id="Hidden_292B7Rrmb0OIBzdjG3jt5w">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_QPYx4oMeRUGjZhjWrANIgQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_HqveaDo_5kK6djqEmTNOng">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_zxUuUxK-20m7HKiQR0vNDA">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_3yYKpsNsfEmRTEPfwg85YA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_0D_QAApif0-GgB_dVkT32A">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_5uAKtK-DiUWVQglCDgI-Rg">001-39801</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_GtQ-dfwTskSgwb7Xrit8og">XOMA CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_wfWDuUcNMkSq1MRPp8SwwA_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_etHbzS3IrEGEuOEQZ3hGQQ_0_1">52-2154066</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_RZC-13jJnk-g351jPc3Bdg">2200 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_dnkMCWYtD0eK1qXtNW_hrQ">Suite 310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr__cw9yhJHeUuKTG5_nwuIPA">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_HZuTYw4xGEmA5X2OQaasZw">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_0WShIeDZNEet7nFdbG4eKw_3_1">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_aLUSO-MZoUmvxlgMVqNrYQ">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_O_Dy1W3hK0CooRFdb2RSOA">204-7200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g"
      id="Tc_x5IxcGwnq0C1YZivujVcRQ_2_0">Common Stock, $0.0075 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g"
      id="Tc_GGxD6m40kU-eKVnsksQ6Aw_2_2">XOMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_1Ixdcn_-4EqnddEa_3Gm2g"
      id="Tc_mdM9_b-fXEqFsAIo91a0VA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"
      id="Tc_Owrf5TdptUem8n0qc5hEJQ_3_0">8.625% Series A Cumulative, Perpetual Preferred Stock, par value $0.05</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"
      id="Tc_NO1kxgxzFEq8dWFFD39KzA_3_2">XOMAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"
      id="Tc_OiSRnyxPMUqaKld5nq2I2w_3_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg"
      id="Tc_dIV6Gb-KIUSWiKgv6Dqp4g_4_0">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg"
      id="Tc_DEnkXhoj-EyDpsK4vTCHTQ_4_2">XOMAO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_LPZKItgoH0-J7Hwj0wzJqg"
      id="Tc_UYGvToHsc0OIDZK8_e0fng_4_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_8Pc65GegxE6gUfgMEP7WNw_1_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_MyUb99FepUWLKHBHjkATDg_1_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_r4ywu6o4PU-NW4wMxen_rQ_2_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_ddAE1Atkc0KQsH6_Ruh2OA">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_saXNnWhOaEG8p4ABtW2CKA">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_LRJ7NhbvUk6MDLLl-Q0iCQ"
      decimals="0"
      id="Narr_KhRimUO1_E2r4ymfoKtKBA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">154564269</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_6_2023_36F4JsyQ5kOhUztw-GFovQ"
      decimals="INF"
      id="Narr_0vj9ikabxUaUMu5JzHJgRg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11460968</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_FZUPeYKFr0adn0BVCCtpNQ">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_WSSLJtjCuE-ilIBbTb3rnQ">DELOITTE &amp; TOUCHE LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_d-lwLJD6D06esCHRdVSjPw">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_je64Ng6DYUuTO26NhKRx7g_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_j_fqfIkV_UGfmwtPzz_OxA_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">93328000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_bZMs2ILblUSHc0BOAJceGA_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2049000</us-gaap:RestrictedCashCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_gd5_3ytlcECpYuZTcn3CWA_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">335000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_HaIA-5omhE2pYEMQ1rLcrA_8_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">774000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_j5iB-Is6G0e1YiPa5t9krw_9_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_43mFhAa2Tkyan7QAO5nSYA_9_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">209000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_dQRjLKvQm06aEpZ5_AjuVA_10_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2366000</xoma:RightsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_pn_z5o2WZUaiPE1PsUe0ig_11_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">725000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_vUyTIGVZskGzUhVtflKM3w_11_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">613000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_u72OOld1Ikqko2MdA-Z2tQ_12_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">61253000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_aNB3WDuF2U2_Tw_w8gxM2A_12_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">96973000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_1LwV4KIwh0eNb5S12XVJGA_13_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_4ycBcGcGlEa3McbbCLhJyg_13_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_TSD1oqLIkUyrvsH-WjPc_A_14_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">29000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_x6_OXW6v0kiPFMBUDRRSaQ_14_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_ARCdnafZyE2GRfkSxWJJKw_15_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_4cM-tjbf-U2U-H3iQpPDdg_15_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">69075000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_TA1Stwx_i0Wz4-9CKuSmTQ_16_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_rZuXeWNytkipeFnbI-IigA_17_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_9D9aPKGLVEu0cNE0Ip9-ag_17_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">301000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_bJaqHN44YEur2dLZ3kj_aw_18_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">140382000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_8rlDrkAcl0mErUifQ5gSMw_18_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">166562000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_P0GFh-W9TESzqxFkFoSp2Q_22_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">524000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_u-LugVfA3kWzf4xAAtXBnA_22_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1072000</us-gaap:AccountsPayableCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_29N-5jpYCEyV94AxoyzZzQ_23_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_CqndnxjKX0i3Ea9ZJZ4MhQ_23_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">525000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_w5iFJfwogUqlSukIyahE-A_24_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">91000</us-gaap:AccruedIncomeTaxesCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_es8cICEX-0ODK59lpti_CA_25_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_ZXUxVNSd7UKBUyoEPLA6ag_25_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8075000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_q37UCdcz2kywthaa4Itj7A_26_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">34000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_NS8n7UQ13keGLqsjGh58RA_26_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">195000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_69opIzDgwUKKy4pslJV9Eg_27_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1899000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_CjxxdSEHkkusxN7cZdrcIg_27_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1641000</us-gaap:DeferredIncomeCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_8ZTqXRUhnUKO13l4D649bA_28_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_cmwzpimFxkCGANE1PVO3jg_28_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_tXXb0Jew5kSSdguGlCBmXA_29_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_qp6Gjf7oxkSRxrx7vcwV7w_29_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">12967000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_cozs0VsSRkW95qWMCUKxPg_30_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">9550000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_ZoTlaP5bz0-32LjiT2Btvg_30_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">11685000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_TMQJgSdG5Eq0T6G8sBAEuA_31_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">34000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_1Uy3WWgLc0SDbNjcYltMzA_32_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">16368000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_RO0EOMPCu0GITbZWUayCNQ_32_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">24686000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_qs4f4Bk1k0WjhLJLjLWPCw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_s3Vc2hMm2UG1rYkyrsISzA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_JeM2sHbMoE6hB2xjPqRYDg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_qeOTFXBY6EWihpURbMdI6w"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ"
      decimals="INF"
      id="Narr_9kj8-UwNUEq2gYckdKv-Kw"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"
      decimals="INF"
      id="Narr_ewfmbA5SIkKVmfdHL--dKg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="INF"
      id="Narr_GUKVgwwBpkeo8Zek90VKVA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="INF"
      id="Narr_3Pdx6mCQA0ay767FWEAT2g"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="INF"
      id="Narr_cTPbbVNPRk2ZDO92qjyiOw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="INF"
      id="Narr_L0_-6EzEYEeQDYZCJxVq2Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="-3"
      id="Tc_WeQsrAQfDEWB6tr4gDqS2A_38_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="-3"
      id="Tc_sPhEOUWAQEK5CPKsargrnQ_38_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg"
      decimals="INF"
      id="Narr_uKAWW8o2KEi3qJQwv2gq_g"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ"
      decimals="INF"
      id="Narr_8d_NJ05ZOUS7dbxE97wKsg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"
      decimals="INF"
      id="Narr_YEohLPJ-CUaqp1cfFvZAXg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ"
      decimals="INF"
      id="Narr_PoMXYC_AZEaYWxCLP5mHBw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"
      decimals="INF"
      id="Narr_Ais0yhna1km6IewkERGMfw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ"
      decimals="INF"
      id="Narr_OVZ8PwBuvEuKdykyyPECKQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA"
      decimals="INF"
      id="Narr_E6WT7qwQEEqghXRQwmSRAw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg"
      decimals="INF"
      id="Narr_noAqZMeDUECA1NbYFdje_A"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_K0BHR3gUGkqiHszS-ZdqYA"
      decimals="INF"
      id="Narr_oy-chCQt6kOlSuyigxIlow"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_c0OByXdiPkK1QhcSB_9JZg"
      decimals="INF"
      id="Narr_KXrM0GPNA0G4mSls3o7j_Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_NM365T6-0Ue1l0tsCy_J1g"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_xAv3JSzj7Euij8TRmg1T7A"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_TlA5n7hsnUS-Harc8Dibew"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_sPQrKpcrBEyShhzItcoaTA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr__wT63UZtWEeUzyULd07cxQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11454025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_oSC_qskqXE2T2WvP6oghDQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11454025</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_fPuNBGXh30uwa4WNNqWMYA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11315263</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Narr_puhPHqk-c02STrUp01qhCw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11315263</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_coJMQUHlLEabqTpv2Ig4Hg_41_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_KLDEeYh1q0aNeoZfQnxsxQ_41_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">85000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_93cPf-s8Kk6JKlgeswEHyQ_42_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1306271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc__QsFFP7JoUWVoTjtoTDPeA_42_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1307030000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_ej2Z-pf0WkmZ0X3TrRrPIw_43_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1182392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_vskXHShsokSwYKdLPChEEw_43_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1165288000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_P1Djw1QfZEmso_CQycSLMg_44_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">124014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_zRGEMsrl2kGLGyay3_C2EA_44_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">141876000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_3NQQv5AkZEex0tJ33NmSyA_45_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">140382000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_8mVyVgfuKkCSAXXqJ41aKg_45_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">166562000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_AfcYSGcJRUShJiSs_lVe2w_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_IR_lEfC56UeUaiofp1S4Uw_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">36518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_FisCD6CUSUKWinUDPrpAKA_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1877000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_p67YrCPWkUO381dA1-Adgg_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1642000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_AJLhfrwdh0uVsPTzpot-qw_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6027000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_eBO_VkXjrECg55hn1Yn2ZA_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">38160000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_oJuDMX0zNUSwWH6iP0-iXQ_10_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">153000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_Aum_luVR1EKdsvklq-gWtw_10_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">171000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_-AB1TrGWKU6F8oxe64FUwA_11_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">23191000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_zfHfuSSJi0GhgChqaRSdeQ_11_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20460000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_ZPENP58OYEO3_XZ62YEp9g_12_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">97000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_bxBcwoUKLEy6rIncOt_8VA_13_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">23441000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_yKxJHKk6HUWZmn9BqPYQuQ_13_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20631000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_KxAoRmvbSkW59kPqKMW3oQ_15_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17414000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_tlhH64Ptsk6tqK7ltEmHbg_15_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">17529000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_g8s2ML_srkiGQpayWa0yDg_18_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">461000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_7AxuJNEcMkOUTLXSwECQ6g_19_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_wrt8fdkU9UKv_WmO-Kuoew_20_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">295000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_ktBuud4qSES9TwB3-SHsYA_20_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-879000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_McbPCeux-kG51nDurAunog_21_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_yodO-Zne5kqFTOsHwRPfVA_21_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_DrGtK3mRVU-0Ngzc-L5gwg_22_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_z5Lolm6esUGUlGRu8_0y-A_22_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_szOhLjMdFEiOKRGSTFBejA_23_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_szOhLjMdFEiOKRGSTFBejA_23_3_2"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_UQwW6XkLvUSYO6DKBgrTAQ_23_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_UQwW6XkLvUSYO6DKBgrTAQ_23_6_2"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_R16ZX2VluUeQ4h6CSK53kA_24_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_ZgxxlN1s2ku9vbGlmd55vQ_24_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7787000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_FDRKkNrYbkmyawEAm_Tegw_25_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_RVrJQoAdAUiPH5SytYxG5w_25_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7968000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_iE-1Fbj6-E6XhYxXOm_daQ_26_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_A33QM__TAUa6xW0NxNXxXQ_26_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_oquLCoxMaE-gw90aL59rTA_27_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_a2DGrW3GbE-fGuHhJv4iEQ_27_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_7TDayCjMOki_MfYvseSQIw_28_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11413000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_5loauwCjqEm2WG9fAM7y9Q_28_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11288000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_1Gu_SCXK50WgP-FRdRYwHg_29_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11413000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_8Keb8gng1UCONHfUTCVFdA_29_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">12192000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw"
      decimals="-3"
      id="Tc_vQwMZUIjlkK21tVvAQmxiw_4_1"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw"
      decimals="-3"
      id="Tc_ZOzNI1DrZEGxVECSfnMO5w_4_4"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA"
      decimals="-3"
      id="Tc_KvTnTgWd0UW5Rjfacfj8TA_4_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g"
      decimals="-3"
      id="Tc_G_kWhrXNpEKAC_CxrE9pPg_4_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g"
      decimals="-3"
      id="Tc_CAH_AcX6CkCrAep7AqoovQ_4_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g"
      decimals="-3"
      id="Tc_N7qdQV4-4EKb_6sUEu6AXA_4_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ"
      decimals="-3"
      id="Tc_RH9hqR8qmEylkS9dmwcVCA_4_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1307030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w"
      decimals="-3"
      id="Tc_BnOCrJhW80iaq81uuV1DfA_4_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1165288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_liSMQo3fXEaIyT466QtrUg_4_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">141876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow"
      decimals="-3"
      id="Tc_z1ynA4I2ykqxBFXvfSU6QQ_5_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">129000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow"
      decimals="-3"
      id="Tc_01oeGB8Ohk6LqicO8ZPtFQ_5_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw"
      decimals="-3"
      id="Tc_4uJ6AivT3E-2WdF1IQm2wA_5_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">929000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_7rZrvhfO-0Oee_0yN3ZF8Q_5_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">930000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw"
      decimals="-3"
      id="Tc_ZeFyjxw37kW3xQq30hD5Tw_6_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc__IbAJiunKkKHjUBrgBnsIw_6_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_yeHFlj3XckeGMcwYsekVow"
      decimals="-3"
      id="Tc_gAIWJ4Spi0es5vQk9FSk3g_7_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">10000</xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw"
      decimals="-3"
      id="Tc_LG0zJQ7iOkGlP9I_WimReg_7_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">176000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_0uI0y7YpZUyvNpX1awooqA_7_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">176000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Vwyw5Bh5n0eX6k-5jquYhw"
      decimals="-3"
      id="Tc_Dcyv7i2IYkWjqZpv_qE21w_8_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_5qq5YBOVmEGEWpiAsuiuDQ_8_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5472000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTSoj4BvgUOQEPopJD5s6A"
      decimals="-3"
      id="Tc_8X3vlz6lMkiAyTymzCOocg_9_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_Nc1ySng0s0uJePV13g44KQ_9_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg"
      decimals="-3"
      id="Tc_Kw6qb0Sfnk-G2qeKRBMjiA_10_1"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_UXjGUFtWFEWksmPfwqo_Xg"
      decimals="-3"
      id="Tc_Qenev3yvV0SWLUoYoE6s_g_10_4"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_zMpMm6r57kGoeIrwyong2g"
      decimals="-3"
      id="Tc_M9OnCtkOk0Saw2wCdR-9oQ_10_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_bnirjFhGZEq0-FJZJXu1DQ"
      decimals="-3"
      id="Tc_js8vShVnOkOKWlXQEAwooA_10_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw"
      decimals="-3"
      id="Tc_6nlcAozO5E6px3sYRHV5eQ_10_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11454000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GjiBijjCJEa0cjsU65bQLw"
      decimals="-3"
      id="Tc_JolEGH37NkusDk0bLGi3jA_10_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zHPRrMM4WkiFXB-GwNaVCw"
      decimals="-3"
      id="Tc_cOILZtbtKku13wrUc3LrhQ_10_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1306271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RKKUO79jyUSa60B9WdlKKw"
      decimals="-3"
      id="Tc_Ws0i1h4KVk-hMXCGmoGKSg_10_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1182392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_r1AyXH-RQkWGefqgr9vAfQ_10_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">124014000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g"
      decimals="-3"
      id="Tc_a3oi0WX4a0K70SSR78LuQQ_4_1"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g"
      decimals="-3"
      id="Tc_4mvkXYIs-UyeGKROWIiCrw_4_4"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_i9sxLuyDfkyzZdNDX8SCMA"
      decimals="-3"
      id="Tc_1gVV6oZyA0GJChC5kgN76g_4_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q"
      decimals="-3"
      id="Tc_nxDXbxyTOEy94T1vySUmdg_4_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11229000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rZFrE-pZekCj4oL3Eagc2Q"
      decimals="-3"
      id="Tc_2HfeCbG150qTODEhtStwOA_4_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">84000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9iAqnNnr4UCD-KQ4aTDILg"
      decimals="-3"
      id="Tc_iJIvMM31Dk-qKT-nbWYcsw_4_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1267377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7mSqMJYiC0-QLMIxAQYuXw"
      decimals="-3"
      id="Tc_rGKQRctgiUulZnFgvHJ54A_4_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1181086000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw"
      decimals="-3"
      id="Tc_JgXlQ-gmyEupBWjz9Bf5hg_4_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">86424000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_ty0cbCyI1UahHddWl2YJhw"
      decimals="-3"
      id="Tc_9GdEmzSAg0KVXXdHi4GmhA_5_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"
      decimals="-3"
      id="Tc_V6ftizE4GEuLav_6HaDKhw_5_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">37140000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_JT66qvFEUkyoP0PVFeOxAA_5_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">37140000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ"
      decimals="-3"
      id="Tc_srgr_IJESU26SJ3yRR-fmg_6_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">77000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ"
      decimals="-3"
      id="Tc_1YHnvxergEGaxHRwwLAVnw_6_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"
      decimals="-3"
      id="Tc_fGeMj7EW_UOkIwvmxXWHbA_6_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1052000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_5p_m61aWfkCMnZ5Hu_U3vw_6_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1053000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"
      decimals="-3"
      id="Tc_0xXKsFB7fUSjetFBI7EZ9A_7_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_4OzBBLY2akWJhm_4bm2AEA_7_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <xoma:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ"
      decimals="-3"
      id="Tc_tY6A1TUQokGn8wlvsxxXEQ_8_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5000</xoma:StockIssuedDuringPeriodSharesWarrantsExercised>
    <xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_dGDmdgNpvEiFdcQdnLihEQ"
      decimals="-3"
      id="Tc_X1FuBj7DIkKSfHXh_psRfg_9_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">4000</xoma:StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"
      decimals="-3"
      id="Tc_Sf4db39o1EurZIwIMVjHJQ_9_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">133000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_TP3C6azz2EehTBjbX0pZpQ_9_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">133000</xoma:StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_e7acm_BlmUaR5GqWom8erA"
      decimals="-3"
      id="Tc_x_inK-YxMkWBmimdfwMB3w_10_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4867000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_dQ5DhTGtMkybri91cyPfLw_10_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4867000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wf94VZSnXU-Wpl7zah_jxg"
      decimals="-3"
      id="Tc_xT-t6o2h-ke0df9Uh4nrWQ_11_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_INZBzDFj10mVN2-D8wKOyA_11_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw"
      decimals="-3"
      id="Tc_Lq2yClLQeEaHLpyHu6hHxQ_12_1"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Hlpd-_RZZEqCb40AhAejTw"
      decimals="-3"
      id="Tc_hwSMMTJ6L0ixjvyAgqwvNQ_12_4"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_P1GChNvWOUi6GZXzUfxffA"
      decimals="-3"
      id="Tc_MGWuKrxDSEWhsJaWdFDs5Q_12_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_BRwAXM40eU2cwNjW806--g"
      decimals="-3"
      id="Tc_ENQ73CanRUSKHC3GBxcfjA_12_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g"
      decimals="-3"
      id="Tc_stYnjBbz60awp1fVuAlISw_12_16"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uc0m1r-_cUaTlYMKN5Il8g"
      decimals="-3"
      id="Tc_AvIViKiMFUqF9FSb8LgIbA_12_19"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jcL_7ONO0ECDG_WAZjLhyQ"
      decimals="-3"
      id="Tc_QrkbwE0_N0WZd1eohg5Ubg_12_22"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1307030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Zmhsmmp5302_pk3RXPAV2w"
      decimals="-3"
      id="Tc_sgN2xx0FCUiRS4vq9bwUag_12_25"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1165288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_hytxBFldUka6YPPaOai6uA_12_28"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">141876000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_k5UBGCmT00ex_rRTshxAjw_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_QQsWsT0SnkO_-BF9_8BrGw_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_9i4VSiuAMEKo1C5XMawBAA_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3608000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_J4MMYUDs4Uu155NbGgl9_w_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6195000</us-gaap:ShareBasedCompensation>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_mllULS75Sk6572iyfNoY-Q_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">85000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_mKK5w8m8iUqQHCeZLwNQ1w_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">90000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_eKHcMKeY90aWQseOvI_yhg_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_ogxcar0Y30--ubdlUe8k_A_8_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000</us-gaap:DepreciationNonproduction>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_tuAXObJBQ0yjBCKFXk8MIQ_9_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_XiuH8eBng0CYjCOw1pToRQ_10_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <xoma:ReductionOfContingentRefundLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_5LSyI3E9xE-pbtCdh2wnIw_11_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">105000</xoma:ReductionOfContingentRefundLiability>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_iLpZS_O5iEq2RSSs-zjwxg_12_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-170000</xoma:OperatingLeasePaymentsNonCash>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_UASHHrSmjUyjpsMrYcd_0w_12_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-160000</xoma:OperatingLeasePaymentsNonCash>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_0bCXZ6ZFd0C-u26jpgD_qA_13_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-439000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_Cwg7Q0WW4USLG4wB4HCzmg_13_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-919000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_dhq0N5T7fUKfgSPoEyUl_w_14_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">97000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_A00Nbfb-UkKfzAx12OLe0g_16_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-208000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_gte2zQB2EEyBN_N7jbDu3A_16_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-54000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_NVjlJ44DjU28XyudVhi9NA_17_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1526000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_WiKGoB-s3ku4ifc0Enjcog_18_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">71000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_PidSA5dzkkGzcIsU5dJ0fw_18_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">169000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_obSUTG7uXkC9khwqkbJAeg_19_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1845000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_OjjHrmwHqUOkCLPx9OCqmA_19_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">765000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_SG2HGTjbK06nS55qQQOCfA_20_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-91000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_UQy92uI3vkmbDz7XieLJuw_20_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">91000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_DeO2_8eLCUepxCkl4hQD3g_21_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-195000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_nv0waxqzzUarrbgRYaKzBg_21_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-179000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_Dyo4iBxEskeH9RSHNdxnrA_22_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1877000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_SP9SSYlZKkimyRg292quPA_22_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1642000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:IncreaseDecreaseInRefundLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_4MidNrVjmkanb71qY0mWtQ_23_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-1305000</xoma:IncreaseDecreaseInRefundLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_g9vbbAxbmEqJ7IKMcoIZCg_24_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-27000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_67hi4SChf025rlRdolLwdg_25_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-12879000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_gPmxJWYiok6q42E0VsZGZg_25_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">22678000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_iKt9Sh_DMkykJ_pXUyVHyw_28_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_W_764I0phUiYQyYqjiHQcQ_28_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">26500000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <xoma:ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_NVn-COJnNkGecl4IWQBN7w_29_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3026000</xoma:ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_SOll8gcOg0Ox1K2q2MNA1w_30_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15247000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_Wk-RUr6r20GHFHIp6RtSTw_31_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-20221000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc__uQBLdFKUkmJdf96Km36MQ_31_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-26500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_byxxEDjSDEGsVNx32NgyIw_34_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_hc5w6_ea7EiDpscBwTkcnw_35_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5472000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_qOdXYfS_0E-8KkEDthB1Pw_35_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3499000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_Syd0HZLqBEWR4Go_5A76PQ_36_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3385000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_gB6RXJDCSEuluQ-ivrG1Pg_37_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2419000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_zEsHHollL0GlSpid_jLo_A_37_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1584000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_LYlzXWrAkEuUTeE8wZ1kgQ_38_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1398000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_p9lRRcFEc0yhRiwl3Qq4_Q_38_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">488000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <xoma:RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_ypYsE3EDVEKDUY_Yo5Z1Lg_39_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4250000</xoma:RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt>
    <xoma:RepaymentsOfLongTermDebtExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_9bwlEa8HRkmCRRndMSaxRQ_40_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">17103000</xoma:RepaymentsOfLongTermDebtExtinguishmentOfDebt>
    <us-gaap:PaymentsOfDebtRestructuringCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_6kvFk2XWt0iAY_cdYHjFhg_41_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">24000</us-gaap:PaymentsOfDebtRestructuringCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_aycmOFsbwkCJmPZG50bvNw_42_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-4451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_w0NFkSj80kqJUW_ajnB71g_42_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">12835000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_kezfMCwzm0S_yvzqNNN_wQ_44_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-37551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_dlLbei7w7EysbYrZ8FYWqw_44_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">9013000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_b7J7HOLBNkOjG5JRFX83Ww_45_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">95377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw"
      decimals="-3"
      id="Tc_f_EI168Za06mTrelYGpdVg_45_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">86364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_IoA2M2oqFkqo3DksrY0Vvw_46_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_ZfTnxYgno0OP_JPq9c2SdQ_46_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">95377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_T2Sng-dxCEOawvEVlYlkGQ_49_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">76000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_01MAdoyVSUmusjprclNdug_50_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">311000</us-gaap:InterestPaidNet>
    <xoma:EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_8kUQDQXqM0yCNiyyJjKalg_52_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000000</xoma:EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_GXMwYciDekqH0-0bqC-wtA_53_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_y43y8Yy__EWquCCn9jfBNA_53_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <xoma:AccruedTransactionCostsRelatedToPurchaseAgreements
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_vwR7xnUeFE6QFsrWdxemVw_54_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">122000</xoma:AccruedTransactionCostsRelatedToPurchaseAgreements>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_EWxP8RXSO0i3BCC2Kcro9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Description of Business&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#x2019;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with outlicensing its proprietary products and platforms from its legacy discovery and development business. The Company&#x2019;s drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Liquidity and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of December&#160;31, 2022, the Company had cash and cash equivalents of $57.8 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these consolidated financial statements are issued.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_vh94xxn-2EW9OKIjdcYegQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_F53THUMTCEG5Xwrvp2nwRA">false</us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_Cy5bZ2fPrk-j8cOsKbosQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of Presentation and Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with GAAP in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2022, the Company had cash equivalent balances of $30.3 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company&#x2019;s Series A and Series B Preferred Stock. As of December 31, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 93,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive (loss) income in the period of sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. Other contingent consideration payments are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s consolidated statement of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the consolidated statement of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Net (Loss) Income per Share (Attributable to) Available to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted (loss) income per share (attributable to) available to common stockholders using the two-class method. The Company&#x2019;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net (loss) income per share attributable to common stockholders is then calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive (Loss) Income &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company plans to adopt ASU 2016-13 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company plans to adopt ASU 2021-08 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_SVwVh-8bikeJBDMECUXFEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The accompanying consolidated financial statements were prepared in accordance with GAAP in the United States for financial information and with the instructions to Form 10-K and Article 10 of Regulation S-X.&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_Xm_35WxdbEKvxXQ8HjGmlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_OPysTSHEHUyxqpqODrkBrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of December 31, 2022, the Company had cash equivalent balances of $30.3 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;changes in value because of changes in interest rates. The Company considers all highly liquid debt instruments with maturities of three months or less at the time the Company acquires them and that can be liquidated without prior notice or penalty to be cash equivalents. As of December 31, 2021, the Company did not have any cash equivalent balances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash as of December 31, 2021 consisted of bank deposits held to pay dividends on the Company&#x2019;s Series A and Series B Preferred Stock. As of December 31, 2022, the Company has paid the first year of dividends for the Series A and Series B Preferred stock and is no longer required to hold a restricted cash balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to any significant credit risk with respect to such cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:31.5pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 93,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_KamTyFYl4k-t4xNuCz2k4Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-5"
      id="Narr_pkuu0t86uEuHLXNh4uS75A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Group_tGEBuxCNEUKC1UVaCKlOTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 93,328&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,049&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,826&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,377&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_DMt2wz3aD0SIo0sqYQ1DNA_4_2"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_c9xNFR63VEeFfNNCbSwWcw_4_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">93328000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_90GZCpTsF0StQz95TJLETw_5_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2049000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_d4YdoIwz8UKWeH1blJ4wKw_6_2"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_-fZlXbVUv0C72_vhjMNSSw_6_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">95377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_1qmZW5H0RUuMhayR9Bmk-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_uA7PJl2oe0GKxgQrKGkqMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;</xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_qoqgKS59FEaTp-hX8597aQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <xoma:EquitySecuritiesPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_fIVhu7PGDECBbC_O40DMBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the consolidated statement of operations and comprehensive (loss) income in the period of sale.&lt;/p&gt;</xoma:EquitySecuritiesPolicy>
    <xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_nyx41DpeKEmjOOPVvs3vsg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their pre-commercial stages of development. The related receivable balance is classified as noncurrent or current based on whether payments are probable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty receivable asset. If an impairment indicator is identified, and the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized by reducing the financial asset to an amount that represents the present value of the most recent estimate of future cash flows. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022 and 2021.&lt;/p&gt;</xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_-X6iqpYqFkiyni-0GHPojA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-5"
      id="Narr_v5skynLYgkaCigj_RmC3MA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AssetAcquisitionsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_RUNl7ioZn0uZBnCeBxJxtA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the consolidated statement of operations and comprehensive (loss) income. Other contingent consideration payments are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s consolidated statement of cash flows. &lt;/p&gt;</xoma:AssetAcquisitionsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_wmQVw2riJkuB0m2LAmNgDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the consolidated statement of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_Qy0R61UYDEOWWQR8GJxwCg"
      id="Narr_VtUksiKWokyeNFgf8E65-w">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_eIX2ST9sgE-qBg6NwodDFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters office space in Emeryville, California. The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the consolidated statements of operations and comprehensive (loss) income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_OpjRhELLuUiObw1yAmpDWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_RXIKzFf980qbd0sROt55Sw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_-28o8Woldke9CFfvfTAPiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Net (Loss) Income per Share (Attributable to) Available to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted (loss) income per share (attributable to) available to common stockholders using the two-class method. The Company&#x2019;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net (loss) income per share attributable to common stockholders is then calculated by dividing the net (loss) income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net (loss) income per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_KAwjXEOuhkSnfS30GApabw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive (Loss) Income &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive (loss) income is comprised of two components: net (loss) income and other comprehensive (loss) income. Other comprehensive (loss) income refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net (loss) income. The Company did not record any transactions within other comprehensive (loss) income in the periods presented and, therefore, the net (loss) income and comprehensive (loss) income were the same for all periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_9KSQOL4lzk-Mo-iVg1F8QQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company adopted ASU 2021-04 and related updates on January 1, 2022. The adoption of ASU 2021-04 had no impact on the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. ASU 2016-13 will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. The Company plans to adopt ASU 2016-13 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The standard will be effective for business combinations that occur after January 1, 2023. The Company plans to adopt ASU 2021-08 and related updates on January 1, 2023. The Company does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_kmnyzOgTGUiJj5DCEuLfVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Consolidated Financial Statement Detail&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, equity securities consisted of an investment in Rezolute&#x2019;s common stock of $0.3 million and $0.8 million, respectively (Note 4). For the years ended December 31, 2022 and 2021, the Company recognized a loss of $0.4 million and $0.9 million, respectively, due to the change in fair value of its investment in Rezolute&#x2019;s common stock in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Intangible assets, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;width:18pt;"/&gt;&lt;span style="display:inline-block;width:18pt;"/&gt;The remaining life of the intangible assets is 16.9 years. The following table presents the projected amortization expense for the next five years (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Accrued and Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Accrued payroll and benefits  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_tIDqLvdLRU-RDFaGl32d5g"
      decimals="-5"
      id="Narr_icYQrOwPYE-DQ3V5SMtUUQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">300000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="As_Of_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_mDszNS3HWE2vdHDJSeC0mw"
      decimals="-5"
      id="Narr_S8NeLlRgQUKHiluphVvJRw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">800000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_ObP3X6UuqEmc0v7i_E4cnQ"
      decimals="-5"
      id="Narr_nZ7FcTbTeECrO-1Ia5F7ZQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_gA6KAG_rhUGJzhjdDOAkdA"
      decimals="-5"
      id="Narr_CPKxupGAd0eRoel8DKm6lQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_cYkmRm-iQEGtq_jFhccCdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang"
      decimals="-3"
      id="Tc_bw3_es1agU6CeEXTHR-l9w_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang"
      decimals="-3"
      id="Tc_kD8Xy66sp0m0kgf1lh9mPg_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_iRZwT3YMFECLrG0lHAWang"
      decimals="-3"
      id="Tc_mtNaLcLAn0yJwlcQ00zqZg_4_9"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_4Cnu27BfqkK8hZJ0j9FOjQ_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_FQ6ShbJhOkqIWMw86EyXPw_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_HzQ9VT-Wg0Ci6pKVbYRaiQ_5_9"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_lFkrNxT43UKki83VfacoxA">P16Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Group_YymV6f6gkkuU2gKcFZEobA">The following table presents the projected amortization expense for the next five years (in thousands): &lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_C-SM891sf0uC-Y9OYz3kIg_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_03tQDPqDOkGttkL7M4kkxw_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_D0EzuYmmUk2U-8qHKSLK9Q_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_a_tA6csFO0uu0m0FcFhenQ_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_bTj03u6qy0Okrf_eSiL9iQ_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_YqNo3mY2CUOiRXjAulR5KQ_9_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4485000</xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_-xO4HZj5tUKz7jVNt54hyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Accrued payroll and benefits  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 135&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 295&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 525&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_6NOFpFV2kUqcmx0yWznaqg_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1449000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_eHrtFRqGF0G1E2RyoVIkAg_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">135000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_63DJA4ZJKU-dOzxACCUzLw_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">867000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_x5Q-AYIXA0KYLy9FruCPdQ_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">295000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_pxfXsPTMokWCs4b6lDIl-g_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">562000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_XgJ1Xki7y065U0wHnolcVg_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">55000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_iuFlBM-dwUScjAmJBFlbgQ_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_nkpkQtRKWkSNWe05nPBHCg_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_bJuezVV100mF9_vHO2SyrA_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_BPm3TPJirEGPl4EzRd4aow_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">525000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:LicensingAndOtherArrangementsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_PNYAaApaoUiy4IK8-0w57A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Licensing and Other Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;ObsEva &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#x2019;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#x2019;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. &#160;If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments to Merck KGaA. &#160;The Company paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company will receive pursuant to the Organon License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#x2019;s cost to acquire said intangible asset of $15.2 million, consisting of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented 17 years. The Company recognized $0.1 million of amortization expense in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022. No impairment indicators were identified, and no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. No revenue was recognized related to this arrangement for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-TGF&#x3b2; Antibody (NIS793)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#x3b2; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#x2019;s anti-transforming growth factor beta (&#x201c;TGF&#x3b2;&#x201d;) antibody program (now &#x201c;NIS793&#x201d;). Under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#x3b2; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The Anti-TGF&#x3b2; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#x3b2; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that there were multiple promised goods and services under the Anti-TGF&#x3b2; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#x3b2; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#x3b2; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#x2019; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#x2019; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#x2019; first NIS793 Phase 3 clinical trial. The Company recognized $35.0 million as revenue from contracts with &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGF&#x3b2; Antibody License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized related to this arrangement for the year ended December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-IL-1&#x3b2; Antibody (VPM087) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#x201c;VPM087&#x201d;), a novel anti-Interleukin-1 (&#x201c;IL-1&#x201d;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, pursuant to a separate agreement (the &#x201c;IL-1 Target License Agreement&#x201d;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#x201c;Exclusivity Option&#x201d;) to such intellectual property for the treatment and prevention of cardiovascular disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal to &#x20ac;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#x2019;s outstanding debt with Les Laboratories Servier (&#x201c;Servier&#x201d;) (the &#x201c;Servier Loan&#x201d;). In addition, Novartis extended the maturity date on the Company&#x2019;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#x2019;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#x2019;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid-single-digits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#x2019; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how and filings to regulatory authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the years ended December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Takeda&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169, and low single-digit royalties on future sales of all products subject to this license. The Company&#x2019;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#x2019;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the first patient was dosed in Takeda&#x2019;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, the Company earned a development milestone pursuant to the Takeda Collaboration Agreement and recognized $0.8 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income. The Company recognized annual license fee revenue of $0.1 million from Takeda in the consolidated statement of operations and comprehensive (loss) income for the each of the years ended December 31, 2022 and 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Rezolute&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#x201c;RZ358&#x201d;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#x2019;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute is obligated to take customary steps to advance RZ358, including using diligent efforts to commence the next clinical study for RZ358 by a certain deadline and to meet certain spending requirements on an annual basis for the program until a marketing approval application for RZ358 is accepted by the FDA. Rezolute&#x2019;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute&#x2019;s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#x2019;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 1 clinical testing. Rezolute&#x2019;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#x2019;s obligation to make payments to Rezolute based on sales of such product in such country&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#x2019; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#x2019;s financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#x2019;s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#x2019;s common stock (as adjusted for the &lt;span style="-sec-ix-hidden:Hidden_osQASCJOc0aG36cPBan18A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1:50&lt;/span&gt;&lt;/span&gt; reverse stock split in October 2020). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $2.0 million and no revenue as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and December 31, 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Janssen Biotech&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company and Janssen were parties to a license agreement which was terminated in 2017.&lt;/span&gt; In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#x2019;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#x2019;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#x2019;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2021, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#x2019;s biologic assets. In December 2021, the Company earned a $0.2 million milestone pursuant to its agreement with Janssen.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company recognized no revenue and $0.7 million as revenue from contracts with customers in the consolidated statement of operations and comprehensive (loss) income for the year ended December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Affimed&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the commercial milestone payments are solely dependent on Affimed&#x2019;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. No revenue was recognized related to this arrangement for the years ended December 31, 2022 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#x201c;Royalty Sale Agreements&#x201d;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#x2019;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#x2019;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized the under units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements, and then applying that ratio to the period&#x2019;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $1.9 million and $1.6 million as revenue under the units-of-revenue method under these arrangements during the&#160;years ended December 31, 2022 and 2021, respectively. As of December&#160;31, 2021, the Company classified $1.6 million and $11.7 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively. As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. &lt;/p&gt;</xoma:LicensingAndOtherArrangementsTextBlock>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lLvvXbzgEakGtNGbJg_Ww"
      decimals="-5"
      id="Narr_AA1G-3oJekOOePSQ2g-yxw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">475000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"
      decimals="-5"
      id="Narr_x13qx5wL-kK-xVQb-PpI-Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <xoma:MaximumEarnOutPayments
      contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA"
      decimals="-5"
      id="Narr_CsfdCyMZ3EW55z9Ud9ZJjw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">97500000</xoma:MaximumEarnOutPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"
      decimals="-5"
      id="Narr_axQwYI-vTE6P431wou4efQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"
      decimals="-5"
      id="Narr_UFIXp2ohxkSl1qO2UxogcA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"
      decimals="-5"
      id="Narr_apzOHecpeUyQ0ZqrjVwyfA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_kq8hwRYLdU2Aq37buLDMsQ"
      id="Narr_bo2nVZP6rkeb0fDMrGiIoQ">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA"
      decimals="-5"
      id="Narr_Ahe5QIsxxUizl2KrKGn_7g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_uoeTAtwhKUeiS5wZpEmauA"
      decimals="-5"
      id="Narr_9XTuiqDn8k-WxjXJbdzMeQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments
      contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA"
      decimals="-5"
      id="Narr_APjb8rJJb0WkHzAs-I-YJg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">46500000</xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments>
    <xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments
      contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zrZTwzfC2UyP4hiYni6RMA"
      decimals="-5"
      id="Narr_h5rtTdjzREiskmVI-eH8lA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">51000000.0</xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g"
      decimals="-5"
      id="Narr_A1kCUnvEVkeIqfayjmaonA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LcyRABZuFUuFttq4VlGQ_g"
      decimals="-5"
      id="Narr_as3kJxdm2k2N9To8DQfWUQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_H1WDisLgxkqIvK7clGpKEQ"
      decimals="-5"
      id="Narr_-m16cPG_e0G0sqDYNO3t7w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A"
      id="Narr_QuNAM6UTBUi0dix_wZDOIw">P180D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_KVu_yvqyJ0yPLDDMilae0A"
      decimals="INF"
      id="Narr_kERFMM1IGkGqX-HRQc5VOQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">1</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA"
      decimals="-5"
      id="Narr_oNHa2zwoIEe3d9OCtmTPKg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">37000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eQF9JLRlyEejj06iy_3irA"
      decimals="-5"
      id="Narr_iJv1Ie6ugE-hMNuM9yQGOA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">37000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7DasBvaAtkS6lYyw7kjKSA"
      decimals="-5"
      id="Narr_pSt56gvjvUGTB7Xj2qxmEQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">480000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_G8esAtNmakKoYvkKmZ81HQ"
      decimals="-5"
      id="Narr_7STsoBHNFEyiW0AtNw_SZA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_9_1_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_GF-6_dQKikmqEGqiVXM_qA"
      id="Narr_sxUK_zsWCUKwlx3CoAOOlQ">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g"
      decimals="-5"
      id="Narr_1LZ3t2nkSEWe3SuWckVpsA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_tseYSGPEEUSQhvhKXj9T9g"
      decimals="-5"
      id="Narr_zysQ4yJds0Ce7B-RDefZXw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">17700000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_0HQ2F4usPUGiRtw00ne_tw"
      decimals="-5"
      id="Narr_Yh9uDECpxkOfNVaEBsjX0A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-7300000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_pQS3U8aNZU-yXj_-Ru7Piw"
      decimals="-5"
      id="Narr_Of-57e0UA0OwTmEsrF4z7w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">35000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1sPaZ1NGOUiQwEfq8TQ6mg"
      decimals="-5"
      id="Narr_EuYRerGYbk-z9SITiDYNAA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">35000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ"
      decimals="-5"
      id="Narr_RJvrk0V6KESPsHjHA8ywIw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">410000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w"
      decimals="-5"
      id="Narr_mUpfRhvkk0KZsrvoYgF1Cw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ"
      decimals="-5"
      id="Narr_rWKiyUA6T0aAFlHkvFLYwQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w"
      decimals="-5"
      id="Narr_5SgqhQEjlkOv32eReShtDQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ"
      decimals="-5"
      id="Narr_anP1oMP0m0SNfn6pyDqBYA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_z7utmOOMN0er5oiDyfID7w"
      decimals="-5"
      id="Narr_N6P_LIilFUyijP2yWXsWjQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__MfytwW7bk6OaDgVTdZIjQ"
      decimals="-5"
      id="Narr_fUOxNf7PVkKeWhHzR6pvmw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_wmOMUEuzuk6yS0QoDP0Ysw"
      decimals="-5"
      id="Narr_j3BwY1d1B0SyWg8s0gv1Wg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_LOXhb2YAVUiCSsgzV707tg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30000000.0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_I6pQyKLUkUuY5x7LOxlanA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_KBknEIw28UqcAdm0ztzRzA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_RGtbFuLmGUWEQv3eV3AbRA"
      unitRef="Unit_Standard_EUR_fwE8yWfrn0K-IqzRprsY2A">12000000.0</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_zxnsIjh_CEWpIY4bqVxV7Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw"
      decimals="INF"
      id="Narr_5HV6RMbJ6kqeVqeUwpkS3g"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">539131</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg"
      decimals="4"
      id="Narr_jPTAzgIwzkuRGvLLLeWmUQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">9.2742</us-gaap:SharesIssuedPricePerShare>
    <xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_4D-kQW7zNUmM8cJ_6D1Hbw"
      decimals="-5"
      id="Narr_Vo6IJGTuVECdfmRH-OJwtg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4800000</xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_EdsryT3a40mWz7xqx0cgfg"
      decimals="INF"
      id="Narr_O4qqeUXvRUOuXlgWB_pilg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">8.93</us-gaap:SharePrice>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      decimals="-5"
      id="Narr_K76MH7biSEC1Pe9Q8-s-Cw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</xoma:CommonStockPremium>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_9ni1jDQqGE2MNc84XrIr5g"
      decimals="-5"
      id="Narr_4dU6Yr6XbkWGPOyxOwuAPQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">438000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_rJ-F8BD5CUu-Uk0PG_Pfyw"
      decimals="-5"
      id="Narr_PTXKBMTsfU6FkEhfEiWlwg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:NumberOfLicenseAgreements
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="INF"
      id="Narr_PAUTxvkh1kmUsdEm1a0MCg"
      unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ">2</xoma:NumberOfLicenseAgreements>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_TK0PaaAIl0KfRdTrm-5GvQ"
      id="Narr_mKpLgvvU_ESS4rWpVijdiQ">P6M</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:ArrangementsNumber
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="INF"
      id="Narr_BezZzAnZc0q5lv8nwbxmcQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">1</xoma:ArrangementsNumber>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA"
      decimals="-5"
      id="Narr_tcv9gnTwCUKECkDxfYg3Lg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueRemainingPerformanceObligation>
    <xoma:LicenseAgreementTransactionPrice
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="-5"
      id="Narr_oufEjfcUPkiZNXdirvkCQg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40200000</xoma:LicenseAgreementTransactionPrice>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="-5"
      id="Narr_-QX8b6_AKE68rdeZBUEfGA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">25700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="-5"
      id="Narr_1N_JNKJu7kSZU2GORTx2dQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="-5"
      id="Narr_RIZvTcOGwUKXPYUvOQ1nIA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</xoma:CommonStockPremium>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="INF"
      id="Narr_dbRbQWs7-02MXgh7yBH72g"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:NumberOfPerformanceObligations>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ"
      decimals="INF"
      id="Narr_px_56qjut0Sns8lermBa2Q"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_r11OGkPAXkWTZaN_G9-weg"
      decimals="-5"
      id="Narr_N8Dy_QCOIEmSUX21_KeCSw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA"
      decimals="-5"
      id="Narr_7mfj_7ebGkGUh0k6xCo79g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw"
      decimals="-5"
      id="Narr_UtuD8ct0kE6ZcmEGtFtJHA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA"
      decimals="-5"
      id="Narr_gro3K76bP0OQmWnemm-I-w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw"
      decimals="-5"
      id="Narr_cQIm4Lti5k-PRwlP0kEKrg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_5RXtyq-dyUqKJ5Y8eyc1pw"
      decimals="-5"
      id="Narr_aMZBjU8EQ0Kgm-_wARFcmQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_HLciOLKKD0iloE22xw-OtA"
      decimals="-5"
      id="Narr_U_TmjdUVK0KwRE_u1_RuLA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_x7uVaLNyW025G4gxpaAXkQ"
      decimals="-5"
      id="Narr_NiltdSfsZk-ZK1L_0_avbA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_kNUrGAqyEkalFB8W0WRezg"
      decimals="-5"
      id="Narr_UPLTthXsyUuUgXa9bzBhEw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_gb8Mq7RYNUyPvOuADsltaQ"
      decimals="-5"
      id="Narr_KnEHTfppvk2dFzYQ2l4M2w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">19000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_daw_HrxdKUKz56KM-1KXIQ"
      id="Narr_EukrVGVLYEuSI9z6J6k3kA">P13Y6M</xoma:RoyaltiesPeriodMinimum>
    <xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ"
      decimals="-5"
      id="Narr_FIp5mhO8yUqHcvDXcXQJvg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3300000</xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_ql6Wy08W2Uef-iqGrYtfYQ"
      id="Narr_8lTCShzHaUKKjZmgyv0_Xg">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_11_16_2020_To_11_16_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eC4aFolUA0GTxlIWZ6Cc1Q"
      decimals="-5"
      id="Narr_PHbUYYF-FEeFP0aTcv-yrA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_aQqKR6_fy0yZBwIQWrikJQ"
      decimals="-5"
      id="Narr_tFiRVlUiAEKRMJaYR1JLoA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_7wxTmOyFPkGXQt3cSa57RA"
      decimals="-5"
      id="Narr_et-e7GgfWUiOwBMbFJUlPA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_EuXVMgiSQkKFYqjEXEEp2Q"
      decimals="-5"
      id="Narr_2M1j78B2XkKk3bgov0AT-A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w"
      decimals="-5"
      id="Narr_KVlM-TrrKkaytvD-T-MHoA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug"
      decimals="-5"
      id="Narr_Nu5yGJg4u0a4xpAMTVp3Rg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w"
      decimals="-5"
      id="Narr_6q7rrgqGBkOnCvdN-oUk-w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug"
      decimals="-5"
      id="Narr_7xl6kinD4kCita5IrTnhpA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w"
      decimals="-5"
      id="Narr_YZvYRbVzLECmq8sDVquTyw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_FbNMSgy_gESr7JJxwc0vug"
      decimals="-5"
      id="Narr_0eq236-WtkGBmxQjnIQVVg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w"
      decimals="-5"
      id="Narr_XYGKxv5BIUGLGdCmTAnZCg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">16000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_DWIu-n3lPUiIYGcRZmhJLA"
      decimals="-5"
      id="Narr_gSk9xJXyMUqEAUPbQlUu5w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">232000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_j83jgfg09UidGXoNWAtd8A"
      id="Narr_0eeoZie_V0-KiSnlJ8t0IA">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:PercentageOfDecreaseInFutureRoyaltyObligations
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw"
      decimals="2"
      id="Narr_BKh8Usf07kap5QzW4E1AXA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.20</xoma:PercentageOfDecreaseInFutureRoyaltyObligations>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_I3wo0vb-CUixzfe_qIAyTg"
      id="Narr_LbleYQ9Or02yDAUZOIg96w">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw"
      id="Narr_WCMTJxnVkkyQwPrv8crMng">P90D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_isl74DFN1k-HZDolcIN9Qw"
      decimals="-5"
      id="Narr_yjwNFP6S2U-RBHFsecGGDg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities
      contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg"
      decimals="-5"
      id="Narr_XkeFsY6t7k229Or54IAf6w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6000000.0</xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities>
    <xoma:LicenseAgreementInstallmentPaymentsReceived
      contextRef="Duration_12_6_2017_To_10_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_qSq-3aaJLkKJbKH1p2mucg"
      decimals="-5"
      id="Narr_7bl7_omANE-4LXBtserg8g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8500000</xoma:LicenseAgreementInstallmentPaymentsReceived>
    <xoma:LicenseAgreementSharesReceived
      contextRef="Duration_12_6_2017_To_10_30_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mfqGdjZYME-gcLNsUw5Lng"
      decimals="INF"
      id="Narr_vHTgM87plU6b5bajISbzHw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">161861</xoma:LicenseAgreementSharesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_867K-w4nlkWwUkggr9tW3w"
      decimals="-5"
      id="Narr_A7vssnfNOUi9NdFa2QnS1w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_8SsPA-cdo0K4zx7dDhkPMA"
      decimals="-5"
      id="Narr_AVqelqyyPk-kU35ev3nW5g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UWK0SRUsv06_NuNedSDLfQ"
      decimals="-5"
      id="Narr_W0bkIcm1FE-rATTiX6cL0w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA"
      decimals="-5"
      id="Narr_dFE8e5qzOECln2Ps7eQaPg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA"
      decimals="-5"
      id="Narr_X113JsXI70-ml5eAOvpXzg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA"
      decimals="-5"
      id="Narr_dhVkumxt2U-3qp5zjfDtNQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA"
      decimals="-5"
      id="Narr_JuceBWqzaE2yAJJk8ekA3A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_6mnYDMuk6E6p3ebx-v0fnA"
      decimals="-5"
      id="Narr_aFnHuC66l0uUMFI6UWbfjA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_onwYZAUcxU6S45_zZqi-UA"
      decimals="-5"
      id="Narr_U1G66e6H_0-BuOJHsyx6mg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg"
      decimals="-5"
      id="Narr_Ju87qs_CPk6pc4jwWfrPPQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg"
      decimals="-5"
      id="Narr_mXT7G1bnEU6g_-Z3RGvhtA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents>
    <xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg"
      decimals="INF"
      id="Narr_gWGeTHxgy0qeL3EVJKaxZw"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0075</xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U2mBKo7TtEGcPUHwD7IglQ"
      decimals="-5"
      id="Narr_4zvYS7eywUq7BCGCiGE5dg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_5_1_2021_To_5_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_PL6qNM8JgkeHSr5yXfQ1uw"
      decimals="-5"
      id="Narr_ZBBREFKWiUCV7JQKQ47Q6g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_12_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_P4EQyfpsBUSEXZiG7S71Fw"
      decimals="-5"
      id="Narr_M6d-w5SrH0GSy4Ll3Lj0Ig"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ"
      decimals="-5"
      id="Narr_QHibXrOq0Uapn27emCVY5Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA"
      decimals="-5"
      id="Narr_P8SQebPFukSCFbOJ3i0dEA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ"
      decimals="-5"
      id="Narr_Jc-3J8t6ek-plJYbk6ebmA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA"
      decimals="-5"
      id="Narr_zqrxwfY-E0eBJbF-4cEnXQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_2UL8kRLktU2owolr1PINxQ"
      decimals="-5"
      id="Narr_MB1k_FE490e3F6hITNFdoQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_iPurz2zLeEOPNxDRvPltEA"
      decimals="-5"
      id="Narr_2nHOGC5Ig0K4jqHxVKJ1gA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xdeG_av2K0qt9xOQHo2aRg"
      decimals="-5"
      id="Narr_R9A_q1kv2ECnWTx0n3djeg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_IXa196Wdf0SCxbIeQySyiQ"
      decimals="-5"
      id="Narr_V7EqN_pGN0OrmQQ3N3xnzA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ"
      decimals="0"
      id="Narr_fkbKOMO31E2L_JoljZNMpg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q"
      decimals="0"
      id="Narr_JPc2PX6ZN0uz4Hm8hpD69g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ"
      decimals="0"
      id="Narr_woVVlZFTpEib8T1ryZt1MA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q"
      decimals="0"
      id="Narr_nUDR9APUUUGizz9lHyrKsg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_gZ2ChkDd50GXLUzwSxDnkQ"
      decimals="0"
      id="Narr_WJishCjv0EKd5KvCF-PA1Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q"
      decimals="0"
      id="Narr_ECqgzF21IEuKDArWEBESeA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_WMb-KT8So0uQN8syGEGdzg"
      decimals="0"
      id="Narr_FQ4vqAqqJUqDq8ae5Xg__A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_cenBgMUh9Uyccspm0H9hgA"
      decimals="0"
      id="Narr_xiig2a_FsEqPdrr8Ckt4LA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg"
      decimals="INF"
      id="Narr_RvEU-Ikvj0mht0fulYuqzw"
      unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_ugLN8Eo-O0CB7wwIKyDDpA"
      decimals="-5"
      id="Narr_8fdrxJMhp0uLYvtNvjcdDQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ"
      decimals="-5"
      id="Narr_1Uex0FhJ0Eu0qF2Y_XkI0w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4000000.0</xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones>
    <xoma:MilestonePeriodsNumber
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_3d1iv32RhkKU82IVCilGQQ"
      decimals="INF"
      id="Narr_IluBSZgUAUqCA1CX0m2nrA"
      unitRef="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw">3</xoma:MilestonePeriodsNumber>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_aPOJphzjLkGSA83nJdzBJw"
      decimals="-5"
      id="Narr_qT3Ygo8rp0GypPSwstTlzQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">11500000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg"
      decimals="-5"
      id="Narr_aPG3qxv3CEa-6nPHXFOX_g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">18000000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg"
      decimals="INF"
      id="Narr_-RzU3nJgZkajpiPN1Pb64Q"
      unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_BsX5M1Uu6EOTSHfP8EnvNA"
      decimals="-5"
      id="Narr_8SvB3dDCxEOzkp2n0kBY3w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1900000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_aM7qfAJs_Ue2FngKRak2-Q"
      decimals="-5"
      id="Narr_vWFy-C4A60eA68eb5o5xWA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw"
      decimals="-5"
      id="Narr_LgHnTr7tQUGlusKD_x4gBw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1600000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_EEJSLzhUO0i2aW-rfeeYCw"
      decimals="-5"
      id="Narr_d43QRzRZM0KHRczmQKBKOg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">11700000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g"
      decimals="-5"
      id="Narr_TXegeEutYEOwrM0WLG6ppA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1900000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_J7EwvA53r0ORC42fQSrJ3g"
      decimals="-5"
      id="Narr_Ae3NIJA-Ykee7NBFk8bHcQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">9600000</us-gaap:DeferredIncomeNoncurrent>
    <xoma:RoyaltyPurchaseAgreementTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_kOXxdNlkoEOsyJqaZo2Kpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Royalty and Commercial Payment Purchase Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The balance of short-term royalty and commercial payment receivables was $2.4 million as of December 31, 2022. There was no balance of short-term royalty and commercial payment receivables as of December 31, 2021. The balance of long-term royalty and commercial payment receivables was $63.7 million and $69.1 million as of December 31, 2022 and 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Agenus Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#x201c;Incyte&#x201d;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen digit percentage of applicable net sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#x2019;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessments and no impairment indicators have been identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Bioasis Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company may be obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Bioasis RPA, the Company paid $0.3 million and will make contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#x201c;Bioasis Contingent Consideration&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $0.1 million. Future changes in the estimated fair value of the contingent consideration will be recognized in the other income (expense), net line item of the consolidated statement of operations and comprehensive (loss) income. As of December 31, 2022, there was no change in the fair value of the contingent consideration from its initial value and no amounts were paid during the year ended December 31, 2022. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that are being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under the Second Bioasis RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Aronora&lt;span style="font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#x201c;Non-Royalties&#x201d;) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora&#x2019;s collaboration with Bayer (the &#x201c;Bayer Products&#x201d;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#x201c;non-Bayer Products&#x201d;) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#x2019;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#x201c;Aronora Contingent Consideration&#x201d;). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#x201c;Royalty Milestones&#x201d;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Palobiofarma Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#x2019;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#x201c;Palo Licensed Products&#x201d;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#x2019; entry into the Palo RPA on September 26, 2019. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Viracta Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Kuros Royalty Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#x2019; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. &#160;Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;As of December 31, 2022, no payments are probable to be received under the Kuros RPA in the near term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Affitech Commercial Payment Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#x2019;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which includes the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Genentech, a member of the Roche group, received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone tied to these U.S. marketing approvals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, in connection with Roche receiving approval from the European Commission to commercialize VABYSMO for the treatment of neovascular or &#x2018;wet&#x2019; age-related macular degeneration and visual impairment due to diabetic macular edema, the Company made a $3.0 million milestone payment to Affitech pursuant to the terms of the Affitech CPPA. As a result of the EC Approval, XOMA is eligible to receive a 0.5% commercial payment stream for ten years from the first commercial sale of VABYSMO in Europe.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Company received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $0.5 million received was recorded as a direct reduction of the long-term royalty receivable balance. In February 2023, the Company received $2.4 million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was reclassified from long-term to short-term royalty and commercial payment receivables in the Company&#x2019;s consolidated balance sheet as of December 31, 2022. Based upon limited available information, the Company is unable to reasonably estimate future net sales and the commercial payments to be received during the year ended December 31, 2023 and, as such, no additional amounts are reflected as short-term royalty and commercial payment receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. &#160;The Company performed its quarterly impairment assessment and no impairment indicators were identified. Accordingly, no impairment was recorded as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty receivable activities during the years ended December 31, 2022 and 2021 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment rights:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Viracta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:RoyaltyPurchaseAgreementTextBlock>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_30eZjgFsLEaw_G0n6V204A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2400000</xoma:RightsReceivableCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-5"
      id="Narr_HwI9NEJxgkqd_um2isqDhw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_JJHmjGixq02zDs_Qpvmj9w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">63700000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-5"
      id="Narr_VnH_PtYmxkCPztXdVqKM5g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">69100000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg"
      decimals="2"
      id="Narr_4-DsOA7VvEWZR9gX9CsQ6A"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_iEIWRBlOt0yzDz75899Udg"
      decimals="INF"
      id="Narr_5vcuh6_8f0ahtGr3x9vu3w"
      unitRef="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ">6</xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lP-1sgwP7kC3A25KNKaI5g"
      decimals="2"
      id="Narr_c0_yRHyDK0u-2CT3doMjIA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng"
      decimals="2"
      id="Narr_JQH3grFnSE2r2ZP0tfOL-A"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_p4dgpct0ik2knGpohVsu9Q"
      decimals="2"
      id="Narr_tTBqu7R9pUajOAXqJ-Msgg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rc-zI64j20utwMuoPeArng"
      decimals="-5"
      id="Narr_Kh-9_d_7_0aQQx_DveJmHA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">59500000</xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_j4ElNZhA0E-_JPRkD0IGeg"
      decimals="-5"
      id="Narr_WX0uziB3Sk6_TGOnGeu6Kg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15000000.0</xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qccAUP40R0mSuKlRmGHvKA"
      decimals="-5"
      id="Narr_ZgT0XiAQEE6cTdaOTmtgXw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CXsrLLVq5kSPUm74NYuFBA"
      decimals="-5"
      id="Narr_ULw8dyDdjk-zrRU4AzhBwA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10000000.0</xoma:MilestoneAchieved>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ"
      decimals="-5"
      id="Narr_Ly4atDKgw0upvsfHyN2RXQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000000.0</xoma:MilestoneAchieved>
    <xoma:CashReceivedForAchievementOfContractualMilestones
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1tJfwKmgUkuC7FQP5ao3GQ"
      decimals="-5"
      id="Narr_yTJctROjQk-3IfwLtVMXzg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000000.0</xoma:CashReceivedForAchievementOfContractualMilestones>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_MAbD5nWZf0aUq7Ov_NLXRQ"
      decimals="-5"
      id="Narr_XYYLTNy10kmhj0v-Y3KeNQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"
      decimals="INF"
      id="Narr_6d-cdSLtZE-DXKAFC0pUdw"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.01</xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements>
    <xoma:NumberOfLicenseAgreementsFutureLicenseAgreements
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg"
      decimals="INF"
      id="Narr_TLQ7hb81_EuLPLcDpGHLLA"
      unitRef="Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ">2</xoma:NumberOfLicenseAgreementsFutureLicenseAgreements>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"
      decimals="-5"
      id="Narr_P2hCrAlYQkO-YKvRZLDW2g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">300000</xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg"
      decimals="-5"
      id="Narr_yw8Hq-BU7kSe_lBtMfW0_Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">400000</xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_-85ep8k6RUms-t9cejJztg"
      decimals="-5"
      id="Narr_PXeVh52tPUK_IDKzxYVSzw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">300000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_FwHL2hBqk0yF5G8wK5a2qg"
      decimals="-5"
      id="Narr_O-To3VAQvEu3CDe1gOzevw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</xoma:ContingentFutureCashPayments>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"
      decimals="-5"
      id="Narr_0gbuwiJPkkeQ96ZgoyPBQQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">400000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"
      decimals="-5"
      id="Narr_8q4lNKGzV0ytGmrv4V-nXg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"
      decimals="-5"
      id="Narr_w99E8bZ4zUqbZLBCG0gtjQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"
      decimals="-5"
      id="Narr_VOU6eoqF-EWDpyy74PZRKg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:PaymentsOfContingentConsideration>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"
      decimals="-5"
      id="Narr_XCX-GXu_aUql7RsveubZrA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_s6Xmk-SskE67Bmh6cHSc5g"
      decimals="-5"
      id="Narr_vMC5JMcovEyDqVJPkFMaKA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1200000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_V_cdDAl530WO8X_Yw2S8dA"
      decimals="-5"
      id="Narr_C5JFS8lPCEKaM2Rj05xCvA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1200000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_8Lp1iopY80moFAsWA0Oicw"
      decimals="-5"
      id="Narr_YxLfgNZs50OdaN0rhpzu-A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="INF"
      id="Narr_uCGbr5fahUmTsmM7d98Osg"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">5</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"
      decimals="INF"
      id="Narr_mFIhKUQDVkKe9JtFWKzj1g"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"
      decimals="INF"
      id="Narr_okNvQN8m8UKdxSetJqzwvQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">1</xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw"
      decimals="INF"
      id="Narr_tC8XyNVia0q5MJokDP5RIg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"
      decimals="INF"
      id="Narr_TDeVtpuRPE-AumUx2VlfqA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw"
      decimals="INF"
      id="Narr_mII8YC2zjkiB0IKNOeOyDQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_7w6-pLKjmEeED7I5wiULyw"
      decimals="INF"
      id="Narr_5UjpruV03EikUQ_3xM5owA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="INF"
      id="Narr_FDbB1j8njUmZTjxG2xR7Lg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="INF"
      id="Narr_Qg26j2I1W0Sac3Es0ym_RA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.05</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage>
    <xoma:AgreementPaymentPercentageFactor
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="INF"
      id="Narr_C4534sMJeE-yB79LZPOl6g"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:AgreementPaymentPercentageFactor>
    <xoma:UpfrontPayment
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"
      decimals="-5"
      id="Narr_m5f8jD6llUO8X0Wzxmyc9g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6000000.0</xoma:UpfrontPayment>
    <xoma:UpfrontPayment
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_83JqH9MaqUu4NibTiAAyew"
      decimals="-5"
      id="Narr_2cdif2Hf6EejCFFVcm28iQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:UpfrontPayment>
    <xoma:ContingentFutureCashPaymentsPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__gBAX88wrkuvOJUQaM7bVw"
      decimals="-5"
      id="Narr_UGrqzTO8TkyLln5PnDW2gg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1000000.0</xoma:ContingentFutureCashPaymentsPerProduct>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"
      decimals="INF"
      id="Narr_54LWm-iYUESIrWHsO7vyRA"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6s2mrIuuWkGCuobCGP5Vwg"
      decimals="-5"
      id="Narr__S8RgYv01UO3gDRnoHx_Dw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:ContingentFutureCashPayments>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"
      decimals="-5"
      id="Narr_wkab-DXxvECqI2EluVPvOQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:MilestonesPaymentsToAggregateAmountOfPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"
      decimals="-5"
      id="Narr_LAGUYSNkekisvCiSFJEUtQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">85000000.0</xoma:MilestonesPaymentsToAggregateAmountOfPerProduct>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"
      decimals="-5"
      id="Narr_vDy71A6aIUOzYMrPc5_xXg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_4PGj03XkF0KFpJXam_Hz-Q"
      decimals="-5"
      id="Narr_g1F0OBf7j0WjQWqPxwZK0w"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="-5"
      id="Narr_saZIlH4B90CGfRJmvskgkA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">9000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A"
      decimals="-5"
      id="Narr_UFUADyCv0UOL7ca-KcSTpQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_jKmiP9r9_kuqlBxvTOdkgA"
      decimals="-5"
      id="Narr_XABpITpnQESxgwHnGeRdtw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:PaymentsOfContingentConsideration>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wVSdoYr4jUereb7ZG5cXaw"
      decimals="-5"
      id="Narr_1aId8b5t10C-6Wm6O1rVKg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg"
      decimals="INF"
      id="Narr_DQz6gMlwmUizNRHwg5QyGA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5i_Uy5BsyEObHFG9u5GxwQ"
      decimals="-5"
      id="Narr_g2jmBdjmFECy9_w2abNx2A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10000000.0</xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg"
      decimals="-5"
      id="Narr_eDWmuuCiJEKMe1ytakqnRA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_VbBrsLclIUqIJDiHDqkKUA"
      decimals="-5"
      id="Narr_hwbaTrVvXkypds8CCBy1rg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"
      decimals="INF"
      id="Narr_qSi-FNKwOUyIYBhH2mNWuA"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights
      contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_EbXYjQ5mzUCNFK-esz7zlw"
      decimals="-5"
      id="Narr_MEHzLlJ2HkmAg8Vdgxr9oA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13500000</xoma:PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights>
    <xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"
      decimals="-5"
      id="Narr_QgGY72jWI0yckroS_jbqcA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">54000000.0</xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum>
    <xoma:MaximumConsiderationRetained
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"
      decimals="-5"
      id="Narr_9BpXX7ddL0CuTirotEJa_Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20000000.0</xoma:MaximumConsiderationRetained>
    <xoma:RegulatoryAndCommercialMilestonesReceivableMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"
      decimals="-5"
      id="Narr_s95A3ozzwEG8ObROWZoWYg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">57000000.0</xoma:RegulatoryAndCommercialMilestonesReceivableMaximum>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ"
      decimals="-5"
      id="Narr_rFnK-vmXR0q6nG-2x7neUw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13500000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_v4dNNnJyNk2mkUC5mofV7g"
      decimals="-5"
      id="Narr_p2qhVL49i0KeWPhgsjU9RQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"
      decimals="INF"
      id="Narr_GC1teheqTUyBM0UdNcMjyg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"
      decimals="-5"
      id="Narr__gePlOh5pUOQfQTw3UpTMQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">25500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones>
    <xoma:UpfrontPayment
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"
      decimals="-5"
      id="Narr_JcwoIZoaJkyMEMgIAP0usQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000000.0</xoma:UpfrontPayment>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"
      decimals="-5"
      id="Narr_K8WSoyU0J0CtiVzVi_NwHQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">142500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_c9juPFjI2UyPCCkvD4DUNA"
      decimals="-5"
      id="Narr_DO-2euXFHUqm4N26RIhVHg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MilestonePaymentReceivedCounterparty
      contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_qkTeCxJPbk-sQaXhYuVwgg"
      decimals="-5"
      id="Narr_gv17kKdVXUeEmeuC7pzEmw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5000000.0</xoma:MilestonePaymentReceivedCounterparty>
    <xoma:MilestonePaymentReceivablePercentage
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA"
      decimals="INF"
      id="Narr_NgrbX__91U61m2ASeL_CXA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</xoma:MilestonePaymentReceivablePercentage>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_43509g1PLEqQVPLib8nQng"
      decimals="-5"
      id="Narr_JOvfy0SbYUezR4UkXJWpag"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_lVrv91FNZU23z9vv3AQpjg"
      decimals="-5"
      id="Narr_H30wB9zhs0ePZ6BTyBifsg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:UpfrontPayment
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw"
      decimals="-5"
      id="Narr_vMcVf9hnuUy7qgq2C52zmw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6000000.0</xoma:UpfrontPayment>
    <xoma:CommercialSalesReceivablePercentageOnNetSales
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw"
      decimals="4"
      id="Narr_duHYrYRSXE2bejomMxNJsQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0050</xoma:CommercialSalesReceivablePercentageOnNetSales>
    <xoma:CommercialPaymentReceivableTerm
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw"
      id="Narr_ooFi4ow-DUqgHa_5CbvaiA">P10Y</xoma:CommercialPaymentReceivableTerm>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"
      decimals="-5"
      id="Narr_AhuzlSoWK0mZkFVm46f1eg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"
      decimals="-5"
      id="Narr_6l94mu3WR023CHJP8x84GQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">14000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:UpfrontPayment
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw"
      decimals="-5"
      id="Narr_2eFlYPyUR0G9JtTbM8hZeQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6000000.0</xoma:UpfrontPayment>
    <xoma:MaximumPayableOnRegulatoryMilestone
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"
      decimals="-5"
      id="Narr_LtzNz1d9_UOkM-mofiIwQQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000000.0</xoma:MaximumPayableOnRegulatoryMilestone>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"
      decimals="-5"
      id="Narr_dL0biRcLQE2o79IGiJORGw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_sA59CTn2UkKxNRGrqU87MQ"
      decimals="-5"
      id="Narr_57EK_vMqWUmNmBpE0DQrcg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">12000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:MilestonePayment
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w"
      decimals="-5"
      id="Narr_DFmBEHTugUOio4mmb0kDRg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5000000.0</xoma:MilestonePayment>
    <xoma:MilestonePayment
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA"
      decimals="-5"
      id="Narr_FwXu1oXt8UaNgv2uqSdq7g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:MilestonePayment>
    <xoma:CommercialSalesReceivablePercentageOnNetSales
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w"
      decimals="INF"
      id="Narr_t3jsfAlmwUalXHIs1yudgA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.005</xoma:CommercialSalesReceivablePercentageOnNetSales>
    <xoma:CommercialPaymentReceivableTerm
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_LhqmQz3yQke4LofsQefn4w"
      id="Narr_JvgOEUtqNkeS8e96_LLK2A">P10Y</xoma:CommercialPaymentReceivableTerm>
    <xoma:CashReceivedForAchievementOfContractualMilestones
      contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qeDzPAJvEkG3H6Q0IdTsfg"
      decimals="-5"
      id="Narr_9fusWFK4WUOGFRUJxybphQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">500000</xoma:CashReceivedForAchievementOfContractualMilestones>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_SHL2DGznK0y-hmUTeZ2Q-A"
      decimals="-5"
      id="Narr_VZuWbdyx4kKN9RPgrzRGlA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:CashReceivedForAchievementOfContractualMilestones
      contextRef="Duration_7_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4AJG2U9b-06BTayaXGugZA"
      decimals="-5"
      id="Narr_P4ZimDNm5ECu3i8DsCMUgw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2400000</xoma:CashReceivedForAchievementOfContractualMilestones>
    <xoma:ImpairmentOfLongTermRoyaltyReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_NqA3jpIWgUS-c7ELvkpPVA"
      decimals="-5"
      id="Narr_MPNl3227WkOgktyd0DznxA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ImpairmentOfLongTermRoyaltyReceivable>
    <xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_a8SH7dVFiEKxwKBTsvE46w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty receivable activities during the years ended December 31, 2022 and 2021 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment rights:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Viracta&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Kuros&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:78.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw"
      decimals="-3"
      id="Tc_luvHZUi680KgF0_cQGAIGA_2_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">34575000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_kB9yfId7VkK_kt3X391buA"
      decimals="-3"
      id="Tc_ptOwam8W7EulDK87yn6QSQ_4_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13500000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_9IG6mnsXWkKJ-8l8yrS4Uw"
      decimals="-3"
      id="Tc_HIbJytQOpE-UX-A_CYdfow_5_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7000000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_m0XXi-6V7kqy8Lqgpe0vfg"
      decimals="-3"
      id="Tc_tMe4-bsZ0EORjp_8cPAQCg_6_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">14000000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_1EFx1whi7UOdqgcw35RAmA_7_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">69075000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_kQY9oDQ6-02HjwmVuO7AAQ"
      decimals="-3"
      id="Tc_4BzmG0ArgEWpUPjUL0I3OQ_9_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q"
      decimals="-3"
      id="Tc_CwZO45sv6Uq0rXZHujiv9g_10_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">526000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ShortTermRightsReceivableReclassification
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q"
      decimals="-3"
      id="Tc_DLPz9HlWp06o0MgeCbmlwQ_12_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2366000</xoma:ShortTermRightsReceivableReclassification>
    <xoma:LongTermRightsReceivableReclassification
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_Z-CnDBX5sUCUQrMJ2YoD0Q"
      decimals="-3"
      id="Tc_YVPN7sYtzEeQPj7_68vNng_12_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2366000</xoma:LongTermRightsReceivableReclassification>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_BUzxMJfSsEOXjho7J0K2gA_13_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2366000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_Bzzrt1uTs0uFcieqx0EbCg_13_5"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_SW8cYPo8dU2pC4vXVhG9pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#160;&#x2013; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#160;&#x2013; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration under RPAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2021 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Equity Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The equity securities consisted of an investment in Rezolute&#x2019;s common stock and are classified on the consolidated balance sheets as current assets as of December 31, 2022 and 2021. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income. As of December 31, 2022 and 2021, the Company valued the equity securities using the closing price for Rezolute&#x2019;s common stock traded on the Nasdaq Stock Market of $2.07 and $4.78, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:12.25pt;margin:12pt 0pt 6pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingent Consideration &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the contingent consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the contingent consideration liability at the inception of the Affitech CPPA represented the future consideration that was contingent upon the achievement of specified regulatory milestones. The fair value measurement was based on significant Level 3 inputs such as anticipated timelines and probability of achieving regulatory milestones. During the year ended December 31, 2022, the estimated fair value of the contingent consideration recorded pursuant to the Affitech CPPA decreased from $8.0 million to zero after the Company paid Affitech a total of $5.0 million for milestones tied to the achievement of U.S. marketing approvals in January 2022 and $3.0 million for milestones tied to the achievement of EC Approvals in September 2022 (Note 5).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the consolidated statements of operations and comprehensive (loss) income until settlement. As &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;of December 31, 2022, there were no changes in the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA from the initial value of $0.1 million. &#160; &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_XOgFj8vJqU-LK_O9WhjxCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Contingent consideration under RPAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2021 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,075&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_rUQ9aQoP0UevSR54GD1sWQ"
      decimals="-3"
      id="Tc_1dT_fcbe_UOuiWVqqZY3gg_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wKH3zH90P0eBo19y-1AFvQ"
      decimals="-3"
      id="Tc_8BJ0JyUTnU-y-axeVEgBLA_8_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w"
      decimals="-3"
      id="Tc_mRH9FOSK6E204DyksHfdpA_9_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g"
      decimals="-3"
      id="Tc_cj4pgs6f5kugEZT380GTTw_9_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w"
      decimals="-3"
      id="Tc_CkaZcYAjOEu1iS4AIu0m8w_10_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">335000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g"
      decimals="-3"
      id="Tc_GjtEX4whe0a3JUgivBcS2w_10_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">335000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_CCAcM73gfEWqVjBYpNb25w"
      decimals="-3"
      id="Tc_pVdCLlK8v0WEaLWGLSw6lw_11_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g"
      decimals="-3"
      id="Tc_SmrCVSMjSEC9DdymsMPA8Q_11_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_1cbEl4Re006vJtiqqHtFKA"
      decimals="-3"
      id="Tc_ujds5pRPe0O7uDGNgO7OPg_13_9"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g"
      decimals="-3"
      id="Tc_AzwVq99w1UGt5n1zt0FmrA_13_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_cxJRCFdTx0yjmZeqnao7Zg"
      decimals="-3"
      id="Tc_j5Vc5Att-kiFFqw0HEaySQ_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">774000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg"
      decimals="-3"
      id="Tc_1vEjGPXT80KiOCUs4c3Plw_7_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">774000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_xgElIxuKbE-siKQSQ-ga1g"
      decimals="-3"
      id="Tc_wBMF1pg8G06iaTvIDrRrHg_9_9"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8075000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_idoFK-hRL0CHJXm5iWbXcg"
      decimals="-3"
      id="Tc_MjAzO5PIVU6mLCv9YfOEIQ_9_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8075000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_r_2JErVgvE6xRp6r7DtTTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA"
      decimals="2"
      id="Narr_wnnfQxVkw0W35DAttJy3RQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">2.07</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_0k8XC5hhM0GGrBlYX_tVYQ"
      decimals="2"
      id="Narr_3Nmh7TPV5UKdkUSUHydUNQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">4.78</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_FAnAp8a72E6w0d6JVWeLow"
      decimals="-5"
      id="Narr_fEs5cLIFjk6V-U5fVvthaw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_4kBNFywoskiicslz4mbomw"
      decimals="-5"
      id="Narr_W9KA5hASrEuFBzdb1PChyQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tYhP_oDaCEeH8nMIezqx3w"
      decimals="-5"
      id="Narr_8PWVw2c9WUO8R-2NQSQFPA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5000000.0</xoma:PaymentsOfContingentConsideration>
    <xoma:PaymentsOfContingentConsideration
      contextRef="Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA"
      decimals="-5"
      id="Narr_ulvKIngzTk2Ba78Yf9RmBg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3000000.0</xoma:PaymentsOfContingentConsideration>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"
      decimals="-5"
      id="Narr_JTi4wJhq2U663DBSLHd2Vw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_r1ERX-00-kOo1Xhy1OfigQ"
      decimals="-5"
      id="Narr_6IlBxBtkFkaju_9rdjEuDA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_LfIqaDLZxUS4-IIygk7V5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Lease Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases one facility in Emeryville, California under an operating lease that expires in February 2023. As of December 31, 2022, the total net lease liability from January 2023 until expiration of the lease was $34,000. &#160;In January 2023, the Company amended the lease to extend the lease period through July 2023 (Note 14). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating lease for the years ended December 31, 2022 and 2021, respectively (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The present value assumptions used in calculating the present value of the lease payments for the Company&#x2019;s operating lease as of December 31, 2022 and 2021 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:LeaseDisclosureTextBlock>
    <xoma:OperatingLeasesNumberOfLeasedFacilities
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA"
      decimals="INF"
      id="Narr_tWRfXGNfsECYrGm5rTBZkA"
      unitRef="Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg">1</xoma:OperatingLeasesNumberOfLeasedFacilities>
    <xoma:LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_JQNeN2TEeU24mxPrSn9wUg"
      decimals="-3"
      id="Narr_2lDg5YcKX0eL_0echm4coA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">34000</xoma:LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_JZDuarbI2EOzPYvW1_osNg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating lease for the years ended December 31, 2022 and 2021, respectively (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 185&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_tSJsDqHR-kOOjeElXE6SUw_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">177000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_SgeIozfjCEmr-qJalSdZkw_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">177000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_3mdANgfhyEmlTAgfTRRc-Q_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">12000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_8QV6AElEfUaVCUYTxaqF1w_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">8000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_Z4s839kttEO1K64EDfsT6g_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">189000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_NCTGXAQu5Uqp6kmGxfFxRQ_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">185000</us-gaap:LeaseCost>
    <xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_-33uM1VZKkabO9hKgld7Kw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 202&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 196&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_vvZ2xV9-H06w7fE4YQmCYw_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">202000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_OPVWFuANYEyg-Du8et94bA_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">196000</us-gaap:OperatingLeasePayments>
    <xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_EJUBfv24gEyq_5w2fovFbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      id="Narr_eZsBYo5TUE-pYHnd0jO8Sw">P0Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      id="Narr_iCqOosI9Q0mgrB3X_bVSsQ">P1Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="4"
      id="Tc_Ma9p7xNYg0OCUKwZ1ILvDA_4_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="4"
      id="Tc_Y4PwaRILREev5MtZduV1Qw_4_5"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_RwA7k6GaDEaiT_6tTw4EYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;8. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has pre-tax book loss of $17.1 million and pre-tax book income of $15.9 million for the years ended December 31, 2022 and 2021, respectively. &#160;The Company had a $15,000 income tax benefit and $0.1 million income tax expense for the&#160;years ended December&#160;31, 2022 and 2021, respectively. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#x2019;s actual effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock compensation and other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax benefit related to net operating loss carryforward utilization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The significant components of net deferred tax assets at December&#160;31, 2022 and 2021 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development and other tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47,006)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_SoJMkvQEd0GCqEyppA4jKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-opkpTvh2U-sJds8V7C3Yw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The net increase (decrease) in the valuation allowance was $3.3 million and $(4.6) million, for the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounting standards provide for the recognition of deferred tax assets if realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company&#x2019;s four sources of taxable income including historical operating performance and the repeal of NOL carryback, the Company&#160;has determined that total deferred tax assets should be fully offset by a valuation allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on an analysis under Section&#160;382 of the Internal Revenue Code (which subjects the amount of pre-change NOLs and certain other pre-change tax attributes that can be utilized to annual limitations), the Company experienced an ownership change in February&#160;2017 which substantially limits the future use of its pre-change NOLs and certain other pre-change tax attributes per&#160;year. The Company has excluded the related tax attributes that will expire as a result of the annual limitations in the deferred tax assets as of December 31, 2022 and 2021.&#160;To the extent that the Company does not utilize its carryforwards within the applicable statutory carryforward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carryforwards will expire unused.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company had federal NOL carry-forwards of approximately $108.8 million and state NOL carry-forwards of approximately $20.9 million to offset future taxable income. $13.6 million of federal NOL carryforwards will begin to expire in 2036 and the remainder may be carried forward indefinitely. The state NOL carryforwards will begin to expire in 2033. The Company had federal orphan credit of $2.0 million which if not utilized will expire in 2037. The Company also had $19.8 million of California research and development tax credits which have no expiration date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under the 2017 Tax Cuts and Jobs Act, as modified by the federal tax law changes enacted in March 2020, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but, for taxable years &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;beginning after December 31, 2020, the deductibility of such federal NOLs may only be utilized to offset 80% of taxable income annually. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;One of the provisions under the 2017 Tax Cuts and Jobs Act that became effective in tax years beginning after December 31, 2021 required the capitalization and amortization of research and experimental expenditures. &#160;The change in this US tax law did not have an impact on the Company's consolidated financial statements. The Company will continue to evaluate the impact of this tax law change on future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#x201c;Inflation Act&#x201d;) into law. The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act did not have an impact on the Company&#x2019;s consolidated financial statements and related notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various states. The Company&#x2019;s federal income tax returns for tax&#160;years 2019 and beyond remain subject to examination by the Internal Revenue Service. The Company&#x2019;s state income tax returns for tax&#160;years 2018 and beyond remain subject to examination by state tax authorities. In addition, all of the NOLs and research and development credit carryforwards that may be used in future&#160;years are still subject to adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s activity related to its unrecognized tax benefits (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to prior year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company had a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as the Company currently has a full valuation allowance against its deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through December 31, 2022, the Company has not accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-5"
      id="Narr_tDzntQ8gcU6yBcgQxCN-zw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_PJT_07eS7US6eTnfJ0zdaA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Narr_Ctae7y2gV0Oz4OYVhMhpyg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_iNDgQJBLqUu6dZ2DBlbCiA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_wh-JIDaMhEuE0QsK33e5uQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The (benefit) provision for income taxes, all classified as current, consists of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_bnwA7iRR70iGJn2HJAifsw_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-15000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_QRB2zGeIoU2aQG_7rg_aGQ_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">91000</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_4djSOyhNF0ytNhqMb1A9Ug_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-15000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_H18YXWtLlU-hcdxFDg5tXA_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">91000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_X7owPNiblkO0hceiB4hpCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Reconciliation between the tax provision computed at the federal statutory income tax rate and the Company&#x2019;s actual effective income tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock compensation and other permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal orphan drug credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Tax benefit related to net operating loss carryforward utilization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Tc_voblypEIDUOqQ92YjUQVZg_3_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="INF"
      id="Tc_Dj7tI91LKkiE0pQqqLn8lg_3_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_p5eUz-cYVkulFFV3CJowCQ_4_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">-0.01</xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent>
    <xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_NAqXxPkXuEWX1WoZ38N7zA_4_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.09</xoma:EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent>
    <xoma:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_q-tmErlBdUSeWV8LHd6CdQ_5_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.02</xoma:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent>
    <xoma:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_6iH77blGzUyr54PYrmjDIg_6_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">-0.11</xoma:EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_28sXm-TZl0i3VB9Vm9Kanw_7_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_xo0iWUJsDkey-ce6J6npMw_7_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_YNb5lo8Xa0ScFJtDJBSU2w_8_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_7Oadxji5K0-eW3d3m83VDw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The significant components of net deferred tax assets at December&#160;31, 2022 and 2021 were as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,732&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,974&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,657&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development and other tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,778&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unearned revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,324&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,006&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (47,006)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_SoJMkvQEd0GCqEyppA4jKg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-opkpTvh2U-sJds8V7C3Yw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_jiCmhbyWy0W_l4_Yorn1zA_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4732000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_W6RxlG9Wg0SIcuWhOA4AIQ_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7822000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_m-bc9oKI30C_hCwiuG5fWw_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">23974000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_6Mo613Crv0mW7UecypWYrg_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">17657000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_ghGhpsjtoUqXbsO6U3BJ_Q_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13176000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_HFsfJdwy3EeyvPQbUQuCZQ_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13125000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_U1SEF4INYUSngkmxQ69CqQ_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4715000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_IPNz5y1fEEiDyJFf-De92A_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4778000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_zKdaPcI4NUCwU2tXrH16pw_7_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2408000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_uzJMEkqkL0uu-_m1GAra3g_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2817000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_GZeKi18ou02RSge55gYtSg_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1324000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_2uIpSkuPbU6dDODRbHbMlQ_8_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">807000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_EmeE-kgjgES063OWES3IgA_9_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">50329000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_NzK7qtXq_EeXBAq0Umh38Q_9_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">47006000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_qtqe7qanwUK3bvWm3TikMw_10_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">50329000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_08e1dt-Tnk2k4o0cZYrFkA_10_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">47006000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-5"
      id="Narr_pB1IY3fQBUmE7mM04T14Lw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_PGzWBy6X4UuulkVDHzexMw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-4600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw"
      decimals="-5"
      id="Narr_lZol9zSOukOk2vDEppi06g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">108800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_I3IaD-K-xEGI556fraBoOA"
      decimals="-5"
      id="Narr_G1z36xkhc0Glld44O6yskQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20900000</us-gaap:OperatingLossCarryforwards>
    <xoma:OperatingLossCarryForwardSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw"
      decimals="-5"
      id="Narr_ZXTIZE9G0UKrIeFMFC3HOg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">13600000</xoma:OperatingLossCarryForwardSubjectToExpiration>
    <xoma:NetOperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_WnhYpE1OH0qWIIqY-1VSWQ"
      id="Narr_ud6dPF-hkEupDR_ykojUnQ">2036</xoma:NetOperatingLossCarryforwardsExpirationYear>
    <xoma:NetOperatingLossCarryforwardsExpirationYear
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ibRXt1hd3k63S2armpWFhg"
      id="Narr_WGxJt5ubfEyuRLQgId86GQ">2033</xoma:NetOperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_bYn_MgYoV0WUzvqn6X6Z0w"
      decimals="-5"
      id="Narr_ORtf20ONP0OtHDYCdvguJQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <xoma:TaxCreditCarryForwardExpirationYear
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_xoma_FederalOrphanCreditMember_T4pTOnp0j0KTjb2iHvM7fg"
      id="Narr_geqv4f3Ic0SRlZzsSQk5uQ">2037</xoma:TaxCreditCarryForwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_stpr_CA_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yTZvacgI1ke_u3yIpm8d6w"
      decimals="-5"
      id="Narr_E0oPNBvusk2gJvMSwVO5Ww"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">19800000</us-gaap:TaxCreditCarryforwardAmount>
    <xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Narr_mc4Qo1bX2k2xssqzxdU3DQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.80</xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_HawNw5c3XEO5NuxtvpX8Yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s activity related to its unrecognized tax benefits (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to current year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Increase related to prior year tax position&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,938&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_WmeKEvOJ9EWljngF5ZPC_A_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw"
      decimals="-3"
      id="Tc_F0QBiGQa-kWlGgiQlrad7g_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_MgyqPr65aEiXYyenxGZoGA_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_VfdCjdlB-kGgIDrIvQQDtA_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_OfwYngzPvUWJfI2UcXCqPA_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_jFkVAvY8YUeadRTX26QqXg_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5938000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_eGP0rIdSSkGq_N0XvS_CYA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_Fe9ZN3IWokW6RFpLVtIONg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_i13uCQL2W02-n-yF4xL0DA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_eKhiSt8xBEuMDOOe5AXGvw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_2-OosS0mWEe-s3uFC2j1Xg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Stock Based Compensation and Other Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may grant qualified and non-qualified stock options, common stock and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#x2019;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In May&#160;2015, the Company&#x2019;s stockholders approved the 2015 Employee Stock Purchase Plan (the &#x201c;2015 ESPP&#x201d;), which replaced the Company&#x2019;s legacy 1998 ESPP. Under the 2015 ESPP, the Company reserved 15,000 shares of common stock for issuance as of its effective date of July&#160;1, 2015, subject to adjustment in the event of a stock split, stock dividend, combination or reclassification or similar event. The 2015 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;to any plan limitations. The 2015 ESPP provides for six-month offering periods ending on May&#160;31 and November&#160;30 of each&#160;year. At the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2017, the Compensation Committee and the Board of Directors adopted, and in May&#160;2017, the Company&#x2019;s stockholders approved, an amendment to the Company&#x2019;s 2015 ESPP. The amendment (a)&#160;increased by 250,000 the shares of common stock (from 15,000 shares to a total of 265,000 shares) available for issuance under the 2015 ESPP; and (b)&#160;increased the maximum number of shares of common stock an employee may purchase in any offering period to 2,500. As of December 31, 2022, the Company had 230,937 remaining authorized shares available for purchase under the ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2022 and 2021, employees purchased 6,090 and 2,225 shares of common stock, respectively, under the 2015 ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Savings Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under section 401(k)&#160;of the Internal Revenue Code of 1986, the Board of Directors adopted, effective June&#160;1, 1987, a tax-qualified deferred compensation plan for employees of the Company. Participants may make contributions which defer up to 50% of their eligible compensation per payroll period, up to a maximum for 2022 and 2021 of $20,500 and $19,500, respectively (or $27,000 and $26,000, respectively, for employees over 50 years of age). The Company may, at its sole discretion, make contributions each plan&#160;year, in cash or in shares of the Company&#x2019;s common stock, in amounts which match up to 50% of the salary deferred by the participants. The expense related to these contributions was $0.1 million for the&#160;years ended December 31, 2022 and 2021, and 100% was paid in common stock for each&#160;year. The Company applies shares from plan forfeitures of terminated employees toward the Company&#x2019;s matching contribution. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2010, the Compensation Committee and Board of Directors adopted, and in July 2010 the Company&#x2019;s stockholders approved the 2010 Plan. The 2010 Plan was amended in 2016, 2017 and 2019 to (a) increase the number of shares of common stock issuable under the 2010 Plan; (b) increase the number of shares of common stock issuable under the 2010 Plan as incentive stock options; and (c) extend the term of the 2010 Plan to April 1, 2029. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From the 2010 Plan, the Company grants stock options to eligible employees, consultants and directors. Stock-based awards granted under the 2010 Plan may be exercised when vested and generally expire ten years from the date of the grant or three months from the date of termination of employment (longer in case of death, certain retirements or subject to certain terminations pursuant to the Retention Plan).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company had 192,964 shares available for grant under the 2010 Plan. As of December&#160;31, 2022, options to purchase 2,025,542 shares of common stock were outstanding under the 2010 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options generally vest&#160;monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus&#160;years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Plans Summary &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the&#160;year ended December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,911,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 292,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,811)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,718,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options exercised in 2022 and 2021 was $2.8 million and $1.6 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of the options granted in 2022 and 2021 was $12.01 and $22.23, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, $4.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 1.8 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based Compensation Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021, was estimated based on the following weighted average assumptions for:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive (loss) income (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"&gt; Thomas Burns Equity Awards Modification&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In April 2022 and November 2022, the Company entered into letter agreements with Thomas Burns that amended and supplemented his amended and restated employment agreement. Pursuant to the November 2022 Letter Agreement, in the event Mr. Burns remains employed by the Company for a twelve-month period beginning on November 1, 2022, he will be deemed &#x201c;retirement eligible&#x201d; for purposes of his equity awards under the terms of his equity award agreements. All other terms of his amended and restated employment agreement remain the same. Conditioned on his execution of a release in favor of the Company, Mr. Burns will also receive this benefit upon any involuntary termination for reasons other than cause. The unrecognized stock compensation cost for the unvested stock options as of November 1, 2022 will be recognized over the shorter of (1) twelve months and (2) the remaining original vesting period (the &#x201c;Revised Vesting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Term&#x201d;). During the year ended December 31, 2022, the Company recognized stock-based compensation expense of $0.6 million related to the Mr. Burns&#x2019; option awards. As of December 31, 2022, there was $0.5 million total unrecognized compensation expense related to Mr. Burns&#x2019; stock options expected to be recognized through the earlier of the vesting date of the option or October 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Retention Bonus &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 25, 2022, the Company approved the Amended Retention Plan which provides that each of its current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#x201c;Initial Period&#x201d;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company will accrue and recognize the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. Pursuant to Amended Retention Plan, as of December 31, 2022, the Company expects to pay $0.8 million in 2023 related to the cash retention bonuses. The Company accrued $0.1 million for cash retention bonuses in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;James R. Neal Departure and Continuity Incentive &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2022, the Company&#x2019;s board of directors (&#x201c;the Board&#x201d;) appointed Owen Hughes as Executive Chairman of the Board and Interim Chief Executive Officer (&#x201c;CEO&#x201d;) effective January 1, 2023 and, in connection with Mr. Hughes&#x2019; appointment, James R. Neal retired as the Company&#x2019;s CEO effective as of December 31, 2022 (the &#x201c;Departure Date&#x201d;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#x2019;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of $1.2 million (the &#x201c;Continuity Incentive&#x201d;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full $1.2 million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss (income) during the year ended December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"
      decimals="2"
      id="Narr_KkqFMkj5UEiv41z424bdcw"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg"
      decimals="INF"
      id="Narr_mtNNjdSvqEOZFT5yUq0h2Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">15000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"
      decimals="2"
      id="Narr_dWNBHoyyHUaDA27HAS9umg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.10</xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"
      id="Narr_EShdbjmpXE231n2F6qI4zg">P6M</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"
      decimals="2"
      id="Narr_Sg3GzIhQJUqUeFrzwKM4LA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg"
      decimals="INF"
      id="Narr_s6BVPPFHj0adHDYlaZkYdw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_4_30_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6gTYL1gbNEamV73yFBPD9w"
      decimals="INF"
      id="Narr_HjSluhsfwUGBQgUoutRcgw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2Eq4oPH3-kmCmCEtd6jqOw"
      decimals="INF"
      id="Narr_i7WWTQc-NEiNQNXTuTOAdw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">265000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="Duration_5_1_2017_To_5_31_2017_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2DQeDeRiuk68aPNM6uYPsg"
      decimals="INF"
      id="Narr_Lf4tBCwjsU-ZqBA8hJeM1Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_innzPLhQmEaLAZC2EVjFOQ"
      decimals="INF"
      id="Narr_a_0R528EmUeM5Dwnsi-TrA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">230937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_eHRUQT2DoU-XpXe35WWMTw"
      decimals="INF"
      id="Narr_1RsmLz3I-0-bqBfxeOniKA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">6090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_mcDXIe1eeUuUz9qtOy-1xw"
      decimals="INF"
      id="Narr_ID7bV_2ESk6OVQHCbt1zWg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Narr_KYyrLEuNPkOLRlX-KwrfUQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Narr_MV3C44QZjkyCGn8CeQ99ZA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_dqF-u1exn0eMTofXVXH82g"
      decimals="-2"
      id="Narr_BPqfntYdbkGtLks2KCRbtw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">20500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeUnderAgeFiftyMember_Bp0iF72XDUmK5_A2DxhSyQ"
      decimals="-2"
      id="Narr_vNmUbbGrmk2xBC_lOZjZww"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">19500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_uQJXomIUj0Gu7qpcedCwyQ"
      decimals="-3"
      id="Narr_o-NMyVuCIESxX8n-SFNpRQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">27000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_xoma_EmployeeAgeFiftyOrOverMember_-p2i8myCR0Cc2q5-v8T5eg"
      decimals="-3"
      id="Narr_H4Zw1ej0x0u79RXgyHLp_A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">26000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Narr_6K8JG9qiHEK9h0uWxaS-ag">P50Y</xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum>
    <xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      id="Narr_FXBG4BQMs0ScsRZGJwkLAQ">P50Y</xoma:DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_9UQegpZ6pk6Io8imyOcdnw"
      decimals="2"
      id="Narr_fXR7Jt3GZ0-ol-jf9nE0Vg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_k3R6O4_a8E2Uzc-CrSZ8Zg"
      decimals="2"
      id="Narr_FNhmXGc_oUWuMKiglgPu0g"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_L8iLUHcJZ0W2atms_c7k2A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-5"
      id="Narr_6H0QwY3RwEekBQ47tubPmw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:DefinedContributionPlanCostRecognized>
    <xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="INF"
      id="Narr_aY5p4BSejEa-D2vckIotUQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">1</xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage>
    <xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Narr_gXq02gpB2UmkOT3ljeQxPQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">1</xoma:DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_S_3GoTwkMUmL0YDsH6p4lA"
      id="Narr__vqtkLVIfUWl9oF2oiWcmg">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_srt_TitleOfIndividualAxis_xoma_EmployeeTerminatedMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_4_yOcoEhi0evQ1_wlkZgQg"
      id="Narr_1YKC94rNWkGKHnkUvmCT_Q">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_le_sU7N1A06C93O-_SOo1A"
      decimals="INF"
      id="Narr_4g_yqEjCuESo6hV--xp4PQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">192964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_c3q8pXA60E2IFa_nifIVng"
      decimals="INF"
      id="Narr_7SHcbLp8T0yOcTWfL2gHKQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2025542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2rqqrvz1g0ady6TBHhDp8A"
      id="Narr_VU9Zjz8weEOG6Z4f5KT8HQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_NmtXsMtquUe4CqwtZxHDmg"
      id="Narr_Mwzq3KGkME6YACmITEtPwQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      id="Narr_NAtNW4r-W0ChtjPN797bNg">P55Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      id="Narr_e30jInzoTEG6ir87vYhTzg">P70Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_aOFoGW66UkWPiMDyKDwgxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the&#160;year ended December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,911,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,103&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 292,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.40&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (128,811)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,718,864&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,764&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Tc_kCd8IcFWxUKqOWRoeCmgYw_6_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1911177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="2"
      id="Tc_af7vH3DwIUuittP9ETH2zw_6_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">20.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      id="Tc_z9_ytmsh60eQMHKD9u6ubQ_6_9">P6Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="-3"
      id="Tc_Qm1uGevROUOW4OWxvMx03Q_6_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15103000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Tc_HSBdF-aSm0uUIje4x85Ydw_7_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">292972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_DpXg_Ex_C0q5dPvoSGO2Uw_7_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">19.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Tc_zcs1HVMs3kazdvn2FqOKgw_8_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">128811</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_jKHHwZ4MjEunomNe6YTRfA_8_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">7.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Tc_6yHZpFiJTE6ol54ElDunyQ_9_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">49796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_vHz15McHf0udNFP8dNi0Tw_9_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">64.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Tc_TeGtOQJ7s0qdoMfptC-1Dg_10_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">2025542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="2"
      id="Tc_K0gOp4S7L0K53FKmAiRaqQ_10_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">20.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_N2ryq6zGkkCNDt3HoGOqGQ_10_9">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_6T4E0CCGh0u8AUFllzkJoQ_10_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Tc_id8QDTvsZkGfqpbtSMKhFA_11_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1718864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="2"
      id="Tc_An7Wce-vxU2GVxtwtfKzqw_11_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">19.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tc_foMWzCh7oEKRm1K4VOv7WQ_11_9">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-3"
      id="Tc_sqCo1_OkQku8bWwzL0fg6Q_11_12"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">10764000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-5"
      id="Narr_cAVLr9ZJJU-x7V389ZoFQw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-5"
      id="Narr_uIuRYQ00q0Wc9NjUojgqSw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Narr_1qy_RSdmh0S_SANcm2VQNw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">12.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Narr_2jkjTkOgIEurqC10S4FlKA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">22.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_v_hV0ir1cEWtoGOP-taG0g"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      id="Narr_XL41bSJFVk-NTU7inR_Opw">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_o6_fOevkt0KoQJ37nnxpxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of stock options granted during the&#160;years ended December&#160;31, 2022 and 2021, was estimated based on the following weighted average assumptions for:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      decimals="2"
      id="Tc_soxqdHr1tUufdGNmzGSLZA_3_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g"
      decimals="2"
      id="Tc_8UcdzDADo0SJzPrerUxlYQ_3_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      decimals="2"
      id="Tc_0Vi4hmevc0OppcbpXyeEZg_4_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g"
      decimals="2"
      id="Tc_eTOBDKrTIEWmXYHw-wT0mA_4_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      decimals="4"
      id="Tc_ZZZAfxP-OEGB9ub1L51M4w_5_2"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g"
      decimals="4"
      id="Tc_en-WFXkMLkiZ80qQnq7lsw_5_4"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.0095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w"
      id="Narr_SSgtrUCvA0Wsdw9qvXpWkg">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LmdDIxosq02Z3GO8RQBt6g"
      id="Narr_X6Zs57Mx0EicRlj1vyl2qg">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_YvDnfn-FxES-HArp-Rm71A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and ESPP in the consolidated statements of operations and comprehensive (loss) income (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA"
      decimals="-3"
      id="Tc_DtxxwLR7u0SbwLsm60y1Bg_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jvwASmfkaEWRGoQyRqS1Rg"
      decimals="-3"
      id="Tc_j8iLtyWWPUuh2fYqNGQTiw_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <xoma:EmploymentPeriodRetirementEligible
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_rAroNAm8f0G6gOtRf-Uv6Q"
      id="Narr_Gn2H34oitUeKwwP4IdYHZw">P12M</xoma:EmploymentPeriodRetirementEligible>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_bdWwrZZvA0WUmM4wVRe4tw"
      id="Narr_OdFkX1SHG0SZMqWOZPT61A">P12M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_SwAbSDClgkW7N51ti2Pz6g"
      decimals="-5"
      id="Narr_3JiW2jQtbkm9W5KEeKZ9kQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_FLXGWQjtYkORU4sQnEG_vA"
      decimals="-5"
      id="Narr_DJOFLDW1Nk2Gjl8X1aTggg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <xoma:NumberOfPeriodsCashRetentionBonus
      contextRef="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q"
      decimals="INF"
      id="Narr_8DrJjy7VuEWk7OwTfB2ZSg"
      unitRef="Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw">2</xoma:NumberOfPeriodsCashRetentionBonus>
    <xoma:PeriodOneRetentionBonusEligibility
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg"
      id="Narr_NB6MfH57iEyCv49JRtmboQ">P3M</xoma:PeriodOneRetentionBonusEligibility>
    <xoma:PeriodTwoRetentionBonusEligibility
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_UKOz_PHdeUqroulQQkJdRg"
      id="Narr_nVZYviua70qF_rtLTm5nPQ">P9M</xoma:PeriodTwoRetentionBonusEligibility>
    <xoma:CashRetentionBonusExpectedPaymentNextTwelveMonths
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_cOp6nGVAs0WrsYuMFKEFVg"
      decimals="-5"
      id="Narr_J-GV7gzSzUOF_3IoPmHONQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">800000</xoma:CashRetentionBonusExpectedPaymentNextTwelveMonths>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_e4kVRRL9ukOGf7-2PTwdVA"
      decimals="-5"
      id="Narr_1GXqO9NY7kaH3_8Tubo4_A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</xoma:RetentionBonusExpenseAccrued>
    <xoma:AccruedCompensationContinuityIncentive
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q"
      decimals="-5"
      id="Narr_RFPrgkx33UKujCTA5NOs_A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1200000</xoma:AccruedCompensationContinuityIncentive>
    <xoma:CompensationExpenseEmploymentAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_q-sxs5W_mkKsWzMqNMcjqw"
      decimals="-5"
      id="Narr_R7KaW5H0j0mC-mpncUVsfg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1200000</xoma:CompensationExpenseEmploymentAgreement>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_0hRYzVEgVk6elrzJODoWmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Potentially dilutive securities are excluded from the calculation of diluted net (loss) income per share (attributable to) available to common stockholders if their inclusion is anti-dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,438)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Allocation of undistributed earnings to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,451)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income (attributable to) available to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Add: Adjustments to undistributed earnings allocated to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income (attributable to) available to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_qJG3o8Npek2J53VK3KBCtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 479&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember_5aGHU9JvxUq_BpGHRTnqYg"
      decimals="-3"
      id="Tc_vtO9YHLJx0uC-Zn6vxL2Dg_3_2"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_q87bEsiOOE6OxrrZkp0I_w"
      decimals="-3"
      id="Tc_iO2MwCo840WWn7jkEj_okQ_4_2"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">885000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_gxn9ucloMEePqYe0bPpnKg"
      decimals="-3"
      id="Tc_Lii2LXtKMkaWa8VUutXRKg_4_4"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">479000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_u8nxMvP_akullwQz4lc9rA"
      decimals="-3"
      id="Tc_rUrf9vc4YE-Y04RPsoK3sg_5_2"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_H2bqQnhw9Ee5mJJDry_ixQ_6_2"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5894000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_jCXnTwWxnUauufebsPG_5w_6_4"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">479000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_JS2kPqb0iUScxzaSuG822Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net (loss) income) and denominator (number of shares) used in the calculation of basic and diluted net (loss) income per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,798&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,122)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,438)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Allocation of undistributed earnings to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,451)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income (attributable to) available to common stockholders, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,787&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Add: Adjustments to undistributed earnings allocated to participating securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net (loss) income (attributable to) available to common stockholders, diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22,576)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effect of dilutive warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,192&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net (loss) income per share (attributable to) available to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.98)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_nG16MTMpLUOFs4MXPQ9N0w_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-17104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_UyrERykj9E2UGIhul9Mkow_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">15798000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_e5gSbsR2x0OJoMqY5piw7w"
      decimals="-3"
      id="Tc_TQhoRVF410uclBhV1JhcMw_5_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2122000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_liEmszi5bk-OlrLCT_DLXQ"
      decimals="-3"
      id="Tc_KfANEcBXDEibQ6Xokccwrw_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2122000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_91M7WTdCpEmxg1J_yApCQQ"
      decimals="-3"
      id="Tc_5G68eWW4cUq0JrTezzPpNw_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3350000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_ZOo_V2kt4kCTZsRHzlIxgg"
      decimals="-3"
      id="Tc_aRKLGQumhkC4C05LvvqTQg_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2438000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_8FdXX2zQrUKCVefYqJIfJw_7_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">3451000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc__SGEsXUoe0-Be93Mn7dPew_8_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_bZkKXytphkyd0twGQSGgzQ_8_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7787000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_B9flZKBSUEKiFAmTY3QKeQ_9_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-181000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_ufQ2YGAP6UK-UllAxC__Sg_10_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">-22576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_3sKvQVBYUUCsmZsKXGBpSQ_10_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">7968000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_3_wOjTxjYESxKzWsGzX8Dw_13_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11413000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_jL-YKfspDEa_chTaoFAXhA_13_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11288000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_L3ooPKk44kqQFYuKwoROkA_14_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_xV_Jl6krLEi_vpK2w-iHMg_15_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">4000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_ovWvedT34UOqLfTdQ4wL6g_16_3"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11413000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_LelWU4JZIEetocEp-zkz0Q_16_6"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">12192000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_Nnq5AktYBEeaahU1A4iNlg_17_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_q_t4SVnhQkO20fVuiiI35Q_17_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="2"
      id="Tc_4fkS154wHkmFg3Z-ktJqZA_18_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="2"
      id="Tc_GC9jrELtFkSzZ__vTBptfA_18_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_KwezC5x3qEKRq89sngjacQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Capital Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Series X and Series Y Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sold directly to BVF 5,003 shares of Series X convertible preferred stock in 2017 and 1,252.772 shares of Series Y convertible preferred stock in 2018. There were no shares of Series Y convertible preferred stock outstanding as of December 31, 2021, after BVF converted all Series Y preferred stock into common stock on April 15, 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were 5,003 shares authorized and issued of Series X convertible preferred stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series&#160;X and Series Y convertible preferred stock have the following characteristics, which are set forth in Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&#x2014; &lt;/i&gt;Holders of convertible preferred stock are entitled to receive dividends on shares of convertible preferred stock equal (on an as if converted to common stock basis) to and in the same form as dividends actually paid on the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Rights&#x2014; &lt;/i&gt;In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of convertible preferred stock will participate, on a pro-rata basis, with any distribution of proceeds to holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&#x2014; &lt;/i&gt;Each share of Series&#160;X and Series Y is convertible into 1,000 shares of registered common stock based on a conversion price of $4.03 per share and $13.00 per share of common stock respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&#x2014; &lt;/i&gt;Convertible preferred stock will generally have no voting rights, except as required by law and except that the consent of the holders of the outstanding convertible preferred stock will be required to amend the terms and to issue additional shares of the preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&#x2014; &lt;/i&gt;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that equity treatment was appropriate because the convertible preferred stock did not meet the definition of the liability instruments defined thereunder for convertible instruments. Specifically, the convertible preferred shares are not mandatorily redeemable and do not embody an obligation to buy back the shares outside of the Company&#x2019;s control in a manner that could require the transfer of assets. Additionally, the Company determined that the convertible preferred stock would be recorded as permanent equity, not temporary equity, given that they are not redeemable for cash or other assets (i)&#160;on a fixed or determinable date, (ii)&#160;at the option of the holder, and (iii)&#160;upon the occurrence of an event that is not solely within control of the Company. The Company has also evaluated the embedded conversion and contingent redemption features within the convertible preferred stock in accordance with the accounting guidance for derivatives and determined that bifurcation is not required for any embedded feature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Series A Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 15, 2020, the Company sold 984,000 shares of its 8.625% Series A cumulative, perpetual preferred stock at the price of $25.00 per share, through a public offering for aggregate gross proceeds of $24.6 million. Total offering costs of $2.0 million were offset against the proceeds from the sale of Series A Preferred Stock, for total net proceeds of $22.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were 984,000 shares authorized and issued of Series A Preferred Stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series A preferred stock have the following characteristics, which are set forth in the Certificates of Designation of Preferences, Rights and Limitations filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&#x2014;&#160;&lt;/i&gt;Holders of &lt;span style="background:#ffffff;"&gt;the Series A Preferred Stock shall be entitled to receive, when, and if authorized by the Board of Directors and declared by the Corporation, cumulative cash dividends at the rate of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;8.625%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per annum of the &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; liquidation preference per share of the Series A Preferred Stock. Such dividends will accumulate and be cumulative from, and including, the date of original issue of the &lt;/span&gt;Series&lt;span style="background:#ffffff;"&gt; A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October of each year beginning on or about April 15, 2021. The amount of any dividend payable on the Series A Preferred Stock for any period greater or less than a full Dividend Period shall be prorated and computed on the basis of a&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;360&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-day&#160;year consisting of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;twelve&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;30&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;-day&#160;months.&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Rights&#x2014;&#160;&lt;/i&gt;In the event of the Company&#x2019;s liquidation, dissolution or winding up, holders of Series A Preferred Stock will &lt;span style="background:#ffffff;"&gt;rank senior to all classes or series of common stock as to dividend rights and rights upon liquidation, dissolution or&#160;winding-up and on parity with respect to the &lt;/span&gt;distribution&lt;span style="background:#ffffff;"&gt; of assets with the Company&#x2019;s Series X Preferred Stock. &lt;/span&gt;The Series A Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25.00 per share plus any accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Redemption and Special Optional Redemption&#x2014;&#160;&lt;/i&gt;The Company, at its option, may redeem the Series A Preferred Stock, in whole or in part, at any time for a cash redemption price, plus any accrued and unpaid dividends, as follows: (i) $26.00 per share between December 15, 2021 and December 15, 2022, (ii) $25.75 per share between December 15, 2022 and December 15, 2023, (iii) $25.50 per share between December 15, 2023 and December 15, 2024 (iv) $25.25 per share between December 15, 2024 and December 15, 2025 and $25.00 per share on or after December 15, 2025. The Company also has a special optional redemption option whereby, &lt;span style="background:#ffffff;"&gt;upon the occurrence of a delisting event or change of control event, the Company may redeem outstanding Series A Preferred Stock at an amount of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$25.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion&#x2014;&#160;&lt;/i&gt;The shares of Series A Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company except upon the occurrence of a delisting event or change in control event and the Company has not, on or before the date of such an event, provided the required notice of its election to redeem the Series A Preferred Stock pursuant to its redemption right or special optional redemption right. In this case, the holder of shares of Series A Preferred Stock can convert some or all of their Series A Preferred Stock into a number of shares of common &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;stock per share equal to the lesser of (A) (i) the sum of the $25.00 liquidation preference per share of Series A Preferred Stock to be converted plus (y) the amount of any accrued and unpaid dividends to, but not including, the event date, as applicable by (ii) the common stock price and (B) 1.46071 (the &#x201c;Share Cap&#x201d;). The common stock price to be used in the latter noted calculation for a delisting event will be the average of the closing price per share of the Company&#x2019;s common stock on the 10 consecutive trading days immediately preceding, but not including, the effective date of the delisting event. The common stock price used in the event of a change in control event will, alternatively, be based on market price according to the definition in the Certificate of Designation.&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&#x2014;&#160;&lt;/i&gt;Holders of the Series A Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&#x2014;&lt;/i&gt;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Depositary Shares Representing Interest in Series B Preferred Stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 9, 2021, the Company sold 1,600,000 Series B Depositary Shares, at the price of $25.00 per Series B Depositary Share, through a public offering for aggregate gross proceeds of $40.0 million. Each Series B Depositary Share represents &lt;span style="-sec-ix-hidden:Hidden_bylnvwbfT0qC2wS2bhBX0Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/1000&lt;/span&gt;&lt;/span&gt; interest in a share of Series B Preferred Stock. Total offering costs of $2.9 million were offset against the proceeds from the sale of Series B Depositary Shares, for net proceeds of $37.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The spouse of James Neal, then CEO and Chairman of the Board of Directors, purchased 8,000 shares of the Series B Depositary Shares in the public offering at the public offering price of $25.00 per share for an aggregate amount of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022 and 2021, there were 3,600 shares authorized and 1,600 issued of Series B Preferred Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Series B Preferred Stock has the following characteristics, which are set forth in the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock, as corrected, filed with the Delaware Secretary of State.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&lt;/i&gt;&#x2014; Holders of Series B Preferred Stock shall be entitled to receive cash dividends, when and if declared by the Board of Directors at the rate of 8.375% per annum of the $25,000.00 liquidation preference per share, which equals $2,093.75 per share each year. Such dividends shall be payable quarterly in arrears on or about the 15th calendar day of each January, April, July and October commencing on or about July 15, 2021. The dividends will accumulate and be cumulative from, and including, the date of original issue of the Series B Preferred Stock, on the basis of a 360-day year consisting of twelve 30-day months. Dividends will be payable to holders of record as they appear in the stockholder records of the Company (or the depositary in the case of Series B Depositary Shares representing underlying Series B Preferred Stock) at the close of business on the applicable dividend record date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Preference&lt;/i&gt; - Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any distribution or payment shall be made to holders of shares of Common Stock or any other class or series of capital stock of the Company ranking junior to the Series B Preferred Stock, the holders of shares of Series B Preferred Stock shall be paid out of the assets of the Company, after payment of or provision for the debts and other liabilities and any class or series of capital stock, as to rights upon any voluntary or involuntary liquidation, dissolution or winding up, senior to the Series B Preferred Stock. The Series B Preferred Stock have a par value of $0.05 per share and a liquidation preference of $25,000.00 per share plus any accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Redemption and Special Optional Redemption&lt;/i&gt; - On and after April 15, 2022, the Company, at its option, may redeem the Series B Preferred Stock, for cash, in whole or in part, at any time or from time to time, as follows: (i) between April 15, 2022 to April 15, 2023, at a redemption price of $26,000.00 per share ($26.00 per depositary share), (ii) between April 15, 2023 to April 15, 2024, at a redemption price of $25,750.00 per share ($25.75 per depositary share), (iii) between April 15, 2024 to April 15, 2025, at a redemption price of $25,500.00 per share ($25.50 per depositary share), (iv) between &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;April 15, 2025 to April 15, 2026, at a redemption price of $25,250.00 per share ($25.25 per depositary share), and (v) after April 15, 2026, at a redemption price of $25,000.00 per share ($25.00 per depositary share), and in each case, plus any accrued and unpaid dividends thereon up to but not including the date fixed for redemption, without interest. If fewer than all of the outstanding shares of Series B Preferred Stock are to be redeemed, the shares to be redeemed will be determined pro rata or by lot. Upon the occurrence of a delisting event or change of control the Company will have the option to redeem the Series B Preferred Stock, in whole or in part, for cash at $25,000.00 per share plus accrued and unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion &lt;/i&gt;- The shares of Series B Preferred Stock are not convertible into or exchangeable for any other property or securities of the Company, except upon the occurrence of a delisting event or a change of control, each holder Series B Preferred Stock will have the right (unless the Company has elected to redeem the Series B Preferred Stock) to convert some or all of the shares of Series B Preferred Stock held by such holder on the delisting event conversion date or change of control conversion date into a number of shares of the common stock (or equivalent value of alternative consideration) per share of Series B Preferred Stock, equal to the lesser of (A) the quotient obtained by dividing (1) the sum of the $25,000.00 per share liquidation preference plus the amount of any accumulated and unpaid dividends up to, but not including, the delisting event conversion date or change of control conversion date, as applicable (unless the delisting event conversion date or change of control conversion date, is after a record date for a Series B Preferred Stock dividend payment and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accumulated and then remaining unpaid dividend will be included in this sum) by (2) the common stock price (such quotient, the &#x201c;Conversion Rate&#x201d;); and (B) 1,253.13 (1.25313 per depositary share) (i.e., the &#x201c;Share Cap&#x201d;), subject to certain adjustments described in the Series B Preferred Stock Certificate of Designation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&lt;/i&gt;&#x2014; Holders of the Series B Preferred Stock generally will have no voting rights, but will have limited voting rights if the issuer fails to pay dividends for six or more quarters (whether or not declared or consecutive) and in certain other events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification&lt;/i&gt;&#x2014;The Company evaluated the convertible preferred stock for liability or equity classification under the applicable accounting guidance and determined that treatment as equity was appropriate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Dividends&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2022, the Company&#x2019;s Board of Directors declared and paid cash dividends on the Company&#x2019;s Series A Preferred Stock and Series B Depositary shares as follows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_cbQH9ljBJEebaeTjfrtxMg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ns1YY3UqQkOJK6UyTHN1bg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March 17, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KkEuaC7pjUygw9Z4wgEdgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Z4eBHZawv0inBmuQccPnkA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;April 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_AffMX3HfskqqtMAs2dYFqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rVEGkExq70yCFYYZq4K5yQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 20, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LQOgbcYcy0O5Ut6RtuujLg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Kelm5qnj-EOoeAXowZDZbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 17, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xxzwN1Kink2tMJX3CRXlnA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NoKAl2q6DEWcRsp0Y0mt6g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;BVF Ownership&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, BVF owned approximately 31.5% of the Company&#x2019;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.3% of the Company&#x2019;s total outstanding shares of common stock. The Company&#x2019;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of December 31, 2022, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2018 Common Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2021 Series B Preferred Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act, and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December&#160;31, 2022 and 2021, the following common stock warrants were outstanding:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2018, the Company issued SVB a warrant in connection with the legacy SVB Loan Agreement which is exercisable in whole or in part for up to an aggregate of 6,332 shares of common stock with an exercise price of $23.69 per share. The warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million. The warrant is classified in stockholders&#x2019; equity on the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2019, the legacy SVB Loan Agreement was amended to extend the draw period from March 31, 2019 to March 31, 2020. In connection with the amendment, the Company issued a second warrant to SVB which is exercisable in whole or in part for up to an aggregate of 4,845 shares of common stock with an exercise price of $14.71 per share. The second warrant may be exercised on a cashless basis and is exercisable within 10 years from the date of issuance or upon the consummation of certain acquisitions of the Company. The fair value of the second warrant issued to SVB was determined using the Black-Scholes Model and was estimated to be $0.1 million.&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;As of December 31, 2022, both warrants are outstanding and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares have been &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_FXGxJuaD7Eqmui9GgIgKuw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"&gt;issued&lt;/span&gt;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; upon exercise of the warrants.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_UYkiYmAOIk2ogIy_KnYMTw"
      decimals="INF"
      id="Narr_RAJIwkWOwk6mKoqkWc-Ljg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_s24vGEKFqEy3_8cKQImkMg"
      decimals="INF"
      id="Narr_CWd4Pz7KK0KJe7gAItqccA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1252.772</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_uxkL92PMnEKbjnT9gFRfjw"
      decimals="INF"
      id="Narr_9vQpbIReOEaZSD0AYkuISw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw"
      decimals="INF"
      id="Narr_fRh-wLj3lEmlKOT8MGvVEA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA"
      decimals="INF"
      id="Narr_F5l_KeqNjkiK_Ay-gH2Hmw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_wSSXAv0XtUCzwNL7-ObeCw"
      decimals="INF"
      id="Narr_HfE9-E3YvUy2tEHofZIIig"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_8SUz8zRIa0KfziAoADr1GA"
      decimals="INF"
      id="Narr_PQC0hltvkUmOJlXURVJkKQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">5003</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_mS1sKPw6CE2n0SBLlBsMLg"
      decimals="INF"
      id="Narr_KkrIDe3vV0K3M2WUn59-LA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_hxzif6f6wkKNy-S4FYzklQ"
      decimals="INF"
      id="Narr_ID6yC1fAl02JvkVL5u0DyQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_xoma_SeriesXConvertiblePreferredStockMember_sp6WSCeDk02ydf80LtVc8g"
      decimals="2"
      id="Narr_HHF5meHFZEm_F3rj7CB4zQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">4.03</xoma:PreferredStockConversionPricePerShare>
    <xoma:PreferredStockConversionPricePerShare
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesYConvertiblePreferredStockMember_1HuefpXb_UKf4eNJQw4how"
      decimals="2"
      id="Narr_ZMteAmfd3ESKy0w9JJIAZg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">13.00</xoma:PreferredStockConversionPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_sO-ZiH9JX0a2e36VG0bf-w"
      decimals="INF"
      id="Narr_84kd6Pr5kkGU99zBRXyafA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="5"
      id="Narr_c4lr6-vztku9OOl5VvIsvA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="2"
      id="Narr_VF1XQaITcE-WO2mrHASYgQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="-5"
      id="Narr_EoI-pQFWLkKUrtASgddEgw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">24600000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="-5"
      id="Narr_T2zunOVqqk-ZQ4hfXgE_ag"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <xoma:ProceedsFromIssuanceOrSaleOfEquityNet
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="-5"
      id="Narr_TD0HcEe2dkWwq1h-2KZMng"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">22600000</xoma:ProceedsFromIssuanceOrSaleOfEquityNet>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="INF"
      id="Narr_1RkD9Ss8B0-aazbjCUtXGQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="INF"
      id="Narr_HvW4lsUBRUqNL9MuHbUxcA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="INF"
      id="Narr_Q5zKUQZlFEe0UC8VxAiQ8w"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="INF"
      id="Narr_hLhJf8VDykajSJTceYjHTA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">984000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="5"
      id="Narr_olg6QBxI6kCJV74oTu5KuA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="2"
      id="Narr_f9OuiDSFEE-rdsinSagn6Q"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockDividendPeriodYearProrated
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="INF"
      id="Narr_djmpNBFem0K5p7CfWKTIjw"
      unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">360</xoma:PreferredStockDividendPeriodYearProrated>
    <xoma:PreferredStockDividendPeriodProratedMonthsInYear
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="INF"
      id="Narr_o4Fm9KBa7EeU2u6wvpmFUg"
      unitRef="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ">12</xoma:PreferredStockDividendPeriodProratedMonthsInYear>
    <xoma:PreferredStockDividendPeriodMonth
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="INF"
      id="Narr_tcBoknTzZU6uzxqFRrtX5Q"
      unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">30</xoma:PreferredStockDividendPeriodMonth>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_rsWhZL3QWUGCgQfG9qr1IA"
      decimals="INF"
      id="Narr_L98IlhLzEkiWvyvWgexUvg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Plx9EsoiUk-kn30CrXdFBQ"
      decimals="INF"
      id="Narr_lmlh4mhC0kaH47iao04EFg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="2"
      id="Narr_4ZyR6GLQ2E2lo01bmJTNLQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_EHfSyV3gW0yDNOYLjydoRw"
      decimals="2"
      id="Narr_TmbPq_Cmj0mCwhR7clGlcQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">26.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_qfx1aT0hdUKuLGbIUvod5Q"
      decimals="2"
      id="Narr_3_I6wqYInUO4IPNhHkUKbA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.75</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HvH-K2iJckyzvUJ368yfOA"
      decimals="2"
      id="Narr_9_jJdFFO-0K54aikL5_lXg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.50</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ECC3Oq74RkeaDZlwSNK7uw"
      decimals="2"
      id="Narr_1bi3yYH2jUa3RDTDlIft1Q"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_12_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_A1kceVHEZkC9lyFdU9dnZg"
      decimals="2"
      id="Narr_SeHcwHDjCkybMVOuwzk6yw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <xoma:PreferredStockRedemptionPricePerShareOptionalRedemption
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="2"
      id="Narr_1ivimnCEgUuGtR_0TVLO7g"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</xoma:PreferredStockRedemptionPricePerShareOptionalRedemption>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="2"
      id="Narr_8_6yrvA5BU2Lu_VjrEzy4w"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lou_2mBPMEW7E_LpJU60VQ"
      decimals="5"
      id="Narr_R7Zw_LFW4E6SBHkWXobmjg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1.46071</xoma:PreferredStockShareCap>
    <xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays
      contextRef="Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ"
      decimals="INF"
      id="Narr_RT8c7wtqg0CnSFl_EdPAkA"
      unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">10</xoma:PreferredStockConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA"
      decimals="INF"
      id="Narr_CrcG42Lh2EGRKLf2sS1hBA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA"
      decimals="2"
      id="Narr_HkTgX1UL_UypJujDv6S3SQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA"
      decimals="-5"
      id="Narr_U2KljEMoV0-XgVAtepgegw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">40000000.0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA"
      decimals="-5"
      id="Narr_K04wTa_lGUKOJDCrLewJ2A"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <xoma:ProceedsFromIssuanceOfPreferredStockNet
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA"
      decimals="-5"
      id="Narr_TAQDK5Shw02UgtnfBj7_6Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">37100000</xoma:ProceedsFromIssuanceOfPreferredStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ"
      decimals="INF"
      id="Narr_-IMfj84v-UCty8g7R2816g"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">8000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ciJIa6qAFU2yV5PeZYq7oQ"
      decimals="2"
      id="Narr_YokCv8B2FkWjpjgmK4dzbQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nPDEpemKCkGRZJd0ALwgdQ"
      decimals="-5"
      id="Narr_CwCdK2FP_kWGD02CAhsIXg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">200000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"
      decimals="INF"
      id="Narr_lLENuL8Pn0S6nRoPXCHv-w"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">3600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ"
      decimals="INF"
      id="Narr_fzv72Z5S_0qtN0EPdKWqAQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">3600</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"
      decimals="INF"
      id="Narr_ztdJVeXdtUCVEdwpOyt_Qg"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="5"
      id="Narr_WnDSCczp7UiwaFt1WW_DWA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="5"
      id="Narr_aEbXM1cIrU2PQeJgezlG9w"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"
      decimals="2"
      id="Narr_6K-iAzL3w0yH9H6hhnPEQg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockDividendAmountPerShare
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="2"
      id="Narr_SzLLFTNCjkqcjrBYtlzzVQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">2093.75</xoma:PreferredStockDividendAmountPerShare>
    <xoma:PreferredStockDividendPeriodYearProrated
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="0"
      id="Narr_vDEhNiq5rUeZUwa1-J2dXg"
      unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">360</xoma:PreferredStockDividendPeriodYearProrated>
    <xoma:PreferredStockDividendPeriodProratedMonthsInYear
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="INF"
      id="Narr_2N9LhdA54kKY3_Bhc0oPVg"
      unitRef="Unit_Standard_M_EsnZ6PG9SkKFQKEhgw-caQ">12</xoma:PreferredStockDividendPeriodProratedMonthsInYear>
    <xoma:PreferredStockDividendPeriodMonth
      contextRef="Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A"
      decimals="0"
      id="Narr__azsI86Sm06Eb4Efu_pGEg"
      unitRef="Unit_Standard_D_3sq-xZ3c6kaYZBPelELouQ">30</xoma:PreferredStockDividendPeriodMonth>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_FcHQ8LJAdUyRPQRUl_-mxQ"
      decimals="INF"
      id="Narr_HfMf4kCxKkGo_1QiyNzmCQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Oxq9b_OfaEml4UUyD9YcGQ"
      decimals="INF"
      id="Narr_Dp4oCU6VzEKflvVR7yiSRw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"
      decimals="2"
      id="Narr_ryJ7TY4Gy0WdVYi_DYLoFw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_10e0GTXDRUWaRkscI-rq2A"
      decimals="2"
      id="Narr_RsV_vGAp806DBLRwLslwhQ"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">26000.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mxRsfmorrkSEqfBuonPH7g"
      decimals="2"
      id="Narr_mRnUDfWaDEKpttSg2-ging"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">26.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_l3gJWyDRYUKye9TcMvxKkA"
      decimals="2"
      id="Narr_zbTRyCOMPUKG4DYPF6amEg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25750.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_DUPN51MSmkqx8eTsUOxe0Q"
      decimals="2"
      id="Narr_freuayKpiESm9cCdNBuCjA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.75</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_VF5VDW6QuUuc3CbbuaDBkw"
      decimals="2"
      id="Narr_6jv8kaKAtkmvsy_kCwugiw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25500.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_3Xidd4rXq0CdoCYMGseM6A"
      decimals="2"
      id="Narr_NjkUhaXCPUu5zdqzMHVAbw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.50</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_HlTz8mGzA0mZC7-lIrM7Uw"
      decimals="2"
      id="Narr_AIgzquZedEqTBk-EYemJUw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25250.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2025_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_ItyWObStzkWwMfLcO4SwBA"
      decimals="2"
      id="Narr_t-3dzaxNLkKE_bhn3aVDsg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.25</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_PyU4HZ2-MUyl0mkJzT2hGg"
      decimals="2"
      id="Narr_o5d86STOEUuH9g7oZYCL_Q"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25000.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="As_Of_4_15_2026_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_P9oH2exeW068heueh9jTxg"
      decimals="2"
      id="Narr_5dDvhP5ddkiIQyXtUOjMjw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25.00</us-gaap:PreferredStockRedemptionPricePerShare>
    <xoma:PreferredStockRedemptionPricePerShareOptionalRedemption
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"
      decimals="2"
      id="Narr_SOtg8VwjfkaiFO80-j1FOw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25000.00</xoma:PreferredStockRedemptionPricePerShareOptionalRedemption>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"
      decimals="2"
      id="Narr_1FWhhDEgUEWwjmCWNbBT8A"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">25000.00</us-gaap:PreferredStockLiquidationPreference>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_81D0GUm6jkaMA5ZEtvf1aw"
      decimals="2"
      id="Narr_0dbhjPN-ZUK58lZHWLIu9g"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1253.13</xoma:PreferredStockShareCap>
    <xoma:PreferredStockShareCap
      contextRef="As_Of_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_RCZjgoVjckqCQyKomm8DTA"
      decimals="5"
      id="Narr_v1mqMXCz5EO1vWki-M8ZQA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">1.25313</xoma:PreferredStockShareCap>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_13VIU7coJUybmctyZNnhTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:22.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 20, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_cbQH9ljBJEebaeTjfrtxMg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ns1YY3UqQkOJK6UyTHN1bg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March 17, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KkEuaC7pjUygw9Z4wgEdgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Z4eBHZawv0inBmuQccPnkA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;April 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May 18, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_AffMX3HfskqqtMAs2dYFqA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rVEGkExq70yCFYYZq4K5yQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 15, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;July 20, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_LQOgbcYcy0O5Ut6RtuujLg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Kelm5qnj-EOoeAXowZDZbA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 17, 2022&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_xxzwN1Kink2tMJX3CRXlnA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.27%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_NoKAl2q6DEWcRsp0Y0mt6g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.36%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:20.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oU8u6lClxEOfghqL98sZqw"
      decimals="5"
      id="Tc_e_wg_juxd0y7BimoFVPg8Q_4_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_20_2021_To_10_20_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_WrEKyI_BW0KQR6sl9XSdjg"
      decimals="5"
      id="Tc_0PiitNbnlkOAAKi86QeTSw_4_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lbU7cay48kKD_gmRJwUG_g"
      decimals="5"
      id="Tc_bq2hc9Cvp0mbCYYt0BsYTQ_5_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_3_17_2022_To_3_17_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_T3jnk2RjiUevKoKd9EnTqQ"
      decimals="5"
      id="Tc_GE4rEzuAn0uEwD1tdzGI3Q_5_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_9mhY0z8wFkeA-5k_gob2uw"
      decimals="5"
      id="Tc_Vz1bpyK91kquvTfcBA9zHg_6_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_18_2022_To_5_18_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_uXlwrNWockK5GTzJTR4xtA"
      decimals="5"
      id="Tc_zRliJZVZtkGXIRnj7zz3uA_6_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BeZq4eB_bk2TnmlVTH1lsQ"
      decimals="5"
      id="Tc_Zs5Cq37zQEOWgNUdM5IQ0Q_7_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_7_20_2022_To_7_20_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_nnI_V8OIx0mQwuOLxFWnCw"
      decimals="5"
      id="Tc_gyayY19G_kWpKIqCf-XwVg_7_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg"
      decimals="5"
      id="Tc_I6McfUQy7EyE3U2m-gNLig_8_3"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CkHConVlPkaisM4vx4ktDA"
      decimals="5"
      id="Tc_2dMfspLqQka_wGhTUUYDvw_8_6"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA"
      decimals="3"
      id="Narr_vwURkgm0wUqLsLPF49LUsQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.315</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA"
      decimals="3"
      id="Narr_VvEJFYZUzkmOEzCxgXQdyQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.523</xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted>
    <xoma:MaximumValueOfCommonStockToBeIssued
      contextRef="As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_p24xpBTiUk-dfPSrxHMCZw"
      decimals="-5"
      id="Narr_5b1g8lthfk6kKmT9cHSr1Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">30000000.0</xoma:MaximumValueOfCommonStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares
      contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_3Ps32ZWrf0q2EllGoG3fog"
      decimals="2"
      id="Narr_DNE-DNRynU-UzZNZttBQng"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares>
    <xoma:MaximumValueOfCommonStockToBeIssued
      contextRef="As_Of_3_10_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_jfpTunIQFUqf7I8Jy9MJPQ"
      decimals="-5"
      id="Narr_RS9j4a0rGUCivk3tV1fEZQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">50000000.0</xoma:MaximumValueOfCommonStockToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_18_2018_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_W-KLX26PfE2wxKbylONFcw"
      decimals="INF"
      id="Narr_FYH4jrnIoUW2iwmdByZ38g"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_yudqPJgz7UaaG7AG1-aQYw"
      decimals="-5"
      id="Narr_I1AmdCHpeEuV1AQQS30ZIA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">50000000.0</xoma:MaximumValueOfStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares
      contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_HhSShoGRe0G87HW8PMEEcg"
      decimals="2"
      id="Narr_OegX9qg3Z0-L5SMe9RHHQQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_5_2021_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_4s6qFO24NU6iO5tq9Aj0Nw"
      decimals="INF"
      id="Narr_UXldOYgoQ0Ko2Ukk92ZdGw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_Q4S3N-LVMUuHJn9I5NYMRA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w"
      decimals="2"
      id="Tc_8NluGu-i-E-t31Iz2m1JSg_3_7"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw"
      decimals="2"
      id="Tc_8NluGu-i-E-t31Iz2m1JSg_3_7_2"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw"
      decimals="INF"
      id="Tc_qnR6Lok3ukOjTlgnrtvYVQ_3_9"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_Vn7HD3CRJUWyaQF2oBmr7w"
      decimals="INF"
      id="Tc_9Ubkbdbn40WGHaN41gA33Q_3_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug"
      decimals="2"
      id="Tc_7YLEteS7LEGf7RzWkm_plA_4_7"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw"
      decimals="2"
      id="Tc_7YLEteS7LEGf7RzWkm_plA_4_7_2"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_BqAnQgxSqEm3QXFfQd9XAw"
      decimals="INF"
      id="Tc_CxolKg1aN0eGymToxxk_-g_4_9"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_72tukc6k-UmoTzm8lKdNug"
      decimals="INF"
      id="Tc__hjZwQcCR0e3ArABgZmbvQ_4_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Tc_ev7B2tbFr0SXLy_9Jb4FQA_5_9"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ"
      decimals="INF"
      id="Tc_FXi2jE4XjE6TwFokSoBY1A_5_11"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">11177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw"
      decimals="INF"
      id="Narr_1g2-D6BSBkSLIamsMD7nMw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">6332</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw"
      decimals="2"
      id="Narr_Gsar_HhBCkar1MZx518Mqw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_5_1_2018_To_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_8nHUuSkvaUSLpkODfJC36A"
      id="Narr_Yx4Rhm0OzUuL0tE2daMq1Q">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw"
      decimals="-5"
      id="Narr__AFbSpKVbEOn0NmO26fmGg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg"
      decimals="INF"
      id="Narr_G4XzFg0O1EqCuRCZOQpB4w"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">4845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg"
      decimals="2"
      id="Narr_Xo_nod8KyUauwrvQcg_9kg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <xoma:ExercisablePeriodOfWarrants
      contextRef="Duration_3_1_2019_To_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_f0_HvkLSs0CosO5uys_l2Q"
      id="Narr_z30aoHcAIEao_Vibyc21GQ">P10Y</xoma:ExercisablePeriodOfWarrants>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_3_31_2019_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_r8Q54L8SWUaflxEmu7HMcg"
      decimals="-5"
      id="Narr_-4qPEv7CvUe68NSbMiXAFA"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <xoma:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_AQY72CQvV02u0NTeC1tQxQ"
      decimals="INF"
      id="Narr_gC19HApppEy4crFutzvGJQ"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">0</xoma:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_KAp18D1mlUaqPQDG55dhmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Collaborative Agreements, Royalties and Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#x2019;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestones events) have not been recorded on the accompanying consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. None of these milestones were assessed to be probable as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contingent Consideration &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Company&#x2019;s agreements with Bioasis, Aronora, Kuros, Affitech, and ObsEva the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, and the Merck KGaA royalties. The Company recorded $0.1 million for the Bioasis Contingent Consideration which, represents the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The contingent consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of December 31, 2022, there has been no change in the estimated fair value of the Bioasis Contingent Consideration from the initial value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, and Affitech Sales Milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is recognized. As of December 31, 2022, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, no liability was recorded on the consolidated balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Arbitration Proceeding&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June 2021, the Company initiated an arbitration proceeding against one of its licensees (the &#x201c;Licensee&#x201d;) with the American Arbitration Association/International Centre for Dispute Resolution. &#160;XOMA seeks damages, plus interest, and fees and costs of the arbitration (which fees and costs are currently estimated to be in the mid-single-digit millions of U.S. dollars range). &#160;In response, the Licensee seeks declarations that the License Agreement, under XOMA&#x2019;s interpretation, is unlawful, void and unenforceable, and that the License Agreement has expired. &#160;To date, the Licensee has not filed any counterclaims against XOMA. However, to the extent the Licensee is deemed to be the prevailing party, the arbitrators, in their discretion, may require XOMA to pay the Licensee&#x2019;s fees and costs of the arbitration (currently estimated to be in the mid-single-digit millions of U.S. dollars range). A hearing before a panel of arbitrators was held on this matter in November 2022, and the parties have submitted post-hearing briefs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xoma:ContractualObligationEstimatedMilestonePayments
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_v6wBrkm7bUu4Sa8415VQpQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6300000</xoma:ContractualObligationEstimatedMilestonePayments>
    <xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="INF"
      id="Narr_8yvRxZTFHkeh8kOvpCdQpQ"
      unitRef="Unit_Standard_product_LIcrrN3p2keAIcOAhQ0LhQ">1</xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ"
      decimals="-5"
      id="Narr_m-sihnkBl0O9A8sgQ_PEEg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_5YoPdBydBkyVJuYBvyiLIg"
      decimals="0"
      id="Narr_RreIGeWgZkS88dJFl-Ax5Q"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_k_sLWKXSlEu9WIjrFJoc0g"
      decimals="-5"
      id="Narr__aPcUlkacEyTG5zv3LirqQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:NumberOfArbitrationProceedingsInitiated
      contextRef="Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A"
      decimals="INF"
      id="Narr_Y1C8wFe-_UOpANI-O6zayg"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">1</xoma:NumberOfArbitrationProceedingsInitiated>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_wIEG0q0x30-trTCNH5lU0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Concentration of Risk, Segment and Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the year ended December 31, 2022, four partners represented&#160;33%, 31%, 13% and 12% of total revenues. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, one partner represented&#160;92% of total revenues. As of December 31, 2022, there is no trade receivables balance. As of December 31, 2021, one partner represented 100% of the trade receivables balance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 18pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined that it operates in one business segment as it only reports operating results on an aggregate basis to the chief operating decision maker of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Asia Pacific&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Europe&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s property and equipment is held in the United States.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_A4To0NeQ0UybzQYa3NDSxg"
      decimals="INF"
      id="Narr_Idu8n98QRkawlM4Agxn2Mw"
      unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw">4</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_pFFI1aKmY0-JrE7vjxLafg"
      decimals="2"
      id="Narr_a7sVA1LUkEGnDhTg2MRDWA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_y18GrbyNrEilibNOBjl-og"
      decimals="2"
      id="Narr_Lus4P_ME3UKAuHe_dDCYVA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qy9rE8Y_SEaSHkgLxZXqAQ"
      decimals="2"
      id="Narr_4WIMPbrtkESWs41Xz5iNkA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_hJHO8BzhGkm3pdbOfFsQrg"
      decimals="2"
      id="Narr_t9x1vl0MJkmlqS-5DOBMNg"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.12</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_Tuhk6nZzwk6xT736Ru4Zyw"
      decimals="INF"
      id="Narr_4R37DvmxvE2UUyD5SRMQLA"
      unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw">1</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_W069niAtjE6EsmPfY337qA"
      decimals="2"
      id="Narr_ThMn-Ilz9km8e9IxYwhRYQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw"
      decimals="-5"
      id="Narr_qX-duOd_ekSRDBb3-naLqQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">0</us-gaap:AccountsReceivableNetCurrent>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_qIclTWez7UKcmOfuHD_oAQ"
      decimals="INF"
      id="Narr_FhMCBZV7AUGFFaXfr2I08g"
      unitRef="Unit_Standard_customer_Rb4eKoFuqEi0eyfESLMZaw">1</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_2vBGTX6yJEWsXPa205KCrg"
      decimals="2"
      id="Narr_OHr5MnguJEGOvi5fbJzczA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="INF"
      id="Narr_vBSTkFr_Q0CEJ1_i6AFGlQ"
      unitRef="Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_6vbuUATA1Uuk83dSaEYcug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Revenue attributed to the following geographic regions was as follows (in thousands) based on the location of the licensees:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,477&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Asia Pacific&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,550&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Europe&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38,160&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_BRZefaTLEE2Yy6v52PFdig"
      decimals="-3"
      id="Tc_o7GUcp_5F0-y_4ancj8SNQ_3_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">4477000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_uq3xBIh_ZEu0t2lz65AnGA"
      decimals="-3"
      id="Tc_iHLlh2lzlUSH_1vcprnfCQ_3_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">2610000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_srt_AsiaPacificMember_Dtmc_sm9HUOpkVYHoPRuoQ"
      decimals="-3"
      id="Tc_OZAylWdRGUK-EDCTOaxC-A_4_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">1550000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_AsiaPacificMember_OSUGOQpK0k66rX6ilVlChg"
      decimals="-3"
      id="Tc_q4lOh0CRKU-IqIXP0Tn8xA_4_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">550000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_srt_EuropeMember_kIunflkcykiOnsDFbUFC3w"
      decimals="-3"
      id="Tc_PJWl1KpJekK3G1TAwFM2Ww_5_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">35000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      decimals="-3"
      id="Tc_5py-pIk6zEiGaqdF69k_mg_6_3"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">6027000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA"
      decimals="-3"
      id="Tc_YX81dCFjKUmOZHtlSnulDQ_6_6"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">38160000</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw"
      id="Tb_5BSRf8KcLEurBMg0-ZgmjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Emeryville Lease Extension&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 13, 2023, the Company entered into an amendment to extend the lease term of its corporate headquarters in Emeryville, California from its original expiration of February 2023 through July 2023. The total remaining undiscounted lease payments due in 2023 under the extended lease term is $0.1 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Appointment of Owen Hughes as Executive Chairman of the Board of Directors and Interim CEO&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer), effective as of January&#160;1, 2023. Pursuant to Mr. Hughes&#x2019; employment agreement, Mr. Hughes will receive an annual base salary of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$125,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and be eligible to receive an annual discretionary cash bonus, with a target amount equal to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;55%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Pursuant to the terms of his employment agreement, on January 3, 2023, the Company granted Mr. Hughes &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;two&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; separate non-qualified stock options to purchase: (i) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;100,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$18.66&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;First Hughes Inducement Award&#x201d;) and (ii) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;75,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$30.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;Second Hughes Inducement Award&#x201d; and together with the First Hughes Inducement Award, the &#x201c;Hughes Inducement Awards&#x201d;). The First Hughes Inducement Award will vest in a series of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;four&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. The Second Hughes Inducement Award will vest in a series of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;36&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; successive equal monthly installments measured from January 1, 2023. The Hughes Inducement Awards are subject to the terms and conditions of the 2010 Plan but were granted outside the 2010 Plan as an inducement material to Mr. Hughes entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;background:#ffffff;"&gt;Appointment of Bradley Sitko as Chief Investment Officer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On December&#160;30, 2022, the Board appointed Bradley Sitko as the Company&#x2019;s Chief Investment Officer, effective as of January&#160;3, 2023. Pursuant to Mr. Sitko&#x2019;s employment agreement with the Company, he will receive an annual base &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;salary of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$500,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and a signing bonus of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$110,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. Mr. Sitko&#x2019;s signing bonus will be paid within &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;30 days&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; after the effective date of his employment agreement and will be subject to standard deductions and withholdings. If Mr. Sitko resigns without good reason or is terminated for cause (each as defined in his employment agreement), in either case, within &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;one year&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; after the effective date of his employment agreement, then Mr. Sitko will be required to repay the signing bonus, based on the gross amount, but prorated on a daily basis for the time employed, to be paid within &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;60 days&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; after his termination date. Mr. Sitko will also be eligible to receive an annual discretionary cash bonus, with a target amount equal to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;50%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of his then-current annual base salary, upon the achievement of annual performance milestones to be established by the Board. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Pursuant to the terms of his employment agreement, on January 3, 2023 the Company granted Mr. Sitko &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;two&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; separate non-qualified stock options to purchase: (i) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;300,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$18.66&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;First Sitko Inducement Award&#x201d;) and (ii) &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;250,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of the Company&#x2019;s common stock at an exercise price of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$30.00&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (together with the First Sitko Inducement Award, the &#x201c;Sitko Inducement Awards&#x201d;). &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;Twenty-five&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; percent of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable on &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_292B7Rrmb0OIBzdjG3jt5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;January 3, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; (the &#x201c;Initial Vesting Date&#x201d;), and the balance of the shares subject to each of the Sitko Inducement Awards will vest and become exercisable in a series of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;36&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; successive equal monthly installments thereafter on the same day of the month as the Initial Vesting Date. The Sitko Inducement Awards are subject to the terms and conditions of the 2010 Plan, but were granted outside the 2010 Plan as an inducement material to Mr. Sitko entering into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <xoma:LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm
      contextRef="As_Of_1_13_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gX6CfAtkvUmCg-Bai3Zw_g"
      decimals="-5"
      id="Narr_a86GUBrlqESAxCGOfDA-BQ"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">100000</xoma:LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm>
    <xoma:EmploymentAgreementAnnualSalary
      contextRef="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA"
      decimals="-3"
      id="Narr_NDF-uFIUXk6LalbL2lYOIw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">125000</xoma:EmploymentAgreementAnnualSalary>
    <xoma:AnnualDiscretionaryCashBonusTargetPercentage
      contextRef="Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA"
      decimals="2"
      id="Narr_MEH-V5XSHk2I5WL9f_cvkA"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.55</xoma:AnnualDiscretionaryCashBonusTargetPercentage>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Qzz2di3EtU2QVCStAbp7Gw"
      decimals="INF"
      id="Narr_arGW7-mq_EqvPZZEELZtcQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw"
      decimals="INF"
      id="Narr_jae3kNoSt0Gbm-t0wzlFkA"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_wJASvGFr8Ue8m31iN23zMw"
      decimals="2"
      id="Narr_yWnl8fZSDEKzPW73ih-cIg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ"
      decimals="INF"
      id="Narr_P2qSAMbeA0WKRTgF-bcGsw"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_gxRKnd1-tUe6gi75Zqg_uQ"
      decimals="2"
      id="Narr_Y8Oc-S9Y7EWEVhxW9r5-Uw"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_3kjZwwrEtk-QxVmWmdRujQ"
      decimals="INF"
      id="Narr_AO2rjcHowUCR4FPGtKg_Jw"
      unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qLzFyf8POkuPzS_GjeXV5Q"
      decimals="INF"
      id="Narr_JSDyB7hhSUyWoNAz5Z6drw"
      unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <xoma:EmploymentAgreementAnnualSalary
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      decimals="-3"
      id="Narr_jixxdWBeW0uTi22CfW1Pbg"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">500000</xoma:EmploymentAgreementAnnualSalary>
    <xoma:EmploymentAgreementSigningBonus
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      decimals="-3"
      id="Narr_wyPu4OsCkEyykJ-KL_cOcw"
      unitRef="Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ">110000</xoma:EmploymentAgreementSigningBonus>
    <xoma:EmploymentAgreementSigningBonusPaymentPeriod
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      id="Narr_frIKYSQeH0SkXgnUO5VaeQ">P30D</xoma:EmploymentAgreementSigningBonusPaymentPeriod>
    <xoma:EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      id="Narr_NnOUGQH3KUmRBpTjLj7Q1g">P1Y</xoma:EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment>
    <xoma:EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      id="Narr_T6cE-nu_sEmqOxL00Lw50A">P60D</xoma:EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination>
    <xoma:AnnualDiscretionaryCashBonusTargetPercentage
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_aCF61ARXg0y8qj2ivWqfbQ"
      decimals="INF"
      id="Narr_cPykt4FXP0S6gAOD1_8lNQ"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.50</xoma:AnnualDiscretionaryCashBonusTargetPercentage>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f4LrCv2BoEiulseA8lIUQA"
      decimals="INF"
      id="Narr_Gatna3HvsUiFc7TgJERrpQ"
      unitRef="Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA"
      decimals="INF"
      id="Narr_mlONrKgkrEmvVpBCyLUeig"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice18.66Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jUwNqEjMm0OCaXiS9NMAnA"
      decimals="2"
      id="Narr_gDchCGnT10G1dnlSL_6FpA"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA"
      decimals="INF"
      id="Narr_Q9g-Dwo8EUWv-7gJgtgC4Q"
      unitRef="Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_xoma_ShareBasedPaymentArrangementExercisePrice30.00Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_cw3eOghGHUmmXnk6WbBgeA"
      decimals="2"
      id="Narr_NDalSWOkMUqDfs95wNuibg"
      unitRef="Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_ZTl4sVqK70qunZuikTjs4A"
      decimals="2"
      id="Narr_CSlIL-c4x0m_wb8XsqtBow"
      unitRef="Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_VTkPPsj7uUqml3L2CsbZfA"
      decimals="INF"
      id="Narr_K9gc868HuU27amYGP56Lkw"
      unitRef="Unit_Standard_installment_WezQhid-EEewt6IHCxEDSQ">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ) ]:58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "0/6E6T,8-U.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M:L,P$$5_I6AOCQ^A4.%XDY)5"H4&6KH3TB01M1Y(4^S\?64U<2CM!Q2TT<S5
MF3.@3GHN7<#GX#P&TACO)C/8R*5?LQ.1YP!1GM"(6*:$3<V#"T90NH8C>"$_
MQ!&AJ:I[,$A""1(P PN_$%G?*<EE0$$N7/!*+GC_&88,4Q)P0(.6(M1E#:R?
M)_KS-'1P \PPPF#B=P'50LS5/[&Y ^R2G*)>4N,XEF.;<VF'&MZ>=B]YW4+;
M2,)*3*^BYG3VN&;7R:_MYG&_97U3-6U1I?.PKQN^6O&Z>I]=?_C=A(U3^J#_
ML?%5L._@U[_HOP!02P,$%     @ D#UI5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "0/6E6XU3_[I (  !-/   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;;7.CMAJ&_XK&[>GTS,0Q;W:<;9(9!R>M3[.Q&V?;L_VF@!PS"\@5(B__
MOA+8ELF(!]B1]\/&;\]MN R/[EN(BU?*OF5K0CAZ2^(TN^RM.=]\&@RR8$T2
MG)W2#4G%.RO*$LS%4_8\R#:,X+ H2N*!8UFC08*CM'=U4;RV8%<7-.=QE)(%
M0UF>))B]7Y.8OE[V[-[NA8?H><WE"X.KBPU^)DO"OVP63#P;[%7"*"%I%M$4
M,;*Z[$WL3U-O+ N*3_P9D=?LX#&2N_)$Z3?Y9!9>]BRY120F 9<26/QY(3Z)
M8ZDDMN.?K6AO_YVR\/#Q3OVVV'FQ,T\X(SZ-_XI"OK[LC7LH)"N<Q_R!OOY&
MMCLTE'H!C;/B?_1:?G;H]5"09YPFVV*Q!4F4EG_QVQ;$0<'8JBEPM@7.AP*[
M[AO<;8';ML#;%G@%F7)7"@Y3S/'5!:.OB,E/"S7YH(!95(O=CU+YNR\Y$^]&
MHHY?36F0BY^1(YR&Z";E$7]'L[0\GN3OTD=?EE/T\X__O1AP\76R:!!LI:]+
M::=&VG;09YKR=29T0Q)6!09B._<;Z^PV]MH!%:<D.$6N?8(<RW$T&^3#Y9\Q
M.T76J"AW->53N/Q_>2J^W=)]>V5OW#UZM]!SF] _OF^(#B]<;EO]WW4,P"K9
M1CYE&QR0RY[H$QEA+Z1W]=,/]LCZ14?$D%B%C[?GX[7C,TG3',?H@6PHXSI0
ML YGN0ZO#U9U!65(K )JN <U; =J05A$Y6D<(M$,M,=4@]+N!*L]P\#ZKM ,
MB56@C?;01BW//H;%*%8TN_HC#-9:X3C3'F)@65=:AL0JM,[VM,[ /=R.#+=1
M3-!]GCP1IJ,$:UB6W7?/QY:M(P66=B5E2*Q":KPG-6Y#ZH$\1QD7AQ9']SC1
MGHJPSO_GGR?(GS\LY@^3Q]G\7@<-5.@*S9!8!=KY'MIY&VBS-*!,G(*E]5AR
MT<.03_.4LW?Q-]12A(6G-SIN8$U7;H;$*MQL2]DWJPVY1_R&9J%H9]$J"DI\
M]:=I@^30Z3OVT+-&(QT[N+@K/%-J57H'YM=N0V\2AD(]V_^]$Q_3=:GK!CE'
MI"VTH*\BQ8BCEPE/KB4(BG0F:$BM2M!1!)WO):CS#]<-<LL\$N>\:UM:<&!M
M9W"&U*K@E/FW8?O^ 9POG\P9>J2OJ99;@UI"V/M+%,=:&P(7=P9WC%!@JU1@
MPW;^ [ARE!#D%HR^1&F@'20:)/V)EIK1@&!*K4I-100;=O8?J"UHQD6D^CO:
MU ZL#8+GWL@::[$9C0BFU*K85$BP86=?G)831G ])EA@6-/*C"8#4VI52"H;
MV+"QOZ.!.)86:YI"X:!!Q+&\_ID8/[6TC*8#4VI56BH?V*T"PE_")/2_I:+=
MHR7!F6 7HEF6Y37P8,U[JL5F-!^84JMB4PG!;A41_J2QR .8E5F495I8L%(-
M+*.AP)1:=9I4I0*G52KP<\;D%$<YKQ&ES\5HF6NA-2A^);HJ'Z[J2LV46I6:
M2@-.JS0P2SEAY?4(.8V&=QBUU&#%.FI&$X IM2HUE0"<5@F@.!V1+\S8,V7O
M6E:PSCU-^S@(B) 1(F$IJ*5G- :84JO24S' :14#E@D6F?$ZS\3;F?[\A'7J
M)KGALLZPCF']'67]G5;67X:=9]G-?A4*?"VL6;+!J?Z8@P5K)V[ANL[8CN']
M'>7]'=BJS_S;!S3)PXA3AB:<$^']BRFBVQ@_:ZG!>O74C%I_4VI5:LKZ.[!S
MWYV9:SF; QUBWWEM *[K#.L8$<!1$<!I=7U@D3_%42".*XKUPZ5)(^\;59MN
MU;Q"32Z7>+FRA]YPY#FC\XO!BPZ/\OQ.*\\OCJ*DF-BFP;<3<61AL5EHGG-Q
M/J:A:&A:9"9-O+]5&Q[NI"V2_/EHO-_'+8YCV'U'V7T'-NF[=G4;L03-IEHR
ML(+K:0$8M?FFU*KK!Y3-=V%3OH-4=X6IH7QZ<S>?/3[>H)]PLOD%/<Z_^+_=
MH+N[A799@5&G;TJM"DXY?1?VY3MP<N9"CH1:>+#$$HOQD^$TB+* G@CC&T<K
MRM((:^$9-?RFU*KPE.%W6QE^7T0BAF,1ET+RAGXGVL&Q0<H2_\[.[7/]3")<
MW)G:,8R^>[#8!S;HNRQ^*XX70>TKP0Q<J-$@U^_;3M_57DJ'*SMC.X;E=Y7E
M=ULN CKD=BM>U(:D!K&Z12UP66=BQW#[KG+[;LO50%MBVT5!]<Q@N=NO6F)&
MG;XIM2HQY?1=V*)/!*ZP1%83B!H$:CT^7-<9TS$\OJL\O@M[_$/WJH5DU-P;
M59N:4JNB4_[?A?W_D@0Y$X.F[3RAQXAKK])>-VA4P\./UJD8.H=H(]KA"X[U
MDS^P8F>&QT@$KDH$+NSG'QD.BRGL]^2)QEJ L(!<4:6E9#02F%*K+IE5D<"#
M/?WN2$,W;\$:I\^D-APT"-U/EM/)'SI><&'GA;/'2 *>2@(>;./'IR-G^!^T
M%(.DR.(3Y.=)'F,Y]W\B1\X-X7+I\8*1%1'^+:SO?O#W=.U^1M6FIM2JC%5@
M\!H6];3I?@T:W_4[G:CV6#3,H1:UT91A2JV*6J4,#XX%S4VR04 V26W^A^LZ
M8SI&JO .[BR @T"'+@D+ 5W2[.T%Q\@4GLH4'AP"MJ?=-9J2#<VBXOI[.7VI
M968R'/A&U::FU*H@5=3PX*30KA4VW+GP\3= /Q,<K!$CQ2:GQ85^>V!;EL77
M*))7LTG&Q0.$428+$%VA\:E[IOKI]4$_[=!.=3>%^?#6=_Z]CI%Y/)5Y/#CS
MM.BGL(#LIW,M)J/YQI1:%9/*-UZ[?-.BGS8L9*KOIT:SC"FUDM?@X/Y+>6VZ
MN(\U0X&\=:&\%7/_ZOY>V4EQA^A ?;R\T?8SEI>V,Q23E2BU3L]$OV+EO:OE
M$TXWQ=V<3Y1SFA0/UP2'A,D/B/=7E/+=$_D%^SN(K_X%4$L#!!0    ( ) ]
M:58\%%-S\ 8  .H>   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK5EM
M;]LV$/XKA->] 4XLDM:+N\1 ZG1H@:X-ZG;[S$A,3%02/9)*FOWZ'27%LB6*
M239_B"/9Q]-SQ^,]#ZFS>ZF^Z0WG!GTO\E*?3S;&;%_/9CK=\(+I4[GE)?QR
M(U7!#-RJVYG>*LZR>E"1ST@01+."B7*R/*N_NU++,UF97)3\2B%=%053#V]X
M+N_/)WCR^,5G<;LQ]HO9\FS+;OF:FZ_;*P5WLYV73!2\U$*62/&;\\D%?KVB
ML1U06_PI^+W>NT8VE&LIO]F;]]GY)+"(>,Y38UTP^'?'5SS/K2? \7?K=+)[
MIAVX?_WH_?<Z> CFFFF^DOE?(C.;\TDR01F_855N/LO[=[P-*+3^4IGK^A/=
MM[;!!*65-K)H!P."0I3-?_:]3<3> #P?&4#: >2Y V@[@-:!-LCJL"Z98<LS
M)>^1LM;@S5[4N:E'0S2BM-.X-@I^%3#.+%>?/JX_?7A_>?'E[25Z<_'AXN/J
M+5J_>_OVRQJ=H*_K2_3+JU_1*R1*]&4C*\W*3)_-##S9CI^E[5/>-$\A(T^Y
MY.DIHGB*2$"(8_CJ^</QX? 9Q+L+FNR")K6_:"SH2BE>&L2TYD:_=L73.*!N
M!W9MO=9;EO+S"2P>S=4=GRQ_^@%'P6^NZ([D["!6NHN5^KPO5TQO$,P:2NT%
M_[L2=RR'X)VSV+B:UZYL [A;AG%"HK/9W7XX0ZL%I23961W@G.]PSKTX/W-M
ME$@-;Y"ZT'D=O'1.&F?A7A DF"_<,82[&$)O#.N-5.;$<%74B38/2/.T4L((
M[DQW.,! :=A+]M FCN=NF-$.9N2%^46QC-<U(<V&*^C&*8>JN,ZYGJ*2&Q?4
M:  #]X .+4@PDL]X!S1^;CZ5?& Y)+2N9%D47*6"Y6C+'@J[DO="<*&/A]AH
MU"_KH5'@AI_LX"=>^%>*;YG($/\.I*NYWDMY>M"!7)"3X;R3?FT,;2),W9@7
M.\P+?VU( VE]&M["\6@2TA[ H=4B6L0C$''0<5;P1&)!QJBV&NQ*V]HB&*W=
MUMM!+GM '29CF<1[U(J],#\!2&9$>8MR#DH#*2LI3N3-204WXZEMO1Y4ZZ*/
MUV$3C)0K[F@1>YEH^4&6M\=8;NUC#JJ#1DF_.EQFBR .1\+H& _[*>]]:5AY
M*P!=F^7QRJ##:0]Q&/2!>I_W'PD<=\R(_=3XJ6X932@@RG*8)61GR1F1@]>B
M03Q#(QK@D;1WY(?][->T#D]=#ZD,SP.:D#XZAUT4A1$9 =C1'HZ>)?MRP:Y%
M7K.R4_MA+WV^5&@<R]MAT!V%8C^'7J2IK$#NV;5K%ZPSX"'UA63>GY:A$0[B
ML4GI.!+[21+PJ0I$7\>->]/C!#MD/;+ 21_MT"HD8YVE(T?L9\?W)31#C@S[
MSOT)];IY<04Y:'1DM9*.0XF?0U>RM-1DUT,J85>>U5P%&^NJA$OT^>JBT2NK
M*[AR[I <K-H7* Z;9+3!DXY8R<N(]8F*(4.RI/WJ=MC@Q1C0O7VFGU"_EIRI
M$JI;\3M>5MP2I[PMQ3_P59/GJA1&6TWP:%%PLY&9,XPA7>)DT5<&+JMH/E8N
M':<2/Z>"EKWAT#XSI(U,OZ%,W$')0'TPNWY9[@3L8%>0 7W 3U@= NY(D_A)
M\U#(/E4A0T*,DD%/<5AALHCB$:@=<1(_<?[G*FG%P,F8&"!#)EV$ W7CL,(X
M2L:*OZ-;XM]F=FI2OG"]'I5_R7!C2D<VT*1C5>)GU::ZGHK#P9B18P$X=J?S
M*(E&,';,2OS,N@+=+HS5ZVTG?^SX*>!%OWR4AB-,?G4B]WIVSP!R)O__.SJ,
MOJ-JLO"*O;5M4QN9P_+1/[?',>Z3OJ-R];&\'9[U=:Q.GV+UH@ .KWOT%+T*
M3@.@6U J"MVQO.)31.)X2BF%/X+TABE[*E%!+U&VVTP1QM-Y.)\&)*Q+!FXI
M#J<DHH_&0NN=6JN,AHU69M<U,^@2]H3%-32KQW/>VJC_+7R"FRVO3^_S!^<A
MI$,T#(X@'38C#8MVLH+Z9<5%E@DK@>J-KLA.1(E2MA7&S6[4H1AH$)&X?S#F
M-HP#.K)?IYV\H'YY =JY*JJ<V4/3C-^(5#AWN70H"4XP3@A=]+=>;LLH),D(
M'].]8VB_@&@ZIG:L2B=DAR@@\P#W99O+;HZ3>*1YTDX^T.?(A[T&7U?SL^$[
ME()KJ^NR\VQU:2<IJ%]2)*<1"7]$:ZXL] NT:NH$UMP477&UY08T&^I$7=TM
MG9%XG_/2[G@L;X=9Z10)]1\ /)L3Z%$5R+&\'4;=:17JURK/F>5X\$IGWM]8
M^&T:;+.]%Y'V+? ?3-V*4H/LNX%!P6D,\Z^:%ZO-C9';^MWDM31&%O7EAC.8
M'VL O]](4"GMC7W=N7N]O?P74$L#!!0    ( ) ]:5:JUIV22P0  ,L4   8
M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULM5AMDZ(X$/XK*6[O:K=J5D@0
MT#FU2AVO=JOVQ5KW[CYG("HU0+@DZ-[]^DN  :,,R,RL'T8(W4\_3P>[>S(Y
M4O; ]X0(\"..$CXU]D*DMZ;)_3V),1_0E"3RR9:R& MYRW8F3QG!0>X41R:R
M+->,<9@8LTF^MF:S"<U$%"9DS0#/XABS?Q<DHL>I 8W'A6_A;B_4@CF;I'A'
M-D3\F:Z9O#,KE"",2<)#F@!&ME-C#F^7R%8.N<5?(3GRDVN@I-Q3^J!N/@93
MPU*,2$1\H2"P_#J0)8DBA21Y_%."&E5,Y7AZ_8C^1RY>BKG'G"QI]'<8B/W4
M&!D@(%N<1>(;/7X@I2!'X?DTXOE?<"QL'<\ ?L8%C4MGR2 .D^(;_R@3<>(
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M%C:RW!J_0%.Z!U(V154;R5CL)/^HJ Z.;Y"^[PR49H+2K(JV7Y^N]6J#YG1
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M*@^7U MH6C1@O]\E2?YR4KR!NGO->OH/4$L#!!0    ( ) ]:59!Y=+-+ D
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M?>F)M<K.UL?$16>5IG('Z.(& A%C1$7Y.Y#SFIMV67(K#_!0A,\-- B/-TO
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MJ+:I_5/<B]3C#DOXM3,2#*0A8/906Z\2J'/KZYRPBL.5J'KF 0IJK6:I^[:
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MJO8719T\H5>,/@V/ SUY>LHGC"?CGP&W9-Z-.NDHQ.=\I5A19<HPW3C/I-@
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M$&$5@QGI3C=28L]UPR?UPL=PCB4A;8Z??):H7U,?G9%FW8@ V'+UA?AB],M
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MTRI1&D9(8 CD>B8?6"Y\<)W$1Y4"G/"W%D\(J9VW5(9/\7'Y7M$8%*A4'<6
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M'J547VX$WY98-J#DU :7MP>323O1%00H6$!E-_W>22+&PV""B'\>]Y(_#'K
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ME;25(</*ZZ/,C^X\R:HW'OC$#.>F/JY9  Q-80D11[B]:VP;,U'E/, AM#G
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M'2!I#\>M6[::9@#)F9ISXR&'@4VPA8#8;A9+MK(3U"*XPP2V#0ES$)1%ILS
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M&^R+^'G%E^JWM91H*G@X"C2<V$WSC+]$TRS05\O)U:V;)[B3SW+[N@/EYK]
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M8KD#(Y;RC?3RYLJ:A;"T&JG1!:O*NU$X59)3'KW%MPKW^9OOI++B5ZEK$.]
MNMH"6MR[J[Y'XK2DGT5"=X'0: >AX4B\,Z6?._&VS"%?)]!'J5K11HUH=Z.]
M%-] UA/C85>,!J/1'GKC5M4QTSO]_:H&0N/MA"A/+EPE,[CN8"(XL,_0N?GV
MF^'IX'*/F,>MF,?[J+]&S+V$MHMYVA,[&(A?YB#N35')<HGIEAF;.Z'P^525
MLLR4U$(Z!_A EKG02DZ45EX!WGLQ)9K/1+/'=#)I[5*5,R$+4Q-Q,Q496(\H
M09=^Q>K;;\Y'P[/+E(TJG;<U"]7%FTS7.9'*I)MWA;<R!Y(/U+.<:, E)6(7
MR22S+#"KY))>=86L*FM>%"8O$$^4<26HR/'/F_C<S8WUF%B^MJQ4-%-8J1PE
M.IH7>3@6'EZRN2QG("JK,J*--EB86N=BT@B'BZ?6% (12+,ERF _82P*J'+F
M;67IIF"%; VZ1(UI+9H?K%Z&)3) V 3\ J!$,>U')%1)ZU6FT(J>G4""%2N/
MBAS5#NZ(EB$Q9K7*T<X@$-!3:X#S:#.%2(*T4')9 .$I+PM$:7>R@2V>/I@K
ML-)F\V4P!UK&D"T_03"9*JL:Y:P=&@95I#V2M?*0S4OU5)/1/Q,692IS:7,T
MO\NLF@39MK$D9,X%49M; *'A&31'76#;I<O%7&5SEF6JK$-[+8R0%H/5X!F#
MUB8"$\H3"A[6C]9JB4OK<O6F&_0KY)*<S?J@*Z/A4^D"/^+ /(W&$Q"UNA _
MDG1B*#CVAY?BYQ771EQ7TU8T5RGS?^ Q@$R>:D,_''&.HX1/M!@-CCV%:J#E
MLE6NXK,D57N1]6@?:U HKA6YPCCV&(%$MFSNT)#\%DU0_A$2K33]$F).%4I+
MNXO4!HEF+SN,'%$:W]#%S4&5&)CMFB0&<$TF*>\P1JPU$V,E,9@LTT4Q&S';
M9!"RGE#<>H0RRE]R?:TUAKDM&NS;ZYQQZYP/2=1MB.GJJD+,"N(@!1_D+4TC
M$.M)@!(BN=FF9J6:HD,0( +ZI2&[3[Y+>H4UD[&8 A:>:F4CKI&'D0^2RTD#
M4_&Y81;;LSP@A\,RL*(W,>O;]!">85T05"(O/]]^6FP# 8ZW+SFQ8K+FZT<7
MP8<D]*XM:X:8@L@O793-B4-%^&)JA_3<T07[:3"^_--^=YWDJ!463U!,,+J;
M DI\<(P]G]/X6\B9AS9GFA>/2:#\S(FR[<V7BGH;DNY=DLS-JP2"FD=K@?^E
M+'YHD>8V>+U]$3)GQ^VNW\.(TD?-U:B]&A^)7XQO&7W]0+C'TD=0QF&<DH>_
M/D>LY6'9(,FTQGAO7QV(\: ['A\G#S@M1Y=[G\1-P7#99PIM\/^,1?J;DOU7
MSR.9M\@) <I1:@<$V%@X/OG]S)!&4&\#@-;,<'KZE]?;CC;]N(*P?T/,&:[!
MJ)!L"J2 Y!@," ;O'VX#KMX_T-7K]#D[V7[S7P"DP_\#Z7\PD.Y.=(RSL]="
M%NWXG\FY\^Y@+>W6[Z/A'C<-1\49;)B5Q>.V!$M&+ %5^8P=)+>=&/KOX9/1
MM0>6@LJUS!0%JN&\R3Z&^H_Z+FRM',9_T[B%3LQHE8<J6VIN5'FXQ748%6;$
MH:GJN,';K'2(/F5J;X?LQ-L"EWRY (GMAP4JI:GFJP#;UEPLL <2H<7G7$Z*
MQ# :"4TLR=PT$:@BB$-XJ:!T<!2F$C22P8H4VL)_34'L$GP$&GQMJNCLX&(D
M5UF8T_@3T_U0&^>.(I<>ILM^S;MIS2RBIGZK,6K'-3?)ACS8!#S2(&#9[T:>
MQ+2N^TFZ7#Z)1WX5T(ED/!CU!F<LU\%Q[^R<&@=7 6.87@8'I8W- AN,MJ5&
M!,IJ'6<W6[J4365X>X)X.YO)V-R';B9L2Z)1TIBA:=(3OLEPI9?FZOU:KG+0
M.<]3IWR+V-FN)%^-@.(P!]T-W",U6^^4X9X$@8!BEJ9ZI7>QQ_1U,LN(31?9
M5+F495U%AV'<*U214Q;)DU>"]K&'XQ?8;J,J6 N&DT:B14U>9Y[:XERM!DS;
MC42LV\%,VG@VC6YT?3,"H*:9YEED-[0?4/H$7R';26,< AR6G8)UA["XAA-;
MH_]+QS.!K7)_)3_=3J>*&EX&ZI6G8A+N=M5"OM)7%F:4(<8N$^WWNH18?&6?
M[!#J31@ADCY+D%8 ?2?8!+& 7;_),2TT5[5U=3+A6/='#ID%-@$/: _.>P,2
M5+,;C/@$U@@Y]3SE6J$HSVQ;0A)74N%"$'>2[.=QZ2H.O0I0ML6)'WJ/O8A'
M/$:A436JR6CU5UG6$LW7@OK!^#?Q>'LO;E.ZCQBFP=I,^? G+%G%R1&"V>JH
MVXZUJY@G[CL]L$ 1XPC\3SXD!8V0-4V1O(Z(O>/4[(:3()P"I4F/_3\^$E,$
MY^@+^*%H6KBB?3#H#1MW]\2VCTK]Y)-? 7;&'S8)/%#M\/6O?=I^.[T-GPQ7
MR\.'5SRL9PH-JF&*6P>]LY..L.%C9KCQIN(/B!/CO2GX<@YX]EM:@.^G!L,H
MWA"#]HORS3\!4$L#!!0    ( ) ]:5:(R!+L' 0  $\+   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;,56;6_;-A#^*P>U*Q(@LU[LQ&YB&TC2%FNQ
M;D';M=A'6CI;1"E2(ZDXWJ_?D905.4Z\MONP+Q*/Y#U\[HYWO.E:Z:^F1+1P
M5PEI9E%I;7T>QR8OL6)FH&J4M+)4NF*61+V*3:V1%5ZI$G&6)&=QQ;B,YE,_
M=Z/G4]58P27>:#!-53&]N4*AUK,HC;83'_BJM&XBGD]KML*/:/^H;S1)<8=2
M\ JEX4J"QN4LNDS/KT9NO]_PF>/:],;@+%DH]=4);XM9E#A"*#"W#H'1[Q:O
M40@'1#3^:C&C[DBGV!]OT=]XV\F6!3-XK<077MAR%DTB*'#)&F$_J/4OV-IS
MZO!R)8S_PCKL3<<1Y(VQJFJ5B4'%9?BSN]8//85)\H1"UBIDGG<XR+-\Q2R;
M3[5:@W:["<T-O*E>F\AQZ8+RT6I:Y:1GY[\BF027*XU(KK9F&EM"=6MQWB)<
M!83L"80T@_=*VM+ :UE@L0L0$YV.4[;E=)4=1'R%^0"&Z0ED298=P!MV-@X]
MWME_L#$@#!]'<)EQ;FJ6XRRBJV]0WV(T?_$L/4LN#O ;=?Q&A]"_B=]AA/$
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M@W0MD'NL?]O:V>_H0*?,BB5***>NA4'E.J<Z>D*MD"S2:#$_&2\++.,C,GX
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M?S1HDN>V4_M8Y^W51EMPN%8RN&J8X.^V*8+L&/F!&%0(8S#N0.QWZJ2"MT>
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MQ9R5PL_=^D(:%5^T0\5 &GTG1!$@>X&/\TZ5=NVKM,NV2NM4M]:P Y.)32>
M!LI9/+X44(*(JI]=8-WCC 9!LB^0*.RCT0/8K"FL,[O< '[O_>E9,DF#NW9E
M/&;X0=(VB_DL5/*<RD?[59^_,X R'>J!PG87\%.1I^/=HI,J&9@/>$$6N!K9
MKQP[GTPA\VAX>.F(GRN,QQZ:131 5(^K41?^&X4?%TW&OL(][GQ570JUIF_'
M\<H=BFO[@758#9^GG]NOLMOM]MOVCURML7,JQ J.QI/3V0%3]GMQ^V#J+7VC
MO:R-J4OZN1&@684;X/VJKHU_0 3AH_TW_P%02P,$%     @ D#UI5MTW4Y^1
M!   4P\  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULS5=M;]LV$/XK
MA#H4-N#:DOPF.[8!.VFQ FT0--V"?:2ED\6%$C62BM-_OR/U,CEVDB5KMWVQ
M1?+NN7ON>$=RL1?R5B4 FMRG/%-+)]$ZGP\&*DP@I:HO<LAP)18RI1J'<C=0
MN00:6:64#WS7G0Q2RC)GM;!S5W*U$(7F+(,K2521IE1^VP 7^Z7C.?7$%[9+
MM)D8K!8YW<$UZ%_R*XFC08,2L10RQ41&),1+9^W--R,C;P5^9;!7K6]BF&R%
MN#6#C]'2<8U#P"'4!H'BWQV< ^<&"-WXH\)T&I-&L?U=HW^PW)'+EBHX%_R&
M13I9.H%#(HAIP?47L?\9*CYC@Q<*KNPOV9>RTYE#PD)ID5;*Z$'*LO*?WE=Q
M:"D$[B,*?J7@6[]+0];+"ZKI:B'%GD@CC6CFPU*UVN@<RTQ2KK7$589Z>G6)
M>>]\$DIUR<<L%"F0*Y#D.J$22&>MM63;0M,M!Z)%EZSO*./5B)R+-,6X7FL1
MWB:"1R#58J#1)X,\""O[F]*^_XA]SR>?1:831=YG$42'  ,DTS#R:T8;_TG$
M"PC[9.CUB._Z_A-XPR9"0XLW^<\B5-H?GK9OJG*N<AK"TL&R4R#OP%F]?>--
MW+,GV(T:=J.GT"V[(UH/6/U='D];\MP^^;ZQ)%="0Z89Y?P;B1@O3($3!6$A
MF6:@B(&%^Y 7N+-(+$5*= (DI#PL.+5-0<2E(JYGQC=N?6.E;SGZIDK?Z$/?
M:-NWL/1-M7UCL3'&I 'CA>UA##U"=]_5KO;)5W0G%AP[(\MVI$17B=@KZ^C>
MMA2(WM$[D-@A"395I6D6&>$6S5!@CT2C2.( 'T>1 <(^)TY'0J0Y<GI))!X$
MXB3U#LL07A0*[:ONG+Q]$_CN\.S5_[\!E65[(%C<D&[1&U/@];HI=//CX2;)
M,%2:&>>P6&*0)BC6N49ZW'/=X8$-SS^KMU<I*G(3$D6"8-P(CJ8S<D.EQ @K
MS)D\8$XF1X!?A:8<C06SD=6MUP]3;K8$GFV8P9!QUF3")"<K4LRZ1DN=HX1T
M;6HCR 0>"95,8>."RC91*%HHY&Y3<;3G\1QC88GQ/\WYZ_? 91.WAQB71QSK
ME9](QYOV/'?4;4UYX]YT%I!/H-2<7(,TI;;&:T18I":48()WAW6'A!NMCM_S
M?+][-#X V3P#TB@/>\.QVSV>]WNC85"#KG$OA4UF"^P.JDP78F/0,MQFRF0M
MIU@8(<M1]+!]/-RY)]P8C;WNB?"]O"WVJJW7"KSO]\;323OPT]XTF))U%"&Y
MZ'>\ ^$E4%L.C["C90APZI_P] +O.W&LB^H9EK-)\.(ZN&C5_'.R-]7Y0>KS
MH^P,36,HV[^)TLOZP2M.PR;&7F_D#=M#/PC(^SC&2WIS!-E3_* 1/Y>ZF>N>
M MG7_?HY_=$+8O4O1P@;R,PG&YN@'V32=+_^+&AO3K<_F9&+'\OTM-GFQ#UU
MN1VT'CK8Y7?V.6<N0$6FRS=/,]N\&-?E0^DO\?*Y^9G*'<.MQ2%&5;<_'3M$
MED^X<J!%;I]-6Z'Q$68_$WSU@C0"N!X+O'U6 V.@>4>O_@102P,$%     @
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M<\DO<3C@&!6YU:K08?V9O@,-BHB.Y8!-2,!:^YP8BJN9F"GXN4>^:=K$:Q\
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M>2"B?0D?'[:FJHZ9.=0PFNU6MBQ*U0#E%]E55<%0K6YR]XX;"U]N&U5;1<H
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M<FSL;7H#,F8Q$@_")\MBL?5O,4,[A,=FA'$A!MHT"DF#BZ-@31&ED2+ P49
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MNN(U-!X#2QE-O9F3?76^:W1;3#3CY1E%%U11R"VU6* P0K?R\4:&G'23+[I
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M'D/4SH'6,Z7LWG $[?,Z_P%02P,$%     @ D#UI5E3*2<4.!@  S!8  !D
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M+W=O<FMS:&5E=',O<VAE970R-2YX;6SM5]MNVS@0_96!NB@:((AD*7:RB6W
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M4=D%-)]*2@MUQV[0U,+C/P!02P,$%     @ D#UI5G.L<U"A P  X0H  !D
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M>OU697GBL1O++>SY\/RS9^M;95^Q4RQJ2- O2="O3<\UX-Z&(A;<M:LIV#6
M=)N,Z:_PXD(E:68I+]:]W89+(656Z4V%->R:PL2,L//09BCT93X'UPB?"AWB
MT[L SRJ D4<5@H5/ ,\+P*8$O*,?TUO )$FA<KEQZ0C.#/5P"@+*()XJ"D-L
MS4EI?A\'W\\]0H3A[D)T\%#@4_YU8U5X[W8&!UR^@12TPJ@U2P'GC<1Z8Y'
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MNBU9@<QV8\%O'W>'E=70"]C?#ECIL-WS=X$-NT%!_4-,V4KUNZATLL,0M/$
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M)LF&\AR(6!)EXR,*0+*2-#/*XERR;$4P/.0)J%0$S/82W!Q(%QBR:H-L%'&
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MX+2TZUQA+I":B/(HY[4"SG(6%<*'_.\0O]O'#:PW%?]Q'/O%SQ2A#7!,F;Y
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MBQI(&V#6-T+HQK O:*]^L[]02P,$%     @ D#UI5I+ZBH'$ @  F 8  !D
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M1[?;C=V;=MKLS=N9_4AD0<WY,LR-:W@U&G@@VSG8"EK4;O:LA3:3S"U+\^M
M:0V,/A="[P0;H/L9)7\ 4$L#!!0    ( ) ]:5;:.I0FC0(  )D&   9
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M%?7-77<4K^Q=]L"5OAEML] ?.R ,0,_GG*O7CKD>V\^GY!]02P,$%     @
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M_[BDFQ)J9T#O,Z7LR\(Y:.Y>\5]02P,$%     @ D#UI5O.#U$KC @  ,PD
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MG G<*-!U65+U<(E<'E8!"1X[/K-]85Q'N%Y6=(^W:+Y6&V5;88^2LQ*%9E*
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M&Z\UQAQI,'Y[S)FVJ:FI5WU>O9P[;/5YL?SSPD>?5X.G#P6QUTS,!K];D>*
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M$M2R *5A*)JM96U9^&[+XFI'WF_Q(5HL>7=RG84#=39 :1B*9@M7.QN^V]D
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MV,%\_B"E?GE3-- \0&CV'U!+ P04    " "0/6E6'^2CZMD$  #8&P  &0
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M ^4 =GTEI7D(7.?K;L;L'U!+ P04    " "0/6E6OUO.<S<&  !7,   &0
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MO!C<&UTIDWG7)A$*U-F(I?F%#RIJDZGE-N,=>_-$$^EZ3<Z5TW$US7<VN(V
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M^TP]T0/*2?%0SM3 R='C\DZ4H_=2?>J28,3WE0 )<TK8Y.B2=5Q8MWW45:<
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MHND*FXP)FS.F9D!^*B/"?O_-9Z;W]@E)<T!I+BC-@Z+IUINL";]GL1$&S8A
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MEF4=*@;JKX#2/% :@:+IBK4>BVTV6;[L%'7'HZ#;_=H^V0ZJJB,F3**,1NI
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M:B!_WU&9"*L;U4%]&+[\#U!+ P04    " "0/6E6Y<?>@J4%  #R*P  &0
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M(<K'%)4;DJ^*9]@\<BEY4KQ<,CIC(F^@WI]S+C<;>8'MPZ(F_P)02P,$%
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M&22S2[;L08MU>D\U%UJ+.&VN* &W30?XOA!0N/,'<_557'7Z_P-02P,$%
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MQ3K1%F@CM6N@(6$!)&P%"0LA81$0K&$:OS:-#[6=^) ^@80%D+ 5)"R$A$5
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MT<!$[1SHO%#*[C9.8!C!Z5]02P,$%     @ D#UI5N5+3^M[ @  T08  !D
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M1"'?*$H8S 22FRS#XN\8*-^-',\Y3+R2=:K,A!N%.5[#'-1;/A,Z<BN6A&3
M).$,"5B-G$=O. E,ODWX16 GC\;(.%ER_FZ"YV3DM(T@H! KPX#U:PL3H-00
M:1E_2DZGVM( C\<']B?K77M98@D33G^31*4C9^"@!%9X0]4KW_V$TD_/\,6<
M2OM$NR*WWW=0O)&*9R58*\@(*]YX7];A". %5P!^"?#/ =TK@$X)Z%BCA3)K
M:XH5CD+!=TB8;,UF!K8V%JW=$&:^XEP)O4HT3D7/+.89H 7>@T3W:";XEM@O
MI'\0=++8F(+"A,JF3GN;3U'CKHGN$&%HD?*-Q"R1H:NT(L/KQN7NXV)W_\KN
MGH]>.%.I1#]8 LDI@:NM5'[\@Y^Q?Y-Q"G$+=;QOR&_[?HV@R>?AW@TYG:J\
M'<L7?**\=>4IT)UZM#G!0YGC&$:./J(2Q!:<Z.L7+VA_K[/VG\A.C'8KH]U;
M[ >C2]#_#>B_PD8*[^M,%TQ=RV2ZS#:Z]_J>]Q"ZVV,[EVE>;S#XR#K1V:MT
M]F[J?(($!*9UL@I@[T16[TS39<Z#5R\HJ 0%-P4MN,+TJ& HKXY@8PD,5D0U
MZ]0&-44\5WN9<Z'6/6H=&8BU[:@2Q7S#5''JJMFJ:3_:7G4V/];-O.B]'S3%
M3?""Q9HPB2BL-&6[U=?E$T5W+0+%<]N@EESI=F>'J;Z00)@$O;[B7!T"LT%U
MQ47_ %!+ P04    " "0/6E61"GX/#<#   6"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970V,BYX;6RM5FU/VS 0_BM6IDV=M#4OA4)9&VF4H>W#) 0;^VR2
M:V/AV)E]H;!?O[,3LA:E :1]:6W']_AYSG>^FV^TN;4% ++[4BJ[" K$ZB0,
M;59 R>U85Z#HRTJ;DB--S3JTE0&>>Z-2ADD43<.2"Q6D<[]V8=*YKE$*!1>&
MV;HLN7DX!:DWBR .'A<NQ;I MQ"F\XJOX0KP9W5A:!9V*+DH05FA%3.P6@2?
MXY/ES.WW&ZX%;.S6F#DE-UK?NLFW?!%$CA!(R- A</J[@R5(Z8"(QN\6,^B.
M=(;;XT?T<Z^=M-QP"TLM?XD<BT5P'+ <5KR6>*DW7Z'5<^CP,BVM_V6;=F\4
ML*RVJ,O6F!B40C7__+[UPY9!/-UCD+0&R5.#@ST&D]9@XH4VS+RL,XX\G1N]
M8<;M)C0W\+[QUJ1&*'>+5VCHJR [3+^I3)? ?O![L.PCNX1,JTQ(P;V3;P W
M (I9Y%BC-@_,< 3&5<Y@M0)_!<W2Z R0"VG?ST,D6@X\S%H*IPV%9 ^%.&'?
MM<+"LB\JAWP7("0]G:CD4=1I,HAX!MF83>(/+(F2I(?0\N7F\0"=2>?CB<>;
M[L'[J0RY=:W$'\@9\GMRJX*50-L$L<"'/J<UF)-^3)?<)[;B&2P"REX+Y@Z"
M]-V;>!I]ZA/\G\!VY!]T\@^&T--SR,%PZ95S?!)+?<H;N+BY'O<,W:71V-W$
MW;:DYW;M<#WLN!X.<KU"G=TR2@EZ)6V3 R[8-19@6 7T;BA0R')!T6] 96#[
M! R?,8K'4?2V+U&6AWV:HEF_IFFG:?HB_VM3%5RQW-1KEAG(!?9Q'\1Z;=@-
M$QLE/8[8D7C423P:1/KQ+ZFHM$B**THTS1150:IW%&="K9G4UK*,&_- Q6_#
M3<YJI)?NC[_F/E<,GOE:5PP+&,5]0;'CB^/.%\>#4-=<UFWD2JK1G(*T3]PP
MR"B)]@;I,Y;Q]#DELT[);/A6-7+9QWW0[+47,^O-N:?O2+A58DLP:]]Y4#CI
M6F%3F+K5KKGY[&OZD_53:GJ:'N4?3-,Q?>=F+91E$E8$&8V/Z#4P31?23%!7
MOI#?:*2VP \+:MS N WT?:4U/D[< 5TKF/X%4$L#!!0    ( ) ]:5:6A-#-
ML ,  !4,   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;*V7VV[;.!"&
M7X50BR(!-M'1DIVU#21VB^U%=X,<NM>,-+:$2*1*TG:Z3[]#2I$=F59ST9M8
MI&9^?4,..9/ICHMGF0,H\E*53,Z<7*GZRG5EFD-%Y26O@>&;%1<553@4:U?6
M FAFG*K2#3PO=BM:,&<^-7.W8C[E&U46#&X%D9NJHN+G#91\-W-\YW7BKECG
M2D^X\VE-UW /ZK&^%3AR.Y6LJ(#)@C,B8#5SKOVKA1]J!V/QO8"=/'@F.I0G
MSI_UX&LV<SQ-!"6D2DM0_-G" LI2*R''CU;4Z;ZI'0^?7]6_F. QF"<J8<'+
M?XM,Y3-G[) ,5G13JCN^^PO:@$9:+^6E-'_)KK7U'))NI.)5ZXP$5<&:7_K2
M+L2!@Q^?< A:AZ#O$)UP"%L'LW)N0V;"6E)%YU/!=T1H:U33#V9MC#=&4S"]
MC?=*X-L"_=3\*TMY!>2!OH D%V3!JYHS8$H2OB)_8QHM805"0*9-R+64@*_.
MEJ!H4<IS]'B\7Y*SC^?D(RD8><CY1E*6R:FK$$Y_PDU;D)L&)#@!X@?D&V<J
ME^0SRR![*^!B5%UHP6MH-\&@XA+22Q+Z?Y# "P(+T.+][OX 3MBM=&CTXG>L
MM&UY&N_0[JU/\Y6L:0HS!X^K!+$%9_[I@Q][?]I"^TUB;P*-ND"C(?7Y@M:%
MHF7Q'R:-5J<BS0DF!9ZN+5X;-5X"BL +7D32OA*-?&3D]36TG4=)B#NX/8SP
MV"@9!WNC-^2CCGPT2*[S'2](057!UJ3D4I*4"O$3;\L=%?:L;A1'!QQ!.$FB
M'NVQE9_$H\2.&W>X\2#NW:G%U6.N<A!$X:%-\?06ZM>1Q,>,(5+V(K%:!2-[
M)$D723(8R;WBZ3/!\Z&3@NK[W0:8''TZ2OQ1C\]FE(SM>.,.;SR(]\APG9E)
MYRVP#=C@QL=Y$'GC'IS%:.R?R())!S<9A/M';[2-:&+9J:"?F,=&8^\$D._M
M:XHWB/3 \?SK8MI4#IV$U%0.:UGPCA!&7AA,>J 6LRC!7N4$ZT']\P=9O]-R
M0YN.HL2>AK+4NKVMRN'G+ZR8%KLASF#/&?SR;GKOB@XJV6]_8JLBOT'H;;3[
M6ND/5BA=++$IE4#.,FB>SG5_@:E.MN_<L/"H0(2AY_6WZ]CJ(HH/S!I^]Z#!
MJD"L3=^)Q8%OF&H:DFZVZVVO34?7F[_1/:]IW/8R3</\C8IUP20I8862WF6"
M*22:'K09*%Z;-NZ)*VP*S6..?3L(;8#O5YRKUX'^0/>?P/Q_4$L#!!0    (
M ) ]:59Y8#6%OP(   T)   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM
M;+66:V_:,!2&_XJ555,KK>0"I-"%2*6L6J7>5-;MLTD.Q*MC9[8A]-_/=D)*
MI9!)U?H%;,?O>QX[]CF)2BZ>90:@T#:G3$Z<3*GBW'5EDD&.98\7P/23)1<Y
M5KHK5JXL!.#4BG+J!IX7NCDFS(DC._8@XHBO%24,'@22ZSS'XF4*E)<3QW=V
M X]DE2DSX,91@5<P!_54/ C=<QN7E.3 ).$,"5A.G O_?.I;@9WQDT I]]K(
M+&7!^;/I7*<3QS-$0"%1Q@+KOPU< J7&27/\J4V=)J81[K=W[E=V\7HQ"RSA
MDM-?)%79Q!DY*(4E7E/UR,OO4"]H:/P23J7]164U=SAT4+*6BN>U6!/DA%7_
M>%MOQ)X@" X(@EH06.XJD*6<887C2/ 2"3-;NYF&7:I5:SC"S%N9*Z&?$JU3
M\35+> [H!]Z"1*?H[OX&'<] 84+E"3I"A*%;0JG>/QFY2L<S*C>IO:>5=W#
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M;:F5YFFE^;IHQ[8>;(G8VM:K#4J7Q3II2ZTT3RO-UT4[MMC96^ST]MSO><!
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M9*YVMN 2;C0Q.R&8?EA"H0Z+@ :/ U_X-K=N($SF)=O"+=AOY8W&7MBP9%R
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M+!8ZOIEC+0K:+<#YC5+VL>,V:*K;Y#]02P,$%     @ D#UI5GS!"H?5 @
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MT>$8+PS=Y/&F8E7E<^=26<S$OECBVP>T&X#]A5)V6W$3=*^I]"]02P,$%
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M,HI9PIZF:(P0\KQ)[VF?U>I-2]9ASCH\B166@L2J.I53GF&-!X_QV,,5'.N
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M108)X_A1@%KEFL:Q^GQ$_Y"11S(;JF IHN\LT.',&ELD@"U-(_U5'/Z @M#
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MW4!=WS(FSP>Z@VI7<_D?4$L#!!0    ( ) ]:5;/(R993 @  !%6   9
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MWI-;)O9,YC0^GIXXIT=M-D/UB(192)B-A#E(F(N$>4B8#X)U]+UN]+W^N=F
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MTAPHC4)I+I3F06D,15-EW!A0AMZ!^KR+ODEQRD[^FO\HY\?\$%QN/\F=SYO
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MO$@&TM64=;60KK:LJX-T=65=/9!KH[HU]6563FT?2NSO4O9ESR)!C$/^^HW
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MC.<[9)_?Q[%X7LF?/JB?_%G]!U!+ P04    " "0/6E6N-I:KBP"  #8!
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MHO)?<BAM'8L$F=(B+<'H0<IX\4]_E$+4 .[X#, K =Y;P/ ,8% "!N\%#$O
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M%>U;O)7#)QCS65F^0K;:?<G@?=>K@!2]1LE'L%' F?!_^C#680:(WST!2$9
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M8QXZJMJ=W6<';A*V@+.VD\Q*\^/'& (A==TA<EX2#+[']UP?S &/=XR_B!6
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M5T!CX$4'=7W!F-PWB@'J/9SI=U!+ P04    " "0/6E6&3_!#BL"  #U!
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MS\&-YU&P?$X%S3]<!K\!4$L#!!0    ( ) ]:5:7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ D#UI5A).(EV9!@
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M'VA4.^+\E=S/*#/M/!A()0-FEUSYZQY,C'/OQ/=>G/DG.+^75HF#40<3R63
M;)-3N=9U&_Q\KU(H))$!LT6:0*+K]DGX'EC\!-8'/A^GN^,0263 ;Q$?H6LK
M7TQ\K=W#'R)7RU>1#VEDP.R1?'/GU)=-@S1^W(DM 3)'P&P..%7X'%!,9(Z
MV1P8,Z28,%'ASE30G*;;FT@H ;-0X'2ABXD<$S [YHWI@CCPF7[9"4$!<DS
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M1;V50&]%O95 ;T6]E4!O1;V50&]%O95 [XAZ1P*](^H="?2.J'<DT#NBWI%
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ D#UI5IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "0/6E6XU3_[I (  !-/   &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ D#UI5CP44W/P!@  ZAX  !@
M             ("!U!   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( ) ]:5:JUIV22P0  ,L4   8              " @?H7  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "0/6E6&C)\?:L%  "0
M%P  &               @(%['   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ D#UI5A1W>7U<!P  <CT  !@              ("!7"(
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ) ]:59!Y=+-
M+ D  -HK   8              " @>XI  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " "0/6E63,4V?<,$  #:"@  &
M@(%0,P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ D#UI
M5H>(/DY9(0  ;6\  !@              ("!23@  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( ) ]:5;,R&"-200  'X,   8
M      " @=A9  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ) ]:5:2%K&1N H  +0?   9              "
M@4V:  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ D#UI
M5BC7C<PN#P  P"\  !D              ("!/*4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " "0/6E6W3=3GY$$  !3#P  &0
M        @(&AM   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( ) ]:59)>BKPXPT  .8O   9              " @6FY  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ D#UI5I),4%HI!P  ]A(
M !D              ("!@\<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " "0/6E6]>W@H24$  "'"@  &0              @('CS@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ) ]:5;C$-[F
M"0<  (@5   9              " @3_3  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ D#UI5NZ_/D5:(@  H'<  !D
M ("!?]H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "0
M/6E6P,4(O.<"  !J!P  &0              @($0_0  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ) ]:594RDG%#@8  ,P6   9
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M970R-RYX;6Q02P$"% ,4    " "0/6E6[ZU&<,@$  #7#0  &0
M    @('Y%@$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M ) ]:583=LNSD00  $T/   9              " @?@; 0!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ D#UI5GA>*[]M P  !@H  !D
M             ("!P" ! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " "0/6E6DOJ*@<0"  "8!@  &0              @(%D) $ >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ) ]:5;:.I0FC0(
M )D&   9              " @5\G 0!X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ D#UI5C5^UDNY @  2@D  !D              ("!
M(RH! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "0/6E6
M<TH;1!$#  "'"0  &0              @($3+0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( ) ]:5;S@]1*XP(  #,)   9
M      " @5LP 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ D#UI5HIE(+*! P  @@P  !D              ("!=3,! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "0/6E6J-6GTKD"  #"!P
M&0              @($M-P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( ) ]:58"/_UYCP4  #@B   9              " @1TZ 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ D#UI5N[=Z% /
M!@  (3$  !D              ("!XS\! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " "0/6E6Y+RT # (  !K0@  &0
M@($I1@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ) ]
M:5:TB>U3IP4  !@L   9              " @9!. 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ D#UI5GBVYNMW!P  3$@  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( ) ]:5:_6\YS-P8  %<P   9
M  " @4AL 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MD#UI5II<0D E!@  =S$  !D              ("!MG(! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " "0/6E6[Z_%SEX'  "8/P  &0
M            @($2>0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( ) ]:58YN2;NJ@,  $T2   9              " @:>  0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ D#UI5FPBL<==!
M&!<  !D              ("!B(0! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " "0/6E6Y<?>@J4%  #R*P  &0              @($<
MB0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ) ]:59P
MTV8L7P<  #A*   9              " @?B. 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ D#UI5BN J^#&!   GQX  !D
M     ("!CI8! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ) ]:5;E2T_K>P(  -$&   9              "
M@76I 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ D#UI
M5@Z<LJWA @  S0<  !D              ("!)ZP! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " "0/6E6(&7GZX\"  #N!@  &0
M        @($_KP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( ) ]:59$*?@\-P,  !8*   9              " @06R 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ D#UI5I:$T,VP P  %0P
M !D              ("!<[4! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " "0/6E6>6 UA;\"   -"0  &0              @(%:N0$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ) ]:59;DW5A
MUP(  "L)   9              " @5"\ 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ D#UI5M$EVCDU P  \PD  !D
M ("!7K\! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "0
M/6E6#%\ZK<H$  "%&P  &0              @('*P@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ) ]:5;G,_OGWP,  $L0   9
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M970W,BYX;6Q02P$"% ,4    " "0/6E6[W:(=H8"  #I!@  &0
M    @(&'VP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M ) ]:5:40P-MLP,  (P.   9              " @43> 0!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ D#UI5@ ;7[=1 P  ; H  !D
M             ("!+N(! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    " "0/6E6T.K/A)H"   5!@  &0              @(&VY0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( ) ]:5:V-#ALD ,
M +</   9              " @8?H 0!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ D#UI5B!#1U4,!0  (Q8  !D              ("!
M3NP! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "0/6E6
M(%B[YD\$  #A'   &0              @(&1\0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ) ]:5;/(R993 @  !%6   9
M      " @1?V 0!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%
M  @ D#UI5D8EJCU0"@  'W0  !D              ("!FOX! 'AL+W=O<FMS
M:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "0/6E6EMNV? 4%   %-
M&0              @($A"0( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+
M 0(4 Q0    ( ) ]:5:XVEJN+ (  -@$   9              " @5T. @!X
M;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ D#UI5F[;<D^R
M!0  '#4  !D              ("!P! " 'AL+W=O<FMS:&5E=',O<VAE970X
M-"YX;6Q02P$"% ,4    " "0/6E6S@@3% 8#  #D"P  &0
M@(&I%@( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( ) ]
M:58"+EK/_P0   (D   9              " @>89 @!X;"]W;W)K<VAE971S
M+W-H965T.#8N>&UL4$L! A0#%     @ D#UI5F=!V)A2 @  # 4  !D
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M=#DQ+GAM;%!+ 0(4 Q0    ( ) ]:5:\1J?G-P,  (<-   9
M  " @:$N @!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @
MD#UI5LMCK2>/"0  T%H  !D              ("!#S(" 'AL+W=O<FMS:&5E
M=',O<VAE970Y,RYX;6Q02P$"% ,4    " "0/6E6[3MYRY$#  !]&0  #0
M            @ '5.P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ) ]:5:7
MBKL<P    !,"   +              "  9$_ @!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ) ]:5823B)=F08  +@]   /              "  7I  @!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "0/6E6*"B!BK$"  "^-@  &@
M        @ % 1P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "0/6E6??/N/T,"   #-0  $P              @ $I2@( 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     90!E +H;  "=3 (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>327</ContextCount>
  <ElementCount>435</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>111</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Consolidated Financial Statements Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Consolidated Financial Statements Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Licensing and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</Role>
      <ShortName>Licensing and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Lease Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreements</Role>
      <ShortName>Lease Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Stock Based Compensation and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders</Role>
      <ShortName>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Concentration of Risk, Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Consolidated Financial Statements Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables</Role>
      <ShortName>Consolidated Financial Statements Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Lease Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsTables</Role>
      <ShortName>Lease Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLeaseAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables</Role>
      <ShortName>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCapitalStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails</Role>
      <ShortName>Description of Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Intangible assets, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails</Role>
      <ShortName>Licensing and Other Arrangements - ObsEva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - NIS793 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails</Role>
      <ShortName>Licensing and Other Arrangements - Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails</Role>
      <ShortName>Licensing and Other Arrangements - Janssen Biotech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails</Role>
      <ShortName>Licensing and Other Arrangements - Affimed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails</Role>
      <ShortName>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Palo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Fair Value Measurements - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails</Role>
      <ShortName>Lease Agreements - Leased facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Lease Agreements - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails</Role>
      <ShortName>Lease Agreements - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Lease Agreements - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Lease Agreements - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation between statutory rate and effective rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes - NOL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails</Role>
      <ShortName>Income Taxes - NOL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40805 - Disclosure - Income Taxes - Tax credit carryforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails</Role>
      <ShortName>Income Taxes - Tax credit carryforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40806 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>40905 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>40906 - Disclosure - Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>40907 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>40908 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>40909 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>40910 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails</Role>
      <ShortName>Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails</Role>
      <ShortName>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails</Role>
      <ShortName>Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Capital Stock - Series X Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails</Role>
      <ShortName>Capital Stock - Series X Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Capital Stock - Series A Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails</Role>
      <ShortName>Capital Stock - Series A Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails</Role>
      <ShortName>Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>41104 - Disclosure - Capital Stock - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails</Role>
      <ShortName>Capital Stock - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>41105 - Disclosure - Capital Stock - BVF Ownership (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails</Role>
      <ShortName>Capital Stock - BVF Ownership (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>41106 - Disclosure - Capital Stock - ATM Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails</Role>
      <ShortName>Capital Stock - ATM Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>41107 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Capital Stock - Summary of Common Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>41108 - Disclosure - Capital Stock - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails</Role>
      <ShortName>Capital Stock - Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails</Role>
      <ShortName>Commitments and Contingencies - Arbitration Proceeding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails</Role>
      <ShortName>Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="xoma-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>93</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PreferredStockDividendsPerShareCashPaid, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, xoma:DepositarySharesRatioToPreferredStock, xoma:StockIssuedDuringPeriodSharesWarrantsExercised -  xoma-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  xoma-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="xoma-20221231x10k.htm">xoma-20221231x10k.htm</File>
    <File>xoma-20221231.xsd</File>
    <File>xoma-20221231_cal.xml</File>
    <File>xoma-20221231_def.xml</File>
    <File>xoma-20221231_lab.xml</File>
    <File>xoma-20221231_pre.xml</File>
    <File>xoma-20221231xex10d14.htm</File>
    <File>xoma-20221231xex10d15.htm</File>
    <File>xoma-20221231xex10d16.htm</File>
    <File>xoma-20221231xex10d56.htm</File>
    <File>xoma-20221231xex10d57.htm</File>
    <File>xoma-20221231xex10d58.htm</File>
    <File>xoma-20221231xex21d1.htm</File>
    <File>xoma-20221231xex23d1.htm</File>
    <File>xoma-20221231xex31d1.htm</File>
    <File>xoma-20221231xex31d2.htm</File>
    <File>xoma-20221231xex32d1.htm</File>
    <File>xoma-20221231xex4d6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="663">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xoma-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 663,
    "http://xbrl.sec.gov/dei/2022": 43
   },
   "contextCount": 327,
   "dts": {
    "calculationLink": {
     "local": [
      "xoma-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xoma-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xoma-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xoma-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xoma-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xoma-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 702,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 16,
    "http://www.xoma.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 8,
    "total": 26
   },
   "keyCustom": 152,
   "keyStandard": 283,
   "memberCustom": 69,
   "memberStandard": 38,
   "nsprefix": "xoma",
   "nsuri": "http://www.xoma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Licensing and Other Arrangements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements",
     "shortName": "Licensing and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements",
     "shortName": "Royalty and Commercial Payment Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Lease Agreements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreements",
     "shortName": "Lease Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Stock Based Compensation and Other Benefit Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans",
     "shortName": "Stock Based Compensation and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders",
     "shortName": "Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Capital Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.xoma.com/role/DisclosureCapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Concentration of Risk, Segment and Geographic Information",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation",
     "shortName": "Concentration of Risk, Segment and Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.xoma.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Consolidated Financial Statements Details (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables",
     "shortName": "Consolidated Financial Statements Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables",
     "shortName": "Royalty and Commercial Payment Purchase Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Lease Agreements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsTables",
     "shortName": "Lease Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Stock Based Compensation and Other Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables",
     "shortName": "Stock Based Compensation and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables",
     "shortName": "Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Capital Stock (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockTables",
     "shortName": "Capital Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Concentration of Risk, Segment and Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables",
     "shortName": "Concentration of Risk, Segment and Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Description of Business - Liquidity (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
     "shortName": "Description of Business - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Cash and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "xoma:ImpairmentOfLongTermRoyaltyReceivable",
       "p",
       "xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ImpairmentOfLongTermRoyaltyReceivable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Purchase of Rights and Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Consolidated Financial Statements Details - Equity Securities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
     "shortName": "Consolidated Financial Statements Details - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_tIDqLvdLRU-RDFaGl32d5g",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFVNINoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Consolidated Financial Statements Details - Intangible assets, net (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
     "shortName": "Consolidated Financial Statements Details - Intangible assets, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedSalariesAndEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
     "shortName": "Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedSalariesAndEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireProductiveAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
     "shortName": "Licensing and Other Arrangements - ObsEva (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:LicensingAndOtherArrangementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_0lLvvXbzgEakGtNGbJg_Ww",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
     "shortName": "Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_0HQ2F4usPUGiRtw00ne_tw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
     "shortName": "Licensing and Other Arrangements - Novartis - VPM087 and IL-1 Beta (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jj0Z5ZIKvE6R9Z-ak75YdQ",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:LicenseAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
     "shortName": "Licensing and Other Arrangements - Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_jY9o4zaQ1USNWU9amxp3_w",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
     "shortName": "Licensing and Other Arrangements - Rezolute (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_867K-w4nlkWwUkggr9tW3w",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
     "shortName": "Licensing and Other Arrangements - Janssen Biotech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_fphKB9tH6kq7YbOJdlXXwg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:ProceedsFromUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
     "shortName": "Licensing and Other Arrangements - Affimed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNet",
       "us-gaap:ContractWithCustomerLiability",
       "us-gaap:ContractWithCustomerLiability",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HUH3Ujntz0-oqDEydQpT1Q",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
     "shortName": "Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ExJBPMa0wEuMARWeSxoKbg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:NumberOfRoyaltyInterestAcquisitionAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_agreement_jQgvZx3CukO-cWfCYIu4WQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:RightsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:RoyaltyPurchaseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CXsrLLVq5kSPUm74NYuFBA",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:MilestoneAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:RoyaltyPurchaseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_vAu3lQbatkGhgpFaivtaPQ",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_wLsypN9FaU6k4kS-oyzb9A",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VoQHydvwcUOxtnx4Nlhe7g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ctkjc9-z50ynHdzy_lCtHg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_SdKDIDHSbU6IwBGUf1K8JQ",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_BqntA-7BkEaUeoEo4FGCcA",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:RoyaltyReceivablePercentageOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__D5IEzO7EEuZNb2FVhvKjw",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:UpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "xoma:RoyaltyPurchaseAgreementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:RightsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_kB9yfId7VkK_kt3X391buA",
      "decimals": "-3",
      "lang": null,
      "name": "xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_QLqdIb7nzU2heoLl5j7N0g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Fair Value Measurements - Equity Securities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
     "shortName": "Fair Value Measurements - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_qToHvf8dLku-l7rbmQGPwA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40604 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_9_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_U5ndoFs5MEqrd7giFaC4aA",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:PaymentsOfContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Lease Agreements - Leased facilities (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
     "shortName": "Lease Agreements - Leased facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_6eHwTZkku0uqlxl9Du9-aA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_facility_lKbrc9AE50yu5B2YgN8Weg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Lease Agreements - Lease costs (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails",
     "shortName": "Lease Agreements - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Lease Agreements - Additional information (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails",
     "shortName": "Lease Agreements - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Income Taxes - Reconciliation between statutory rate and effective rate (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails",
     "shortName": "Income Taxes - Reconciliation between statutory rate and effective rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Income Taxes - NOL (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
     "shortName": "Income Taxes - NOL (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_FnNbkWGFJUy8xckPikpNqw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40805 - Disclosure - Income Taxes - Tax credit carryforward (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails",
     "shortName": "Income Taxes - Tax credit carryforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "xoma:OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40806 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_OFgVc0mz80W_mgaJzjvVYw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Stock Based Compensation and Other Benefit Plans - ESPP (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_5_31_2015_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember__7ubhxn22U6DZolHf99Nrg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Deferred Savings Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_S_3GoTwkMUmL0YDsH6p4lA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Options (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_8LeYAAzdJEmaDOba7dZ4QQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40906 - Disclosure - Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_qGq5trte_kqEOZ0Hcmbu0w",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40907 - Disclosure - Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_jAqpa7VgZ0KMwJJLYh_GXA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40908 - Disclosure - Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Equity Awards Modification (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember_rAroNAm8f0G6gOtRf-Uv6Q",
      "decimals": null,
      "lang": "en-US",
      "name": "xoma:EmploymentPeriodRetirementEligible",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfPeriodsCashRetentionBonus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40909 - Disclosure - Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - Employee Retention Bonus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_86tyVMpU0EuyPsogU0xa3Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfPeriodsCashRetentionBonus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_period_f6DG9wpVTE6eZjZyYf42qw",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40910 - Disclosure - Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
     "shortName": "Stock Based Compensation and Other Benefit Plans - CEO Departure and Continuity Incentive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_B2gWHkPfvEuzHqMxSvYT-Q",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
     "shortName": "Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Outstanding Securities Considered Anti-Dilutive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
     "shortName": "Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders - Reconciliation of Numerator and Denominator Used in Calculation of EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Capital Stock - Series X Convertible Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
     "shortName": "Capital Stock - Series X Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_xoma_SeriesXAndSeriesYConvertiblePreferredStockMember_mS1sKPw6CE2n0SBLlBsMLg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Capital Stock - Series A Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
     "shortName": "Capital Stock - Series A Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_12_15_2020_To_12_15_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_dGDTofdWPkS_jkIkABdjrQ",
      "decimals": "5",
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_yfYmZfhnNkKYkUD-IUpuzA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
     "shortName": "Capital Stock - Depositary Shares Representing Interest in Series B Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Sx_RlxTaN02KYbcRuibk8A",
      "decimals": "5",
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - Capital Stock - Dividends (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
     "shortName": "Capital Stock - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_XrLq8VPahkKtRqXG1btPQg",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - Capital Stock - BVF Ownership (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
     "shortName": "Capital Stock - BVF Ownership (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_N-_RsbApbkmFPEV5ZsuUkA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_CGMTl4Lal0yOntfmu49m1A",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_4_9_2021_To_4_9_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0FZJm_Wu50-AxSsDkHiPeA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41106 - Disclosure - Capital Stock - ATM Agreements (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
     "shortName": "Capital Stock - ATM Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_18_2018_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_p24xpBTiUk-dfPSrxHMCZw",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:MaximumValueOfCommonStockToBeIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41107 - Disclosure - Capital Stock - Summary of Common Stock Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails",
     "shortName": "Capital Stock - Summary of Common Stock Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TujnzcczekqsQV6tLOnJaw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_Alvn4m_wP0qncBgzIYB7zg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41108 - Disclosure - Capital Stock - Common Stock Warrants (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
     "shortName": "Capital Stock - Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_5_31_2018_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_UwP8pUTvX0O4si5JO34Rvw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails",
     "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
     "shortName": "Commitments and Contingencies - Contingent Consideration and Employee Retention Bonus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember_k_sLWKXSlEu9WIjrFJoc0g",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Commitments and Contingencies - Arbitration Proceeding (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails",
     "shortName": "Commitments and Contingencies - Arbitration Proceeding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_6_1_2021_To_6_30_2021_JU5Fs0p6Vkm4LEYFurBn0A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_Vc6zMxgnCkaM7QFrPfUzcA",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Consolidated Financial Statements Details",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails",
     "shortName": "Consolidated Financial Statements Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Concentration of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_tan53UIW_kCV2squc-ULrw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Concentration of Risk, Segment and Geographic Information - Segment Information (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_KLuhiXb_yUqVBBNjHDBV1A",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
     "shortName": "Concentration of Risk, Segment and Geographic Information - Revenue by Geographical Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_BRZefaTLEE2Yy6v52PFdig",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_pYvwNQz-XEaYNegCO7nqlw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_QFt-vqeCYUiAuMFC-W9OzA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.xoma.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20221231x10k.htm",
      "contextRef": "Duration_1_1_2023_To_1_1_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_s7b4N_xB60ubb6yQjT_rrA",
      "decimals": "-3",
      "lang": null,
      "name": "xoma:EmploymentAgreementAnnualSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Zb7LZtXi2UGyy0lwyITCPQ",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 111,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS).",
        "label": "Series B Depositary Shares"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r280",
      "r296",
      "r504",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r249",
      "r521",
      "r588",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r337",
      "r453",
      "r480",
      "r499",
      "r500",
      "r518",
      "r525",
      "r537",
      "r585",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r337",
      "r453",
      "r480",
      "r499",
      "r500",
      "r518",
      "r525",
      "r537",
      "r585",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r249",
      "r521",
      "r588",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r246",
      "r457",
      "r519",
      "r535",
      "r579",
      "r580",
      "r588",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r246",
      "r457",
      "r519",
      "r535",
      "r579",
      "r580",
      "r588",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r328",
      "r337",
      "r365",
      "r366",
      "r367",
      "r452",
      "r453",
      "r480",
      "r499",
      "r500",
      "r518",
      "r525",
      "r537",
      "r578",
      "r585",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r328",
      "r337",
      "r365",
      "r366",
      "r367",
      "r452",
      "r453",
      "r480",
      "r499",
      "r500",
      "r518",
      "r525",
      "r537",
      "r578",
      "r585",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r280",
      "r296",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r338",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r198",
      "r338",
      "r550",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r247",
      "r248",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r520",
      "r536",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r487",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r520",
      "r536",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r198",
      "r338",
      "r550",
      "r551",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r574",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables balance"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued incentive compensation"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r127",
      "r138"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities [Abstract]",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued legal and accounting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible asset"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Consolidated Financial Statements Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r564",
      "r565",
      "r566",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r103",
      "r104",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r292",
      "r430",
      "r516",
      "r517",
      "r559"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization Of Financing Costs And Discounts",
        "terseLabel": "Amortization of debt issuance costs, debt discount and final payment on debt"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r37",
      "r61",
      "r67"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r530",
      "r625",
      "r626",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Cost to acquire assets"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r530",
      "r625",
      "r626",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r136",
      "r153",
      "r178",
      "r237",
      "r240",
      "r244",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r403",
      "r407",
      "r422",
      "r534",
      "r583",
      "r584",
      "r638"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r148",
      "r158",
      "r178",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r403",
      "r407",
      "r422",
      "r534",
      "r583",
      "r584",
      "r638"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost Net",
        "terseLabel": "Capitalized contract costs"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r150",
      "r502"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails",
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r43"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash and restricted cash at the beginning of the period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r123"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r178",
      "r202",
      "r207",
      "r215",
      "r219",
      "r226",
      "r227",
      "r253",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r294",
      "r295",
      "r298",
      "r302",
      "r309",
      "r422",
      "r501",
      "r549",
      "r561",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r83",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "positiveTerseLabel": "Exercise price of warrants (in dollars per share)",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Aggregate number of unregistered shares of common stock called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "positiveTerseLabel": "Warrant outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r83",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Agreements",
        "verboseLabel": "Licensing and other arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r131",
      "r142"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies.",
        "terseLabel": "Commitments and Contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r72",
      "r262",
      "r263",
      "r489",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r564",
      "r565",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,454,025 and 11,315,263 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation and Other Benefit Plans"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r160",
      "r162",
      "r168",
      "r472",
      "r476"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r120",
      "r121",
      "r249",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r120",
      "r121",
      "r249",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r50",
      "r51",
      "r120",
      "r121",
      "r249",
      "r488",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Concentration of Risk, Segment and Geographic Information"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r50",
      "r51",
      "r120",
      "r121",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r52",
      "r120",
      "r122",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r120",
      "r121",
      "r249",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r312",
      "r314",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r312",
      "r313",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r5",
      "r6",
      "r77",
      "r80",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock Shares Issued Upon Conversion",
        "terseLabel": "Number of shares issued for each share of convertible preferred stock that is converted"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r49",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r126",
      "r129",
      "r135",
      "r184",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r431",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "negatedLabel": "Reduction in debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r17",
      "r184",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r431",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Employee Retention Bonus",
        "verboseLabel": "Departure and Continuity Incentive"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income, Current",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r582"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Unearned revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets In Process Research And Development",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r621"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r111",
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards",
        "terseLabel": "Research and development and other tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r113",
      "r622"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r387"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Contribution expense"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Deferred Savings Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Amount",
        "terseLabel": "Maximum annual contribution per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan Maximum Annual Contributions Per Employee Percent",
        "terseLabel": "Maximum annual contribution per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationNonproduction": {
     "auth_ref": [
      "r37",
      "r69"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "DepreciationNonproduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of declared and paid cash dividends"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r2",
      "r4",
      "r128",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Preferred stock dividend accrual"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Dividends Payable [Line Items]",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsPayableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableTable": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.",
        "label": "Dividends Payable [Table]"
       }
      }
     },
     "localname": "DividendsPayableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStockStock": {
     "auth_ref": [
      "r81",
      "r134"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends"
       }
      }
     },
     "localname": "DividendsPreferredStockStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net (Loss) Income Per Share (Attributable to) Available to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r169",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r199",
      "r202",
      "r215",
      "r218",
      "r219",
      "r223",
      "r411",
      "r412",
      "r473",
      "r477",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "verboseLabel": "Basic net (loss) income per share (attributable to) available to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r169",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r202",
      "r215",
      "r218",
      "r219",
      "r223",
      "r411",
      "r412",
      "r473",
      "r477",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "verboseLabel": "Diluted net (loss) income per share (attributable to) available to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r46",
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net (Loss) Income per Share (Attributable to) Available to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r180",
      "r378",
      "r396"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "verboseLabel": "Federal tax at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r619",
      "r623"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period over which unrecognized compensation expense is expected to be recognized",
        "verboseLabel": "Period over which unrecognized compensation expense is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r617"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r76",
      "r146",
      "r164",
      "r165",
      "r166",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r197",
      "r225",
      "r254",
      "r311",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r410",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r443",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Long-term equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r154",
      "r421",
      "r503"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Short-term equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Measurement Input",
        "terseLabel": "Valuation assumptions, measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r478",
      "r575"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Gain (loss) recognized due to change in fair value of investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r413",
      "r414",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Summary of Changes in Estimated Fair Value of Level 3 Financial Assets"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r414",
      "r449",
      "r450",
      "r451",
      "r514",
      "r515",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r413",
      "r414",
      "r416",
      "r417",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r285",
      "r329",
      "r334",
      "r414",
      "r449",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r414",
      "r451",
      "r514",
      "r515",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r285",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r449",
      "r450",
      "r451",
      "r514",
      "r515",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r179",
      "r377"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense Benefit Continuing Operations",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r151",
      "r258"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 5.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 4.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 3.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Projected amortization expense for the next five years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r66",
      "r459"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r62",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r66",
      "r458"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r37",
      "r73",
      "r74"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": {
     "auth_ref": [
      "r634",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship.",
        "label": "Spouse of James Neal, then CEO and Chairman of the Board of Directors"
       }
      }
     },
     "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r559",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible asset"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r23",
      "r124",
      "r132",
      "r144",
      "r237",
      "r239",
      "r243",
      "r245",
      "r474",
      "r512"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "(Loss) income before income tax",
        "verboseLabel": "Income before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r379",
      "r384",
      "r390",
      "r394",
      "r397",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r181",
      "r196",
      "r197",
      "r236",
      "r377",
      "r395",
      "r398",
      "r479"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedTerseLabel": "Income tax benefit (expense)",
        "totalLabel": "Total income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesProvisionForIncomeTaxesDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r375",
      "r376",
      "r384",
      "r385",
      "r389",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase Decrease In Accrued Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r558",
      "r632"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase Decrease In Stockholders Equity Roll Forward",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r219"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Effect of dilutive warrants"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r203",
      "r204",
      "r206",
      "r219",
      "r342"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r65",
      "r454",
      "r455",
      "r456",
      "r458",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Ebopiprant IP"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r28",
      "r290",
      "r293",
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r172",
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r442",
      "r533"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of cost components of operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r178",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r404",
      "r407",
      "r408",
      "r422",
      "r511",
      "r583",
      "r638",
      "r639"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r130",
      "r140",
      "r534",
      "r563",
      "r576",
      "r631"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r149",
      "r178",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r404",
      "r407",
      "r408",
      "r422",
      "r534",
      "r583",
      "r638",
      "r639"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Closing Common Stock Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r38",
      "r133",
      "r143",
      "r147",
      "r159",
      "r161",
      "r166",
      "r178",
      "r188",
      "r190",
      "r191",
      "r192",
      "r193",
      "r196",
      "r197",
      "r212",
      "r237",
      "r239",
      "r243",
      "r245",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r412",
      "r422",
      "r512",
      "r583"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r200",
      "r214",
      "r219",
      "r237",
      "r239",
      "r243",
      "r245",
      "r512"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net (loss) income (attributable to) available to common stockholders, basic",
        "verboseLabel": "Net (loss) income (attributable to) available to common stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r201",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r219"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Diluted",
        "totalLabel": "Net (loss) income (attributable to) available to common stockholders, diluted",
        "verboseLabel": "Net (loss) income (attributable to) available to to common stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r237",
      "r239",
      "r243",
      "r245",
      "r512"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "(Loss) income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r437",
      "r533"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r434",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r441",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r440",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets - long term"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "negatedLabel": "Payments of consideration under RPAs and CPPAs"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtRestructuringCosts": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage.",
        "label": "Payments of Debt Restructuring Costs",
        "negatedLabel": "Payment for debt modification fee"
       }
      }
     },
     "localname": "PaymentsOfDebtRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Payment of preferred stock dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of preferred and common stock issuance costs",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r170",
      "r625",
      "r626",
      "r627"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Payment for IP acquired under the ObsEva IP Acquisition Agreement",
        "terseLabel": "Upfront cash payment to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred stock, dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r45",
      "r570"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Less: Accumulated preferred dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareCashPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividend paid (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "terseLabel": "Cash dividend declared (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r6",
      "r77",
      "r78",
      "r561",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred Stock, Liquidation Preference Per Share",
        "terseLabel": "Liquidation preference (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r75",
      "r77",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Redemption price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Gross proceeds from issuance of preferred stock",
        "verboseLabel": "Proceeds from issuance of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r31",
      "r101"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of options and other share-based compensation"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r147",
      "r159",
      "r161",
      "r173",
      "r178",
      "r188",
      "r196",
      "r197",
      "r237",
      "r239",
      "r243",
      "r245",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r402",
      "r405",
      "r406",
      "r412",
      "r422",
      "r474",
      "r512",
      "r531",
      "r532",
      "r556",
      "r583"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r71",
      "r141",
      "r475",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward",
        "terseLabel": "Unrecognized tax benefits activity"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r335",
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r335",
      "r444",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r106",
      "r145",
      "r646"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r552",
      "r560"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndRestrictedCashDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r81",
      "r139",
      "r484",
      "r485",
      "r534"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r197",
      "r254",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r410",
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r234",
      "r235",
      "r238",
      "r241",
      "r242",
      "r246",
      "r247",
      "r249",
      "r324",
      "r325",
      "r457"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue from contracts with customers",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r327",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r557"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r167",
      "r178",
      "r234",
      "r235",
      "r238",
      "r241",
      "r242",
      "r246",
      "r247",
      "r249",
      "r253",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r422",
      "r474",
      "r583"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues From External Customers And Long Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r249",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenues."
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of accrued and other liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of outstanding securities considered anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of of cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Provision for Income Taxes (All Current)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of Net Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation Between the Tax Provision Computed at the Federal Statutory Income Tax Rate and Actual Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r62",
      "r65",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r62",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of cost, accumulated amortization, and net carrying value of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r26",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule Of Revenue From External Customers Attributed To Foreign Countries By Geographic Area [Text Block]",
        "terseLabel": "Revenue by Geographical Region"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r22",
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]",
        "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationRevenueByGeographicalRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r83",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r529",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of projected amortization expense for next five years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r553",
      "r554",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "8.625% Series A Cumulative, Perpetual Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r553",
      "r554",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "8.375% Series B Cumulative, Perpetual Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee",
        "terseLabel": "Maximum shares per employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Increase in aggregate number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available for grant",
        "verboseLabel": "Shares available for purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "periodEndLabel": "Number of shares, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of shares, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of shares, Granted",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period",
        "terseLabel": "Number of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Shares purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "verboseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing stock price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Remaining Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Remaining Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage related to employees to purchase shares at the lower fair market value at offering period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Unrecognized tax benefits expected to change significantly over the next twelve months"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r178",
      "r202",
      "r207",
      "r215",
      "r219",
      "r226",
      "r227",
      "r253",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r294",
      "r295",
      "r298",
      "r302",
      "r309",
      "r422",
      "r501",
      "r549",
      "r561",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r76",
      "r146",
      "r164",
      "r165",
      "r166",
      "r185",
      "r186",
      "r187",
      "r189",
      "r195",
      "r197",
      "r225",
      "r254",
      "r311",
      "r371",
      "r372",
      "r373",
      "r392",
      "r393",
      "r410",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r443",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r225",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Common stock options"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r76",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r76",
      "r81",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionActivityDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r76",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "verboseLabel": "Issuance of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r76",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r59",
      "r534",
      "r563",
      "r576",
      "r631"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r177",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r307",
      "r308",
      "r311",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r429",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r429",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r429",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r429",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Sale of stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.",
        "label": "Substantial Doubt about Going Concern, within One Year [true false]",
        "terseLabel": "Substantial Doubt about Going Concern, within One Year"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carry forward amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r213",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings Loss Allocated To Participating Securities Basic",
        "negatedLabel": "Less: Allocation of undistributed earnings to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "auth_ref": [
      "r213",
      "r216",
      "r217",
      "r548"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings Loss Allocated To Participating Securities Diluted",
        "negatedLabel": "Add: Adjustments to undistributed earnings allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r374",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Income tax penalties or interest charged",
        "verboseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase (decrease) in the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r438",
      "r533"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants for common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "terseLabel": "Estimated fair value of warrants"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r219"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders",
        "verboseLabel": "Weighted average shares used in computing diluted net (loss) income per share (attributable to) available to common stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r199",
      "r219"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders",
        "verboseLabel": "Weighted average shares used in computing basic net (loss) income per share (attributable to) available to common stockholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedCompensationContinuityIncentive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense for compensation under employment agreement related to retirement of individual.",
        "label": "Accrued Compensation, Continuity Incentive",
        "terseLabel": "Accrued cash payment related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "localname": "AccruedCompensationContinuityIncentive",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedPreferredStockDividendCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preferred Stock Dividend, Current",
        "terseLabel": "Preferred stock dividend accrual"
       }
      }
     },
     "localname": "AccruedPreferredStockDividendCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedSalariesAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries and Employee Benefits, Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "AccruedSalariesAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedTransactionCostsRelatedToPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued transaction costs in connection with acquisition.",
        "label": "Accrued Transaction Costs Related To Purchase Agreements",
        "terseLabel": "Accrued transaction costs in connection with ObsEva IP Acquisition"
       }
      }
     },
     "localname": "AccruedTransactionCostsRelatedToPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AffimedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affimed",
        "label": "Affimed"
       }
      }
     },
     "localname": "AffimedMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AffitechResearchAsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affitech Research AS, a Norwegian biotech company.",
        "label": "Affitech"
       }
      }
     },
     "localname": "AffitechResearchAsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AgenusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agenus Inc.",
        "label": "Agenus"
       }
      }
     },
     "localname": "AgenusIncMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates subject to exclusive license option.",
        "label": "Agreement, Drug Candidates, Exclusive License Option, Number",
        "terseLabel": "Number of drug candidates subject to exclusive license option"
       }
      }
     },
     "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementDrugCandidatesNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates under the terms of the agreement.",
        "label": "Agreement, Drug Candidates, Number",
        "terseLabel": "Number of drug candidates"
       }
      }
     },
     "localname": "AgreementDrugCandidatesNumber",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementPaymentPercentageFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiplier used in determining change in payment percentage.",
        "label": "Agreement, Payment Percentage, Factor",
        "terseLabel": "Multiplier for cumulative amount of consideration paid"
       }
      }
     },
     "localname": "AgreementPaymentPercentageFactor",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementTerminationPriorWrittenNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Agreement Termination Prior Written Notice Period",
        "terseLabel": "Agreement termination prior written notice period"
       }
      }
     },
     "localname": "AgreementTerminationPriorWrittenNoticePeriod",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_AnnualDiscretionaryCashBonusTargetPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual discretionary cash bonus target as a percentage of current annual base salary.",
        "label": "Annual Discretionary Cash Bonus, Target Percentage",
        "terseLabel": "Annual discretionary cash bonus target (as a percent)"
       }
      }
     },
     "localname": "AnnualDiscretionaryCashBonusTargetPercentage",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_AronoraIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aronora, Inc.",
        "label": "Aronora",
        "terseLabel": "Aronora [Member]"
       }
      }
     },
     "localname": "AronoraIncMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aronora, Kuros, Affitech, ObsEva, and Merck KGaA.",
        "label": "Aronora, Kuros, Affitech, ObsEva, and Merck KGaA"
       }
      }
     },
     "localname": "AronoraKurosAffitechObsevaAndMerckKgaaMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ArrangementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arrangements the agreements are accounted for.",
        "label": "Arrangements, Number",
        "terseLabel": "Number of arrangements"
       }
      }
     },
     "localname": "ArrangementsNumber",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AssetAcquisitionsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for asset acquisitions.",
        "label": "Asset Acquisitions, Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionsPolicyPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_AtMarketIssuanceSalesAgreement2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.",
        "label": "2021 ATM Agreement"
       }
      }
     },
     "localname": "AtMarketIssuanceSalesAgreement2021Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer products.",
        "label": "Bayer Products"
       }
      }
     },
     "localname": "BayerProductsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BioasisTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioasis Technologies Inc.",
        "label": "Bioasis",
        "terseLabel": "Bioasis"
       }
      }
     },
     "localname": "BioasisTechnologiesIncMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BiotechnologyValueFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biotechnology Value Fund, L.P.",
        "label": "BVF"
       }
      }
     },
     "localname": "BiotechnologyValueFundLPMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CashReceivedForAchievementOfContractualMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash receipts for achievement of contractual milestones.",
        "label": "Cash Received for Achievement of Contractual Milestones",
        "terseLabel": "Cash receipts for achievement of contractual milestones"
       }
      }
     },
     "localname": "CashReceivedForAchievementOfContractualMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CashRetentionBonusExpectedPaymentNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash retention bonus expected to be paid in next fiscal year following current fiscal year.",
        "label": "Cash Retention Bonus, Expected Payment, Next Twelve Months",
        "terseLabel": "Cash retention bonuses expected to be paid in 2023"
       }
      }
     },
     "localname": "CashRetentionBonusExpectedPaymentNextTwelveMonths",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ChangesInEstimatedFairValueOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated fair value of contingent consideration.",
        "label": "Changes In Estimated Fair Value Of Contingent Consideration",
        "terseLabel": "Changes in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangesInEstimatedFairValueOfContingentConsideration",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ChiefExecutiveOfficerInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of interim chief executive officer and Executive Chairman of the Board.",
        "label": "Executive Chairman of the Board and Interim CEO, Owen Hughes"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerInterimMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ChiefExecutiveOfficerRetiredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer prior to retirement.",
        "label": "Chief Executive Officer, Retired, James R. Neal"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerRetiredMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ChiefInvestmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of  chief investment officer.",
        "label": "Chief Investment Officer, Bradley Sitko"
       }
      }
     },
     "localname": "ChiefInvestmentOfficerMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about collaboration agreement member.",
        "label": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CommercialPaymentPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial payment purchase agreement.",
        "label": "Commercial Payment Purchase Agreement"
       }
      }
     },
     "localname": "CommercialPaymentPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CommercialPaymentReceivableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Payment Receivable Term",
        "terseLabel": "Commercial payment receivable term"
       }
      }
     },
     "localname": "CommercialPaymentReceivableTerm",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_CommercialSalesReceivablePercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments entity eligible to receive as a percentage of net sales.",
        "label": "Commercial Sales, Receivable Percentage On Net Sales",
        "terseLabel": "Payments eligible to receive (as a percent)"
       }
      }
     },
     "localname": "CommercialSalesReceivablePercentageOnNetSales",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommonStockPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock premium received on sale of common stock.",
        "label": "Common Stock Premium",
        "terseLabel": "Common stock premium"
       }
      }
     },
     "localname": "CommonStockPremium",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CommonStockWarrantExercisePrice14.71Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $14.71 per share.",
        "label": "Common stock warrant, Exercise price $14.71 per share, Issued March 2019"
       }
      }
     },
     "localname": "CommonStockWarrantExercisePrice14.71Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CompensationExpenseEmploymentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for compensation under employment agreement related to retirement of individual.",
        "label": "Compensation Expense, Employment Agreement",
        "terseLabel": "Compensation expense related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "localname": "CompensationExpenseEmploymentAgreement",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ConcentrationOfRiskSegmentAndGeographicInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of risk segment and geographic information.",
        "label": "Concentration of Risk, Segment and Geographic Information"
       }
      }
     },
     "localname": "ConcentrationOfRiskSegmentAndGeographicInformationAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "xoma_ConsolidatedFinancialStatementDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated financial statement detail.",
        "label": "Consolidated Financial Statements Detail"
       }
      }
     },
     "localname": "ConsolidatedFinancialStatementDetailAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "xoma_ContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration, fair value disclosure.",
        "label": "Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Contingent consideration under RPAs and CPPAs"
       }
      }
     },
     "localname": "ContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentConsiderationUnderPurchaseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements.",
        "label": "Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Contingent consideration under RPAs and CPPAs"
       }
      }
     },
     "localname": "ContingentConsiderationUnderPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent future cash payments.",
        "label": "Contingent Future Cash Payments",
        "terseLabel": "Potential future cash payments"
       }
      }
     },
     "localname": "ContingentFutureCashPayments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPaymentsPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent future cash payment for each product.",
        "label": "Contingent Future Cash Payments, Per Product",
        "terseLabel": "Contingent future cash payment for each product"
       }
      }
     },
     "localname": "ContingentFutureCashPaymentsPerProduct",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.",
        "label": "Contractual Obligation Estimated Milestone Payments",
        "terseLabel": "Estimate of milestone payments"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePayments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.",
        "label": "Contractual Obligation, Estimated Milestone Payments, Number Of Products",
        "terseLabel": "Assumed number of products per contract"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement",
        "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount",
        "terseLabel": "Threshold amount of cumulative royalties on net sales per product"
       }
      }
     },
     "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current employees of entity, excluding Chief Executive Officer.",
        "label": "Current employees, excluding Chief Executive Officer"
       }
      }
     },
     "localname": "CurrentEmployeesExcludingChiefExecutiveOfficerMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The age requirement for participants to be eligible for a catch-up contribution amount to a defined contribution plan.",
        "label": "Defined Contribution Plan Age Required For Catch Up Contribution Minimum",
        "terseLabel": "Age requirement for participant to be eligible for a catch-up contribution, minimum"
       }
      }
     },
     "localname": "DefinedContributionPlanAgeRequiredForCatchUpContributionMinimum",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of defined contribution plan expense paid through the issuance of common shares.",
        "label": "Defined Contribution Plan Cost Recognized And Paid Through Issuance Of Common Shares Percentage",
        "terseLabel": "Deferred savings plan expense paid in common shares (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognizedAndPaidThroughIssuanceOfCommonSharesPercentage",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan issuance of Common stock for services or claims.",
        "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims",
        "terseLabel": "Common stock contribution to 401(k)"
       }
      }
     },
     "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_DepositarySharesRatioToPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents depositary share's fractional interest in share of preferred stock.",
        "label": "Depositary Shares, Ratio To Preferred Stock",
        "terseLabel": "Depositary share's fractional interest in share of preferred stock"
       }
      }
     },
     "localname": "DepositarySharesRatioToPreferredStock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to federal orphan drug credit.",
        "label": "Effective Income Tax Rate Reconciliation, Orphan Drug Credit, Percent",
        "negatedLabel": "Federal orphan drug credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOrphanDrugCreditPercent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement and other permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Stock Compensation And Other Permanent Differences Percent",
        "terseLabel": "Stock compensation and other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStockCompensationAndOtherPermanentDifferencesPercent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense (benefit) related to net operating loss carryforward utilization.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Net Operating Loss Carryforward Utilization, Percent",
        "terseLabel": "Tax benefit related to net operating loss carryforward utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitNetOperatingLossCarryforwardUtilizationPercent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesReconciliationBetweenStatutoryRateAndEffectiveRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable per discovery product candidate.",
        "label": "Eligible Milestone Payments Receivable Per Discovery Product Candidate",
        "terseLabel": "Maximum eligible milestone payments receivable per discovery product candidate"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development, Commercialization And Sales Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones",
        "terseLabel": "Pre-commercial milestone payments"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of sales and/or regulatory milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Regulatory and Sales Milestones",
        "terseLabel": "Maximum additional payments upon achievement of regulatory and sales milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of sales milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Sales Milestones",
        "terseLabel": "Potential future sales milestone payments"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfSalesMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.",
        "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones",
        "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years"
       }
      }
     },
     "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EmployeeAgeFiftyOrOverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity age 50 or over.",
        "label": "Employee, Age Fifty or Over"
       }
      }
     },
     "localname": "EmployeeAgeFiftyOrOverMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity.",
        "label": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EmployeeTerminatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated employee of entity.",
        "label": "Terminated employee"
       }
      }
     },
     "localname": "EmployeeTerminatedMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EmployeeUnderAgeFiftyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity under 50 years old.",
        "label": "Employee, Under Age Fifty"
       }
      }
     },
     "localname": "EmployeeUnderAgeFiftyMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansDeferredSavingsPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EmploymentAgreementAnnualSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of annual base salary pursuant to employment agreement.",
        "label": "Employment Agreement, Annual Salary",
        "terseLabel": "Amount of annual base salary"
       }
      }
     },
     "localname": "EmploymentAgreementAnnualSalary",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EmploymentAgreementSigningBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount of signing bonus pursuant to employment agreement.",
        "label": "Employment Agreement, Signing Bonus",
        "terseLabel": "Amount of signing bonus"
       }
      }
     },
     "localname": "EmploymentAgreementSigningBonus",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EmploymentAgreementSigningBonusPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period within which signing bonus will be paid pursuant to employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employment Agreement, Signing Bonus, Payment Period",
        "terseLabel": "Period within which signing bonus will be paid"
       }
      }
     },
     "localname": "EmploymentAgreementSigningBonusPaymentPeriod",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period within which signing bonus would need to be repaid upon resignation or termination for cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employment Agreement, Signing Bonus, Repayment Period Upon Resignation Or Termination",
        "terseLabel": "Period within which signing bonus would need to be repaid upon resignation or termination"
       }
      }
     },
     "localname": "EmploymentAgreementSigningBonusRepaymentPeriodUponResignationOrTermination",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employment Agreement, Signing Bonus, Resignation Or Termination, Period Requiring Repayment",
        "terseLabel": "Maximum period from effective date of employment agreement resignation or termination for cause would require signing bonus to be repaid"
       }
      }
     },
     "localname": "EmploymentAgreementSigningBonusResignationOrTerminationPeriodRequiringRepayment",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_EmploymentPeriodRetirementEligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which individual will be deemed retirement eligible for purposes of equity award if employed through the period under terms of amended employment agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employment Period, Retirement Eligible",
        "terseLabel": "Period for which individual will be deemed retirement eligible for purposes of equity award"
       }
      }
     },
     "localname": "EmploymentPeriodRetirementEligible",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_EquitySecuritiesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity securities.",
        "label": "Equity Securities Policy",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesPolicy",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of contingent consideration under purchase agreements.  May include royalty purchase agreements and commercial payment purchase agreements.",
        "label": "Estimated Fair Value Of Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Estimated fair value of contingent consideration under the Affitech CPPA"
       }
      }
     },
     "localname": "EstimatedFairValueOfContingentConsiderationUnderPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ExercisablePeriodOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the exercisable period for warrants beginning on the date of issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable Period Of Warrants",
        "terseLabel": "Exercisable period of warrants"
       }
      }
     },
     "localname": "ExercisablePeriodOfWarrants",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_FaricimabSvoaVabysmoProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Faricimab-svoa, (VABYSMO) products.",
        "label": "VABYSMO"
       }
      }
     },
     "localname": "FaricimabSvoaVabysmoProductMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FederalOrphanCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal orphan tax credit carryforward.",
        "label": "Federal Orphan Credit"
       }
      }
     },
     "localname": "FederalOrphanCreditMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial assets.",
        "label": "Financial Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Through Year Five",
        "totalLabel": "Total for next five years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Royalty Interest Acquisition Agreement.",
        "label": "First Royalty Sale Agreement"
       }
      }
     },
     "localname": "FirstRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policy for future milestones, royalties purchase rights and commercial payments.",
        "label": "Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]",
        "terseLabel": "Purchase of Rights to Future Milestones, Royalties and Commercial Payments"
       }
      }
     },
     "localname": "FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners II, L.P (HCRP).",
        "label": "HealthCare Royalty Partners II, L.P"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_IL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-1 target license agreement with Novartis.",
        "label": "IL-1 Target License Agreement"
       }
      }
     },
     "localname": "IL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ImpairmentOfLongTermRoyaltyReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets.",
        "label": "Impairment Of Long Term Royalty Receivable",
        "terseLabel": "Impairment of long-term royalty receivable"
       }
      }
     },
     "localname": "ImpairmentOfLongTermRoyaltyReceivable",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_IncreaseDecreaseInRefundLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in contingent refund liability.",
        "label": "Increase (Decrease) in Refund Liability",
        "terseLabel": "Contingent NIH refund liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInRefundLiability",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_IncyteImmunoOncologyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte immuno-oncology assets.",
        "label": "Incyte Immuno-Oncology Assets"
       }
      }
     },
     "localname": "IncyteImmunoOncologyAssetsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_JanssenBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech, Inc.",
        "label": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechInc.Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.",
        "label": "Kuros",
        "terseLabel": "Kuros [Member]"
       }
      }
     },
     "localname": "KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseDisclosureTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California.",
        "label": "Leased facilities, Emeryville, California"
       }
      }
     },
     "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid under extended lease term.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Under Extended Lease Term",
        "terseLabel": "Remaining undiscounted lease payments under extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidUnderExtendedLeaseTerm",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's net lease liability until expiration of operating lease to be paid in next fiscal year following current fiscal year. Excludes payments after  extension of lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One, Prior To Expiration of Lease",
        "terseLabel": "Net lease liability until expiration of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearOnePriorToExpirationOfLease",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Summary of supplemental cash flow information related to operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.",
        "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]",
        "terseLabel": "Schedule of present value assumptions used in calculating the present value of lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement and common stock purchase agreement.",
        "label": "License Agreement and Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement consideration received.",
        "label": "License Agreement Consideration Received",
        "terseLabel": "License agreement consideration received"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceived",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments received upon achievement of financing activities during the period.",
        "label": "License Agreement Consideration Received, Achievement of Financing Activities",
        "terseLabel": "Payments received upon achievement of financing activities"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license agreement consideration received as repayment of debt.",
        "label": "License Agreement Consideration Received, Debt Repayment",
        "terseLabel": "License agreement consideration received, repayment of debt"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceivedDebtRepayment",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementInstallmentPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of installment payments received during the period.",
        "label": "License Agreement, Installment Payments Received",
        "terseLabel": "Installment payments received"
       }
      }
     },
     "localname": "LicenseAgreementInstallmentPaymentsReceived",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementNonRz358ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with non-RZ358 products.",
        "label": "License Agreement, Non-RZ358 products"
       }
      }
     },
     "localname": "LicenseAgreementNonRz358ProductsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementRz358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with RZ358.",
        "label": "License Agreement, RZ358"
       }
      }
     },
     "localname": "LicenseAgreementRz358Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of counterparty's common stock entity received under the terms of the agreement.",
        "label": "License Agreement, Shares Received",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "localname": "LicenseAgreementSharesReceived",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_LicenseAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement transaction price.",
        "label": "License Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "LicenseAgreementTransactionPrice",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicensingAndOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "xoma_LicensingAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing And Other Arrangements [Text Block]",
        "terseLabel": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LongTermRightsReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term royalty and commercial rights receivables, non current.",
        "label": "Long Term Rights Receivable, Non-Current",
        "periodEndLabel": "Long-term royalty receivable, Balance at end of period",
        "periodStartLabel": "Long-term royalty receivable, Balance at beginning of period",
        "terseLabel": "Long-term royalty and commercial payment receivables"
       }
      }
     },
     "localname": "LongTermRightsReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LongTermRightsReceivableReclassification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in long term rights receivable due to reclassification to short-term rights receivable.",
        "label": "Long Term Rights Receivable, Reclassification",
        "negatedLabel": "Reclassification to long-term royalty and commercial payment receivable"
       }
      }
     },
     "localname": "LongTermRightsReceivableReclassification",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.",
        "label": "Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events",
        "terseLabel": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events"
       }
      }
     },
     "localname": "MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumConsiderationRetained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.",
        "label": "Maximum Consideration Retained",
        "terseLabel": "Amount of maximum consideration retained"
       }
      }
     },
     "localname": "MaximumConsiderationRetained",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for various milestones under arrangement.",
        "label": "Maximum Earn-Out Payments",
        "terseLabel": "Maximum earn-out payments"
       }
      }
     },
     "localname": "MaximumEarnOutPayments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.",
        "label": "Maximum Earn-Out Payments, Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum earn-out payments for development and regulatory milestones"
       }
      }
     },
     "localname": "MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.",
        "label": "Maximum Earn-Out Payments, Sales-Based Milestone Payments",
        "terseLabel": "Maximum earn-out payments for sales-based milestones"
       }
      }
     },
     "localname": "MaximumEarnOutPaymentsSalesBasedMilestonePayments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPayableOnRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable on regulatory milestone.",
        "label": "Maximum Payable on Regulatory Milestone",
        "terseLabel": "Maximum payable on regulatory milestone"
       }
      }
     },
     "localname": "MaximumPayableOnRegulatoryMilestone",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPayableOnSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable on sales milestone.",
        "label": "Maximum Payable on Sales Milestone",
        "terseLabel": "Maximum payable on sales milestone"
       }
      }
     },
     "localname": "MaximumPayableOnSalesMilestone",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumValueOfCommonStockToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum value of common stock to be issued.",
        "label": "Maximum Value Of Common Stock To Be Issued",
        "terseLabel": "Maximum amount of common shares to be issued"
       }
      }
     },
     "localname": "MaximumValueOfCommonStockToBeIssued",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumValueOfStockToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of stock to be issued.",
        "label": "Maximum Value Of Stock To Be Issued",
        "terseLabel": "Maximum amount of shares to be issued"
       }
      }
     },
     "localname": "MaximumValueOfStockToBeIssued",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MerckImmunoOncologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck immuno-oncology product.",
        "label": "Merck Immuno-Oncology Product"
       }
      }
     },
     "localname": "MerckImmunoOncologyProductMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MezagitamabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mezagitamab antibody (TAK-079).",
        "label": "TAK-079"
       }
      }
     },
     "localname": "MezagitamabMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone achieved.",
        "label": "Milestone Achieved",
        "terseLabel": "Amount of milestone achieved"
       }
      }
     },
     "localname": "MilestoneAchieved",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment during the period.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonePaymentReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestone payment received by counterparty entity is entitled to receive.",
        "label": "Milestone Payment Receivable, Percentage",
        "terseLabel": "Percentage of milestone payment received by Kuros that company is entitled to receive"
       }
      }
     },
     "localname": "MilestonePaymentReceivablePercentage",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_MilestonePaymentReceivedCounterparty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.",
        "label": "Milestone Payment Received, Counterparty",
        "terseLabel": "Milestone payment received by Kuros"
       }
      }
     },
     "localname": "MilestonePaymentReceivedCounterparty",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonePeriodsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.",
        "label": "Milestone Periods, Number",
        "terseLabel": "Number of milestone periods"
       }
      }
     },
     "localname": "MilestonePeriodsNumber",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.",
        "label": "Milestones Payments To Aggregate Amount Of Per Product",
        "terseLabel": "Aggregate milestones payments per product"
       }
      }
     },
     "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.",
        "label": "Milestones Receivable, Excluding Consideration Retained, Maximum",
        "terseLabel": "Maximum amount of potential milestones and other payments receivable"
       }
      }
     },
     "localname": "MilestonesReceivableExcludingConsiderationRetainedMaximum",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net income loss available to common stockholders basic and diluted.",
        "label": "Net Income Loss Available To Common Stockholders Basic And Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureNetLossIncomePerShareAttributableToAvailableToCommonStockholdersReconciliationOfNumeratorAndDenominatorUsedInCalculationOfEpsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_NetOperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration year.",
        "label": "Net Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "xoma_NonBayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-bayer products.",
        "label": "Non-Bayer Products"
       }
      }
     },
     "localname": "NonBayerProductsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted",
        "terseLabel": "Ownership interest, if shares are converted (as a percent)"
       }
      }
     },
     "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_NovartisInternationalPharmaceuticalLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd.",
        "label": "Novartis International"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalLtdMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured note agreement and subsequent amendments with Novartis referred to as the \"Note Agreement\".",
        "label": "Novartis Note"
       }
      }
     },
     "localname": "NovartisNoteMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Pharma AG.",
        "label": "Novartis Pharma AG"
       }
      }
     },
     "localname": "NovartisPharmaAGMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NumberOfArbitrationProceedingsInitiated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arbitration proceedings initiated by entity against one of its licensees.",
        "label": "Number of Arbitration Proceedings Initiated",
        "terseLabel": "Number of arbitration proceedings initiated"
       }
      }
     },
     "localname": "NumberOfArbitrationProceedingsInitiated",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesArbitrationProceedingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of license agreements.",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreementsFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of future license agreements under optional purchase right.",
        "label": "Number Of License Agreements, Future License Agreements",
        "terseLabel": "Number of future license agreements under optional purchase right"
       }
      }
     },
     "localname": "NumberOfLicenseAgreementsFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licensed products related to milestones and royalties purchased.",
        "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased",
        "terseLabel": "Number of licensed products related to milestone and royalties"
       }
      }
     },
     "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfMajorPartners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major partners.",
        "label": "Number Of Major Partners",
        "terseLabel": "Number of major partners"
       }
      }
     },
     "localname": "NumberOfMajorPartners",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfPeriodsCashRetentionBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.",
        "label": "Number of Periods, Cash Retention Bonus",
        "terseLabel": "Number of periods in which employees will be eligible to receive cash retention bonus"
       }
      }
     },
     "localname": "NumberOfPeriodsCashRetentionBonus",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfRoyaltyInterestAcquisitionAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of royalty interest acquisition agreements.",
        "label": "Number Of Royalty Interest Acquisition Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfRoyaltyInterestAcquisitionAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ObsevaIntellectualPropertyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ObsEva intellectual property rights.",
        "label": "ObsEva IP"
       }
      }
     },
     "localname": "ObsevaIntellectualPropertyRightsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_OperatingLeasePaymentsNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payments, non cash.",
        "label": "Operating Lease Payments Non Cash",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeasePaymentsNonCash",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLeasesNumberOfLeasedFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, number of leased facilities.",
        "label": "Operating Leases Number Of Leased Facilities",
        "terseLabel": "Operating leases, number of leased facilities"
       }
      }
     },
     "localname": "OperatingLeasesNumberOfLeasedFacilities",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_OperatingLossCarryForwardSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carry forward that is subject to expiration.",
        "label": "Operating Loss Carry Forward Subject To Expiration",
        "terseLabel": "Net operating loss carry forward subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryForwardSubjectToExpiration",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesNolDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards offset of taxable income percentage.",
        "label": "Operating Loss Carryforwards Offset Of Taxable Income Percentage",
        "terseLabel": "Operating loss carryforward offset (as a percent)"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsOffsetOfTaxableIncomePercentage",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_OrganonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon.",
        "label": "Organon"
       }
      }
     },
     "localname": "OrganonMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_OtherAntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other antibody technologies.  Excludes TAK-079 (mezagitamab).",
        "label": "Other antibodies"
       }
      }
     },
     "localname": "OtherAntibodiesMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PalobiofarmaSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palobiofarma, S.L.",
        "label": "Palobiofarma, S.L {Member]",
        "terseLabel": "Palo"
       }
      }
     },
     "localname": "PalobiofarmaSLMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 1"
       }
      }
     },
     "localname": "Partner1Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 2"
       }
      }
     },
     "localname": "Partner2Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 3"
       }
      }
     },
     "localname": "Partner3Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 4"
       }
      }
     },
     "localname": "Partner4Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConcentrationOfRiskSegmentAndGeographicInformationConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PaymentsOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of contingent consideration.",
        "label": "Payments Of Contingent Consideration",
        "terseLabel": "Payments of contingent consideration"
       }
      }
     },
     "localname": "PaymentsOfContingentConsideration",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to purchase of royalty rights and other commercial payment rights.",
        "label": "Payments Related To Purchase Of Royalty Rights And Other Commercial Payment Rights",
        "negatedLabel": "Payments related to purchase of royalty rights and other commercial payment rights",
        "terseLabel": "Payments related to purchase of royalty rights and other commercial payment rights"
       }
      }
     },
     "localname": "PaymentsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Second License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, second agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Third License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, third agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.",
        "label": "Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions",
        "terseLabel": "Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions"
       }
      }
     },
     "localname": "PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.",
        "label": "Percentage Of Decrease In Future Royalty Obligations",
        "terseLabel": "Percentage of decrease in future royalty obligations"
       }
      }
     },
     "localname": "PercentageOfDecreaseInFutureRoyaltyObligations",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares",
        "terseLabel": "Sales commission paid per transaction (as a percent)"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares",
        "terseLabel": "Sales commission paid per transaction, preferred stock (as a percent)"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfShares",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty rights entity has option to  purchase in future license agreements.",
        "label": "Percentage Of Optional Royalty Rights Purchase On Future License Agreements",
        "terseLabel": "Percentage of option to purchase royalty right on future license agreements"
       }
      }
     },
     "localname": "PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales upon commercialization.",
        "label": "Percentage Of Royalty On Net Sales Upon Commercialization",
        "terseLabel": "Percentage of royalty on worldwide net sales of each product upon commercialization"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PeriodOneRetentionBonusEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period One, Retention Bonus Eligibility",
        "terseLabel": "Initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "localname": "PeriodOneRetentionBonusEligibility",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_PeriodTwoRetentionBonusEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period Two, Retention Bonus Eligibility",
        "terseLabel": "Period following initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "localname": "PeriodTwoRetentionBonusEligibility",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock conversion price per share.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred stock conversion price per share"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xoma_PreferredStockConvertibleThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible stock must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Preferred Stock, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "localname": "PreferredStockConvertibleThresholdConsecutiveTradingDays",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_PreferredStockDividendAmountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The dividend amount per share based on the dividend rate on preferred stock.",
        "label": "Preferred Stock Dividend Amount Per Share",
        "terseLabel": "Preferred stock, dividend amount (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockDividendAmountPerShare",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xoma_PreferredStockDividendPeriodMonth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of days in month over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Month",
        "terseLabel": "Number of days in month over which dividend will be prorated and computed"
       }
      }
     },
     "localname": "PreferredStockDividendPeriodMonth",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_PreferredStockDividendPeriodProratedMonthsInYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of months in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Prorated Months in Year",
        "terseLabel": "Number of months in year over which dividend will be prorated and compute"
       }
      }
     },
     "localname": "PreferredStockDividendPeriodProratedMonthsInYear",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_PreferredStockDividendPeriodYearProrated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of days in year over which dividend will be prorated and computed for any period greater or less than a full dividend period.",
        "label": "Preferred Stock, Dividend Period, Year Prorated",
        "terseLabel": "Number of days in year over which dividend will be prorated and computed"
       }
      }
     },
     "localname": "PreferredStockDividendPeriodYearProrated",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_PreferredStockRedemptionPricePerShareOptionalRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share the company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event.",
        "label": "Preferred Stock, Redemption Price Per Share, Optional Redemption",
        "terseLabel": "Redemption price at which company has option to redeem outstanding shares upon the occurrence of a delisting event or change of control event (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShareOptionalRedemption",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "xoma_PreferredStockShareCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share cap for which holder of shares can convert preferred shares into common stock pursuant to redemption rights.",
        "label": "Preferred Stock, Share Cap",
        "terseLabel": "Share cap (in shares)"
       }
      }
     },
     "localname": "PreferredStockShareCap",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_ProceedsFromIssuanceOfPreferredStockNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock, Net",
        "terseLabel": "Net proceeds from issuance of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockNet",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDepositarySharesRepresentingInterestInSeriesBPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ProceedsFromIssuanceOrSaleOfEquityNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity, net of offering costs.",
        "label": "Proceeds from Issuance or Sale of Equity, Net",
        "terseLabel": "Net proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityNet",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ProceedsFromUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Cash payment received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPayment",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Purchase of Rights to Future Milestones and Royalties [Abstract]",
        "terseLabel": "Purchase of Rights to Future Milestones and Royalties"
       }
      }
     },
     "localname": "PurchaseOfRightsToFutureMilestonesAndRoyaltiesAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPurchaseOfRightsAndIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.",
        "label": "Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones",
        "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchasedPercentageOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased percentage of milestones.",
        "label": "Purchased Percentage Of Milestones",
        "terseLabel": "Purchased percentage of milestones"
       }
      }
     },
     "localname": "PurchasedPercentageOfMilestones",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased percentage of non-royalties on net sales of products.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products",
        "terseLabel": "Non-royalties to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage",
        "terseLabel": "Future non-royalty payments to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in long-term rights receivable due to receipt of royalty and commercial payment receivable.",
        "label": "Receipt of Royalty and Commercial Payment Receivable Non Current",
        "negatedLabel": "Receipt of royalty and commercial payments, Long-Term",
        "terseLabel": "Reduction in long-term royalty receivable balance due to receipt of payment"
       }
      }
     },
     "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receipts related to purchase of royalty rights and other commercial payment rights.",
        "label": "Receipts Related To Purchase Of Royalty Rights And Other Commercial Payment Rights",
        "terseLabel": "Receipts under RPAs and CPPAs"
       }
      }
     },
     "localname": "ReceiptsRelatedToPurchaseOfRoyaltyRightsAndOtherCommercialPaymentRights",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReductionOfContingentRefundLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction in contingent refund liability.",
        "label": "Reduction of Contingent Refund Liability",
        "negatedLabel": "Reduction of contingent NIH refund liability",
        "terseLabel": "Reduction of contingent refund liability"
       }
      }
     },
     "localname": "ReductionOfContingentRefundLiability",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RegulatoryAndCommercialMilestonesReceivableMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.",
        "label": "Regulatory and Commercial Milestones Receivable, Maximum",
        "terseLabel": "Maximum amount of potential regulatory and commercial milestones receivable"
       }
      }
     },
     "localname": "RegulatoryAndCommercialMilestonesReceivableMaximum",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, excluding extinguishment of debt.",
        "label": "Repayments of Long-term Debt, Excluding Extinguishment of Debt",
        "negatedLabel": "Principal payments - debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtExcludingExtinguishmentOfDebt",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RepaymentsOfLongTermDebtExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer, considered extinguishment of debt.",
        "label": "Repayments of Long-term Debt, Extinguishment of Debt",
        "negatedLabel": "Payment for extinguishment of debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtExtinguishmentOfDebt",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RetentionBonusExpenseAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recorded as expense during the period for cash retention bonuses.",
        "label": "Retention Bonus, Expense Accrued",
        "terseLabel": "Amount recorded as expense for cash retention bonuses"
       }
      }
     },
     "localname": "RetentionBonusExpenseAccrued",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for sale of future revenue streams.",
        "label": "Revenue Recognition Deferred Revenue Policy [Text Block]",
        "terseLabel": "Sale of Future Revenue Streams"
       }
      }
     },
     "localname": "RevenueRecognitionDeferredRevenuePolicyTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_RezoluteIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rezolute, Inc.",
        "label": "Rezolute"
       }
      }
     },
     "localname": "RezoluteIncMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RightsReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and commercial rights receivables, due within one year or the normal operating cycle, if longer.",
        "label": "Rights Receivable, Current",
        "periodEndLabel": "Short-term royalty receivable, Balance at end of period",
        "periodStartLabel": "Short-term royalty receivable, Balance at beginning of period",
        "terseLabel": "Short-term royalty and commercial payment receivables"
       }
      }
     },
     "localname": "RightsReceivableCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RoyaltiesPeriodMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties, Period, Minimum",
        "terseLabel": "Royalty payment period"
       }
      }
     },
     "localname": "RoyaltiesPeriodMinimum",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract",
     "nsuri": "http://www.xoma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty and commercial payment rights acquired, classified as noncurrent.",
        "label": "Royalty And Commercial Rights Acquired, Non-Current",
        "terseLabel": "Acquisition of royalty and commercial payment rights, Long-Term"
       }
      }
     },
     "localname": "RoyaltyAndCommercialRightsAcquiredNonCurrent",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RoyaltyInterestAcquisitionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Interest Acquisition Agreements.",
        "label": "Royalty Sale Agreements"
       }
      }
     },
     "localname": "RoyaltyInterestAcquisitionAgreementsMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty milestones, sales milestones, non-sales milestones, and royalties.",
        "label": "Royalty milestones, sales milestones, non-sales milestones, and royalties"
       }
      }
     },
     "localname": "RoyaltyMilestonesSalesMilestonesNonSalesMilestonesAndRoyaltiesMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationAndEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Text Block]",
        "verboseLabel": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_RoyaltyPurchaseAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A second royalty purchase agreement.",
        "label": "Second Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTwoMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyReceivablePercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties entity has the right to receive as a percentage.",
        "label": "Royalty Receivable Percentage On Net Sales",
        "terseLabel": "Royalties entity has right to receive (as a percent)"
       }
      }
     },
     "localname": "RoyaltyReceivablePercentageOnNetSales",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in royalty and commercial payment receivables.",
        "label": "Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]",
        "terseLabel": "Summary of royalty receivable activities"
       }
      }
     },
     "localname": "ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_SecondRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Royalty Interest Acquisition Agreement.",
        "label": "Second Royalty Sale Agreement"
       }
      }
     },
     "localname": "SecondRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeniorVicePresidentFinanceAndChiefFinancialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Vice President, Finance and Chief Financial Officer of entity.",
        "label": "Senior Vice President, Finance and Chief Financial Officer, Thomas Burns"
       }
      }
     },
     "localname": "SeniorVicePresidentFinanceAndChiefFinancialOfficerMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEquityAwardsModificationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesXAndSeriesYConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X and series Y convertible preferred stock.",
        "label": "Series X And Series Y Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXAndSeriesYConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesXConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X convertible preferred stock.",
        "label": "Series X Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_SeriesYConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Y convertible preferred stock.",
        "label": "Series Y Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesYConvertiblePreferredStockMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockSeriesXConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age required for employees to qualify for immediate vesting of award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award",
        "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The length of each offering period under the plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age",
        "terseLabel": "Threshold years required for retirement age"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments",
        "terseLabel": "Number of successive equal monthly vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments",
        "terseLabel": "Number of equal quarterly vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedPaymentArrangementExercisePrice18.66Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation award with exercise price of $18.66 per share.",
        "label": "Exercise price, $18.66 per share"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementExercisePrice18.66Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ShareBasedPaymentArrangementExercisePrice30.00Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation award with exercise price of $30.00 per share.",
        "label": "Exercise price, $30.00 per share"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementExercisePrice30.00Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.",
        "label": "Share-Based Payment Arrangement, Number of Awards Grants",
        "terseLabel": "Number of award grants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNumberOfAwardsGrants",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShortTermRightsReceivableReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in short term rights receivable due to reclassification from long-term rights receivable.",
        "label": "Short Term Rights Receivable, Reclassification",
        "terseLabel": "Reclassification to short-term royalty and commercial payment receivable"
       }
      }
     },
     "localname": "ShortTermRightsReceivableReclassification",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.",
        "label": "SVB Loan"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a 401(K) and to an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan and Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlanAndEmployeeStockPurchasePlans",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrant",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as 401(K) plan, and to employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan and Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to 401(k) contribution and ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlanAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.",
        "label": "Stock Issued During Period Value New Issues, Common Stock",
        "verboseLabel": "Issuance of common stock, fair value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TaxCreditCarryForwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carry forward expiration year",
        "label": "Tax Credit Carry Forward Expiration Year",
        "terseLabel": "Tax credit carry forward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryForwardExpirationYear",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesTaxCreditCarryforwardDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "xoma_TenYearWarrantsIssuedThirdRangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.",
        "label": "Ten Year Warrants Issued in May 2018"
       }
      }
     },
     "localname": "TenYearWarrantsIssuedThirdRangeMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockCommonStockWarrantsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockSummaryOfCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandEighteenAtMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the Market Agreement, 2018 in which the company may sell common shares.",
        "label": "2018 ATM Agreement [Member]",
        "terseLabel": "2018 Common Stock ATM Agreement"
       }
      }
     },
     "localname": "TwoThousandEighteenAtMarketAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.",
        "label": "2015 ESPP"
       }
      }
     },
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Long Term Incentive and Share Award Plan and subsequent amendments.",
        "label": "2010 Plan"
       }
      }
     },
     "localname": "TwoThousandTenLongTermIncentiveAndStockAwardPlanMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationAndOtherBenefitPlansStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for initial payment under agreement.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ViractaTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viracta Therapeutics, Inc. (\"Viracta\").",
        "label": "Viracta"
       }
      }
     },
     "localname": "ViractaTherapeuticsInc.Member",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_XOMA052LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gevokizumab License Agreement with Novartis.",
        "label": "Gevokizumab License Agreement"
       }
      }
     },
     "localname": "XOMA052LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA-052 license agreement and IL1 target license agreement.",
        "label": "Gevokizumab License Agreement and IL-1 Target License Agreement"
       }
      }
     },
     "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087AndIl1BetaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_XomaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xoma Corporation.",
        "label": "Xoma Corporation"
       }
      }
     },
     "localname": "XomaCorporationMember",
     "nsuri": "http://www.xoma.com/20221231",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=116846462&loc=SL51888449-203568",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2793-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2814-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2740-109256",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001558370-23-003259-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-003259-xbrl.zip
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M\$QE'3DM$1@KV/@&C[*P[7XP<1F+:?SB.9B.5IA=>GLNY:00RF2V8EJG=/J
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M T)858)C2RCP?8-L,H/A$CY]A^7BG=W5+<.S@I*]>375JB%Q:;*,54OW\%M
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M;# )Y=O"8+*AIAML)%M74^$FT3V$\07:BS8Y5O6?,QI0SW24]9]EM:?@'G.
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MP,]Q1,U33_Y\1^!+?Z2&+M\KQM0MXHB&K](8YZ/!(;]RDTV>H'B!W;@UI77
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M<M4N W\C9I*OCN@1[E]FC*%GD3^3&#(.R5!^XNNEU0>V ?8#TN37-Q_>S/R
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MKZ0AX(%GI6/?KZU@8]DHCK!MN3>1PP_24NL_WA@N-3P!I9-,*G:^W^VS@0R
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MY#X\WFZ<*>?7GT 6$TD',K>^PTBZKNK49$<2\]K :#3E5'D>SOUOH5:X3N6
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M[*W.K! KNEE_^/"QZF:E(\^2H6=%L.B7'+)9"EKBB2T -\N@FUE1<13?FQU
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MC;E@FPNVN6";"_;@%^P0V>]6_NY]&&V#E#7TIT+&$?GM7^?S"N4/?QW+1?D
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MHY7?GS^\^_"A WZ7QH'@HP?%[Q)U])XO7\F]%7LK@6Y1:J%!)^"\J2.K$Y3
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MQ-\8CT=%NL:5G[A.\"MU8G5)X8:AB$VLC<'B@:EB'%)#:R77^.%IEG<F(!,
M;;'$, HV1ZPT7#)VQ3ZI2[I0CT1L="WL'9<9/AJ&U.3:J.U=9%C610[:7DEO
M>SR.;FRBK+B>N57'SL;@:EBL-SEIX"R,KH[>H50R*S>/PO!L\3G&H0##[7'.
MZK,NCK]';&2UK!3' ?*72(VIGD;CHX <6FW*Q/@F,R4WTW:O6ZVO_- )79]Y
M@DBT'5@^02UK]_B*N^-4I,9E(H#:GG<-\Q":I!'YQAN>U>W#ZN;Z8OEX>4'>
M+V^6M^>7Y.&GR\O'!RO*ODP2FB8M:GTR"+D"US,EJVIU!&*E5!!J[%XY./);
M#M!21\:AN7IXL&L_V3&&EAF=CIV%-2E8/#6JHX'H;4M%;T\3RT^V<)C:T$SF
MW#D<^@]63._<23;+T(/_7/ZQ]U^<@%&4+--S)XX/?OC\LQ/LCP_0N\Y%;IJ=
M1"";JM9$Q*;;C7YC+6?@B1-ZA/\A(5H0)R4Y+L*1V;'NB>7@PA^T1&3%[N\I
M<V*^FU+.=OV#^+:QR.VZD479CFL'(K;;9GI-];.$RBUUH7K]/HU-CLXC6*$5
MRP,7DQZR^FP^3:Y>;GV%$!1#D=M=$X.RV=6-0VQUC>0:9TMPH*2$NB!7/Y_=
M7MLQNE%8?-A$<7K&<&_YHL>X30H$=G:;K@N=QQ*VY*_2#8WOJ4O96OP4T.26
MILU+H>Y<Y";:2025W:G.1,1&W(U^X]UKAH6'>QP/D1 M"$-E>7F=1@Y0\I9R
M(41<"+$LA) :/0[Z'&T=;M-OWKY[P^T:/OG'O?^\29.2C7HS;AF*U&IU& 0C
M;1IGV2:][.*V+IE:BVSCB"\Z. %;<_C&*]IN:0PW$B3FZ*H*Z>TI^>2G&S\D
M4$_^ &D=44R8YI(PBK=L5K2CT,&2[5;=@QO0!?'7)(C"9QJ_'L6,ZSS9N-(2
M8BD!C^NF=OSZ_C+TZES5J(Q*04F<:4@L,?W>87!="@<4%+S7F@A21Y3"0^K$
M*6(Y/-%G/PQ!]\>5AG+IFEH.1QYCYQSXC;KD,JQ$KW<QW3F^=_EY1\.$YNMW
MY8!:L>;KS42Z!AJP+\>M&M,01ZU=J#>U@ P'R9"091&Z5N]B[,2K4TJ "B2)
M%+BZE9L:^W>D.M=4^&VYU6KG8I_#ZN$4]A:E3J!]X=E_'PCH,!C170PA?'JX
M8XRDS(O @=<.EG6VZ55ZGL8IR$U,A^'J.JD>C]@ M<@V7Q<$<,*A\X6Q@ ]'
M.;96Q"E8AB60YI"-SVQZV^TJWWC?4$8?WP2LUA]9( "N1"&@MCG(+5>+9=ET
M&R<@MET]NDTUN8!..'C"X9/5FGR$&!=0V#'?J;@..-?\N.LL6I_MV3_,UU_%
MV>M-%#X_LJWS\>;\-@H;CF&U9B$UTHYL%X>S[5.PG]-VX,!4>0%%XU%,W>%M
M&(5Y@#GQ6>Q$$B& @]0<T#(\9W8/::WH!.KC6DP2P7%PB\%O8#G"O6;^-7SV
M&7ZQS681^^5G-]A#E;4?H\C[Y >JL$%S*M)ETT0 <HBK,P]QI-N)?.-:T 62
M[."6IQN05P4FDJ/ZQD[D.[44G$P*UO:NY4DU<W9NXP&N:BQR>VYDL;)'K1N(
MV&*;Z37>G<G7*B5<2QO1$5D4ID?.>)($@:79XM5)XTDW?ANK,G%Z2X+8BHX(
M['<O8O,^9*"+$(L7(#>^\^0'//=V&7J\UN\F"CSF)$3N;\OCRP[3D9M35T'(
M!J<[%[%)=F;!>%-6(N(W)S(JDF6_VW[=.9TPKI?OKV^N'Z\O'\CR]H(\/*[.
M__[3ZN;B\O[A:W+Y'Q^O'W^U[1;T7F$W3IB/Z6N\QU:/GH=Y#_UH639H+,^S
M1V0W9S$H4=AYJ)UG[-\Y!W5^>^M@Y*;9S&3=0Y3J2,0FV4)P[Z<F&5P<STK&
M8G(GX YX=\E QWOJY1F%IYZD[C!;9Q)22^O&='%QV3H#^[VE/@/F[_NS2@8O
M4"Z ;?+@O@4>CSQE=S')AM*4>$Y*X9OH*?"?.;D)\<6YB\<O+#(=7_!_2,L.
M<0.V<?37/HQ+1&*J\M%*]I'Z[8JUIROC_Q 9!BF#N29FL7 %-AWG9>*RI#_3
M'IQ,Q#$_4+$5CP%OUZ$;;>FC\UFU8.B,1[I6:+-Z%)C5#\8=F[70W-<B!6C"
M8=M_^CL2LQF3*< <(50[CT)8OQBE[*_$]_AZ%H4?0_;7'1/3AA&Q?(XI+S]Y
M?-QO!@&I8?801Q'1=9N./;PSY*;O(0A/NHEBCUGXFD5=;D$%_%F20?9 !]EE
MA!"GH.0U^> <(/X+]AXM\E9J!JIR6>I@3AO032SZ$AVIX",<(<DQDA*EA5#/
MGDSJ].[^;BGTY_R._84@@;\PG^:0J7424O?<C6EU#O_Q#,01E";A0V7QE_[7
M:B@U&=<BB[]A,S>)$5_0-85C"A'G-=NN:BQRDVUD4;;4VH&(#;297E,-S:%F
M^QO+.YMQ>/P84B<.&8\Q?:'AGO*0[SGT_V0?B?5U'_II J]K\A%;FFY&RK)N
M:!>-5 R+_%W&\*?V=W'&*K^SO_!?6.03>NT']VWSD#JISJP?']\W3L*^Q>O$
M@\U#_'031_OG#?NODXV4CO7Y/G&7\T 2WFK>R[AX#:\2&8"(&=<ZH&[*4>?O
MYG=1S(/ZC"+Y:N!5_VN ;^S< XS[<^;';P46D7]$<CR6%JSI!'"GT#3B '9+
M1^>MEZR- Y$ZYW;FFK.*$,>.(]S;3'8CUY;8.]:=5.&U<6W:6E^@- Q';GAM
MC*IW;[-XBM)*\F![.-LO4D;CU'@+D[U@.:M[P6)G5X=!*OS1?8^]W5B'RNVO
M[#3F(7=VVJQKG"[/POWITS[\&;-MAS@^[^73^0C9F;,4G[5'</CMMH8=Q;8
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MN?NA31NT+\^QR&+JZ5H U)?E7"H<V7 O0,!L',P@TF*F__U,7,P5D_I@TLN
M?7$.1A92/_\"D+XH]U)AR()W ?QS<2Z#R(K9_+_.Q;>PL<,)3P#[\GR+)*2>
MOH6-_;)\B\R0#=_"YLS&MPPA*V;S?QFP[).:BUSJ,C,L](KVSQN%XQ@$(%+G
M,9RPBM)3O:!A+U,U#'/&.5M%?XW*C0K<I#C"I]#/;K"'\C!D[8=.Z$(S/OX5
M+WSS'$7>)S\(%B1PW-]AU&YS2'B_ST1T[W,I;]!'>%\C*BJ:T]Q/I1%YHG+[
MCE3PQT:O^1Q^ P:W.(RD((@^ 8:LPH7\[6OF^H!,FHCBN_Z64^>$X9Z-$(U
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MAJQX\?KD&J1N>PHIUCAJCO:,X\7LF>WHF%J)[!R=9:<"O_CIYGS/"-G2F.]
M&@[/FJ<@];]=&*X<H#6,1[S-UB+;_&8_.TH"Z"0'+W;6%L_1)F'98A9#'8-Y
M%<E#!Z'(<V9HK2<LMYEK,6%F]GI*]\ &6R# 8[ C\&R[#NJ#NZ'>/N#W=0'#
M'\%-V0L]K63B*KZ62XPT%5$=!1%R!S&><&6O,CP6Q*YH1&9-;3DG25S.2UA)
MI3[/4M3G<54C*L5Z5+5GI_%]_^1"[G&P=!N].''J)U"M+P[YN8(3W&V<>.NX
M=)]"H]";U%,7)>@X'ZG_,Q9%<9+493+V0R0C7DSM)$=&*MA(%1UA^"8^ T(@
M!"OQU05]2J_#)(VYCC04M:P=B-2^VYF3XY/348CCBP9B3;410)(2ILTBEE7N
ME%6<-(;/2C/K:S6UC9V-E@Y8D>E(5Q=#5V7*/?-ME-+V**@R"JG&M;!U$M&4
M0^82M]10;!S%4W</=U9AE$JE(L7#\/U30O_8\W^R#ST1ST-_35(LYTRS:)S=
M>3D)[[KY%5!7EF?\RE)8,Z","FX!IJ6CW-Z;OIN6.E(#HT#J&\84:/5<>3CX
MB%>]4=@T/\$=ZA#BQG8I+51R+5SY.'?Q+S1^BF8D#E& &-J.EDVUI4R.(9.B
M"LD_TGCKBUWS7>Q'\2^QGZ8T9.L1(^:.LH^.L^!-YB/UV<:B*"*]+I.QQX!&
MO/0V?9*6V,@.T)%/ A]$C@PA='QG&*&-//GZ+OPU_!!>/(8_L?\\? U)+%N'
M;5T@F85^=K:[@"[8J#>_?O_AS;N+KUD4N6.RHJ*>$?1\Y^_'7)Y_GO=V9[/!
M:6^C,-TD"VY[Z<9G0QD)GG,8QS<IHTQ+OX*$C7!T),-'!$(B,-KHYXY:+8?<
M+^]A3[%:,U:X6C.WM7H*_&=.0VU6:NL,S'Y7C]UR3]TX'+MOU:3>>!_)P8-3
MVY4(2%1BF'JK/ F[JS61$! )@P4W9?L7'M 1W<612ZF77#%C_;AC)AOFJ:IU
MC#>.QNR VMDLG(]Z*';'HT&Y^9O>9 /M\CC\K%PD"Z^R#/2B-PSYX!R@H7NP
M]UAL]K1/B9_ &DH"?^NG_(!O0?:"M"([>0'1V5GJ;Z6"E!"8N0SG&<1QL"R#
M,52K5=*IKSI'%&\.F@!LD@'/D]<M.+C1-4D *WY)/)6XR[=2R] KR[..6H=;
M!R=FYSJ5R(>JP=V*$+NCGXQ_+#6'I7>#?&4H:):K;_/%QPF2*%^!R"Y*X745
M='J57\(<87(9W3Q[9JZ5O,?_/8>IXRT_GH6S])+461?Q_C+-:< E^3XZ. %D
MPHN#FP_,W!@W=;^$<B3FY:^9O6+1JA^&?:EIH=I8HP6<[&"-1"]L&_%IX[L;
MIHQ2[S"V>\BVO>6#V#BG*-M]P.%= BI>;$/^68Z/1_IM"K"+["!X03+0%GSS
MJ#P>BHV(^0'OP+E[UZ$;4T;B!17_O8IBP;GZ:6PG $@=J;DPU!E_3;,19T,8
M,#%85F".C;S*\7VS&/YM[=^$$$+*_7K3E?V$LKBGWE[4\&6+AP>"*0]<1TB4
M%"GRRQ_;DR5/1B(U80WV3I(FJ\.PQT(M5/=.#!1PR?)'2\F.H_,UH!W])_N?
M[[Y_>]P>G.W KF_>/#KQ,TWUN]GW 8;9&GL+J3!88TC8;;H_8Z;F\9^K#\LS
MAIH$62_Z:MXT0T]2CO]TP,3^P9Z,?J0OT>_^G_NM\T0R%&5.>":FLS=$T' Z
M8DA_PWZM&ADT^)26":C]A@ZSI6]H&HW>_K6('T=_*X\@IK9I>WP/:)4&:_V\
M5_2NZ_;,5^>QUQ>^>JA66:OV.0GG$ZR;Q^1+V?1WL5\*2^9=8PYF&]5EN3#2
MM@G8K52;_GZ/)6333*6>2SO ,;%Y3L:RE+4ML<QQ6#B-'YWMQ^/?=4175&E?
M<Y]E(NEPK9HX)Z?4R+S2,]7.FIM[:F9B.!]5:5%D*VEQ6N9+;U7M%GBOR/.S
MX++L_OI3NS.X0+FG.W5&MQ&4V3NZ6K%T\WH5$%^$"ZSGR/AUU182.2!YXG1C
M56\;4/HASO&+G*6GJ8\Z+0A*UW="+XHGR*';64L+MRB=-N59G*J.G;JK&X?)
M_3I)]M3C(?$=C?EGBAONIO%(W:PVJY5BIJK!B#,QVFDVKI?#(1,!>B&V<Y!L
M1?@7EHJ#CL;M':-U UDE?$='7D&"!11;B!/(NR()(/EFP,CH(8W<WP4C%_O8
M#Y]%E@CO7WI+/_%O$DC4C4(^M,[5&<! :JZ]1%+$1%T!8(^(C/DQ3J'_8P]M
M7OSM+LLIA2I716?;D'[B:=AL14L '?$Y:<3CM/&Q(D7Q->1HP>.&1-A-DH]D
M1N5 [I(OWCOLGUC8Q2"O*0< KQY(0IF:>$Y\./YZP?"+-GT,%G]LRMMU3AQ[
M3?Z3<"B9$R8"99;QFG5E9EC%U\F"",2$SYFZ@HT=\5SGRL [+Y>ZN9"Z,MN+
ML>IN#VH'('7+:F9.PB8,EP"M<=(PY[\<E(WC[1%X.0\B7N!)./2)8A_) =S%
M=.O7O[.I'8744%K8*B*4TR'88Y &BLVKUTDQQ$X +0]8X!LG.''H$Z_SX[$M
M%O0,J(7SD8E^T!'J$!V?[#26(*H;C-EYM#)Y4GCH9"1V5]).>/]B-"?GN+8J
M#8W&Y&I]F@MCL[[0M+_FD"4GI4J6 F4=F[6C,#L2-5MED<B3(=A=1P/%_;5,
M+FG*3S%*=2,0Z3NN>._KP;/<B=W)"(S+(!=$ +511G&JG]3*]O^>OM!P3^\I
M=$80YR"G5=@4VSO=N4B]D)$(Y/,$K8F(CQJZT6_^%I1C(04:1>U!.T<44\D@
MYWW\(H2/SN_4<ZI=H]C&9^>$AQM1.$Z=S]]A+E*C-A)!$7#H3L0>AG3FPSC%
ME",Z[IR6H2(9KHE#D8F9'_2\L:B:'X4:SV]:QF,V41U6I=-(]6#LIJA%N_FZ
M4I3983CVD,\C89/R?+8<W^1GDR.R7@'>[[5-?1"=Q*D40+-_E<$S^P=4]80:
M%ZOX@<8O;/M?T[6P81A2TVQC#"Q2-09AH-M*:H\2LP"4K&*2@1V\8:&>^D&[
ME8R"I+9+8=M8_(JH9O%(&T\'XE;)!GK[ZB4\YL] #QB>?*!_.L]^ZFR=)W5,
M4C<(J9(U,U5$'R<CL(<<:H*-*PR6$)ENI?Y3Y!W(J\?EW\^^^\O?OIDXK!B>
MO8R1 4UE!3VHED)2/DW4YJ(:B-ED&IDKS*9V%';3:2;:5+]6HB-9;C@I=3=A
M%$3//A1:)I>?LQS$3 W)JVVIX5,;UP0"\,WJX?8^ZLXN &MM434&J1DVLB0?
M45<&( R'FNGL^<YEVD8(=S2^\!,7JN\>LCCLG,5AON>DM849^H-$JIQ#"JQ+
MEX(F>-C7G:'8FZ@H.F1;>CDQT,J&[SK<G!Q\%?]'%9YF07]XDE000?*M6D$&
MSEK],]*Z$9^#9[T(\G3$[ F6Q@F]*2#,KKV7<)3OPK6@8'?C_9@:[EEOWHBB
M3';-7PW:*GMI5S+5,I?5!.=<,E,4[+K_\]WW?]7W%M7A<_()-8PJ+5\:.S?[
MKB-]."N.:9#WZH J3B\^;]3A)$GD^OP+7E/O_G\R&BQ;\QAR*( O!(LCFN5M
M%'(.\H-Y?0M5SIR3L3:SK[3;^FES,^$6+J:VYC *S[BZY_'MU.\")I:/9.6W
M)ZP/V9J7,@$QM7BFT&Y,M+RX#J_VZ3ZF6?^:EI[AG2%@=@%FXBC;^G::CMTE
M&')C?$E;H!/%=;(N,7Y(UAQEUI3K(.>'BC9T+HU3AXV#R@-^]KEHV[6A9>NN
MRLN J=OZ6A,E[XZ8B?(Z) (ER5M3V6UQ/@,%F[J67J7_XY4?.J'KA\_+8F'4
M69I, 6-VS(,*KUL1OC:HV-WXL$SV+]5WTF*]MI?H.J=!C@I/*]4@K-PWNBCU
MB_DMJS(MB"$E-5@K_(TNQ3MC-1QQ38 ^=$X0P)_5.P>]HM'-T^?DWS4$H?3B
M#7/GYJMU6.GOD?T22XUWQN9TQY1)S?9;0G=\?8FBUO28XKAN4HP1W: H$]G%
M\YW,F).SJV=7Z=^JP^?FTA34]W\S+C?U_CJIWO,QO% 8L5SJ<1T/C"RC&J^6
M%8=%Y,=&TXNLA&4?M]4[QY+?J6ZB@&E=(HITWD8IY9\^[ (?0N 7]A7$OV!(
M;XX$U@,,4C_85S"5^H4=82#.]S1FI5=YT@SAUR2K'PLX%UD> $<+E4ESQ(1C
MME0X<6KQ0!D$1E.VBB2 8\"PY_]WPB2AX7L_@M3WZ]!]K;YA;1B+U,2U6"R"
M'-5 [.%-*]VFJI<!)AEDV(BX$X<E4_%6RUJ?!WDB?U)L<,N<S9-TSH^[**R<
M,YV+BZ1SA@*J(URP+X)HE^5EW=/G?0 T'):[71R].,'E"U54,9R< LP^P,[/
M4;Y3G!0]=G]E21I]4Z$=<5@E93W7Y$37'> 6=\,9W<0K">=9CW%!.G$RV@GE
MQ$_]?G.>OTQVC"@E]->D^P/-E=N(U9ID9).<;B(13ACEI"2=Y+030;R%[>I,
M?QT;=C-2>E*>$1#>TO3!84R J"%GF8WQG<#_4RN111L*YA757"RUJ4IZ(+"O
M;#TX&B:CI$@?"7FK$ZB"GB<H'6.VF'XTO6B8KR_RC4+"T!*.5RP*)Y@MYR'9
MUIQ/41QXGWR/2CK$1E#FGHNG7?4Z-61IY?7:WS851#P>@-E9UC)3UE*6O\7N
MXNJ)-;X %M F+H@\!0L]5/\GRBQQ<^X4&8AW3IR&S'T\?HJR,HGY)VKS, &"
MV82,A5*866<(V$W1G"%372\Q%LMICH%<7R_(S>L[\NJG\_N[J6NCH!3%@"XA
M0W$-M\MLZ[1T_]C[B5\IWMC@"SK-QNP$NHNAL'[]J=C-WH 3X[NG3+-S7$1"
M)K4.F=C8+0@ PO"&7BD]+/O*CY-4@R.U=7>&@-G"S<116'FWZ=@MW9 ;4V7G
MZ(B>S4]L\E8E437^(1LX\T:UO8R_.PC,UF\HD+)[<[?YV.W?E!WC3!R.#Z<'
ML"R+T7Q W@--)ZBIDTO'^9BMWT04)RT-=29CMWLC7OIGJ>9'P'YN]XYD]]:[
M(4XI#.FZH&7K8[%KXL3:,4H#Q;S,W5V40GZ\$RP]\7S>"4X+WIW<:S_LJ.NO
M?>J)]]KY=4EQ(5[K,,='B=G'3B3PD^*@(^'#[LFG8K]W?<Q=3B!Q"@IK*SW6
M)6HD.9UY%8/RWK!(]9AZV9B-Y L"24EA;9'2N@2F@LZ\JD9YM5W2:K%\*7KI
M#Z3W=0HO5?4X4"<><MDL4[[X:]B&WL/*D9@7J6;VRJS:VF'8EX06JOL':E)V
MG<  /8?)IXWO;O)'B'Y2%O9-H_Q=6G,V7@%VZIS4<>0E98@*N!;[&$^O$D,F
MZCS3<)]<AVY#JL[)$,S>1\%0F:Y3_1Z[OU&1:YSOPN%9> HT#B,#6L)[/W(2
M/WF4>L@TFD7+>,PVHL-J83!-@[%;CQ;MIAJ8 2<R= N&-06/%E95&VSU64?C
M*(QBIWDA/1V#V4NH6"J7TJ,!V+V!DE[C-4@ M/&R=BQ>+%CZ6*R0WP0\H]ZQ
MJN=$3A ]^=$:6J _W*A-73$.L[DWL58^^JD9A-WL&VDV+_Y7 EV0A]<W4S_(
MF80I\K\5)C2!6QB-PP'=P<]^[+BI\[BAL;.C^]1WD^8B'&T3,#L(+68+3]$X
M&KO+T"/>5 DSZ$0&+V((\NJK[,NOIL[!GX3E 4WO[_LX2E@<G[@^97J;+)_Y
M)Q^3F\!=AA[_1W;'?K4//?ZYVBY[0<-LM/W%5%BT.2CLYCX 9^;UH7:,)7YL
M[X?KB*UU/$5E)Q[/\[*I$>$$$(E LOQQD7WZ\8'<W)SS!_7B@SSU!2@EKSX^
M? /?3^Q,+ J4P[80KMAF>8S=#CR.A/)*]TQ#F</9+!M>*36,Q>P?VUBL//.M
M&XC=M[72W>?E+*^]E4,FRX<%<<AM%'^BS[X3DJ>L.)<;;7=.>)CZA&1LQH=_
M(-BA_VGK#,Q&I\?N\>._F;8NU:2^[QLWZXU()^)SU+:B;,=S2.GU=KL/HU7H
MPKW#89DDM.EYKL8<S+:HRW)AC6T3L-NC-OWF->\! ?$YAK,H0P$-">GDZ?=3
M,2LPG.4HB, Q9,X<C=W?JWQDC1/5EJDQ![-EZK)<9M2U3,!NF=KT&V>- 8(3
MP\R*(DV=&#<-L\>&F>'H7<,^H>[KY^CE6X_ZW_+R]>R/LFH]^\<_;NBS$USR
MC,7E9__X,4?]"*3FV, .&%_-UP@KQ#=1::IC'!X1 ,EO -+H^*&C9@E\%\R*
M_&,_4O,U8IVJ8R17*/D[I-I42Z)Q3C\'-OR>NGRH(!7I*VKS-6QD6B<B5:SN
MS!]OM)MG88\BNC'1;SL*&7]94C[;D_(.0+'_O$GEM'SVN0/G^1D-=G;EDTCC
M(+]WDLMW2C4[+9S,6U2($V5X)6O#-R,4(LB:(GEY5_E[&C@I]1ZC\OG5,B_$
MP(C-3U-J6Z0- !.SCQQ*9"=%#$P!8O>L@_'7_TE,D)&0;][@L1\G HQ->L3'
MZXP7EIF?D4[=@!*+X%9KDI.0;P3AC:H0W&,D/3H5Y?,+P1646"R88%MXVEI7
M5;HADT]SEN1RT\WE$MJG8/;0F@R7V:G-X['[5UWRC9,?<_A2.%IY7SCUZ?1T
M#%>+R5M]7&__5Q[#)>5/\D_:F304"BC*"T@M3:1^)J%75LW7]')34C$+QSGY
MSW+JBR<C83;N?7J)]/<E1<&!FNX_+74VRB(=4@>@1:7]#PN8RFX4\GI$/CCL
MZR")B!^ZP=ZC93LA^ZO6''_'HG1*38^MEFHU9:D;N<^6W&.+_8PE^4A6V3G^
M2':,;8P*-YE8:X^7Z@9A7E253)V6M,E'8%^2U 0;)T>*=G&5JB69BDY]ZC(\
M<Z7/S$':+#<SR6\VH%,X=Y*-<+K4NXKB:H_#*$SAA="^+=0W 8+9J1@+I7 Z
MG2%@=TKF#)D: & 4"^LN%?6VCGM9EFCMQ9V6Y)*CY')95N4BH;4;[LU&9R9X
M-/#X*>K^;D">A-E?:C/=^GJ@F('='^HS8!P D$34RX^Q/R88CN>C#@'#/"NH
M)+*MG>2)8T[B5&2RT2!-X%]E.AO[QS_N&0.T)D7R^#ND9EG+ EA?Y0N$*6SU
M]!GG?P"DH7(@.ZE.K;,__1:[^IRZ[Z.O,*O04(^< -9DVI.U>%?JS_'WB#6H
MEI5<ARI?(M6B>AJ-#RH$M"$O^J3+RM5.5-K.$^L@R:W(MUB%HNQWEJ[1W/YF
M$*A(U7)@L947:[U!8@]X!^30^"R^MKLZ3^>L)'A&G#Q(_RECYK)P?)8O9*_[
M#BY)KM8D)Z*(NP499?B]"O->"!DI=KOUX!(@4\52X0I]JV@GB1JT;[Q\XY+?
M#M[?  9F7V\J$E7^<"L ['[<F)_^F9I*$R#[T(,AN1\JK0BLQVY>\&0"*O.
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M1#,S&4(>BJT)4=!N/2E&W6?%Z&16U%0"H5SB<NV2E5 OPFEM+ MH.W,MB.2
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M\%<IQB(V=LCF[#3 +!&M;?9F^]ZSPZ%1DA&K(6;"),VF:Z83ZD/<0[4" B>
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MGP7AKQSX'KC&(+$P_L!\>+V*QX*76T;7\D?F>/?K-6\6EJX#AHZ%U/.-J B
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M37P:$R^((KBS02*AR6^8+_\5?6NR< J-Y<MLMYS:\M5A'NQW/P=RB2068=O
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MHD?XBNF]Z ^%>]'WZV/P1G4Q>G)S'A.NRY(VE[L@\>/V)>PJ^^$&ZO:B-V2
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MU#6$9&C9&N&H44B\8=<UA*1#(744U2DHX@C*Y %0IJ R2@:EI)!@U*FJ3AL
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ME:]&)=.TWSQI+.G -ARI53,9)29W'5GZ;!:DRY[205RT0>X?N!N'86B8(\O
M]@@/V'C#5NA*)8OA,/9AY5A$1"_RM%8<5HHV!T>+VH?7C236NI=H_U@[A878
MV3:[ 3B"--(SES8BD@_L_#OQQS\9'VQ_-?]AR 01T2C[D$) 3EAT8.PUB3QN
M@.:)=[6(3]E6L[+1</3>0-Z!^:!B$.C]1VOT:KRS&%+Y_'#(44]4K3XHZ?TE
MPRY<.S9UK,6).'B.H@NOOMKDIZ? -5>&AZ9+%X7+L?SNHD8/PR&%*N$'YK/*
M^FH3=#_X-H3?:#B<:2"O5F]5^[/,3?S1D2WELZ/TV0Q(%T?=1UPW)H6XF%H]
M5]+A4_P59S9UXP9OB9&TY]6+3FZ[X2B_F<BJ_%U YH[*70G[P>$P0E)&SFV5
M?71Y9HU@Y4$&ZW'(=%#AL9*2>V 1UXS%4_6A5U6[H9.F'@"P0BE4SC'5D\O0
M&5$EJJJ]*9#)A188Q7ZX%:<I3,G>W61S@=-BZ-R0%7U@&U3ITU9!P ?(%$G)
M!Q9WD=VU\9)%2Y[, G1, /K<]=&[E"Z+9! 5$M:IF9*I):Y=S<T7SCTV//T+
M23BT([/Y'$<2/!F8[,FNC0WV#59H)N/IX5%!1M"![3*>D6]@&\UO#=<FRR9O
M:IK!.K!HD3NR=<<F9F>*5S4<'D]JR@PK&U3#@E-XH3D\2@C*J&K/ 61_6K4N
MKQGG"9 >FN([M4XMI23IK#SJ4XCR"OG8W*\T*FNEGHG72IW\)?.*O_YPJ)T*
MNW;JQ4EWD1$::J<FXHRH=FJ7&I30"$>-0N():+3]<'E5M5-!Z5!('25[>#$1
MP13;U%8[%8(R!951,B@EA82ESBMI=9:V&)HZQ85D^MA:]XS:6^3Z-$%70J45
MK8:CUCJ",G<T/:UR#$&!S=8]?+E 5CG.LHWL]69N*,X\=-L_(3>\@U/H*(O5
M&*Z2^?JJ.M62DG=@U9*S2$3WM$X#?T4^Z,^]RX%+EWRCH=)$2,Z!91V7QS _
M$SS)(#&I'I=B-J6\Z5"I(B&MUI.RSR#LR;WG!5*V)&HP5')4RJCU)*QK&U)U
M3[I@JV&3HTI0K<%Y'3CK]D$FD@M7@999 $][S)2ZPFJ-T.N4+8+K54Z+0;)#
M2$BMR68 6,%==3">'C ;. *JRCF#RH3JQ0:OR8 Y425E3(S+WM]$N_NE-UO$
M:5/DKV$>Q)J\9H5L#V_1@^-Y40:>8 #&"?^RVI=7\C]?;A]?7R:SN\GLZ?9Y
M^GI/'IA,'V_(DU^>GF__<?OX<O_M=O*7A]G+RU\G]X_DU[=]",V(<,HC&/^V
M,DI#K'7K09Y;9 >HZJ:X_&-@[$--[61#-P5DT^ ![4;3=P0VF@A%)?T5^ZOK
MP/,)0.ZNWBPM34G^;_YJO//)(-,3&+Y(*9W)E<:B#RQS)(;ET?%9R/"IQ&DX
M,.;(2CJP+),$O(II9F!*+Y=':TQOA_<^Q)?@5"TIF,^#4;Z"M86<D!H&>_L7
M2B("++U=\X9PWW+"FT]BX9F#GM,&#!GJ:;3,),A*.["UPB_()@A:1/[I?(UM
M3-'SR6#BDZ2BU>!H4D?>@:T5IFO']?&?H=:H!<Y>D<'@";]1%K9/!+:.LXB:
MTJ2&N+!*NJI?=H@N-P;'!3$)!U8.9R=TM!:CWLPJ NR?!$,!E2O-"O$T[#I:
M5OFC8SM989-K-_D;CLIV0Z)#/6$5&8<M<M^<KK8@9!)$1%7)DOH&O;$(4?(D
M& HTTV.1#Z*R-MUL7$8,L-&2'D$!F"!^,;#M46N(O)E]^TYQ#+"WBD87AQR5
M[09+E7J2#ZU )[T\@XDH:XG!;318PM006]$J)#O1=,F7_:HK<>]C.R!0[ _>
MK]#"<5'JW@TRM%R# (%MP_T(0QIH%5-Z,.!85HAB9+*9LY>V-X)AJH*%4-LP
M:2CGT@F5"1+Q +Y"-EHPBSTQGAX>A<1$;!IVFET_O7;GR7]$?N66.O/,D#1>
M+9B&6SK;CQC,0T+$GBW8<1^<%D-2OJR86F\O:-^AFN'^=&M@BR83OSJI0,JX
M7M65X6%3Q#14]S(D_J@075$0:J>.&'$<;K 5^,RP=>E^LHB>$42/1T FGO")
M5^>HSWQ*2FLF:3\\\U/Z[)!X(2Y@HONF\0.@=,^W&(RGAZQ_D='?U#?7*0-^
M17BY(A).R5<82_08T,HRLT4AIX-G%:3Z&!);F@N><$BMQPX&A^*Q(YHW)=G+
M"'@D)7K")!V'C"UG5;&K&U?D4)W*Y%"]O,ZN__F/V</-[?/+_YS<_I^O]Z__
M[D.VE/#M,X)M^E;*%L90K]:":"W;W/@=2)3A3N(('&H0'9L.;Y%*N&5MP)!
M0J<<(@B+"++&L42UQNK*A9!T*:R6HFJ%!54TTJVNW-N)@Z2B2&?NN2P4GX>A
M<S$I%<5P=*-PQDT]7.5SVPR2"/(20RG4FK]AAZO8\H<'J5$)416%=W8SOG,0
M<>O;ESX[2.V+2\H)3 &P^E9[!P4DY=9:=0N)![(DL\:+#"!I54A!)0J6E'4$
M]QD,1JOBLH[H6H,!:+>.O% 6S<IN!!J"'L5$9"Z2^WHQ!235U5H,\>4:V*V[
M][;I(H-F:$7_>V\7/?C/CF7=.>YWPV5%0$CV I<P?-T72:-"\,&=<"BZE!<
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MZ$^'9B20U=(7M'Y#^6" \H= J:P&IKE]KIA\BA31^DQ/EI3HGDQ^++]Z[?[
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M9TI-B+0:DF-0)Y*1ITWV0/)$R8%D].[#>>3A/%)T;=&A">O->63UQ-?3\T@
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M2H8B)V7@4D0E,@EC9_[B&ZX/8/?% ( ,;3>\_.H9>8%%UPSA_3.!2_7Z%$I
MGGYR/,RKUZ:F\P-WI;BK MV!A4KJ,J%CJBFHPH8J*'"<,:*W-H2\9X;\KRO#
M_]4)K/G]>D-61+O*BZ_<2Q/J=9;%^G1DY2ZEJ5D'3:U%?-JOQ?J""2H+;!KV
M+N^8-9^0B<3PB*QOU@>9-3S\9J%(78E:"3)):2161HJ>MQUH7T[[-N'66LRH
M_>MPV(NJ:*O[A(AP/D;>U)XG-RE.3=,-$,L=T*#' []E5[[U(%54FZGRVAM=
MSLSP2I1"/;KD7I08GB?+L+U;;[.1<VQ>%N_F#5\W"=\W2;\PO(DN?&7BVYR$
M+R5-;E^>GGK@YTQ+\XPL6EB'5O4K7 $=#_'JQ]N>U<T5F@<6FBW*2Q1.79=.
M!^'E]E<?^V?B"^^G= SR(K^5]0_&LHEJ/#.]:D4!UKFMFA1F*O;M'P'YA'TA
M=$[T)+<-&.JT0X<2^DFC(Q"1WL%M$-FOYT99ECX+CPC2BBDJ5UQ2*/%ZY%O7
M\:ULW)"]PG/@]">.?5%O8M)!T1E=EM%P1(X-3C\"3E-MF]Q*,$!&M"=?S36M
MV8? :;H2>;:R]-M.5E#;=^=UY00>V0[=X86/D'V[WEC.!XHV:D^!:ZX(&^EW
MLB/5I3L!JSHA.ZI09BA&MM(TL2S30T7(=/..P7&E]36T'@@'%IJ=6M1<&QOL
M&U8(2G@-D+M%\SO'O0M\&DWG>0&G^K-T/UEP/Q%P3SOFIQZ^<->1#:#2?(^W
MJNCO?83I;)'&=;:XM?"2GD4D]M][=1+K'^%!'K']:+6>X#7UJ9>2.IQ?5ZX3
M+%=$#T0,ZX98%K,L3*63;Q@?M>' W(L;OVOK8T9O/<?V,HKQ*>.ZHJY'2F&=
MZ&E=.+1_TW&(PULU5&]YJ'9+?!>;D:5(AGSYM>#Z7S@^LG>$Z<!NR:JMIL>
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MST9QU]X'F"Z]AO86K4*';O,34/S/]#.=4B(0^F5DYF%W]>2YFR=\0*NQ[Z.
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MXZ9W#=6:H8?4;5B&Z K.5MT5B86!SD<(P\G+U1CR9I'V.O>F[FZ,VM.D_9X
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MX8R,Y8\K@8W6=1>H+3@S+&</= 5S#D'6X$FE3(E3D]4ZM;HNG3*T6XJUH63
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M@?*:H!^PYN7:S(^-A$I:2#D18^#Q\;>#UJA9O;TNBP^?W> V^*/5F0(&UN_
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M-8)RG,\4_XG18,,BJ<TBDEI$4A\927TVCO=8P3$5B8L'&#IPG)+V8O<C!P6
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M8@\#.MD=VZ72R^QM,^2W0VR?"<1XX:9B<J(':H"72O?!08F0DB0>Y0E( M[
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MQGGWJM4ZVQK[WCX/Q&^'Y2^'%-7$P/B;@B.O L3GF(AKN^S6=O&R[?V"+Z\
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MW]C80TP' ##!?;?L16$R+Y"+.J_V3F4['AJ/*'4NOAA$@/R>/UMR(/@8('R
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MYEBFX5VMU.,A0R]>!2I0. 'LC98<IXSD -2G **6O;F4&Q!C@%D/@ Z)N31
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MYF"@797S!UR?O)]%5K6))T9J3&M)YJD);HQKQ IL"*IAP&4:$;().'8/@Q+
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MC\7$N[7_C;#-20Y[?PX#>F!,J0UE"<W86[O%LZ5-7!_$O*:GP7TY&\&Y_W\
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MEB+@CE>GJK0IN"VC D1=77PRV^7/0%D"N+P:!1=,;7U)6>JA_Q>9M0J_ WR
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M"1?[(=AI@P8+7VR9/[D0B\UW5:5]* 8^&4FVVT>O07(U"FAGP+=<KCR$P2P
MU2Z(^TQK=F9V*HS]:@TC]HTQUWDDB],M9!>2!Y5A(\7->V 7L+&"!STG#WJ@
M.D<*]K-QH+7B"IFN0O.)AN@:Z&E_CT2!V-;0:;FQS6-(>%6K8B8(+\UX-/!U
M%5F*M59NDN)R)6BM3B:Y:P,LXU,/5$RJ0[D2HS$B-I#-B6M52O&]B^B4,JIA
ME2YDPM7DP_1T[-7IQX_G%6^7B#FFTLBHX";)05@:O%HWE7CN>C 32_/;B<J6
MBKN)L,BT7;D/6FU:O*5>Q%N*>,N+QEM6[NRX$/]Z3@3*W#KQHKC1:9SGG D
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MDO03\9077]4@$Y..HP^J.:TY0<9Y0\T4E[AJ3&\4*<R)0\KP1.G!ESJB8C=
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MC-0E- -,K'"EXPWD25RWKV[2C;H.R7E49^T)1<S-2VSHLF_L$@TKC0LL<#,
MAEN=G &D#V!,VB8;7JQ8&W?T_HT:_4#V,\_4UN#H %FPM>T@=?/N)!6Y4R28
M.I?X3@5_[D#B0GJ%W9XO;\&A^^5=]"RZ'F6N^[+#(D;G#? ',?S-K G9N,>+
M0EC"R Z5^S#;0HS:@5&)%FT8\#B IQWN4^,?U4S,%UF-X%[;60A)KXN=4F6F
M ICOFJ8G8GT4J+1Q@SO7N]22"\G,ZPD'FQN)(%7@AO(+P"XP:H17R]*=)$@2
MJ/B65*$<=1Y*$TV)VA2E;SV; +K124T$R'L4:HC=*DD@2;XS:JOB*Z,8? /D
M);$SB1LFF@&.JYHVW,G #,J6;1N,8WOH#I"**!& THE0P: B)NK<(&O=0)R[
MI?AG"\.(U'IK;%/TU#>JZ0;8)@2+DJE4*S"?4RWHJ0F6<M%S99NJ?BO*/</4
M';))OF%R\QZE<N+3TB<&^Y?W7Y<2-HD@CRU[@XBUVR9AO,GEW&*.3$J&4QTX
MDH,K6'@*I02(&@!]W82K)*F-7J#FG]1Z!1@?K,62W;W=-#&#^6-9GH]L ]$]
M3!TP;D1!KRM"G GS3<=C510N4<G,:!6*5:*Y;I2AG6+2B)1;@8$R.G]EHI)(
M*-2%_;A 6"*W0^,.%,E,HI>QL4SH!*BUJUT;V&D_0<6<N([FZMEDW,37D#F
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M30.&.O@&;]J\<;HL)VGR(_B%FRMPSER:O(2!@: 4>98\.[\X><JF$EC9;KU
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MXS1 F4NU$L$%H2_!A,# (7E'DQ2CNNO.61Q>"7\(41GD!<SB7TZ08[#17>^
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M#%MN&NP!4''1%H<K4=WP@;2$"8B(ITK<$#U%/A?^KZO)<\4_&F(44$MPF-*
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M*@-)V7*7)4,-F#7PW:I<PZ9KXV(ZXI+&S/EX5YYF:*!R\Z#<^X_*[PTD0K@
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M4*(X 076T#W="J\^FW>3)LH$^@Q1:N%VM?H7,].>E=#Y8(6&N%I0]'$+8KI
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M*6@Z2IH%I#9AQO%7*#B8-'TQ\)SP;12^\$=YN ?7TDGBTJ&"Q0$G*FD0D;V
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M!.I1T]@*_0D^$F)_1J$;A>Z&,AV?.M#6>AUW6MJLWU(R9>M\GL8$'9^#[W]
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M2'6Q'W$\ GVO/]G4$$.<N!!E*Y=LG&:1HV27S0,NNH-4UI=X%.9]+XAJ JE
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M2K&Q0[D.#F0X==M1,T]F9J ")%#&?!6+2[@^-@.\D;C*A!0866-3 YJN4/J
M!!9)">;9==\8S=N]V >KOKR6+CF <>A:Q:Q/N+3)AME%QWSR#=^M^0Z0B5H.
M." (KM\JM#!HA&0UF%\$6L+.8A_E8G!^;!53Q&.X+J&^22AM(=5 I=6&R*<U
MS6E+7'C$;[ B@)YX(+_MTVJ$)E)O/K';*U6]EUKM%39'?8IK%FLA<UB@X"*
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M5WN4K4G*Z1-\D.2F;MQY:S<SU+Q?[@Q[*(:^DE)@;!QW'QO3(H2!,PB3;QC
MB"TZ3@JB5.0F/3>:X[#Y,2&S1[IZT)KZ5M0SK-0QXJ,/P_.4-<14Z&"3.O$*
MS7:@/]I8?Q[,)#"$FS Y=]-4$6W6)(6]8D@#%+3;2V'#P:B0HP5&Q- RO^18
MLY-<RIY:X5.)(T]J8(^[H(]QL%8V&:7WG>SOX &&]TZK,DDUK\.GF>.* 9LQ
M_UUS419<&+2FD#WZ .%M@]4MNHD#7N\&Y?%\)3>G"X5!=P<OI^Z-PY[TRC V
MW2FZJI^O(N<9-[O@79&TM8 '8J /P2)C8ORT V=N-SXO\@CM>^5/>?CD&"6?
MLJ\F6L;VY^F2./]U%)U)<(A91^GE7J"\OS9,A@KB*.%V.#?@@B\TQIYH4Z&$
M+:<4LB8V7Q0_3]&6^/>+))^K2'E>-:<9B'%"/T]T6K#6L'1V"(D.X@K)<W(S
MI3")#(463/Y.IF2I?V'"^0OIB:53(1'&)85$N>Y2M)N45GB#4]@S5NU-P_XZ
M'TC>59R1K(LE/\43+'0:?OEG&!^,HP4I\ESZF(?SYLSP+>2_I.6H 1MY6?$+
MW]EQP9OZYM2,->=&G57)%KZPA6FO,9 H;0Q4><ZD /HKJ>88GYP<<C[QQ>O3
MTP@CMZCG,4JDHNYZ?5@YNK[]&\ZOA/DI&57/+K ,F5=86)Z#JG*.H#?NDO9Z
M(,,0#PT5SRNWP\?<T\1<R0K[2R=[Z9.1S1,F&%\D']0^TK^A&L']183(&26)
M6Y)*&F=+W?%6,7#[=U%(.;]M@DA-CG0<UQ994)4&CM>GD)9Y4K^PT"6*8;-)
M"*<D"3<T);SP^N[?N;Y[0IC53E3YJ+T*4#':N)S7U\N*CBK1-(6HH?:@F=;G
M-9.0+Z.J!H@ 5"&!1>[BK#K5UT5L[ ,S$EFZ7C2>PV9SG6HXVG1Q8%QJ!%D>
MC 6?$D_VM0X&+V 6%V7;(1EL",(8BP@$T\4%D.NZG&6VFX<_"./S:33Y/)J*
M(KTZOGFKG7D"OZYLYV23D;G%B7"Z!:L.5NA-&)82=X=Q\.VS0;+KX:*S5+$9
M+<%RLCLTJHQY%P(3G0<7.WVF@YP1<Y+'!OX1[X'SIYX)USW1+NJ=ZM7-A00Q
MY>/I&E[MJ-2?YJF$1CP.5A:!YD]SHGW7#&(GIQ9<AUW\Z!4Y8&O_:^/JM8^-
M@0EVD]L(3L/]\HJ2T?D@_0-[S]K\/&F<PADRMDYMF@0=6!5V%]W(RYGNHDZ6
MO=5SEYKN&0W, X!99FRTI\S!)8/S<AK0JV3THA7D<X92$!8U\I7HY0W49;;\
MA1R36YG5I:1WC]]1@)UU2.Y-I/_F4C)[F>1<7K.\N*XQ/5W4P[:0';.7U1\6
M(=X'-?H'0T>N'2=$B;$[-<NJ6;O ;C-:@$604</A"$B+62Q%$M@R(>"#C-C<
MR1CGL]LP!G(0-Z3.3V4RP*>Q?8>NH$/@1]\0&YI)$&=)TX&_EE[!S8DY_2"=
M5:*M,(&1-A>NQL45KU))#_BHF JJZS!B0(@8'R6A%T2$B7,IF:.;7$V)B4WI
M6V*I&@D+^%4A$O]W]6FA;&VR'<##=PQLWA7LNM78JY*(,A5%*B@"A2P?97IK
MO$UO;=-;F]:B]2DX9X3S_ZDZ@%3]',5:8C99X6&YE_/(5? -9Z\Z)IK+Y'MF
MQAV2+)\S]'Z5G@UM^:ZK?R=1*"RVKK2T 7L%<P25;Q\B3".Q@L.#;7Y>5AQS
MY#[ZK"X+^0E$ZYSOW@Y DB"]A/!"/=8D]-5AR+4M.?+B-$%5A%_#86LV],:!
MZQ\Y6KAVN6+#J45;1F(YO^>><.FDP0*<3Z,>OZDB)["BKUR2%N0)>2W-T-;;
M1FU8S_(<HP<^PBL]PLIU'5Q7/2: 0;JE388^^=5TL]*VI.LG682SLB(RT]<V
M1JX)23FM&'Z?\8<4+R_V/6-DH:@:6PPHT6<JD^,@,]%Y:5B:63(H:$R5_=G,
M0ZBQ&\*O[IBT99#1?5#4@J]Y7:-.YKPST:%Q=Y,-9Z]//92#%"Q1I'W'5IDI
M1N$TX:/%K50D-SZF3Y\QN,#1L\FNCY3PK@(=DKMPU>HUE!0/!0 H'*B%F02Q
M@DHC+5TK* ,M*?\26^K^(G%E8WYM@ZE*,!RPHTB#''(E(J-P95,ARA1M@;L$
MP\MEB/V\\ UIX 4SQ\C':20FM1ZF(.5=4VR7\&2L?TE4W-Z%41(-I6+"L?LK
MF1R75*'[@?[E>/VJZ)S\>'(KZ'M.86-[2 /W(94WZH6CMT5RCKXBU_.VE*G$
M<GM9-*>XKRZ\BCRBR:#O$QS?DG^;A:@2(801A]@P=YE0HXB%.G6W&>VST_66
ME(D1:9A"G$1&^8$\'\QU:UEPG0PK764N,/J: 7GQS./NY=P8T/.< @*S&Q%Y
M]2@QTPQ75@_I#",(D"S:U$KR<4G5"+G%S/^-K*B5*6N.9-FA]B]:J5D%MQ\7
M7%Q8Z<&9P?Y0JERN\[DV4ZY %<.YLGF@M.A5H?:.7[%#AI)WE]OZUZ+@F(*2
M\66,!,J%,/HMM=THX5Q6?I*<Q;0R(8LVBK\[^5UK-E27JP;M6Y<!GJP_&(F=
MN4-I8P!];"B/\D KB9^WJ K U8%/A^Q'GF'=N3R"8/[ !4'WQF(*5UQI@G+Z
ML*Y=-$7,@HAY8RQ%(FG5#1B\HH+=YS]4W"5I"UF"$09821R3XY":!%O?T65W
MYMV,I,@9_JC CVF.3;&!M2J;(D@@ ]@'[-%R.X:U#J_?$(+P\"GL7X%.P[(J
M6(6L-S0;]MDTVC: :MSX]Y:[#;N7(0RA__C88Z+S#65-([K2 -_C\3P<[Z6A
M#.'L4G(<I'Z;=2S/7\CG._S76ABM3H%K;[J5'RX>=A/D8H'%3HE\\9?L@T$
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M_@2A,"_SG('ZN1O-WVA: -VQ4UU>*Z.AK<'3H9LKE^X -=XY BK_[KQ&)NL
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M%S&.#W=WZ0L]?R)F%.' JTBB\7=C^/1_@S$2AN#P\CX:86P0/4>-%U+ 3(L
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MM*/V3VHX,)+./#H>'4[8V<'??CLY&('YSLE<,2UI?A2!1L?P&K1:] 2W#XP
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MM.V"ZG>)>(.ED1M>6&U79L=@=C3A>C.N\\RO1]%/<+40!CH'F B"LQ&>$)_
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MR/V1>'S:3./LKD1"J9;I"LPID><^VNU("4!YE/]:&&\'V&YI94D3A+2W82K
M ]KLVL KTP<#>0(A7ASB1=Z8>\!EK7=TL6=Y(ER$,@6_.(^8 +G= L/4W#=
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M-8MC8SL?/83W+[< -XOJ $S#!J?\6'OB5F$@Q1U_?^/01&1;U=\A#:6H,A(
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M=:@$4X M&6L1H#GD0:*1;?4?N'SA5@&%Z5M6[9+ _ATTO^+!(P ]%G-)RY-
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M26RO[=G9?;^H(!*R>(<2-205V_OK'S1 2J0DRU)B40#5LSL>'2@2?4#CZ@M
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M9- 1[V\FYW/U(%]/\F507^.4.,D$R2F+G- ;RYHIK^\E6T\)E':37#:@HY?
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MTAT=H06UQU$_QB768MKS&?^OZWW[^('_2>_D^(R&, <]2!Y7D?/1AS8\-E$
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MP'0$TQ$,(?J(@R%$@W3DDL8T&E">EH0CESYA&,%49(_C TZ;B#QE+BA@CH(
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MR-@;,QCL9YJ547%4F:F#^YA[()\VAL '(#6].@&%,D$[/ST6\4W@RZSQQ<_
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MX:;#N;RKVXZX;LRA>@L1(QH7!$?':O;*]O"6SB)C/!33"0%$?,#)=X B3,I
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M-,Q=_?;YW/YB#?:?].% Y!P/!\)X\U->L8%549<^ZGOU93#-VP5H/Y"Z]J!
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MV\/"\MA7FCR3L%Y$/=0/.%9S,Q\ Y?_T!.XH.J?VY0(\=/:CQOOI'GZ4F!S
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M0;$SH]^/KPL_OUVXNJ+R,TH]>*^62R_X>28N#.59Z4%[2=_9_""Y0L8Q2D-
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M/OM/LB5>[FL9=3Q35JVD..+[V^JDP">"3YKJ:_J^OYRVN/H+6&P*3YGNR.[
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MC"!OI4+(I7$O=[*E\:+,#2?KNEP>STK*=HP>#8S:5(IR:=6JB@-AHE;3U:'
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M9#J3RJ?2?]WS)OE'5X:IPU>&;UJ%GW)E^'?:(2CZ1!S)(7U/O)Z1@$1V:,S
M"]9396DROF:T])8.^\A()1I4H7RT?^"6>OB:SW9)(*&DFX=;2B[UY;C>2^<K
MG-!?Q"9/N70^*W0NQM;';7>+.,3C7_E96OD^V\_?(MAIP4S,+15UD?9Z"3ON
MK;!&J?D[A!Y0L_.%JF\!;56,6J$*3CA$@NI=M'3#9PO[.6B%VD*Y<3*O[:HO
MKY.$ 4B4EQK%I/&,3MQT.K_=)#3JL4M4]^.[<@9UPB0F35&%BC#6$R<ZBG,]
MH!1E\IJ0+SPC1=&@K6GN-,[UUN(S W6:-NQ=@>E(RN*@-+;$%7,6DU'?JIW.
M6' &.MH"*.<5C(.U8[[LO&G7<]B]ND);ZC.924HE"6[@>W,W,(PE#-H\$N=&
M;8E"NT'O;SC8H.M_G)L&]8@5<UXH(E=/57T9Q]ZZR>Z&KL>W.<I>S'2?SGSS
MVQ_:VU.TE8&1M@KJN"2L!$4E:E3;ZX/>1WVI;6/+O )#A\81#M IT-3$+&.@
MW&04F2(5+P=/'F]G\.K$($V59* @[]9T(V-;$F(-_\%!1J51(\JFE/SQ]0&^
MN(#R+*:BG#S2)]M519B,H=H';H:W<Z-" K:*/PTXA)#\2\1!8;H1A,><XA8#
M6)!72'-V*+EH01M.\*!77C<H F=.4-,6XV,['^- %BHOM+8](-(F<D0[N4I)
MKCU.[&R[6N9*Q5&);Z78\D-Q?2E*B2R.\59WEMH(NS'8@,'1ZV L!^?!=L&K
MKMH6SHYRT;43;#R+BZXHS5J>_VE.!(/<Q9&F7%1H8;??'>M[4X?_3?VX9>A6
M*1HB<V*2P6'=!W$^API]S9V<Y+<:"T&- ,B8IKO]5.SM?XQ'GV.!0W25I^YN
M:*F=USW1^\Z+N-/ID#0S11/17<MW*B-^W."4>"P"\*61F\\;UL$(9_0O: 3+
M=!+P%P: (LI$SO=WU&WLA_,2.%=\B;H?F=D7871Q]*(TN-6'QJ&7%R3NKLQ]
M=4'>KW%@'H4.4;*$8I(69KI\R]1V[^W1K39:D>^G-_2J%^6NH4 \#A.B-=.6
M:E1;.#$U_+=W:DY4?M<&/]K>!FYNT30^04*2Z+6;-V&Z5[5MZM]T<;@60:>Y
MJ8!M&E@ATO20Q:]M-ZEX>0'JW'S::K4?5V9R98Z#OF+X<Y=U%^!L%CK(KAO?
MIC<#WN;>,.[V8@+QMI1IGUO*W?Z]@>/O2B$7!RBKT7 [NM%;A&!"J:"^5?]#
MKJ'GOLTR=C:+&J3XRA4)?*<*R,U$%0F8$:YK@N)<T;#MZ'O_KMRB_6$E(G_H
MHK "0<ERNDT+#IW7N^+8YZOCYIHT-F\"9PQ4T:QKXQBV%9W@O'=5:E*]E/Z!
MKT]0R(MX$'YQAFZ%1^Y=.W&?YL(,4.X9 _]-M"^YU=E\YYK&GU_FWUJ\B]CL
M=0Q\(K^(\/(-2$_14=ON9N,^\[XT"6]PLLMA\\3^(,W@D?RYE>2*&1GT.%&)
M7+YXG8#A!B.#0$*[#ST?N(TX\]'5 6'ODI&'>ZA(,Q=/WQS\Y6%US0@A::A[
MMTKD,H#&LPF/T,&<>+=OO /:%>4/^6P"R^=,23O3,8)6PC&4TQGE&>XR+$T[
M0!RWF]/E<AGA0!_][H@?9J$L +:57#K&KA0J)H.C&S9N^HH<*2]Z(*+\3;3+
M./';27WM8X;_W> D.U"+^;/HD4^$WX?S_WS%B_3.B*:"5,H%1/?$Z O)/70N
MG:"8PF%%6W-8W[N1W)5W-.]_"\U%)\D#[A/*"MZB'07P=Y;#[KY;S3$D#TQ:
M"JIQ #&_Q+:$,9'! 2'KG( O0\2QH-&UGF=KXZZW&A7=N.* _NEZ](Z<V&%0
M+^UT]UZ*<@&Z[<2^NO\R,NPDB8T8>IWJA,2\L<W=+!@:[H(?HO/SB0/WJ>#J
M;YFAEWYU\"DO0TJVD8-.*^,!G:ZC,N 1.-G2[A.N4* VJW?/>SZI5+O>PTH!
M:V1>0%4GPO,C8$,TA=75XI9;7H'2@2!U8<@0S /V0L)!';=F&L7(-7*[CMC&
M4'$+=Q?8 ?,"?+EBT)M]";X!!RT1]7EBUXWY4))Q,TUI-<L;*AZG+5E8/R&/
M).1E.)_9K8+U$@1#,#+<>01Y$SI$6"3Z*U<)]SCQ0*2Z2<6G0/4#Q3NF*L11
M8&B^NQ8(]G\(C?I60+C;MZ(0-VFT)2SA2% /K 6_AC2@WD-10><*G HG^H_=
M*<XI]^)@DR^T&-B56Z:I'SC@-4I,V=_V(V-L[?MD\1V?+,YOY>?YBSS1FK/Z
M\VQ0CM4&"_NUL .YE=Z!W(I!IQ3!;JU1H!!H.]Y;S5UF2VY @NQ#HB$NQK;K
M4J,+K)4AOED3D@ ?>\HHR\7SLC)3MIH28ZMW;7U:^/;KQ+OQ7@_U@W=CE39G
M6ZWQ/)X))64\Y;OS4O(![H:FAP",[7VPPPW"KHZ ].GO%<>@-6.B0Z00[NU_
M@;R$.!LE)D2)"?\\,2&1C+/Q]-\G)J3^*#$A?3@QX<T0U8=GYQ:0%BV(Y(('
M^7-OQ^&Z@Z::5?07C;5?BEH)%#?W&ZMP*9$UO%C&O]JS,6,+R >0%0/:)0C\
MZ@;[I:0JU9ON?MJG:]8I3@4=LH6\YW$1#S-"_B>RV]!5O4;M)O]3)&<3QS+8
M].W._N 1T _(KQDD:1>^#['%)>G8&9P#0._. ;32PB: +$CJ> ,2ZT*NS_Y\
MS-T)Q=+LS;X+#0>A]4[P'8[SA5.%G91Z])1CC_HWT"N[<5Q<?\T5^AFJS0E!
M?:$+=@-]-.!/KTKE4& IWZ71V1!:Z0O'TOQ$+>&ZIG\>/^L?#)B%OS.LN#1
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M/PD.9X'#2-HZ#I^+(85\/B0GW,%5CE6 @D ^>"H>OZ+C0&)>=[#T#SN2,<"
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M"0B]AAKD1/&XFF9Q[4GY_C26&E1(%B"_Z;#LF@.:RQ"1C<-!JP*;5HXY!G8
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MX/9[A'H'M_YMCV6/K64-EFQ!Y_ HP^55%>)*R*L@[L%Y"^N\P"ORUCGTY,O
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M'S=4,AX "\;BFGPF7_\\PRU_4&7ZM_F#LT%*C^ZX9IAMUWILBIMO%I'1MY9
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M8S,"!,,ZM*JNF$L&20=EX8-Y8I8S7 G-%'/>&P_%P+D/3;1\)6H(\\1C=+>
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M.')LF\^% _&CT!_\1^5W8COXH1T.U?*?CNSP/#J@J(6JW':?"?W&<4<Q7[5
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M8%#IU+9A4IE/9^2*&$3*8BUX#J.?E,=*(K!0[)G+0=*RSIGRCZD'R8ECP^:
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MM E]NQNGZ*]61GIWSQJVE/$\CPL3<^U,?FS$)MR4G7?,>34AI))U4_KK/Q-
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M5-H'X;KQ')^=[&>XX 5H!_"4-S>&/0,0&#:I@&YH<PJT.P^Z._SQQT][_>#
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MAP\^LE'T91/([7L;&!$0L)O;6(.W,XB"I>9^@\'S%.!\TZH)%CAOG(.,'F3
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M R-_YQE1[S&RQ>=$@Y4UP])YXW1"4:>?8H=-+<51V#P;7PYZTT)Z3GBL#%
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M;M3:S52K1W?<<>Q'%TLG)F,6P7B>GDP2"!V?Q!DZ'4LP-):(I1*36&R20$_
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MW4@T2ST*5ZK997HX:9"E%N B,-[Y'ALYF&GM+ZM;"@ L>S6L%]6H/Z,&@/Z
M#(Z9P>Z;\(\?9 U7Q]J999CBQ/$^$E78^<HMHT_L]HYB/@WCY[F:]W#X\V_1
M!$]E_SE3K^HG0G?V$J%WISH Q0&*YRP/.VB4]J>V=[7]&>[SX=*NM];1 <D,
MZ[R0;235A6P?A]6WN.55E_J8SC74+9YG&$,T]CM'NC(:_%E360 5=P]=L*F,
MK+&2CXUC6J>Q,JGWA"6)K]IS7$_FS&X7O)T'>#L'[S=UB[\!0_VJ6+D)QK^#
M2S'\5!9L$ ILLSOE(_QQCKSG:C),GHMHDP@XI[A-BP _1MK\VIW-Y!HPR7_@
M<D71X&T V+C>*$;G(ZS,&(8X$>%#U(@)W@.?"JN]&?C@,2,S*LM'C"D/,"+"
M@*< 3(!O8%P<@9^ EV]&OT1BZ$L$8IS[?,AL7R/G]P[?K?-+B&U<A&?8*?AM
MKNF0Y47FX 8U+F*+YC3"3AG ! UXH E SXC[#;"6A2*-@Q_#/6MP4 +X!1R1
MC_S%K^:\:O!_OT14WHS(HLI'@'14X$9/#FB8X#^7F<,_:W.?S7KN.O"XN<Y/
MP</$)7@N8+?&W_Y;7B/$.R=_<5^6!8]@5"?BG]0\>QD6G([C[0V\P[T".!X$
M2HIWP&CJ#+<#79TQ.&81Z;A_JKE=H.$>__NR0,V)2R!>7'%J3 %<#)J0EVI<
MH>TFLE#9C+ N#3/)M7!1JF);2;DG(%WNT'7F_($H/5[0@2]UYZ'X8G31U8K+
M28JK2E943NICI55HVL2^&,4^D2SDL=0=1\TOZ^+Q%K8B%/&85IW1==I6U4EK
MU9-LI!]+Y C3+#NQ=NO7O]@KDCP1GR[8O^.BT2M>-"*E!MG$=%I#"@4](P\'
MM-D;MK[]HF-U99KL-GL)JL))5(<J.AQ5!Q<=?TVF3B[Z!1"_,>?==N>RX[$7
MT;44 0DP9L3F 6>Q#$AK6@2\B[5D0.$N>>PQ$)\5G)*B^_6=?/,(T64_C/O*
MB.(U5W?A#;D.#^Z'][ZVQTL!6V0BKND:0???J^SNX_6Q-96]D,>!@AKY=CWL
M([(3?$MQ^?TI#K!OQ6YD/VG.B0"T,ETT8_FY^R?_JQE1@PH1C.] \040TQ4D
M+JY9IJ7S1T]T$50T]E]IS7W>#42@"/#%E=[@\1#%/53B(!9I<_</X/[ 4305
M7!^4#0Q 3XVS6+!S@(ZN1/,(XCS&P5>/&<.3%\9NHHR/J+$-'1D6$,<0@V%[
M5W'NWANX/QY*4@_QP6O'F\N!NH>[=RBWWM@L6./*>(!+4#)SY_;]$Q"&F$R
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M3D@,V<H X:LT DPH)<YJ *EB\1<$.?74;BR)TH&7/7:8F :V[<9;=[ $YB0
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M[[FS#EU9[@S/KUC$]S[[76J! G#NJR7(W*W"ZT(8Q-4.[@!8]-ZU;G="Z'@
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MO#G[K3+--KRQI+*:PG>956[;/><TGZQM$TD)+S YDA&[-&YV[3@Y]'FXJ%J
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M5$?\=)]Y;1Q#*ARSDI2";%.M67:)D#98>;)/=)BES5RM,2>=UKS<&]48J<O
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M9UH@)&!^1H"W,3X$:%KQ4$5XK3!V5F"X.HXECUP'4P:/VF/H"+HNG@6.8&_
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MG*X3=*YL&JKJ1[FPY]*&[T^ID)-_!$9@GE]4%Q$AW&=KD:J[=.9F/SX8_R
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M,Q<>B_#:E!,50Y0EV;,@/AU+Y+-(NC9:WDQB!9U(FI:L;OMG5XVY-RK9&VZ
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MI>[YQYQ *27P;I!5N#=,P\L0W(OK"H;MX,<X>+$W)^(PE1##[1#%&_0>CMC
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M5LR%C7C5! I=C(2[I7 IE78:QQQR>MU%.>3-VO*9EIXH-1KS&A!#_!R:V6-
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MCRHHO092\ T&'LN"U[A!_RC/1_E%N+8W,OM$P3#J+"EXS[@7:?YU19KAO[.
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M6KHG,O5UK%0B2T40&R<+SDP0DE ^/= 1^C$6.[XC.4;<X!6(BS\2D!>AV[U
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M;TI.;:UFWIPX<:=V7_>(A+\+FME91,_0L>Z:*H^51;<5=Z1V:_F]VGW]R&"
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M8SVH:E@#?,_SDE<:XR$)M<1$TP_VT(3ZR!B""MC/K2/>P=K&N'*QY?==!6
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M*U.$0[T"U?2[4V4D5'L0:G?3(=9O?P[G; "*TP279-%8#'B/(H@LYZ!K*SH
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M_,Z=;.Q)57=A;O\L(*&"$V^KQJNW',]\"@GJ3-'=B=#L=J+.]CIW'I[;V$=
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M8.VM]]5.Z6V@M);$CI8(+W2)/UXAO"D!_N](YQWPS\12E7_^?U!+ P04
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MK_\[FC/RE<:0 X7W^\_@[15]($?L>Q"7D.3(SQH2HR'#BO]A0E896T;E4O[
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M'XXG_.-1>$*'4)U80RL9IGGXXM8M&2MR!=#[SS+*A.&<*T+5<$B2F@,&Q"?
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MSHXEOAQ8L^D&:"P]1R[+:+$@1])[5_<MAI>E5>E<2O9!,AARG420G%G!(7R
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M\2:P-C.6E[&88&-!XHWF,JT:GED"AGR^!Q2SH485"IVD#II7D2RKB6DDS$+
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M^F!&UK4.JLY! -W.& '8Z40# [;+)J*$O#XE(7W@%AB4CFZHOK#$8DY-WUG
M(FC9M_TM;+%=6PHVJS=PTRMEFQ3,8"+V2G%U9$&4!>62FQHBQ(T9+6. )&2M
M)\-X$SNS$_B0N;WNT@":ME4KFEC< L]:E/E$P8($-&<;"WP6-"?E2O2U2T@=
M#JGH$VJ(A,&;BY[D1@4/ B#ZVK:(,^3.&FK 2%M[UMU:W+SFUGML KQ7NXVZ
MR4BD;T7MH;7BTO!4RWHOW!:HC'W4.^B#P58-N]&+9N[S,N-W:"'P@ P&/V/\
MR&6Q'*O+V_B5*Z+J7@%8?92&NP)[W;DHJS9'2C.M?XB5**Y,6IQ6!0<B@.#0
M;*)F)G!KB/*@\N47##!Q)7/:P):B7!;^B49*X*D,^:!B0JDL>^QU:BU.I56,
M/WBUZ_@MUKYPUL'R0H@&2KX(J\0C%J3J\W"49K+J5?Y<58W6N#/$P(49/TC@
ME&V)'>1^D2Y'MP/\04,YNX$P8[D>#*[40I5:C^YL<@2AP@PA2\7=C&<?D&VH
M\CHH=A\_I+;' '>8W1)P */3EVL+95P*V6K%''U_F!*(!L8!5VL44B1H091D
M+5&I<0S235J/\@V\Z/@&FJ@.%9##V"@(ZV<O&CZ "@SVI01#)%4C"/@]U_NX
MU,V%:NQ0T7- =3J@.L$+!U2G<:=R0'4:>Y,?']5I;* _8S-V@/OWKP)Z>78
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M8=-K)J>AG5U%QO\+]13;4N59$3;_.)RY-DG7\-H*<N)FVSJW4"- KK99S5X
MD;0GV7Y@!Y+AK*]@_");A^]((/4<%L741UW^=6VA/_86;)$MHV[!Y8Q?N,=>
M_!;\J%$7__>T7%=SX77M6TH:1UW[!O^SWWO_.$L74/N/N_*+1SGU3:K7NZHI
MT$Q)T&<@8Y\)H;S'Y=Z^N\]/^W6?O_K.-RCAVAR8]X*]6E\:5LXAW0D3X@B9
M@T+-\@5EX#F,X]Z7'ENNDL[GKJ4WF"B(:S\1% Y405).$!FI>DH0?MN$/I5/
M2%X&"T)S<I]FWW)^G?BO:!R3, U*@5E+;E.N4+=*78GKK%$!-<K-J]6#AKZ(
M*9_:^!>')DGI6%F,&29CJS0;G^,<_9(Z(F=A%O/\^>FITR 8$*"O7%:Q_-A#
MC_+(0S&<:I$VBQU[%J$&$[W;QA<'GK# B!^QX]R)#7,_O8CIWT^^.H3RD7+L
M P/W%P@,8-B_TEDJT5CI'8UBX=72O:O*&:=\\B'*@SC-RXQQK31=:BZO76Q$
MZ[H0:"PS"+8,8&,-%8++O#J]:K]1DGRKS6?]U.9/,_"C3@C4 '7:038K>5N*
MVP2$.6?@<-"5:C'^+:YTE_'5%2]W.5VQS!U(V -2C(]T)LPRO-34N*K#*.-1
M7Y^]/1;,C@W0YC&;-D";1]W] >H\2I-SU^<QNP;Z/-'Z-C1Q;&BK4J@GG/L#
MME=(CKCEF#"H::79PS'Y6BZ7D#DA!, 'T3%U!>QJ_%Q"(Z,#VC0OZ3<FFA/3
M/$V$#B(],!6BD[Q3;YOF['ZC,_E6"<[[J00J/L7W.E?GG\Z[N%CR,I)YE- D
MB/B_Y*TQ*&Q/LTY1[&!]AA'H2%$F^G&/SREB>@_*V+SDVD^^((P&"S*H6R6N
M+Z96XT7F5-.1$^45C2AZD%3@T%YQ;Q7W'P'>]'-6PF?)I<I_F"F>_8M*?N-\
MT5/%P75"-,2#R-/@[+H 9Z-*U !>+6;62</()S*?@D1+P.7+25@6H"()PT0
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M7(0S>2#W/OJM%R"@H66 6-OXXXE>G.E,0R33T4].=E50*ALG(/:=94&4P^#
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MPMGP[+*[- IMR67/9FGXP/_/HEC&/___4$L#!!0    ( ) ]:5:[>.BB;3$
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M>[T>)1._'_!,,(1@K62I<P74*S["<<QPM=QJ &T"#YVH4@5<< ,>4<)=J"D
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MB)TG^]AE(/E+ORU1-576'Y"F5IOJVRWZ25D$Y=Q,[7ET'5&53%O. 'V&N/W
M,O(QS@8=G'E:V4@3+AF%OUSJAJ1FFWU53A&F4G-"!E6'.@(UVX4_-RN.<9I;
MT/.0BJL;"1M,1G0Q//Q<O-^^V39%RY^>[&WM/>F$8=!!E::8_64BH;4<H+HJ
MV>Q<JZL^9JW "BB.T@[XP-A<:%-.WY=ZE<'8".=F(AYVW3JFGA!EY%!Q.,;3
M&?6B3<!S=89CFHG-'*3@-C, ^M-E/)J?3#P7%2@8;$&2);>N-U?<NRX'",Q]
M;Z6]6@&YI=5,*440ZRJ#M#*)@7KSQ/K%R[;"D-_NO9;B7_XNNJ^O>[WSR]?B
M]DK<OCF_$=WKE^>WU]W;\ZM+\>[ZZK1W]OZZUQ$OKV[?B-[;=Q=7O_=ZHGMY
M!E?WQ.G5VW?=R]_%A^[YKSWZYOK\]9M;?-AU[^;JXE>\]'=Q\_[TC3@[OWGW
M_K9W Y==7[U__49TQ>WU>?="P"C^^?[Z=W%U#?^>O>[A'^Z:2]$]>WM^>7Y#
M8X+GT9AZ9S#D6I<*0VE4;!"F3% Q4DESR\,_P2II\G]R&* D$G9.*Q 4BA0&
M:<G34*>CS8 TZZFX(9D',46MO)I<>Y/QI5$97#@EUN%D9=6PR*?8S\)YMIK'
MI?VT4$P0U"5&KX+&1*>3;C8FLZN>@5G4YN#Y9[<]='XV';=.89#%D+%C;S8G
MK4^%W1S+(-\Z(5GNDI@ >Q($ 27&UIS2P9WD=@>Y!&<Z&0RH5S,-'3@AX06X
M^['I.FI\]P2_*/  F-[(1;/3-:V^PC/#?GKLD<VI=AXRHV)_UNRZS[?$#F/#
MK>1H,Q2#!S<>6:^ZTGPL+XU]"LZ"VIS<F31)6W>OI94WS=W/-!!SM11S V"<
M(!Z1N @^A9'$-BJ',-XAB.H1A1(&!,H BKY+\I0,OIK4L/6-?5B<;VBX@%U^
M](;>1"ZEAKP!=N-K?=2EF0T7(N0IL1^%#$QKT<**NS >2C-_+L/",>%Q]<M3
M0P,$5VAG*QBT..] S%N ;Q$HI9#+^$VWC66JR C6?W;?WG2PA<SV:C-_\+VU
M@DVP:#>P.J^P:$ZBHQSL\&X0HJ%,MF _\7Y15* P..QZ704*))/3AC9\"(C0
MN1C)18V#Q;_.!1ECA'WU5P(9\A:-RG)RO+,SG4ZW_Y!C+>-B.\K'.S2(+?^Z
MK6 ;=S;G6K0T52I2N)Q4<,$L\M&9DV/:&U T"TT(C;TZ3"9;*\F@\<EV:CU4
MAJ:J29A=(J..!4*>W)!J4HDR 1$]C.VB2NX:DU-8L'T72NXL@\M_(C;ZF]P5
M*0B=AQ, 8J%@1X=+"S  C(;@!N@5#ZV-+C=@)<\U32)I:LMJ2';]A+4B)/:
MY!+"F G65V'X'84F_L[LU#9*,0'$.E:Z+EH\8(^X8\K/TDI]G&<'X=K;V]>A
MG.\0RCE:AW+6H9Q'',J!U[H*Q\B)2.B%'-/X$ GSIYW;W91MP*JXQ'7HJJ#Z
M7(@J#L%]28U?BREZN9$GQVTZC6=B@47A%&64U#,+6?15:]ANX:HA,C,:=6"P
MC+&T,!F$-0M=<P>VDB$@Y !PMF7'113(N+0 <U9BK<[6]%$$+OYW17)'/:^M
MNU:\-ATNNA'-=1]X!_?TX);3G>837F$;7M\R@23+F[PB%P$Y/L)[G?CW]U](
M.+*4M]YX34T?)H/+3 NU6%*Z%[M(C [!GA%C<B]8W2PVU43J#S#%,";H=YBX
M%*F%_IUZ!2"+L&C4LBI77.RX]XF4B%B<TL*UM9*L@4E\+*<@E6)<I24&HIQ5
MZET:Y)KE ]-X"Q B=0B';;WCXNES5QC?,(>3N"$G'R[JFY.JL)0+WT$GBP$F
M]QX8.[7+' M^#IVU9$]IK9I9[K!@*J$7+E)PV-O5+PW$)<G^J#(N$PA<$JO0
MLX.[*,-G)J!/HY&&1#628!&"\AF[LBY.6:L!UVHS0;N(_06LE]D"INVFDFL5
MZ;SO5%+*@.3^J.)AF(YA8X%T BA":**"9C2D[-+AFXLNNBBH]$TQ3-G,E<@)
M<GHO%HDMP9T'2LEU>&E1*&"UM1S/364U@RH.PP$+2N0'9]592:Y6O_7&)/7'
M!BDP+LD<SQ"RI'7 \1Z*V%]M@C-5]U2E6EX(%M6&(?M!2:[,>>P7MF_SO739
MVVR_USZ%/W;I(TA/VC!Q,ZRZ+UN-^WF<A'8WOI)@$[X ,P>C0C!1HU81BRTC
M[E@#--V%*W1' O]F,Q^$3"HYX7LV/W[&/X\3="%3M9XP3;I/)0B!&+P#.2\X
M,\7X*+:_JFT^;]<^',JUO!_<_[JXKD!#D>)@5*/A_V)?N*\HF];NA8>Y%YZL
MW0MK]\)#W0MX)]'C/W["Y8)O2M*:+;GPLJ,Y)2=:'=L_PGF@K#-$@6^D^A99
M6=\%WN=P#^97M"S@?[&;?T,F$I69.XYV?PY7SCS8KN*WV!EW%-^D'_?V]PZ?
M'>P?[?%Y>]&OO6_**]'/4Y*>'! ^?K'3-_M5QC1+6$B0Z[#J^S\]SADOFQ7A
M#4^OKM]=<6"\/KL=VLA'O)E_Y9C]*-OV5^>VWK0?<&X_U*9]@17RF?O]@*4X
MV'YVN.+%>#D[%I\[S,,GVWM'3OFQ-NSDDZ!U$59%6^D\=O2.^+ MSE0&MXI?
MX7^72NL?A"B=BKW?4G^BZ1?XMR"[+V&<GTVAJ"M_9_)L(<UP!;S]<_RW ?RW
MB[:$L)/O%[]<*!D+=(.ARQC]!6=49B@O?A *7\O*'U16+E.X+=#TJ]@1CTZ:
M7$U5)MY4PY'ZX<1(BVOX"Z7(7]_01\!\%^_D#KD55M7Z]8%K_MB&8:,*%"1H
MO*7F>UOZUK\ZF<\AUO\,3^K3M2=U[4E=+5!K3O@OI/.V0,UB'>);HEU^>W/^
M\OQ6=)UR\@B6PJ7FG%Y=OCH_ZUW>8FK-^>6KJ^NWG,R#.3NH\)]?_HJ_7EW>
MB.[-S?GKR[?PD?. \*]'*2@>\TE9"??_2G-8\_0U3U_S]"4\_>5CXNG(N\5U
M[Z+7O>F)JU?B]*)[_O;FF[#JS\/!-0=*V!C;_1KKD#"8TF->;,[37'MPGY>D
M'8B0^DA9U J'WDP)>X12V4?9\I)T-X)3 EO,713"<AB-ZDI%.F3*8NRL0<OX
MMQ1<,L T$I69N#)E) -8\ORDVWZLC9RSO*5M=J^/UQ#!I1#!E>+!;GUJ-@/!
M[DW.Y@ZPYC9N)_,O_J\C]G?_]:\UXN\^Q-]*-WB.;[GJA[4VE!:$9QOT=7RK
M'E]LQG;U8U95;RE:@\/YC,M6UE%/@3,I A[V'^:^4:<3!,"[RQ$\V)^)(>=7
MF!H6%C](17IIPMKS0NXU\/YF4UQ<G+KDB00[;)JT39,B:>OF8MV=H:(VFK$)
M%V!='C," O#?*6W*2(^ ;XY ]JFV(M/(3S/^Q6:&^&<G5(Z#?H3WIM@DFM[H
M:JR&77+I67P?C#96II:]R;LPGR(O26P+%*H@/M<.?-4I%(8*8PO1K+<%QZ2
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MY]'/22 6F/23"CCG$&@?B2>)-;QQDL]QP?V?]Y-?>"D!+<_J8C@!/FOW:I[
M/]3P'S6<<U3/< H[ R!4I)-I#I_!&#"/$9X0&L)DJ#SZ6\\<T#!5)>EX)7"
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MRZ_#FK(%UJB'>?OY ZIE@[6J91?_J-$#>38'GBSQ F;&5ZOC3/W =4(:W+A
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M?O#V4W(1,@+.EQY=H+(]B%^:@!>#1+FTROL:?:%9OW'XY.3@Y-DCJ=\ JBA
MW!?6KQ#4,/B5\9T3HZLYS^LTYGPKDP3?>F@;_/T.P=^3;?!W&_Q=;T?A>P33
MZNZWGLE![E,2XI[:U'ON@@W* 75AM&B92A 4GYGHR2@I,;.5L,=L?E]+P4#M
M$+U%*AW6J4DNGF(7)= BC4TON(#!:^!G"C/%AES*0T&+>@K\OV)CG-\7M+Z!
M[Z6V3=)AO>(PY2]0\0]ZMB#*6XHTD6J@\LQ5Z3K!<:F?Y,VV"YJ\]5MX4)!^
M64Z?=L]^KE.T:@^/>@W@C>60<:&ZZD([I/U;($641O[R.A"':&U>.P73QT))
M+:'@(TFF';8P8.M\H+&/%[NV\5/[PP2;%\;W5CTL>\_(^,MIPDW$K97)@&JL
M$'B5IY.3,44(1^84QG@-1@K',5G:-N/55;&1/*8A:&+2Y0NFIPRFI9T>XS(%
MB@G#?^AR6"2#1K(^J'"HM-C=(+@[^$$G:"RAVGJ$(43==S:=-#F;Y]'.4<\6
MJG4.QKGMYGTJ2NLIL*IZ^E!8O7M=*1Q>G4JOQ67O-G/S '&Y#=6H1F\:_F;)
MCI:KMK1K3[_I&C>M8?&FF2;KK=MZ#0K7+'JC58IM5/&>@,I#5'@.LP82C*[(
MC#:^&#9>7C4**MI7RR\ 7^+'"#/0N[T21>M7@UZS[]?:ZSJO7EQCO$I/$[@0
M706>#=N.^$M-49F2=H%'$"<3;\;0;/WW74[8$]TO>.KTDY6SG 0F?&>E7JQG
MFFB_#-N\KQD [(YZ1'V@%JR-+CE_'+)JYZS'%1+D%0I?TO#K.-QY9WPOR/3N
M:%)W\NSIP8N=<0\!:$7SN403#(&>K_'RU-JFB1\^>_J82Q:EP]%ZNR[!+/S=
M% 7X1:^!7JU3P@7OIG$OD($0#R**?*^]J40@^#MZ-^EI5],L&8!Z\Z*.4;N]
MQF#O$"P1'O]L6,D&/?J.&X37*83>#X Q_7H@TC'&Q($GS('M%@D2&44J AVY
M7<3=8KYF$TVW=B?@!T#]Y&TV#>0-<FP8B2L3$,:D+\IL#.Y%XUIQS-T6\O#\
MG.3WV0>:()F@RO)G!;FZY@&*,JW7-'H+D,]7L<QF-H"S5 BKTY,Y][;0320R
M:>L.&76#(J-YZB.K]P7$CJH.,6)E.'W(3UW[X+S2+M*)=@[A,,#$@((5RP;.
MS-5PZZD^4I!/75P+"UB='=:W8Q/PGQA)YK"/GAP^MDC\]0"&,%+^AEW+>%UZ
MV,X:G6V$@4*V%'O-FP=-U]F [W4>#)^%R#[46;6*?1F8^R[.+"BLI)(,\;.G
M&@'$A8[_<#Q2=.!*?:%]&Z+_U9@307,8;W-Y(3-S;B/34YNGXIF_]!S#J5M9
M'CS6>5,P1)H% /X\!('-+EP>I?J"-7?<7H'X _^N[$G'0EO0_*!^A=X(;/>O
MDQ7>8,HHK)3<WQ_4HAG0[GOIK6CMQ*ZK2)>.%:('"#( XX((V";9PGU"[J2%
M=TT N<N<+5/=4,C,(6[#)YN% '!55X071-?W0Y&/"S7UT\0>'#E]B,61I8N'
MF!W-?.%[\*-](;W+',6"1F-@TJUOQNMSX3Z2G-ZOASEP2JHU*,(G)638QSAH
MD',N,.YT4["CR9>AAG'__? 1]3XB7%DT]&-J IDN#&^D%RU[R_KME( *1(:5
M;46K\V=\1D;I\1Q\C;86PGW:&2Q^)XE*6DEL\6%_L.C3HVWT:1M]^N%+#S<L
M.>S9]TX.>\E!I@>E]/P J6'/-BXU+/Z*#0X3M^Y-#/N:H;?96/^TYL3WS\9J
M>"_OB;&V8Y1 ;B:%BBS]" : CP[W'GUE.I5?4>+\?DL+8=:6+G5O)H3@VW[-
M#@0Y"FX+_D!2Q/-63MG3QT^.3AZSXB<I&@FCP\)PJ,6C]Z#.R/ 9V%P,_)YW
MW8^$S\3]X+KRM0G@+X^9;EG(/UW4E.P%K3.X)4]=2L)]P<,.'[-M.A7X'/M^
M9T8J]\%ZD<ZFM-U5/["I6\+[45QA*]U1U5+'"#';CL28/TLZPRWI;!@HH728
M/AL.=:I%N24+YTO%85+IE7QA&IO[)I,3?;;1]XA"%"C:=[F!J;0B5NA=+UW+
MYSP( A)WVPDKQ[F@>\;T9)Y#7EF"]'25W&4--'LGGD\QP_!?7(YNF6#3DF [
M#B:-N/UU92-_:XT*(VGOOJ!M.IL;\ ";9R$67PV$K2I!/AU0B1P?%3Q5YJRK
MT9[#,EL#VG[1<GRH\HR\^%8O4"W)KKRWX:O5B4S; RF:%M[ K=]=SMH,)-2N
M/X:9BR_ST(!K3KXU5:=_&^(TT6\%N\UA(D^KDI0CY]8UL *,!^_-*$RO\P).
M4_4EF8*NAC^V3S;GZ;(=FC ^K#DZG5&N1$E-ON5&K)7@/GCZ:P?%&8L94RXZ
M]JGO97 BY +Z6;!1HLY*WD?X!\$LZ![+&T7EY"@"O+10'"/5V%(6F<5PDL#?
MQEIJ[!<\IM+2)46TI^]:3MO8_)+(O.0(H^^EX\5$J(T7[Y0]#OAP&O6J&;@[
MR0G?$?P9Y$,O>]@V>=[!"IL@PYJ, KK=A#JC4S7#WXISI!&F;ALFL'0;*:)#
MS1$;N3&\2;=I/TT4O>C)KB%PS=)#H[5U;!Y'7MHL"8?NV K790\=:9+MX2D<
MKL-*I\8AA^CMB4@>D"HH"^ZHVH^8DT@5R@-QF<O>DW0U(V7\=)A@"]J0YLVB
MIK>;V(IXTQ09"\RU2<CE+47 ARV?:B2(+L=J1P<C<K66I]N*L>\0LWN\C=EM
M8W8;53'&V)3+:\;0#WP_9^:E'!WN/7["V\7;H( S%6/,C513E8Z5M'I&_7L(
M0H[7[+RAG&S'.5#WFTA]2OV8F7X(%5A:)=>$22JN[<[%+-P55R64DSEDCHJ_
M_1UTDS*V0)AAODE>C%66_ ]-_3D=[(8<S%><S.'3O>,3_V38"Y+J/N\;-B3&
MU!B&(8-QA!Z-74R*K)]3Z]E/J"Q7%LQILW;H:[;HT=[!84"\MO=:H7T:P,VP
M2-S#?#HPUIBEXU$RJL@>&%)0X]'!WWK<EMIUW7;4Y=GP=SGY(K!U1R%]ZK"S
MAQR0]-7F]M$X,.9%ZJ)D]SS,9\SM[W O65\A9H)/N:M1;M3YW'W5\31X"Z("
MWR$JNOA34$,V6V(@F03 5A$A2_DC6'$),)]8^;=]D[;E:W;E60?1BEHZ([^Y
M41$QY<O:Q<@!ZS((EI?1X?%.S-ZEPQ/\2Z[WC:/&BR_",VUIPO&)7YK08UPD
M8^;)/&S!"'",>:8+?T9>\<AU#>1[>!SO'DNV8HFA)\[JMKE\A"9A_M4G(\Y-
MSQQZH;$, X4$3,0UQ^F\E2//QI3K-\OG=.=E$-?+RSF6,,M_Y<5E&.K-H:BO
MXX--(2ZG+D8W7B-//%C72K]9/R',4,\-2A>V,O@=^VV25<+'F!?,Y2ZS(9KX
M!/TAG^\9"NKXSA 1&]]H_WCCS2<Y=:G$<=VGACR4M;G)KX;ICXA]C6XP+@>@
M;DM]!KHV)=6H8] W[$YJ=K9D03@:(38GF>Q $=J]YZ%SP*Z?YW_)-&Q_IO ,
MJ@DJ1L'.E=J^P7LW);NH4L#,6GU8"*C(4\""BES4' R3076RFH"1,YY0@U.&
MAVD/AWUV:^Z.!3_7L'AJFE7D7Q86>YQU989<(V^JG?:HO>5[Z[N.3XY6WL;[
M+Z(W/MI)+7>&YP-I#/>GEN65#V;HXTKYDSD;E?)1@%O\,#?)VDM 'Y8YUW:>
MB M1$JN)LJ2"7ESRC=(URF%W7)"$6<)P@#;5FHV3]I3(>V=<U/2F%37'Q';3
MO+28_*WQMN3]S<A[W"#O-2%U4F3I5GVA".4&Z0Y)[\'F_TE#<[CT@;]L7J,%
M9[5)AR,#$A8DCG(>ETMH=/F,F,TXG.!'DJ]DKK)7B8NW6JZ+K2%\>O#:)9?$
M D^!F5.<HY50L_,*G:?]A@^?[SL=4:6^8*?&O&3%T-4\/WOF#[[>^%A(/B8N
MMJ/6RG=I?SL+XTAAMK%Q_W?K+[SIF* 7H/6K*:\Q]Q##/U1PR%&A]<+G^N_W
M19:;;T(."A.$2S$%$1NRNP >1WX6KGT&7RO1TK$C>[[LYSL<@;8IF#W!:VG<
M"T=[I+\N.J>"A=H<6(ZCL/:4;*]^X]U]-AXP+]%4ENXD>WJO[Y>K>MU4X2(.
M4\;/^$)*I??!HH=-RCF8KCY;.&E$[,513':ZA-!&&@X')X3M0C@)#E@<$(6?
MSXA5K528C2# \B\3CO.V8X<#@P2/'IL@]03$#6Z,]T[FOH@)#*^D(F8\''+L
M+$-\IZIC5)-Q7;O(DP;8^=[NXYAT9C 6@'^"!C\T7!<5^$;%N*1AH.<(E[.$
M&"0?8^G94\-U%>;K*OMTXE?ZUD59J\R.P=UEV'YF[DM[^0U%X#8Z];#HU)-M
M=&H;G=JHZ-1J/,.VD.8&WJ[)ML=J?/DP6L)X^I)-97@8RUF*J1OO%RPJ0XF[
M;K7EVD[JG:XF(403,W%/:C@) (*F)0)0VS5RA=BV\Y%BO<.4QN?X@7DG92HY
MG<'FT#;'Y@U,*CW%/"8>0,<VB=?\VV8:K5_[@S=?XYM7[>?>MQ0^WR#,]Q7Q
MUS#*UX2'X8(0*=9SA?%951":4S)R>J^W-:8MX-*]:^F4])YN/:*M0A)$B']3
MK4EU\.S,UUD)&@/UW3GJ' UE9.4H8H%T+@ZV9O^^!?9-EV^LU1-5J.^T\&D>
M,S962:T]4+F\RQ-6!Y/06;YZL<HX?<I3=F"C0YUQ9<CU1%%OXD+TQJ'RN!2%
M*XH[;8[5W?\O!)&)/7(0YJ;_%=R!\;TL.^U4.9^SY[RD0C+,:_.FZD!*2,LL
MM$3QQY2!ET6CNL*V=9R1%.WHO?%>7RAD&9QIS]MWPTYVR"N>R.][!GZT_7:D
MH!4SD'S8<UD.]LA;O1KA7+&6\.S02RI]F$^"COW/+:CS[0]X[48YF;Z"RQT^
M]5G<QXQPA )@/PZQ<,8LDVQ*Z'.V4TO-L4&,DXA%R1\JW%RY3ISH*;ES@JAE
MP8HQEF'*""Y'K2'P:*C(%GENZ7U%J2]@^R+6KRD,Q(#F71+7:'2:Y/]"<-2D
MP8R8RFTOLA=S"4JMP+B$^6*TAV,WE+.!;;?&&9Q9W-P$Y!E3]5F+&]M+G?;L
M-HJS.P^=67[3^S]E&YNYI=NMI>.T#P#Y*\V&$= XLQ6+)Z2F@A*7,?K_)9DJ
M]Q$^5F U !F?L ;@B)5\C\!Z0 &-!&1?/I'/SD$@HY@A6&571.WR7["V84),
MP5QRY(:%)I%'$63F^.PRDKQ;TZZTAFF4$_:$)1DE$]M<?MMAS<B;YK;8'5F8
M/H$H;LG"L6>H&@#&!GRP?70>P0RP+)4;L-D]9PRWYC0([:TK:!><-L7HX$ZJ
M:CGE>*]'S9S"+L4P$5JUTX [ /O**5NDPC=GM()X\11E_;GQ-U.2O3]9#*2.
M&2AN+OC/*L%2L[*>F2,U)V/J"?(.CB,L%_,,N SR4<]!P#6ZK'))1]8 W&[7
M)ZO06\I]ITJ?#M+DLV:4([93L/C$]9!4QO&.I1$#UY@#60Q.NA>%+2CI=ZKT
M1NAX:*,DQ]U7"(YF?,)#=)1R^-)S6@7<H&EHSM4#+4T;T$! U*1G_80M1%0#
M9.C &ID+&:*!4USEH,/HQ3+GG ?O16*QE.L '+6CU2.,,\*$'1S5(0.N\@P_
M?/D]6_K5]CL[D/"'K(D+D(D7H+*M).4]SNM!%9HR7W5HBUX+G)[*6&"Z LLG
MII/LV@I3YWY'YZ:!AV\8&,_AP5K1>%XD;"4'[0I1A@=])ZVR/I"?8_%A7P(;
M:$O(:1M["O-ZO/(;<_^3PM3;H5+J^OP"+QZ"0DMI4=0&%O$IRBTXVP_F2G^Z
M=:5O7>E;<+9O+ \.URH/SAN(:('/QC,;)6-G6U7Y,%2L2]+KT$+//+RS0,8:
M?%/$C%NY]2QV*[17QM;VQ,_&=1+3;!IM&]9;M.E/NY$18W***D[,\-%90ZTW
M]&,;ZZ%#'[$^#_'4LGNVU25)' _X <?L,T[?]RO*@[F D0\*B>!ZL:N!$K98
M;5YR2*'.0^>9Z7%>)0(A[-?5YSR!YILY7YRB;40CQL$MA:X@12AG@I?B=&]^
M8[B_GKELW."(G1\IF^8,4TE%>8,/.WPFT>&A;+4Y&S*6!"N!6H+WP1:W32O1
M@\M Q7WG(> !T&E+-@55& 5&!=ZN:097V59C4:QCQOFKSC A&#_:AN!Q1%BB
M5&R3H (4@3ZB#AS^AB=XR[P>AL?UJ0,HH]#)= "VG@ +H'-L]W.2Q=8$4$6!
MCEMIWF5* (1SH5\QB;F7*1.ZE_+8[=L?-5RNX<63JD@L,7 $9.T+/V71WE.7
M:>Q#(1G&XC*5."KEI6 %O1."?>AW;(1+^>R;;A F)]#;(F(SF7:N,X+,0^\G
M7AS%J'I_8@X,T-"<2=<L7 5@.)<=V>)F2JL ,^!4.4,48?.PF85I$6&:)% C
M!DZHLA.F,"O"[?6D%J5%65.X*!1N5#'Y#C'-C0-#G'#GND^(\]V;<B.7//@N
M0",TZ.KH*N'&'KA')BY&;AJ'G;B:[DM3R^M)LZ#T#EFDU!8Q- ]OMCR^%WV:
MP%^8 FC;S7A\V4D*51C4#=H9A%'QFLSU&:1'Q)[]W)&WH(3P"!C$)+!4'30=
M7';;MISSP8!REV&[2MEU@V\C"$</ ZS=83*X!ZBV9X_4C(K],RA.KSU_^T,'
M3'HFD5G DL;4=D.PD@QPJJ5>ON1&_XH)R;";F[?E<:#AFN:2J-))RBJ5@#QL
MJ\PL;/2-]P1T8X7]2MOOQJZ)1SUD0$$R^XK\65B^#UY#K)$$"/R(;IV\&S<(
MH_>$NM/>+Y=-H;C!O2T/$!KQP+*XBJRK>U29?(EV'INF%%+0,X5CK7'Q5FTR
M]-8*O*S>U;[95DQT3F022\?BMN9KK0-XB>?:T<1/>HNT]\M_H!\)2J>$('U.
M'A),0S&&2]Y C/4E<0B:%V+)<A^AA>?Z7_+Z6G?S_M9KFU1CVZYBNDMD60!'
M#WRV'N9&M<K89&"*F$O<P4-+IDO G8T\FBX9F"[WQ:]:#G^,B=]4VC]D V89
M<2X=P%56$\04]E,B5&2$G?).B/3+HC8PT"..CG[E5?A*7KQY@G+3?%M':_5M
MO0=37!K.4!<Y0D^EVVC1RC >7V>2)K$DHM_IAHCF6 1/Z89QEYI%MN\ 0^1Q
M#18Y(G5G?%.DZ!=>A5DI.C;5#M09'"ST/GQ5%PF#E2#+2*DGMLW,\[APGQ[0
ME#5(BW/F3!R# =?D2Z8Z R.L#)A=4E\S>HMYAL6IZ]N54Q4R!A'2A;=?/+2T
MCC.[T9HI?O_ 65+&0@Z\JN!J<17_HU8%W&NI.Q&O0C@"ET [L$E54<L^9AHX
M(MQ3S) I%MOHT@\677JVC2YMHTO;Z-(WEL#'Z^W]8P/]V_C1YG55"?!^&D<5
MG;'7DC^SHGZ'!:Z/4=1'Q06,C.&$>OQ0&[Y^)R9>G[1R[@Q-_VPXRJPKMV<A
M99= L@4SMSAEC#^N;7HS@Y$WH,AL+&&9HRT3<%DT)%$[X;Q#DRK]=8/Y9402
MYJ'@EH?0+]$;54I^)56!D,_4.3/,RSF'T7NIC*\&I45#-8=&.:BO! 7<VH!=
MLV3W.$%FK=.,Q^6VZ[VY;EH;IWE(?JN.G+V[C%<B:CX&1^\0*8WVR"97>\ E
M 81/:/ ?8U\MFQQI<E('J')8U.;NSF'X=3[3S@>1JOF6]6U6-YB6(Z#)_CY)
M/0Z>,QHW<$F)>XDOA.V:1@XEA6XHEXVJR0SF9(,Z3.=SBC @UW/1S4X>(MY7
MME?99"/+D*HH]J(W^1S#!]TA,=?I@QN@]E?2K;&R:&JE;VC:R[DD]X_]6# G
M>-E0DX]TL.BWW2W6XH0%I'J,:  &@HY4.0QDT W.R>J+@?:2$C:2_^W2!OL1
M)A>6")H'7R<#N/+X;*Q!W=1R^W%\_'CSKMZFZ80G:]4)S_Q$C$8:*A?_=(-"
M-'IM(0P$9_-C32]CO WE<2>Y)9TB;DD0<6\2K)QS9KN&!$8>>%)2)#*(6,,0
M@@I%QNIT2(KL&8+M;]07<*LU\@I)B0T6*^68C<Z.?P;U=&NS9<Q;0KZ'D!^M
ME9 _*=0NG+:,#<07EI:\9!MABTWO>]'J*:J;Z6&"1(@/SCF4[OS:5+XYISD8
M[SR'G;K?T(?!\-\,5*7,?&VXR-1@\&0)@1I#RDBM*%^L  JC!]Z,N1!,9(?7
M2LC/6&(IQ$6R];1.I5K1M F1TE6'A14N+]Q@5SX$"F!1>4Y=(UFP=PX*@SLX
M"I))Y&6T4A;FD!0P#30OAELY<?_U>OP=^@:S[X@O60"U=E\H*P3)X(APDMW!
M0BF$5F>>LM+G])"<L:7A;Z2T/H\8UAEZBA[GZ#0#>X77=<6_B)X*MV+2MBV3
M_0U,AHK4W,L[:_')8,PX N]K87Z"83-)DNMRNQ(+$[#21U@K6=I40I/+Y(+@
M&VG5;-J5>;+6*_,:NTD2(;Y5\]6%/9X<R2S)<!?4(8P>ASVRX:RMB+JI)!?@
M''8 'LL29=$+7,((AK> 4MB,@,=-JX(4&*W3A9RB)K95*>X.MA*"E@4X3RXB
M-%X5"UXF>&84.*NX)=59JH#]J^@<X]5@BGB3-1W2<%$U@D%0<(J+H=588?Y4
MN_^=@IE07!S%)47^4V4%G+_%VSMQWYUXNM8[\<K8@^=8Z6TN1;-BG70=J@_G
MLK5\GG%I>)^2!8&KC\C"5' *1:87I:@A]#$-S\R=_FE2"KL*R+?$\G7$\FS-
MU3 U%1@ ;92=_--U;!P2WB&=L'M&O(7=:9=&.<"\7Y/9SZZ3D1J6"9PX<S."
M^"[R+!F2^:@0O,4+>:,5>H>YK:3\VA(!]]-MI/L'BW0?'FQ#W=M0]S;4_6U%
MQ]%Z"^O/BD%2\3=!_V5T_Y2UU"\@\@CZ_9#+"R89>2I@$(NRCUM&(2Q;08&Z
MI[9M+@-'(B<O3V>@S_8C)*&E7T?3&O/.\.T4W>1RLP9ZPRM1I+W%8'>:?O0L
M^KAWLW?.JWKR_'#W\''?#V5BNWL?A\TOQ0EM1B]J0CZ?LAY@\0@VA.5(ZXCE
MHD$>D$ZBHP2I@'")O+E12JI$+<R^];E0K:3"& +3X=17L2*Z]'CNKW%**S$5
M?!2@MNT/^@VTI;[?4Q4F6Y "F1OWF=>ZUE<?**=ZE6/;&ESFT+RVVXCACHX'
M*K9AI8(J]6!"&"^1^KRR]]SXMALIM'_U>PW%O_@M.GM]?7%Q^?YU='L5W;ZY
MO(G.KE]<WEZ?W5Y>O8\^7%^=7[S\>'W1CUY<W;Z)+MY]>'OUV\5%=/;^)?SZ
M(CJ_>O?A[/UOT:>SRU\OZ)/KR]=O;G&PZXN;J[>_XD]_BVX^GK^)7E[>?/AX
M>W$#/[N^^OCZ3706W5Y?GKV-8!;_]?'ZM^CJ&O[_Y>L+_,/^YGUT]O+=Y?O+
M&YH3C$=SNG@)4_;[IIM;@%'@Q&"DD.69&U7M"^Q223Y,@Y9%[<MLN^/YA#&7
ME"%/H4Y+FQYIAB6Q/IE[<4%I,F/NGGN3^,/ B*_Q!ANGD5%)08.88SLGZYUJ
M7I?NVT)Q/;"*.-$<#".ZG7[W/+-A9UC-+!?/C=TU:'LU?;M/#2"F@+V9TK !
M==:Q+(/\XQ[ '+P0! '5IP:.9>])<IV#7(([G8Q&A$1(4P=.2#%_^$=91E--
M[9@-U">F4!1X ?C;O&C$+GGW"?N&?>V_YPPH67AI+]KK863V?;0ROMM)CJ90
MT!NX,60(=]L<MF_!Y' 47 5BAN5W4JU(R2:$C1LLT.Z,6ZDGYH)2;\DT;J,!
ME3:RAAGW8Q#5$PH'C"BQ BCZ+LE3\NL$4H-<J-A9T(:V^8&&&]>6*6-[<.!2
M>LP'8 X>]F"@P9 :<:H,KX8H1);$#E/R(QG'%>RX#<6A-'/WTI)^%GSL;4\0
MT?=^45J7@!1V\ G$? 3X%M/K4+E#-SVUZZ$(UO\Z>W?3QZ9B>^LMP,'W!M#,
MV&$/=N=5 =(P*8=Y/SH_\\(L5%#FG2<^'Q4U* RVS"14@3S)9+6A'1?&H31Z
M PW(XK_,(^X)C4GJ[I= AGQ$DZJ:G>[OS^?SO=_5M%1QL3?,I_LTB5WWNEWO
M&/>M1%NJ4I'"9:6"#4B1,S[HK,<1*?04@,:*LU)+209]3.R."L-=Z)&2NM45
M,NHTPK0E.Z5 *E%!'J;Y8P,0K+O&HZ+07O<I4-T7;__S:&< QUR6M1_^]A<
MQ$(!BSY7^',2%TW!3M I'F4INMR(E3S;+YZDJ86_9 ^OC]E O=\%P7;8HQ("
M%T)'H<F]X3."%F"D1PD"AD4-H6AQ27?$'5,>J]3Z<YL=^'MO'T^XI(S>2,3M
M[XRX!"D_I[1>=(<YQZ/3KSP<:#\#T$_$28)SB>;HM,:]C[MXEYNLISE8@8@W
M<F'2BQQ*!.LG7*2O,I&<GF("4C)6I/@%FGA)@::JXG M*?I6A^S;  $ID289
ME(65X<U-6\3SV'\HDCNDV#/C?8U>ZXP-%6[2>71P$#3I[#='>*42HWG;0-N;
MO"93@ P<_UE[S=WS;]4 MD8:*OFO">0>*5:R+(-<O,(4$E[!%I"HUDMV-XNE
M>#\<0&K/9VA?S&S-TE([+@3<,-'0!G8,/K_FMD[(+.+HG#8NK.@4]&$_\.M"
M,P6QCFF=5AA7LMJG,UW(T\H7IO$6($2&#AT !^QW_D)<O1P=XHZ-?+FH;T^J
M?>0$?D(:"& P^-X+8Y;V/D<\U;'5BLPM#="#<INW(;V0EC$RMFH'E82CD^SW
M.F/P/;!S$ST2?W51^6,F(#=1&4.BFBC0_$#(V,Y%CBD'22;!2E#_8;N ^:]H
MS$M4(@=7:YSIA. B"2V_U_'83YTVH3VZ 13PDR"?S(:$&EV^5K#0!C4YHHGZ
MU *['FR=XS^4<_QPZQS?.L>WSO%O[!Q?+\K@I4!^2:ZL[R!OI)A+9-67:M9N
MH!8O*&",?R()A_4*.RQ" DH;%-[F==N ^SV$L=X2?8*?U)5>C4?<!*]ON;+/
MO0 !6KOMC#I6U"R!E Z&(K:U$4A6T@+'3"MT\NKI((\3WR#%5Q9^*V03I?'3
MZ1I8.JSGB7[()E-?-'STTX'"P_8O:&6I8LB"17O^G-P[3="W2F@R?J'_@"#R
M@!B<9S4ON.Q"C/=OFR305@2:1+BBEW(23('I XQ$L'/@V_]K\QHB%*P4("*<
MD?_W\W[RR[9_XOKUL:.M/K;5Q];;0#%<AB7<-^GGPZ/#DZ?'1X\.F3K_R!)Q
M<71G_O,G/%$8J")3V% T4P;Z2-2LU*?F#W^.*(^%;G%3"$4FJT)"85+TR:1]
MZ%4!_XWM_!MRFRZ"//'HX&_^KLC 9H?^BET?!&-*0_E!GI(4YXCMZ<_[ R&;
M*J:5P&:!?@$[>_33C[<JROL]O[K^<,61ZW!U^W18&WQ@_E5HK6X-[HD?A03^
M"%?<$L"6 +8$\$ ">,C>K'EK7BQ.HZ^=X\DCJR8:<W_V):(=B8PRN]9%[)?[
MT:>]Z*7.X-'H5_CO>UV6/PA]6FODJ .'HNE"^?$)[@\SF:^F3;0GOC-A=A"E
MOWQG(Y[^VPC^<X#V5F16/BA^>:M5'*'+$ -1Z%1Y24!#>?&#T/:?/.^MP/S1
M%K8]M TUX4QN\3>Q3#=.^+\H5)SJ17235)_S'^3$K-SO"'O\2;'_QX]T V3F
MJK/<)X?4+VO*7'C@KMMIF& 5Q9X:;PD\NO?;)W]@,5]#)_\B#OKCK8-^ZZ!?
MKX.^V[O01>A= <#E$ORO3#O\^YO+%Y>WT9E5#39@*VPMU/G5^U>7+R_>WV(M
MT^7[5U?7[[AZ"HNDT$:Z?/\K?GOU_B8ZN[FY?/W^'?R3"Z_PKTT*C&[(-#:
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MF^_)-MH?Y/$"_F]23=-?_C]02P,$%     @ D#UI5M1D>Q^01@  2.T! !D
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M%W1Y$?]3G??[\- D3M7.1-&P^KO]IQ>E^ESNP%/&,"[\](*'<0XC"/#/H?R
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M\3!6Z7".0[B;Q+#>>*;Q\<@(AY]@=Q,%!D;$=\_"O(QAX? "V H:&_+E49;
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M:MO(;!9 B;9Q2>["$4M"<D:":CHD:T_$9:[" B0V:K$IF&A%$>8L.G%<%9K
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M.G9.FR%02P$6^9+,F%XP2ZK"VA<(A^-%3:RG>K2];1^8@3@FGYRVU'9]G\*
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MB@G-6&+B@N/KK45FM=4"D^<XG:FI.Z\U*_&$RTRHHV^EH2]S[!V*7$ZXI)_
MSOAY=4 Y=E=JC!'@XA@WK3!6AD!4:NC%X#2:N 7<*R0;EQJLEB'^%F@&^N/;
M%YUPXJ;PN!I#,L&YGF[^)M>9+RR]F$N(JX-T0YS+V23G^ :CABI)V Z'&"$1
MXT5<[<"6O*>B%.96KQFYB3+*O,R=%XKG$B%4XA09TWS34XG;*CB.GQZ=/5TC
M?R&F+ZFE5%3C3K7UR2 BT*@PS$;F@.Y^/'<SN9CK;C-^/$)OWL(R1U2**[XJ
MB7A1D,QHDU9Z(6P]D0](O7_"7'1O#;3920DQN1"44L$ZH.18SBT(D16,C%V+
M)=X87H:C2V><[_BG3MX0&T(R5-"[!>.&S]U*$RR'01V)FW"7<Z.VP<&@+RS*
M*T+"WNGO5&06#3T3N#[4#(X;(V6F%,6Y'Y>H:*X2NM@QM.3F$UM02E),Y<G:
ML9C7G^!TJ4+P5S]/F5L&Y,P&&077BA^R[ M]Z%MS7.<US5MF[??UD.4C,48^
M3%5N/-:?*9M9R^&_--MEV/1%<*4;()%?PM,K)I*A0MBFDOL]XU82WNFC["34
M\#$=/&NKHM+&6]W4L/53U/K"I&#U3/Y5S[W?IHEX;[#8P\;!1Z=-'W9+\Y:)
M9 XC1$H>:B^Y8[VDF4ZO'PH48Z8[+6JW/EA<SDUU]%XS #_!S)V=Y'#IR=FI
M-*>ICQ,/R7SL%;&)+:*[U [F3H\:+EPY/F)Q<^,_W%\Y@Y_@I,+509Y[G!)C
M(,JJ92ET"RKK:G,I6B<CR1F9('IYI8OR(/RY5W^)[7.D<YU6?2/EA"R8C%T#
M"G4SNK9Y$W85)LE'-QGW@S4='07);3VF&[(M;B 6BY#BW KR'^QVP9"6V,%I
M%PSI@B%=,*0+AFQVAY+A6E7+MQEU/@ ;H"P0(H*M*M8F5];LEB@_5H!_&3H3
M"_2>;GUH,M3@EW/B;K=QECC<"2=@_:Y>J\41!@JLP8M--';8<#+Y_#6ETN(&
M./HV<<^%;T4%3Y=>]]CTHGH#<B"C]XYT#'@M?1FG7"2!EEN/@4FU[78A[0V]
MQ\LUE,$)0F*+7IGE)NS!_5,H9S:<<?X?ICM1) 5FN-VC\?'@9?DIF#8*\8D2
M-T#;$_U%.::_H(HF[FM\&#5AU=6KPZ%*E%Y,N&N:18X%R^:FJSG!J++"&*(#
ME:I17-IHQ9QV/A==O=X6TVV=TJI5MX>NT$&IFX1L^6C!.M)S@8] 0#1G98EX
M4 +*P..IYDUZ^"H%VA@P%H:V)FHOQ\P8[:#H&>=$+[@+\?QP#8?KSJBWHL;V
M'@-1">S1HF <5<N4P%NX%6?AVQ:<$X9X?5DUDR30@FM=<C3TT.2K+097V)#;
MH<T_L+TH9_G;^0(G-BLNG6U!BR98:,JV:P>!WG071+0 X.#X>)UN2=UZEB7&
M58NK/ULW/$?? TT0?==&Z:A;K@;T_O+">(W\C=\UDO+09ZDD*(+:CGX-/1_Y
M+1RC@G.Z_U"ZK"Z)%?ZCF^R:$7@(FB[;<;V3NC4\0=/'?LA:5\_1( 4-PG/W
MM3+.-&H$4$U_8><X8FRG2_Q>= ;7V2G'HTB;I"I*W \X>]JBE4A#3M6/TD"W
M)TYX::2@VQ4P(I"=QTQ00ISI!&0<*',B6_) %I_4LHY\J[_<6@TA%S0HAI*E
M'F<AA6@YKZ*.VX-:+7,3-JP)M(-.$'_2'@J('4<>)093MA."XD<]<5ARSGS%
MQ82YEXY<L(U/4<^!^92OM0HX/;=^J\!L1*8(Q2@B_(V@\V-3A=KZ-]89]Q+'
M_4/X/1?0T?I)HC\MGE;.(T;\E*$3A(R'$9.H6W1^+(2(<=SFZ)76_A)=C&FZ
M:-Q'PUS168I00.9(0V;,8VPXT8@A>4Y] T?B%$TY87@Y5,-L)CD'7I^%.DX*
MAWYM>;> LZ@%O3]XJ5RJT,XECS3,4M3IPYL(0PG%2-W&M',SG?C[>6]1JI-L
M9)PBX&R6%PTSP)SOF-3V[4W7%ILI@^'3PZ<'!^M4%FV3C7JL2EJQ3*? >AEU
MV('5820"K*W+LU+7S.>LK3@AG)HIYM9)F!P4CEJ[WDP*JCF$57/&NF*&E!X:
M+Z>LJE2R*4Q.BF?OM%=M4.B#  MS+@;?^.R*\5K]7?_ &$\LN0!M(50TW9,P
MGFI(ZT6,Q<;=N& 26!&%CS!@2668)0-/36>*Q( K]ZU,;BHK[+>0.B&^T(TW
M61*[![6,W7>-YR_%IGJ 3/,5P:EJ1%I#R3]Y*"_SIH70SKH06A="ZT)H70CM
M$=43Y02,ZW;LII;@2C(L,.$%SPO!?&RA0<P-:+:Q,!O[?8SY^)!,9K4_SCE5
M@_('15@:8"7ER71;^;P(YS55,1DVJYD3*2?HQ+EIIXAL@OH$<NP(#<^0+$\8
MJU.7/S=\A*L&@#M5O%%2(X4)2;G"?O046="6ZNK8J:O65-314R6"@$L"6ZRM
M5C8.=5S"5'RY'<_; P-N%\6Z%OQ>-\(D-CJ%&7@K$TSCPDETQ\A27.2UQ'I9
M&#3@EX]\]?$MV.P>QX=PJ$"%P/Q,FQ,=JL+QLAL'HSU$A4X0,JHX86\(^V51
M7&#@K)HQL9EL35Q9]#[$U':9>Q=&#:M&T^$=FB*T@%(L(KE6EH+1R%MXORV8
M@BG8VG!G3<J<'HX!3 &$;Y6\3@S56F1\OC'RY,[TWD&Q+$5^@5'@;*XDX73L
M1V)!>'.&GU?6P\5LSAJP-8=<0T/$M[VQ88TA:!,[L82TJ"42#TAGP.U)AGV5
M<'ZT&Y)D]@M?3N*9ZZ>G(/8=3DXOD#GU-.TI<%:"7Q&6$>FQ>2XI<=D8MV$H
M,#I-5Y-5<=@/MF7F99Q=SEEV+.#M73>3DL&K_'Q,6Q"(4"/D1Q*DAB)$OR=P
MQ43'3O-2IY;6>1F=(\092M!A9=(4%]A:M])\-]8N/;P.V9^!T"ATN<CA<?!Q
M]WKWQ:XN(@D.SDZWPNU6B*&&DVJCZTHG32?1T=.CP_XZ"ZG>4-#J<NB$,&[(
M\<**A.DS48MC?[S6TO'&*.N7LYF"'Y]GB&MC<X")JUQ5F-4>IL&[F8GPO[>7
M;&, LR3ONV@JO9JJ8C45=RBU5FIT-(C-<$"?&C1S0(&S6%##&>LY %]%22OQ
M\3IG=EBME\C!+*]4!+E7<0L\+G?P.7(KD].H-J@X+4,=X>"@),%HQ4QK4U89
M8SXDNE>OIHOUG)[/1B1@5#'+G1#C IT!+VIZT^##MC;H1>VL<Y[QA97G3C[T
M-VX NGMJB]N^=AL?*VUIK\ZQTK5R%_'F-ES07Q-9L8"7F?$_(_"@T2MS9$0F
M8[T7A/9)#*P[K')T#R C*<F5B'H?8U5*B'W;ZW6.U7Y.LA4^$AX=Z<=3)P;0
M 42!+IU<>\X]DL^D<N,*4^!U%3'H*'2.>SKYO6=R"^@0LR=2H&P;7LEF!7DS
M\]^D^U.)AIA=<@?853U;@-12*>EF.;G5\I(#(1!^+7EMO#D%'W237[7TEFTW
M3:S'R&@.A9"6-U3Q+959S,WNZ22\D7UTKR7'3@P(J=0DTY$:#-@4.TT_9@0I
MFP^+%R>6U>4$.X8=S0Q6LQTP?4^&' _6.P*HHBZ;&"6@Z>)S/1&-5*?IE;59
M?17/C@9S!U2U$U%2%YGBM!9%5:!X%;19'?[1:7$.>J,M-ZQ7OVN>3#BX'O"C
M[@3/F(]AA/2/II+N*T4(G@EMF#PL0A4 *P!;\P+J2!&\+[#4FNI=]9XWH?.V
M_YF][4\[;WOG;>^\[9VW_?%XV\D+PZT9N,Q=Y/0RF4^JH:@U"4$^%!/1 ,2:
MTLCO#C[R1OM)_EAO]3<W143W/W5%;'&*@ IF$<HC-2"7+?H^)=G8YK>(>@**
M9I6[,"/!W421=HU:98KH1/(#&"E@!F&>U@ &1%4LC!_"VBO_W)/DK3')@$BQ
M,HMWZ9_)3'!U-?O&B+,223$')9 JDDW&#LH%J1ZZQ>PU? SV62QTFB3<MK11
MO)$CC) B2ZD;3/[ -/6CKF_R:0MPT^G9T?'Z@%6LX#__RXC^6PG+B9P$? [9
M7[ $R<ET%W]T4$ZG/P3*B1=L-22G#7>9M0 /P>8?KK7 Y^MQAV3L[ZM\"*H&
MA\%"-OYAA[7(HJ8W,Y!)O0=#(B+ L%)J/U^"AH:&.;N=-"B1='?ZGEA$VDNX
M0I_)!X,MVO#S\@-1>8BKM8/R"-CDSX/)HP>L"RJ^'I-'-\SZ(DP>:;GP$) \
MT@WAH1!YOA)ZQS2[VUSD'1U5^3K@'2&C-MP=VR1]==B=366/+2W1@0F>'JQ1
MG7@HN(D%!_OG1YL0.;(VL D3$G\(O(G>CP&<Z*T)<2(N=!;K R,\2*\;C*]U
MO<.[<-."Z$Q_OXLW=?&F+M[4Q9L>3[S)IGHOAACZ3LA""U3 M6;P/C)_^EG3
MG\XI=F<_UJ'^&FZ=ID9E$V"2S3;&VD#E::_6B2I_7>6W(,,228>T)5IKC4.<
M44_/;8Y&P$%?R\OYI?)6DYGH]H=VHC]W-OICE1&\24"B^#ZV)25FCJF)/MG7
M&_HL2J\$.Z6,DZ#?/S]^&LQVI[O!UE6(F&@,;;*M_641I]V%I-10DVTT(*1Y
M*IO36%B1AL8U[;MP?)7*FCG2-I)(@[UMNB$K#TS:X3 WEJ*HFO.%G2Z2?TU/
M^0'^E].#1W;D30;TS43=1V8>L 5NKK\KS9[JLD?4*&33U_D+%]KX$+]@G7>_
M=VKG%RAA2_NPBJ\;^U*/==43>S_R>?/P][B>%?TF#?8EL!@%UQUZK>G5YUF<
M>[XV)^I5B)#1K0+;^85T5OLAW7K.&#$01I%RII0S>I]\>IITYCW#7+E(L9U[
M,E(89V31\C$+I>J!K*#: 2?1>*" T+9-2V#TM+'CC%UQ^!GQ>.=Y-DICNY2M
MML(UIRG9OAB[U3M8VS;*)++M]7YX\@+MF>[5#=LUUP63DO?$EA+3_"@/J\AD
MVXO;M5%;O-FU?X/6X,#1.H,#5@6!/=,V@P11J5:%*S]6KG0WCT R>(_W>H7O
M3#L(RHF1.<WMQ-A$?%TX7/DTP4"['TS#2C94J73M@XV5^4H/O"!7 M3;,UVW
M#/*:!H^SU<Y; BF8?M'T8JJ2J\^.& 5K?1PIH\0&XCDPEG :CA5ACWJ)@S"L
M6*5#^HW/4<_BP^F( V&58G&D_*+Q2GM4 1%1U@0<,'XF,C;\1S&L7"%E]=AG
M/97N;'>@PJI;3#V,>2.T\\#!  OA%.6IFA=2_2(/9&'&$)(<'=1.!]-YL2[%
M3)3<C17Q$ZC1HJT%! 9(_%/*:'+8'R#VA#<WF?=6VB3F\M[.--E[BR>$BD,Q
M=B&E1+DI8+)U2S3/!>*)G)(F+H6/):DM@>'FR8 Q< #=-INL1X=[@<=Z],'O
MT\%GM4OG_/@CUV&?92\WQ9HRKW;A>N\<6M296%;R"A& L=+JC4OS2Z?$<O'6
MFQ95>NXP)Z(C@A D6,X4#DU\RLEMT$=Z)6*YH6?S7%[@L]OIAJNOJ$M?+4./
M#SQ07$Z)"'+RW=4RS,(3D,NCHRW+ZJ&>+M>%NZ#51@>M^EW0J@M:=4&K+FC5
M=?597VKJ&VNG:U13WT5D/$)-]V_-1\1*=CB&[\?(-\(I5M#4LUG([;!8,9-G
M-I403MY><[1A8*(-(TD$?3 M^SX=6HQ.9.)82T'9HGI)%;:"-2WJ-=P 2(;L
M3MTR?+PP=NN&J==AK-T+0X1M'#$,C%SK,B$.&5SKE1TQ&QT:7-39Y61_C<Z8
M6LR6P9&B*M?8*9L>8UASES8-+2)F(>[ 9=K"4*?A7 Q 1)LA%_&("S7=W;3%
ME_1E23U>M$<ZXT_EMSBESAV11CIB-UCSQ?#U.+[5X8<6&5!#$]%X(5NK&,:-
M^5NS6%R#M2LT+I[EQ#^$.48N<Q2+ /;%P?GIL>_#.+HB!=<D-JY"D&94BKM0
MB/:TQWX$UCMZV>(<# T4]4/>375+,5_9'IUM:X,(B+PS9G)@WY/_=BGP:[S7
M -',B%(*G??/-5.ED(S7K'S;15 2?$60 !;_:,J-RQDG"1:KU'Y,'V*+AAU*
M501(4 7'?RKIUZ2ND$3M82#+K"U"+J)[0QJUR)5"Y21:;2P%<XQ#3!Q&A!J;
MI]NZ#)0+C)BO5%"-WB[@,/6:EG;M!VO9EIZ9L$'73$I8J ^[*@G'/@8.XCLB
M")7;-L[IYNY6#.G2N1\3NZE2\JUOB1L65CU-YC7*QWW97NCN*QQ4'[<A">VU
M^J.*8.DB7;Y#=&PC8$:31?@?)@+D>ISX36>C_8VR?JSYFJ#!HI.IY]9KFQR\
MF9O&Z+%V4G6]8O4E QG0R2JT4!7NPO*NY=!FJ881<$B'R4;*1Z1P@D]>T'#J
M L6OY UV1]<2N$(]6WMZ%_&F>]A+G;FTH29R(E'+S3P*XIGH$HO">2%.:60S
M!"0VLS1>?Q6U>J1R<1=)4XLE=^J[P<O* E##JW;@51*4[BV8MH2%,6]C(6L5
MV#&PLT8LO-"?%MW&199+]M8MBI6Q@)LA<RFY]98K8%U<.:^8!6]QI\%Y)Z)U
M26-!C'QI9D"H9<R18HM/X0=&ZL^T(:Q%2^!(OV&&Y<0$-Z@3 IK+8F2ZG7W,
M*)="2;0)KI]3(@ZQ+,>6WXS-A.'4YQ 106B:3L%3+AW2"MN@,9F[[:0:Y+ =
M2"%MRY[:EK"+=Q;ENK,JZ,> B>X&KTW"590I!L8I+(WBDL7I_238.!\(Z<P-
M8F R=%B V2LLUFY.K6>!G0E&<MG&#A2WFD28/U1R%3\.^SQ&U+"LT!I,> NZ
MB=OQL96EV?P01I$TF:#E1-4 EFOYUL%-)NTL=?LOW(8 L9]CBV7H'84.%N]/
M'?(YZ$(^7<BG"_ET(9]'4*=TRB>8$D?(]U)31!>*;VK(( 5(<)MV49C&S5HV
M<O)P4Z:*QH"LP^"U.#KR??JQ^HP>\<*H7/:]E#+VF;PC$L!INH]<H)Q1J-4]
M 09&O1Y-W:T5\\S>F5?S('WOVRN3':VGM- 8$0VV_KP>YQO/%RGS=1W7;)*H
M0J"=3&=E,M>M1-O7'5BP4JRBE)C:4HH)DB52Y&#1\IF1FC0^BU_-I1:<',L:
MSX(ID3K9/N;%&KL[&#2IJ8B?'".,/DV3Y)^-'XN])]*6AOQ\[@(\UPOP$A9@
MNY;(3J\S?7":IL77;8:@H+@ ('!ZIFH*%G@:55-*':1$9@I:^;'%ES# ,'<<
M,T3Z8F)KDVBA%KMR7NAU&<\JMC NZ54N16L8=7AQXSJK>^LT:S8,4^PH[T7B
MUNQG5ML2E-$!H__ZH$;'_9/]I_N'IWV.&KWFT3*1&(7A2W98W!MFB]UM#6LY
M8^$@NU6+F6 V^@9V06=B&>]%RX?@Q,E 3PT:N#WPNIG53-.J8,NP[V)Q#PE]
MU+C!IV-:&:;*]0.ZS>=J.:)Q*2[%ESPBG\-^G(E]YI_8,&C<UW/]FI2,JZ(E
M80/-=K5AVWC>ZD?J$E_6<IH>^XE99\K_(_2VKM?=VO"$?IO/M584T^9I?2!/
M:4L<Y@M<I34UA3' ),$F2PS.)M8A%$I4-]?Y)A<T9L=-W$PC0L>IA8 YLW*I
MM+S?=<CU1$N\AEX<R\E?I]5@%"'X@N&^T)VU2.(8GR.VLN-D?-%Q&6KZIO6=
MR.-),QO&V'5(LQ:]C%IYN&_5=%3L#J8PR;C,E5R:I?V\,:*E'C_R'%)]!$F*
M)E%J$*5[@JI47Z?-#L$:"K;$/2B_>EDW5>J0 +YDHI*(T"DC,LHPETC')U6T
MO41'Q6BF.&='5<'=*)=3[9+E7D9CY! URG</E(32;^U'36&X1,>DLR]ZD?4\
MT_(;TZFY VR"R8G7^0B9@<+VJ%8+1Y%9%)^6C\1?6BR8(E(H^GX#VT4*:.>M
MTV]T\>[K>#*Z=P7NL89Q]<-BMY+4P-U/VKIA+@MW>S23.W5$VD^\B(=+Q%O[
MZ!];,-NEOGJ?0<+-E\(K 5!N!KGUQ(8AI4$@/&)NZ_L=K,GV&#?68^BXHV36
M['H^O<XY+<[IP\XYW3FG.^=TYYS>['H$M5;+[WTXUT)>%\0VW%5'3Y\>G1X?
M'[&WZO>%0M1)TVJU%8'U$ Y9XJ=HF<Q74ED$LV?&XRIJ>1:NV]&8D 7<7^![
M)$R?<4.3..4D/S$:O,RQIEZG$B6NH<'\7'K'<[F%](W$G[4>JEVEV<@?DJGH
MQJK6,$]WT)IXKZ="[%8ZJ3@^4XLFTP8-X4?XUZH_'8HO9BTOK56NLNK&&+C8
M(#J7,MB1J)A3S*8 Z80VM?'UC2IL:4@^AT6ISNSV1,-MJ[^_W1H 8C_AE-O1
M8 ^.49R25F>[YTAM322].9S-;*>RS6XF\[0)?H?T<OACH>^N_KN*V1/S05)S
M&G@6<)ONY"FG%[N5ATY1DM-V6CX<2$LOK^/P<J/(UB!Q0TPO6RW.<P7/HH$B
MZH6V4-R.JY;O@GFB2L0/$AP)>:*N_@$6$V$Q4ZDX'VE^P8KA@)&%W&JK]JFI
ML#XUB8$Z?:RP=ZX@0+B#1-AN8M"H)6FOO\OR^6)Q\>.')F6*EKXM:<I9:;B"
M8+5#*M>BIB%>\G6+'.%I]?"IKEQ2AC#(M!UY?7[Q(<"(.,(K^-Z$R/1'E8K\
MP)>@5'-A,:65A*G2X"<OF)@X33F2 8/%E'M%]N@?%9 %V)52*2+N*JZ#HZH_
M72>(\FM&WC&P!SAQGU]<*-@=6)T+PUM1P"C=]U:3329MD9KT).#KB+$"TV\A
MJ<WF=?W]5F9W](-Q/E\X!IQI?[+AQ7SM/9Q.UR>6&MM"3.)CH;P>Z(2Q4IP;
MDQY.=U4H0<*Q7@2= T'QQT*E:%%A'0H[..D0]^JFO#0;M#5G)I<FIQ;IY*(>
MJCS5\9?+H=06?R NW1.F N^F5 C@C,";L,68VQ]&?<;FT847P;4-8582C!<:
M!,V;?CWC62,Y4:\JTP$QX3@JWB">8I&@H,[EL39^!+.8ON0& !)-1M9+2XF)
MRF%: A<,M)F*%TM;"/&O8#?##-X3<T%9(R<;/Z-%,ON@98/,3;JOJ>:MFMO3
M"Y<'(W:#Y^@$TNDQ1$%4[XNU6W.G/4:-_-QMJ'FEE&XP6G#8Y[>*Y,5;(.F7
MMF&<TZQ(^LZ;#CLFAYO"V%1('1>Z1TU1(52UBOAM2!$XJ%R5IF%.2Z+S6FTA
MA/A?>U/(1\<RVZ'H3H_6RC+A1"8)IT((W8GF_GH42 AGIOT-0W.U>[;JO+,>
M%Z"236K.@DQR(3@C'#QMNZ_ZIF_@TO?RX@&UGHEIS*C!1[#%Y-7E7#FL$B^(
M\PZL%FJ41AH2*=".3DT>%I8\)D:.0;E1O8G5W"D5$EYMEH#+ZW#>3N%!@[OI
M: I7#H*T(*>WC@4[A4AP0:+&9(_7D"[T&R.7&U=4=VFR, >@O2.8,XRD\%B]
M&PK$R9:28D@JOE6?7>"[0L/0T=B]'2,G.EMTL:0YD&M'UY8X,^\@NKIZC84A
ML:,N)-:%Q+J06!<2V^R0V'HANMX;E(R&AKD0K&L1?/L/L%%ZKI/6)OF:27V9
M(NRYI[?8O'429(P*U@ 4Z?E0[;JO(8,,NU]A?W'C3"Z!1C 59Q*F8V*S_UUE
M&D]K7I1JBBE>[.J6UJ,Z)&<KC,LZVK.%@PX2X.GLW<S#"&.([ Y%*]G",K?A
MMSI0[+P"_BM<F*Q;+O*U/A QH+GA8\XIZAQ3-.$GQ)I/,J2H0A1P:MWDV.XX
M/S "!BA"6#6V?1*]>FHG$PUN^Z34S"DA;G:O]62P=D1X'A:^TS:8]R961T?F
M<("=*?6_WMYPGW"_Z1,^.>L?K;&_:ZM3^#=@ W!ZPE1E5=&Y-]H[/YT</CU9
M)]3^:S0P@)DPUV.Q\XJA"T$G4*V.".++<,;O"*]!JD(X:*5Z4O!1^[@PG^.9
M][X#>6:^RUV0!$0VH$(UFZWOO5%[*"T(HCQ'7 +Z!GU]ENOWQ(4&7F2D"<^?
M6G\-=W>JSTO8=,NG@WG;IV76M@(&@UY_EZN1]AC[3;\QK9-237:#CZEI14"5
M5I]+#_2))"3(/7J4(N@OGL)YL/5YFS- -)+_]7"B(I2(+&^N/D] KR30EI%U
M7.O+ RV6S%W^36%9AOA-"]HE[,A\FP.P%L2]Y[3:=9HB:],KF"K0IR4]8M5[
M<)W@!X+++"H0^W07_D:P4-0N&$;(.1O 3&B.^E^K9WC(935_L&35"LW\DZ<5
M2+-E=]#Z(SNFEO=RE0>?$2T#4=YACQ4T"1/MK[(]VSG^:C0<\I55B4!1&8IJ
M-*F/"P;;C,SIHM[K>:4BX^S'\LL\TI%RU#&JZ8R=:#FI3D)?J(/*W4/]=>QQ
M$@]SGI7#* =5A]58M\DR&K=A53CM%ISVR^AGP]M4Q'& !:1']"JN.=V-+5?+
MYRLQ\H*'4ZIQCBUN&*:M@=8JY%' 1AJ<G@*3&.#3>7 'KW2*V&Y5/H!%F,I0
M-EW,+6@HL\[VAERTI:O,.*4 /^AIV!_J2<(]Z&W#$T8A+'0W;V&2S'&PJK1*
M)9>PL,U$K GD.)&ID'@!"A#YD0BDDCW?=Q/"/Z2":>8_$V(TI.XZ@;=1G-NF
M]E)"NRV2CYY!G]U:%A9&$0()@'H/9$M%0VA$!=Q;71S<PVR< IW!)+%3*T$V
MH?40P[RV=)FNK)B*^&VQWX90/W@4#@N0RYP:">L8)QR$>/_RE>766U*!Y4^&
M$N^DAF3;##9B[*^4@2*-)3-!X\;6Z@_C64SRQG3L,(.;URTM'!1*!K1N&+I9
M15SKA*XX6GT:]Y9;!H044U9Y&C26HT<9,!BOG6$*58R%5=<$K>F3"N%)#&2E
MA*^T@ R(7]"6ZNO](WM2)Y@R,<I7C&*M$Y3<C%5.$9(6C;K0B9%16_- U^Q*
M^->_]$_V+_I]8A75LW/+,)_]PJE1VJW)[D'LOA/."G6N?W!9)#(F<9^ADXM4
MI-1GD6%59K[+DC[Q'(KLLG3=B77G8$ ,]6]/V$D/W*S,X4^DQWJ+-#4,$^&[
MP(KE[N/]?W'=?_(2[0I\&)"46AC&Z1&(M7XZ"?B<W81EM-*X^\>[9T^_?.C?
M'C'X;N&!2SXWYY[3=,75.#S:[:]S'S$6/5$@@!$T.+BLDL^]H'^ ?P[.?AGD
MS]Z#80V46^R\JZ@1V=]5JFY#4/'A2/\3#B-U ]7SVT-2W:.C]>QQ! 2[F-YW
MBND==S&]+J;7Q?2ZF)Y9I)],I]+CU,O'J_O->I:SA,Z3T>X9@<*M]T#_OH/&
M[#E3.GH'[Z5 \WTX(*P>T(3%%E\#+39T)M?P/M;-0QZ$)S?\$5],R_+W0RFA
MCV1?OV9N]ZF4CW5JI$W^%,;/$M3?X^5!O2\! =Y8>^J5=OH8B^H!'XY&SG=X
M[!7Z>'ZB\5Z6TC#K9[%:__=1/]C:WSXX",[.CH+^\?%)@$L#:CS^\V*"A6FO
M3/;S.^Z(73-5?PKFPIX5RA/I'"M-Q\I/-XF.,WQGSG!PL+\?O,_N5)($UV A
M*S#-KZL8C.-#S"U;2#/?]-(OXCOK=I$]TC3Y38U<KC<1](IJT&S0F:.5-[7D
M&[]#FZZ2,R".MJ6*1,]-)-&$*'NF!%ZW5U$FA0,#E38GA +F,24Q4/0[2S1&
M+HW49&7H^)L!R&[DK[25/&GH;.FG8QUV.H*?2CY#G&HL9BG;8\@6*D7$SP5O
M&!&(,;6,2SIUTBQ/R@P5"Y<R)Y+*;>:P]K0^1,[A\,:X\37,+0U)T:/07V,H
M_QI;X(;,M$P='K4%5/E4LE,Y5:<E^Y1R8&YA]1"[)Z'"+LHBJE*!?=:]EO"!
M/OJ!%%+1S03W(/=KZ ?G$30V!Y(S'(V0ABP<PRI#I8P:>IMXBW-%^07^4$W&
MK/\XF0&_S9W'IN>BJ"8!'YX<G*TUY?):9W@Q:[HL"EB+HHW;VPC^(.8*@&HF
MC1_XFS@5;%#DIP.5JE'<8,9.YE@CC[SPAQ+R4#:=2$8+VBX?K;/M\M\Y!0?V
M_$UX=Q'\0Z65LOE++(\0+RJFS#E,WH-])S:!SCU=(]).36-ZMF[E&SF)<0M0
MP2BW#[/]D_#.9-M<E])H%2GA/[+\DTDC%$!=Q7Q/L@F'DXR LSGNE<2,C ,/
M=-D@9QDR$CBQ5R#1&+0>C://7 [[I5-*S)?,/N/4'\HN"H<6=<!T*M#@ #:!
M2Y0?@TDP MT#LP0)*L>LP\<TQFMH.>C#RRD<@V&HW^A?W5PU#V48J#9TWO@\
MR[-J3.WG?PO3":;8\OE_@7AA<_<YK",YQ3@(Y72;#0D%&O28:5P6-LU5,I\]
MX6 JI67$(D7HHWLW8].9QKA=-5JG8+G$+&-.@P9*^(V2G8=.7G]-N$RI.W'"
M:% Z:5JG2-/NNAG4 LEO=7XGOQ&E!E_AD)] X6\X64S:R6*=J#^_4_:JKBB4
M9%;=Q;V.&U=+=I?>[(8G,DM'QB%-F[$!53R,$:K!Z^+AI;X:\K#)X 4/!!E'
M<&5JO6P=@_>P>@%*FKFXZ!KPQX+:$TOE3^$%C/0IP/(,&H:YFG=2QH<)&3&V
M;C7B1! =6V2G;H& J!9N/CF79_#">O4!Q#_AF9P'2RI9F%B((EGW%<963S!&
MNV*6*RH<<'1]N&<$O!M_-"^1 6EQ5'^Y@X.W= B[7;?./W>FV$F7*=9EBG69
M8EVFV&:C/\1MUO_!<7]_O;!C%973@<+0[AD2%%=IP1=Q;;R]1U 90,0S>D&]
M^BA$6SL>(](T-]LA[49?;6(,+45+ X384B;>0!5QQB@ PUUK>\-L-F]Q:WJ5
M3:9(J,<E0DY%)]=1POT$E)YG:3ST"H,6UE.90;'%*CX(8*?R9E%VS?27CW?#
MD00.=M<: ..V6L$'%4\'B%EAHV >."GW;Y1K!/(12Y^J&7Z#4A_IAA^&7HQA
ME0O!\;4M.!++/4-DN?C0).6*_1!;Y]32'U%JQ99=[M1SJ9)Z 1CH^?=5/IR@
M^^A]CCZV%B_>FI'\!]LNP,,:E$G1E>D31NX'_>Z\FH'!AGZU[X-+!RHF<@_&
M2T0-1\KUBO_\[JKT]X+:6T'_6+C&G=GU-6;7:6=V=6979W9U9A<OT@_PKKU^
M&_S^^N;MU?5U\/NO5Q^NWKWJ&84+S@\K3:1<TX&+6L Q7%,D-+$N2ET8Q7E1
MVGP;:@?.KF _%AU5V%RG*B>@F1,$ 6?D%:8U<U>W](B*0'ZB;-Z&V?6=2Y1.
M=D^.?X(=_)JI'1WN'A[]!'/;5.K\WL42&Y#KK(\"B)-B%@)+/WBR64OYY-F[
MY]=7_[@,KG<O=QLKTU%81V&/;"D[DGPPDOQ6U>8G6\ GSY[/OZI82O0@,4&T
M-W_V.2!/:*#-^S_10NT5>\'OV%SD>9[=I4%W"+M#^&"T]3:<J@<XAF@*_*G/
MH#U_W?'KCM^#D=4-MJ+]EO/W)UJ+A67!W7GKSMM/NH!_ME/:F8^/<ATWV:/Q
MY-F_O_OM,MCZ>+T=O'GSHJ.Q3ES\M O8B8M.7#P.2OR3'>7.V_A%WL9_"_&N
M#[MP8YATQ[ [AIV_<<WKY)W SN7?'<'.Y_C]?(Y7E#Z)B9#B<UQPX-8 2>@E
M.E&RZ%E[ZGN7\/\U"?]G7<)_E_"_(.'_6[/[;[,XNB^Y?V^017/X9U).DV?_
M'U!+ P04    " "0/6E66".(B>#U  "H<0< &0   'AO;6$M,C R,C$R,S%X
M97@Q,&0U-RYH=&WLO6MWVT:V)OQ7\&;FS!%G0;+E>^QTUE(D.5&?V-:1E>[5
M,VL^@$"11 P"#"Z2V;_^W;>Z 2!%VK1-)9@U?6*1(%"HVK5K7Y[][!_^O\/#
M\WP6Y;%*@E^NW_P:)$7<S%5>!W&IHAH^O4WK67!=+!91'KQ199EF6?!3F293
M%03?'QT_.7IX]/VSP\,??X!;G<IOBOQE\/C!BP>/'CYZ'#Q\\?+XV<NGQ\'E
MF^#@M^O3$5U\]N[T^E^7Y_S0R]]^^O7B-/CN\,&#?SX^??#@[/J,OX"['P?7
M9917:9T6>90]>'#^]KO@NUE=+UX^>'![>WMT^_BH**</KJ\>S.IY]N1!5A25
M.DKJY+L??\!/X/^J*/GQA[FJHR">166EZK]]]]OUZ\,7<$6=UIGZ\8<'^K]\
M[;A(EC_^D*0W054O,_6W[^91.4WSP[I8O'S\<%&_@E\^@*];UWP\O$V3>O;R
M^.'#_WBUB)(DS:>'F9K4+X^/CYX_LY^5Z71F/RSXY5Z6*HOJ]$;AW=<\VWD&
M7+C0ETV*O#Z<1/,T6[[\S^MTKJK@K;H-KHIYE/]GR)_ ?RM5II/_?$575^F_
M%8P"[IFEN3J<*1[6T?'WK_BA+^5=\6K]G)NT2L=IEM;+E[,T250.%_RO__'B
MT</'KWYX@!?"U"QZIB?.5%2^'!?U[%5[IOHFX N]5ZT^UH=1ED[A:?BI\Z(!
M_N_X!?\#AS#VAG#+=QD760)?GG^<P2S ]0^/GC[_X<&87_K+#_KWIJK3R?)3
MA_U___?_"_X6G)Y?79]<O U.W[U]?7%V_O;ZXN37X.+MZW=7;TZN+][1%WC!
M^1E\&ES_<O$^@.WZVQNX,@S>G%S]%WSQT[\"N%D8_'+R/OCI_/QM\.[-Q?4U
M?G%^>O+;^_/@XCJ W_WT[OJ7X.!B%+Q]=PT_O3Z_PF>=O#V##^%3N.+ZE_.
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MO0"E*81[16B#T Y.:!/AO\LFH_]P9%SV?9,F]#7GR-%=(3L"]=#/!;Q4CE*
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ML1NQV 94>(9-C<I/,(S^9T_;BZ/W1T%"-QSLW)VTCM@&3K:RTTQWH3!W]<9
M_L7R$924VZ)FHW:D;TY.O-Q9U8R%NQALA_,W)^20.9T!T&BPJ,WS!OM 1D0,
M*7R:4DTCT%'V$?585Q@<YDK+P PK9ZI)Q#\SS_HM)X0-TZ:A#.JYV^[-WY[Y
M;T[V_D^2\',Z\#KWG:291_!4")J!K"TFFI)7?'UV0H11!.]&FI6EZ<.G&_B]
M/CL]"76B$0T^O,T-<DH@E':*@%9^:M09@3SXKI9&Y$OKU8#?\$+T+P'%+I?&
M"7;R?-VY%ZQ.FQ?;31UZ*"F$(R=LCQ/$/5.<*?8(/JL!^+%+W;,-8 ^V>3]A
M@5GV-RI!-#<2V!*=;JCA<543HQ]8E,/J[7+UMH'MG". *][[2//3(=*\0P'9
M!KWC*^]/,!;/CWX[ZE<0\&IY,4?L:84-0&$F\=^ZET0M<!G+,4HX%29EJI@J
MF\&:4=5[Q,/'F''C7U!K!5UOFG$K^PXE-#^\5S.]:G4[:!DV/:#CL._LZT$U
M"E^+>R;^%VRWI!@HA7<B[-MDWLX_JK@A\##QD/=P^'5COXQ7%7[U6:HF0><N
M!(UE6"M"MU)&<&$S)JX 5XR>ZMS9K4VP-_T'=J:\A.L(A1L&OZ@HX8BA$U?V
M*B(F;A? GL</@K8+0=LF?W>N,^\7;\^J_3QT+1A\$(]=B,<V>2LC'AI2VG^
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ME;-E1#@XX)>EL&7<GZ(EX\H+6DH:GIX$OAZ#"<%@8D+L01DBU+7@B&#TT<"
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M='(F_JF4SE!/FUAF._H9*B>7V^D;D$P9]$W(QC0"4J6M./VM_4S^R!X-B#C
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M:D2RFQ1!5>AB 1#="A44(KUR+%JL9Q%6!<3$H!2<1AG*?!G\"_SO=4EPAR;
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M3@QM,=%ZWA29&&\)O"3<C&Q7Z:A6];2/_MK4I<<40<<FD_Y4R&S2+*B/V+/
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M:3=WZ BV3A)'2,T)ZY<FF-6WH1$JR]3@'(IL\?7<S)?V@<G%&M_3; 5/=AW
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M75N5?82YY#!2_3B*^4HLPLE"].<50&*0(TRW7L)_=\Y&_'+<9!]Z#E,0OU9
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M[U1>8JSJ6Z5 58$,Y:IL _F02!%G@/A**QRCP^YA>Y"WVHWT#8Z$!I41]BP
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M#&4H^[XB0PG*$ S]]A,X1.H'X=S;"1R$<Q#.O9W 03@'X=S;"1R$<Q#.O9W
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M0M%E6J*F$#%=8TDDD,O)DV=]GKG Y^,PIBM5'.SM.*<5U7+H5Y+E9>]G%<6
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M\@T"!0:1]?)J>59K[REY4[5W8(X6Z'[!7T7'2'D/704?0 23A5G"/*,3;0H
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MD\T8<V<J.'GMS_0#XLGK7F8(A-E]=]CCQ%;<1O-D@U%CROZ<YV018I4GPU?
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MU?VW=NRF88!CCH;E02#@0'09"6SG$UY_ )KUUDE#O[+[X9*QOJQSFI"U[P@
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MGG7V+0Y/I2MM&ZZA'/&?K=$C@QE3W5L5GT^>&U09J1AB55]S@>:<"_?(M&W
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M@J?$B5 0UD:OM5G_47_FCCK/DVV=2[5>N@=@*KI&IE:OGYF;V'2CB3''JFU
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MD4;OYNN]FVL_G='GUP9QF"E)5.JG5OD,2A[+D09SX?EL*=S%(5+D&N-5#E9
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MV!)Q/U(&%LS#"C<8!Z%80(V<-?QUQ[#J-6M2M&2/:$T%W6<5)5E:=S"QN3.
M'DU&JSY;(KSND=S5O4^]!GERS92IQ(/<$$3(Q,PPTDB@$2FL6%8W%:D*_&-E
M+I:@.,H*7*\R704\,S#'CP?G![JP:,Y]J!*$^*X^,7^Z44P.? -L++5PP@6
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MDS!+#[_[&0-47/'EN" 0#F9<(ITQ:S?[]AXZ&4V-MYS4.9&*\T*^F/C7+\_
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M+DF?9$'@2+%%L\+!B<)IE"<E6>Z,<7::%@C=*%ZHF]9 "XJ&<RE8*&4 FQM
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M!:\#QU[)/)P%9BD#,.%I-86UKG)% A9F\SD\']8&IMZN*7Z\R.,"3P1X1SV
M2!S!YQBV*LP>>4L2O .6DCT!BAS!XZ8@M-'NL#?Z4IUN7V234L9I0*O7E.SK
M.$EHS3)QF<,XP2GSMA&N5^V*"Q7.TBS)+I>B6F2\H+!\\T)OC32B.%4AP)R*
M:9:#4N95_D'7]32[#L0%3@%,ANIA>4&(8)8+D%]]&@$UBXL <CB/"\7K,*_*
M"O1MF%VI%,:(PIGB%@!QY-5@J5^P[R@DAF1PN4$FI^#.9M?%*W^IO!#EW0.F
M)NZ,ZU"+.]_.4^PWE4QWCU2HCW9[&"CG%,C*H.>5RLF:Z6&"$E5XU>OK65RJ
MO6(!Y@[N<)W+!05*X+>)$@=]'*<;22)_&DSV)DXIU#])LO!S1\I$Q^!I&AL!
M:4PW]7_'?OWI-\=O3TY/$&9QSIXU!=#O@R*YBTQ?H%=+4D=ZF)1I,0.E(F82
M['59^QKL\T+'%,EBLK;]_M*Z<M)NLU'ON#$01<7[D)[X%9GV=,DWB?+!: U"
M;&,%=[(+MPH4C*=3D%PO#MWS6QS</1O!D<>Y@DT);LA'E1=HWW(X?92@<D 2
M9$F6+,\2/'(4YH\$[-IDB;^$S\#5!'<2G=0L-3_@D!W<$@- @9A4<#I)DR4Z
M**( OQG/-&#[BBJ<V4O4E[@HBY%X"[\A8UGEBPP-+!E<>- YRF&F8^^P.]BF
M@GL=F1"0OI6)%NW$*3CA&#,/>$"P14T^3^!;TS?.HZK?A5_219[,U_R^>%7'
M.]NX+D\J_@H]>3R+9=<J#X2*Z2@7Q3F\3<)SF-J_REF>59<S@>%Q^&8.+@Q\
MC:.#0S;X/WCR [>!?T]WAY6%@R*=_] 1662P&V.>-)K=YJ+"3,P4#6&RI!MD
MURG\9!8O\!)8[P2\8O DXREL #3!>.>=I_O_NLOSKKV?JZQ$[5B4H$[LL\P3
M,KHY30N\//Y)YU?PCY6+=35SL8/J[%-U'FZUZOQ%II_S:E&&2W%\U6_FD@7S
M%1R']8:^RI(*?/5<BZ+[$QS\4"G4'H56=O(27/JB-'I-X!]Q66$6%$X)$S=H
M5A$RI9]DL(53^#"1URA\,0B*=VM0JU/_L8%V1=*L9'=DHE0* E_ 8:/0D')X
M6!%_@0'L/-O7;Q')):AP.MA36 C,#HHE6J#T$C3A1/].@D,3*M!_.;Y0")*0
M@6))*>RW6&2H:R+2TOH=X=)07^K/AR2]9-^^>WKP-B:-@QF)++\$E?LG[?0
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M1J2>\"3FPE/Z#LC3=Q5'%8[59__$(:DOJ&H+D^>GKQ/.<>FO%*,YE8G<PP[
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M$K0;Z>DR5U+WVK$W[5P-25#3*?,;P%-.'('1S=52=GZPUT-[IV(56ZWB-&4
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M---1T2P,*[C,0Y%W;8&V*%:@C25I+<3SL6#BU;<2SL:._BX[BCTNO &/WD/
M(U8;@PDP)S$<)"+,?R=+?]9:"TEP4I/4QIRZ@FGE\P92 &LJ5.1'AIV $1G8
M@L=7V!\WSG(3!+_M6G1@,-LE"BY2B!A%]-RP!24XEW!8F\4+@GU3M 0T,QH@
M#%@3XML$O'4D(J0AZ-T$1SF1(ZB3YA@_I1GTWC9+/>@I!_6+UH_XVJGI(:Z9
MG?6S<J>\]9%LKVL:<-WWU'Q!F_V,3(>1! >/A^T98K3%4X+P"GO>*]@WY (.
M&JE^^NV?K!\<W$("SGES>J46%56)(("4!KCDM22&7-Z9/$FU1=>SW( TWX,3
MPH_@?ZTAVV9(&K3[4-P=R'1/]\+SPX>T%W;D[OKVPAF+="^.^+@0TRHG-=MV
MQ'W-8K'_79ZY5S):-+#ZRG?;:Y_K>*$.LG',T$7J?'82L1./U.CF>B3P<A9R
MV=*'TA2YTM67ESEX/27&]U-D\+<%3#!5I3@'=["P?,VM>#[."'U3BP &QIWP
M;&F.CW#,!6OC:KZ%U'GH$?P3ZPJF.!H=$>A$8_B[RD!6]#,.1PR6\7$L^K/6
MG9H"]"?]\>75P6N' 'I%TG-7<@TW(YZSG6)-7/(U.:)5'?-NJ.V!=B#.?0U+
M7=\$'-QH>^Q&@;'FTK"E@\67UW9][+3)"9U1E(_O,3.V;^(U3[K/(TDFRU>T
M&'7843\K<]>CSRT71W]$:#TK*_H_WZO.X <P5),U&"I;RZ8EK2]CA17$1ITW
M=&PGM93)*GMF11NGFJAWMTZUIL;698&S7H4,W\'\;6223$M4"'$6<5\;;C6.
MW2R$UVR#GU,S34S!:'.PYFETO#VB C#^HFMP_A4WU_SZI85GIG>..V5$E3)
M;#, %R@"!6<,?<T<K^Q[J0F]^(_F, ?'<Q/R'*Y!GF]L/-5;^NPO O]BKZ,:
M9:$*[E&U"I;7>H$=]!V]=E8L&%B_6R9\PHX4.X ($Z$*5BM'X'(:M5*3[8Y^
MK20;C#1!49VC5-@P!&N5N@>N)8\*?0?H_P#]'Z#_ _1_@/ZOS0_H0=EX?J;O
MINY2@U"M\15F7-!>(+O#G-,&D@&!.G?%/T3;$M>@XC6WJ]7&L,NLH6>G$S^K
MJLHT@\*E)(!\81UDW4W18]I98=-&XC0K,?%8E)(R:[K+5:XN,_@KT)>!30SC
M/*SF^+/0>J E]<K"@9!Y-UQ)36H#LIVAPXA6B25ET-.ZRA!S\LCSW.M3CHW?
M) ;A+9N1OA]E'JYQ0LR=5[U^+?U(SKMC =%M8O7 M!MAF(;LHZ8F?C1'R%OD
M)D0TW07TUIMOJ#_#7^$;@7F/Y]5<7]%*SW5[-KCM\/WP#T4,',C7H1]*@\#L
M&C)]8!6NWI_9=4?^8<?P5[$2;7WOX*[2#A4F0&]_?P'@[KO#F6$C9X9HC<%J
M/##V=?[O.+\:Z:38<%.Y89"XI?#X1+&"U,H*G#[1V[_?$D+"P4<I>M 5)VR=
MY^'_QJSHT,\O2-YM9((_A@\CZAR=&G:Q[G-_P7$!I;M?^N$%#?VX58B!^O-:
M=#N";'<.#%1D"<;;8$7HFK_^XCOX<@^"TGS00YO10VH->NBC<62F+OS5ESX"
MSV>&I@S#?MQ&&G$5RN)UV7?R4EZZ[J2!I&=Z+KE$L0RIH(/;5Y,#V#2@SG_!
M (>?W"(;'I==LCD2YV!I$W"]5%85SMF)8#5@B2Q W]!Q^413'4$,K2OPM;-I
MR\6 -PFZ7B5H)^<TW2$C:F31>%.8D79ECN7:\M@O RYZL]8!=!BN@N\O=_N4
MVH?L /?_SPJ\:N24'!O M>TO;FT/M1>'6QQ7>78O4-@_@(J8KC.O3KN_>"V.
M&&RU1)I-C,,C-TE/04XRI"G58UDI;&XZVMGD!]SH>72E+0K;\[Z6:M<ZQY+%
MB#JY24N$P8F'LT@GOI13X$;OF&.B=*H#5&!BJG3P>%65-ISI)!0/+?"92\.8
M8CGC//BH@-;\W(Z=46<O2'A;M]A!-[#QUJRPNI2SG@][J.>-8A2^.?02M"W!
M<B3*O]!,[+(&L<JC.:46'-%0*\0J2 $3O!=I&*.MD'$QAB_L4<F$ R8R_4RE
MD!63Q'Z3-H4'FI(K.+/"R_O\D"/Q.RZ]B27@ VG5\'0+@DQ 2LUH3$.UU.+U
MPR*_(H.-)\H/?NM7"XW@X;K!$P)3B*]=2W,WGX]80Q0IYH\/%U5A%@3.L6 H
M#2##%*'!;Q8*[.>1PN+\1/R"TZ9Q<]H7MP:QM6_@(4XT]9YGDLJ"\W!Z_DWY
M692%%;6;)QG0]9L%(V$,VQ NS97,66;GJIQEM'&-;+DDI_8S)!_8:0&)N'->
ME17UL[=)$:I\PYP>O_^-_,V@_>'B1%Y;) N98V\$1-2)P0D,W0R&;B.&[G(=
MA@Z'B30 N $([WV2,BP<#%Q//G%#IWY6:N&<P3ICF28/L:H6A8M^CV8C4267
M84O$/J/\YC3Z@L^9<),PQKW):A8O55Q6[FP*%3RW4G4K4G/LI\+Y''X4%S.L
M"D=I-H$ 5$@-<S.'^9GY!H?.\!0!9!)O^VAB\]7/QS80Q/#-+[-2,EN<NXR/
M\?7+ DQD&,-,@>H9E]8V8(R!@QP<;*C'YR95Z4+/TYQC>LG2'"E \-L8MUV,
M7^-.7BC:SJA64!LR<#W$?4W(_ 6MI1FBI!^"NDO1N-2CLC (+E'G6$;-6=$U
M[[:$W='!3W#U+/?PDB9JAGT<,B3'!4%7T:Z;48D<SRHR[,/:HX!9!V.% 1^T
M$_C%+(-S@C6B9F$6R,RN;7O6."64US"1AWH;U&:*:CT3@B%>H5SPJ_$69K-&
M<!'C#9"IOUWNF/GSO:EUTP):+DRRHGTGIM>SY/ :3D\KS2S3FLH^JV .D=!/
MY53-X)UD*::D[1R,WF.Q4U?Z:-4E<,L:P!X_MYYB'I-]7B&&<@)[HD6VB!U
M:IK"K)*\ N&O!_[U:I$S!AI8$^;7D$(K$@R7]S;.\]" \NO@L9=?>BM.G/I
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MDCN,>E]JJ&O_=RJ0&QBIGC63VTRTQY]H>[PAGP*F""DX$AL1'_6_#/:->EN
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M1XFF.;S%0"CQW.CPWF UMIEF2K5<.1,=2@S<S6$ %)+C']*:KWKPJWM@$W\
M3]!!(^ZB +"]JDQ F*.EKOJW)YCZ/M!X@_$4RZN90]P[2O"6@G^X#8LGBK"N
MP5K\H'J+@HYX/6R:S::_[[II0%.KG+B':H &7%U2P6%= V.TQIPQ]?=1QA1W
M]2V!F\QMBQ6[\?4 %1Z@P@-4>( *#U#AP?)]*]SB+NISHD()=JH_XX<"UK1Y
MKKI0AVD9F$7MC$,JBLJ([(]]K"YG#>Z, FS:LOHGC,'1VG#R^:Z.5E%-"B3C
M31&7FLCK:87[KG;*O)6_WH8?F]CGU]QV?S/&J6[FJ3MG,OE]ZX+:[5JI")-
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M6R)DSN/!'GW6)-SNM0PC E[:-23;/;RSB0 J&S2P- ]<M4LO"A_P8&XSAOL
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MVUS"=/C+K_ ^M2/H!?<^Y0@Y"9F!@SP3.T?U_KW@LMCR1;'3P)##EXTS#-S
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M]2%0OV.'5W8?M.H/L7_7P @U)D<#=], +M^*;=!30\ICKLR1A><M.=>2G*5
MI#KNV5 [J<Z$VB;VKN&D<V=I7S%H)*W5-SDW#KOSJ$O^C8\=Q<-M5K%#6:?K
MTDV'6GVM=\C5I:-DE7H<NWBG&8(^"%$."ZZB7>Q67>(7R-=K:\@LX7"=ATR_
M1P??&!?\^$-=-3@8%RR:)EN&:;"1$"H7FE@:9G#A0U@(SK_B^;^4!,7"XP#B
M5]FX3*HB[BPRM4T-&V/EM"R%YEK=DG189$'<,2J_Q..$^;O$*CHZQIN>XU/8
M;" G[D^LXBJ]#DZFU(S<2R[;&I3"%C7RK&W;E;L_<-N?JSC1KPBX6*^QN_U-
M3:6B6F&L$!L;ZNTJS;O$8W6;MZ]-Z^VB5]*4WTMKY8;]N$4QH]/,6SD+,X2]
M6(L;H6-DH;I)K'3(AJ_$;:#[NM9"'S5PCVE#U]E#V0]X!";B8=(66/II Z^.
MN]T..O"&XB"8AID>S!7UEJ705E(/PVCU[M["T7/0N(:-O)&-'/74(;FCC@Y7
M/V8/A.*8N-Q671:F8Z$.?O(^*)I'S&$3;&(3J'ZZ9J9+7YUI)LMV4N<&_09;
MYBJ+!]Z031VXUT!0^U:'S,=<X]97D.C8,3B1>2DT\TY(+<IE^!E>*U'1)2=D
M=5M4ME8FB(\L"GDU=[C]#(/P7)QJ:T0D@3D+T[8%3A.@KF3./<T]SAQ+E(-!
M*)GC#\R)KLHQI%]H&M92^WXW5KD.\- !'CK 0P=XZ  /':SU:FN]!HKI<4B$
M1'3^0OZD"#F2UV"S-?1 )B$6<2BRNG*.CVX=1;F)N37'=GP+.SY'+%^_M XS
MBCO=3X[X!G2R=3^W\<M/*<%DSTL"<EVJ%$D/,4 98C@9SRG^@.(TC!<(7MKY
M="Y^'8\_[M9"GB<8#F+0ADS$VSB%82 :X4QAB1_>XAQ#M#*/P)2\/3O?U?@)
MA#TPOB&?T].K@N$A'M$EN1UF-HG\R][>2&5@B>!Q'8B<"F-1<8$N2:+!)LT;
M#Z[WAH1Y#3RQ;ZDKU'OYAP(IZ2T[6V.HL<<T[*68-#C<$1:'M)PZT4H)">'X
MU:G>&@6Q'JEJ8W,: 7Y#15G"T#H 5.SCMQY;,+<=QYXT+\VOR*L)QJR<_;.B
M^ML\SLI A/%53$VYYIE&5:H\S_*XF ?8AS* J<OCSQZ=H$CD!)\$^X\I!Z<Q
MMBJ:)AD^H#46]/XQ8X!2KX&4D9I*[+9)LD=RF-/MJU2W=^":/+@RE]<.KQR(
MRPPV&AVP0=+YO0B7!2/4I"(-BC[,%>G$"<S)1"TS7;)LRNIUQ,7#=K$B(!8A
M?>(BWA&>2VX]-N=-UN@CV>3R)8U+#<N8*!&T54YHJ%Q1=D44&>+;"M35$X5=
MT4 K7Q-6F@=5R'FMKSCU.,4 ._POGGLHU036!U2:WA)T!*SJ[;9\6D$>&-X,
MDSA7%"#=975)5"I8>^WJKN&^9ZZ?^?$4 5=T_,2EH%9NA)F-D8NQ8L!K"/-.
MI8*:;5CO6J16F;=DH2D$GE%S,[3(<:ADK085O2$5O1Y:5<?>R51G_<%H&,49
MF(PW9:_F9.,#E'U#[T+=>6H:EIK 6;\"=[_F185'I9KZ($51K.D63J":STO[
M6EF[B4=':K;#*#1&Y3-O]K\2HP&1M@$16@=U)#5!\_=)+67P6HSATXC"?'V)
MUD4'[S=:)W#5HRK1H3[UA8KL6'\WH&E<OF!)NA6_@J;XTB@-[@;>_5+6.FLT
MAZGP!Q.(W.?&H.)C4)@230, \@4>4+TX2K?@49?@Z[#!04A$SOG"B$EW:P,K
MZB,KNA!R>'!1C'[)N=9*)[*1P/<2#CBVUJ(^<L2J@(L5$\Y[GD5>&VS0-&8=
M;]-ZW.4/D,27<'Z6@U'W Z)6Z<0 C(/#$>6*'0*>UM8::X@Z]2N =5XBAGT&
M?N&?"$<DYN6<6GO*X?"T8;7RHG^U<B07O28L+H@0FN_9T00#G=Q&$TKB[F,O
M%+_E_#GLK]2V"3:;6MM33&=H-BSR;L'JEP86HO5'G05T.Y@V']QN74.W]3?Z
MZ-E#TY<3;%&BC[)T9HVGYI@DX0RLS*F<(4YM-Z[IL[GCBS$4+8(:']?GE]1.
M*DX;)_$\UDPKN)=7#*[@*%_A-K\^7),)T+S[?N'4CMQPBVF]2GUVF:YY!0RT
MF<9@JXWCSB@A>UI%[#R5(C5*"[EPM"P3/KSJ@8[$V/3*0WYZ1Z!O?D"=5VA7
MI&(.HLN@M=7]_-!I ?$V;@NL0^4.]^:>N",TG9%]HO_]A((3&6B?R'06/:;$
M+SZ;.R#DA>GE-XVGNI3SJ=]XD!\9YWJR* X*6U368$V1F863Z:JG@'O%]- T
MGMIE/8Z 4%4I5Y.:=L*4R=+!KNXGF,8QJMG947=&X%XYIG6\\P@-8HQ+ )OL
M#K69&2S&A@IY]OLW&;]2Y! E[)V\7M/)R'KA'*;4SK/&09"*5M&J2N]$7G-[
M*/CD3Y4GW*G$A.3:_:0LB:/XHP*-%,6A'^X+0>=QT!?QWHK"@K7?P7Z0>C3X
M^R.9EGSUKRI55W+8ZIO:ZFLH6CLE@\0'US<,!8I[\940XL;6+G <N%+3T6FN
MVH*+$G2&$FE'+,B177JTF6EWJL/O#&T.J:YO5ZWRC4JW)V@&B@JM4\Q)/;YY
M/#40*-[A& BP;"JNW'PJ0RII4&(G5Z&*%U@H!R\;JVA7DYB;6"+*4XP&2.57
M:.QWJ/R%S+EYUUTCF3:2J-,.5,@7P4\HAZ ;W\LH,D%*-XRTFD^HR@8YB)C;
MO$[A>]-5LO 3I%Z_FT1J3X5HZ5=Z*PV1[QF-(?!_*/&B2X2_=2NBA]+BGN"Y
MH>WQ:HV@HG[?9'QV?"XNSL9O3DY_%>?C=8][OZ=A_S>V&CQ)HPHS;RI)4#1%
MHGD7/J"LE*7\<UO>YN#@^;X85Q,\W&W+F#T_X;;PI0%*.4 I!RCE *7<%BCE
MO3;<;XW_]0IE?VO\C=^I+AC\V<5RJ_RD6A#U?#1>IZX;/*4?P5.ZST,>EV7Z
M2KPCGOHWR/%>,H7'E@CKENI&/E6ZS,QVGB@__')^_(_Q5NG(@\- '"%K+7*&
M%*!?DB_;,_3#%^(CZ):]=ZK8^U Q%P<'4;?E'3:H(/N+FY"&;&B7(4R]MC#U
M&KBI?B?@4U^IF+$&4E'4UD\!.KC]2D+=-IY* T"Q9I;2-*XUKHM"ZWAW2?UO
M.;8MS2#\MBKZAYI$PL#YIQ5&CXDHWHR08:6M*QC>-A)CS&U3EC+@WO&$/*-
M>BD_(U0MJ+?FK>/6- +/Y'RZ ^]A-:_X $:7X][1,S>O1><)HF"3MS[@GGO:
M:RBN-SA_; 1O\[%^_H(-J:=-R?0:RM_/L7A+EV_T)=F_(\<M]D2,B4J,\(8W
M82%-PK21="5YU(AN!L],_$[5N-T9/*F+#QI<Q C.B;\.Q(P1 )L8?5!O/4$0
MHIN>04-T=W<OXH;9T>#6Z!KS,"U@^E&P$($E9-*?28ND95+PB#56DTK\PL/:
ML/!CVSY0<AZ01E$]"%=W@"B$2E>;6!QJE6K0!;VF_W(4B-"_ S6CLV7< A/V
M>YK-X] B_@HQSPQNA"KX7.;\ZP\;5,JF5,H::G2/L. 4!!DVXKH0[9KM0O-I
MD+8@PY?#ILL)3&%'X,C&>;\:&=4^@431BV$/8/L-#V&DJ?NR2Z4[S33SV1.B
MR';8>BPK<8P=B$QS"5]B7J-J.MSEIE><X(:N8N?CF[>['.#KH$IW:$-ZC,UB
M8Z0;<>PK7V<=Z>&OTV8WC@^X?84.2,=](1=_^MO_>UZ;!UP/9IG[_WY^%#<.
M0T8^25Z^Z>5K28I;*H>NX].=4U]N%?!6+9'K(;H_9!J'3..0:1PRC3]4IO&.
M^OPN'M.5A*'",PHDS-@+Y:+H\J1.4O%[7!*[\.\<5+BS(\4$F M]2-"E?X0Z
MT_0#[5);W]'RR,K8[8HJ.A$A['VI >/-TC,X9V!#<6J.>Z4T8IM;^N+M#.>B
M/C@TNCHQ^EQ.,D<V.UH10?0%>>_)Z/E37"9!Z_L?/^&GL&;L@1F]PM()JB.!
M!5"OS#_\?8)[0&L/W)<8DX$WT3+U\L7HQ4N2JC*'_T56".H&#R117_!T_U]]
MV='B3;OKZ>B)WF/TKUXV^4%+5.^R9YW@=&S56A)CTI.=:8^_#Q^JXRSX]/:&
M:GBIX:7N_E(__>V7I<U0WNE@5!?*VCFI&3:H^TB=004*<U'$H/DUW[G(DCBJ
M11- M^_I>((0CXI'XCA/D?'D75;!*5W1>:SJY077]CH_>2/LC.9@<<@43I=F
MN[5=DE6N!'VTAX#N^N=N),TQWA#,T>>F6B@'&;>LA_=R=,B]+[4T"",57XU7
M>:?<NKMHY*G2_[OG<M56%G?8%P]"SYS*N;*:YIX+XDJ]TM0IU;U_E0>C4UZ,
MG@PZ9= I-9UR@4V!MUZI'!U_&#3)YC3)4_!.7@Z:9- D/1SM'I71#QYO:94A
M#C&7X:6&E_I!8RY_ESCN<]!MB2JS= BZ;#;H,K@U@UOS\((N+:4RG)4VJ%3V
M#P>E,BB5AQ=U&3M@P%D-&##HEXWIE^>'H\<;\%GHE/Z(H!%; (^P%7H'ST8O
MG_8NO0?[H_UGH\/]@Z?;HG$>Y"'P0;[4 S[9OI636&&5L7@GHRP-9W*^*(;S
M[>9,Q=/1LR'_-WBB#^]XNT*S#$[HIC3+L]'3IX-F&33+PSOC<NM,9(1'#MDL
M'[3*YD)G!P>C%QL(G6U-!GHX.0TO]1!>Z@&?<8]4E,>A^&T9#7#Y#5J*P\>C
MYT\&!W1P0!_<T;:F4 ;7<X,*9<#*#PKE(9YHAZSM]]<O&\_:/J)J^37UE[F;
MF'VK:AA(@ 82H)9J_EE2-_C_^.G_^2WY?'#X8O_YL^=/'J-42"L9?WV]!A:A
M@45H8!'ZH5B$-"?>FCB#&L2MX4Q%5:+$P>CP<7_E/]_QC32/?R2.LOD"Y;3H
M][5N:94[':BFZ^:1<WZ+4;\A JE=/7]>]$>X]5\^>_[2;?U^3-/%+)9_HH,,
MKRF.9#[)OL -(B7>P*^N-%F3+,3[+$**Z2RWS$P?\ZPHY27RS\>I> M'@E M
M*,^U-O,P+-G6+=E&//S!GQW\V<&?'?S9P9]]0/[L\P?AS]8ZX/UGFEWO_99=
M?Q>7]B\H^L$OV&Z_8##K@UD?S/I@UK^W$?3-^HN'9];?2W@NC/K[A*H>DET?
M$EJ#H1\,_6#H!T._G6;1-_0O'YZA_RBQ[\-VF_D!!#/X#(//,/@,@\\P^ S?
M:&$/GZS#PKX].3N_$&-0$V]058B+#RC.9&/[>\C/$X2R]GK+=R='QZ>@L<:_
MGAT?X\C7YN_<S[YDW(UUKM*(>H2=_MN_'#Q_]OI 7&34@E@#>5P7L9Z:P.Z@
M^!SNO[Y[+ILGG$ <NO*O:W=2ZS'[FGUDT.D%#E[O!GX?:\)H_+U*ECQ-+P)Q
MN'_P3'S?MQ7'=H!OP/7M]^6Q.;2,N'DNJ1OJ)8>MYI;<$DZ5UTJE9MOPH]>_
MK<<YW.HBE]2.KF>5H2FZ[S)_@9#B_#HN"A%F^4*7%W WO5Q=8I-MG,=L.@7Q
M*X0LQ7]C@^*3- (=DL?@?F*78)'@,AP\?_VA@L_*4OX9B(.#Y_MB7$VR-%4!
M/J+\4^6(%-KT'O1/7'WN.-Q4F]Y,'R:%NI(][R+77V^C&^EHIN;8ZQ'^&E?)
M%]@QA_B_PQ?B(VP3\-.*O0\5:(DB$+^J%%[[N^XB;7YZU5DC48L&X%N9QYAF
MY+F:JCSGYN#85Q,F#%0[8N\V^_H?95XN>WQWD>6!P-:8; Z29?#]WBM618]O
MUO]1\-Y[;M1&5A8]JZ6@)P>/@*JZ-6W-+Y!MGU* RCK8YP?_O0)#A]2:WTG5
MN%'UN#O[,%7UT>[VM$QAEH8J3]%+\K6B=BP*L<BS!3H7,E^"XM!8?O$YS:Y)
M)?ZO__&_^ZW?_9$E[\Z+R7N"(G/@EJ=9*<)$PH\BXXSC1\5"A?$4(Y?)4D1Q
M$299P?V?462[ N4B03\B0BFM908,'KTE.<.6N&=;POHWX"G.T ^$O5!W@G#I
M"G1WX%>?Q8(6'H6_1$\!%GZ:Y2CL=6\I3N$T4H6X-XX2F7^F;X^3"6J3=^\^
MHF^:R&OL^SV_R24]V#\0;U6D<IF(\Q(&4HJW"3BE3_?WQ2]9468I!I[W#P\.
M]@/QZ7S3AN'HW^1\\?JXUT,,3/0B5PN9\\%Y&H-(E=>92.%J>$,]_W+!#=EA
M ="_OX+;P,SB,ES/XG FKA5>CTL7B6H!J\1]VZW=Q5N#C/*/\0LY@063(8@T
M/1F.C"C/IG4\Z//C+[-X$I=B/(CP/1-A7#[<(5U;@_8![B'2T4^T(R73"JTV
M!:!P)^ =/HW.1UJMB[&[A3C-1J]H8Q'# >Z,+$\5V(<L_ SBB-^ IU!*D'AX
M!!B.3D T/<9Y"7T^%&/HP0U/M3K)?/J@-G!CH_YV?'8\/N]S9UF-@<H$%@VT
M,G[<WFRT*L4,Y C/R;++7Q R#+.< F^@5,[9@/"CGHX>KW0:]':Y]9/MBM_B
MJ4]VY.YJ;P6?_)!VRT-1=V93ECA2<$#8?<'EE1C:7K6-"O!A2G18P.'@X,T/
M&!PXS:X#3.#PQ-W3& &<.4#!%S&Z?B3B6D3G55F!+X@>3RKQ *+-@'958O '
MR6L"GS3#S2$NLRRBCZYD4B%$HW[?H.85L;<38#1"I49A@$I)U"6=B29HO0+Z
M&1Z;2"/"IIIF29)=%Z_NVUZZRP(<R07YO<@%!6[YO! 5G@4G54E'19I<D#E,
M-DR]Z==J>":O%*^7DAA!P'+E,(\G'#<M*G0ZZ:;Z;-F2U7LGE_Y<KBY$Y_LC
MHN$KA>D]=HSE0TI'E;H6R1-.)?0>9WJ?110L,.)9"P#</7W!B@03S2Q>*(T=
MIM^9_2CBW;4R5A'?-DAQ?P3YFWD,-E0.\.,*T[JDZ4S%\TF5%T;[]2(]XQL=
MW\EJQ[<N0"QCN1FA\Z__SQ<Z&OSRQ<O1\Z=D=K6,JB\+_ U*75A1P@PLIA<>
M8E>> ATLR#K8@8/5HUKAZ+L(E9%]"2=$^,>TRLGDAUE1\A'3#@+NR/<.,')5
MJ+"RSYR#]X >!,T2(EXZ'JN'>Z'R/(:3Z/)>6Z=OW2IO8=$H G25Q1$U-(#9
MBK)JPN<N3'#2-J*O*%;W+4>HP"TZ+U>1)0I=*;-J=UFME7ODOBW8MBN]=6D]
M?4!_+\GCQAW6E^H[@JMR#'*!YKO&T$%,&:NK.&)5]"W:,.B.B)N 1,=>#=QF
MY=?">W\M<,&Q+KQCKHH%GE(86(K7&B$*W$O0\W?BW48</\Q(Y2-.0[#:IGMQ
M")]#ZR#0%!W$A'\%T[2$8W'"\Q$8'8S1X%)=+@.A4E#KH3Y!(S@@MA%DF2[U
M,6LN2W#H!4%6V0U;\;:D0)R+IC?  -L?8/L#;'^ [0^P_=NY&FMR!=^@.UZ2
MI@</ZHW,YT4I([ R'-RA#<3FYGL@1K6M^'4^^:U_3\3"<>[H?1 *%<RRL<LU
MS^$JEJ+U+JN/5WB<XJ]DD:4Z>&F\Y:PJ][+IWH(S8M9W]BQP#[X)K3A^"DZ'
M3 @KTO$"YF*=I0M$7((_0UX$(TJ,MT*!/WLW?F^,)E:I?44"6:*3,%-)-!(G
M*9Q*$ P0RI33BQ,\-F;P$4%3R&-;<LXZBG+^%-Z]-<CO?0)8RY'-^GIT/'*^
M6:1,M-4=M$,5<0@M!_]5+F9K"G+IMW]^V$<$Z.Z\GG<[_UB>3SCA]LCQV=J<
M%E-'V8RP% N5%QAW*-@K6R5/JW0)AD,Q9LJR$,YD>JE8^!H/6'&8B%'_@_:9
M%[60C137<)R&AZ'0XCEBD<>X$W5$7S^GKO]P]Z7J&@07Y#Y#G1,U!]%(&11R
M#O_G<YPDA44-*'AHR*2G>CM?Q5G5G*\UIFL?Z+:>]+FM&X$>WD$=>U1.P';=
MJ+^:(3[T2N(P1CMC--J*2P."@_!F+6& L.]@M"D8L1WXC.]3)3+'7US%\#9@
M^_ 4"V9374D&MJ%MX8MAW8K=U^:1ZLI%1OWWF<HXH=-U!(*0D;2"X-)IOB@Q
M_=C 7I&L-2;+[GYRH1D$!@,!83%13<RMH90U1_H@#5L[%NG%$6%R=1#1QDD2
M=I8ZO1T_9,BE:"Z><7.D^;Y%$1]2'N4?:XHHVH+&%&6C)S0"5<(V2R?___:N
MK#=M( C_E56D2GV@=LI-TT8" @U2E$80I7TUWJ6U!'$$MAK^?69VU\:.0P[%
M;&$[3QS"X&%GOKEG$E4+^DD4&CV1;Y[OM21F*HV9=L5+?8R.BB5JC=4)&WKW
M)VP"U'M1#,"S4][2S6;B'E%,F_%_0_:QJJTJ/W-G6*[BSV-IW8.FF7G^*EA@
MU3  XM79L,*$!VHC*?:MP ,8<"N@0W"==E$_4MD8CQSCWEP7OZ#C!5H)=.U<
MM>VB@MW4#H>_A=1/ZF(LKHF""+Y/B@"VIN(UTJ;CH1]3;4>YG+^KQ,PPAL,<
MHIY4E?L2NLIB^<$];B7(E^-)75N4A,J6_'02,T'E#J:6<CVXPYZ2IJR !%&F
MDCW#\? )W22;-J,!V5H.4,RVI\IGRW#Q"KQG2>0%S<U9C!BBFDG1LTG"-=L(
M500HF5*%4\HSNN6!JO.6=U<D_6E1LVY"% V$HLP2998HLT29)<MJU4>W[&<0
MH2O'9%-"."MA+$:NXAOC+KXG:YN?4J#:!DX-<17*"9:,QQC2W.S+7>;VY>:C
M,D76E"S^J>ZT<'?R$9-'\.T(WX6_52J.5/25 .%D!OB/Q)?D2?8H\9BT@"/K
M8% 4FU<4"W7:3KLC&1^7O48\Y=.\3@)AT1<TCC]DV5M+H&2 AJ,'A*EGI?!A
M<2USB?;SHV$MO<G@IKN9KK+O:Z6+:[8MV)5-1!T*44>GO76:)0S*=FIUMM_\
MDG-WY;+!$G1*Q"[">.&MQ5<WH.WF9K:;?S[N.-7VW<[7F^^S7!7!XAU\807.
M7'H+D2+-G@OB5EQYC"GQWI-B#::TG3IA"F%*#E.N@VA^^*#2'_P@)#&') VP
M3CJ$)(0D);AV;L3_\WA+=SR8L.MQ]VQT^9WIT<C6'C<11411S.69F$M?\&7@
ML_,UIX"+09.F6G-:=3)IR*2Q+N"2 Q3RD0P""D5;"%!LC+9T-_G\<2Z?3_AB
M#%]:5:=F( 0CO7-7ED0<2%D$^1@O^QA#;QH(7&'#+CP>8EGPXFY%WH8YX6TX
M3;(-R#:PS]G8@BQD%IA"EJ;3:!"R$++8YW7<7+%A(">Q$)Z8"V/4P,\P "@'
MDP4D]^)E]V(BIL"<: ?TPCB**(]ALLBKY32K9 "0 6"=:U%$%;("C*%*TZ%X
M!8&*A5X%Y3+^/;P8SV6XLG<TZ2XVT>;^:M9Y*S18-Z1"OLH62-+4"II:05,K
M:&I%^KTTM>*M4RM\@6/0S.Q6'?PZ'_5 [$NL8W\5-=7Z+JB16\&FI&%(PY"&
MR6B8]ZL3G%S[DC9QIR%?P\.?:#$_?0!02P,$%     @ D#UI5EN]D1S- P
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MKAAM:6YSJ=7>?#57:>'?4$L#!!0    ( ) ]:5;R;1VXX0,  !$-   8
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MDA:V<31*5E6FD(P;@,HLD]8*00MMF!8J%$2Z%DO8YA2\ ,1 ,88H#)_4JM5
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M*<S']%QF#4Z!@[AQ#/9><^A[RJ'NMYA#/(WQT8 PA$X49C#"9;D)<!+#4@8
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M>-DCU],(\+7N\OW477K?7MV%YW7UO*HNTC TY8^RFLX:E<ME39)K8DYT>,L
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M\,8"0!CUI" 6*/0.LW3L%;!* B[\"0".JQJD(@MQB2' ?5"D&<Q"#\?R2L1
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M/J=$:R]/QUP2'/TS2^BT3F8BX5<?8+*Y$R"A7S2K?;6I"RBF.^DLW$Z0#"1
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MFRXLP'G;O\'06JQO$&#Q,F$:S5<:<;1WX=#!HED9RYS^ @*-A<2TR8![/?!
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M4D/WCY:DH-JN\:Y<\K?WOU^G4;C,_;X_2,,9_!@5X_C\_P%02P$"% ,4
M" "0/6E6&6,7L;DD  !LJP$ $0              @ $     >&]M82TR,#(R
M,3(S,2YX<V102P$"% ,4    " "0/6E6*N03LC04   >%@$ %0
M    @ 'H)   >&]M82TR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ D#UI
M5C2'5&?58@  1J(' !4              ( !3SD  'AO;6$M,C R,C$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( ) ]:5;#N(6Z2KL  !:9"P 5
M  "  5><  !X;VUA+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "0/6E6
M#EWU82*&  "LS0H %0              @ '45P$ >&]M82TR,#(R,3(S,5]P
M<F4N>&UL4$L! A0#%     @ D#UI5M"8*8G=%@0 2#(L !4
M ( !*=X! 'AO;6$M,C R,C$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( ) ]:58.
MLP0ESG0  "7)!  9              "  3GU!0!X;VUA+3(P,C(Q,C,Q>&5X
M,3!D,30N:'1M4$L! A0#%     @ D#UI5KMXZ*)M,0  CS$! !D
M     ( !/FH& 'AO;6$M,C R,C$R,S%X97@Q,&0Q-2YH=&U02P$"% ,4
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M+FAT;5!+ 0(4 Q0    ( ) ]:59;O9$<S0,  !T4   8              "
M 7>7" !X;VUA+3(P,C(Q,C,Q>&5X,C%D,2YH=&U02P$"% ,4    " "0/6E6
M\FT=N.$#   1#0  &               @ %ZFP@ >&]M82TR,#(R,3(S,7AE
M>#(S9#$N:'1M4$L! A0#%     @ D#UI5G'*^+AK"   )RD  !@
M     ( !D9\( 'AO;6$M,C R,C$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    (
M ) ]:5;7R/7,<@@  .$I   8              "  3*H" !X;VUA+3(P,C(Q
M,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " "0/6E61XXNS2T'  !%(   &
M            @ ':L @ >&]M82TR,#(R,3(S,7AE>#,R9#$N:'1M4$L! A0#
M%     @ D#UI5OXB*E+4*@  ](\! !<              ( !/;@( 'AO;6$M
H,C R,C$R,S%X97@T9#8N:'1M4$L%!@     2 !( VP0  $;C"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
